	assay_description	canonical_smiles	document_journal	document_year	molecule_chembl_id	relation	standard_relation	standard_type	standard_units	standard_value	type	units	value
0	Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL152968	=	=	IC50	nM	37000.0	IC50	uM	37.0
1	Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM)	COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1	J. Med. Chem.	1999.0	CHEMBL292759	=	=	IC50	nM	6000.0	IC50	uM	6.0
2	Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL153741	=	=	IC50	nM	7900.0	IC50	uM	7.9
3	Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL150614	=	=	IC50	nM	39000.0	IC50	uM	39.0
4	Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM)	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl	J. Med. Chem.	1999.0	CHEMBL542139	=	=	IC50	nM	40000.0	IC50	uM	40.0
5	Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL154751	=	=	IC50	nM	23000.0	IC50	uM	23.0
6	Inhibition of Cytochrome P450 3A4 as BFC substrate	CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C	J. Med. Chem.	2003.0	CHEMBL168471	=	=	IC50	nM	81000.0	IC50	uM	81.0
7	Inhibition of Cytochrome P450 3A4 as BQ substrate	CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C	J. Med. Chem.	2003.0	CHEMBL168471	=	=	IC50	nM	531000.0	IC50	uM	531.0
8	In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3cccnc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706623	=	=	IC50	nM	440.0	IC50	uM	0.44
9	In vitro inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
10	In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccn3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706619	=	=	IC50	nM	5200.0	IC50	uM	5.2
11	Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2c[nH]c3ncnc-3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL352806	=	=	IC50	nM	4000.0	IC50	uM	4.0
12	Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2cccc3cnccc23)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL170159	=	=	IC50	nM	1000.0	IC50	uM	1.0
13	Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]c(C)nc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL349638	=	=	IC50	nM	5000.0	IC50	uM	5.0
14	Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]nnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168563	=	=	IC50	nM	7500.0	IC50	uM	7.5
15	Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]cnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168538	=	=	IC50	nM	100.0	IC50	nM	100.0
16	In vitro inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706620	=	=	IC50	nM	10.0	IC50	uM	0.01
17	Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3ncoc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL263004	=	=	IC50	nM	1000.0	IC50	uM	1.0
18	Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]c(C(F)(F)F)nc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168726	>	>	IC50	nM	10000.0	IC50	uM	10.0
19	In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL114756	=	=	IC50	nM	320.0	IC50	uM	0.32
20	Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nsnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL169620	=	=	IC50	nM	1000.0	IC50	uM	1.0
21	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10501	=	=	IC50	nM	5000.0	IC50	uM	5.0
22	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10532	=	=	IC50	nM	17000.0	IC50	uM	17.0
23	Inhibitory activity against CYP450 3A4 isozyme	CCCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL274551	=	=	IC50	nM	5000.0	IC50	uM	5.0
24	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Br)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10271	=	=	IC50	nM	39000.0	IC50	uM	39.0
25	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cl)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10769	=	=	IC50	nM	29000.0	IC50	uM	29.0
26	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c(C)c1C	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10759	=	=	IC50	nM	22000.0	IC50	uM	22.0
27	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(C)cc(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL268764	=	=	IC50	nM	22000.0	IC50	uM	22.0
28	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL204021	=	=	IC50	nM	27000.0	IC50	uM	27.0
29	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10921	=	=	IC50	nM	10000.0	IC50	uM	10.0
30	Inhibitory activity against CYP450 3A4 isozyme	CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(Cl)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL273503	=	=	IC50	nM	7000.0	IC50	uM	7.0
31	Inhibitory activity against CYP450 3A4 isozyme	CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10604	=	=	IC50	nM	11000.0	IC50	uM	11.0
32	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(SC)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10600	=	=	IC50	nM	15000.0	IC50	uM	15.0
33	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10440	=	=	IC50	nM	13000.0	IC50	uM	13.0
34	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10663	=	=	IC50	nM	18000.0	IC50	uM	18.0
35	Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10441	=	=	IC50	nM	10000.0	IC50	uM	10.0
36	Inhibition of heterologously expressed human Cytochrome P450 3A at 100 uM	CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2	J. Med. Chem.	1997.0	CHEMBL276140	>	>	IC50	nM	100000.0	IC50	uM	100.0
37	Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM	Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1	J. Med. Chem.	1997.0	CHEMBL297784	>	>	IC50	nM	100000.0	IC50	uM	100.0
38	Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM	Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	1997.0	CHEMBL14563	>	>	IC50	nM	100000.0	IC50	uM	100.0
39	Inhibitory activity against cytochrome P450 3A4	COC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL27257	=	=	IC50	nM	2530.0	IC50	uM	2.53
40	Inhibition of cytochrome P450 3A4 of human liver microsomes	Cn1c2cc(Cl)ncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26686			IC50	nM		IC50	uM	
41	Inhibitory activity against cytochrome P450 3A4	Cn1c2cccnc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL282365	=	=	IC50	nM	19300.0	IC50	uM	19.3
42	Inhibition of cytochrome P450 3A4 of human liver microsomes	COc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL431503			IC50	nM		IC50	uM	
43	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1	J. Med. Chem.	2004.0	CHEMBL29743	=	=	IC50	nM	5780.0	IC50	uM	5.78
44	Inhibitory activity against cytochrome P450 3A4	CN(C)c1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL26150	=	=	IC50	nM	26410.0	IC50	uM	26.41
45	Inhibition of cytochrome P450 3A4 of human liver microsomes	CC(=O)Nc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL287181			IC50	nM		IC50	uM	
46	Inhibition of cytochrome P450 3A4 of human liver microsomes	Fc1ccc(CCN2CCN(c3[nH]cnc4c5c(Cl)cccc5nc3-4)CC2)cc1F	J. Med. Chem.	2004.0	CHEMBL28584			IC50	nM		IC50	uM	
47	Inhibitory activity against cytochrome P450 3A4	CC(C)Oc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL283253	>	>	IC50	nM	100000.0	IC50	uM	100.0
48	Inhibition of Cytochrome P450 3A4 with testosterone	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	2500.0	IC50	uM	2.5
49	Inhibition of Cytochrome P450 3A4 with midazolam (4-OH)	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	1000.0	IC50	uM	1.0
50	Inhibition of Cytochrome P450 3A4 with midazolam (1'-OH)	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	1100.0	IC50	uM	1.1
51	Inhibition of Cytochrome P450 3A4 with nifedipine	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	4100.0	IC50	uM	4.1
52	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1	J. Med. Chem.	2004.0	CHEMBL283693	>	>	IC50	nM	100000.0	IC50	uM	100.0
53	Inhibition of cytochrome P450 3A4 of human liver microsomes	Cc1nc2c(c(C(N)=O)c1[N+](=O)[O-])c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL26779			IC50	nM		IC50	uM	
54	Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	OC1N=C(c2ccccc2F)c2cc(Cl)ccc2-n2cncc21	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL121550	=	=	IC50	nM	10000.0	IC50	uM	10.0
55	Inhibitory activity against cytochrome P450 3A4	NC(=O)c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL283438	=	=	IC50	nM	1360.0	IC50	uM	1.36
56	Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL386630	=	=	IC50	nM	10000.0	IC50	uM	10.0
57	Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc([N+](=O)[O-])c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL30052	>	>	IC50	nM	100000.0	IC50	uM	100.0
58	Inhibitory activity against cytochrome P450 3A4	COc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL284676	>	>	IC50	nM	100000.0	IC50	uM	100.0
59	Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(Cl)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL27415	=	=	IC50	nM	9440.0	IC50	uM	9.44
60	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cc([N+](=O)[O-])c2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1	J. Med. Chem.	2004.0	CHEMBL284024	=	=	IC50	nM	42260.0	IC50	uM	42.26
61	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL25867	=	=	IC50	nM	12580.0	IC50	uM	12.58
62	Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26678	=	=	IC50	nM	260.0	IC50	uM	0.26
63	Inhibitory activity against cytochrome P450 3A4	CCOC(=O)Cn1c2ccc([N+](=O)[O-])cc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26039	=	=	IC50	nM	15000.0	IC50	uM	15.0
64	Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(Cl)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL418382	=	=	IC50	nM	20030.0	IC50	uM	20.03
65	Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(N3CCOCC3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL28629	=	=	IC50	nM	20800.0	IC50	uM	20.8
66	Inhibitory activity against cytochrome P450 3A4	Cn1c2nccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL25903	=	=	IC50	nM	1230.0	IC50	uM	1.23
67	Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL439727	=	=	IC50	nM	31310.0	IC50	uM	31.31
68	Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(NCc3ccccn3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL281326	=	=	IC50	nM	18480.0	IC50	uM	18.48
69	Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL1188	=	=	IC50	nM	10000.0	IC50	uM	10.0
70	Inhibitory activity against cytochrome P450 3A4	CNc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL25731	=	=	IC50	nM	53810.0	IC50	uM	53.81
71	Inhibition of cytochrome P450 3A4 of human liver microsomes	CCOC(=O)n1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL27536			IC50	nM		IC50	uM	
72	Inhibitory activity against cytochrome P450 3A4	Cc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL27007	>	>	IC50	nM	100000.0	IC50	uM	100.0
73	Inhibitory activity against cytochrome P450 3A4	NC(=O)c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1	J. Med. Chem.	2004.0	CHEMBL283255	=	=	IC50	nM	200.0	IC50	uM	0.2
74	Inhibitory activity against cytochrome P450 3A4	Cc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL26369	=	=	IC50	nM	9250.0	IC50	uM	9.25
75	Inhibitory activity against cytochrome P450 3A4	Cc1cc(C#N)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1	J. Med. Chem.	2004.0	CHEMBL28168	>	>	IC50	nM	100000.0	IC50	uM	100.0
76	Inhibitory activity against cytochrome P450 3A4	COCc1nc(N2CCN(CCc3ccc(F)c(F)c3)CC2)c2c(n1)c1c(Cl)nccc1n2C	J. Med. Chem.	2004.0	CHEMBL25905	=	=	IC50	nM	36820.0	IC50	uM	36.82
77	Inhibitory activity against cytochrome P450 3A4	COc1ccc2c(c1)[nH]c1c(N3CCN(CCc4ccc(F)c(F)c4)CC3)ncnc12	J. Med. Chem.	2004.0	CHEMBL281284	=	=	IC50	nM	1530.0	IC50	uM	1.53
78	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1cccnc1	J. Med. Chem.	2004.0	CHEMBL29631	=	=	IC50	nM	8100.0	IC50	uM	8.1
79	Inhibition of cytochrome P450 3A4 of human liver microsomes	Fc1ccc(CCN2CCN(c3ncnc4c5cnccc5n(Cc5ccccc5)c34)CC2)cc1F	J. Med. Chem.	2004.0	CHEMBL26081			IC50	nM		IC50	uM	
80	Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL193	=	=	IC50	nM	10000.0	IC50	uM	10.0
81	Inhibition of cytochrome P450 3A4 of human liver microsomes	N#Cc1cccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c12	J. Med. Chem.	2004.0	CHEMBL430925			IC50	nM		IC50	uM	
82	Inhibition of cytochrome P450 3A4 of human liver microsomes	O=S(=O)(c1ccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c2c1)N1CCCC1	J. Med. Chem.	2004.0	CHEMBL27128			IC50	nM		IC50	uM	
83	Inhibition of cytochrome P450 3A4 of human liver microsomes	Cn1c2nccc(C#N)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL286948			IC50	nM		IC50	uM	
84	Inhibitory activity against cytochrome P450 3A4	Cn1c2nccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL281496	=	=	IC50	nM	33690.0	IC50	uM	33.69
85	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL282156	=	=	IC50	nM	6620.0	IC50	uM	6.62
86	Inhibitory activity against cytochrome P450 3A4	COc1ccc2c3nc[nH]c(N4CCN(CCc5ccc(F)c(F)c5)CC4)c-3nc2c1[N+](=O)[O-]	J. Med. Chem.	2004.0	CHEMBL281743	=	=	IC50	nM	1790.0	IC50	uM	1.79
87	Inhibition of cytochrome P450 3A4 of human liver microsomes	COc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1[N+](=O)[O-]	J. Med. Chem.	2004.0	CHEMBL27191			IC50	nM		IC50	uM	
88	Inhibitory activity against cytochrome P450 3A4	Cc1cc(C(N)=O)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1	J. Med. Chem.	2004.0	CHEMBL287400	=	=	IC50	nM	210.0	IC50	uM	0.21
89	Inhibition of cytochrome P450 3A4 of human liver microsomes	NC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL286963			IC50	nM		IC50	uM	
90	Inhibition of cytochrome P450 3A4 of human liver microsomes	O=C(Nc1ccncc1)c1cccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c12	J. Med. Chem.	2004.0	CHEMBL281235			IC50	nM		IC50	uM	
91	Inhibitory activity against cytochrome P450 3A4	Cn1c2ccncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL430724	=	=	IC50	nM	17850.0	IC50	uM	17.85
92	Inhibition of cytochrome P450 3A4 of human liver microsomes	Nc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL25972			IC50	nM		IC50	uM	
93	Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2CCc1ccccc1	J. Med. Chem.	2004.0	CHEMBL285343	=	=	IC50	nM	11790.0	IC50	uM	11.79
94	Binding affinity for progesterone 6-beta-hydroxylase of hepatic microsomes	Nc1ccc(SC[C@H]2CO[C@@](CCc3ccc(Cl)cc3)(Cn3ccnc3)O2)cc1	J. Med. Chem.	1993.0	CHEMBL305220	=	=	Ki	nM	33.0	Ki	nM	33.0
95	Binding affinity for progesterone 6-beta-hydroxylase of hepatic microsomes	Nc1ccc(SC[C@@H]2CO[C@](CCc3ccc(Cl)cc3)(Cn3ccnc3)O2)cc1	J. Med. Chem.	1993.0	CHEMBL70611	=	=	Ki	nM	28.0	Ki	nM	28.0
96	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2ccnc2)cc1	J. Med. Chem.	2003.0	CHEMBL112532	=	=	IC50	nM	348.0	IC50	nM	348.0
97	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cccnc2)cc1	J. Med. Chem.	2003.0	CHEMBL151646	=	=	IC50	nM	29300.0	IC50	nM	29300.0
98	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc(C)no2)cc1	J. Med. Chem.	2003.0	CHEMBL422858	>	>	IC50	nM	100000.0	IC50	nM	100000.0
99	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2[nH]ncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL434317	=	=	IC50	nM	26800.0	IC50	nM	26800.0
100	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL150681	>	>	IC50	nM	100000.0	IC50	nM	100000.0
101	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1cccc(-c2ccno2)c1	J. Med. Chem.	2003.0	CHEMBL151449	>	>	IC50	nM	100000.0	IC50	nM	100000.0
102	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cncn2)cc1	J. Med. Chem.	2003.0	CHEMBL345544	>	>	IC50	nM	100000.0	IC50	nM	100000.0
103	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[nH]c2)cc1	J. Med. Chem.	2003.0	CHEMBL359116	=	=	IC50	nM	7520.0	IC50	nM	7520.0
104	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[n+](C)[nH]2)cc1	J. Med. Chem.	2003.0	CHEMBL347303	>	>	IC50	nM	100000.0	IC50	nM	100000.0
105	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccncc2)cc1	J. Med. Chem.	2003.0	CHEMBL151280	=	=	IC50	nM	51100.0	IC50	nM	51100.0
106	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccccc1-c1ccno1	J. Med. Chem.	2003.0	CHEMBL150799	>	>	IC50	nM	100000.0	IC50	nM	100000.0
107	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2ccnc2C)cc1	J. Med. Chem.	2003.0	CHEMBL358214	=	=	IC50	nM	50900.0	IC50	nM	50900.0
108	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccnn2C)cc1	J. Med. Chem.	2003.0	CHEMBL151037	=	=	IC50	nM	93800.0	IC50	nM	93800.0
109	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(N/C=N\O)cc1	J. Med. Chem.	2003.0	CHEMBL348263	>	>	IC50	nM	100000.0	IC50	nM	100000.0
110	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cnccn2)cc1	J. Med. Chem.	2003.0	CHEMBL150146	>	>	IC50	nM	100000.0	IC50	nM	100000.0
111	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccns2)cc1	J. Med. Chem.	2003.0	CHEMBL151354	=	=	IC50	nM	22900.0	IC50	nM	22900.0
112	In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccccc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL341089	=	=	IC50	nM	400.0	IC50	uM	0.4
113	In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3cccc(Cl)c3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL276081	=	=	IC50	nM	80.0	IC50	uM	0.08
114	Inhibition of Cytochrome P450 3A4; not tested	COc1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL347302			IC50	nM		IC50	nM	
115	In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(F)c(F)c3F)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL334379	=	=	IC50	nM	50.0	IC50	uM	0.05
116	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cnco2)cc1	J. Med. Chem.	2003.0	CHEMBL358216	=	=	IC50	nM	58100.0	IC50	nM	58100.0
117	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccon2)cc1	J. Med. Chem.	2003.0	CHEMBL433737	>	>	IC50	nM	100000.0	IC50	nM	100000.0
118	Inhibition of Cytochrome P450 3A4; not tested	CCCCOc1ccc(-c2cocn2)cc1	J. Med. Chem.	2003.0	CHEMBL151096			IC50	nM		IC50	nM	
119	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2nn[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL150278	>	>	IC50	nM	100000.0	IC50	nM	100000.0
120	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccncn2)cc1	J. Med. Chem.	2003.0	CHEMBL151974	>	>	IC50	nM	100000.0	IC50	nM	100000.0
121	In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(Cl)cc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL127589	=	=	IC50	nM	50.0	IC50	uM	0.05
122	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL149750	=	=	IC50	nM	70600.0	IC50	nM	70600.0
123	Inhibition of Cytochrome P450 3A4; not tested	c1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL81948			IC50	nM		IC50	nM	
124	In vitro inhibition of Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
125	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL358880	=	=	IC50	nM	116.0	IC50	nM	116.0
126	Concentration required to inhibit cytochrome P450 3A4.	CCCCc1ccc(/N=C/NO)c(C)c1	J. Med. Chem.	2003.0	CHEMBL267865	=	=	IC50	nM	65400.0	IC50	nM	65400.0
127	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc(C)[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL356594	>	>	IC50	nM	100000.0	IC50	nM	100000.0
128	In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL444533	=	=	IC50	nM	430.0	IC50	uM	0.43
129	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccccn2)cc1	J. Med. Chem.	2003.0	CHEMBL150653	>	>	IC50	nM	100000.0	IC50	nM	100000.0
130	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2c[nH]cn2)cc1	J. Med. Chem.	2003.0	CHEMBL151170	=	=	IC50	nM	883.0	IC50	nM	883.0
131	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ncc[nH]2)cc1	J. Med. Chem.	2003.0	CHEMBL150999	=	=	IC50	nM	44300.0	IC50	nM	44300.0
132	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2oncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL151038	>	>	IC50	nM	100000.0	IC50	nM	100000.0
133	Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cnc(C)c2)cc1	J. Med. Chem.	2003.0	CHEMBL151207	=	=	IC50	nM	9170.0	IC50	nM	9170.0
134	Inhibition of human Cytochrome P450 3A4	O=C1c2ccccc2CCCN1CCN1CCC(n2c(O)nc3cc(F)ccc32)CC1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL273921	>	>	IC50	nM	100000.0	IC50	uM	100.0
135	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL163	=	=	IC50	nM	250.0	IC50	uM	0.25
136	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	COc1ccc(CN2CCN(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)OCc3csc(C)n3)C(C)C)[C@H](C(=O)NC(C)(C)C)C2)cc1OC	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL442398	=	=	IC50	nM	120000.0	IC50	uM	120.0
137	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CCc1ncc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc(OC)c(OC)c3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)s1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL331186	=	=	IC50	nM	35000.0	IC50	uM	35.0
138	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccnc3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL324033	=	=	IC50	nM	2300.0	IC50	uM	2.3
139	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc4c(c3)OCO4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL116772	=	=	IC50	nM	9600.0	IC50	uM	9.6
140	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cncs3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL263179	=	=	IC50	nM	15000.0	IC50	uM	15.0
141	Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccc4c3COC4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL3706711	=	=	IC50	nM	12000.0	IC50	uM	12.0
142	Inhibition of cytochrome P450 3A4	CC(C)(c1cc2cnccc2o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL79236			IC50	nM	30.0	IC50	uM	0.03
143	Inhibition of cytochrome P450 3A4	CN(C)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87355	=	=	IC50	nM	17000.0	IC50	uM	17.0
144	Inhibition of cytochrome P450 3A4	CCN(CC)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL315766	=	=	IC50	nM	2000.0	IC50	uM	2.0
145	Inhibition of cytochrome P450 3A4	CN(C)C(=O)CN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL85080	>	>	IC50	nM	500.0	IC50	uM	0.5
146	Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CC(=O)O)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL89750	=	=	IC50	nM	31000.0	IC50	uM	31.0
147	Inhibition of cytochrome P450 3A4	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL10921	=	=	IC50	nM	10000.0	IC50	uM	10.0
148	Inhibition of cytochrome P450 3A4	COc1ncc(Cc2cn(CC(=O)N(CC(=O)N(C)C)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL84894	<	<	IC50	nM	500.0	IC50	uM	0.5
149	Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87071	=	=	IC50	nM	15000.0	IC50	uM	15.0
150	Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCO)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL276856	=	=	IC50	nM	19000.0	IC50	uM	19.0
151	Inhibition of cytochrome P450 3A4	CN(C)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL415274	=	=	IC50	nM	8000.0	IC50	uM	8.0
152	Inhibition of cytochrome P450 3A4	CN1CCN(CCCN(Cc2ccc(-c3ccc(Cl)cc3)cc2)C(=O)Cn2cc(Cc3cnn(C)c3)c(=O)nc2SCc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL327705	=	=	IC50	nM	10000.0	IC50	uM	10.0
153	Inhibition of cytochrome P450 3A4	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL86932	=	=	IC50	nM	5000.0	IC50	uM	5.0
154	Inhibition of cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(C(C)(C)c2cc3cnccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL312238	=	=	IC50	nM	310.0	IC50	uM	0.31
155	Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN3CCCCC3)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL314768	=	=	IC50	nM	10000.0	IC50	uM	10.0
156	Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN3CCCC3)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL405981	=	=	IC50	nM	6000.0	IC50	uM	6.0
157	Inhibition of cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
158	Inhibition of cytochrome P450 3A4	CN(C)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87792	=	=	IC50	nM	30000.0	IC50	uM	30.0
159	Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706622	=	=	IC50	nM	40.0	IC50	uM	0.04
160	Inhibition of human liver microsome Cytochrome P450 3A4	COc1cncc(-c2cnc(C(C)(C)N3CCN(C[C@@H](O)C[C@@H](Cc4ccccc4)C(=O)N[C@H]4c5ccccc5OC[C@H]4O)[C@H](C(=O)NCC(F)(F)F)C3)o2)c1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706615	=	=	IC50	nM	40.0	IC50	uM	0.04
161	Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
162	Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706621	=	=	IC50	nM	5000.0	IC50	uM	5.0
163	Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706613	=	=	IC50	nM	110.0	IC50	uM	0.11
164	Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(C)c(N/C=N/O)c1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL319862	=	=	IC50	nM	94000.0	IC50	uM	94.0
165	Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(C)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL330425	>	>	IC50	nM	50000.0	IC50	uM	50.0
166	Inhibition of recombinant human Cytochrome P450 3A4	CC(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101180	>	>	IC50	nM	100000.0	IC50	uM	100.0
167	Inhibition of recombinant human Cytochrome P450 3A4	Cc1ccccc1/N=C/NO	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103651	>	>	IC50	nM	100000.0	IC50	uM	100.0
168	Inhibition of human cytochrome P450 3A4	Cc1cc(C)cc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1	J. Med. Chem.	2004.0	CHEMBL96347	=	=	IC50	nM	14000.0	IC50	uM	14.0
169	Inhibition of recombinant human Cytochrome P450 3A4	CCCCCCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL321051	=	=	IC50	nM	50000.0	IC50	uM	50.0
170	Inhibition of recombinant human Cytochrome P450 3A4	Cc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103320	>	>	IC50	nM	100000.0	IC50	uM	100.0
171	Inhibition of recombinant human Cytochrome P450 3A4	Nn1nnc2ccccc21	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101168	=	=	IC50	nM	450.0	IC50	uM	0.45
172	Inhibition of human cytochrome P450 3A4	CCCCc1cccc([C@]2([C@H](Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1	J. Med. Chem.	2004.0	CHEMBL330354	=	=	IC50	nM	5000.0	IC50	uM	5.0
173	Inhibition of recombinant human Cytochrome P450 3A4	CCC(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL100899	>	>	IC50	nM	100000.0	IC50	uM	100.0
174	Inhibition of recombinant human Cytochrome P450 3A4	CC(C)(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103163	>	>	IC50	nM	100000.0	IC50	uM	100.0
175	Inhibition of recombinant human Cytochrome P450 3A4	CCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101296	>	>	IC50	nM	100000.0	IC50	uM	100.0
176	Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103313	=	=	IC50	nM	65000.0	IC50	uM	65.0
177	Inhibition of recombinant human Cytochrome P450 3A4	ON/C=N/c1ccc(Cc2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL445120	>	>	IC50	nM	100000.0	IC50	uM	100.0
178	Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(/N=C/NO)c(C)c1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL267865	=	=	IC50	nM	71000.0	IC50	uM	71.0
179	Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccccc1/N=C/NO	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL100917	=	=	IC50	nM	51000.0	IC50	uM	51.0
180	Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL329477	=	=	IC50	nM	41000.0	IC50	uM	41.0
181	Inhibition of recombinant human Cytochrome P450 3A4	CCCOc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL317798	>	>	IC50	nM	100000.0	IC50	uM	100.0
182	Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL319754	=	=	IC50	nM	7000.0	IC50	uM	7.0
183	Inhibition of cytochrome P450 3A4	c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL262968	=	=	IC50	nM	417.0	IC50	nM	417.0
184	Inhibition of cytochrome P450 3A4	CCOC(=O)N1CCN(CCOc2ccc(-n3ccnc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL114555	>	>	IC50	nM	100000.0	IC50	nM	100000.0
185	Inhibition of cytochrome P450 3A4	c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113018	=	=	IC50	nM	5670.0	IC50	nM	5670.0
186	Inhibition of cytochrome P450 3A4	CN(C)CCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL325429	>	>	IC50	nM	100000.0	IC50	nM	100000.0
187	Inhibition of cytochrome P450 3A4	c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113227	=	=	IC50	nM	344.0	IC50	nM	344.0
188	Inhibition of cytochrome P450 3A4	CN(C)CCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL114297	=	=	IC50	nM	39000.0	IC50	nM	39000.0
189	Inhibition of cytochrome P450 3A4	c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL115876	=	=	IC50	nM	252.0	IC50	nM	252.0
190	Inhibition of cytochrome P450 3A4	CCCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL112532	=	=	IC50	nM	348.0	IC50	nM	348.0
191	Inhibition of cytochrome P450 3A4	CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113275	=	=	IC50	nM	4460.0	IC50	nM	4460.0
192	Inhibition of cytochrome P450 3A4	c1ccc(COc2ccc(-n3ccnc3)cc2)nc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL112592	=	=	IC50	nM	630.0	IC50	nM	630.0
193	Inhibition of cytochrome P450 3A4	CCCCCCOc1ccc(-n2ccnc2)cn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL320105	=	=	IC50	nM	76900.0	IC50	nM	76900.0
194	Inhibition of heterologously expressed human cytochrome P450 3A4	CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2	J. Med. Chem.	2000.0	CHEMBL276140	>	>	IC50	nM	100000.0	IC50	uM	100.0
195	Inhibition of heterologously expressed human cytochrome P450 3A4	Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	2000.0	CHEMBL14563	>	>	IC50	nM	100000.0	IC50	uM	100.0
196	Inhibition of heterologously expressed human cytochrome P450 3A4	Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	2000.0	CHEMBL14460	>	>	IC50	nM	100000.0	IC50	uM	100.0
197	Inhibition of heterologously expressed human cytochrome P450 3A4	COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2	J. Med. Chem.	2000.0	CHEMBL14276	=	=	IC50	nM	9000.0	IC50	uM	9.0
198	Inhibition of human liver microsome cytochrome P450 3A4	COCCN(C)c1nc(N)c(CN)c(-c2ccc(Cl)cc2Cl)n1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL324777	=	=	IC50	nM	30000.0	IC50	uM	30.0
199	Inhibition of human liver microsome Cytochrome P3A4	NCc1c(N)nc(-c2ccccc2)nc1-c1ccc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL36020	=	=	IC50	nM	10000.0	IC50	uM	10.0
200	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL444533	=	=	IC50	nM	430.0	IC50	uM	0.43
201	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL326796	=	=	IC50	nM	1500.0	IC50	uM	1.5
202	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL114756	=	=	IC50	nM	320.0	IC50	uM	0.32
203	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL326849	=	=	IC50	nM	470.0	IC50	uM	0.47
204	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL325829	=	=	IC50	nM	2200.0	IC50	uM	2.2
205	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL419396	=	=	IC50	nM	310.0	IC50	uM	0.31
206	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL324461	=	=	IC50	nM	480.0	IC50	uM	0.48
207	Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3cccc(Cl)c3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL321814	=	=	IC50	nM	500.0	IC50	uM	0.5
208	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc(Cn2cncc2CN[C@H]2CCN(Cc3cccc(Cl)c3)C2=O)cc1	J. Med. Chem.	2002.0	CHEMBL312137	=	=	IC50	nM	1000.0	IC50	uM	1.0
209	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1cccc(c1)CN1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL502560	=	=	IC50	nM	8900.0	IC50	uM	8.9
210	Inhibition of human Cytochrome P450 3A4 by macrocycles	CN1Cc2cncn2Cc2ccc(C#N)c(c2)Oc2ccc3cccc(c3c2)N2CCC1C2=O	J. Med. Chem.	2002.0	CHEMBL312121	=	=	IC50	nM	5000.0	IC50	uM	5.0
211	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526466	=	=	IC50	nM	6600.0	IC50	uM	6.6
212	Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526466	=	=	IC50	nM	10400.0	IC50	uM	10.4
213	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526656	=	=	IC50	nM	2800.0	IC50	uM	2.8
214	Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526656	=	=	IC50	nM	14800.0	IC50	uM	14.8
215	Inhibition of recombinant human Cytochrome P450 3A4 with BFC	CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1	J. Med. Chem.	2003.0	CHEMBL355905	>	>	IC50	nM	40000.0	IC50	uM	40.0
216	Inhibition of recombinant human Cytochrome P450 3A4 with BzRes	CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1	J. Med. Chem.	2003.0	CHEMBL355905	>	>	IC50	nM	40000.0	IC50	uM	40.0
217	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL80702	=	=	IC50	nM	6000.0	IC50	uM	6.0
218	Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL80702	=	=	IC50	nM	600.0	IC50	uM	0.6
219	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL53821	=	=	IC50	nM	8000.0	IC50	uM	8.0
220	Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL53821	=	=	IC50	nM	5000.0	IC50	uM	5.0
221	Inhibition of dog Cytochrome P450 3A by macrocycles	CC1c2ccc(C#N)c(c2)Oc2cccc(c2)CN2CCC(NCc3cncn31)C2=O	J. Med. Chem.	2002.0	CHEMBL78742	=	=	IC50	nM	6100.0	IC50	uM	6.1
222	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc(Br)c(c1)CN1CCC(NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL311561	=	=	IC50	nM	6100.0	IC50	uM	6.1
223	Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1cccc(c1)-c1ccccc1N1CCC(NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL310586	<	<	IC50	nM	50.0	IC50	uM	0.05
224	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL421841	=	=	IC50	nM	1600.0	IC50	uM	1.6
225	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL421841	=	=	IC50	nM	10000.0	IC50	uM	10.0
226	Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL26485	=	=	IC50	nM	30150.0	IC50	uM	30.15
227	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL164261	=	=	IC50	nM	2300.0	IC50	uM	2.3
228	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL164261	=	=	IC50	nM	8100.0	IC50	uM	8.1
229	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL162383	=	=	IC50	nM	2500.0	IC50	uM	2.5
230	Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL162383	=	=	IC50	nM	10000.0	IC50	uM	10.0
231	Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	COc1cccc(CNC(=O)c2c3n(c4c(N5CCN(CCc6ccc(F)c(F)c6)CC5)ncnc24)CCCC3)c1OC	J. Med. Chem.	2004.0	CHEMBL27102	=	=	IC50	nM	2440.0	IC50	uM	2.44
232	Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	NC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL26599	=	=	IC50	nM	45800.0	IC50	uM	45.8
233	Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL280981	=	=	IC50	nM	9730.0	IC50	uM	9.73
234	Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	CCNC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL286272	>	>	IC50	nM	100000.0	IC50	uM	100.0
235	Inhibition of human cytochrome P450 3A4	COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2003.0	CHEMBL296419	=	=	IC50	nM	3300.0	IC50	uM	3.3
236	Inhibition of human cytochrome P450 3A4	COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2	J. Med. Chem.	2003.0	CHEMBL107	>	>	IC50	nM	50000.0	IC50	uM	50.0
237	Inhibition of human cytochrome P450 3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	uM	0.05
238	Inhibition of human cytochrome P450 3A4	COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O	J. Med. Chem.	2003.0	CHEMBL44657	>	>	IC50	nM	50000.0	IC50	uM	50.0
239	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	16.0	IC50	uM	0.016
240	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	13.0	IC50	uM	0.013
241	Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	17.0	IC50	uM	0.017
242	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	22.0	IC50	uM	0.022
243	Inhibition of human cytochrome P450 3A4	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J. Med. Chem.	2003.0	CHEMBL6966	=	=	IC50	nM	4700.0	IC50	uM	4.7
244	Inhibition of human cytochrome P450 3A4	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	J. Med. Chem.	2003.0	CHEMBL1484	=	=	IC50	nM	420.0	IC50	uM	0.42
245	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin]	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	27000.0	IC50	uM	27.0
246	Inhibition of recombinant human Cytochrome P450 3A4 with Benzoylresorufin	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	76000.0	IC50	uM	76.0
247	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	96000.0	IC50	uM	96.0
248	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	62000.0	IC50	uM	62.0
249	Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	33000.0	IC50	uM	33.0
250	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	22000.0	IC50	uM	22.0
251	Inhibition of human cytochrome P450 3A4	CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O	J. Med. Chem.	2003.0	CHEMBL294616	>	>	IC50	nM	50000.0	IC50	uM	50.0
252	Inhibition of human cytochrome P450 3A4	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	J. Med. Chem.	2003.0	CHEMBL584	=	=	IC50	nM	550.0	IC50	uM	0.55
253	Inhibition of human cytochrome P450 3A4	CN/C(=N/CCSCc1nc[nH]c1C)NC#N	J. Med. Chem.	2003.0	CHEMBL30	=	=	IC50	nM	15000.0	IC50	uM	15.0
254	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	18000.0	IC50	uM	18.0
255	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	21000.0	IC50	uM	21.0
256	Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	19000.0	IC50	uM	19.0
257	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	19000.0	IC50	uM	19.0
258	Inhibition of human cytochrome P450 3A4	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO	J. Med. Chem.	2003.0	CHEMBL389621	>	>	IC50	nM	50000.0	IC50	uM	50.0
259	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	61000.0	IC50	uM	61.0
260	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	33000.0	IC50	uM	33.0
261	Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	20000.0	IC50	uM	20.0
262	Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	16000.0	IC50	uM	16.0
263	Inhibition of human cytochrome P450 3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2003.0	CHEMBL45816	=	=	IC50	nM	130.0	IC50	uM	0.13
264	Inhibition of human cytochrome P450 3A4	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	J. Med. Chem.	2003.0	CHEMBL655	=	=	IC50	nM	8100.0	IC50	uM	8.1
265	Inhibition of human cytochrome P450 3A4	CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	J. Med. Chem.	2003.0	CHEMBL17157	=	=	IC50	nM	320.0	IC50	uM	0.32
266	Inhibition of human cytochrome P450 3A4	CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5	J. Med. Chem.	2003.0	CHEMBL70	>	>	IC50	nM	50000.0	IC50	uM	50.0
267	Inhibition of human cytochrome P450 3A4	C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O	J. Med. Chem.	2003.0	CHEMBL1751	>	>	IC50	nM	50000.0	IC50	uM	50.0
268	Inhibition of human cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	J. Med. Chem.	2003.0	CHEMBL114	=	=	IC50	nM	1500.0	IC50	uM	1.5
269	Inhibition of human cytochrome P450 3A4	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	J. Med. Chem.	2003.0	CHEMBL104	=	=	IC50	nM	20.0	IC50	uM	0.02
270	Inhibition of human cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2003.0	CHEMBL163	=	=	IC50	nM	30.0	IC50	uM	0.03
271	Inhibition of human cytochrome P450 3A4	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2003.0	CHEMBL64391	=	=	IC50	nM	700.0	IC50	uM	0.7
272	Inhibition of human cytochrome P450 3A4	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O	J. Med. Chem.	2003.0	CHEMBL1200633	>	>	IC50	nM	50000.0	IC50	uM	50.0
273	Inhibition of human cytochrome P450 3A4	O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL1423	=	=	IC50	nM	9700.0	IC50	uM	9.7
274	Inhibition of human cytochrome P450 3A4	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	J. Med. Chem.	2003.0	CHEMBL384467	>	>	IC50	nM	50000.0	IC50	uM	50.0
275	Inhibition of human cytochrome P450 3A4	C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	J. Med. Chem.	2003.0	CHEMBL1294	>	>	IC50	nM	50000.0	IC50	uM	50.0
276	Inhibition of human cytochrome P450 3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	J. Med. Chem.	2003.0	CHEMBL91	=	=	IC50	nM	180.0	IC50	uM	0.18
277	Inhibition of human cytochrome P450 3A4	CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1	J. Med. Chem.	2003.0	CHEMBL1790041	>	>	IC50	nM	50000.0	IC50	uM	50.0
278	Inhibition of human cytochrome P450 3A4	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	J. Med. Chem.	2003.0	CHEMBL160	=	=	IC50	nM	6500.0	IC50	uM	6.5
279	Inhibition of human cytochrome P450 3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2003.0	CHEMBL532	=	=	IC50	nM	33000.0	IC50	uM	33.0
280	Inhibition of human cytochrome P450 3A4	CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1	J. Med. Chem.	2003.0	CHEMBL159	=	=	IC50	nM	26000.0	IC50	uM	26.0
281	Inhibition of human cytochrome P450 3A4	C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL2111784	>	>	IC50	nM	2000.0	IC50	uM	2.0
282	Inhibition of human cytochrome P450 3A4	COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL419409	>	>	IC50	nM	2000.0	IC50	uM	2.0
283	Inhibition of human cytochrome P450 3A4	CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL120185	>	>	IC50	nM	2000.0	IC50	uM	2.0
284	Inhibition of human cytochrome P450 3A4	OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL121405	>	>	IC50	nM	2000.0	IC50	uM	2.0
285	Inhibition of human cytochrome P450 3A4	COc1cc2[nH]c(C)nc2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL120067	>	>	IC50	nM	2000.0	IC50	uM	2.0
286	Inhibition of cytochrome P450 CYP3A4 in human liver microsomes	Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL416146	>	>	IC50	nM	50000.0	IC50	uM	50.0
287	Inhibition of human cytochrome P450 3A4	CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL118258	>	>	IC50	nM	2000.0	IC50	uM	2.0
288	Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL157101	=	=	IC50	nM	786.0	IC50	uM	0.786
289	Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL328863	=	=	IC50	nM	897.0	IC50	uM	0.897
290	Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL319160	=	=	IC50	nM	570.0	IC50	uM	0.57
291	Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL157101	=	=	IC50	nM	1260.0	IC50	uM	1.26
292	Inhibitory concentration value against human cytochrome P-450 3A4	CNc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL179529	=	=	IC50	nM	6300.0	IC50	uM	6.3
293	Inhibitory concentration value against human cytochrome P-450 3A4	Cn1cnc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL360999	=	=	IC50	nM	262000.0	IC50	uM	262.0
294	Inhibitory concentration value against human cytochrome P-450 3A4	CCn1cnc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL361364	=	=	IC50	nM	79200.0	IC50	uM	79.2
295	Inhibitory concentration value against human cytochrome P-450 3A4	c1ccc(Cn2cnc(-c3cccnc3)c2)cc1	J. Med. Chem.	2005.0	CHEMBL178780	=	=	IC50	nM	75100.0	IC50	uM	75.1
296	Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cn(-c2cccnc2)cn1	J. Med. Chem.	2005.0	CHEMBL178781	=	=	IC50	nM	109000.0	IC50	uM	109.0
297	Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2cccs2)c1	J. Med. Chem.	2005.0	CHEMBL179618	=	=	IC50	nM	57000.0	IC50	uM	57.0
298	Inhibitory concentration value against human cytochrome P-450 3A4	Cc1ccsc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179669	=	=	IC50	nM	6000.0	IC50	uM	6.0
299	Inhibitory concentration value against human cytochrome P-450 3A4	O=Cc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL179398	=	=	IC50	nM	23900.0	IC50	uM	23.9
300	Inhibitory concentration value against human cytochrome P-450 3A4	CC(=O)c1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL362702	=	=	IC50	nM	27000.0	IC50	uM	27.0
301	Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2ccsc2)c1	J. Med. Chem.	2005.0	CHEMBL361153	=	=	IC50	nM	56900.0	IC50	uM	56.9
302	Inhibitory concentration value against human cytochrome P-450 3A4	Fc1ccc(-c2ccsc2)cn1	J. Med. Chem.	2005.0	CHEMBL179005	=	=	IC50	nM	114000.0	IC50	uM	114.0
303	Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cscc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179704	=	=	IC50	nM	80900.0	IC50	uM	80.9
304	Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cscc1-c1ccc(F)nc1	J. Med. Chem.	2005.0	CHEMBL425519	=	=	IC50	nM	39100.0	IC50	uM	39.1
305	Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL179763	=	=	IC50	nM	64700.0	IC50	uM	64.7
306	Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2c[nH]cn2)c1	J. Med. Chem.	2005.0	CHEMBL178516	=	=	IC50	nM	139900.0	IC50	uM	139.9
307	Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL178534	=	=	IC50	nM	13000.0	IC50	uM	13.0
308	Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178547	>	>	IC50	nM	400000.0	IC50	uM	400.0
309	Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C\c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178330	>	>	IC50	nM	400000.0	IC50	uM	400.0
310	Inhibitory concentration value against human cytochrome P-450 3A4	NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL359657	=	=	IC50	nM	58700.0	IC50	uM	58.7
311	Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1	J. Med. Chem.	2005.0	CHEMBL178711	>	>	IC50	nM	400000.0	IC50	uM	400.0
312	Inhibitory concentration value against human cytochrome P-450 3A4	NCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178090	=	=	IC50	nM	47100.0	IC50	uM	47.1
313	Inhibitory concentration value against human cytochrome P-450 3A4	C[n+]1c[nH]cc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179399	=	=	IC50	nM	262000.0	IC50	uM	262.0
314	Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)o1.O/N=C\c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL1795039	=	=	IC50	nM	51900.0	IC50	uM	51.9
315	Inhibitory concentration value against human cytochrome P-450 3A4	N=Cc1ccc(-c2cccnc2)s1.N=Cc1ccc(-c2cccnc2)s1.NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL178681	=	=	IC50	nM	77500.0	IC50	uM	77.5
316	Inhibitory concentration value against human cytochrome P-450 3A4	Cc1nccn1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL368883	=	=	IC50	nM	152000.0	IC50	uM	152.0
317	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181385	=	=	IC50	nM	580.0	IC50	nM	580.0
318	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181385	=	=	IC50	nM	40.0	IC50	nM	40.0
319	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccccc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180856	=	=	IC50	nM	200.0	IC50	nM	200.0
320	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)Cc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL179825	=	=	IC50	nM	4.0	IC50	nM	4.0
321	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362412	=	=	IC50	nM	220.0	IC50	nM	220.0
322	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362412	=	=	IC50	nM	140.0	IC50	nM	140.0
323	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181309	=	=	IC50	nM	210.0	IC50	nM	210.0
324	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181309	=	=	IC50	nM	160.0	IC50	nM	160.0
325	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180805	=	=	IC50	nM	700.0	IC50	nM	700.0
326	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180805	=	=	IC50	nM	220.0	IC50	nM	220.0
327	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178474	=	=	IC50	nM	40.0	IC50	nM	40.0
328	Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178474	=	=	IC50	nM	10.0	IC50	nM	10.0
329	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL359627	=	=	IC50	nM	320.0	IC50	nM	320.0
330	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL359627	=	=	IC50	nM	260.0	IC50	nM	260.0
331	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc([N+](=O)[O-])cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180592	=	=	IC50	nM	344.0	IC50	nM	344.0
332	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178873	=	=	IC50	nM	2200.0	IC50	nM	2200.0
333	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(CC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180348	=	=	IC50	nM	4.0	IC50	nM	4.0
334	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OCC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL179550	=	=	IC50	nM	750.0	IC50	nM	750.0
335	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL426789	=	=	IC50	nM	3790.0	IC50	nM	3790.0
336	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL426789	=	=	IC50	nM	1590.0	IC50	nM	1590.0
337	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL368448	=	=	IC50	nM	640.0	IC50	nM	640.0
338	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL368448	=	=	IC50	nM	1180.0	IC50	nM	1180.0
339	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360771	=	=	IC50	nM	6300.0	IC50	nM	6300.0
340	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360771	=	=	IC50	nM	1488.0	IC50	nM	1488.0
341	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(N)=O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360148	=	=	IC50	nM	481.0	IC50	nM	481.0
342	Selectivity towards cytochrome P450 3A4 enzyme activity	CNC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL182438	=	=	IC50	nM	397.0	IC50	nM	397.0
343	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)N(C)C)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360072	=	=	IC50	nM	357.0	IC50	nM	357.0
344	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(N)=O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362489	=	=	IC50	nM	1835.0	IC50	nM	1835.0
345	Selectivity towards cytochrome P450 3A4 enzyme activity	CNC(=O)C(C)(C)COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180829	=	=	IC50	nM	2010.0	IC50	nM	2010.0
346	Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)N(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL367357	=	=	IC50	nM	2032.0	IC50	nM	2032.0
347	Inhibitory concentration against Cytochrome P450 3A4	O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360033	=	=	IC50	nM	30000.0	IC50	uM	30.0
348	Inhibitory concentration against Cytochrome 450 3A4	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2	J. Med. Chem.	2005.0	CHEMBL3350935	=	=	IC50	nM	20000.0	IC50	uM	20.0
349	Inhibitory concentration against Cytochrome P450 3A4	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	J. Med. Chem.	2005.0	CHEMBL385517	=	=	IC50	nM	100000.0	IC50	uM	100.0
350	Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21	J. Med. Chem.	2005.0	CHEMBL192530	=	=	IC50	nM	24000.0	IC50	uM	24.0
351	Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21	J. Med. Chem.	2005.0	CHEMBL192530	>	>	IC50	nM	30000.0	IC50	uM	30.0
352	Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21	J. Med. Chem.	2005.0	CHEMBL189942	=	=	IC50	nM	10000.0	IC50	uM	10.0
353	Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21	J. Med. Chem.	2005.0	CHEMBL189942	>	>	IC50	nM	30000.0	IC50	uM	30.0
354	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)ncn3C)cc21	J. Med. Chem.	2005.0	CHEMBL193305			IC50	nM		IC50	uM	
355	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)cc21	J. Med. Chem.	2005.0	CHEMBL434957			IC50	nM		IC50	uM	
356	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL364572	=	=	IC50	nM	6.3	IC50	nM	6.3
357	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL192848	=	=	IC50	nM	1600.0	IC50	uM	1.6
358	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL192850	=	=	IC50	nM	800.0	IC50	uM	0.8
359	In vitro inhibitory concentration against Cytochrome P450 3A4	CCc1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL191053	=	=	IC50	nM	4400.0	IC50	uM	4.4
360	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)c1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL364925	=	=	IC50	nM	6100.0	IC50	uM	6.1
361	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL193055	=	=	IC50	nM	31800.0	IC50	uM	31.8
362	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3F)cc21.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL363831			IC50	nM		IC50	uM	
363	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)(C)c1nc(-c2ccc(F)cc2F)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL190514			IC50	nM		IC50	uM	
364	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(Cl)cccc4Cl)nc3-c3ccccc3)cc21.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL192889			IC50	nM		IC50	uM	
365	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C4CCNCC4)nc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL191113			IC50	nM		IC50	uM	
366	In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)CN1CCC(c2nc(-c3ccc4nc(N)n(S(=O)(=O)C(C)C)c4c3)c(-c3ccccc3)[nH]2)CC1	J. Med. Chem.	2005.0	CHEMBL371145	=	=	IC50	nM	5300.0	IC50	uM	5.3
367	In vitro inhibitory concentration against Cytochrome P450 3A4	CS(=O)(=O)O.CS(=O)(=O)O.Nc1nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc2n1S(=O)(=O)C1CCCC1	J. Med. Chem.	2005.0	CHEMBL193247	=	=	IC50	nM	13000.0	IC50	uM	13.0
368	In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CN(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL363852			IC50	nM		IC50	uM	
369	Inhibitory concentration against human cytochrome P450 3A4	CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F	J. Med. Chem.	2005.0	CHEMBL193306	=	=	IC50	nM	5100.0	IC50	uM	5.1
370	In vitro inhibitory concentration against human Cytochrome P450 3A4	O=C(O)Cc1ccc2oc(-c3ccc(NC(=O)/C=C/c4ccc(Br)cc4)c(F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL196875	>	>	IC50	nM	30000.0	IC50	uM	30.0
371	Inhibitory concentration against human hepatic cytochrome P450 3A4 enzyme	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2005.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	nM	50.0
372	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin	O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL222460	=	=	IC50	nM	8100.0	IC50	uM	8.1
373	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzylether	O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL222460	>	>	IC50	nM	100000.0	IC50	uM	100.0
374	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL195561	=	=	IC50	nM	13000.0	IC50	uM	13.0
375	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL195561	=	=	IC50	nM	18000.0	IC50	uM	18.0
376	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL371409	=	=	IC50	nM	26000.0	IC50	uM	26.0
377	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL371409	=	=	IC50	nM	50000.0	IC50	uM	50.0
378	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL193647	=	=	IC50	nM	30000.0	IC50	uM	30.0
379	Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL193647	=	=	IC50	nM	13000.0	IC50	uM	13.0
380	Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL231306	<	<	IC50	nM	18.0	IC50	uM	0.018
381	Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL231306	<	<	IC50	nM	18.0	IC50	uM	0.018
382	Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
383	Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL401930	=	=	IC50	nM	5300.0	IC50	uM	5.3
384	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1	J. Med. Chem.	2005.0	CHEMBL197202	=	=	IC50	nM	74000.0	IC50	uM	74.0
385	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL196945	=	=	IC50	nM	48000.0	IC50	uM	48.0
386	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1	J. Med. Chem.	2005.0	CHEMBL372751	=	=	IC50	nM	84000.0	IC50	uM	84.0
387	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1	J. Med. Chem.	2005.0	CHEMBL364738	=	=	IC50	nM	59000.0	IC50	uM	59.0
388	Inhibition of cytochrome P450 3A4 at 100 uM; activation observed	O=C(O)C1(c2ccc(-c3ccc(C4CCCCC4)cc3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL194838	=	=	IC50	nM	59000.0	IC50	uM	59.0
389	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)c(F)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL372846	=	=	IC50	nM	58000.0	IC50	uM	58.0
390	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL427548	=	=	IC50	nM	38000.0	IC50	uM	38.0
391	Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1	J. Med. Chem.	2005.0	CHEMBL197140	=	=	IC50	nM	27000.0	IC50	uM	27.0
392	Inhibitory activity against cytochrome P450 3A4 isoform	O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)N/N=C1\C(=O)Nc2ccccc21	J. Med. Chem.	2005.0	CHEMBL2113177	=	=	IC50	nM	310.0	IC50	nM	310.0
393	Inhibitory activity against CYP3A4	CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3cnccc3s2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL373039	<	<	IC50	nM	1000.0	IC50	uM	1.0
394	Inhibitory activity against CYP3A4	CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3ccncc3o2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL381630	<	<	IC50	nM	1000.0	IC50	uM	1.0
395	Inhibitory activity against CYP3A4	c1ccc(OCCCN2CCC(Cc3c[nH]cn3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL200267	>	>	IC50	nM	20000.0	IC50	uM	20.0
396	Inhibitory activity against CYP3A4	CN(C)CCCOc1ccc(CN2CCCCC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381717	>	>	IC50	nM	30000.0	IC50	uM	30.0
397	Inhibition of cytochrome P450 3A4	Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1	J. Med. Chem.	2006.0	CHEMBL203567	=	=	IC50	nM	25000.0	IC50	uM	25.0
398	Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2006.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	nM	50.0
399	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCCC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL205142	=	=	IC50	nM	1000.0	IC50	uM	1.0
400	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCNS(C)(=O)=O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206545	=	=	IC50	nM	1000.0	IC50	uM	1.0
401	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL383077	=	=	IC50	nM	17000.0	IC50	uM	17.0
402	Inhibitory activity against CYP3A4	COC[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	J. Med. Chem.	2006.0	CHEMBL205710	=	=	IC50	nM	1000.0	IC50	uM	1.0
403	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL427202	=	=	IC50	nM	4000.0	IC50	uM	4.0
404	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL377300	=	=	IC50	nM	18000.0	IC50	uM	18.0
405	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCN5CC[C@H](O)C5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL380957	=	=	IC50	nM	10000.0	IC50	uM	10.0
406	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206146	=	=	IC50	nM	3400.0	IC50	uM	3.4
407	Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCC5CCN(C)CC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206145	=	=	IC50	nM	700.0	IC50	uM	0.7
408	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205742	=	=	IC50	nM	16000.0	IC50	uM	16.0
409	Inhibition of CYP3A4	Cc1nc(Cl)c(Cl)n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205245	>	>	IC50	nM	50000.0	IC50	uM	50.0
410	Inhibition of CYP3A4	Cc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204772	>	>	IC50	nM	50000.0	IC50	uM	50.0
411	Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL426851	>	>	IC50	nM	50000.0	IC50	uM	50.0
412	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ncccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205092	=	=	IC50	nM	6700.0	IC50	uM	6.7
413	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205807	=	=	IC50	nM	1000.0	IC50	uM	1.0
414	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cncc4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207100	<	<	IC50	nM	70.0	IC50	uM	0.07
415	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cccc4ncccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204476	=	=	IC50	nM	20000.0	IC50	uM	20.0
416	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL411885	=	=	IC50	nM	82.0	IC50	nM	82.0
417	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2CSc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL380360	=	=	IC50	nM	15000.0	IC50	nM	15000.0
418	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381076	=	=	IC50	nM	25000.0	IC50	nM	25000.0
419	Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1C(=O)COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205345	=	=	IC50	nM	14.0	IC50	nM	14.0
420	Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1C(=O)CCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL193816	=	=	IC50	nM	35.0	IC50	nM	35.0
421	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCC(=O)O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL382144	=	=	IC50	nM	10000.0	IC50	nM	10000.0
422	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCCO)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL372416	=	=	IC50	nM	455.0	IC50	nM	455.0
423	Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377531	=	=	IC50	nM	12.0	IC50	nM	12.0
424	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCOC(=O)C(C)C)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208112	=	=	IC50	nM	54.0	IC50	nM	54.0
425	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCOC2=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381568	=	=	IC50	nM	3790.0	IC50	nM	3790.0
426	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCCC2=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL380866	=	=	IC50	nM	42.0	IC50	nM	42.0
427	Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN(C)C(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377512	=	=	IC50	nM	18.0	IC50	nM	18.0
428	Inhibition of CYP3A4	CCOC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205808	>	>	IC50	nM	10000.0	IC50	uM	10.0
429	Inhibition of CYP3A4	CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)C1	J. Med. Chem.	2006.0	CHEMBL205993	>	>	IC50	nM	10000.0	IC50	uM	10.0
430	Inhibition of CYP3A4	O=C(NC1CCN(Cc2cccc(Oc3ccccc3Cl)c2)CC1)C1(c2ccccc2)CCNC1	J. Med. Chem.	2006.0	CHEMBL381619	>	>	IC50	nM	10000.0	IC50	uM	10.0
431	Inhibition of CYP3A4	CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL380492	>	>	IC50	nM	10000.0	IC50	uM	10.0
432	Inhibition of CYP3A4	CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL204419	>	>	IC50	nM	10000.0	IC50	uM	10.0
433	Inhibition of CYP3A4	CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4OC)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL209350	>	>	IC50	nM	10000.0	IC50	uM	10.0
434	Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL205447	>	>	IC50	nM	10000.0	IC50	uM	10.0
435	Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccc(Cl)cc4)CCCCC3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL205457	>	>	IC50	nM	10000.0	IC50	uM	10.0
436	Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)Cc3ccccc3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL210322	>	>	IC50	nM	10000.0	IC50	uM	10.0
437	Inhibition of CYP3A4	O=C(Cc1ccccc1)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205692	>	>	IC50	nM	10000.0	IC50	uM	10.0
438	Inhibition of CYP3A4	CCC(=O)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL381354	>	>	IC50	nM	10000.0	IC50	uM	10.0
439	Inhibition of CYP3A4	CCNC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205304	>	>	IC50	nM	10000.0	IC50	uM	10.0
440	Inhibition of CYP3A4	O=C(O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL377931	>	>	IC50	nM	10000.0	IC50	uM	10.0
441	Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)(C(=O)O)CC2)c1	J. Med. Chem.	2006.0	CHEMBL379834	>	>	IC50	nM	10000.0	IC50	uM	10.0
442	Inhibition of CYP3A4	CCN1CCC(C(=O)NC2(C(=O)O)CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL436753	>	>	IC50	nM	10000.0	IC50	uM	10.0
443	Inhibition of CYP3A4	NC(=O)c1sc(-c2ccc(F)cc2)cc1N	J. Med. Chem.	2006.0	CHEMBL207071	=	=	IC50	nM	2000.0	IC50	uM	2.0
444	Inhibition of CYP3A4	Cc1cc(C)c2c(N)c(C(N)=O)sc2n1	J. Med. Chem.	2006.0	CHEMBL377085	>	>	IC50	nM	30000.0	IC50	uM	30.0
445	Inhibition of CYP3A4	NC(=O)c1sc2ncccc2c1N	J. Med. Chem.	2006.0	CHEMBL207012	>	>	IC50	nM	30000.0	IC50	uM	30.0
446	Inhibition of CYP3A4	NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N	J. Med. Chem.	2006.0	CHEMBL377928	>	>	IC50	nM	30000.0	IC50	uM	30.0
447	Inhibition of CYP3A4	NC(=O)c1nc(-c2ccccc2)oc1N	J. Med. Chem.	2006.0	CHEMBL207987	>	>	IC50	nM	30000.0	IC50	uM	30.0
448	Inhibition of CYP3A4	NC(=O)c1sc(-c2ccccc2)cc1N	J. Med. Chem.	2006.0	CHEMBL207028	=	=	IC50	nM	3500.0	IC50	uM	3.5
449	Inhibition of CYP450 3A4	O=C(O)c1cccc(-n2cncc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207293	<	<	IC50	nM	1000.0	IC50	uM	1.0
450	Inhibition of CYP450 3A4	O=C(O)c1cccc(-c2ncccc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL206096	>	>	IC50	nM	50000.0	IC50	uM	50.0
451	Inhibition of CYP450 3A4	O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL209244	=	=	IC50	nM	1400.0	IC50	uM	1.4
452	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208154	=	=	IC50	nM	6300.0	IC50	nM	6300.0
453	Inhibition of CYP3A4	CC[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208443	=	=	IC50	nM	3300.0	IC50	nM	3300.0
454	Inhibition of CYP3A4	CN(C)C(C)(C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL382574	=	=	IC50	nM	2100.0	IC50	nM	2100.0
455	Inhibition of CYP3A4	CN(C)C[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204684	>	>	IC50	nM	20000.0	IC50	nM	20000.0
456	Inhibition of CYP3A4	CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205862	=	=	IC50	nM	1010.0	IC50	nM	1010.0
457	Inhibition of CYP3A4	CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207304	=	=	IC50	nM	800.0	IC50	nM	800.0
458	Inhibition of CYP3A4	CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207942	=	=	IC50	nM	2300.0	IC50	nM	2300.0
459	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208158	=	=	IC50	nM	2150.0	IC50	nM	2150.0
460	Inhibition of CYP3A4	CCCCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205280	=	=	IC50	nM	2270.0	IC50	nM	2270.0
461	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C1CCCCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207411	=	=	IC50	nM	448.0	IC50	nM	448.0
462	Inhibition of CYP3A4	CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207486	=	=	IC50	nM	400.0	IC50	nM	400.0
463	Inhibition of CYP3A4	CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208155	=	=	IC50	nM	580.0	IC50	nM	580.0
464	Inhibition of CYP3A4	CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL210780	=	=	IC50	nM	1700.0	IC50	nM	1700.0
465	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCOCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL378132	>	>	IC50	nM	20000.0	IC50	nM	20000.0
466	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207638	=	=	IC50	nM	8000.0	IC50	nM	8000.0
467	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377177	=	=	IC50	nM	8200.0	IC50	nM	8200.0
468	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207345	=	=	IC50	nM	7000.0	IC50	nM	7000.0
469	Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL206884	=	=	IC50	nM	7500.0	IC50	nM	7500.0
470	Inhibition of CYP3A4	CCC(CC)(COc1ccc2cc([C@H]([C@@H](C)N(C)C)n3ccnc3)ccc2c1)C(=O)O	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377286	=	=	IC50	nM	5300.0	IC50	nM	5300.0
471	Inhibition of human recombinant CYP3A4	CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208528	=	=	IC50	nM	7900.0	IC50	uM	7.9
472	Inhibition of human recombinant CYP3A4	C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207831	=	=	IC50	nM	5500.0	IC50	uM	5.5
473	Inhibition of CYP3A4	COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1	J. Med. Chem.	2006.0	CHEMBL210514	>	>	IC50	nM	30000.0	IC50	uM	30.0
474	Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1	J. Med. Chem.	2006.0	CHEMBL208787	=	=	IC50	nM	4300.0	IC50	uM	4.3
475	Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1	J. Med. Chem.	2006.0	CHEMBL208787	=	=	IC50	nM	2500.0	IC50	uM	2.5
476	Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2006.0	CHEMBL377414	=	=	IC50	nM	89000.0	IC50	uM	89.0
477	Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2006.0	CHEMBL377414	=	=	IC50	nM	62000.0	IC50	uM	62.0
478	Inhibition of P450 3A4	CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212689	>	>	IC50	nM	10000.0	IC50	uM	10.0
479	Inhibition of CYP3A4	CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212521	=	=	IC50	nM	3604.0	IC50	nM	3604.0
480	Inhibition of CYP3A4	Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534942	>	>	IC50	nM	30000.0	IC50	uM	30.0
481	Inhibition of CYP3A4	CCOc1ccccc1C[C@@H](c1ccccc1)N1CCNCC1.Cl	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL540107	=	=	IC50	nM	10000.0	IC50	uM	10.0
482	Inhibition of CYP3A4	CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1.Cl	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534723	=	=	IC50	nM	30000.0	IC50	uM	30.0
483	Inhibition of CYP3A4	Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534942	>	>	IC50	nM	30000.0	IC50	uM	30.0
484	Inhibition of CYP3A4 in human liver microsome	CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213743	>	>	IC50	nM	10000.0	IC50	uM	10.0
485	Inhibition of CYP3A4 in human liver microsome	c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212084	=	=	IC50	nM	254.0	IC50	nM	254.0
486	Inhibition of cytochrome P450 3A4	O=C(Nc1ccc2cccnc2c1)c1ccc(-c2ccccc2)nc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213390	>	>	IC50	nM	18000.0	IC50	uM	18.0
487	Inhibition of CYP450 3A4	Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213221	>	>	IC50	nM	100000.0	IC50	uM	100.0
488	Inhibition of CYP3A4	C#C[C@H]1CC[C@@H](C#N)N1C(=O)CNC1(C)CCN(c2cc(C(=O)O)ccn2)CC1	J. Med. Chem.	2006.0	CHEMBL386369	>	>	IC50	nM	30000.0	IC50	uM	30.0
489	Inhibition of CYP3A4	N[C@H]1CC(C(=O)N2CCn3c(nnc3C(F)(F)F)C2)=CC[C@@H]1c1cc(F)c(F)c(F)c1.O=C(O)C(F)(F)F	J. Med. Chem.	2006.0	CHEMBL437341	>	>	IC50	nM	30000.0	IC50	uM	30.0
490	Inhibition of human CYP3A4	NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL359657	=	=	Ki	nM	29400.0	Ki	uM	29.4
491	Inhibition of human CYP3A4	NCc1cc(-c2cccnc2)n[nH]1	J. Med. Chem.	2006.0	CHEMBL385008	>	>	Ki	nM	400000.0	Ki	uM	400.0
492	Inhibition of human CYP3A4	NCCCc1cccnc1	J. Med. Chem.	2006.0	CHEMBL385023	>	>	Ki	nM	400000.0	Ki	uM	400.0
493	Inhibition of human CYP3A4	c1cncc(-c2cc[nH]n2)c1	J. Med. Chem.	2006.0	CHEMBL218397	>	>	Ki	nM	400000.0	Ki	uM	400.0
494	Inhibition of human CYP3A4	Cc1csc(-c2cccnc2)n1	J. Med. Chem.	2006.0	CHEMBL410355	=	=	Ki	nM	22900.0	Ki	uM	22.9
495	Inhibition of human CYP3A4	c1ccc(-c2ccsc2)cc1	J. Med. Chem.	2006.0	CHEMBL386250	>	>	Ki	nM	400000.0	Ki	uM	400.0
496	Inhibition of human CYP3A4	Cc1cscc1-c1ccccc1	J. Med. Chem.	2006.0	CHEMBL215183	>	>	Ki	nM	400000.0	Ki	uM	400.0
497	Inhibition of human CYP3A4	NCc1ccc(-c2ccccc2)s1	J. Med. Chem.	2006.0	CHEMBL215134	=	=	Ki	nM	95500.0	Ki	uM	95.5
498	Inhibition of human CYP3A4	NCc1ccc(-c2ccccc2)o1	J. Med. Chem.	2006.0	CHEMBL214859	=	=	Ki	nM	63000.0	Ki	uM	63.0
499	Inhibition of human CYP3A4	c1cncc(-c2ccc(C3SCCS3)o2)c1	J. Med. Chem.	2006.0	CHEMBL215174	=	=	Ki	nM	1100.0	Ki	uM	1.1
500	Inhibition of human CYP3A4	CSCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL214990	=	=	Ki	nM	7400.0	Ki	uM	7.4
501	Inhibition of human CYP3A4	SCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL214784	=	=	Ki	nM	3100.0	Ki	uM	3.1
502	Inhibition of human CYP3A4	CC(=O)SCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL386124	=	=	Ki	nM	1500.0	Ki	uM	1.5
503	Inhibition of human CYP3A4	Cc1cscc1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL179704	<	<	Ki	nM	25000.0	Ki	uM	25.0
504	Inhibition of human CYP3A4	c1cncc(-c2c[nH]cn2)c1	J. Med. Chem.	2006.0	CHEMBL178516	=	=	Ki	nM	70000.0	Ki	uM	70.0
505	Inhibition of human CYP3A4	Cc1nccn1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL368883	=	=	Ki	nM	76000.0	Ki	uM	76.0
506	Inhibition of human CYP3A4	c1cncc(-c2ccsc2)c1	J. Med. Chem.	2006.0	CHEMBL361153	=	=	Ki	nM	28000.0	Ki	uM	28.0
507	Inhibition of human CYP3A4	Cc1ccsc1-c1ccc(F)nc1	J. Med. Chem.	2006.0	CHEMBL179621	=	=	Ki	nM	19600.0	Ki	uM	19.6
508	Inhibition of human CYP3A4	Cn1cnc(-c2cccnc2)c1	J. Med. Chem.	2006.0	CHEMBL360999	=	=	Ki	nM	131000.0	Ki	uM	131.0
509	Inhibition of human CYP3A4	Cc1ccsc1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL179669	=	=	Ki	nM	3000.0	Ki	uM	3.0
510	Inhibition of human CYP3A4	CN(C)CC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL180270	>	>	Ki	nM	400000.0	Ki	uM	400.0
511	Inhibition of human CYP3A4	CNCC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL149808	=	=	Ki	nM	251000.0	Ki	uM	251.0
512	Inhibition of human CYP3A4	NCC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL360541	=	=	Ki	nM	15200.0	Ki	uM	15.2
513	Inhibition of human CYP3A4	CN(C)Cc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL360998	=	=	Ki	nM	147000.0	Ki	uM	147.0
514	Inhibition of human CYP3A4	CNCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL178938	>	>	Ki	nM	400000.0	Ki	uM	400.0
515	Inhibition of human CYP3A4	NCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL178090	=	=	Ki	nM	23600.0	Ki	uM	23.6
516	Inhibition of human CYP3A4	CN(C)Cc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL361969	=	=	Ki	nM	110000.0	Ki	uM	110.0
517	Inhibition of human CYP3A4	CNCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL369285	>	>	Ki	nM	400000.0	Ki	uM	400.0
518	Inhibition of human CYP3A4	NCc1cc(-c2cccnc2)no1	J. Med. Chem.	2006.0	CHEMBL217125	>	>	Ki	nM	400000.0	Ki	uM	400.0
519	Inhibition of CYP3A4	O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL214021	=	=	IC50	nM	23500.0	IC50	uM	23.5
520	Inhibition of CYP450 3A4	O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL216884	=	=	IC50	nM	26000.0	IC50	uM	26.0
521	Inhibition of CYP450 3A4	O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL217716	=	=	IC50	nM	53000.0	IC50	uM	53.0
522	Inhibition of CYP450 3A4	O=C(CCCCCCC(=O)Nc1ccccc1)NO	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL98	=	=	IC50	nM	12000.0	IC50	uM	12.0
523	Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(NC(=O)C3CCCC3)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL220407	>	>	IC50	nM	25000.0	IC50	uM	25.0
524	Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(C)(C)C)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL219128	>	>	IC50	nM	25000.0	IC50	uM	25.0
525	Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(=O)OC(C)(C)C)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL218410	>	>	IC50	nM	25000.0	IC50	uM	25.0
526	Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(=O)N3CC4CCC(CC4)C3)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL218834	>	>	IC50	nM	25000.0	IC50	uM	25.0
527	Inhibition of human CYP3A4	O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12	J. Med. Chem.	2007.0	CHEMBL218583	=	=	IC50	nM	55000.0	IC50	uM	55.0
528	Inhibition of human CYP3A4	Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C	J. Med. Chem.	2007.0	CHEMBL267210	=	=	IC50	nM	7000.0	IC50	uM	7.0
529	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL205742	=	=	IC50	nM	16000.0	IC50	uM	16.0
530	Inhibition of CYP3A4	Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL375166	=	=	IC50	nM	100000.0	IC50	uM	100.0
531	Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL218628	=	=	IC50	nM	22000.0	IC50	uM	22.0
532	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3c[nH]c4ncccc34)sc21	J. Med. Chem.	2007.0	CHEMBL384536	=	=	IC50	nM	15000.0	IC50	uM	15.0
533	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccccc3C(F)(F)F)sc21	J. Med. Chem.	2007.0	CHEMBL218573	=	=	IC50	nM	8300.0	IC50	uM	8.3
534	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccnc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL219861	=	=	IC50	nM	46000.0	IC50	uM	46.0
535	Inhibition of CYP3A4	CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL387125	=	=	IC50	nM	44000.0	IC50	uM	44.0
536	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Oc3cccc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL219098	=	=	IC50	nM	7200.0	IC50	uM	7.2
537	Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL219483	=	=	IC50	nM	1000.0	IC50	uM	1.0
538	Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccc(F)cc34)sc21	J. Med. Chem.	2007.0	CHEMBL218468	>	>	IC50	nM	50000.0	IC50	uM	50.0
539	Inhibition of CYP3A4 in human liver microsomes	COC(=O)N(NC(=O)c1c(CN2CCN(C(C)(C)C)CC2)c(-c2ccccc2)nc2c(F)cccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL221445	>	>	IC50	nM	30000.0	IC50	uM	30.0
540	Inhibition of CYP3A4 in human liver microsomes	COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL219162	=	=	IC50	nM	12000.0	IC50	uM	12.0
541	Inhibition of CYP3A4	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL373751	<	<	IC50	nM	50118.72	Log IC50		-4.3
542	Inhibition of CYP3A4	CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL223156	>	>	IC50	nM	10000.0	IC50	uM	10.0
543	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccncc2)CC1	J. Med. Chem.	2007.0	CHEMBL219060	>	>	IC50	nM	25000.0	IC50	uM	25.0
544	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1	J. Med. Chem.	2007.0	CHEMBL218068	=	=	IC50	nM	5100.0	IC50	uM	5.1
545	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2nncs2)CC1	J. Med. Chem.	2007.0	CHEMBL219113	>	>	IC50	nM	25000.0	IC50	uM	25.0
546	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2nccs2)CC1	J. Med. Chem.	2007.0	CHEMBL218547	>	>	IC50	nM	10000.0	IC50	uM	10.0
547	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ncccn2)CC1	J. Med. Chem.	2007.0	CHEMBL435316	>	>	IC50	nM	25000.0	IC50	uM	25.0
548	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1	J. Med. Chem.	2007.0	CHEMBL220660	=	=	IC50	nM	22000.0	IC50	uM	22.0
549	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1	J. Med. Chem.	2007.0	CHEMBL218067	=	=	IC50	nM	9100.0	IC50	uM	9.1
550	Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccccn2)CC1	J. Med. Chem.	2007.0	CHEMBL218017	>	>	IC50	nM	25000.0	IC50	uM	25.0
551	Inhibition of CYP3A4	CCOC(=O)N1CCC(NS(=O)(=O)c2ccc(NC(=O)c3ccccc3C)c3ccccc23)CC1	J. Med. Chem.	2007.0	CHEMBL218375	>	>	IC50	nM	10000.0	IC50	uM	10.0
552	Inhibition of CYP3A4	O=C(O)C[C@@H]1CCc2cc(OCCCOc3ccc(-c4nc5c(s4)CCCC5)cc3)ccc21	J. Med. Chem.	2007.0	CHEMBL375812	>	>	IC50	nM	10000.0	IC50	uM	10.0
553	Inhibition of CYP3A4	CCCc1cc(C2=NC3OCCCC3S2)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O	J. Med. Chem.	2007.0	CHEMBL221044	>	>	IC50	nM	10000.0	IC50	uM	10.0
554	Inhibition of CYP3A4	CCCc1cc(-c2nc3c(s2)CCCC3)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O	J. Med. Chem.	2007.0	CHEMBL2113263	>	>	IC50	nM	10000.0	IC50	uM	10.0
555	Inhibition of cytochrome P450 3A4	CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21	J. Med. Chem.	2007.0	CHEMBL221113	=	=	IC50	nM	8700.0	IC50	uM	8.7
556	Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1	J. Med. Chem.	2007.0	CHEMBL222424	=	=	IC50	nM	91900.0	IC50	uM	91.9
557	Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(Cl)c2)CC1	J. Med. Chem.	2007.0	CHEMBL223079	>	>	IC50	nM	100000.0	IC50	uM	100.0
558	Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(F)c2)CC1	J. Med. Chem.	2007.0	CHEMBL221401	>	>	IC50	nM	100000.0	IC50	uM	100.0
559	Inhibition of human CYP3A4	CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2)CC1	J. Med. Chem.	2004.0	CHEMBL375248	>	>	IC50	nM	50000.0	IC50	uM	50.0
560	Inhibition of human CYP3A4	CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2C)CC1	J. Med. Chem.	2004.0	CHEMBL376722	>	>	IC50	nM	100000.0	IC50	uM	100.0
561	Inhibition of CYP3A4	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1	J. Med. Chem.	2007.0	CHEMBL228133	=	=	IC50	nM	10000.0	IC50	uM	10.0
562	Inhibition of CYP3A4	CN(C)C(C)(C)c1nc(O)c(O)c(C(=O)NCc2ccc(F)cc2)n1	J. Med. Chem.	2007.0	CHEMBL386515	>	>	IC50	nM	20000.0	IC50	uM	20.0
563	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccccc2c1=O	J. Med. Chem.	2007.0	CHEMBL227954	=	=	IC50	nM	2000.0	IC50	uM	2.0
564	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(N3CCOCC3)c(F)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL227356	=	=	IC50	nM	790.0	IC50	uM	0.79
565	Inhibition of human CYP3A4	COc1cccc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc12	J. Med. Chem.	2007.0	CHEMBL390776	=	=	IC50	nM	630.0	IC50	uM	0.63
566	Inhibition of human CYP3A4	COc1cc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2cc1OC	J. Med. Chem.	2007.0	CHEMBL227089	=	=	IC50	nM	500.0	IC50	uM	0.5
567	Inhibition of human CYP3A4	COc1cc2c(=O)n(Cc3ccccc3C#N)c(N3CCC[C@@H](N)C3)nc2cc1F	J. Med. Chem.	2007.0	CHEMBL375508	=	=	IC50	nM	250.0	IC50	uM	0.25
568	Inhibition of human CYP3A4	COc1ccc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2c1	J. Med. Chem.	2007.0	CHEMBL227670	=	=	IC50	nM	200.0	IC50	uM	0.2
569	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Br)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL227676	=	=	IC50	nM	250.0	IC50	uM	0.25
570	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2c(Cl)cc(Cl)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL390529	=	=	IC50	nM	80.0	IC50	uM	0.08
571	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cccc2c1=O	J. Med. Chem.	2007.0	CHEMBL387552	=	=	IC50	nM	130.0	IC50	uM	0.13
572	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(Cl)ccc2c1=O	J. Med. Chem.	2007.0	CHEMBL228004	=	=	IC50	nM	250.0	IC50	uM	0.25
573	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Cl)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL389074	=	=	IC50	nM	250.0	IC50	uM	0.25
574	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL425483	=	=	IC50	nM	2500.0	IC50	uM	2.5
575	Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cccc(F)c2c1=O	J. Med. Chem.	2007.0	CHEMBL227464	=	=	IC50	nM	500.0	IC50	uM	0.5
576	Inhibition of human CYP3A4	O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL389908	=	=	IC50	nM	5000.0	IC50	uM	5.0
577	Inhibition of human CYP3A4	O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226067	=	=	IC50	nM	82000.0	IC50	uM	82.0
578	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(F)cc(F)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL390526	>	>	IC50	nM	100000.0	IC50	uM	100.0
579	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225465	>	>	IC50	nM	100000.0	IC50	uM	100.0
580	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225464	=	=	IC50	nM	68000.0	IC50	uM	68.0
581	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225413	>	>	IC50	nM	100000.0	IC50	uM	100.0
582	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225412	=	=	IC50	nM	38000.0	IC50	uM	38.0
583	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)c(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL389408	>	>	IC50	nM	25000.0	IC50	uM	25.0
584	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225411	>	>	IC50	nM	100000.0	IC50	uM	100.0
585	Inhibition of human CYP3A4	O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL387620	=	=	IC50	nM	10000.0	IC50	uM	10.0
586	Inhibition of human CYP3A4	O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL227899	=	=	IC50	nM	75000.0	IC50	uM	75.0
587	Inhibition of human CYP3A4	O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226386	=	=	IC50	nM	65000.0	IC50	uM	65.0
588	Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226385	=	=	IC50	nM	51000.0	IC50	uM	51.0
589	Inhibition of human CYP3A4	O=C(NCc1ccncc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL375955	<	<	IC50	nM	100.0	IC50	uM	0.1
590	Inhibition of human CYP3A4	CCC(C)COc1ccc(C(CC(=O)O)c2ccccc2)cc1	J. Med. Chem.	2007.0	CHEMBL229176	>	>	IC50	nM	22000.0	IC50	uM	22.0
591	Inhibition of CYP3A4	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231334	=	=	IC50	nM	12000.0	IC50	uM	12.0
592	Inhibition of CYP3A4	CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231430	=	=	IC50	nM	58000.0	IC50	uM	58.0
593	Inhibition of CYP3A4	CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231350	=	=	IC50	nM	7500.0	IC50	uM	7.5
594	Inhibition of CYP3A4	Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL436137	=	=	IC50	nM	42000.0	IC50	uM	42.0
595	Inhibition of CYP3A4	Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230686	=	=	IC50	nM	62000.0	IC50	uM	62.0
596	Inhibition of CYP3A4	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccnc5)cnc(N)c34)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL427267	=	=	IC50	nM	250.0	IC50	nM	250.0
597	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5ccnc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230080	=	=	IC50	nM	35.0	IC50	nM	35.0
598	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5cccc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231147	>	>	IC50	nM	10000.0	IC50	nM	10000.0
599	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5ccncc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL266738	=	=	IC50	nM	300.0	IC50	nM	300.0
600	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccnc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389608	=	=	IC50	nM	1100.0	IC50	nM	1100.0
601	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccc(C#N)c5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389810	>	>	IC50	nM	10000.0	IC50	nM	10000.0
602	Inhibition of CYP3A4	N#Cc1cccc(-c2ccc(CN3CCC4(CC3)C(=O)NC(=O)N4c3ccccc3)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230626	>	>	IC50	nM	10000.0	IC50	nM	10000.0
603	Inhibition of CYP3A4	COc1cncc(-c2ccc(CN3CCC4(CC3)C(=O)N(c3cccc(OC)c3)C(=O)N4Cc3ccccc3F)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL267690	=	=	IC50	nM	2000.0	IC50	nM	2000.0
604	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cncc(C#N)c5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389809	=	=	IC50	nM	6200.0	IC50	nM	6200.0
605	Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cnccc5OC)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL266513	=	=	IC50	nM	1700.0	IC50	nM	1700.0
606	Inhibition of CYP3A4 in microsomes	CNC(=N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL425819	=	=	IC50	nM	15000.0	IC50	uM	15.0
607	Inhibition of CYP3A4 in microsomes	Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231620	=	=	IC50	nM	360.0	IC50	uM	0.36
608	Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2nc(-c3c(NCc4ccccn4)cc[nH]c3=O)[nH]c12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397666	=	=	IC50	nM	80.0	IC50	uM	0.08
609	Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230043	=	=	IC50	nM	16000.0	IC50	uM	16.0
610	Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NC(C)(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230042	=	=	IC50	nM	13000.0	IC50	uM	13.0
611	Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NC(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL390002	=	=	IC50	nM	4300.0	IC50	uM	4.3
612	Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL387611	=	=	IC50	nM	35000.0	IC50	uM	35.0
613	Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231610	=	=	IC50	nM	11000.0	IC50	uM	11.0
614	Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231609	=	=	IC50	nM	1600.0	IC50	uM	1.6
615	Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231510	=	=	IC50	nM	10000.0	IC50	uM	10.0
616	Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231509	=	=	IC50	nM	2200.0	IC50	uM	2.2
617	Inhibition of CYP3A4 in microsomes	CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231409	=	=	IC50	nM	3700.0	IC50	uM	3.7
618	Inhibition of CYP3A4 in microsomes	Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230309	=	=	IC50	nM	710.0	IC50	uM	0.71
619	Inhibition of CYP3A4 in microsomes	COc1ccc(-c2cc(C)c3nc(-c4c(N[C@H](CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL440964	=	=	IC50	nM	6800.0	IC50	uM	6.8
620	Inhibition of CYP3A4 in microsomes	Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230308	=	=	IC50	nM	6300.0	IC50	uM	6.3
621	Inhibition of CYP3A4 in microsomes	Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230205	=	=	IC50	nM	3600.0	IC50	uM	3.6
622	Inhibition of CYP3A4 in microsomes	Cc1cc(Br)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397667	=	=	IC50	nM	3100.0	IC50	uM	3.1
623	Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231306	<	<	IC50	nM	46.0	IC50	uM	0.046
624	Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230204	=	=	IC50	nM	60.0	IC50	uM	0.06
625	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230367	=	=	IC50	nM	8000.0	IC50	nM	8000.0
626	Inhibition of CYP3A4	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL411885	=	=	IC50	nM	82.0	IC50	nM	82.0
627	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCC(=O)OC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230262	=	=	IC50	nM	12000.0	IC50	nM	12000.0
628	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)OC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL390642	=	=	IC50	nM	10000.0	IC50	nM	10000.0
629	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230260	=	=	IC50	nM	2800.0	IC50	nM	2800.0
630	Inhibition of CYP3A4	CC[C@H]1[C@@H]2[C@@H](O)CCN2C(=O)N1c1ccc(C#N)c(Cl)c1C	J. Med. Chem.	2007.0	CHEMBL229861	>	>	IC50	nM	40000.0	IC50	uM	40.0
631	Inhibition of CYP3A4	CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1	J. Med. Chem.	2007.0	CHEMBL229008	=	=	IC50	nM	13000.0	IC50	uM	13.0
632	Inhibition of CYP3A4 in human liver microsomes	CCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12	J. Med. Chem.	2007.0	CHEMBL244403	>	>	IC50	nM	200000.0	IC50	uM	200.0
633	Inhibition of human recombinant CYP3A4	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1	J. Med. Chem.	2007.0	CHEMBL394864	=	=	IC50	nM	6800.0	IC50	uM	6.8
634	Inhibition of human recombinant CYP3A4	Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL231383	=	=	IC50	nM	10700.0	IC50	uM	10.7
635	Inhibition of human recombinant CYP3A4	Cc1nccn1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL388012	>	>	IC50	nM	20000.0	IC50	uM	20.0
636	Inhibition of human recombinant CYP3A4	Cc1cn(CC(=O)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)cn1	J. Med. Chem.	2007.0	CHEMBL387785	>	>	IC50	nM	20000.0	IC50	uM	20.0
637	Inhibition of human recombinant CYP3A4	O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL230964	=	=	IC50	nM	300.0	IC50	uM	0.3
638	Inhibition of human recombinant CYP3A4	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccc(CO)nc2)c(F)c1	J. Med. Chem.	2007.0	CHEMBL398160	>	>	IC50	nM	20000.0	IC50	uM	20.0
639	Inhibition of CYP3A4	O=C(O)COc1c(C(=O)O)sc(-c2cccc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)c1Br	J. Med. Chem.	2007.0	CHEMBL541214	>	>	IC50	nM	500000.0	IC50	uM	500.0
640	Inhibition of CYP3A4	CCCc1[nH]cnc1CNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1	J. Med. Chem.	2007.0	CHEMBL230654	=	=	IC50	nM	16000.0	IC50	uM	16.0
641	Inhibition of CYP3A4	N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1	J. Med. Chem.	2007.0	CHEMBL436817	=	=	IC50	nM	9000.0	IC50	uM	9.0
642	Inhibition of CYP3A4	N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1	J. Med. Chem.	2007.0	CHEMBL395573	=	=	IC50	nM	18000.0	IC50	uM	18.0
643	Inhibition of CYP3A4	Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1	J. Med. Chem.	2007.0	CHEMBL230761	=	=	IC50	nM	15000.0	IC50	uM	15.0
644	Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2	Bioorg. Med. Chem.	2007.0	CHEMBL348475	>	>	IC50	nM	100000.0	IC50	uM	100.0
645	Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL242983	=	=	IC50	nM	195.0	IC50	uM	0.195
646	Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL266212	=	=	IC50	nM	20200.0	IC50	uM	20.2
647	Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL244239	=	=	IC50	nM	1620.0	IC50	uM	1.62
648	Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2	Bioorg. Med. Chem.	2007.0	CHEMBL348475	>	>	IC50	nM	100000.0	IC50	uM	100.0
649	Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL242983	=	=	IC50	nM	2480.0	IC50	uM	2.48
650	Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL266212	=	=	IC50	nM	3580.0	IC50	uM	3.58
651	Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL244239	=	=	IC50	nM	7750.0	IC50	uM	7.75
652	Inhibition of human recombinant CYP3A4	O=c1ccc2c(O)c3ccoc3cc2o1	Bioorg. Med. Chem.	2007.0	CHEMBL242711	=	=	IC50	nM	24920.0	IC50	uM	24.92
653	Inhibition of human recombinant CYP3A4	C/C(=C\COc1ccc2ccc(=O)oc2c1)C/C=C/C(C)C	Bioorg. Med. Chem.	2007.0	CHEMBL241896	=	=	IC50	nM	42930.0	IC50	uM	42.93
654	Inhibition of CYP3A4	CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL536743	=	=	IC50	nM	9300.0	IC50	uM	9.3
655	Inhibition of CYP3A4	CC(=O)Nc1cc(C(=O)O)cc(-n2c(C)ccc2-c2cc(Br)ccc2OCc2ccc(F)cc2F)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL427844	>=	>=	IC50	nM	18000.0	IC50	uM	18.0
656	Inhibition of CYP3A4	O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL207881	>	>	IC50	nM	33000.0	IC50	uM	33.0
657	Inhibition of CYP3A4	CCCC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1N	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL234412	>	>	IC50	nM	50000.0	IC50	uM	50.0
658	Inhibition of CYP3A4	COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](c3cccc(C)c3)CN1CC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391070	>	>	IC50	nM	50000.0	IC50	uM	50.0
659	Inhibition of CYP3A4	CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)N[C@@H](Cc3ccccc3)C(=O)O)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL400404	>	>	IC50	nM	20000.0	IC50	uM	20.0
660	Inhibition of CYP3A4	CN(Cc1ccccc1)C(=O)[C@@H](NC(=O)c1cc2cc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)ccc2n1C)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL410414	>	>	IC50	nM	30000.0	IC50	uM	30.0
661	Inhibition of human CYP3A4	O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231924	>	>	IC50	nM	25000.0	IC50	uM	25.0
662	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2	Bioorg. Med. Chem.	2007.0	CHEMBL400431	>	>	IC50	nM	30000.0	IC50	uM	30.0
663	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)[C@](C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241663	=	=	IC50	nM	1700.0	IC50	uM	1.7
664	Inhibition of CYP3A4	CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21	Bioorg. Med. Chem.	2007.0	CHEMBL393109	=	=	IC50	nM	1060.0	IC50	uM	1.06
665	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241241	=	=	IC50	nM	270.0	IC50	uM	0.27
666	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC#N)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL429642	>	>	IC50	nM	30000.0	IC50	uM	30.0
667	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241032	=	=	IC50	nM	670.0	IC50	uM	0.67
668	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240813	=	=	IC50	nM	2180.0	IC50	uM	2.18
669	Inhibition of CYP3A4	CCNC(=O)CN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21	Bioorg. Med. Chem.	2007.0	CHEMBL398811	>	>	IC50	nM	30000.0	IC50	uM	30.0
670	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240598	=	=	IC50	nM	160.0	IC50	uM	0.16
671	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240391	=	=	IC50	nM	1670.0	IC50	uM	1.67
672	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL429459	=	=	IC50	nM	4790.0	IC50	uM	4.79
673	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL393218	=	=	IC50	nM	30000.0	IC50	uM	30.0
674	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398584	=	=	IC50	nM	860.0	IC50	uM	0.86
675	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239496	=	=	IC50	nM	1140.0	IC50	uM	1.14
676	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239085	=	=	IC50	nM	530.0	IC50	uM	0.53
677	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL391463	>	>	IC50	nM	30000.0	IC50	uM	30.0
678	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239078	=	=	IC50	nM	1900.0	IC50	uM	1.9
679	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239074	=	=	IC50	nM	590.0	IC50	uM	0.59
680	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL393363	=	=	IC50	nM	120.0	IC50	uM	0.12
681	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL238866	=	=	IC50	nM	920.0	IC50	uM	0.92
682	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239497	=	=	IC50	nM	460.0	IC50	uM	0.46
683	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398584	=	=	IC50	nM	860.0	IC50	uM	0.86
684	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239496	=	=	IC50	nM	1140.0	IC50	uM	1.14
685	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C1(CC1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398387	>	>	IC50	nM	30000.0	IC50	uM	30.0
686	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239495	=	=	IC50	nM	3000.0	IC50	uM	3.0
687	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(CC)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240566	>	>	IC50	nM	30000.0	IC50	uM	30.0
688	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C(F)(F)F)O2	Bioorg. Med. Chem.	2007.0	CHEMBL394016	>	>	IC50	nM	22000.0	IC50	uM	22.0
689	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240355	>	>	IC50	nM	30000.0	IC50	uM	30.0
690	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccccc3)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391963	=	=	IC50	nM	18000.0	IC50	uM	18.0
691	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392465	=	=	IC50	nM	100000.0	IC50	uM	100.0
692	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@H](c3ccc(F)cc3C)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392464	=	=	IC50	nM	28000.0	IC50	uM	28.0
693	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392463	=	=	IC50	nM	23000.0	IC50	uM	23.0
694	Inhibition of human CYP3A4	Cc1cnc(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)cn1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235882	=	=	IC50	nM	11000.0	IC50	uM	11.0
695	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391615	=	=	IC50	nM	49000.0	IC50	uM	49.0
696	Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391964	=	=	IC50	nM	11000.0	IC50	uM	11.0
697	Inhibition of human CYP3A4	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL1471	=	=	IC50	nM	46.0	IC50	nM	46.0
698	Inhibition of CYP3A4	C[C@H]1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236902	>	>	IC50	nM	50000.0	IC50	uM	50.0
699	Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391914	=	=	IC50	nM	120.0	IC50	nM	120.0
700	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396186	=	=	IC50	nM	15000.0	IC50	nM	15000.0
701	Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)CCN(C)C)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236521	=	=	IC50	nM	6000.0	IC50	nM	6000.0
702	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397584	=	=	IC50	nM	6900.0	IC50	nM	6900.0
703	Inhibition of microsomal CYP3A4	CNCCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397583	=	=	IC50	nM	3400.0	IC50	nM	3400.0
704	Inhibition of microsomal CYP3A4	CNCCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397582	=	=	IC50	nM	1300.0	IC50	nM	1300.0
705	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397581	=	=	IC50	nM	5400.0	IC50	nM	5400.0
706	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236520	=	=	IC50	nM	6400.0	IC50	nM	6400.0
707	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397580	=	=	IC50	nM	6700.0	IC50	nM	6700.0
708	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391028	=	=	IC50	nM	2900.0	IC50	nM	2900.0
709	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)C(C)(C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397368	=	=	IC50	nM	28000.0	IC50	nM	28000.0
710	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)[C@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397367	=	=	IC50	nM	8600.0	IC50	nM	8600.0
711	Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)[C@@H](C)N)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL262321	=	=	IC50	nM	2900.0	IC50	nM	2900.0
712	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)[C@@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396434	=	=	IC50	nM	5300.0	IC50	nM	5300.0
713	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL412024	=	=	IC50	nM	15000.0	IC50	nM	15000.0
714	Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL412023	=	=	IC50	nM	3600.0	IC50	nM	3600.0
715	Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL441136	=	=	IC50	nM	6500.0	IC50	nM	6500.0
716	Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235640	=	=	IC50	nM	2300.0	IC50	nM	2300.0
717	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235421	=	=	IC50	nM	3600.0	IC50	nM	3600.0
718	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL262320	=	=	IC50	nM	25000.0	IC50	nM	25000.0
719	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCC(=O)O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235955	=	=	IC50	nM	21000.0	IC50	nM	21000.0
720	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396433	>	>	IC50	nM	50000.0	IC50	nM	50000.0
721	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCC(N)=O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393789	=	=	IC50	nM	720.0	IC50	nM	720.0
722	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL438683	=	=	IC50	nM	15000.0	IC50	nM	15000.0
723	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393788	=	=	IC50	nM	16000.0	IC50	nM	16000.0
724	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237578	=	=	IC50	nM	3400.0	IC50	nM	3400.0
725	Inhibition of microsomal CYP3A4	CCN(CC)CCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396432	=	=	IC50	nM	37000.0	IC50	nM	37000.0
726	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396431	=	=	IC50	nM	32000.0	IC50	nM	32000.0
727	Inhibition of microsomal CYP3A4	CNCCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237577	=	=	IC50	nM	11000.0	IC50	nM	11000.0
728	Inhibition of microsomal CYP3A4	CNCCN[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393204	=	=	IC50	nM	4800.0	IC50	nM	4800.0
729	Inhibition of microsomal CYP3A4	CC(C)C[C@@H](c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1)N(C)CCN	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237365	=	=	IC50	nM	650.0	IC50	nM	650.0
730	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236519	=	=	IC50	nM	6300.0	IC50	nM	6300.0
731	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237364	=	=	IC50	nM	8900.0	IC50	nM	8900.0
732	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393576	=	=	IC50	nM	4900.0	IC50	nM	4900.0
733	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCO)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396884	=	=	IC50	nM	35000.0	IC50	nM	35000.0
734	Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCO)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237147	=	=	IC50	nM	480.0	IC50	nM	480.0
735	Inhibition of microsomal CYP3A4	CCN(CC)[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237146	=	=	IC50	nM	2700.0	IC50	nM	2700.0
736	Inhibition of microsomal CYP3A4	CCN[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391915	=	=	IC50	nM	640.0	IC50	nM	640.0
737	Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236940	=	=	IC50	nM	49000.0	IC50	nM	49000.0
738	Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@@H](N)CC(C)C)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236939	=	=	IC50	nM	1900.0	IC50	nM	1900.0
739	Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236732	=	=	IC50	nM	220.0	IC50	nM	220.0
740	Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236731	=	=	IC50	nM	170.0	IC50	nM	170.0
741	Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](N)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL401250	=	=	IC50	nM	8300.0	IC50	uM	8.3
742	Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL240364	=	=	IC50	nM	10000.0	IC50	uM	10.0
743	Inhibition of CYP3A4	CNCCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240780	=	=	IC50	nM	6000.0	IC50	uM	6.0
744	Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL427860	=	=	IC50	nM	9200.0	IC50	uM	9.2
745	Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3C)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL240572	=	=	IC50	nM	6800.0	IC50	uM	6.8
746	Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3F)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL391056	=	=	IC50	nM	6400.0	IC50	uM	6.4
747	Inhibition of CYP3A4	CNCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240571	=	=	IC50	nM	6900.0	IC50	uM	6.9
748	Inhibition of CYP3A4	CNCCN[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240568	=	=	IC50	nM	9000.0	IC50	uM	9.0
749	Inhibition of human CYP3A4 after 10 mins	CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)Nc5nccs5)CC4)c(Cl)cnc3[nH]2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392525	=	=	IC50	nM	10000.0	IC50	uM	10.0
750	Inhibition of human CYP3A4	NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12	J. Med. Chem.	2007.0	CHEMBL392760	=	=	IC50	nM	33000.0	IC50	uM	33.0
751	Inhibition of CYP3A4	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1CCOC(=O)NCCCCO	J. Med. Chem.	2007.0	CHEMBL398372	>	>	IC50	nM	100000.0	IC50	uM	100.0
752	Inhibition of human liver microsome CYP3A4	NC(=O)[C@H]1CN(c2ccc([C@H]3CC[S@+]([O-])CC3)c(F)c2)C(=O)O1	J. Med. Chem.	2007.0	CHEMBL2062151	>	>	IC50	nM	900000.0	IC50	uM	900.0
753	Inhibition of CYP3A4	CC(C)C[C@H](NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1	J. Med. Chem.	2007.0	CHEMBL266647	>	>	IC50	nM	10000.0	IC50	uM	10.0
754	Inhibition of human CYP3A4 using diethoxyfluorescein substrate	O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO	J. Med. Chem.	2007.0	CHEMBL240185	>	>	IC50	nM	100000.0	IC50	uM	100.0
755	Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO	J. Med. Chem.	2007.0	CHEMBL240185	=	=	IC50	nM	100000.0	IC50	uM	100.0
756	Inhibition of human CYP3A4 using diethoxyfluorescein substrate	N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239099	>	>	IC50	nM	100000.0	IC50	uM	100.0
757	Inhibition of human CYP3A4 using diethoxyfluorescein substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	>	>	IC50	nM	100000.0	IC50	uM	100.0
758	Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239099	>	>	IC50	nM	100000.0	IC50	uM	100.0
759	Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	=	=	IC50	nM	100000.0	IC50	uM	100.0
760	Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	>	>	IC50	nM	100000.0	IC50	uM	100.0
761	Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate	Cl.N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1	J. Med. Chem.	2007.0	CHEMBL534958	>	>	IC50	nM	100000.0	IC50	uM	100.0
762	Inhibition of CYP3A4 in presence of BFC substrate	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246970	=	=	IC50	nM	700.0	IC50	uM	0.7
763	Inhibition of CYP3A4 in presence of BQ substrate	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246970	=	=	IC50	nM	1400.0	IC50	uM	1.4
764	Inhibition of CYP3A4 in presence of BFC substrate	O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246161	=	=	IC50	nM	28000.0	IC50	uM	28.0
765	Inhibition of CYP3A4 in presence of BFC substrate	CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246160	=	=	IC50	nM	1700.0	IC50	uM	1.7
766	Inhibition of CYP3A4 in presence of BFC substrate	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392642	=	=	IC50	nM	6900.0	IC50	uM	6.9
767	Inhibition of CYP3A4 in presence of BQ substrate	O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246161	>	>	IC50	nM	30000.0	IC50	uM	30.0
768	Inhibition of CYP3A4 in presence of BQ substrate	CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246160	=	=	IC50	nM	13000.0	IC50	uM	13.0
769	Inhibition of CYP3A4 in presence of BQ substrate	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392642	>	>	IC50	nM	30000.0	IC50	uM	30.0
770	Inhibition of CYP3A4	CCc1ccccc1N(CC(=O)NCc1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240436	=	=	IC50	nM	251.19	Log IC50		-6.6
771	Inhibition of CYP3A4	NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL395426	>	>	IC50	nM	10000.0	IC50	uM	10.0
772	Inhibition of CYP3A4	CS(=O)(=O)c1cccc(-c2ncnc(N3CC(N)C(c4cc(F)c(F)cc4F)C3)n2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246530	>	>	IC50	nM	10000.0	IC50	uM	10.0
773	Inhibition of CYP3A4	NC1CN(c2cc(-c3cccc(S(=O)(=O)N4CCOCC4)c3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246322	>	>	IC50	nM	10000.0	IC50	uM	10.0
774	Inhibition of CYP3A4	NC1CN(c2cc(-c3cccc(C(=O)O)c3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL245585	>	>	IC50	nM	10000.0	IC50	uM	10.0
775	Inhibition of CYP3A4	Cl.NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL536086	>	>	IC50	nM	10000.0	IC50	uM	10.0
776	Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239772	=	=	IC50	nM	8000.0	IC50	uM	8.0
777	Inhibition of CYP3A4	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239816	=	=	IC50	nM	490.0	IC50	uM	0.49
778	Inhibition of CYP3A4	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392609	=	=	IC50	nM	170.0	IC50	uM	0.17
779	Inhibition of CYP3A4	N[C@@H](Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240889	=	=	IC50	nM	1000.0	IC50	uM	1.0
780	Inhibition of CYP3A4	N[C@H](C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238763	=	=	IC50	nM	450.0	IC50	uM	0.45
781	Inhibition of CYP3A4	C[C@H](N)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238762	>	>	IC50	nM	10000.0	IC50	uM	10.0
782	Inhibition of CYP3A4	O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241271	=	=	IC50	nM	3500.0	IC50	uM	3.5
783	Inhibition of CYP3A4	O=C([C@@H](O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241270	=	=	IC50	nM	2000.0	IC50	uM	2.0
784	Inhibition of CYP3A4	O=C([C@@H](O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392064	=	=	IC50	nM	4000.0	IC50	uM	4.0
785	Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241064	=	=	IC50	nM	1000.0	IC50	uM	1.0
786	Inhibition of CYP3A4	C[C@H](O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL395942	=	=	IC50	nM	1000.0	IC50	uM	1.0
787	Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240867	=	=	IC50	nM	410.0	IC50	uM	0.41
788	Inhibition of CYP3A4	C[C@@H](N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397114	=	=	IC50	nM	10000.0	IC50	uM	10.0
789	Inhibition of CYP3A4	N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240646	=	=	IC50	nM	7000.0	IC50	uM	7.0
790	Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240645	=	=	IC50	nM	250.0	IC50	uM	0.25
791	Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL394438	=	=	IC50	nM	530.0	IC50	uM	0.53
792	Inhibition of CYP3A4	N[C@@H](C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391189	=	=	IC50	nM	470.0	IC50	uM	0.47
793	Inhibition of CYP3A4	O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL442086	=	=	IC50	nM	10000.0	IC50	uM	10.0
794	Inhibition of CYP3A4	O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239150	=	=	IC50	nM	4000.0	IC50	uM	4.0
795	Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239149	=	=	IC50	nM	10000.0	IC50	uM	10.0
796	Inhibition of CYP3A4	CC(C)[C@@H](O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238945	=	=	IC50	nM	10000.0	IC50	uM	10.0
797	Inhibition of CYP3A4	O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL394993	=	=	IC50	nM	3000.0	IC50	uM	3.0
798	Inhibition of CYP3A4	O=C([C@H](O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238744	=	=	IC50	nM	3500.0	IC50	uM	3.5
799	Inhibition of CYP3A4	O=C(O)COc1ccc(Cl)cc1C1CCCCCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL398126	>	>	IC50	nM	10000.0	IC50	uM	10.0
800	Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399719	>	>	IC50	nM	20000.0	IC50	uM	20.0
801	Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248407	=	=	IC50	nM	9000.0	IC50	uM	9.0
802	Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248231	=	=	IC50	nM	12000.0	IC50	uM	12.0
803	Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4cc(F)c5c(c4)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL247428	>	>	IC50	nM	19000.0	IC50	uM	19.0
804	Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4F)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL247609	>	>	IC50	nM	16000.0	IC50	uM	16.0
805	Inhibition of CYP3A4	CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)c(F)c21	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL443060	>	>	IC50	nM	9000.0	IC50	uM	9.0
806	Inhibition of CYP3A4	O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248849	=	=	IC50	nM	2330.0	IC50	uM	2.33
807	Inhibition of CYP3A4	O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248849	=	=	IC50	nM	1000.0	IC50	uM	1.0
808	Inhibition of human CYP3A4	O=C(/C=C/c1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399045	>	>	IC50	nM	40000.0	IC50	uM	40.0
809	Inhibition of CYP3A4 after 30 mins	O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCCCC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL398430	=	=	IC50	nM	1200.0	IC50	uM	1.2
810	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249494	=	=	IC50	nM	11000.0	IC50	uM	11.0
811	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249493	=	=	IC50	nM	1500.0	IC50	uM	1.5
812	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399507	=	=	IC50	nM	19500.0	IC50	uM	19.5
813	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393941	=	=	IC50	nM	400.0	IC50	uM	0.4
814	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249293	=	=	IC50	nM	500.0	IC50	uM	0.5
815	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236184	=	=	IC50	nM	2200.0	IC50	uM	2.2
816	Inhibition of CYP3A4 after 30 mins	C[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249292	=	=	IC50	nM	800.0	IC50	uM	0.8
817	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](c4cc(F)cc(F)c4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249087	=	=	IC50	nM	400.0	IC50	uM	0.4
818	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401323	=	=	IC50	nM	30000.0	IC50	uM	30.0
819	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249086	=	=	IC50	nM	15600.0	IC50	uM	15.6
820	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249085	=	=	IC50	nM	10100.0	IC50	uM	10.1
821	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL438525	=	=	IC50	nM	30000.0	IC50	uM	30.0
822	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248880	=	=	IC50	nM	300.0	IC50	uM	0.3
823	Inhibition of CYP3A4 after 30 mins	O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401122	=	=	IC50	nM	300.0	IC50	uM	0.3
824	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248879	=	=	IC50	nM	24300.0	IC50	uM	24.3
825	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248867	=	=	IC50	nM	3400.0	IC50	uM	3.4
826	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248866	=	=	IC50	nM	5000.0	IC50	uM	5.0
827	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248677	=	=	IC50	nM	1300.0	IC50	uM	1.3
828	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239629	=	=	IC50	nM	60.0	IC50	uM	0.06
829	Inhibition of CYP3A4 after 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(CCO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240070	=	=	IC50	nM	400.0	IC50	uM	0.4
830	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240069	=	=	IC50	nM	400.0	IC50	uM	0.4
831	Inhibition of human CYP3A4	CC(=O)N1CCN(CC(O)CN2CCN(CCc3c(-c4cc(C)cc(C)c4)[nH]c4sc(C(C)(C)C(=O)N5C6CCC5CC6)cc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401352	=	=	IC50	nM	6000.0	IC50	uM	6.0
832	Inhibition of human CYP3A4	Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(O)CN3CCNCC3)CC2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401418	>	>	IC50	nM	10000.0	IC50	uM	10.0
833	Inhibition of human CYP3A4	Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(=O)N3CCOCC3)CC2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399772	=	=	IC50	nM	100.0	IC50	uM	0.1
834	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2007.0	CHEMBL157101	=	=	IC50	nM	210.0	IC50	uM	0.21
835	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)-c1cc3ccc(O)c(OC)c3c[n+]1CC2	J. Nat. Prod.	2007.0	CHEMBL251229	>	>	IC50	nM	2500.0	IC50	uM	2.5
836	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1[C@@H](O)C[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O)[C@H]1O[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL398472	>	>	IC50	nM	100000.0	IC50	uM	100.0
837	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2.[Cl-]	J. Nat. Prod.	2007.0	CHEMBL274189	=	=	IC50	nM	900.0	IC50	uM	0.9
838	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O	J. Nat. Prod.	2007.0	CHEMBL255034	>	>	IC50	nM	100000.0	IC50	uM	100.0
839	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@H]2C=C[C@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O2	J. Nat. Prod.	2007.0	CHEMBL399973	>	>	IC50	nM	100000.0	IC50	uM	100.0
840	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1O[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL399731	>	>	IC50	nM	100000.0	IC50	uM	100.0
841	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O	J. Nat. Prod.	2007.0	CHEMBL254592	>	>	IC50	nM	100000.0	IC50	uM	100.0
842	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1CC[C@@]1(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(=O)C=CC[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL251672	>	>	IC50	nM	100000.0	IC50	uM	100.0
843	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12[C@H]3CC=C[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]2C[C@]1(O)C(=O)O[C@H](c2ccoc2)C[C@@]31C	J. Nat. Prod.	2007.0	CHEMBL249243	>	>	IC50	nM	100000.0	IC50	uM	100.0
844	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@@H](c3ccoc3)OC(=O)[C@@]1(O)C[C@H]1OC(=O)[C@@]3(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=CC[C@@H]2[C@@]13C	J. Nat. Prod.	2007.0	CHEMBL400494	>	>	IC50	nM	100000.0	IC50	uM	100.0
845	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2	J. Nat. Prod.	2007.0	CHEMBL400345	=	=	IC50	nM	30600.0	IC50	uM	30.6
846	Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)CC[n+]1cc3c(OC)c(OC)ccc3cc1-2	J. Nat. Prod.	2007.0	CHEMBL251055	=	=	IC50	nM	2100.0	IC50	uM	2.1
847	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(N)=O)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252615	=	=	IC50	nM	11500.0	IC50	uM	11.5
848	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(CN4CCCC4)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252200	=	=	IC50	nM	700.0	IC50	uM	0.7
849	Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CC[C@@H](O)C3)no2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399283	=	=	IC50	nM	600.0	IC50	uM	0.6
850	Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254080	=	=	IC50	nM	300.0	IC50	uM	0.3
851	Inhibition of CYP3A4 pre-incubated before 30 mins	CN(Cc1noc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)n1)C(C)(C)CO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252404	=	=	IC50	nM	300.0	IC50	uM	0.3
852	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(CN(C)C(C)(C)CO)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252001	=	=	IC50	nM	300.0	IC50	uM	0.3
853	Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2noc(CN3CCCC3)n2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL251800	=	=	IC50	nM	1200.0	IC50	uM	1.2
854	Inhibition of CYP3A4 pre-incubated before 30 mins	CN(Cc1nc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)no1)C(C)(C)CO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL443065	=	=	IC50	nM	3100.0	IC50	uM	3.1
855	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(CN4CCOCC4)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253655	=	=	IC50	nM	2600.0	IC50	uM	2.6
856	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(C)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252616	>	>	IC50	nM	30000.0	IC50	uM	30.0
857	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(CN(C)C(C)(C)CO)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253023	=	=	IC50	nM	4000.0	IC50	uM	4.0
858	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(C)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252817	=	=	IC50	nM	16900.0	IC50	uM	16.9
859	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3ncco3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403999	<	<	IC50	nM	30.0	IC50	uM	0.03
860	Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252614	=	=	IC50	nM	1000.0	IC50	uM	1.0
861	Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252414	=	=	IC50	nM	7000.0	IC50	uM	7.0
862	Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN2CCCC[C@H]2C1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL428586	=	=	IC50	nM	1800.0	IC50	uM	1.8
863	Inhibition of CYP3A4 pre-incubated before 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL249493	=	=	IC50	nM	1500.0	IC50	uM	1.5
864	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403998	=	=	IC50	nM	2200.0	IC50	uM	2.2
865	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4C)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL438699	=	=	IC50	nM	4700.0	IC50	uM	4.7
866	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252211	=	=	IC50	nM	300.0	IC50	uM	0.3
867	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC4(CCN4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252210	=	=	IC50	nM	5600.0	IC50	uM	5.6
868	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN4CCCC[C@H]4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252209	=	=	IC50	nM	4200.0	IC50	uM	4.2
869	Inhibition of CYP3A4 pre-incubated before 30 mins	CCCC1(O)CCN(C(=O)CC2([C@H]3CCC[C@@H](CC)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL398773	=	=	IC50	nM	5000.0	IC50	uM	5.0
870	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC[C@H]3CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429836	=	=	IC50	nM	9000.0	IC50	uM	9.0
871	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL398772	=	=	IC50	nM	4700.0	IC50	uM	4.7
872	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC(N4CCCCC4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254912	=	=	IC50	nM	1200.0	IC50	uM	1.2
873	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254705	=	=	IC50	nM	11900.0	IC50	uM	11.9
874	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399590	=	=	IC50	nM	2600.0	IC50	uM	2.6
875	Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL236184	=	=	IC50	nM	2200.0	IC50	uM	2.2
876	Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL239629	=	=	IC50	nM	60.0	IC50	uM	0.06
877	Inhibition of CYP3A4	COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403268	=	=	IC50	nM	696.0	IC50	nM	696.0
878	Inhibition of CYP3A4	O=C(N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1OC(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400262	=	=	IC50	nM	1800.0	IC50	uM	1.8
879	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254497	=	=	IC50	nM	980.0	IC50	uM	0.98
880	Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)ccc(F)c1F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403809	=	=	IC50	nM	980.0	IC50	uM	0.98
881	Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)cccc1F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404229	>	>	IC50	nM	20000.0	IC50	uM	20.0
882	Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1Cl)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252838	>	>	IC50	nM	20000.0	IC50	uM	20.0
883	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400846	=	=	IC50	nM	3400.0	IC50	uM	3.4
884	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252240	=	=	IC50	nM	810.0	IC50	uM	0.81
885	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252837	=	=	IC50	nM	2000.0	IC50	uM	2.0
886	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400845	=	=	IC50	nM	5300.0	IC50	uM	5.3
887	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)ccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252836	=	=	IC50	nM	3900.0	IC50	uM	3.9
888	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400642	=	=	IC50	nM	6100.0	IC50	uM	6.1
889	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252636	=	=	IC50	nM	4600.0	IC50	uM	4.6
890	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404622	>	>	IC50	nM	20000.0	IC50	uM	20.0
891	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(Cl)c1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252438	=	=	IC50	nM	2400.0	IC50	uM	2.4
892	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1OC(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253660	=	=	IC50	nM	1300.0	IC50	uM	1.3
893	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404621	>	>	IC50	nM	10000.0	IC50	uM	10.0
894	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252437	>	>	IC50	nM	10000.0	IC50	uM	10.0
895	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252239	=	=	IC50	nM	6000.0	IC50	uM	6.0
896	Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1C(F)(F)F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400261	=	=	IC50	nM	1900.0	IC50	uM	1.9
897	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254918	=	=	IC50	nM	820.0	IC50	uM	0.82
898	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC1CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399568	=	=	IC50	nM	2430.0	IC50	uM	2.43
899	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC(F)(F)C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252632	=	=	IC50	nM	980.0	IC50	uM	0.98
900	Inhibition of CYP3A4	CC(C1CC1)n1c(CNC(=O)[C@@H](Cc2ccccc2C(F)(F)F)NC(=O)OC(C)(C)C)nc2cccnc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253883	=	=	IC50	nM	860.0	IC50	uM	0.86
901	Inhibition of CYP3A4	Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255858	=	=	IC50	nM	5300.0	IC50	nM	5300.0
902	Inhibition of human CYP3A4	O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4CO)ccc23)cn1)Nc1cccc(F)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253968	>	>	IC50	nM	10000.0	IC50	uM	10.0
903	Inhibition of human CYP3A4	O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4COP(=O)(O)O)ccc23)cn1)Nc1cccc(F)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL250766	=	=	IC50	nM	6100.0	IC50	uM	6.1
904	Inhibition of CYP3A4	CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403313	>	>	IC50	nM	5000.0	IC50	uM	5.0
905	Inhibition of CYP3A4	COc1ccc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)c(CN(C)C)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429850	=	=	IC50	nM	1600.0	IC50	nM	1600.0
906	Inhibition of CYP3A4	Cc1cc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253528	=	=	IC50	nM	1100.0	IC50	nM	1100.0
907	Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)COc3cccc(CN(C)C)c3)nc(-c3ccc(C)o3)n2)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401895	>	>	IC50	nM	6000.0	IC50	nM	6000.0
908	Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL196478	=	=	IC50	nM	4000.0	IC50	uM	4.0
909	Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(C(F)(F)F)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401960	=	=	IC50	nM	3000.0	IC50	uM	3.0
910	Inhibition of CYP3A4	Cc1nc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401910	>	>	IC50	nM	100000.0	IC50	uM	100.0
911	Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(Br)s1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL410420	=	=	IC50	nM	1000.0	IC50	uM	1.0
912	Inhibition of CYP3A4	Cc1ccc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL209864	=	=	IC50	nM	7000.0	IC50	uM	7.0
913	Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N(C)CCO)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256391	>	>	IC50	nM	100000.0	IC50	uM	100.0
914	Inhibition of CYP3A4	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429736	>	>	IC50	nM	100000.0	IC50	uM	100.0
915	Inhibition of CYP3A4	CC[C@@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401858	>	>	IC50	nM	100000.0	IC50	uM	100.0
916	Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N2CCOCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271039	>	>	IC50	nM	100000.0	IC50	uM	100.0
917	Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N2CCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403149	>	>	IC50	nM	100000.0	IC50	uM	100.0
918	Inhibition of CYP3A4	C[C@@H](NC(=O)[C@@](C)(O)C(F)(F)F)c1ncc(-c2cc(Cl)cc(F)c2-c2nnn(C)n2)cc1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258324	>	>	IC50	nM	10000.0	IC50	uM	10.0
919	Inhibition of CYP3A4	CN(C)S(=O)(=O)N(C)[C@@H]1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	J. Med. Chem.	2008.0	CHEMBL408479	>	>	IC50	nM	100000.0	IC50	uM	100.0
920	Inhibition of CYP3A4	CN(C)C(=O)C(=O)N(C)[C@H]1CCCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	J. Med. Chem.	2008.0	CHEMBL408962	>	>	IC50	nM	100000.0	IC50	uM	100.0
921	Inhibition of human CYP3A4	CNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404401	=	=	IC50	nM	2100.0	IC50	nM	2100.0
922	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	5000.0	IC50	nM	5000.0
923	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(OCC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270368	=	=	IC50	nM	7600.0	IC50	nM	7600.0
924	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(O[C@H]3CCNC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402279	=	=	IC50	nM	4800.0	IC50	nM	4800.0
925	Inhibition of human CYP3A4	CC(N)COc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256195	>	>	IC50	nM	40000.0	IC50	nM	40000.0
926	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N3CCN(C)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429845	=	=	IC50	nM	200.0	IC50	nM	200.0
927	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N3CCC(N)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271864	=	=	IC50	nM	300.0	IC50	nM	300.0
928	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	25000.0	IC50	nM	25000.0
929	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	29000.0	IC50	nM	29000.0
930	Inhibition of human CYP3A4	CNCCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271512	>	>	IC50	nM	40000.0	IC50	nM	40000.0
931	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402319	>	>	IC50	nM	40000.0	IC50	nM	40000.0
932	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCC(C)(C)CN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270869	=	=	IC50	nM	1400.0	IC50	nM	1400.0
933	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCC(C)(C)N)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271087	>	>	IC50	nM	40000.0	IC50	nM	40000.0
934	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCO)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271941	=	=	IC50	nM	5200.0	IC50	nM	5200.0
935	Inhibition of human CYP3A4	CC(C)Nc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL407708	=	=	IC50	nM	400.0	IC50	nM	400.0
936	Inhibition of human CYP3A4	CCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL407944	=	=	IC50	nM	400.0	IC50	nM	400.0
937	Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255394	=	=	IC50	nM	800.0	IC50	nM	800.0
938	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	37000.0	IC50	uM	37.0
939	Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	29000.0	IC50	uM	29.0
940	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	10000.0	IC50	uM	10.0
941	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	27000.0	IC50	uM	27.0
942	Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	5000.0	IC50	uM	5.0
943	Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	25000.0	IC50	uM	25.0
944	Inhibition of human recombinant CYP3A4	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O	J. Med. Chem.	2008.0	CHEMBL270515	=	=	IC50	nM	3500.0	IC50	uM	3.5
945	Inhibition of CYP3A4	O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1	J. Med. Chem.	2008.0	CHEMBL217716	=	=	IC50	nM	510.0	IC50	uM	0.51
946	Inhibition of CYP3A4	COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403525	=	=	IC50	nM	1300.0	IC50	uM	1.3
947	Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)Cc3ccc(S(C)(=O)=O)cc3)nc(-c3ccccn3)n2)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270654	>	>	IC50	nM	10000.0	IC50	uM	10.0
948	Inhibition of CYP3A4	Cc1cc(C)cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429420	>	>	IC50	nM	10000.0	IC50	uM	10.0
949	Inhibition of CYP3A4	CCOc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1OC	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270655	=	=	IC50	nM	7000.0	IC50	uM	7.0
950	Inhibition of CYP3A4	COc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402071	=	=	IC50	nM	1800.0	IC50	uM	1.8
951	Inhibition of CYP3A4	COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257670	>	>	IC50	nM	5000.0	IC50	uM	5.0
952	Inhibition of human CYP3A4	NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255590	>	>	IC50	nM	20000.0	IC50	uM	20.0
953	Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271876	=	=	IC50	nM	59000.0	IC50	uM	59.0
954	Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271876	=	=	IC50	nM	11000.0	IC50	uM	11.0
955	Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270666	=	=	IC50	nM	9800.0	IC50	uM	9.8
956	Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270666	=	=	IC50	nM	5500.0	IC50	uM	5.5
957	Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL377300	=	=	IC50	nM	18000.0	IC50	uM	18.0
958	Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL377300	=	=	IC50	nM	40000.0	IC50	uM	40.0
959	Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL270996	=	=	IC50	nM	160.0	IC50	uM	0.16
960	Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL270996	=	=	IC50	nM	310.0	IC50	uM	0.31
961	Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408444	=	=	IC50	nM	510.0	IC50	uM	0.51
962	Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408444	=	=	IC50	nM	1600.0	IC50	uM	1.6
963	Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408443	=	=	IC50	nM	95.0	IC50	uM	0.095
964	Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408443	=	=	IC50	nM	370.0	IC50	uM	0.37
965	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271240	=	=	IC50	nM	50000.0	IC50	uM	50.0
966	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271240	=	=	IC50	nM	830.0	IC50	uM	0.83
967	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL272336	=	=	IC50	nM	4700.0	IC50	uM	4.7
968	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404451	>	>	IC50	nM	40000.0	IC50	uM	40.0
969	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256468	>	>	IC50	nM	40000.0	IC50	uM	40.0
970	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL272963	=	=	IC50	nM	20000.0	IC50	uM	20.0
971	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255389	=	=	IC50	nM	17000.0	IC50	uM	17.0
972	Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL411118	=	=	IC50	nM	33000.0	IC50	uM	33.0
973	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257517	=	=	IC50	nM	12000.0	IC50	uM	12.0
974	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429734	=	=	IC50	nM	20000.0	IC50	uM	20.0
975	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404646	=	=	IC50	nM	19000.0	IC50	uM	19.0
976	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404451	>	>	IC50	nM	40000.0	IC50	uM	40.0
977	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256468	=	=	IC50	nM	28000.0	IC50	uM	28.0
978	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255389	=	=	IC50	nM	19000.0	IC50	uM	19.0
979	Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL411118	=	=	IC50	nM	26000.0	IC50	uM	26.0
980	Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1	J. Med. Chem.	2008.0	CHEMBL271202	=	=	IC50	nM	13000.0	IC50	uM	13.0
981	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL406917	=	=	IC50	nM	1300.0	IC50	uM	1.3
982	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL270902	=	=	IC50	nM	60.0	IC50	uM	0.06
983	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	O[C@](Cn1cccn1)(c1ccc(F)cc1F)n1cncn1	J. Med. Chem.	2008.0	CHEMBL3085388	=	=	IC50	nM	44000.0	IC50	uM	44.0
984	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COC(=O)[C@H](Cc1c[nH]cn1)NCc1ccccc1	J. Med. Chem.	2008.0	CHEMBL270272	=	=	IC50	nM	1500.0	IC50	uM	1.5
985	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL410503	=	=	IC50	nM	7700.0	IC50	uM	7.7
986	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL270271	=	=	IC50	nM	210.0	IC50	uM	0.21
987	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271579	=	=	IC50	nM	130.0	IC50	uM	0.13
988	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1	J. Med. Chem.	2008.0	CHEMBL258502	=	=	IC50	nM	45.0	IC50	uM	0.045
989	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1	J. Med. Chem.	2008.0	CHEMBL271581	=	=	IC50	nM	13000.0	IC50	uM	13.0
990	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271580	=	=	IC50	nM	230.0	IC50	uM	0.23
991	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1	J. Med. Chem.	2008.0	CHEMBL270903	=	=	IC50	nM	26000.0	IC50	uM	26.0
992	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL271121	=	=	IC50	nM	71.0	IC50	uM	0.071
993	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL271120	=	=	IC50	nM	9600.0	IC50	uM	9.6
994	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1	J. Med. Chem.	2008.0	CHEMBL405565	=	=	IC50	nM	1300.0	IC50	uM	1.3
995	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	O=C(Nc1ccccc1)OCc1cn(-c2ccc(Cl)cc2)nn1	J. Med. Chem.	2008.0	CHEMBL407246	>	>	IC50	nM	20000.0	IC50	uM	20.0
996	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1	J. Med. Chem.	2008.0	CHEMBL271622	=	=	IC50	nM	33000.0	IC50	uM	33.0
997	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1	J. Med. Chem.	2008.0	CHEMBL271621	=	=	IC50	nM	12000.0	IC50	uM	12.0
998	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1	J. Med. Chem.	2008.0	CHEMBL271326	=	=	IC50	nM	34000.0	IC50	uM	34.0
999	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1	J. Med. Chem.	2008.0	CHEMBL271624	=	=	IC50	nM	28000.0	IC50	uM	28.0
1000	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccccn3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL406832	>	>	IC50	nM	40000.0	IC50	uM	40.0
1001	Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccccc2)n1	J. Med. Chem.	2008.0	CHEMBL271620	>	>	IC50	nM	40000.0	IC50	uM	40.0
1002	Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271580	=	=	Kd	nM	380.0	Kd	uM	0.38
1003	Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL410503	=	=	Kd	nM	3500.0	Kd	uM	3.5
1004	Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL270271	=	=	Kd	nM	210.0	Kd	uM	0.21
1005	Inhibition of CYP3A4	CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL273208	>	>	IC50	nM	3000.0	IC50	uM	3.0
1006	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL429743	>	>	IC50	nM	50000.0	IC50	uM	50.0
1007	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3F)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL429585	>	>	IC50	nM	50000.0	IC50	uM	50.0
1008	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)no5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL270978	=	=	IC50	nM	40000.0	IC50	uM	40.0
1009	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccncc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL272693	=	=	IC50	nM	100.0	IC50	uM	0.1
1010	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cccnc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL406388	=	=	IC50	nM	2000.0	IC50	uM	2.0
1011	Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccccn5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL269915	=	=	IC50	nM	13000.0	IC50	uM	13.0
1012	Inhibition of CYP3A4	Nc1nccn2c(C3CCC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12	Bioorg. Med. Chem.	2008.0	CHEMBL261805	=	=	IC50	nM	3400.0	IC50	uM	3.4
1013	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL258648	=	=	IC50	nM	12000.0	IC50	uM	12.0
1014	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCSCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL258951	=	=	IC50	nM	7800.0	IC50	uM	7.8
1015	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL408712	=	=	IC50	nM	7500.0	IC50	uM	7.5
1016	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL261146	=	=	IC50	nM	17000.0	IC50	uM	17.0
1017	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411082	>	>	IC50	nM	20000.0	IC50	uM	20.0
1018	Inhibition of CYP3A4	CN(C)[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL430051	=	=	IC50	nM	19000.0	IC50	uM	19.0
1019	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@H](CN2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL261253	>	>	IC50	nM	20000.0	IC50	uM	20.0
1020	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411074	>	>	IC50	nM	20000.0	IC50	uM	20.0
1021	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@H](CN2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL260298	=	=	IC50	nM	17000.0	IC50	uM	17.0
1022	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL410659	>	>	IC50	nM	20000.0	IC50	uM	20.0
1023	Inhibition of CYP3A4	CN(C)C[C@H]1C[C@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411062	=	=	IC50	nM	15000.0	IC50	uM	15.0
1024	Inhibition of CYP3A4	CN(C)C[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL413828	=	=	IC50	nM	15000.0	IC50	uM	15.0
1025	Inhibition of human recombinant CYP3A4	O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21	J. Med. Chem.	2008.0	CHEMBL410333	>	>	IC50	nM	10000.0	IC50	uM	10.0
1026	Inhibition of human CYP3A4	Oc1cccc(-c2ccc3cc(O)ccc3c2)c1	J. Med. Chem.	2008.0	CHEMBL195217	=	=	IC50	nM	1580.0	IC50	uM	1.58
1027	Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	54.0	IC50	uM	0.054
1028	Inhibition of CYP3A4	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2008.0	CHEMBL263664	>	>	IC50	nM	50000.0	IC50	uM	50.0
1029	Inhibition of CYP3A4	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL259922	>	>	IC50	nM	40000.0	IC50	uM	40.0
1030	Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260636	=	=	IC50	nM	1.0	IC50	nM	1.0
1031	Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL261288	=	=	IC50	nM	4300.0	IC50	uM	4.3
1032	Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2cc(O)c(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL405895	=	=	IC50	nM	1.0	IC50	nM	1.0
1033	Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(C2CCN(CCC(=O)Nc3ccccc3F)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409494	=	=	IC50	nM	10000.0	Log IC50		-5.0
1034	Inhibition of CYP3A4	CN(C)C(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260200	<	<	IC50	nM	10000.0	Log IC50		-5.0
1035	Inhibition of CYP3A4	CNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL264961	<	<	IC50	nM	10000.0	Log IC50		-5.0
1036	Inhibition of CYP3A4	CCNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL412083	<	<	IC50	nM	10000.0	Log IC50		-5.0
1037	Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(C2CCN(Cc3ccc(C(=O)NC4CC4)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409493	<	<	IC50	nM	10000.0	Log IC50		-5.0
1038	Inhibition of CYP3A4	COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260259	>	>	IC50	nM	29000.0	IC50	uM	29.0
1039	Inhibition of CYP3A4	Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258694	>	>	IC50	nM	40000.0	IC50	uM	40.0
1040	Inhibition of CYP3A4	CNc1nnc(-c2cn3ncnc(Nc4cnc5[nH]c(C)cc5c4)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409442	=	=	IC50	nM	6400.0	IC50	uM	6.4
1041	Inhibition of CYP3A4	Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL261592	=	=	IC50	nM	11500.0	IC50	uM	11.5
1042	Inhibition of CYP3A4	COc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403080	>	>	IC50	nM	10000.0	IC50	uM	10.0
1043	Inhibition of CYP3A4	Cc1cc(Oc2ccc(Cl)cc2C)c(CN(C)C)cn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256970	>	>	IC50	nM	10000.0	IC50	uM	10.0
1044	Inhibition of CYP3A4	CN(CC(=O)N1CCC[C@H](c2ccccc2)[C@@H]1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402303	=	=	IC50	nM	1400.0	IC50	uM	1.4
1045	Inhibition of CYP3A4	Cc1cc(NC(=O)OC(C)(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258199	>	>	IC50	nM	100000.0	IC50	uM	100.0
1046	Inhibition of CYP3A4	Cc1cc(NC(=O)OC(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256092	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
1047	Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254356	=	=	IC50	nM	1400.0	IC50	uM	1.4
1048	Inhibition of CYP3A4	O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255460	=	=	IC50	nM	680.0	IC50	uM	0.68
1049	Inhibition of CYP3A4	O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255462	=	=	IC50	nM	1000.0	IC50	uM	1.0
1050	Inhibition of CYP3A4	O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404289	=	=	IC50	nM	1300.0	IC50	uM	1.3
1051	Inhibition of CYP3A4	O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257150	=	=	IC50	nM	2100.0	IC50	uM	2.1
1052	Inhibition of CYP3A4	Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCOCC3)c2cc1C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256721	=	=	IC50	nM	2700.0	IC50	uM	2.7
1053	Inhibition of CYP3A4	Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCCC3)c2cc1C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257415	=	=	IC50	nM	6800.0	IC50	uM	6.8
1054	Inhibition of CYP3A4	O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256988	=	=	IC50	nM	1000.0	IC50	uM	1.0
1055	Inhibition of CYP3A4	O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256989	=	=	IC50	nM	1200.0	IC50	uM	1.2
1056	Inhibition of CYP3A4	Cc1cc2c(cc1C)N(CC(=O)N1CCCC(c3ccccc3)C1CN1CCCC1)C(=O)CO2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257171	=	=	IC50	nM	3900.0	IC50	uM	3.9
1057	Inhibition of CYP3A4	O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402520	=	=	IC50	nM	730.0	IC50	uM	0.73
1058	Inhibition of CYP3A4	O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255509	=	=	IC50	nM	1800.0	IC50	uM	1.8
1059	Inhibition of CYP3A4	COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402813	=	=	IC50	nM	480.0	IC50	uM	0.48
1060	Inhibition of CYP3A4	COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256937	=	=	IC50	nM	1200.0	IC50	uM	1.2
1061	Inhibition of CYP3A4	N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258251	=	=	IC50	nM	490.0	IC50	uM	0.49
1062	Inhibition of CYP3A4	N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257767	=	=	IC50	nM	1100.0	IC50	uM	1.1
1063	Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402805	=	=	IC50	nM	770.0	IC50	uM	0.77
1064	Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cnccc3N)ccc2c1	J. Med. Chem.	2008.0	CHEMBL453169	=	=	IC50	nM	21070.0	IC50	nM	21070.0
1065	Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cncc4ccccc34)ccc2c1	J. Med. Chem.	2008.0	CHEMBL500394	=	=	IC50	nM	3540.0	IC50	nM	3540.0
1066	Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1	J. Med. Chem.	2008.0	CHEMBL502824	=	=	IC50	nM	9070.0	IC50	nM	9070.0
1067	Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1cncc(-c2ccc3cc(OC)ccc3c2)c1	J. Med. Chem.	2008.0	CHEMBL447591	=	=	IC50	nM	1913.0	IC50	nM	1913.0
1068	Inhibition of human recombinant CYP3A4 expressed in insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
1069	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2cccnc2)CCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498471	>	>	IC50	nM	20000.0	IC50	nM	20000.0
1070	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	72.0	IC50	nM	72.0
1071	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2008.0	CHEMBL254328	=	=	IC50	nM	2704.0	IC50	nM	2704.0
1072	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496469	=	=	IC50	nM	3386.0	IC50	nM	3386.0
1073	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1O	J. Med. Chem.	2008.0	CHEMBL522228	=	=	IC50	nM	632.0	IC50	nM	632.0
1074	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496456	=	=	IC50	nM	2300.0	IC50	nM	2300.0
1075	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL496289	=	=	IC50	nM	2173.0	IC50	nM	2173.0
1076	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL496288	=	=	IC50	nM	1093.0	IC50	nM	1093.0
1077	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1	J. Med. Chem.	2008.0	CHEMBL496287	=	=	IC50	nM	1697.0	IC50	nM	1697.0
1078	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496286	=	=	IC50	nM	2114.0	IC50	nM	2114.0
1079	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1O	J. Med. Chem.	2008.0	CHEMBL526081	=	=	IC50	nM	357.0	IC50	nM	357.0
1080	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL497481	=	=	IC50	nM	3643.0	IC50	nM	3643.0
1081	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL497480	=	=	IC50	nM	4199.0	IC50	nM	4199.0
1082	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1.Cl	J. Med. Chem.	2008.0	CHEMBL497309	=	=	IC50	nM	2394.0	IC50	nM	2394.0
1083	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL498662	=	=	IC50	nM	159.0	IC50	nM	159.0
1084	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CC=C3c2cccnc2)cc1	J. Med. Chem.	2008.0	CHEMBL522730	>	>	IC50	nM	6947.0	IC50	nM	6947.0
1085	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCCC3(O)c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496263	=	=	IC50	nM	15190.0	IC50	nM	15190.0
1086	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCCc2cc(-c3ccc(F)c(F)c3)ccc21	J. Med. Chem.	2008.0	CHEMBL496262	=	=	IC50	nM	13841.0	IC50	nM	13841.0
1087	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498652	=	=	IC50	nM	8757.0	IC50	nM	8757.0
1088	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL539168	=	=	IC50	nM	3364.0	IC50	nM	3364.0
1089	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL498643	=	=	IC50	nM	3291.0	IC50	nM	3291.0
1090	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498472	=	=	IC50	nM	3231.0	IC50	nM	3231.0
1091	Inhibition of CYP3A4	CC(C)OC(=O)c1ccc(NC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H]2CCC[N+](C)(Cc3cccc(O)c3)C2)cc1.[I-]	J. Med. Chem.	2008.0	CHEMBL540359	=	=	IC50	nM	10000.0	pIC50		5.0
1092	Inhibition of recombinant CYP3A4	O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446545	=	=	IC50	nM	3700.0	IC50	uM	3.7
1093	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL448656	=	=	IC50	nM	36000.0	IC50	uM	36.0
1094	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@@H](c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509267	=	=	IC50	nM	42000.0	IC50	uM	42.0
1095	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL451916	=	=	IC50	nM	13000.0	IC50	uM	13.0
1096	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454774	=	=	IC50	nM	28000.0	IC50	uM	28.0
1097	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505033	=	=	IC50	nM	8200.0	IC50	uM	8.2
1098	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL448253	=	=	IC50	nM	10000.0	IC50	uM	10.0
1099	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL449468	=	=	IC50	nM	22000.0	IC50	uM	22.0
1100	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL444989	=	=	IC50	nM	25000.0	IC50	uM	25.0
1101	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCC(C)(C)CC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL447424	=	=	IC50	nM	10000.0	IC50	uM	10.0
1102	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509347	=	=	IC50	nM	22000.0	IC50	uM	22.0
1103	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL506338	=	=	IC50	nM	10000.0	IC50	uM	10.0
1104	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCNCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499442	=	=	IC50	nM	33000.0	IC50	uM	33.0
1105	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
1106	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455769	=	=	IC50	nM	510.0	IC50	uM	0.51
1107	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499849	=	=	IC50	nM	36000.0	IC50	uM	36.0
1108	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL503624	=	=	IC50	nM	350.0	IC50	uM	0.35
1109	Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
1110	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL466555	=	=	IC50	nM	870.0	IC50	uM	0.87
1111	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL466555	=	=	IC50	nM	84.0	IC50	uM	0.084
1112	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	=	=	IC50	nM	26000.0	IC50	uM	26.0
1113	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL454791	=	=	IC50	nM	36000.0	IC50	uM	36.0
1114	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL454751	>	>	IC50	nM	40000.0	IC50	uM	40.0
1115	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL454791	=	=	IC50	nM	6000.0	IC50	uM	6.0
1116	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL454751	=	=	IC50	nM	4000.0	IC50	uM	4.0
1117	Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	=	=	IC50	nM	7800.0	IC50	uM	7.8
1118	Inhibition of human recombinant CYP3A4 expressed in insect microsomes assessed as metabolism of testosterone	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	>	>	IC50	nM	40000.0	IC50	uM	40.0
1119	Inhibition of CYP3A4	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1	J. Med. Chem.	2009.0	CHEMBL495727	>	>	IC50	nM	10000.0	IC50	uM	10.0
1120	Inhibition of human recombinant CYP3A4	O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1	Eur. J. Med. Chem.	2008.0	CHEMBL452101	=	=	IC50	nM	5100.0	IC50	mM	0.0051
1121	Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL270361	=	=	IC50	nM	64900.0	IC50	mM	0.0649
1122	Inhibition of human recombinant CYP3A4	CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL497137	=	=	IC50	nM	73500.0	IC50	mM	0.0735
1123	Inhibition of human recombinant CYP3A4	CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498371	=	=	IC50	nM	77600.0	IC50	mM	0.0776
1124	Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498373	=	=	IC50	nM	38300.0	IC50	mM	0.0383
1125	Inhibition of human recombinant CYP3A4	Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL407034	=	=	IC50	nM	40300.0	IC50	mM	0.0403
1126	Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL493001	=	=	IC50	nM	13200.0	IC50	mM	0.0132
1127	Inhibition of human recombinant CYP3A4	O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1	Eur. J. Med. Chem.	2008.0	CHEMBL452101	=	=	IC50	nM	5105050.0	log(1/IC50)		2.292
1128	Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL270361	=	=	IC50	nM	64863443.35	log(1/IC50)		1.188
1129	Inhibition of human recombinant CYP3A4	CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL497137	=	=	IC50	nM	73451386.82	log(1/IC50)		1.134
1130	Inhibition of human recombinant CYP3A4	CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498371	=	=	IC50	nM	77624711.66	log(1/IC50)		1.11
1131	Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498373	=	=	IC50	nM	38282474.33	log(1/IC50)		1.417
1132	Inhibition of human recombinant CYP3A4	Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL407034	=	=	IC50	nM	40271703.43	log(1/IC50)		1.395
1133	Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL493001	=	=	IC50	nM	76032627.69	log(1/IC50)		1.119
1134	Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL116438	=	=	IC50	nM	16300.0	IC50	uM	16.3
1135	Inhibition of CYP3A4	CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497999	>	>	IC50	nM	29100.0	IC50	uM	29.1
1136	Inhibition of CYP3A4	CCCCNc1nccc2[nH]c3ccccc3c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497171	=	=	IC50	nM	100.0	pIC50		7.0
1137	Inhibition of CYP3A4	COCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(CN(C)C3CCCCC3)ccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL486757	>	>	IC50	nM	14000.0	IC50	uM	14.0
1138	Inhibition of CYP3A4 green	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464234	=	=	IC50	nM	13600.0	IC50	uM	13.6
1139	Inhibition of CYP3A4 red	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464234	>	>	IC50	nM	25000.0	IC50	uM	25.0
1140	Inhibition of CYP3A4 red	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](CC2=O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL480016	=	=	IC50	nM	320.0	IC50	uM	0.32
1141	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517440	=	=	IC50	nM	2000.0	IC50	uM	2.0
1142	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517440	=	=	IC50	nM	4000.0	IC50	uM	4.0
1143	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL512127	=	=	IC50	nM	3000.0	IC50	uM	3.0
1144	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL461012	=	=	IC50	nM	700.0	IC50	uM	0.7
1145	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL467633	=	=	IC50	nM	2000.0	IC50	uM	2.0
1146	Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL520276	=	=	IC50	nM	4000.0	IC50	uM	4.0
1147	Inhibition of CYP3A4	CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464907	=	=	IC50	nM	100000.0	IC50	uM	100.0
1148	Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464245	=	=	IC50	nM	500.0	IC50	uM	0.5
1149	Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517933	=	=	IC50	nM	76000.0	IC50	uM	76.0
1150	Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465451	=	=	IC50	nM	100000.0	IC50	uM	100.0
1151	Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@@](C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL489500	>	>	IC50	nM	100000.0	IC50	uM	100.0
1152	Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@](C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL460962	>	>	IC50	nM	100000.0	IC50	uM	100.0
1153	Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465955	>	>	IC50	nM	100000.0	IC50	uM	100.0
1154	Inhibition of human CYP3A4 by microplate-based direct fluorometric assay	CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL460542	>	>	IC50	nM	10000.0	IC50	uM	10.0
1155	Inhibition of human CYP3A4 by microplate-based direct fluorometric assay	CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2-c2ccccc21.Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL473763	>	>	IC50	nM	10000.0	IC50	uM	10.0
1156	Inhibition of human CYP3A4	COCCCN1CCN([C@H]2CC[C@H](n3nc(-c4ccc5nc(Cc6ccccc6OC)[nH]c5c4)c4c(N)ncnc43)CC2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL443098	>	>	IC50	nM	20000.0	IC50	uM	20.0
1157	Activation of human CYP3A4 using DEF substrate	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1F	J. Med. Chem.	2009.0	CHEMBL453384	>	>	IC50	nM	100000.0	IC50	uM	100.0
1158	Activation of human CYP3A4 using DEF substrate	CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147587	>	>	IC50	nM	100000.0	IC50	uM	100.0
1159	Inhibition of human CYP3A4 using DEF substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	24000.0	IC50	uM	24.0
1160	Inhibition of human CYP3A4 using PPR substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	100000.0	IC50	uM	100.0
1161	Inhibition of human CYP3A4 using DEF substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	=	=	IC50	nM	28000.0	IC50	uM	28.0
1162	Inhibition of human CYP3A4 using PPR substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	>	>	IC50	nM	100000.0	IC50	uM	100.0
1163	Inhibition of CYP3A4 in human liver microsomes	Clc1cccc(COc2cncc(N3CCNCC3)n2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494947	>	>	IC50	nM	50000.0	IC50	uM	50.0
1164	Inhibition of CYP3A4 in human liver microsomes	C[C@H](Cc1cccc(F)c1)Oc1nc(N2CCNC[C@H]2C)ncc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494948	=	=	IC50	nM	4900.0	IC50	uM	4.9
1165	Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxyquinoline as substrate	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1	J. Med. Chem.	2009.0	CHEMBL493937	>	>	IC50	nM	30000.0	IC50	uM	30.0
1166	Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxy 4-trifluoromethylcoumarin as substrate	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1	J. Med. Chem.	2009.0	CHEMBL493937	>	>	IC50	nM	30000.0	IC50	uM	30.0
1167	Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465956	=	=	IC50	nM	65000.0	IC50	uM	65.0
1168	Inhibition of CYP3A4	C[C@@H]1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522964	=	=	IC50	nM	440.0	IC50	uM	0.44
1169	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL253641	=	=	IC50	nM	400.0	IC50	uM	0.4
1170	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL253641	=	=	IC50	nM	1600.0	IC50	uM	1.6
1171	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL445734	=	=	IC50	nM	6300.0	IC50	uM	6.3
1172	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL445734	=	=	IC50	nM	75000.0	IC50	uM	75.0
1173	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL399656	>	>	IC50	nM	89000.0	IC50	uM	89.0
1174	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL399656	>	>	IC50	nM	89000.0	IC50	uM	89.0
1175	Inhibition of human CYP3A4 by radiometric assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2004.0	CHEMBL157101	=	=	IC50	nM	245.0	IC50	uM	0.245
1176	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL519761	=	=	IC50	nM	14400.0	IC50	uM	14.4
1177	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL240954	=	=	IC50	nM	20600.0	IC50	uM	20.6
1178	Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/CC1	J. Nat. Prod.	2004.0	CHEMBL245412	=	=	IC50	nM	21800.0	IC50	uM	21.8
1179	Inhibition of human CYP3A4 by radiometric assay	COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1	J. Nat. Prod.	2004.0	CHEMBL309061	=	=	IC50	nM	21800.0	IC50	uM	21.8
1180	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL471074	=	=	IC50	nM	31600.0	IC50	uM	31.6
1181	Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/[C@H](O)C1	J. Nat. Prod.	2004.0	CHEMBL469850	=	=	IC50	nM	35500.0	IC50	uM	35.5
1182	Inhibition of human CYP3A4 by radiometric assay	COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O	J. Nat. Prod.	2004.0	CHEMBL165064	=	=	IC50	nM	36200.0	IC50	uM	36.2
1183	Inhibition of human CYP3A4 by radiometric assay	CCCCC[C@H](O)CC(=O)CCc1ccc(OC)c(O)c1	J. Nat. Prod.	2004.0	CHEMBL471072	=	=	IC50	nM	36400.0	IC50	uM	36.4
1184	Inhibition of human CYP3A4 by radiometric assay	C/C1=C\[C@H](O)C[C@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL513372	=	=	IC50	nM	42600.0	IC50	uM	42.6
1185	Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL512339	=	=	IC50	nM	48400.0	IC50	uM	48.4
1186	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL469851	=	=	IC50	nM	55800.0	IC50	uM	55.8
1187	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL469431	=	=	IC50	nM	59000.0	IC50	uM	59.0
1188	Inhibition of human CYP3A4 by radiometric assay	C/C1=C\[C@H](O)C[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL503727	=	=	IC50	nM	62500.0	IC50	uM	62.5
1189	Inhibition of human CYP3A4 by radiometric assay	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	J. Nat. Prod.	2004.0	CHEMBL25948	=	=	IC50	nM	77700.0	IC50	uM	77.7
1190	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL470049	=	=	IC50	nM	90000.0	IC50	uM	90.0
1191	Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@@H]1[C@@H](O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL470048	=	=	IC50	nM	98300.0	IC50	uM	98.3
1192	Inhibition of human CYP3A4 by radiometric assay	C[C@@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL240528	>	>	IC50	nM	100000.0	IC50	uM	100.0
1193	Inhibition of human CYP3A4 by radiometric assay	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C)C(C)C	J. Nat. Prod.	2004.0	CHEMBL221542	>	>	IC50	nM	100000.0	IC50	uM	100.0
1194	Inhibition of CYP3A4	O=C(O)c1cc2occc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL492591	>	>	IC50	nM	10000.0	IC50	uM	10.0
1195	Inhibition of CYP3A4	O=C(O)c1cc2sccc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL507614	>	>	IC50	nM	10000.0	IC50	uM	10.0
1196	Inhibition of human CYP3A4	Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#CCO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL500157	=	=	IC50	nM	700.0	IC50	uM	0.7
1197	Inhibition of human CYP3A4	NCC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526929	=	=	IC50	nM	1800.0	IC50	uM	1.8
1198	Inhibition of human CYP3A4	C#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502531	=	=	IC50	nM	800.0	IC50	uM	0.8
1199	Inhibition of human CYP3A4	Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#Cc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL500422	=	=	IC50	nM	37000.0	IC50	uM	37.0
1200	Inhibition of human CYP3A4	CN(C)CC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL525049	=	=	IC50	nM	2700.0	IC50	uM	2.7
1201	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
1202	Inhibition of CYP3A4	CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](NCCCC(=O)O)c2ccccc2)c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL508020	=	=	IC50	nM	48000.0	IC50	uM	48.0
1203	Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526887	=	=	IC50	nM	20000.0	IC50	uM	20.0
1204	Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450471	=	=	IC50	nM	17000.0	IC50	uM	17.0
1205	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453167	>	>	IC50	nM	50000.0	IC50	uM	50.0
1206	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526327	=	=	IC50	nM	33000.0	IC50	uM	33.0
1207	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
1208	Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL445691	=	=	IC50	nM	130.0	IC50	uM	0.13
1209	Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455769	=	=	IC50	nM	510.0	IC50	uM	0.51
1210	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CNCCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL456279	=	=	IC50	nM	31000.0	IC50	uM	31.0
1211	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499849	=	=	IC50	nM	36000.0	IC50	uM	36.0
1212	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CSCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499589	=	=	IC50	nM	16000.0	IC50	uM	16.0
1213	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499588	=	=	IC50	nM	20000.0	IC50	uM	20.0
1214	Inhibition of CYP3A4	CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL503624	=	=	IC50	nM	350.0	IC50	uM	0.35
1215	Inhibition of CYP3A4	NCC(=O)OCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499307	=	=	IC50	nM	670.0	IC50	uM	0.67
1216	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499026	=	=	IC50	nM	120.0	IC50	uM	0.12
1217	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)C3CC3)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL508435	=	=	IC50	nM	48.0	IC50	uM	0.048
1218	Inhibition of CYP3A4	NCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497747	=	=	IC50	nM	9100.0	IC50	uM	9.1
1219	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL495882	=	=	IC50	nM	800.0	IC50	uM	0.8
1220	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL365985	=	=	IC50	nM	300.0	IC50	uM	0.3
1221	Inhibition of CYP3A4	CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](N)c2ccccc2)c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL371613	=	=	IC50	nM	180.0	IC50	uM	0.18
1222	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL192172	=	=	IC50	nM	440.0	IC50	uM	0.44
1223	Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL189164	=	=	IC50	nM	160.0	IC50	uM	0.16
1224	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL364914	=	=	IC50	nM	380.0	IC50	uM	0.38
1225	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL191817	=	=	IC50	nM	600.0	IC50	uM	0.6
1226	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	39810.72	pIC50		4.4
1227	Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450471	=	=	IC50	nM	15848.93	pIC50		4.8
1228	Inhibition of CYP3A4	Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1	J. Med. Chem.	2008.0	CHEMBL254316	>	>	IC50	nM	50000.0	IC50	uM	50.0
1229	Inhibition of CYP3A4	CN(C)C(=O)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	J. Med. Chem.	2008.0	CHEMBL495331	>	>	IC50	nM	50000.0	IC50	uM	50.0
1230	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
1231	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL401930	=	=	IC50	nM	50.0	IC50	uM	0.05
1232	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL459729	=	=	IC50	nM	26000.0	IC50	uM	26.0
1233	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NCCn5cc(Cl)cn5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL460997	=	=	IC50	nM	19500.0	IC50	uM	19.5
1234	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCO)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL460996	=	=	IC50	nM	23000.0	IC50	uM	23.0
1235	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL461422	=	=	IC50	nM	40000.0	IC50	uM	40.0
1236	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COc1ccc([C@H](O)CNc2cc[nH]c(=O)c2-c2nc3c(C)cc(C4CCN(CCCF)CC4)cc3[nH]2)cc1Cl	J. Med. Chem.	2008.0	CHEMBL469292	=	=	IC50	nM	10000.0	IC50	uM	10.0
1237	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5ccc(OC)c(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL512126	=	=	IC50	nM	7700.0	IC50	uM	7.7
1238	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL468672	=	=	IC50	nM	28000.0	IC50	uM	28.0
1239	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL468671	=	=	IC50	nM	11000.0	IC50	uM	11.0
1240	Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL461198	=	=	IC50	nM	14000.0	IC50	uM	14.0
1241	Inhibition of human recombinant CYP3A4 in human liver microsomes using BzRes as a substrate	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL401930	=	=	IC50	nM	5300.0	IC50	uM	5.3
1242	Inhibition of CYP3A4	C[C@H]1CN(Cc2cccc(-c3cc(CNC(=O)c4cccc(CC5CCNCC5)c4)ccc3F)c2)CCN1	J. Med. Chem.	2008.0	CHEMBL521523	<	>	IC50	nM	10000.0	pIC50		5.0
1243	Inhibition of CYP3A4 in human liver microsomes	Cc1ccccc1-c1nncc2cc(-c3c(C)ccc4c(NC5CC5)noc34)ccc12	J. Med. Chem.	2008.0	CHEMBL495084	=	=	IC50	nM	1800.0	IC50	uM	1.8
1244	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(N)nsc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL524054	=	=	IC50	nM	4000.0	IC50	uM	4.0
1245	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(C(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL492661	>	>	IC50	nM	25000.0	IC50	uM	25.0
1246	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(OC(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL494917	>	>	IC50	nM	25000.0	IC50	uM	25.0
1247	Inhibition of CYP3A4 in human liver microsomes	CC[C@H](C)Nc1nncc2cc(-c3c(C)ccc4c(NC)noc34)ccc12	J. Med. Chem.	2008.0	CHEMBL522689	>	>	IC50	nM	25000.0	IC50	uM	25.0
1248	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(NC(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL494305	>	>	IC50	nM	25000.0	IC50	uM	25.0
1249	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL493496	>	>	IC50	nM	25000.0	IC50	uM	25.0
1250	Inhibition of CYP3A4 in human liver microsomes	CC(C)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12	J. Med. Chem.	2008.0	CHEMBL523516	=	=	IC50	nM	4500.0	IC50	uM	4.5
1251	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12	J. Med. Chem.	2008.0	CHEMBL495118	=	=	IC50	nM	6000.0	IC50	uM	6.0
1252	Inhibition of CYP3A4 in human liver microsomes	CC(=O)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL521860	>	>	IC50	nM	25000.0	IC50	uM	25.0
1253	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(N)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL494916	=	=	IC50	nM	12000.0	IC50	uM	12.0
1254	Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL523374	>	>	IC50	nM	25000.0	IC50	uM	25.0
1255	Inhibition of CYP3A4 in human liver microsomes	CCNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL495493	=	=	IC50	nM	10000.0	IC50	uM	10.0
1256	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(NC(C)C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL495492	=	=	IC50	nM	5600.0	IC50	uM	5.6
1257	Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1CCN(c2nncc3cc(-c4c(C)ccc5c(NC6CC6)noc45)ccc23)[C@@H](C)C1	J. Med. Chem.	2008.0	CHEMBL495290	=	=	IC50	nM	4200.0	IC50	uM	4.2
1258	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL522877	=	=	IC50	nM	5600.0	IC50	uM	5.6
1259	Inhibition of CYP3A4	COc1ccc(C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3ncccc23)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455126	>	>	IC50	nM	100000.0	IC50	uM	100.0
1260	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
1261	Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
1262	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL179691	=	=	IC50	nM	700.0	IC50	uM	0.7
1263	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@@H](c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL503705	=	=	IC50	nM	69000.0	IC50	uM	69.0
1264	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL510538	=	=	IC50	nM	29000.0	IC50	uM	29.0
1265	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3Cl)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL502341	=	=	IC50	nM	11000.0	IC50	uM	11.0
1266	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]	J. Med. Chem.	2008.0	CHEMBL502182	=	=	IC50	nM	56000.0	IC50	uM	56.0
1267	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL506877	=	=	IC50	nM	135000.0	IC50	uM	135.0
1268	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL501329	=	=	IC50	nM	69000.0	IC50	uM	69.0
1269	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL509440	=	=	IC50	nM	36000.0	IC50	uM	36.0
1270	Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	J. Med. Chem.	2008.0	CHEMBL510285	=	=	IC50	nM	440.0	IC50	uM	0.44
1271	Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL468551	=	=	IC50	nM	230.0	IC50	uM	0.23
1272	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL473921	=	=	IC50	nM	20000.0	IC50	uM	20.0
1273	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	1900.0	IC50	uM	1.9
1274	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL473921	=	=	IC50	nM	1400.0	IC50	uM	1.4
1275	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	190.0	IC50	uM	0.19
1276	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL474130	=	=	IC50	nM	10000.0	IC50	uM	10.0
1277	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL474934	=	=	IC50	nM	41000.0	IC50	uM	41.0
1278	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489094	=	=	IC50	nM	4900.0	IC50	uM	4.9
1279	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489095	=	=	IC50	nM	26000.0	IC50	uM	26.0
1280	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL523933	=	=	IC50	nM	29000.0	IC50	uM	29.0
1281	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	CC(C(=O)N1CCC(Nc2ccc(F)cc2)CC1)c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	J. Med. Chem.	2009.0	CHEMBL489297	=	=	IC50	nM	8700.0	IC50	uM	8.7
1282	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL489479	=	=	IC50	nM	4700.0	IC50	uM	4.7
1283	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489480	=	=	IC50	nM	36000.0	IC50	uM	36.0
1284	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL474130	=	=	IC50	nM	18000.0	IC50	uM	18.0
1285	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL474934	=	=	IC50	nM	59000.0	IC50	uM	59.0
1286	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489094	=	=	IC50	nM	14000.0	IC50	uM	14.0
1287	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489095	=	=	IC50	nM	69000.0	IC50	uM	69.0
1288	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL523933	=	=	IC50	nM	69000.0	IC50	uM	69.0
1289	Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489480	=	=	IC50	nM	58000.0	IC50	uM	58.0
1290	Inhibition of CYP3A4	CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1	J. Med. Chem.	2009.0	CHEMBL490672	>	>	IC50	nM	30000.0	IC50	uM	30.0
1291	Inhibition of CYP3A4	C#Cc1c(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)ccnc1N	J. Med. Chem.	2009.0	CHEMBL462622	<	<	IC50	nM	1000.0	IC50	uM	1.0
1292	Inhibition of CYP3A4	Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	J. Med. Chem.	2009.0	CHEMBL462624	=	=	IC50	nM	4000.0	IC50	uM	4.0
1293	Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	=	=	IC50	nM	28000.0	IC50	uM	28.0
1294	Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL146826	>	>	IC50	nM	100000.0	IC50	uM	100.0
1295	Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	24000.0	IC50	uM	24.0
1296	Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	>	>	IC50	nM	100000.0	IC50	uM	100.0
1297	Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147587	>	>	IC50	nM	100000.0	IC50	uM	100.0
1298	Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147806	>	>	IC50	nM	100000.0	IC50	uM	100.0
1299	Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL146826	>=	>=	IC50	nM	55000.0	IC50	uM	55.0
1300	Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	>	>	IC50	nM	100000.0	IC50	uM	100.0
1301	Inhibition of CYP3A4	O=C(CCN1C(=O)c2ccccc2C1=O)N1CCCCC1	J. Med. Chem.	2009.0	CHEMBL491273	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1302	Inhibition of CYP3A4	CCc1ccc(N2CC(C(=O)OC)CC2=O)cc1	J. Med. Chem.	2009.0	CHEMBL491274	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1303	Inhibition of CYP3A4	CC(C)c1ccc(OCC(=O)Nc2nc3ccccc3s2)cc1	J. Med. Chem.	2009.0	CHEMBL491275	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1304	Inhibition of CYP3A4	CCc1ccc(OCC(=O)Nc2ccc(C)cc2Br)cc1	J. Med. Chem.	2009.0	CHEMBL489096	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1305	Inhibition of CYP3A4	Cc1ccc(C)c(OCN2Cc3ccccc3C2C=O)c1	J. Med. Chem.	2009.0	CHEMBL504747	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1306	Inhibition of CYP3A4	CCc1ccc(OCC(=O)NCc2cccc3ccccc23)cc1	J. Med. Chem.	2009.0	CHEMBL452613	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1307	Inhibition of CYP3A4	CCc1ccc(OCC(=O)NCCc2ccccc2)cc1	J. Med. Chem.	2009.0	CHEMBL446965	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1308	Inhibition of CYP3A4	CCc1ccc(CCNS(=O)(=O)c2ccc(SC)cc2)cc1	J. Med. Chem.	2009.0	CHEMBL490678	<	<	Ki	nM	50000000.0	Ki	mM	50.0
1309	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL487569	=	=	IC50	nM	380.0	IC50	uM	0.38
1310	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL486950	=	=	IC50	nM	740.0	IC50	uM	0.74
1311	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COCCN(C)c1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)n1	J. Med. Chem.	2008.0	CHEMBL485972	=	=	IC50	nM	2500.0	IC50	uM	2.5
1312	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2ccncc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520238	=	=	IC50	nM	8500.0	IC50	uM	8.5
1313	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC1CN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)C1	J. Med. Chem.	2008.0	CHEMBL487554	=	=	IC50	nM	11000.0	IC50	uM	11.0
1314	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COCCOc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL519383	=	=	IC50	nM	14000.0	IC50	uM	14.0
1315	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL519549	=	=	IC50	nM	16000.0	IC50	uM	16.0
1316	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486140	=	=	IC50	nM	17000.0	IC50	uM	17.0
1317	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL458242	=	=	IC50	nM	18000.0	IC50	uM	18.0
1318	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cncc(O)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486130	=	=	IC50	nM	18000.0	IC50	uM	18.0
1319	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCOC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL485752	=	=	IC50	nM	20000.0	IC50	uM	20.0
1320	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N(C)C)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487572	=	=	IC50	nM	25000.0	IC50	uM	25.0
1321	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2ccccc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487765	=	=	IC50	nM	43000.0	IC50	uM	43.0
1322	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccnc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487766	>	>	IC50	nM	20000.0	IC50	uM	20.0
1323	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1F	J. Med. Chem.	2008.0	CHEMBL486745	>	>	IC50	nM	20000.0	IC50	uM	20.0
1324	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cncc(-c2cc(NC(=O)CN3CCOCC3)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL486131	>	>	IC50	nM	20000.0	IC50	uM	20.0
1325	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cncc(N3CCOCC3)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL521029	>	>	IC50	nM	20000.0	IC50	uM	20.0
1326	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCOCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520229	>	>	IC50	nM	20000.0	IC50	uM	20.0
1327	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487372	>	>	IC50	nM	20000.0	IC50	uM	20.0
1328	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL485765	>	>	IC50	nM	20000.0	IC50	uM	20.0
1329	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCCOCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520036	>	>	IC50	nM	20000.0	IC50	uM	20.0
1330	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486162	>	>	IC50	nM	20000.0	IC50	uM	20.0
1331	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1	J. Med. Chem.	2008.0	CHEMBL487553	>	>	IC50	nM	20000.0	IC50	uM	20.0
1332	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCC(O)CC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL521223	>	>	IC50	nM	20000.0	IC50	uM	20.0
1333	Inhibition of CYP3A4	Br.CC(=O)SCC(=O)c1ccc(NS(=O)(=O)c2ccc(OCCCN(C)C)cc2)nc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL520237	>	>	EC50	nM	50000.0	EC50	uM	50.0
1334	Inhibition of CYP3A4	CC(=O)SCC(=O)c1ccc(NS(=O)(=O)c2ccc3c(c2)COOC3)nc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL487965	>	>	EC50	nM	50000.0	EC50	uM	50.0
1335	Inhibition of CYP3A4	O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3nnc[nH]3)cc(C(F)(F)F)c2)CC1	J. Med. Chem.	2009.0	CHEMBL529213	=	=	IC50	nM	4700.0	IC50	uM	4.7
1336	Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL528996	=	=	IC50	nM	11000.0	IC50	uM	11.0
1337	Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL475684	=	=	IC50	nM	7900.0	IC50	uM	7.9
1338	Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)O)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL478902	>	>	IC50	nM	100000.0	IC50	uM	100.0
1339	Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCCO)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL478283	=	=	IC50	nM	47000.0	IC50	uM	47.0
1340	Inhibition of CYP3A4 assessed as midazolam 1'- hydroxylation	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2ccccc2)C1=O)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2009.0	CHEMBL507731	=	=	Ki	nM	18.0	Ki	nM	18.0
1341	Inhibition of CYP3A4 assessed as midazolam 1'- hydroxylation	COC(=O)N[C@H](C(=O)N[C@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2cccc(C(C)(C)O)n2)C1=O)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2009.0	CHEMBL470508	=	=	Ki	nM	66.0	Ki	nM	66.0
1342	Inhibition of human CYP3A4	O=C(/C=C/c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL266564	=	=	IC50	nM	700.0	IC50	uM	0.7
1343	Inhibition of human CYP3A4	CC(C)CC(=O)c1c(O)cc(O)cc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL484029	=	=	IC50	nM	120000.0	IC50	uM	120.0
1344	Inhibition of human CYP3A4	O=C(/C=C\c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL499705	=	=	IC50	nM	700.0	IC50	uM	0.7
1345	Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL157101	=	=	IC50	nM	20.0	IC50	uM	0.02
1346	Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](C)(c4ccc(F)cc4F)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479575	>	>	IC50	nM	40000.0	IC50	uM	40.0
1347	Inhibition of CYP3A4	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401930	=	=	IC50	nM	0.5	IC50	nM	0.5
1348	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)N4CCN(C)CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454515	=	=	IC50	nM	40.0	IC50	nM	40.0
1349	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)N4CCOCC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL459118	=	=	IC50	nM	19.0	IC50	nM	19.0
1350	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)OCCO)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505652	=	=	IC50	nM	1.8	IC50	nM	1.8
1351	Inhibition of CYP3A4	COCCOC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450610	=	=	IC50	nM	2.4	IC50	nM	2.4
1352	Inhibition of CYP3A4	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505919	=	=	IC50	nM	3.5	IC50	nM	3.5
1353	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)C4CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL510298	=	=	IC50	nM	1.7	IC50	nM	1.7
1354	Inhibition of CYP3A4	COCCOCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502778	=	=	IC50	nM	3.0	IC50	nM	3.0
1355	Inhibition of CYP3A4	COCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499584	=	=	IC50	nM	5.6	IC50	nM	5.6
1356	Inhibition of CYP3A4	CC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL506169	=	=	IC50	nM	0.8	IC50	nM	0.8
1357	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL451331	=	=	IC50	nM	2.4	IC50	nM	2.4
1358	Inhibition of CYP3A4	Cc1cc(N2CCC(N3C[C@@H]4C[C@@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL474469	=	=	IC50	nM	0.5	IC50	nM	0.5
1359	Inhibition of CYP3A4	Cc1cc(N2CCC(N3C[C@H](C)O[C@H](C)C3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502092	=	=	IC50	nM	3.1	IC50	nM	3.1
1360	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482126	=	=	IC50	nM	4.1	IC50	nM	4.1
1361	Inhibition of CYP3A4	COCCN(CCOC)C1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454467	=	=	IC50	nM	1.0	IC50	nM	1.0
1362	Inhibition of CYP3A4	COC(=O)NC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL521271	=	=	IC50	nM	0.5	IC50	nM	0.5
1363	Inhibition of CYP3A4	Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480966	=	=	IC50	nM	0.7	IC50	nM	0.7
1364	Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480965	=	=	IC50	nM	4.5	IC50	nM	4.5
1365	Inhibition of CYP3A4	Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL519300	=	=	IC50	nM	3.9	IC50	nM	3.9
1366	Inhibition of CYP3A4	CNC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482102	=	=	IC50	nM	2.6	IC50	nM	2.6
1367	Inhibition of CYP3A4	Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482101	=	=	IC50	nM	0.7	IC50	nM	0.7
1368	Inhibition of CYP3A4	Cc1cc(N2CCC(OCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482089	=	=	IC50	nM	1.3	IC50	nM	1.3
1369	Inhibition of CYP3A4	COCCOC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482088	=	=	IC50	nM	0.9	IC50	nM	0.9
1370	Inhibition of CYP3A4	COC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL519132	=	=	IC50	nM	1.0	IC50	nM	1.0
1371	Inhibition of CYP3A4	Cc1cc(N2CCC(O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL520419	=	=	IC50	nM	0.4	IC50	nM	0.4
1372	Inhibition of CYP3A4	CCCCC[C@H]1OC(=O)c2ccc(OC)cc2[C@H]1OC(C)=O	J. Nat. Prod.	2008.0	CHEMBL529220	>	>	IC50	nM	65000.0	IC50	uM	65.0
1373	Inhibition of CYP3A4	Cn1c(N(Cc2ccc(C(=O)Nc3nnn[nH]3)cc2)[C@H]2CC[C@H](C(C)(C)C)CC2)nc2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480501	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1374	Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254356	=	=	IC50	nM	1400.0	IC50	uM	1.4
1375	Inhibition of CYP3A4	COc1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(Cl)c(Cl)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453329	=	=	IC50	nM	1000.0	IC50	uM	1.0
1376	Inhibition of CYP3A4	CC(=O)Nc1ccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(C)c(C)cc43)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL449192	=	=	IC50	nM	6400.0	IC50	uM	6.4
1377	Inhibition of CYP3A4	CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(Cl)c(Cl)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL507691	=	=	IC50	nM	5000.0	IC50	uM	5.0
1378	Inhibition of CYP3A4	CN(C(=O)CN(CC#N)c1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453587	=	=	IC50	nM	2200.0	IC50	uM	2.2
1379	Inhibition of CYP3A4	COCCN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccc(C(N)=O)cc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453067	=	=	IC50	nM	2600.0	IC50	uM	2.6
1380	Inhibition of CYP3A4	CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(C)c(C)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499582	=	=	IC50	nM	9000.0	IC50	uM	9.0
1381	Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452808	=	=	IC50	nM	4200.0	IC50	uM	4.2
1382	Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453075	=	=	IC50	nM	9100.0	IC50	uM	9.1
1383	Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453074	=	=	IC50	nM	4600.0	IC50	uM	4.6
1384	Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452298	=	=	IC50	nM	2100.0	IC50	uM	2.1
1385	Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL488642	=	=	IC50	nM	4900.0	IC50	uM	4.9
1386	Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCCC1)c1ccccc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL527199	=	=	IC50	nM	3300.0	IC50	uM	3.3
1387	Inhibition of CYP3A4	O=C(O)[C@H](Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481659	=	=	IC50	nM	62000.0	IC50	uM	62.0
1388	Inhibition of CYP3A4	O=C(O)[C@H](Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL487438	=	=	IC50	nM	10000.0	IC50	uM	10.0
1389	Inhibition of CYP3A4	CC(C)c1nc2cccnc2n1-c1ccc(C[C@H](NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL486444	=	=	IC50	nM	79000.0	IC50	uM	79.0
1390	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517503	=	=	IC50	nM	22000.0	IC50	uM	22.0
1391	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517828	=	=	IC50	nM	12000.0	IC50	uM	12.0
1392	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478223	=	=	IC50	nM	2500.0	IC50	uM	2.5
1393	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446054	=	=	IC50	nM	3000.0	IC50	uM	3.0
1394	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477387	=	=	IC50	nM	39000.0	IC50	uM	39.0
1395	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517503	=	=	IC50	nM	9700.0	IC50	uM	9.7
1396	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515624	=	=	IC50	nM	12000.0	IC50	uM	12.0
1397	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478870	=	=	IC50	nM	12000.0	IC50	uM	12.0
1398	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518591	=	=	IC50	nM	15000.0	IC50	uM	15.0
1399	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478871	=	=	IC50	nM	7800.0	IC50	uM	7.8
1400	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517828	=	=	IC50	nM	20000.0	IC50	uM	20.0
1401	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446054	=	=	IC50	nM	7000.0	IC50	uM	7.0
1402	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477386	=	=	IC50	nM	27000.0	IC50	uM	27.0
1403	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477387	=	=	IC50	nM	77000.0	IC50	uM	77.0
1404	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515624	=	=	IC50	nM	19000.0	IC50	uM	19.0
1405	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478870	=	=	IC50	nM	20000.0	IC50	uM	20.0
1406	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518591	=	=	IC50	nM	71000.0	IC50	uM	71.0
1407	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478871	=	=	IC50	nM	13000.0	IC50	uM	13.0
1408	Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478223	=	=	IC50	nM	3200.0	IC50	uM	3.2
1409	Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477386	=	=	IC50	nM	17000.0	IC50	uM	17.0
1410	Inhibition of CYP3A4	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1	J. Med. Chem.	2008.0	CHEMBL520828	=	=	IC50	nM	2700.0	IC50	uM	2.7
1411	Inhibition of CYP3A4	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1	J. Med. Chem.	2008.0	CHEMBL483401	=	=	IC50	nM	5500.0	IC50	uM	5.5
1412	Inhibition of CYP3A4	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1	J. Med. Chem.	2008.0	CHEMBL483574	=	=	IC50	nM	2500.0	IC50	uM	2.5
1413	Inhibition of CYP3A4	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1	J. Med. Chem.	2008.0	CHEMBL483402	=	=	IC50	nM	4300.0	IC50	uM	4.3
1414	Inhibition of CYP3A4	CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1	J. Med. Chem.	2008.0	CHEMBL521347	=	=	IC50	nM	2500.0	IC50	uM	2.5
1415	Inhibition of CYP3A4	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1	J. Med. Chem.	2008.0	CHEMBL485612	=	=	IC50	nM	5300.0	IC50	uM	5.3
1416	Inhibition of CYP3A4	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1	J. Med. Chem.	2008.0	CHEMBL519680	=	=	IC50	nM	350.0	IC50	uM	0.35
1417	Inhibition of human hepatic CYP3A4	Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1	J. Med. Chem.	2008.0	CHEMBL456379	=	=	IC50	nM	800.0	IC50	uM	0.8
1418	Inhibition of human hepatic CYP3A4	Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1	J. Med. Chem.	2008.0	CHEMBL502908	=	=	IC50	nM	2100.0	IC50	uM	2.1
1419	Inhibition of human hepatic CYP3A4	Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1	J. Med. Chem.	2008.0	CHEMBL462513	=	=	IC50	nM	1900.0	IC50	uM	1.9
1420	Inhibition of human CYP3A4	O=C(N[C@H]1C[C@@H]2CC[C@H](C1)N2Cc1ccc2cc(F)ccc2c1)c1cc[n+]([O-])cc1C(=O)N1CCCCC1	Bioorg. Med. Chem.	2008.0	CHEMBL3084581	>	>	IC50	nM	40000.0	IC50	nM	40000.0
1421	Inhibition of human CYP3A4	O=C(NC1CC2CCC(C1)N2Cc1ccc2cc(F)ccc2c1)c1ccccc1-c1ccccc1	Bioorg. Med. Chem.	2008.0	CHEMBL522295	>	>	IC50	nM	20000.0	IC50	nM	20000.0
1422	Inhibition of CYP3A4	O=C(CCc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514681	>	>	IC50	nM	50000.0	IC50	uM	50.0
1423	Inhibition of CYP3A4	O=C(Cc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476762	>	>	IC50	nM	50000.0	IC50	uM	50.0
1424	Inhibition of CYP3A4	O=C(CNC(=O)c1ccccc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476763	>	>	IC50	nM	50000.0	IC50	uM	50.0
1425	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
1426	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475926	>	>	IC50	nM	50000.0	IC50	uM	50.0
1427	Inhibition of CYP3A4	N#Cc1ccc(C(=O)NCC(=O)NC(c2ccccc2)c2ccc(Cl)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475927	>	>	IC50	nM	50000.0	IC50	uM	50.0
1428	Inhibition of CYP3A4	O=C(CNC(=O)c1ccncc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452423	>	>	IC50	nM	50000.0	IC50	uM	50.0
1429	Inhibition of CYP3A4	O=C(CNC(=O)c1ccsc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476360	>	>	IC50	nM	50000.0	IC50	uM	50.0
1430	Inhibition of CYP3A4	O=C(CNC(=O)C1CCCC1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514209	>	>	IC50	nM	50000.0	IC50	uM	50.0
1431	Inhibition of CYP3A4	CC(=O)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476567	>	>	IC50	nM	50000.0	IC50	uM	50.0
1432	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476568	>	>	IC50	nM	50000.0	IC50	uM	50.0
1433	Inhibition of CYP3A4	Cc1ccccc1C(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476775	>	>	IC50	nM	50000.0	IC50	uM	50.0
1434	Inhibition of CYP3A4	Cc1cccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479084	>	>	IC50	nM	50000.0	IC50	uM	50.0
1435	Inhibition of CYP3A4	Cc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479085	>	>	IC50	nM	50000.0	IC50	uM	50.0
1436	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518287	>	>	IC50	nM	50000.0	IC50	uM	50.0
1437	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475926	>	>	IC50	nM	50000.0	IC50	uM	50.0
1438	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1cccc(F)c1)c1cccc(F)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476557	>	>	IC50	nM	50000.0	IC50	uM	50.0
1439	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479071	>	>	IC50	nM	50000.0	IC50	uM	50.0
1440	Inhibition of CYP3A4	COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479072	>	>	IC50	nM	50000.0	IC50	uM	50.0
1441	Inhibition of CYP3A4	COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccc(OC)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514198	>	>	IC50	nM	50000.0	IC50	uM	50.0
1442	Inhibition of CYP3A4	CCC(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478229	>	>	IC50	nM	50000.0	IC50	uM	50.0
1443	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccncc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478230	>	>	IC50	nM	50000.0	IC50	uM	50.0
1444	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccnn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516125	>	>	IC50	nM	50000.0	IC50	uM	50.0
1445	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ncccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514241	>	>	IC50	nM	50000.0	IC50	uM	50.0
1446	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1nccs1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478037	>	>	IC50	nM	50000.0	IC50	uM	50.0
1447	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2Sc2ccc(Cl)cc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478035	>	>	IC50	nM	50000.0	IC50	uM	50.0
1448	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2CCc2ccccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478036	>	>	IC50	nM	50000.0	IC50	uM	50.0
1449	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2COc2ccc(F)cc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515644	>	>	IC50	nM	50000.0	IC50	uM	50.0
1450	Inhibition of CYP3A4	CN1C(=O)c2ccccc2C(CNC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL490609	>	>	IC50	nM	50000.0	IC50	uM	50.0
1451	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
1452	Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
1453	Inhibition of CYP3A4	Cc1nc(-c2ccc(F)cc2)ccc1C(=O)Nc1ccc2cccnc2c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477204	>	>	IC50	nM	10000.0	IC50	uM	10.0
1454	Inhibition of CYP3A4	CC(C)N1CCC(COc2ncc(C(=O)c3ccc(Cl)cc3)n2C)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL481745	>	>	IC50	nM	10000.0	IC50	uM	10.0
1455	Inhibition of CYP3A4	COC[C@H]1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2009.0	CHEMBL458224	>	>	IC50	nM	50000.0	IC50	uM	50.0
1456	Inhibition of CYP3A4	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C	J. Med. Chem.	2009.0	CHEMBL490153	>	>	IC50	nM	10000.0	IC50	uM	10.0
1457	Inhibition of CYP3A4	CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL450061	>	>	IC50	nM	10000.0	IC50	uM	10.0
1458	Inhibition of CYP3A4	CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL471757	>	>	IC50	nM	10000.0	IC50	uM	10.0
1459	Inhibition of CYP3A4	CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL474484	>	>	IC50	nM	10000.0	IC50	uM	10.0
1460	Inhibition of CYP3A4	O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL515387	>	>	IC50	nM	30000.0	IC50	uM	30.0
1461	Inhibition of CYP3A4	NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL512414	>	>	IC50	nM	30000.0	IC50	uM	30.0
1462	Inhibition of human CYP3A4 using DEF substrate	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL513491	=	=	IC50	nM	35000.0	IC50	uM	35.0
1463	Inhibition of human CYP3A4 using PPR substrate	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL513491	>	>	IC50	nM	100000.0	IC50	uM	100.0
1464	Inhibition of human CYP3A4	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL467114	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
1465	Inhibition of human recombinant CYP3A4	NCc1noc(-c2nn(Cc3ccccc3)c3ccccc23)n1	J. Med. Chem.	2009.0	CHEMBL512079	=	=	IC50	nM	3100.0	IC50	uM	3.1
1466	Inhibition of human CYP3A4	C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	J. Med. Chem.	2009.0	CHEMBL447955	=	=	IC50	nM	39000.0	IC50	uM	39.0
1467	Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL522771	=	=	EC50	nM	7000.0	EC50	uM	7.0
1468	Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1c[n+]([O-])cc2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL524109	=	=	EC50	nM	1800.0	EC50	uM	1.8
1469	Inhibition of CYP3A4	Cn1cncc1C(=O)N(Cc1cc(=O)[nH]c2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL491923	=	=	EC50	nM	1400.0	EC50	uM	1.4
1470	Inhibition of CYP3A4	CC1=C(C(=O)N(Cc2cc(=O)[nH]c3c(F)c(F)ccc23)c2cccc(Cl)c2)CNCC1	J. Med. Chem.	2009.0	CHEMBL491922	=	=	EC50	nM	3400.0	EC50	uM	3.4
1471	Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL489724	=	=	EC50	nM	4900.0	EC50	uM	4.9
1472	Inhibition of CYP3A4	CC(C)C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL470908	=	=	EC50	nM	7600.0	EC50	uM	7.6
1473	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1O	J. Nat. Prod.	2005.0	CHEMBL482034	=	=	IC50	nM	7400.0	IC50	uM	7.4
1474	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2[C@@H](O)OC[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL482233	=	=	IC50	nM	830.0	IC50	uM	0.83
1475	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC1=CC(=O)C2=C(C)C[C@@H]3OC(=O)C(C)=C3C[C@@H]12	J. Nat. Prod.	2005.0	CHEMBL501260	=	=	IC50	nM	8800.0	IC50	uM	8.8
1476	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC1=C[C@@H](O)[C@@]23O[C@]2(C)C[C@@H]2OC(=O)C(C)=C2C[C@@H]13	J. Nat. Prod.	2005.0	CHEMBL501119	=	=	IC50	nM	98200.0	IC50	uM	98.2
1477	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	C/C=C/c1cc(OC)c(OC)cc1OC	J. Nat. Prod.	2005.0	CHEMBL333306	=	=	IC50	nM	92300.0	IC50	uM	92.3
1478	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CO[C@@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL520915	=	=	IC50	nM	7700.0	IC50	uM	7.7
1479	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c([C@@H]2[C@H](C)[C@@H](C)[C@H]2c2cc(OC)c(OC)cc2OC)cc1OC	J. Nat. Prod.	2005.0	CHEMBL156339	=	=	IC50	nM	85400.0	IC50	uM	85.4
1480	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL242011	=	=	IC50	nM	8000.0	IC50	uM	8.0
1481	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL399831	=	=	IC50	nM	9100.0	IC50	uM	9.1
1482	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL479701	=	=	IC50	nM	830.0	IC50	uM	0.83
1483	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL479314	=	=	IC50	nM	14900.0	IC50	uM	14.9
1484	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL486597	=	=	IC50	nM	9500.0	IC50	uM	9.5
1485	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL471067	=	=	IC50	nM	1000.0	IC50	uM	1.0
1486	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c(OC)cc1CC(C)=O	J. Nat. Prod.	2005.0	CHEMBL481233	=	=	IC50	nM	28700.0	IC50	uM	28.7
1487	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CCOc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc2c1OCO2	J. Nat. Prod.	2005.0	CHEMBL480295	=	=	IC50	nM	440.0	IC50	uM	0.44
1488	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL480296	=	=	IC50	nM	15000.0	IC50	uM	15.0
1489	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL469916	=	=	IC50	nM	800.0	IC50	uM	0.8
1490	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c(C(=O)C(C)=O)cc1OC	J. Nat. Prod.	2005.0	CHEMBL450829	=	=	IC50	nM	74000.0	IC50	uM	74.0
1491	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@@H]2COC(=O)[C@H]2Cc2cc(OC)c(O)c(OC)c2)ccc1O	J. Nat. Prod.	2005.0	CHEMBL469917	=	=	IC50	nM	1100.0	IC50	uM	1.1
1492	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc([C@H]2OC[C@@H]3C(c4cc(OC)c(O)c(OC)c4)OC[C@H]23)ccc1O	J. Nat. Prod.	2005.0	CHEMBL513023	=	=	IC50	nM	13700.0	IC50	uM	13.7
1493	Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2005.0	CHEMBL157101	=	=	IC50	nM	720.0	IC50	uM	0.72
1494	Inhibition of CYP3A4	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2006.0	CHEMBL226335	>	>	IC50	nM	80000.0	IC50	uM	80.0
1495	Inhibition of CYP3A4	CN1[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)OCO3)OCO4	J. Nat. Prod.	2006.0	CHEMBL481839	=	=	IC50	nM	13400.0	IC50	uM	13.4
1496	Inhibition of CYP3A4	C[N+]1(C)[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)COC3)OCO4.[Cl-]	J. Nat. Prod.	2006.0	CHEMBL538357	>	>	IC50	nM	80000.0	IC50	uM	80.0
1497	Inhibition of CYP3A4	CN1CCc2cc3c(cc2C(=O)Cc2cc4c(cc2C1)OCO4)OCO3	J. Nat. Prod.	2006.0	CHEMBL486179	>	>	IC50	nM	80000.0	IC50	uM	80.0
1498	Inhibition of CYP3A4	COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)ccc1O	J. Nat. Prod.	2006.0	CHEMBL258394	>	>	IC50	nM	80000.0	IC50	uM	80.0
1499	Inhibition of CYP3A4	Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1	J. Med. Chem.	2008.0	CHEMBL476323	>	>	IC50	nM	27000.0	IC50	uM	27.0
1500	Inhibition of human recombinant CYP3A4 transfected in Escherichia coli co-expressed with human NADPH reductase	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478649	>	>	IC50	nM	10000.0	IC50	uM	10.0
1501	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12	J. Med. Chem.	2008.0	CHEMBL477611	=	=	IC50	nM	7600.0	IC50	uM	7.6
1502	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C	J. Med. Chem.	2008.0	CHEMBL477563	=	=	IC50	nM	27000.0	IC50	uM	27.0
1503	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C	J. Med. Chem.	2008.0	CHEMBL478612	=	=	IC50	nM	26000.0	IC50	uM	26.0
1504	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1	J. Med. Chem.	2008.0	CHEMBL478402	=	=	IC50	nM	4700.0	IC50	uM	4.7
1505	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1	J. Med. Chem.	2008.0	CHEMBL476572	=	=	IC50	nM	74000.0	IC50	uM	74.0
1506	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl	J. Med. Chem.	2008.0	CHEMBL1794074	=	=	IC50	nM	16000.0	IC50	uM	16.0
1507	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl	J. Med. Chem.	2008.0	CHEMBL1794073	=	=	IC50	nM	13000.0	IC50	uM	13.0
1508	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12	J. Med. Chem.	2008.0	CHEMBL477611	=	=	IC50	nM	16000.0	IC50	uM	16.0
1509	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C	J. Med. Chem.	2008.0	CHEMBL477563	=	=	IC50	nM	45000.0	IC50	uM	45.0
1510	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C	J. Med. Chem.	2008.0	CHEMBL478612	=	=	IC50	nM	1700.0	IC50	uM	1.7
1511	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1	J. Med. Chem.	2008.0	CHEMBL478402	=	=	IC50	nM	3900.0	IC50	uM	3.9
1512	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1	J. Med. Chem.	2008.0	CHEMBL476572	=	=	IC50	nM	79000.0	IC50	uM	79.0
1513	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl	J. Med. Chem.	2008.0	CHEMBL1794074	=	=	IC50	nM	31000.0	IC50	uM	31.0
1514	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl	J. Med. Chem.	2008.0	CHEMBL1794073	=	=	IC50	nM	1700.0	IC50	uM	1.7
1515	Inhibition of CYP3A4 in pooled human liver microsome using midazolam substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	7200.0	IC50	nM	7200.0
1516	Inhibition of CYP3A4 in pooled human liver microsome using atrovastatin substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	4600.0	IC50	nM	4600.0
1517	Inhibition of CYP3A4 in pooled human liver microsome using nifedipine substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	8800.0	IC50	nM	8800.0
1518	Inhibition of CYP3A4	CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476312	>	>	IC50	nM	3000.0	IC50	nM	3000.0
1519	Inhibition of CYP3A4	CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476116	>	>	IC50	nM	3000.0	IC50	nM	3000.0
1520	Inhibition of CYP3A4	CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478834	>	>	IC50	nM	3000.0	IC50	nM	3000.0
1521	Inhibition of CYP3A4	CC1OC(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)=NNC1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL467187	=	=	IC50	nM	270.0	IC50	uM	0.27
1522	Inhibition of CYP3A4	Cc1ccc(Cc2n[nH]c(=O)n2C)c(F)c1Oc1cc(Cl)cc(C#N)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL513510	=	=	IC50	nM	12000.0	IC50	uM	12.0
1523	Inhibition of CYP3A4	CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476954	=	=	IC50	nM	17900.0	IC50	uM	17.9
1524	Inhibition of recombinant CYP3A4	O=C(c1cccc(Cl)c1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446793	=	=	IC50	nM	600.0	IC50	uM	0.6
1525	Inhibition of recombinant CYP3A4	O=c1ccc(Cc2cc(Oc3cccc(Cl)c3)c3occc3c2)n[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL513868	=	=	IC50	nM	410.0	IC50	uM	0.41
1526	Inhibition of recombinant CYP3A4	O=c1ccc(Cc2cc(Cc3cccc(Cl)c3)c3occc3c2)n[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL504522	=	=	IC50	nM	180.0	IC50	uM	0.18
1527	Inhibition of recombinant CYP3A4	Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477145	=	=	IC50	nM	24000.0	IC50	uM	24.0
1528	Inhibition of CYP3A4	C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1	J. Med. Chem.	2008.0	CHEMBL452864	=	=	IC50	nM	3860.0	IC50	nM	3860.0
1529	Inhibition of CYP3A4	CC1(C)CN2C(CS/C(=N\C3CCCCC3)NC3CCCCC3)=CSC2=N1	J. Med. Chem.	2008.0	CHEMBL460491	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1530	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	=	=	IC50	nM	25200.0	IC50	uM	25.2
1531	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	>	>	IC50	nM	40000.0	IC50	uM	40.0
1532	Inhibition of human CYP3A4 using dibenzylfluorescein as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	=	=	IC50	nM	20600.0	IC50	uM	20.6
1533	Inhibition of CYP3A4 using diethoxyfluorescein substrate	COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL501315	=	=	IC50	nM	200.0	IC50	uM	0.2
1534	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465244	=	=	IC50	nM	7000.0	IC50	uM	7.0
1535	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL464909	=	=	IC50	nM	6000.0	IC50	uM	6.0
1536	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465941	=	=	IC50	nM	1400.0	IC50	uM	1.4
1537	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465948	=	=	IC50	nM	3000.0	IC50	uM	3.0
1538	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516551	=	=	IC50	nM	40000.0	IC50	uM	40.0
1539	Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465289	=	=	IC50	nM	900.0	IC50	uM	0.9
1540	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479418	=	=	IC50	nM	600.0	IC50	uM	0.6
1541	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518142	=	=	IC50	nM	8400.0	IC50	uM	8.4
1542	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479419	=	=	IC50	nM	12000.0	IC50	uM	12.0
1543	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481575	=	=	IC50	nM	5200.0	IC50	uM	5.2
1544	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480210	=	=	IC50	nM	4800.0	IC50	uM	4.8
1545	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL473921	>	>	IC50	nM	100000.0	IC50	uM	100.0
1546	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480219	=	=	IC50	nM	58000.0	IC50	uM	58.0
1547	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465925	=	=	IC50	nM	13000.0	IC50	uM	13.0
1548	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL501315	=	=	IC50	nM	400.0	IC50	uM	0.4
1549	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465244	=	=	IC50	nM	24000.0	IC50	uM	24.0
1550	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL464909	=	=	IC50	nM	7300.0	IC50	uM	7.3
1551	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465941	=	=	IC50	nM	1500.0	IC50	uM	1.5
1552	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465948	=	=	IC50	nM	8900.0	IC50	uM	8.9
1553	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516551	>	>	IC50	nM	100000.0	IC50	uM	100.0
1554	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465289	=	=	IC50	nM	1500.0	IC50	uM	1.5
1555	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479418	=	=	IC50	nM	500.0	IC50	uM	0.5
1556	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518142	=	=	IC50	nM	14000.0	IC50	uM	14.0
1557	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479419	=	=	IC50	nM	17000.0	IC50	uM	17.0
1558	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481575	=	=	IC50	nM	3500.0	IC50	uM	3.5
1559	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480210	=	=	IC50	nM	3600.0	IC50	uM	3.6
1560	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL473921	>	>	IC50	nM	100000.0	IC50	uM	100.0
1561	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480219	=	=	IC50	nM	46000.0	IC50	uM	46.0
1562	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465925	=	=	IC50	nM	5600.0	IC50	uM	5.6
1563	Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL520413	=	=	IC50	nM	57000.0	IC50	uM	57.0
1564	Inhibition of CYP3A4	CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL466191	=	=	IC50	nM	58000.0	IC50	uM	58.0
1565	Inhibition of CYP3A4	CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465470	=	=	IC50	nM	64000.0	IC50	uM	64.0
1566	Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517646	>	>	IC50	nM	100000.0	IC50	uM	100.0
1567	Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Br)c2)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL480398	>	>	IC50	nM	100000.0	IC50	uM	100.0
1568	Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2Cl)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL479628	>	>	IC50	nM	100000.0	IC50	uM	100.0
1569	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COC1CCc2cc(-c3cccnc3)ccc2C1	J. Med. Chem.	2008.0	CHEMBL460178	=	=	IC50	nM	12200.0	IC50	uM	12.2
1570	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc2C1	J. Med. Chem.	2008.0	CHEMBL462093	=	=	IC50	nM	6210.0	IC50	uM	6.21
1571	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc21	J. Med. Chem.	2008.0	CHEMBL448743	<	<	IC50	nM	200000.0	IC50	uM	200.0
1572	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1	J. Med. Chem.	2008.0	CHEMBL499007	=	=	IC50	nM	3800.0	IC50	uM	3.8
1573	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc2N1	J. Med. Chem.	2008.0	CHEMBL62811	=	=	IC50	nM	127000.0	IC50	uM	127.0
1574	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CN1C(=O)CCc2cc(-c3cccnc3)ccc21	J. Med. Chem.	2008.0	CHEMBL446083	<	<	IC50	nM	200000.0	IC50	uM	200.0
1575	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cncc4ccccc34)ccc2N1	J. Med. Chem.	2008.0	CHEMBL456390	<	<	IC50	nM	50000.0	IC50	uM	50.0
1576	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57000.0	IC50	uM	57.0
1577	Inhibition of CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O	Bioorg. Med. Chem.	2009.0	CHEMBL425483	=	=	IC50	nM	2500.0	IC50	uM	2.5
1578	Inhibition of CYP3A4	CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC	J. Med. Chem.	2009.0	CHEMBL514800	>	>	IC50	nM	10000.0	IC50	uM	10.0
1579	Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C	J. Med. Chem.	2009.0	CHEMBL289228	=	=	IC50	nM	1700.0	IC50	nM	1700.0
1580	Inhibition of human recombinant CYP3A4	Cc1c(Cl)cccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12	J. Med. Chem.	2009.0	CHEMBL456001	=	=	IC50	nM	1300.0	IC50	nM	1300.0
1581	Inhibition of human recombinant CYP3A4	Cc1ccccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12	J. Med. Chem.	2009.0	CHEMBL456002	=	=	IC50	nM	1350.0	IC50	nM	1350.0
1582	Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc3ccccc13)cc(=O)n2C	J. Med. Chem.	2009.0	CHEMBL470996	=	=	IC50	nM	550.0	IC50	nM	550.0
1583	Inhibition of human recombinant CYP3A4	CO[C@](c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1cccc(Cl)c1C)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2009.0	CHEMBL471195	=	=	IC50	nM	870.0	IC50	nM	870.0
1584	Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	40.0	IC50	nM	40.0
1585	Inhibition of human recombinant CYP3A4	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2009.0	CHEMBL1397	=	=	IC50	nM	350.0	IC50	nM	350.0
1586	Inhibition of CYP3A4	O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL234940	=	=	IC50	nM	89000.0	IC50	uM	89.0
1587	Inhibition of human CYP3A4	CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cccc(C#N)c1	J. Med. Chem.	2009.0	CHEMBL443928	=	=	IC50	nM	1700.0	IC50	uM	1.7
1588	Inhibition of human CYP3A4	CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cc(Cl)cc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL502381	<	<	IC50	nM	400.0	IC50	uM	0.4
1589	Inhibition of CYP3A4	CO/C(C)=C1/NC(=O)[C@H]([C@@H](C)O)NC(=O)c2csc(n2)-c2cc(OC)c(-c3nc(C(=O)NCCCN4CCOCC4)cs3)nc2-c2csc(n2)[C@@H]2COC(=O)c3c4c5c(cccc5n3O)COC(=O)[C@@H](O[C@H]3C[C@](C)(O)[C@H](N(C)C)[C@H](C)O3)[C@@H](OC4)[C@H](NC(=O)c3csc1n3)c1nc(cs1)C(=O)N2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL504492	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
1590	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccc(-c3ccncc3)cc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495992	<	<	IC50	nM	10000.0	IC50	uM	10.0
1591	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc4CC3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL519149	<	<	IC50	nM	10000.0	IC50	uM	10.0
1592	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496189	>	>	IC50	nM	10000.0	IC50	uM	10.0
1593	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496189	>	>	IC50	nM	10000.0	IC50	uM	10.0
1594	Inhibition of CYP3A4	Cn1nccc1-c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495792	>	>	IC50	nM	10000.0	IC50	uM	10.0
1595	Inhibition of CYP3A4	Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495793	>	>	IC50	nM	10000.0	IC50	uM	10.0
1596	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495794	>	>	IC50	nM	10000.0	IC50	uM	10.0
1597	Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ccccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495995	>	>	IC50	nM	10000.0	IC50	uM	10.0
1598	Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL483876	>	>	IC50	nM	10000.0	IC50	uM	10.0
1599	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL519336	>	>	IC50	nM	10000.0	IC50	uM	10.0
1600	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL482637	>	>	IC50	nM	10000.0	IC50	uM	10.0
1601	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2cccnc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495993	>	>	IC50	nM	10000.0	IC50	uM	10.0
1602	Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CC1)CC(O)c1ncccc1O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523565	>	>	IC50	nM	10000.0	IC50	uM	10.0
1603	Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ncccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522211	>	>	IC50	nM	10000.0	IC50	uM	10.0
1604	Inhibition of CYP3A4	O=C(c1ccc(C(F)(F)F)cc1)N1CCC2(CCc3ccccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL524992	>	>	IC50	nM	10000.0	IC50	uM	10.0
1605	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)c3ccc(C(F)(F)F)cc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497828	>	>	IC50	nM	10000.0	IC50	uM	10.0
1606	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)Cc3ccc(Cl)cc3Cl)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497829	>	>	IC50	nM	10000.0	IC50	uM	10.0
1607	Inhibition of CYP3A4	O=C(CCc1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447085	>	>	IC50	nM	10000.0	IC50	uM	10.0
1608	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc4C3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495601	>	>	IC50	nM	10000.0	IC50	uM	10.0
1609	Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc43)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL482845	>	>	IC50	nM	10000.0	IC50	uM	10.0
1610	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@@H]3CC[C@@H](c4ccccc4)C3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495586	>	>	IC50	nM	10000.0	IC50	uM	10.0
1611	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498114	=	=	IC50	nM	31000.0	IC50	uM	31.0
1612	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498434	=	=	IC50	nM	21000.0	IC50	uM	21.0
1613	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498252	=	=	IC50	nM	2600.0	IC50	uM	2.6
1614	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498251	=	=	IC50	nM	15000.0	IC50	uM	15.0
1615	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498840	>	>	IC50	nM	100000.0	IC50	uM	100.0
1616	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521724	=	=	IC50	nM	86000.0	IC50	uM	86.0
1617	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL510171	=	=	IC50	nM	5500.0	IC50	uM	5.5
1618	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496402	=	=	IC50	nM	36000.0	IC50	uM	36.0
1619	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497419	=	=	IC50	nM	4200.0	IC50	uM	4.2
1620	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497418	=	=	IC50	nM	24000.0	IC50	uM	24.0
1621	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL526841	=	=	IC50	nM	2900.0	IC50	uM	2.9
1622	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498220	=	=	IC50	nM	13000.0	IC50	uM	13.0
1623	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498026	=	=	IC50	nM	3800.0	IC50	uM	3.8
1624	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495787	=	=	IC50	nM	17000.0	IC50	uM	17.0
1625	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495786	=	=	IC50	nM	28000.0	IC50	uM	28.0
1626	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523563	=	=	IC50	nM	4800.0	IC50	uM	4.8
1627	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496387	=	=	IC50	nM	8500.0	IC50	uM	8.5
1628	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496386	=	=	IC50	nM	14000.0	IC50	uM	14.0
1629	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496227	=	=	IC50	nM	15000.0	IC50	uM	15.0
1630	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496035	=	=	IC50	nM	21000.0	IC50	uM	21.0
1631	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496624	=	=	IC50	nM	13000.0	IC50	uM	13.0
1632	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521889	=	=	IC50	nM	5300.0	IC50	uM	5.3
1633	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496426	=	=	IC50	nM	1500.0	IC50	uM	1.5
1634	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496606	=	=	IC50	nM	6700.0	IC50	uM	6.7
1635	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447822	=	=	IC50	nM	1800.0	IC50	uM	1.8
1636	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496605	=	=	IC50	nM	48000.0	IC50	uM	48.0
1637	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL453246	=	=	IC50	nM	2100.0	IC50	uM	2.1
1638	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496400	=	=	IC50	nM	22000.0	IC50	uM	22.0
1639	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496806	=	=	IC50	nM	2600.0	IC50	uM	2.6
1640	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523752	=	=	IC50	nM	6300.0	IC50	uM	6.3
1641	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	14000.0	IC50	uM	14.0
1642	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3900.0	IC50	uM	3.9
1643	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498114	=	=	IC50	nM	10000.0	IC50	uM	10.0
1644	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498434	=	=	IC50	nM	9200.0	IC50	uM	9.2
1645	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498252	=	=	IC50	nM	700.0	IC50	uM	0.7
1646	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL525001	=	=	IC50	nM	7700.0	IC50	uM	7.7
1647	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498251	=	=	IC50	nM	3100.0	IC50	uM	3.1
1648	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498840	=	=	IC50	nM	62000.0	IC50	uM	62.0
1649	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521724	=	=	IC50	nM	18000.0	IC50	uM	18.0
1650	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL510171	=	=	IC50	nM	5100.0	IC50	uM	5.1
1651	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496402	=	=	IC50	nM	13000.0	IC50	uM	13.0
1652	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497419	=	=	IC50	nM	4600.0	IC50	uM	4.6
1653	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497418	=	=	IC50	nM	19000.0	IC50	uM	19.0
1654	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL526841	=	=	IC50	nM	5200.0	IC50	uM	5.2
1655	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498220	=	=	IC50	nM	3400.0	IC50	uM	3.4
1656	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498026	=	=	IC50	nM	17000.0	IC50	uM	17.0
1657	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495787	=	=	IC50	nM	7200.0	IC50	uM	7.2
1658	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495786	=	=	IC50	nM	16000.0	IC50	uM	16.0
1659	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523563	=	=	IC50	nM	2100.0	IC50	uM	2.1
1660	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496387	=	=	IC50	nM	7200.0	IC50	uM	7.2
1661	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496386	=	=	IC50	nM	7200.0	IC50	uM	7.2
1662	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496227	=	=	IC50	nM	13000.0	IC50	uM	13.0
1663	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496035	=	=	IC50	nM	16000.0	IC50	uM	16.0
1664	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496624	=	=	IC50	nM	7500.0	IC50	uM	7.5
1665	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521889	=	=	IC50	nM	6500.0	IC50	uM	6.5
1666	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496426	=	=	IC50	nM	1800.0	IC50	uM	1.8
1667	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496606	=	=	IC50	nM	17000.0	IC50	uM	17.0
1668	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447822	=	=	IC50	nM	1300.0	IC50	uM	1.3
1669	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496605	=	=	IC50	nM	13000.0	IC50	uM	13.0
1670	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL453246	=	=	IC50	nM	2900.0	IC50	uM	2.9
1671	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496400	=	=	IC50	nM	6800.0	IC50	uM	6.8
1672	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496806	=	=	IC50	nM	1700.0	IC50	uM	1.7
1673	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523752	=	=	IC50	nM	4700.0	IC50	uM	4.7
1674	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	8400.0	IC50	uM	8.4
1675	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3800.0	IC50	uM	3.8
1676	Inhibition of CYP3A4	C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL466496	=	=	IC50	nM	1300.0	IC50	uM	1.3
1677	Inhibition of CYP3A4	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL467079	=	=	IC50	nM	8600.0	IC50	uM	8.6
1678	Inhibition of CYP3A4	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1	Bioorg. Med. Chem.	2009.0	CHEMBL511410	>	>	IC50	nM	10000.0	IC50	uM	10.0
1679	Inhibition of CYP3A4	C[C@@H](Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL524472	=	=	IC50	nM	40000.0	IC50	uM	40.0
1680	Inhibition of CYP3A4 expressed in human hepatocytes	C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL468927	>	>	IC50	nM	100000.0	IC50	uM	100.0
1681	Inhibition of CYP3A4 coincubated with compound	CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565195	>	>	IC50	nM	30000.0	IC50	uM	30.0
1682	Inhibition of CYP3A4 coincubated with compound	COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557885	>	>	IC50	nM	30000.0	IC50	uM	30.0
1683	Inhibition of CYP3A4 coincubated with compound	CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561696	>	>	IC50	nM	30000.0	IC50	uM	30.0
1684	Inhibition of CYP3A4 preincubated with compound	CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565195	>	>	IC50	nM	20000.0	IC50	uM	20.0
1685	Inhibition of CYP3A4 preincubated with compound	COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557885	>	>	IC50	nM	15000.0	IC50	uM	15.0
1686	Inhibition of CYP3A4 preincubated with compound	CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561696	<	<	IC50	nM	15000.0	IC50	uM	15.0
1687	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of testosterone 6-beta-hydroxylation	Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1	J. Med. Chem.	2009.0	CHEMBL564840	>	>	IC50	nM	100000.0	IC50	uM	100.0
1688	Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ncsc2Cl)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL549534	=	=	IC50	nM	300.0	IC50	uM	0.3
1689	Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2[nH]ncc2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL563956	=	=	IC50	nM	3800.0	IC50	uM	3.8
1690	Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL559825	>	>	IC50	nM	5000.0	IC50	uM	5.0
1691	Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C3CCCCC3)c2n1	J. Med. Chem.	2009.0	CHEMBL559565	=	=	IC50	nM	2500.0	IC50	uM	2.5
1692	Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C(C)C)c2n1	J. Med. Chem.	2009.0	CHEMBL559506	=	=	IC50	nM	3100.0	IC50	uM	3.1
1693	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558873	=	=	Ki	nM	260.0	Ki	uM	0.26
1694	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564408	=	=	Ki	nM	210.0	Ki	uM	0.21
1695	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL251077	=	=	Ki	nM	7600.0	Ki	uM	7.6
1696	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1OC(C)=O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465295	=	=	Ki	nM	11000.0	Ki	uM	11.0
1697	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL98745	=	=	Ki	nM	630.0	Ki	uM	0.63
1698	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	24.0	Ki	uM	0.024
1699	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558873	=	=	Ki	nM	251.19	pKi		6.6
1700	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564408	=	=	Ki	nM	158.49	pKi		6.8
1701	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL251077	=	=	Ki	nM	7943.28	pKi		5.1
1702	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1OC(C)=O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465295	=	=	Ki	nM	10000.0	pKi		5.0
1703	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL98745	=	=	Ki	nM	630.96	pKi		6.2
1704	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	25.12	pKi		7.6
1705	Inhibition of CYP3A4	CCNC(=O)c1cc2c(-c3cc(OCCN(CC)CC)c(Cl)cc3Cl)nc(N)nc2s1	J. Med. Chem.	2009.0	CHEMBL549749	>	>	IC50	nM	10000.0	IC50	uM	10.0
1706	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3	J. Med. Chem.	2009.0	CHEMBL551964	=	=	IC50	nM	10000.0	IC50	uM	10.0
1707	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2ccnn2)CC1	J. Med. Chem.	2009.0	CHEMBL564975	>	>	IC50	nM	10000.0	IC50	uM	10.0
1708	Inhibition of CYP3A4	Cn1cc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)nn1	J. Med. Chem.	2009.0	CHEMBL562869	>	>	IC50	nM	10000.0	IC50	uM	10.0
1709	Inhibition of CYP3A4	Cn1cnnc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1	J. Med. Chem.	2009.0	CHEMBL550652	>	>	IC50	nM	10000.0	IC50	uM	10.0
1710	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2cncn2)CC1	J. Med. Chem.	2009.0	CHEMBL563732	>	>	IC50	nM	10000.0	IC50	uM	10.0
1711	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2cccn2)CC1	J. Med. Chem.	2009.0	CHEMBL559101	>	>	IC50	nM	10000.0	IC50	uM	10.0
1712	Inhibition of CYP3A4	Cc1c(O)noc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1	J. Med. Chem.	2009.0	CHEMBL552196	>	>	IC50	nM	10000.0	IC50	uM	10.0
1713	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1	J. Med. Chem.	2009.0	CHEMBL561379	>	>	IC50	nM	10000.0	IC50	uM	10.0
1714	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2ncon2)CC1	J. Med. Chem.	2009.0	CHEMBL561259	>	>	IC50	nM	10000.0	IC50	uM	10.0
1715	Inhibition of CYP3A4	Cc1noc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)n1	J. Med. Chem.	2009.0	CHEMBL564547	>	>	IC50	nM	10000.0	IC50	uM	10.0
1716	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1	J. Med. Chem.	2009.0	CHEMBL552402	>	>	IC50	nM	10000.0	IC50	uM	10.0
1717	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1	J. Med. Chem.	2009.0	CHEMBL561788	>	>	IC50	nM	10000.0	IC50	uM	10.0
1718	Inhibition of CYP3A4	CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1	J. Med. Chem.	2009.0	CHEMBL551058	>	>	IC50	nM	10000.0	IC50	uM	10.0
1719	Inhibition of CYP3A4	O=C(O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1	J. Med. Chem.	2009.0	CHEMBL559531	>	>	IC50	nM	10000.0	IC50	uM	10.0
1720	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552382	>	>	IC50	nM	10000.0	IC50	uM	10.0
1721	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL564757	<	<	IC50	nM	10000.0	IC50	uM	10.0
1722	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL556487	>	>	IC50	nM	10000.0	IC50	uM	10.0
1723	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL557032	>	>	IC50	nM	10000.0	IC50	uM	10.0
1724	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ncccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL551517	>	>	IC50	nM	10000.0	IC50	uM	10.0
1725	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552061	>	>	IC50	nM	10000.0	IC50	uM	10.0
1726	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL551921	<	<	IC50	nM	10000.0	IC50	uM	10.0
1727	Inhibition of CYP3A4	O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL555347	>	>	IC50	nM	10000.0	IC50	uM	10.0
1728	Inhibition of CYP3A4	O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL562926	=	=	IC50	nM	10000.0	IC50	uM	10.0
1729	Inhibition of CYP3A4	O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL550242	<	<	IC50	nM	10000.0	IC50	uM	10.0
1730	Inhibition of CYP3A4	O=C(N[C@@H]1C[C@H]1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL562822	>	>	IC50	nM	10000.0	IC50	uM	10.0
1731	Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552382	>	>	IC50	nM	10000.0	IC50	uM	10.0
1732	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome at 1 uM	CCC(c1ccc(-c2ccc(O)c(Cl)c2)cc1)n1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL541941	=	=	IC50	nM	91.0	IC50	nM	91.0
1733	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	72.0	IC50	nM	72.0
1734	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL254328	=	=	IC50	nM	2704.0	IC50	nM	2704.0
1735	Inhibition of CYP3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Eur. J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	132129.56	-Log IC50(M)		3.879
1736	Inhibition of CYP3A4	CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Eur. J. Med. Chem.	2009.0	CHEMBL76	=	=	IC50	nM	349945.17	-Log IC50(M)		3.456
1737	Inhibition of CYP3A4	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL23	=	=	IC50	nM	217270.12	-Log IC50(M)		3.663
1738	Inhibition of CYP3A4	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12	Eur. J. Med. Chem.	2009.0	CHEMBL493	=	=	IC50	nM	2999.16	-Log IC50(M)		5.523
1739	Inhibition of CYP3A4	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21	Eur. J. Med. Chem.	2009.0	CHEMBL1732	=	=	IC50	nM	2999.16	-Log IC50(M)		5.523
1740	Inhibition of CYP3A4	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Eur. J. Med. Chem.	2009.0	CHEMBL1191	=	=	IC50	nM	835603.02	-Log IC50(M)		3.078
1741	Inhibition of CYP3A4	[O-][S+](Cc1ccccn1)c1nc2ccccc2[nH]1	Eur. J. Med. Chem.	2009.0	CHEMBL9861	=	=	IC50	nM	309029.54	-Log IC50(M)		3.51
1742	Inhibition of CYP3A4	CCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1	Eur. J. Med. Chem.	2009.0	CHEMBL564109	=	=	IC50	nM	289734.36	-Log IC50(M)		3.538
1743	Inhibition of CYP3A4	CN/C(=N/CCSCc1nc[nH]c1C)NC#N	Eur. J. Med. Chem.	2009.0	CHEMBL30	=	=	IC50	nM	1000000.0	-Log IC50(M)		3.0
1744	Inhibition of CYP3A4	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Eur. J. Med. Chem.	2009.0	CHEMBL193	=	=	IC50	nM	46989.41	-Log IC50(M)		4.328
1745	Inhibition of CYP3A4	COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1	Eur. J. Med. Chem.	2009.0	CHEMBL1503	=	=	IC50	nM	77983.01	-Log IC50(M)		4.108
1746	Inhibition of CYP3A4	Cc1ncc[nH]1	Eur. J. Med. Chem.	2009.0	CHEMBL293391	=	=	IC50	nM	1253141.17	-Log IC50(M)		2.902
1747	Inhibition of CYP3A4	Oc1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL237847	=	=	IC50	nM	767361.49	-Log IC50(M)		3.115
1748	Inhibition of CYP3A4	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1cncn1	Eur. J. Med. Chem.	2009.0	CHEMBL520897	=	=	IC50	nM	9289.66	-Log IC50(M)		5.032
1749	Inhibition of CYP3A4	CCCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	Eur. J. Med. Chem.	2009.0	CHEMBL560579	=	=	IC50	nM	1039.92	-Log IC50(M)		5.983
1750	Inhibition of CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	199.99	-Log IC50(M)		6.699
1751	Inhibition of CYP3A4	CC(C)(C(=O)c1cccnc1)c1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL934	=	=	IC50	nM	4931.74	-Log IC50(M)		5.307
1752	Inhibition of CYP3A4	Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1	Eur. J. Med. Chem.	2009.0	CHEMBL1073	=	=	IC50	nM	7447.32	-Log IC50(M)		5.128
1753	Inhibition of CYP3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Eur. J. Med. Chem.	2009.0	CHEMBL91	=	=	IC50	nM	851.14	-Log IC50(M)		6.07
1754	Inhibition of CYP3A4	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Eur. J. Med. Chem.	2009.0	CHEMBL106	=	=	IC50	nM	25003.45	-Log IC50(M)		4.602
1755	Inhibition of CYP3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL808	=	=	IC50	nM	430.53	-Log IC50(M)		6.366
1756	Inhibition of CYP3A4	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Eur. J. Med. Chem.	2009.0	CHEMBL6966	=	=	IC50	nM	76032.63	-Log IC50(M)		4.119
1757	Inhibition of CYP3A4	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Eur. J. Med. Chem.	2009.0	CHEMBL564085	=	=	IC50	nM	7998.34	-Log IC50(M)		5.097
1758	Inhibition of CYP3A4	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O	Eur. J. Med. Chem.	2009.0	CHEMBL527	=	=	IC50	nM	1000000.0	-Log IC50(M)		3.0
1759	Inhibition of CYP3A4	Cn1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL543	=	=	IC50	nM	2697739.43	-Log IC50(M)		2.569
1760	Inhibition of CYP3A4	c1ccc(Nc2ccccn2)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL555260	=	=	IC50	nM	430526.61	-Log IC50(M)		3.366
1761	Inhibition of CYP3A4	S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL260374	=	=	IC50	nM	6095.37	-Log IC50(M)		5.215
1762	Inhibition of CYP3A4	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL104	=	=	IC50	nM	50.0	-Log IC50(M)		7.301
1763	Inhibition of CYP3A4	c1ccc2nc(COc3ccc(-c4n[nH]cc4Cc4ccncc4)cc3)ccc2c1	J. Med. Chem.	2009.0	CHEMBL562317	=	=	IC50	nM	450000.0	IC50	uM	450.0
1764	Inhibition of CYP3A4	c1ccc2nc(COc3ccc(-c4n[nH]cc4-c4ccncc4)cc3)ccc2c1	J. Med. Chem.	2009.0	CHEMBL560377	>	>	IC50	nM	10000.0	IC50	uM	10.0
1765	Inhibition of CYP3A4	COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL560386	>	>	IC50	nM	10000.0	IC50	uM	10.0
1766	Inhibition of CYP3A4 using BFC as substrate	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	=	=	IC50	nM	18500.0	IC50	uM	18.5
1767	Inhibition of CYP3A4 using BZR as substrate	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	>	>	IC50	nM	40000.0	IC50	uM	40.0
1768	Inhibition of CYP3A4 in human TC5 cells	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	>	>	IC50	nM	200000.0	IC50	uM	200.0
1769	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL539650	=	=	IC50	nM	1.4	IC50	nM	1.4
1770	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL538632	=	=	IC50	nM	4.7	IC50	nM	4.7
1771	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	J. Med. Chem.	2009.0	CHEMBL16596	=	=	IC50	nM	5.8	IC50	nM	5.8
1772	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL38958	=	=	IC50	nM	11.5	IC50	nM	11.5
1773	Inhibition of CYP3A4	COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1	J. Med. Chem.	2009.0	CHEMBL552567	=	=	IC50	nM	15.1	IC50	nM	15.1
1774	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3ncccn3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL557052	>	>	IC50	nM	10.0	IC50	nM	10.0
1775	Inhibition of CYP3A4	COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1	J. Med. Chem.	2009.0	CHEMBL557527	>	>	IC50	nM	50.0	IC50	nM	50.0
1776	Inhibition of human CYP3A4	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL560993	>	>	IC50	nM	30000.0	IC50	uM	30.0
1777	Inhibition of human CYP3A4	CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551813	>	>	IC50	nM	30000.0	IC50	uM	30.0
1778	Inhibition of human CYP3A4	O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL361812	>	>	IC50	nM	30000.0	IC50	uM	30.0
1779	Inhibition of human CYP3A4	CN([C@@H]1CCC2=C(C1)C1C=CC=CC1N2CC(=O)O)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563664	>	>	IC50	nM	30000.0	IC50	uM	30.0
1780	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561132	=	=	IC50	nM	7000.0	IC50	uM	7.0
1781	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccn3c2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564920	>	>	IC50	nM	30000.0	IC50	uM	30.0
1782	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564845	=	=	IC50	nM	11000.0	IC50	uM	11.0
1783	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ncccc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550465	>	>	IC50	nM	30000.0	IC50	uM	30.0
1784	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ccncc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550868	>	>	IC50	nM	30000.0	IC50	uM	30.0
1785	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3cccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552211	>	>	IC50	nM	30000.0	IC50	uM	30.0
1786	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3nccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556849	>	>	IC50	nM	30000.0	IC50	uM	30.0
1787	Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ncccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557117	>	>	IC50	nM	30000.0	IC50	uM	30.0
1788	Inhibition of CYP3A4 using felodipine as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	22000.0	IC50	nM	22000.0
1789	Inhibition of CYP3A4 using midazolam as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	12200.0	IC50	nM	12200.0
1790	Inhibition of CYP3A4 using testosterone as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	31200.0	IC50	nM	31200.0
1791	Inhibition of CYP3A4	Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561932	>	>	IC50	nM	30000.0	IC50	uM	30.0
1792	Inhibition of CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(F)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563949	>	>	IC50	nM	10000.0	IC50	uM	10.0
1793	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557263	=	=	IC50	nM	40.0	IC50	uM	0.04
1794	Inhibition of human recombinant CYP3A4 after 45 mins	CC(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL549930	=	=	IC50	nM	320.0	IC50	uM	0.32
1795	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cncn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557262	=	=	IC50	nM	570.0	IC50	uM	0.57
1796	Inhibition of human recombinant CYP3A4 after 45 mins	Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL539475	=	=	IC50	nM	790.0	IC50	uM	0.79
1797	Inhibition of human recombinant CYP3A4 after 45 mins	Cc1nccn1CC(NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL549595	=	=	IC50	nM	2020.0	IC50	uM	2.02
1798	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550068	=	=	IC50	nM	2490.0	IC50	uM	2.49
1799	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL562285	=	=	IC50	nM	3220.0	IC50	uM	3.22
1800	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556927	=	=	IC50	nM	4400.0	IC50	uM	4.4
1801	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563791	=	=	IC50	nM	13400.0	IC50	uM	13.4
1802	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550816	=	=	IC50	nM	16500.0	IC50	uM	16.5
1803	Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557329	=	=	IC50	nM	20600.0	IC50	uM	20.6
1804	Inhibition of CYP3A4	CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557461	>	>	IC50	nM	12000.0	IC50	uM	12.0
1805	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL541483	>	>	IC50	nM	41000.0	IC50	uM	41.0
1806	Inhibition of CYP3A4	CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL94454	>	>	IC50	nM	5000.0	IC50	uM	5.0
1807	Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(n4cc(C)cn4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL562894	>	>	IC50	nM	5000.0	IC50	uM	5.0
1808	Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
1809	Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551347	>	>	IC50	nM	5000.0	IC50	uM	5.0
1810	Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556449	=	=	IC50	nM	72000.0	IC50	uM	72.0
1811	Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4cccc4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558339	>	>	IC50	nM	5000.0	IC50	uM	5.0
1812	Inhibition of CYP3A4	O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552026	>	>	IC50	nM	5000.0	IC50	uM	5.0
1813	Inhibition of CYP3A4	CN(C)CCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL559061	>	>	IC50	nM	5000.0	IC50	uM	5.0
1814	Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563055	>	>	IC50	nM	5000.0	IC50	uM	5.0
1815	Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL559060	>	>	IC50	nM	5000.0	IC50	uM	5.0
1816	Inhibition of CYP3A4	CN(CCO)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557210	>	>	IC50	nM	5000.0	IC50	uM	5.0
1817	Inhibition of CYP3A4	COCCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550337	>	>	IC50	nM	5000.0	IC50	uM	5.0
1818	Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(N(C)CC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558663	>	>	IC50	nM	5000.0	IC50	uM	5.0
1819	Inhibition of CYP3A4	CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550818	>	>	IC50	nM	5000.0	IC50	uM	5.0
1820	Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558468	>	>	IC50	nM	5000.0	IC50	uM	5.0
1821	Inhibition of CYP3A4	Cc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563451	>	>	IC50	nM	5000.0	IC50	uM	5.0
1822	Inhibition of CYP3A4	CN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558467	>	>	IC50	nM	5000.0	IC50	uM	5.0
1823	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC1(C)O[C@@H](CO[Si](C)(C)C(C)(C)C)[C@H]([C@H](O)[C@@H](CNC(=O)c2ccccc2)c2ccc3c(c2)OCO3)O1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL574914	=	=	Ki	nM	170.0	Ki	uM	0.17
1824	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573430	=	=	Ki	nM	30.0	Ki	uM	0.03
1825	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577811	=	=	Ki	nM	1550.0	Ki	uM	1.55
1826	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583953	=	=	Ki	nM	320.0	Ki	uM	0.32
1827	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583954	=	=	Ki	nM	580.0	Ki	uM	0.58
1828	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573665	=	=	Ki	nM	70.0	Ki	uM	0.07
1829	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COC(C)=O)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573149	=	=	Ki	nM	1010.0	Ki	uM	1.01
1830	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	30.0	Ki	uM	0.03
1831	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC1(C)O[C@@H](CO[Si](C)(C)C(C)(C)C)[C@H]([C@H](O)[C@@H](CNC(=O)c2ccccc2)c2ccc3c(c2)OCO3)O1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL574914	=	=	Ki	nM	165.96	pKi		6.78
1832	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573430	=	=	Ki	nM	31.62	pKi		7.5
1833	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577811	=	=	Ki	nM	1548.82	pKi		5.81
1834	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583953	=	=	Ki	nM	316.23	pKi		6.5
1835	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583954	=	=	Ki	nM	575.44	pKi		6.24
1836	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573665	=	=	Ki	nM	70.79	pKi		7.15
1837	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COC(C)=O)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573149	=	=	Ki	nM	1023.29	pKi		5.99
1838	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	33.11	pKi		7.48
1839	Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1	J. Med. Chem.	2009.0	CHEMBL575448	>	>	IC50	nM	40000.0	IC50	uM	40.0
1840	Inhibition of CYP3A4 using 7-benzyloxy-resorufin as substrate	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1	J. Med. Chem.	2009.0	CHEMBL575448	=	=	IC50	nM	7000.0	IC50	uM	7.0
1841	Inhibition of CYP3A4	CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584554	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1842	Inhibition of human CYP3A4	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12	J. Med. Chem.	2009.0	CHEMBL1645462	=	=	IC50	nM	1600.0	IC50	uM	1.6
1843	Inhibition of CYP3A4 in pooled human liver microsome	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12	J. Med. Chem.	2009.0	CHEMBL1645462	=	=	IC50	nM	12000.0	IC50	uM	12.0
1844	Inhibition of human hepatic CYP3A4	Cc1cc(-c2csc(-c3cccc(O)c3)c2)ccc1O	J. Med. Chem.	2009.0	CHEMBL569862	=	=	IC50	nM	1500.0	IC50	uM	1.5
1845	Inhibition of human hepatic CYP3A4	Oc1cccc(-c2ccc(-c3ccc(O)c(F)c3)s2)c1	J. Med. Chem.	2009.0	CHEMBL577338	=	=	IC50	nM	820.0	IC50	uM	0.82
1846	Inhibition of human hepatic CYP3A4	Cc1cc(-c2ccc(-c3cccc(O)c3)s2)ccc1O	J. Med. Chem.	2009.0	CHEMBL570596	=	=	IC50	nM	500.0	IC50	uM	0.5
1847	Inhibition of CYP3A4 in human liver microsomes	COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1	J. Med. Chem.	2009.0	CHEMBL569185	=	=	IC50	nM	37000.0	IC50	microM	37.0
1848	Inhibition of CYP3A4	CN(C)Cc1nc2c(sc3ccc(-c4ccc(O)cc4)cc32)c(=O)[nH]1	J. Med. Chem.	2009.0	CHEMBL585182	>	>	IC50	nM	20000.0	IC50	microM	20.0
1849	Inhibition of CYP3A4	Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1	J. Med. Chem.	2009.0	CHEMBL575966	=	=	IC50	nM	1258.93	pIC50		5.9
1850	Inhibition of CYP3A4	Cc1ccc(N(C)C(=O)c2c(-c3ccccc3Cl)noc2C)cc1Cl	J. Med. Chem.	2009.0	CHEMBL576138	=	=	IC50	nM	1258.93	pIC50		5.9
1851	Inhibition of human recombinant CYP3A4	CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12.CS(=O)(=O)O	J. Med. Chem.	2009.0	CHEMBL593763	=	=	IC50	nM	5000.0	IC50	uM	5.0
1852	Inhibition of CYP3A4	N#Cc1cc(Cl)cc(Oc2cc(OCc3n[nH]c4nc(N)ccc34)cc(F)c2Cl)c1	J. Med. Chem.	2009.0	CHEMBL572324	=	=	IC50	nM	4400.0	IC50	uM	4.4
1853	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(/N=C(/NC(=O)c3cccnc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567904	=	=	IC50	nM	300.0	IC50	uM	0.3
1854	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc[n+]([O-])c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565383	=	=	IC50	nM	900.0	IC50	uM	0.9
1855	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3cncc(C(N)=O)c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577965	=	=	IC50	nM	400.0	IC50	uM	0.4
1856	Inhibition of CYP3A4 using BFC as a substrate	Cc1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565390	=	=	IC50	nM	7000.0	IC50	uM	7.0
1857	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(Cl)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567487	=	=	IC50	nM	8000.0	IC50	uM	8.0
1858	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570639	=	=	IC50	nM	87000.0	IC50	uM	87.0
1859	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(N)=O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576093	=	=	IC50	nM	18000.0	IC50	uM	18.0
1860	Inhibition of CYP3A4 using BFC as a substrate	CNC(=O)c1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576094	=	=	IC50	nM	18000.0	IC50	uM	18.0
1861	Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	=	=	IC50	nM	39000.0	IC50	uM	39.0
1862	Inhibition of CYP3A4 using BZR as substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	>	>	IC50	nM	40000.0	IC50	uM	40.0
1863	Inhibition of CYP3A4 by HHA assay	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	>	>	IC50	nM	200000.0	IC50	uM	200.0
1864	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12	J. Med. Chem.	2010.0	CHEMBL565591	=	=	IC50	nM	1500.0	IC50	uM	1.5
1865	Inhibition of human CYP3A4 using dibenzylfluorescein as substrate	Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12	J. Med. Chem.	2010.0	CHEMBL565591	=	=	IC50	nM	7600.0	IC50	uM	7.6
1866	Inhibition of CYP3A4	Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578413	<	>	IC50	nM	10000.0	pIC50		5.0
1867	Inhibition of CYP3A4	C[C@H](NC(=O)C(C)(C)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL582806	=	=	IC50	nM	2030.0	IC50	uM	2.03
1868	Inhibition of CYP3A4	C[C@H](NC(C)(C)C(=O)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL571204	>	>	IC50	nM	35000.0	IC50	uM	35.0
1869	Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	IC50	nM	4.0	IC50	uM	0.004
1870	Inhibition of human CYP3A4	COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc6cccnc56)cc1)(C4)C3)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577316	=	=	IC50	nM	2840.0	IC50	uM	2.84
1871	Inhibition of human CYP3A4	COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc(C#N)c5)cc1)(C4)C3)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570403	>	>	IC50	nM	5000.0	IC50	uM	5.0
1872	Inhibition of human CYP3A4	COC(=O)c1ccccc1NC(=O)COc1ccc(C23CC4CC(CC(C(=O)N5CCc6cc(OC)c(OC)cc6C5)(C4)C2)C3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577103	=	=	IC50	nM	3790.0	IC50	uM	3.79
1873	Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7cccc(OC)c7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567798	=	=	IC50	nM	820.0	IC50	uM	0.82
1874	Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(OC)cc7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570402	=	=	IC50	nM	890.0	IC50	uM	0.89
1875	Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(C(F)(F)F)cc7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568012	=	=	IC50	nM	2030.0	IC50	uM	2.03
1876	Inhibition of CYP3A4	Cc1c(-c2cn(C(C)C)cn2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584261	>	>	IC50	nM	10000.0	IC50	uM	10.0
1877	Inhibition of CYP3A4	Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12	J. Med. Chem.	2009.0	CHEMBL567911	=	=	IC50	nM	48000.0	IC50	uM	48.0
1878	Inhibition of CYP3A4	Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21	J. Med. Chem.	2009.0	CHEMBL567292	=	=	IC50	nM	24000.0	IC50	uM	24.0
1879	Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496102	=	=	IC50	nM	32000.0	IC50	uM	32.0
1880	Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522196	>	>	IC50	nM	50000.0	IC50	uM	50.0
1881	Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494979	=	=	IC50	nM	29000.0	IC50	uM	29.0
1882	Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494630	>	>	IC50	nM	50000.0	IC50	uM	50.0
1883	Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567908	=	=	IC50	nM	17000.0	IC50	uM	17.0
1884	Inhibition of human CYP3A4	COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585293	=	=	IC50	nM	14000.0	IC50	uM	14.0
1885	Inhibition of human CYP3A4	COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566253	=	=	IC50	nM	18000.0	IC50	uM	18.0
1886	Inhibition of human CYP3A4	COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566683	>	>	IC50	nM	50000.0	IC50	uM	50.0
1887	Inhibition of human CYP3A4	COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567089	=	=	IC50	nM	4500.0	IC50	uM	4.5
1888	Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566875	>	>	IC50	nM	50000.0	IC50	uM	50.0
1889	Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566242	>	>	IC50	nM	50000.0	IC50	uM	50.0
1890	Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565843	>	>	IC50	nM	50000.0	IC50	uM	50.0
1891	Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568138	>	>	IC50	nM	50000.0	IC50	uM	50.0
1892	Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566685	>	>	IC50	nM	50000.0	IC50	uM	50.0
1893	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496102	=	=	IC50	nM	4100.0	IC50	uM	4.1
1894	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522196	=	=	IC50	nM	6400.0	IC50	uM	6.4
1895	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494979	=	=	IC50	nM	2000.0	IC50	uM	2.0
1896	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494630	=	=	IC50	nM	8300.0	IC50	uM	8.3
1897	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567908	=	=	IC50	nM	4800.0	IC50	uM	4.8
1898	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585293	=	=	IC50	nM	3900.0	IC50	uM	3.9
1899	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566253	=	=	IC50	nM	8900.0	IC50	uM	8.9
1900	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566683	=	=	IC50	nM	50000.0	IC50	uM	50.0
1901	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567089	=	=	IC50	nM	7000.0	IC50	uM	7.0
1902	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566875	=	=	IC50	nM	41000.0	IC50	uM	41.0
1903	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566242	=	=	IC50	nM	9100.0	IC50	uM	9.1
1904	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565843	=	=	IC50	nM	16000.0	IC50	uM	16.0
1905	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568138	=	=	IC50	nM	29000.0	IC50	uM	29.0
1906	Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566685	=	=	IC50	nM	26000.0	IC50	uM	26.0
1907	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(C(C)(C)C)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576457	>	>	IC50	nM	5000.0	IC50	uM	5.0
1908	Inhibition of human CYP3A4	COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565361	=	=	IC50	nM	3700.0	IC50	uM	3.7
1909	Inhibition of human CYP3A4	CCOc1ccccc1CNC(=O)CC1(C)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578968	>	>	IC50	nM	5000.0	IC50	uM	5.0
1910	Inhibition of human CYP3A4	COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579199	=	=	IC50	nM	1700.0	IC50	uM	1.7
1911	Inhibition of human CYP3A4	COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579200	=	=	IC50	nM	1900.0	IC50	uM	1.9
1912	Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567169	=	=	IC50	nM	3200.0	IC50	uM	3.2
1913	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(OC(F)F)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583442	>	>	IC50	nM	5000.0	IC50	uM	5.0
1914	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568242	=	=	IC50	nM	4200.0	IC50	uM	4.2
1915	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565983	=	=	IC50	nM	2900.0	IC50	uM	2.9
1916	Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577694	=	=	IC50	nM	4900.0	IC50	uM	4.9
1917	Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(Br)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL572184	>	>	IC50	nM	5000.0	IC50	uM	5.0
1918	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565362	=	=	IC50	nM	4400.0	IC50	uM	4.4
1919	Inhibition of human CYP3A4	CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567374	=	=	IC50	nM	1000.0	IC50	uM	1.0
1920	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(C(=O)O)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577470	>	>	IC50	nM	5000.0	IC50	uM	5.0
1921	Inhibition of human CYP3A4	COC(=O)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578547	>	>	IC50	nM	5000.0	IC50	uM	5.0
1922	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567376	=	=	IC50	nM	1900.0	IC50	uM	1.9
1923	Inhibition of human CYP3A4	CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578588	=	=	IC50	nM	4800.0	IC50	uM	4.8
1924	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc([N+](=O)[O-])cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568444	>	>	IC50	nM	5000.0	IC50	uM	5.0
1925	Inhibition of human CYP3A4	CSc1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578594	>	>	IC50	nM	5000.0	IC50	uM	5.0
1926	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(S(N)(=O)=O)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568456	>	>	IC50	nM	5000.0	IC50	uM	5.0
1927	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578578	=	=	IC50	nM	1600.0	IC50	uM	1.6
1928	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(N3CCOCC3)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578579	>	>	IC50	nM	5000.0	IC50	uM	5.0
1929	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565360	=	=	IC50	nM	1200.0	IC50	uM	1.2
1930	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584886	=	=	IC50	nM	2600.0	IC50	uM	2.6
1931	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCCO3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585191	>	>	IC50	nM	5000.0	IC50	uM	5.0
1932	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCC=CO3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567582	>	>	IC50	nM	5000.0	IC50	uM	5.0
1933	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccn2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568438	>	>	IC50	nM	5000.0	IC50	uM	5.0
1934	Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccncc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579016	>	>	IC50	nM	5000.0	IC50	uM	5.0
1935	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12	J. Med. Chem.	2009.0	CHEMBL567570	>	>	IC50	nM	40000.0	IC50	uM	40.0
1936	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12	J. Med. Chem.	2009.0	CHEMBL567570	>	>	IC50	nM	40000.0	IC50	uM	40.0
1937	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12	J. Med. Chem.	2009.0	CHEMBL585487	>	>	IC50	nM	40000.0	IC50	uM	40.0
1938	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12	J. Med. Chem.	2009.0	CHEMBL585487	>	>	IC50	nM	40000.0	IC50	uM	40.0
1939	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12	J. Med. Chem.	2009.0	CHEMBL585498	=	=	IC50	nM	18000.0	IC50	uM	18.0
1940	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12	J. Med. Chem.	2009.0	CHEMBL585498	=	=	IC50	nM	9300.0	IC50	uM	9.3
1941	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12	J. Med. Chem.	2009.0	CHEMBL583867	>	>	IC50	nM	40000.0	IC50	uM	40.0
1942	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12	J. Med. Chem.	2009.0	CHEMBL583867	>	>	IC50	nM	40000.0	IC50	uM	40.0
1943	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12	J. Med. Chem.	2009.0	CHEMBL442078	>	>	IC50	nM	40000.0	IC50	uM	40.0
1944	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12	J. Med. Chem.	2009.0	CHEMBL442078	>	>	IC50	nM	40000.0	IC50	uM	40.0
1945	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12	J. Med. Chem.	2009.0	CHEMBL337301	>	>	IC50	nM	40000.0	IC50	uM	40.0
1946	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12	J. Med. Chem.	2009.0	CHEMBL337301	>	>	IC50	nM	40000.0	IC50	uM	40.0
1947	Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12	J. Med. Chem.	2009.0	CHEMBL238103	>	>	IC50	nM	40000.0	IC50	uM	40.0
1948	Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12	J. Med. Chem.	2009.0	CHEMBL238103	>	>	IC50	nM	40000.0	IC50	uM	40.0
1949	Inhibition of human CYP3A4	CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL462360	=	=	IC50	nM	1000.0	IC50	uM	1.0
1950	Inhibition of CYP3A4	Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL571581	>	>	IC50	nM	10000.0	IC50	uM	10.0
1951	Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL596515	<	<	IC50	nM	1000.0	IC50	uM	1.0
1952	Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL595632	>	>	IC50	nM	30000.0	IC50	uM	30.0
1953	Inhibition of CYP3A4	O=C(O)CCc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL605833	>	>	IC50	nM	30000.0	IC50	uM	30.0
1954	Inhibition of CYP3A4	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596583	=	=	IC50	nM	630.0	IC50	uM	0.63
1955	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593374	=	=	IC50	nM	100.0	IC50	uM	0.1
1956	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593375	=	=	IC50	nM	1000.0	IC50	uM	1.0
1957	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595944	=	=	IC50	nM	5000.0	IC50	uM	5.0
1958	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595459	=	=	IC50	nM	1300.0	IC50	uM	1.3
1959	Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL606467	=	=	IC50	nM	790.0	IC50	uM	0.79
1960	Inhibition of CYP3A4	Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594523	=	=	IC50	nM	630.0	IC50	uM	0.63
1961	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594755	=	=	IC50	nM	3200.0	IC50	uM	3.2
1962	Inhibition of CYP3A4	CCNc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593573	=	=	IC50	nM	5000.0	IC50	uM	5.0
1963	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593813	=	=	IC50	nM	500.0	IC50	uM	0.5
1964	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605410	=	=	IC50	nM	1600.0	IC50	uM	1.6
1965	Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594072	=	=	IC50	nM	4000.0	IC50	uM	4.0
1966	Inhibition of CYP3A4	NC[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL536636	=	=	IC50	nM	9700.0	IC50	uM	9.7
1967	Inhibition of human CYP3A4	Cc1cc(NC2CCCCC2)nc(NCc2ccccc2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL578928	>	>	IC50	nM	5000.0	IC50	uM	5.0
1968	Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL16596	=	=	IC50	nM	5200.0	IC50	uM	5.2
1969	Inhibition of CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595092	=	=	IC50	nM	16700.0	IC50	uM	16.7
1970	Inhibition of CYP3A4	FC(F)(F)c1ccccc1OC1CCN(c2ccc(-n3ccnc3)nn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595154	=	=	IC50	nM	400.0	IC50	uM	0.4
1971	Inhibition of CYP3A4	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593490	=	=	IC50	nM	50.0	IC50	uM	0.05
1972	Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596072	=	=	IC50	nM	200.0	IC50	uM	0.2
1973	Inhibition of CYP3A4	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596073	=	=	IC50	nM	100.0	IC50	uM	0.1
1974	Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596290	=	=	IC50	nM	400.0	IC50	uM	0.4
1975	Inhibition of CYP3A4	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603197	=	=	IC50	nM	1300.0	IC50	uM	1.3
1976	Inhibition of CYP3A4	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594933	=	=	IC50	nM	16.0	IC50	uM	0.016
1977	Inhibition of human liver CYP3A4	O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL376487	=	=	IC50	nM	400.0	IC50	uM	0.4
1978	Inhibition of human liver CYP3A4	C[C@@H](NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(/C=C/C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL590850	=	=	IC50	nM	12300.0	IC50	uM	12.3
1979	Inhibition of CYP3A4	Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL575966	=	=	IC50	nM	1258.93	pIC50		5.9
1980	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596699	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1981	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596700	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1982	Inhibition of CYP3A4	Cl.Cl.Cl.Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)[C@H]2CC[C@@H](N)CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3217125	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1983	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(OC3CCCC3)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599060	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1984	Inhibition of CYP3A4	CC(C)Oc1cccc(CN(C(=O)c2cn(C)cn2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1985	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC3CCCC3)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603691	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1986	Inhibition of CYP3A4	COc1ccc(CN(C(=O)c2cn(C)cn2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)cc1OC1CCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603893	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1987	Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL598659	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1988	Inhibition of CYP3A4	CCN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599480	=	=	IC50	nM	5000.0	IC50	nM	5000.0
1989	Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603695	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1990	Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(OC4CCCC4)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599482	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1991	Inhibition of CYP3A4	CCN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL604805	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1992	Inhibition of CYP3A4	CC(F)CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605540	=	=	IC50	nM	7900.0	IC50	nM	7900.0
1993	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CCC(F)(F)F)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL597032	=	=	IC50	nM	8700.0	IC50	nM	8700.0
1994	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(O)c4ccccc4)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL597033	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1995	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(C)(C)O)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605744	>	>	IC50	nM	10000.0	IC50	nM	10000.0
1996	Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL607982	=	=	IC50	nM	8200.0	IC50	nM	8200.0
1997	Inhibition of CYP3A4	O=C(O)CC1CC2(CCN(C(=O)NC3C4CC5CC(C4)CC3C5)CC2)c2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605162	>	>	IC50	nM	15000.0	IC50	uM	15.0
1998	Inhibition of CYP3A4	Cc1cccc2c1C(=O)NC1CNCCN21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL590078	>	>	IC50	nM	40000.0	IC50	uM	40.0
1999	Inhibition of CYP3A4	CCCc1nc(-c2ccccc2)oc1C(=O)NC(C)CN1CCN(c2ncccn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605325	<	<	IC50	nM	10000.0	IC50	uM	10.0
2000	Inhibition of CYP3A4	CCN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL601030	>=	>=	IC50	nM	16000.0	IC50	uM	16.0
2001	Inhibition of CYP3A4	CC(C)N1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL601031	>=	>=	IC50	nM	8000.0	IC50	uM	8.0
2002	Inhibition of CYP3A4 muscle isoform in human liver microsomes	O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL602483	>	>	IC50	nM	100000.0	IC50	uM	100.0
2003	Inhibition of CYP3A4 tissue isoform in human liver microsomes	O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL602483	>	>	IC50	nM	100000.0	IC50	uM	100.0
2004	Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	COc1c(C(C)(C)C)cc(C(=O)Cn2c(NCCCO)nc3cc(C)c(C)cc32)cc1C(C)(C)C	Bioorg. Med. Chem.	2010.0	CHEMBL590750	=	=	IC50	nM	67000.0	IC50	uM	67.0
2005	Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C	Bioorg. Med. Chem.	2010.0	CHEMBL374350	=	=	IC50	nM	85000.0	IC50	uM	85.0
2006	Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	COCCCNc1nc2cc(C)c(C)cc2n1CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	Bioorg. Med. Chem.	2010.0	CHEMBL600058	=	=	IC50	nM	97000.0	IC50	uM	97.0
2007	Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@]2(COC3CCC3)[C@H]3CNC[C@H]32)cc1Cl	J. Med. Chem.	2010.0	CHEMBL590472	=	=	IC50	nM	3000.0	IC50	uM	3.0
2008	Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@]2(COCC3CC3)[C@H]3CNC[C@H]32)cc1Cl	J. Med. Chem.	2010.0	CHEMBL598644	=	=	IC50	nM	4000.0	IC50	uM	4.0
2009	Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@@]1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21	J. Med. Chem.	2010.0	CHEMBL2021582	>	>	IC50	nM	5000.0	IC50	uM	5.0
2010	Inhibition of human CYP3A4 by fluorescence assay	COC[C@@H]1[C@H]2CNC[C@]21c1ccc2ccccc2c1	J. Med. Chem.	2010.0	CHEMBL598215	>	>	IC50	nM	4000.0	IC50	uM	4.0
2011	Inhibition of human CYP3A4 by fluorescence assay	CC(C)OC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL605209	>	>	IC50	nM	8000.0	IC50	uM	8.0
2012	Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21C	J. Med. Chem.	2010.0	CHEMBL2021577	>	>	IC50	nM	9000.0	IC50	uM	9.0
2013	Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL608151	>	>	IC50	nM	9000.0	IC50	uM	9.0
2014	Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL608151	>	>	IC50	nM	9000.0	IC50	uM	9.0
2015	Inhibition of human CYP3A4 by fluorescence assay	COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL596809	>	>	IC50	nM	6000.0	IC50	uM	6.0
2016	Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COCC2CC2)cc1Cl	J. Med. Chem.	2010.0	CHEMBL610795	>	>	IC50	nM	10000.0	IC50	uM	10.0
2017	Inhibition of CYP3A4 in human microsomal preparation	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2010.0	CHEMBL263664	>	>	IC50	nM	10000.0	IC50	uM	10.0
2018	Inhibition of CYP3A4 in human microsomal preparation	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2010.0	CHEMBL598194	>	>	IC50	nM	10000.0	IC50	uM	10.0
2019	Inhibition of CYP3A4 in human microsomal preparation	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1	J. Med. Chem.	2010.0	CHEMBL597211	>	>	IC50	nM	10000.0	IC50	uM	10.0
2020	Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL605360	>	>	IC50	nM	30000.0	IC50	uM	30.0
2021	Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl	J. Med. Chem.	2010.0	CHEMBL592709	>	>	IC50	nM	30000.0	IC50	uM	30.0
2022	Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C	J. Med. Chem.	2010.0	CHEMBL604249	=	=	IC50	nM	13500.0	IC50	uM	13.5
2023	Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604087	>	>	IC50	nM	30000.0	IC50	uM	30.0
2024	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1	J. Med. Chem.	2010.0	CHEMBL590810	=	=	IC50	nM	5900.0	IC50	uM	5.9
2025	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL597127	>	>	IC50	nM	30000.0	IC50	uM	30.0
2026	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599792	=	=	IC50	nM	8100.0	IC50	uM	8.1
2027	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599791	=	=	IC50	nM	1700.0	IC50	uM	1.7
2028	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604085	>	>	IC50	nM	30000.0	IC50	uM	30.0
2029	Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL598336	=	=	IC50	nM	4000.0	IC50	uM	4.0
2030	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604085	>	>	IC50	nM	30000.0	IC50	uM	30.0
2031	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599792	>	>	IC50	nM	30000.0	IC50	uM	30.0
2032	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599791	>	>	IC50	nM	30000.0	IC50	uM	30.0
2033	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL597127	>	>	IC50	nM	30000.0	IC50	uM	30.0
2034	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1	J. Med. Chem.	2010.0	CHEMBL590810	>	>	IC50	nM	30000.0	IC50	uM	30.0
2035	Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL598336	=	=	IC50	nM	21000.0	IC50	uM	21.0
2036	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
2037	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097357	=	=	IC50	nM	3000.0	IC50	uM	3.0
2038	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097358	=	=	IC50	nM	3500.0	IC50	uM	3.5
2039	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078891	=	=	IC50	nM	800.0	IC50	uM	0.8
2040	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078892	=	=	IC50	nM	18000.0	IC50	uM	18.0
2041	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078991	>	>	IC50	nM	4400.0	IC50	uM	4.4
2042	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077324	=	=	IC50	nM	16000.0	IC50	uM	16.0
2043	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@H](NC(=O)OC(C)(C)C)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077325	>	>	IC50	nM	13000.0	IC50	uM	13.0
2044	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL480966	=	=	IC50	nM	700.0	IC50	uM	0.7
2045	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL482126	=	=	IC50	nM	1700.0	IC50	uM	1.7
2046	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(N3C[C@@H]4C[C@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077339	=	=	IC50	nM	500.0	IC50	uM	0.5
2047	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL505919	=	=	IC50	nM	3500.0	IC50	uM	3.5
2048	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL482101	=	=	IC50	nM	700.0	IC50	uM	0.7
2049	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401766	=	=	IC50	nM	2100.0	IC50	uM	2.1
2050	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ncn(C)c4Cl)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL256072	=	=	IC50	nM	1900.0	IC50	uM	1.9
2051	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCn6cc(Cl)cn6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077340	=	=	IC50	nM	1000.0	IC50	uM	1.0
2052	Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCc6ncn(C)c6Cl)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077343	=	=	IC50	nM	700.0	IC50	uM	0.7
2053	Inhibition of CYP3A4	CC(C)(Cc1nc(-c2ccc(O)cn2)no1)C(=O)NC1=C(C(=O)O)CCCC1	J. Med. Chem.	2010.0	CHEMBL1086657	>	>	IC50	nM	100000.0	IC50	uM	100.0
2054	Inhibition of CYP3A4	O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL376487	=	=	IC50	nM	440.0	IC50	uM	0.44
2055	Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077334	=	=	IC50	nM	30000.0	IC50	uM	30.0
2056	Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077335	=	=	IC50	nM	30000.0	IC50	uM	30.0
2057	Inhibition of CYP3A4	Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1086754	>	>	IC50	nM	20000.0	IC50	uM	20.0
2058	Inhibition of human CYP3A4	Cc1ncccc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C	J. Med. Chem.	2010.0	CHEMBL1081687	>	>	IC50	nM	10000.0	IC50	uM	10.0
2059	Inhibition of human CYP3A4	Cn1c(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1	J. Med. Chem.	2010.0	CHEMBL1081867	>	>	IC50	nM	10000.0	IC50	uM	10.0
2060	Inhibition of human CYP3A4	Cc1ccc2c(-c3nnc(SCCCN4CC5CC5(c5ccc(C(F)(F)F)cc5)C4)n3C)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1080293	>	>	IC50	nM	10000.0	IC50	uM	10.0
2061	Inhibition of human CYP3A4	c1ccc(COc2ccc3cccnc3c2)cc1	J. Med. Chem.	2010.0	CHEMBL1081779	=	=	IC50	nM	25000.0	IC50	uM	25.0
2062	Inhibition of CYP3A4	O=C(NC1CC1)c1ccc(Cl)c(Nc2nncc3c2cnn3-c2c(F)cccc2F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1082158	>	>	IC50	nM	27000.0	IC50	uM	27.0
2063	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080982	=	=	IC50	nM	11000.0	IC50	uM	11.0
2064	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079957	=	=	IC50	nM	1600.0	IC50	uM	1.6
2065	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079437	=	=	IC50	nM	2200.0	IC50	uM	2.2
2066	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079436	=	=	IC50	nM	22000.0	IC50	uM	22.0
2067	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076245	=	=	IC50	nM	1800.0	IC50	uM	1.8
2068	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080473	=	=	IC50	nM	6600.0	IC50	uM	6.6
2069	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080472	=	=	IC50	nM	90000.0	IC50	uM	90.0
2070	Inhibition of CYP3A4 using diethoxyfluorescein substrate	C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080088	=	=	IC50	nM	2400.0	IC50	uM	2.4
2071	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080982	=	=	IC50	nM	6000.0	IC50	uM	6.0
2072	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080803	=	=	IC50	nM	5600.0	IC50	uM	5.6
2073	Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079958	=	=	IC50	nM	2900.0	IC50	uM	2.9
2074	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079957	=	=	IC50	nM	1600.0	IC50	uM	1.6
2075	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079437	=	=	IC50	nM	1300.0	IC50	uM	1.3
2076	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079436	=	=	IC50	nM	22000.0	IC50	uM	22.0
2077	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076245	=	=	IC50	nM	1000.0	IC50	uM	1.0
2078	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080473	=	=	IC50	nM	7700.0	IC50	uM	7.7
2079	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080472	=	=	IC50	nM	3000.0	IC50	uM	3.0
2080	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076210	=	=	IC50	nM	9600.0	IC50	uM	9.6
2081	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076192	=	=	IC50	nM	4300.0	IC50	uM	4.3
2082	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081870	=	=	IC50	nM	21000.0	IC50	uM	21.0
2083	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081505	=	=	IC50	nM	9000.0	IC50	uM	9.0
2084	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081504	>	>	IC50	nM	100000.0	IC50	uM	100.0
2085	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080717	=	=	IC50	nM	1600.0	IC50	uM	1.6
2086	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076536	=	=	IC50	nM	18000.0	IC50	uM	18.0
2087	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076210	=	=	IC50	nM	9000.0	IC50	uM	9.0
2088	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076192	=	=	IC50	nM	3100.0	IC50	uM	3.1
2089	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081870	=	=	IC50	nM	12000.0	IC50	uM	12.0
2090	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081505	=	=	IC50	nM	13000.0	IC50	uM	13.0
2091	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081504	=	=	IC50	nM	8800.0	IC50	uM	8.8
2092	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080717	=	=	IC50	nM	4700.0	IC50	uM	4.7
2093	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076536	=	=	IC50	nM	5500.0	IC50	uM	5.5
2094	Inhibition of CYP3A4 assessed as ratio of IC50 at 0 mins to IC50 at 10 mins using 7-benzyloxyquinoline substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	56.23	pIC50		7.25
2095	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL47529	=	=	IC50	nM	12000.0	IC50	uM	12.0
2096	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	12000.0	IC50	uM	12.0
2097	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3900.0	IC50	uM	3.9
2098	Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	14000.0	IC50	uM	14.0
2099	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL47529	=	=	IC50	nM	9000.0	IC50	uM	9.0
2100	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	9000.0	IC50	uM	9.0
2101	Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3800.0	IC50	uM	3.8
2102	Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	6000.0	IC50	uM	6.0
2103	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078207	<	<	IC50	nM	100.0	IC50	uM	0.1
2104	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080046	=	=	IC50	nM	800.0	IC50	uM	0.8
2105	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(N2CCOCC2)nc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078595	>	>	IC50	nM	8000.0	IC50	uM	8.0
2106	Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078207	<	<	IC50	nM	100.0	IC50	uM	0.1
2107	Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080046	=	=	IC50	nM	1900.0	IC50	uM	1.9
2108	Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(N2CCOCC2)nc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078595	>	>	IC50	nM	8000.0	IC50	uM	8.0
2109	Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CCNC1)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1088290	=	=	IC50	nM	1300.0	IC50	uM	1.3
2110	Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@H]2CC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076449	=	=	IC50	nM	1900.0	IC50	uM	1.9
2111	Inhibition of CYP3A4	COc1cccc(CN(C(=O)C2=C(c3ccc(CCCOc4c(F)ccc(F)c4Cl)cc3)C[C@H]3COC[C@H]2N3)C2CC2)c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076461	=	=	IC50	nM	1000.0	IC50	uM	1.0
2112	Inhibition of CYP3A4 using felodipine as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2113	Inhibition of CYP3A4 using midazolam as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2114	Inhibition of CYP3A4 using testosterone as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2115	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL163	=	=	IC50	nM	50.0	IC50	uM	0.05
2116	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079722	=	=	IC50	nM	148.0	IC50	uM	0.148
2117	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079896	=	=	IC50	nM	90.0	IC50	uM	0.09
2118	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079897	=	=	IC50	nM	99.0	IC50	uM	0.099
2119	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079228	=	=	IC50	nM	65.0	IC50	uM	0.065
2120	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079229	=	=	IC50	nM	110.0	IC50	uM	0.11
2121	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079230	=	=	IC50	nM	100.0	IC50	uM	0.1
2122	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080964	=	=	IC50	nM	150.0	IC50	uM	0.15
2123	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081147	=	=	IC50	nM	110.0	IC50	uM	0.11
2124	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081874	=	=	IC50	nM	110.0	IC50	uM	0.11
2125	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077929	=	=	IC50	nM	110.0	IC50	uM	0.11
2126	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077930	=	=	IC50	nM	90.0	IC50	uM	0.09
2127	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077931	=	=	IC50	nM	67.0	IC50	uM	0.067
2128	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(CC1CC1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077932	=	=	IC50	nM	52.0	IC50	uM	0.052
2129	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077933	=	=	IC50	nM	50.0	IC50	uM	0.05
2130	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077934	=	=	IC50	nM	135.0	IC50	uM	0.135
2131	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077935	=	=	IC50	nM	87.0	IC50	uM	0.087
2132	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077936	=	=	IC50	nM	60.0	IC50	uM	0.06
2133	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	COc1cccc(CN(C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C[C@@H](Cc2ccccc2)NC(=O)OCc2nccs2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077937	=	=	IC50	nM	50.0	IC50	uM	0.05
2134	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077938	=	=	IC50	nM	66.0	IC50	uM	0.066
2135	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccncc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077939	=	=	IC50	nM	49.0	IC50	uM	0.049
2136	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1c[nH]cn1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077940	=	=	IC50	nM	66.0	IC50	uM	0.066
2137	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1cnc2ccccc2c1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077941	=	=	IC50	nM	70.0	IC50	uM	0.07
2138	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CCNC(=O)OCc1cncs1)CCNC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1082053	>	>	IC50	nM	3000.0	IC50	uM	3.0
2139	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080244	>	>	IC50	nM	3000.0	IC50	uM	3.0
2140	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080417	=	=	IC50	nM	1790.0	IC50	uM	1.79
2141	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080418	=	=	IC50	nM	1330.0	IC50	uM	1.33
2142	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](CC(C)C)NC(=O)OCc1cncs1)C[C@H](CC(C)C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080419	=	=	IC50	nM	136.0	IC50	uM	0.136
2143	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(CC(=O)OC)NC(=O)OCc1cncs1)CC(CC(=O)OC)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081514	=	=	IC50	nM	88.0	IC50	uM	0.088
2144	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(CC1CCCCC1)NC(=O)OCc1cncs1)CC(CC1CCCCC1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081515	=	=	IC50	nM	66.0	IC50	uM	0.066
2145	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(COCc1ccccc1)NC(=O)OCc1cncs1)CC(COCc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078121	=	=	IC50	nM	135.0	IC50	uM	0.135
2146	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(Cc1ccc(O)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(O)cc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078122	=	=	IC50	nM	91.0	IC50	uM	0.091
2147	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078123	=	=	IC50	nM	300.0	IC50	uM	0.3
2148	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnco1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncco1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081693	=	=	IC50	nM	274.0	IC50	uM	0.274
2149	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnc[nH]1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncc[nH]1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079712	=	=	IC50	nM	348.0	IC50	uM	0.348
2150	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080603	=	=	IC50	nM	741.0	IC50	uM	0.741
2151	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078218	=	=	IC50	nM	3000.0	IC50	uM	3.0
2152	Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1)C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080604	>	>	IC50	nM	300.0	IC50	uM	0.3
2153	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079360	<	<	IC50	nM	10000.0	IC50	uM	10.0
2154	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2noc3ccccc23)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079361	>	>	IC50	nM	10000.0	IC50	uM	10.0
2155	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccncc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079362	<	<	IC50	nM	10000.0	IC50	uM	10.0
2156	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(-c3ccccc3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080076	>	>	IC50	nM	10000.0	IC50	uM	10.0
2157	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(Cl)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080973	<	<	IC50	nM	10000.0	IC50	uM	10.0
2158	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccc3C(F)(F)F)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080974	<	<	IC50	nM	10000.0	IC50	uM	10.0
2159	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3cccc(Cl)c3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080975	<	<	IC50	nM	10000.0	IC50	uM	10.0
2160	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccn3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081703	<	<	IC50	nM	10000.0	IC50	uM	10.0
2161	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccc4[nH]ccc4c3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078264	>	>	IC50	nM	10000.0	IC50	uM	10.0
2162	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078265	<	<	IC50	nM	10000.0	IC50	uM	10.0
2163	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCCc2cccnc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078353	<	<	IC50	nM	10000.0	IC50	uM	10.0
2164	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nc[nH]c3c2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078354	>	>	IC50	nM	10000.0	IC50	uM	10.0
2165	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nccnc3c2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078452	<	<	IC50	nM	10000.0	IC50	uM	10.0
2166	Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)N[C@H]2C[C@@H]2c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077780	<	<	IC50	nM	10000.0	IC50	uM	10.0
2167	Inhibition of CYP3A4	O=C(O)CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077781	>	>	IC50	nM	10000.0	IC50	uM	10.0
2168	Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079256	>	>	IC50	nM	10000.0	IC50	uM	10.0
2169	Inhibition of CYP3A4	O=C(O)CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078565	>	>	IC50	nM	10000.0	IC50	uM	10.0
2170	Inhibition of CYP3A4	O=C(O)CCCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078657	>	>	IC50	nM	10000.0	IC50	uM	10.0
2171	Inhibition of CYP3A4	N#CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078755	>	>	IC50	nM	10000.0	IC50	uM	10.0
2172	Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCO)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079290	>	>	IC50	nM	10000.0	IC50	uM	10.0
2173	Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCCO)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079291	<	<	IC50	nM	10000.0	IC50	uM	10.0
2174	Inhibition of CYP3A4	NC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079292	>	>	IC50	nM	10000.0	IC50	uM	10.0
2175	Inhibition of CYP3A4	CN(C)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079140	<	<	IC50	nM	10000.0	IC50	uM	10.0
2176	Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCC2=NNNN2)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079244	<	<	IC50	nM	10000.0	IC50	uM	10.0
2177	Inhibition of CYP3A4	O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)NC1=NNNN1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079245	>	>	IC50	nM	10000.0	IC50	uM	10.0
2178	Inhibition of CYP3A4	CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079246	=	=	IC50	nM	10000.0	IC50	uM	10.0
2179	Inhibition of CYP3A4	CCN(CC)C(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078628	<	<	IC50	nM	10000.0	IC50	uM	10.0
2180	Inhibition of CYP3A4	O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078232	>	>	IC50	nM	10000.0	IC50	uM	10.0
2181	Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079256	>	>	IC50	nM	100000.0	IC50	uM	100.0
2182	Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2C(F)(F)F)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079257	>	>	IC50	nM	10000.0	IC50	uM	10.0
2183	Inhibition of CYP3A4	O=C(O)CCC1(c2cccc(C(F)(F)F)c2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079258	>	>	IC50	nM	10000.0	IC50	uM	10.0
2184	Inhibition of CYP3A4	O=C(O)CCC1(c2ccc(C(F)(F)F)cc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078715	>	>	IC50	nM	10000.0	IC50	uM	10.0
2185	Inhibition of CYP3A4	O=C(O)CCC1(c2ccncc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078336	>	>	IC50	nM	10000.0	IC50	uM	10.0
2186	Inhibition of CYP3A4	O=C(O)CCC1(c2cccnc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078337	>	>	IC50	nM	10000.0	IC50	uM	10.0
2187	Inhibition of CYP3A4	O=C(O)CCC1(c2ccccn2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077963	>	>	IC50	nM	10000.0	IC50	uM	10.0
2188	Inhibition of CYP3A4	O=C(O)CCC1(c2ccc(-c3ccccc3)cc2)CCCN(C(=O)Nc2ccc(OC(F)(F)F)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079061	>	>	IC50	nM	10000.0	IC50	uM	10.0
2189	Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	J. Nat. Prod.	2009.0	CHEMBL1078442	=	=	IC50	nM	2420.0	IC50	uM	2.42
2190	Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O	J. Nat. Prod.	2009.0	CHEMBL1079119	=	=	IC50	nM	1580.0	IC50	uM	1.58
2191	Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CCCCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1	J. Nat. Prod.	2009.0	CHEMBL1078190	=	=	IC50	nM	270.0	IC50	uM	0.27
2192	Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1	J. Nat. Prod.	2009.0	CHEMBL1078189	=	=	IC50	nM	130.0	IC50	uM	0.13
2193	Inhibition of CYP3A4	CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091356	>	>	IC50	nM	30000.0	IC50	uM	30.0
2194	Inhibition of CYP3A4	CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092169	>	>	IC50	nM	100000.0	IC50	uM	100.0
2195	Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092600	>	>	IC50	nM	10000.0	IC50	uM	10.0
2196	Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092258	>	>	IC50	nM	10000.0	IC50	uM	10.0
2197	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092259	>	>	IC50	nM	10000.0	IC50	uM	10.0
2198	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092649	>	>	IC50	nM	10000.0	IC50	uM	10.0
2199	Inhibition of CYP3A4	COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092650	>	>	IC50	nM	10000.0	IC50	uM	10.0
2200	Inhibition of CYP3A4	COc1nccnc1CC1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092651	>	>	IC50	nM	10000.0	IC50	uM	10.0
2201	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092652	>	>	IC50	nM	10000.0	IC50	uM	10.0
2202	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092662	>	>	IC50	nM	10000.0	IC50	uM	10.0
2203	Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092663	>	>	IC50	nM	10000.0	IC50	uM	10.0
2204	Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090175	>	>	IC50	nM	10000.0	IC50	uM	10.0
2205	Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090176	>	>	IC50	nM	10000.0	IC50	uM	10.0
2206	Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccnc1OC	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090186	>	>	IC50	nM	10000.0	IC50	uM	10.0
2207	Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090526	>	>	IC50	nM	10000.0	IC50	uM	10.0
2208	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2cc(F)ccc21)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090527	>	>	IC50	nM	10000.0	IC50	uM	10.0
2209	Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090528	>	>	IC50	nM	10000.0	IC50	uM	10.0
2210	Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093623	>	>	IC50	nM	10000.0	IC50	uM	10.0
2211	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091777	=	=	IC50	nM	4000.0	IC50	uM	4.0
2212	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091790	=	=	IC50	nM	2800.0	IC50	uM	2.8
2213	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ccnc(C(C)c2c(CCN(C)C)sc3ccccc23)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091791	>	>	IC50	nM	10000.0	IC50	uM	10.0
2214	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1cccc(C(C)c2c(CCN(C)C)sc3ccccc23)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091792	>	>	IC50	nM	10000.0	IC50	uM	10.0
2215	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1cccc(F)n1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091793	>	>	IC50	nM	10000.0	IC50	uM	10.0
2216	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092126	>	>	IC50	nM	10000.0	IC50	uM	10.0
2217	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091069	>	>	IC50	nM	10000.0	IC50	uM	10.0
2218	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ncccc1F)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092377	>	>	IC50	nM	10000.0	IC50	uM	10.0
2219	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ncccc1Cl)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092494	>	>	IC50	nM	10000.0	IC50	uM	10.0
2220	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092495	>	>	IC50	nM	10000.0	IC50	uM	10.0
2221	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092496	>	>	IC50	nM	10000.0	IC50	uM	10.0
2222	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092812	>	>	IC50	nM	10000.0	IC50	uM	10.0
2223	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092813	>	>	IC50	nM	10000.0	IC50	uM	10.0
2224	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093294	>	>	IC50	nM	10000.0	IC50	uM	10.0
2225	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1F)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092765	>	>	IC50	nM	10000.0	IC50	uM	10.0
2226	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092766	>	>	IC50	nM	10000.0	IC50	uM	10.0
2227	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090432	>	>	IC50	nM	10000.0	IC50	uM	10.0
2228	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL564144	>	>	IC50	nM	10000.0	IC50	uM	10.0
2229	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090433	>	>	IC50	nM	10000.0	IC50	uM	10.0
2230	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CNCCc1sc2ccccc2c1[C@@H](C)c1ccccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093044	>	>	IC50	nM	10000.0	IC50	uM	10.0
2231	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN2CCCC2)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091774	>	>	IC50	nM	10000.0	IC50	uM	10.0
2232	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN2CCC2)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091775	>	>	IC50	nM	10000.0	IC50	uM	10.0
2233	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091776	>	>	IC50	nM	10000.0	IC50	uM	10.0
2234	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091778	>	>	IC50	nM	10000.0	IC50	uM	10.0
2235	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1nccs1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092767	>	>	IC50	nM	10000.0	IC50	uM	10.0
2236	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cscn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091782	>	>	IC50	nM	10000.0	IC50	uM	10.0
2237	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cncs1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092118	>	>	IC50	nM	10000.0	IC50	uM	10.0
2238	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093607	=	=	IC50	nM	5200.0	IC50	uM	5.2
2239	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1c(CCN(C)C)sc2ccccc12)n1cccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093058	>	>	IC50	nM	10000.0	IC50	uM	10.0
2240	Inhibition of CYP3A4 preincubated for 30 mins	O=C1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089202	=	=	IC50	nM	1200.0	IC50	uM	1.2
2241	Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(c1ccc(Cl)cc1)C12CCC(O)CC1COc1c(F)ccc(F)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089525	=	=	IC50	nM	9100.0	IC50	uM	9.1
2242	Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090209	>	>	IC50	nM	30000.0	IC50	uM	30.0
2243	Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C1CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090210	>	>	IC50	nM	30000.0	IC50	uM	30.0
2244	Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2cnn(-c3ccc(F)cc3F)c21	J. Med. Chem.	2010.0	CHEMBL1089866	=	=	IC50	nM	1600.0	IC50	uM	1.6
2245	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O	J. Med. Chem.	2010.0	CHEMBL1089865	>	>	IC50	nM	25000.0	IC50	uM	25.0
2246	Inhibition of CYP3A4	C[C@@H](O[C@H]1CN2C(=O)C=C(C3=CCN(C(C)(C)C)CC3)CC2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089270	>	>	IC50	nM	50000.0	IC50	uM	50.0
2247	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089299	=	=	Ki	nM	30.0	Ki	uM	0.03
2248	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089299	=	=	Ki	nM	28.84	pKi		7.54
2249	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089300	=	=	Ki	nM	240.0	Ki	uM	0.24
2250	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089300	=	=	Ki	nM	239.88	pKi		6.62
2251	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091763	=	=	Ki	nM	1780.0	Ki	uM	1.78
2252	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091763	=	=	Ki	nM	1778.28	pKi		5.75
2253	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089957	=	=	Ki	nM	70.0	Ki	uM	0.07
2254	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089957	=	=	Ki	nM	69.18	pKi		7.16
2255	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL157101	=	=	Ki	nM	30.0	Ki	uM	0.03
2256	Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL157101	=	=	Ki	nM	33.11	pKi		7.48
2257	Inhibition of human recombinant CYP3A4	CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095040	>	>	IC50	nM	10000.0	IC50	uM	10.0
2258	Inhibition of human recombinant CYP3A4	CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093747	>	>	IC50	nM	10000.0	IC50	uM	10.0
2259	Inhibition of human CYP3A4	COC(=O)N(CC(=O)O)Cc1cccc(OCc2nc(-c3ccc(Cl)cc3)oc2C)c1	J. Med. Chem.	2010.0	CHEMBL1089501	>	>	IC50	nM	40000.0	IC50	uM	40.0
2260	Inhibition of CYP3A4	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	J. Med. Chem.	2009.0	CHEMBL236184	>	>	IC50	nM	2000.0	IC50	uM	2.0
2261	Inhibition of CYP3A4 after 30 mins	COCCCc1ccc(Cl)c(CN(C(=O)[C@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093286	=	=	IC50	nM	130.0	IC50	nM	130.0
2262	Inhibition of CYP3A4 after 30 mins	COCCCc1cc(CN(C(=O)[C@@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093937	=	=	IC50	nM	1300.0	IC50	nM	1300.0
2263	Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092929	>	>	IC50	nM	10000.0	IC50	uM	10.0
2264	Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093469	>	>	IC50	nM	10000.0	IC50	uM	10.0
2265	Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092238	>	>	IC50	nM	10000.0	IC50	uM	10.0
2266	Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093802	>	>	IC50	nM	10000.0	IC50	uM	10.0
2267	Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089793	>	>	IC50	nM	10000.0	IC50	uM	10.0
2268	Inhibition of CYP3A4	CCOC(=O)[C@H](C)NP(=O)(COc1cc(C)c(C)c2c1-c1ncsc1C2)N[C@@H](C)C(=O)OCC	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096789	=	=	IC50	nM	580.0	IC50	uM	0.58
2269	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094552	=	=	IC50	nM	420.0	IC50	uM	0.42
2270	Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096871	=	=	IC50	nM	2700.0	IC50	uM	2.7
2271	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097165	=	=	IC50	nM	650.0	IC50	uM	0.65
2272	Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097180	=	=	IC50	nM	730.0	IC50	uM	0.73
2273	Inhibition of CYP3A4	COc1cccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097507	=	=	IC50	nM	270.0	IC50	uM	0.27
2274	Inhibition of CYP3A4	COc1cccc([C@@H]2CCO[P@@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098147	=	=	IC50	nM	300.0	IC50	uM	0.3
2275	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccccn3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098148	=	=	IC50	nM	8400.0	IC50	uM	8.4
2276	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097192	=	=	IC50	nM	2900.0	IC50	uM	2.9
2277	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccncc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095681	=	=	IC50	nM	2200.0	IC50	uM	2.2
2278	Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096103	=	=	IC50	nM	5800.0	IC50	uM	5.8
2279	Inhibition of CYP3A4	Cc1ccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096104	=	=	IC50	nM	5200.0	IC50	uM	5.2
2280	Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096105	=	=	IC50	nM	15000.0	IC50	uM	15.0
2281	Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095511	>	>	IC50	nM	5000.0	IC50	uM	5.0
2282	Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C3CCOCC3)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095510	>	>	IC50	nM	5000.0	IC50	uM	5.0
2283	Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C3CCCCC3)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095678	>	>	IC50	nM	5000.0	IC50	uM	5.0
2284	Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094852	>	>	IC50	nM	5000.0	IC50	uM	5.0
2285	Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094851	=	=	IC50	nM	3300.0	IC50	uM	3.3
2286	Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C(C)C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095364	>	>	IC50	nM	5000.0	IC50	uM	5.0
2287	Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094525	>	>	IC50	nM	5000.0	IC50	uM	5.0
2288	Inhibition of CYP3A4	CC(C)N1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098766	>	>	IC50	nM	5000.0	IC50	uM	5.0
2289	Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2CC2CCCO2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098125	>	>	IC50	nM	5000.0	IC50	uM	5.0
2290	Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094512	>	>	IC50	nM	5000.0	IC50	uM	5.0
2291	Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2Cc2ccccn2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094511	>	>	IC50	nM	5000.0	IC50	uM	5.0
2292	Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095031	>	>	IC50	nM	5000.0	IC50	uM	5.0
2293	Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094510	>	>	IC50	nM	5000.0	IC50	uM	5.0
2294	Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094509	>	>	IC50	nM	5000.0	IC50	uM	5.0
2295	Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087089	>	>	IC50	nM	5000.0	IC50	uM	5.0
2296	Inhibition of CYP3A4	CCOCCn1c(N2CC[C@H](N(C)C)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087493	>	>	IC50	nM	5000.0	IC50	uM	5.0
2297	Inhibition of CYP3A4	COc1ccc(Cn2c(N3CC[C@@H](N(C)C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087367	>	>	IC50	nM	5000.0	IC50	uM	5.0
2298	Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
2299	Inhibition of CYP3A4	CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL550818	>	>	IC50	nM	5000.0	IC50	uM	5.0
2300	Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095818	>	>	IC50	nM	5000.0	IC50	uM	5.0
2301	Inhibition of CYP3A4	CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1	J. Med. Chem.	2010.0	CHEMBL1098726	>	>	IC50	nM	35000.0	IC50	uM	35.0
2302	Inhibition of CYP3A4	O=c1c(-c2c(O)cc(O)c3c(=O)cc(-c4ccc(O)cc4)oc23)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12	J. Nat. Prod.	2010.0	CHEMBL515252	=	=	IC50	nM	80.0	IC50	uM	0.08
2303	Inhibition of CYP3A4	Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65	J. Nat. Prod.	2010.0	CHEMBL286494	=	=	IC50	nM	8700.0	IC50	uM	8.7
2304	Inhibition of CYP3A4	CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@]1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O	J. Nat. Prod.	2010.0	CHEMBL501711	=	=	IC50	nM	2300.0	IC50	uM	2.3
2305	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)n2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099330	>	>	IC50	nM	7500.0	IC50	uM	7.5
2306	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccc4c(c3)OCO4)cc(-c3ccccc3F)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1094349	>	>	IC50	nM	7500.0	IC50	uM	7.5
2307	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3cccc(F)c3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1094348	>	>	IC50	nM	7500.0	IC50	uM	7.5
2308	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1098560	>	>	IC50	nM	7500.0	IC50	uM	7.5
2309	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099326	>	>	IC50	nM	7500.0	IC50	uM	7.5
2310	Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099323	>	>	IC50	nM	7500.0	IC50	uM	7.5
2311	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
2312	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097357	=	=	IC50	nM	3000.0	IC50	uM	3.0
2313	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097358	=	=	IC50	nM	3500.0	IC50	uM	3.5
2314	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098395	=	=	IC50	nM	2200.0	IC50	uM	2.2
2315	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098711	=	=	IC50	nM	1100.0	IC50	uM	1.1
2316	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COCC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098712	=	=	IC50	nM	800.0	IC50	uM	0.8
2317	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C(=O)CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096717	=	=	IC50	nM	800.0	IC50	uM	0.8
2318	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1099314	=	=	IC50	nM	1900.0	IC50	uM	1.9
2319	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097032	=	=	IC50	nM	700.0	IC50	uM	0.7
2320	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CCOC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095404	=	=	IC50	nM	1000.0	IC50	uM	1.0
2321	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(S(C)(=O)=O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097425	=	=	IC50	nM	600.0	IC50	uM	0.6
2322	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097426	=	=	IC50	nM	3300.0	IC50	uM	3.3
2323	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095439	=	=	IC50	nM	1900.0	IC50	uM	1.9
2324	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CNC(=O)CN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094457	=	=	IC50	nM	2600.0	IC50	uM	2.6
2325	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CC(=O)NCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097982	=	=	IC50	nM	2400.0	IC50	uM	2.4
2326	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094458	=	=	IC50	nM	450.0	IC50	uM	0.45
2327	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078891	=	=	IC50	nM	2200.0	IC50	uM	2.2
2328	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096089	=	=	IC50	nM	1400.0	IC50	uM	1.4
2329	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094164	=	=	IC50	nM	1100.0	IC50	uM	1.1
2330	Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COCCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094165	=	=	IC50	nM	2900.0	IC50	uM	2.9
2331	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1	J. Med. Chem.	2010.0	CHEMBL1090479	=	=	IC50	nM	15000.0	IC50	uM	15.0
2332	Inhibition of CYP3A4	Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1	J. Med. Chem.	2010.0	CHEMBL1096182	=	=	IC50	nM	3300.0	IC50	uM	3.3
2333	Inhibition of human CYP3A4 expressed in insect cell microsome after 30 mins by fluorescence assay	CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1098230	=	=	IC50	nM	470.0	IC50	nM	470.0
2334	Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C	J. Med. Chem.	2010.0	CHEMBL289228	=	=	IC50	nM	4060.0	IC50	nM	4060.0
2335	Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccccc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097772	=	=	IC50	nM	2345.0	IC50	nM	2345.0
2336	Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(Cl)cc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097078	=	=	IC50	nM	923.0	IC50	nM	923.0
2337	Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(F)cc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097079	=	=	IC50	nM	1628.0	IC50	nM	1628.0
2338	Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1c(F)cccc1F)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097187	=	=	IC50	nM	275.0	IC50	nM	275.0
2339	Inhibition of human recombinant CYP3A4	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2010.0	CHEMBL1397	=	=	IC50	nM	82.0	IC50	nM	82.0
2340	Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2010.0	CHEMBL157101	=	=	IC50	nM	11.0	IC50	nM	11.0
2341	Inhibition of CYP3A4 from human liver microsome by LC-MS/MS analysis	Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(N5CCN(C)CC5)nc34)CC2)no1	J. Med. Chem.	2010.0	CHEMBL1086579	>	>	IC50	nM	10000.0	IC50	uM	10.0
2342	Inhibition of CYP3A4	CC(C)[C@]1(C)SC(N[C@H]2C[C@@H]3CC[C@H]2C3)=NC1=O	J. Med. Chem.	2010.0	CHEMBL1085107	>	>	IC50	nM	15000.0	IC50	uM	15.0
2343	Inhibition of CYP3A4	CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL403441	=	=	IC50	nM	30000.0	IC50	nM	30000.0
2344	Inhibition of CYP3A4	COc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL214335	=	=	IC50	nM	194000.0	IC50	nM	194000.0
2345	Inhibition of CYP3A4	O=C(O)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1171008	=	=	IC50	nM	100000.0	pIC50		4.0
2346	Inhibition of CYP3A4	O=C(NCCO)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1169660	=	=	IC50	nM	20417.38	pIC50		4.69
2347	Inhibition of CYP3A4	O=C(O)c1ccccc1Oc1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1171786	=	=	IC50	nM	10000.0	pIC50		5.0
2348	Inhibition of CYP3A4	O=S(=O)(Nc1cc(Cl)cnc1Oc1cncc(Cl)c1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1169994	=	=	IC50	nM	436.52	pIC50		6.36
2349	Inhibition of CYP3A4	Cc1ncccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1170725	=	=	IC50	nM	19498.45	pIC50		4.71
2350	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1172346	=	=	IC50	nM	87.0	IC50	nM	87.0
2351	Inhibition of human CYP3A4 after 10 mins	C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173087	=	=	IC50	nM	3000.0	IC50	uM	3.0
2352	Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2	J. Med. Chem.	2010.0	CHEMBL1172744	=	=	IC50	nM	8000.0	IC50	uM	8.0
2353	Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
2354	Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
2355	Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
2356	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1172882	=	=	IC50	nM	538.0	IC50	nM	538.0
2357	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2cccc(O)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173259	=	=	IC50	nM	730.0	IC50	nM	730.0
2358	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F	J. Med. Chem.	2010.0	CHEMBL1173260	=	=	IC50	nM	896.0	IC50	nM	896.0
2359	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173335	=	=	IC50	nM	17650.0	IC50	nM	17650.0
2360	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O	J. Med. Chem.	2010.0	CHEMBL1172779	=	=	IC50	nM	7580.0	IC50	nM	7580.0
2361	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(O)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1172847	=	=	IC50	nM	464.0	IC50	nM	464.0
2362	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1171987	=	=	IC50	nM	1520.0	IC50	nM	1520.0
2363	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2cccc(N)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173326	=	=	IC50	nM	1330.0	IC50	nM	1330.0
2364	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(N)c(N)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1171991	=	=	IC50	nM	1770.0	IC50	nM	1770.0
2365	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2010.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
2366	Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2010.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
2367	Inhibition of CYP3A4	Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C	J. Med. Chem.	2010.0	CHEMBL374350	=	=	IC50	nM	3000.0	IC50	uM	3.0
2368	Inhibition of CYP3A4	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C	J. Med. Chem.	2010.0	CHEMBL2021600	>	>	IC50	nM	24000.0	IC50	uM	24.0
2369	Inhibition of CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1.[Na+]	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210423	=	=	IC50	nM	8800.0	IC50	uM	8.8
2370	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2371	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2372	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2373	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1081957	>	>	IC50	nM	10000.0	IC50	uM	10.0
2374	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2375	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2376	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2377	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1079481	>	>	IC50	nM	10000.0	IC50	uM	10.0
2378	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2379	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2380	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
2381	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1081957	>	>	IC50	nM	10000.0	IC50	uM	10.0
2382	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2383	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2384	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
2385	Inhibition of CYP3A4 using diethoxyfluorescein substrate	CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210434	=	=	IC50	nM	300.0	IC50	uM	0.3
2386	Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210434	=	=	IC50	nM	600.0	IC50	uM	0.6
2387	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208894	=	=	IC50	nM	1400.0	IC50	uM	1.4
2388	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208958	=	=	IC50	nM	1100.0	IC50	uM	1.1
2389	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208959	=	=	IC50	nM	400.0	IC50	uM	0.4
2390	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208960	=	=	IC50	nM	20000.0	IC50	uM	20.0
2391	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208961	=	=	IC50	nM	800.0	IC50	uM	0.8
2392	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208964	=	=	IC50	nM	1100.0	IC50	uM	1.1
2393	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208965	=	=	IC50	nM	3400.0	IC50	uM	3.4
2394	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208966	=	=	IC50	nM	1000.0	IC50	uM	1.0
2395	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209016	=	=	IC50	nM	200.0	IC50	uM	0.2
2396	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209017	=	=	IC50	nM	900.0	IC50	uM	0.9
2397	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209018	=	=	IC50	nM	1000.0	IC50	uM	1.0
2398	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208894	=	=	IC50	nM	5900.0	IC50	uM	5.9
2399	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208958	=	=	IC50	nM	27000.0	IC50	uM	27.0
2400	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208959	=	=	IC50	nM	1900.0	IC50	uM	1.9
2401	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208960	=	=	IC50	nM	2800.0	IC50	uM	2.8
2402	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208961	=	=	IC50	nM	27000.0	IC50	uM	27.0
2403	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208962	=	=	IC50	nM	3500.0	IC50	uM	3.5
2404	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208963	=	=	IC50	nM	3700.0	IC50	uM	3.7
2405	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208964	=	=	IC50	nM	4700.0	IC50	uM	4.7
2406	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208965	=	=	IC50	nM	16000.0	IC50	uM	16.0
2407	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208966	=	=	IC50	nM	15000.0	IC50	uM	15.0
2408	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209015	=	=	IC50	nM	2100.0	IC50	uM	2.1
2409	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209016	=	=	IC50	nM	1900.0	IC50	uM	1.9
2410	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209017	=	=	IC50	nM	5000.0	IC50	uM	5.0
2411	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209018	=	=	IC50	nM	4500.0	IC50	uM	4.5
2412	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209842	=	=	IC50	nM	200.0	IC50	uM	0.2
2413	Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccncc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209674	<	<	IC50	nM	100.0	IC50	uM	0.1
2414	Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208835	=	=	IC50	nM	6500.0	IC50	uM	6.5
2415	Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208892	=	=	IC50	nM	6800.0	IC50	uM	6.8
2416	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209842	=	=	IC50	nM	200.0	IC50	uM	0.2
2417	Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208892	>	>	IC50	nM	100000.0	IC50	uM	100.0
2418	Inhibition of CYP3A4	CC(C)C(=O)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209049	>=	>=	IC50	nM	7000.0	IC50	uM	7.0
2419	Inhibition of CYP3A4	O=C(C1CCOC1)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209217	>	>	IC50	nM	10000.0	IC50	uM	10.0
2420	inhibition of CYP3A4	Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209538	=	=	IC50	nM	1000.0	IC50	uM	1.0
2421	inhibition of CYP3A4	Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209853	=	=	IC50	nM	1000.0	IC50	uM	1.0
2422	Inhibition of CYP1A2	CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209322	>	>	IC50	nM	5000.0	IC50	uM	5.0
2423	Inhibition of CYP1A2	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209617	>	>	IC50	nM	5000.0	IC50	uM	5.0
2424	Inhibition of CYP1A2	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209685	>	>	IC50	nM	5000.0	IC50	uM	5.0
2425	Inhibition of CYP1A2	CC[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209686	>	>	IC50	nM	5000.0	IC50	uM	5.0
2426	Inhibition of CYP3A4	CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209322	>	>	IC50	nM	5000.0	IC50	uM	5.0
2427	Inhibition of CYP3A4	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209617	>	>	IC50	nM	5000.0	IC50	uM	5.0
2428	Inhibition of CYP3A4	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209685	=	=	IC50	nM	4300.0	IC50	uM	4.3
2429	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209553	<	<	IC50	nM	68.0	IC50	nM	68.0
2430	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209553	=	=	IC50	nM	87.0	IC50	nM	87.0
2431	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209554	=	=	IC50	nM	1400.0	IC50	nM	1400.0
2432	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209555	=	=	IC50	nM	490.0	IC50	nM	490.0
2433	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209556	=	=	IC50	nM	280.0	IC50	nM	280.0
2434	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209623	=	=	IC50	nM	1160.0	IC50	nM	1160.0
2435	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209625	<	<	IC50	nM	68.0	IC50	nM	68.0
2436	Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209627	<	<	IC50	nM	68.0	IC50	nM	68.0
2437	Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209628	<	<	IC50	nM	68.0	IC50	nM	68.0
2438	Inhibition of human CYP3A4-mediated testosterone oxidation	COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209693	=	=	IC50	nM	530.0	IC50	nM	530.0
2439	Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209694	=	=	IC50	nM	120.0	IC50	nM	120.0
2440	Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208801	=	=	IC50	nM	180.0	IC50	nM	180.0
2441	Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209695	=	=	IC50	nM	900.0	IC50	nM	900.0
2442	Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209696	=	=	IC50	nM	1920.0	IC50	nM	1920.0
2443	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209554	=	=	IC50	nM	100.0	IC50	nM	100.0
2444	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209555	<	<	IC50	nM	68.0	IC50	nM	68.0
2445	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209556	<	<	IC50	nM	68.0	IC50	nM	68.0
2446	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209623	<	<	IC50	nM	68.0	IC50	nM	68.0
2447	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209625	<	<	IC50	nM	68.0	IC50	nM	68.0
2448	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN([C@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209626	<	<	IC50	nM	68.0	IC50	nM	68.0
2449	Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209627	<	<	IC50	nM	68.0	IC50	nM	68.0
2450	Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209628	<	<	IC50	nM	68.0	IC50	nM	68.0
2451	Inhibition of human CYP3A4-mediated midazolam oxidation	COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209693	<	<	IC50	nM	68.0	IC50	nM	68.0
2452	Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209694	<	<	IC50	nM	68.0	IC50	nM	68.0
2453	Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208801	<	<	IC50	nM	68.0	IC50	nM	68.0
2454	Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209696	<	<	IC50	nM	68.0	IC50	nM	68.0
2455	Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209695	=	=	IC50	nM	100.0	IC50	nM	100.0
2456	Inhibition of human CY3A4	CCc1ccc(S(=O)(=O)Nc2ccccc2Br)cc1NC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210646	=	=	IC50	nM	9620.0	IC50	uM	9.62
2457	Inhibition of human CY3A4	COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1NC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210648	=	=	IC50	nM	8440.0	IC50	uM	8.44
2458	Inhibition of human recombinant CYP3A4 after 30 mins	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Antimicrob. Agents Chemother.	2010.0	CHEMBL1269597	=	=	IC50	nM	58500.0	IC50	uM	58.5
2459	Inhibition of human recombinant CYP3A4 after 30 mins	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Antimicrob. Agents Chemother.	2010.0	CHEMBL160	=	=	IC50	nM	6600.0	IC50	uM	6.6
2460	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214452	>	>	IC50	nM	10000.0	IC50	uM	10.0
2461	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(Cl)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214451	>	>	IC50	nM	10000.0	IC50	uM	10.0
2462	Inhibition of human CYP3A4 after 10 mins	Cc1cccnc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2	J. Med. Chem.	2010.0	CHEMBL1214450	>	>	IC50	nM	10000.0	IC50	uM	10.0
2463	Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)nc1	J. Med. Chem.	2010.0	CHEMBL1214449	>	>	IC50	nM	10000.0	IC50	uM	10.0
2464	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214448	>	>	IC50	nM	10000.0	IC50	uM	10.0
2465	Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)C[C@@H](NS(=O)(=O)C(C)C)C3)cn1	J. Med. Chem.	2010.0	CHEMBL1214447	>	>	IC50	nM	10000.0	IC50	uM	10.0
2466	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214399	>	>	IC50	nM	10000.0	IC50	uM	10.0
2467	Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1	J. Med. Chem.	2010.0	CHEMBL1214397	>	>	IC50	nM	10000.0	IC50	uM	10.0
2468	Inhibition of human CYP3A4 after 10 mins	Cc1ccncc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2	J. Med. Chem.	2010.0	CHEMBL1214396	>	>	IC50	nM	9000.0	IC50	uM	9.0
2469	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cncc(C#N)c3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214395	>	>	IC50	nM	10000.0	IC50	uM	10.0
2470	Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)c(C)n1	J. Med. Chem.	2010.0	CHEMBL1214394	>	>	IC50	nM	10000.0	IC50	uM	10.0
2471	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214338	>	>	IC50	nM	10000.0	IC50	uM	10.0
2472	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3F)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214337	>	>	IC50	nM	10000.0	IC50	uM	10.0
2473	Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214336	>	>	IC50	nM	10000.0	IC50	uM	10.0
2474	Inhibition of CYP3A4	COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215552	=	=	IC50	nM	200.0	IC50	uM	0.2
2475	Inhibition of CYP3A4	COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215620	=	=	IC50	nM	1100.0	IC50	uM	1.1
2476	Inhibition of CYP3A4	COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215621	=	=	IC50	nM	800.0	IC50	uM	0.8
2477	Inhibition of CYP3A4	COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215622	=	=	IC50	nM	1200.0	IC50	uM	1.2
2478	Inhibition of CYP3A4	COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215623	>	>	IC50	nM	10000.0	IC50	uM	10.0
2479	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(C(O)c3ccncc3)cc2)cc1	J. Med. Chem.	2010.0	CHEMBL1215664	=	=	IC50	nM	3210.0	IC50	nM	3210.0
2480	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Nc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1	J. Med. Chem.	2010.0	CHEMBL1215665	=	=	IC50	nM	2450.0	IC50	nM	2450.0
2481	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1171987	=	=	IC50	nM	1520.0	IC50	nM	1520.0
2482	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1172882	=	=	IC50	nM	538.0	IC50	nM	538.0
2483	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O	J. Med. Chem.	2010.0	CHEMBL1172779	=	=	IC50	nM	7580.0	IC50	nM	7580.0
2484	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F	J. Med. Chem.	2010.0	CHEMBL1173260	=	=	IC50	nM	896.0	IC50	nM	896.0
2485	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Fc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1215732	=	=	IC50	nM	668.0	IC50	nM	668.0
2486	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1	J. Med. Chem.	2010.0	CHEMBL1214739	=	=	IC50	nM	1140.0	IC50	nM	1140.0
2487	Inhibition of CYP3A4 in human liver microsomes	COc1ccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223003	=	=	IC50	nM	400.0	IC50	uM	0.4
2488	Inhibition of CYP3A4 in human liver microsomes	COc1cccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223002	=	=	IC50	nM	200.0	IC50	uM	0.2
2489	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccc(Cl)cc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223001	=	=	IC50	nM	400.0	IC50	uM	0.4
2490	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222940	=	=	IC50	nM	300.0	IC50	uM	0.3
2491	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3Cl)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222939	=	=	IC50	nM	500.0	IC50	uM	0.5
2492	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222938	=	=	IC50	nM	400.0	IC50	uM	0.4
2493	Inhibition of CYP3A4 in human liver microsomes	CN(C)CCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222865	>	>	IC50	nM	30000.0	IC50	uM	30.0
2494	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222864	=	=	IC50	nM	30000.0	IC50	uM	30.0
2495	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222863	=	=	IC50	nM	30000.0	IC50	uM	30.0
2496	Inhibition of CYP3A4 in human liver microsomes	CN(C)CCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222800	>	>	IC50	nM	30000.0	IC50	uM	30.0
2497	Inhibition of CYP3A4 in human liver microsomes	CCOCCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222799	=	=	IC50	nM	10600.0	IC50	uM	10.6
2498	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222798	=	=	IC50	nM	9000.0	IC50	uM	9.0
2499	Inhibition of CYP3A4 in human liver microsomes	CC(C)OCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222719	=	=	IC50	nM	6000.0	IC50	uM	6.0
2500	Inhibition of CYP3A4 in human liver microsomes	CCOCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222718	=	=	IC50	nM	13500.0	IC50	uM	13.5
2501	Inhibition of CYP3A4 in human liver microsomes	COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222717	=	=	IC50	nM	11000.0	IC50	uM	11.0
2502	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCO)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222651	>	>	IC50	nM	30000.0	IC50	uM	30.0
2503	Inhibition of CYP3A4 in human liver microsomes	CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222650	=	=	IC50	nM	1500.0	IC50	uM	1.5
2504	Inhibition of CYP3A4 in human liver microsomes	Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222649	=	=	IC50	nM	7500.0	IC50	uM	7.5
2505	Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222485	=	=	IC50	nM	9500.0	IC50	uM	9.5
2506	Inhibition of CYP3A4	CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224382	>	>	IC50	nM	10000.0	IC50	uM	10.0
2507	Inhibition of CYP3A4	Cc1cc(C(N)=O)nn1-c1cccc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224194	>	>	IC50	nM	100000.0	IC50	uM	100.0
2508	Inhibition of CYP3A4	Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224195	=	=	IC50	nM	51000.0	IC50	uM	51.0
2509	Inhibition of CYP3A4	FC(F)(F)c1ccccc1-c1cccc(-c2c[nH]cn2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224524	<	<	IC50	nM	50.0	IC50	uM	0.05
2510	Inhibition of CYP3A4	NC(=O)c1nc(-c2cccc(-c3ccccc3C(F)(F)F)c2)c[nH]1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224590	>	>	IC50	nM	40000.0	IC50	uM	40.0
2511	Inhibition of CYP3A4	NC(=O)c1csc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224655	>	>	IC50	nM	50000.0	IC50	uM	50.0
2512	Inhibition of CYP3A4	NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224197	=	=	IC50	nM	18000.0	IC50	uM	18.0
2513	Inhibition of CYP3A4	CNC(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1221429	>	>	IC50	nM	50000.0	IC50	uM	50.0
2514	Inhibition of CYP3A4	CS(=O)(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223157	>	>	IC50	nM	50000.0	IC50	uM	50.0
2515	Inhibition of CYP3A4	CN1CCN(Cc2ccc(C(c3nnnn3Cc3ccccc3)N3CCCN(C4CCC4)CC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223158	>	>	IC50	nM	50000.0	IC50	uM	50.0
2516	Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223235	=	=	IC50	nM	29000.0	IC50	uM	29.0
2517	Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223236	=	=	IC50	nM	12000.0	IC50	uM	12.0
2518	Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223237	=	=	IC50	nM	2400.0	IC50	uM	2.4
2519	Inhibition of CYP3A4	Cc1n[nH]c(C)c1CC(=O)NCc1ccc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210558	>	>	IC50	nM	100.0	pIC50		100.0
2520	Inhibition of CYP3A4	CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222883	>	>	IC50	nM	100.0	pIC50		100.0
2521	Inhibition of CYP3A4 in human liver microsome	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	IC50	nM	14000.0	IC50	uM	14.0
2522	Inhibition of CYP3A4 in human liver microsome	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	Ki	nM	3200.0	Ki	uM	3.2
2523	Inhibition of CYP3A4 in human liver microsome preincubated for 30 mins	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	IC50	nM	120.0	IC50	uM	0.12
2524	Inhibition of CYP3A4 in human liver microsomes after 30 mins	Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1	Bioorg. Med. Chem.	2010.0	CHEMBL111	>	>	IC50	nM	20.0	IC50	nM	20.0
2525	Inhibition of CYP3A4 in human liver microsomes after 30 mins	FC(F)(F)C1(c2nnc(-c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3Cn3cncn3)s2)CCC1	Bioorg. Med. Chem.	2010.0	CHEMBL1222969	>	>	IC50	nM	20.0	IC50	nM	20.0
2526	Inhibition of CYP3A4 in human liver microsomes after 30 mins	C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem.	2010.0	CHEMBL220360	>	>	IC50	nM	20.0	IC50	nM	20.0
2527	Inhibition of CYP3A4 in human liver microsomes after 30 mins	CC(C)(C)c1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1	Bioorg. Med. Chem.	2010.0	CHEMBL1223034	>	>	IC50	nM	20.0	IC50	nM	20.0
2528	Inhibition of CYP3A4 in human liver microsomes after 30 mins	CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1	Bioorg. Med. Chem.	2010.0	CHEMBL1223259	>	>	IC50	nM	20.0	IC50	nM	20.0
2529	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241738	>	>	IC50	nM	10000.0	IC50	uM	10.0
2530	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241738	>	>	IC50	nM	10000.0	IC50	uM	10.0
2531	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241546	>	>	IC50	nM	5000.0	IC50	uM	5.0
2532	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241546	>	>	IC50	nM	5000.0	IC50	uM	5.0
2533	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241736	>	>	IC50	nM	5000.0	IC50	uM	5.0
2534	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241736	>	>	IC50	nM	5000.0	IC50	uM	5.0
2535	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241824	>	>	IC50	nM	10000.0	IC50	uM	10.0
2536	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241824	>	>	IC50	nM	10000.0	IC50	uM	10.0
2537	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	>	>	IC50	nM	9000.0	IC50	uM	9.0
2538	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	>	>	IC50	nM	9000.0	IC50	uM	9.0
2539	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	>	>	IC50	nM	9000.0	IC50	uM	9.0
2540	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	>	>	IC50	nM	9000.0	IC50	uM	9.0
2541	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241998	>	>	IC50	nM	8000.0	IC50	uM	8.0
2542	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241998	>	>	IC50	nM	8000.0	IC50	uM	8.0
2543	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242081	>	>	IC50	nM	7000.0	IC50	uM	7.0
2544	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242081	>	>	IC50	nM	7000.0	IC50	uM	7.0
2545	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242345	>	>	IC50	nM	10000.0	IC50	uM	10.0
2546	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242345	>	>	IC50	nM	10000.0	IC50	uM	10.0
2547	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242533	>	>	IC50	nM	6000.0	IC50	uM	6.0
2548	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242533	>	>	IC50	nM	6000.0	IC50	uM	6.0
2549	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242623	>	>	IC50	nM	10000.0	IC50	uM	10.0
2550	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242623	>	>	IC50	nM	10000.0	IC50	uM	10.0
2551	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242717	>	>	IC50	nM	10000.0	IC50	uM	10.0
2552	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242717	>	>	IC50	nM	10000.0	IC50	uM	10.0
2553	Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
2554	Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
2555	Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	88000.0	IC50	uM	88.0
2556	Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	61000.0	IC50	uM	61.0
2557	Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
2558	Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
2559	Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	21000.0	IC50	uM	21.0
2560	Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	8000.0	IC50	uM	8.0
2561	Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	100000.0	IC50	uM	100.0
2562	Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	5000.0	IC50	uM	5.0
2563	Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	3000.0	IC50	uM	3.0
2564	Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	82000.0	IC50	uM	82.0
2565	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1cn2c(n1)COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241547	<	<	IC50	nM	4000.0	IC50	uM	4.0
2566	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C)c(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241548	<	<	IC50	nM	4000.0	IC50	uM	4.0
2567	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C(F)(F)F)cn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241641	<	<	IC50	nM	4000.0	IC50	uM	4.0
2568	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241642	=	=	IC50	nM	100.0	IC50	uM	0.1
2569	Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241825	=	=	IC50	nM	4000.0	IC50	uM	4.0
2570	Inhibition of CYP3A4	FC(F)(F)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1	J. Med. Chem.	2010.0	CHEMBL1243305	=	=	IC50	nM	17000.0	IC50	uM	17.0
2571	Inhibition of CYP3A4	CC(C)(C)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1	J. Med. Chem.	2010.0	CHEMBL1243333	=	=	IC50	nM	6500.0	IC50	uM	6.5
2572	Inhibition of CYP3A4	CC(C)(C)c1ccc(SCC(c2ccccn2)c2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1243335	=	=	IC50	nM	270.0	IC50	uM	0.27
2573	Inhibition of CYP3A4	FC(F)(F)c1ccc(SCC(c2ccncc2)c2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1243367	=	=	IC50	nM	350.0	IC50	uM	0.35
2574	Inhibition of CYP3A4	CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1098230	=	=	IC50	nM	470.0	IC50	uM	0.47
2575	Inhibition of CYP3A4	CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C	J. Med. Chem.	2010.0	CHEMBL1230065	=	=	IC50	nM	18000.0	IC50	uM	18.0
2576	Inhibition of human CYP3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Antimicrob. Agents Chemother.	2008.0	CHEMBL163	<	<	Ki	nM	100.0	Ki	uM	0.1
2577	Inhibition of CYP3A4	C[C@@H](O[C@H]1CN2C(=O)[C@H]3C[C@@](C)(O)C[C@H]3[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257706	=	=	IC50	nM	22680.0	IC50	uM	22.68
2578	Inhibition of CYP3A4	O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258517	>	>	IC50	nM	30000.0	IC50	uM	30.0
2579	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257487	=	=	IC50	nM	6000.0	IC50	uM	6.0
2580	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@@H](C)CNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257964	=	=	IC50	nM	26000.0	IC50	uM	26.0
2581	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc(C(=O)N2CCC(F)(F)CC2)n3C(C)C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL497031	>	>	IC50	nM	50000.0	IC50	uM	50.0
2582	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258754	>	>	IC50	nM	50000.0	IC50	uM	50.0
2583	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCCNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258755	>	>	IC50	nM	50000.0	IC50	uM	50.0
2584	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(C)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258873	>	>	IC50	nM	50000.0	IC50	uM	50.0
2585	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CC3CC3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257138	>	>	IC50	nM	50000.0	IC50	uM	50.0
2586	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccc(F)cc3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257376	>	>	IC50	nM	50000.0	IC50	uM	50.0
2587	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CCO)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257607	>	>	IC50	nM	50000.0	IC50	uM	50.0
2588	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)NC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257729	>	>	IC50	nM	50000.0	IC50	uM	50.0
2589	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@H](C)NC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257850	>	>	IC50	nM	50000.0	IC50	uM	50.0
2590	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@H](C)CNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257851	>	>	IC50	nM	50000.0	IC50	uM	50.0
2591	Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)N(CC3CC3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257965	>	>	IC50	nM	50000.0	IC50	uM	50.0
2592	Inhibition of CYP3A4	CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CNC4=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258078	>	>	IC50	nM	50000.0	IC50	uM	50.0
2593	Inhibition of CYP3A4	CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CN(CC2CC2)C4=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258079	>	>	IC50	nM	50000.0	IC50	uM	50.0
2594	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc2c(c1)cc1n2CCNC1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258308	>	>	IC50	nM	50000.0	IC50	uM	50.0
2595	Inhibition of human CYP3A4	O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL117	>	>	IC50	nM	50000.0	IC50	nM	50000.0
2596	Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(C)(C)C)cc2)C3)n1C	J. Med. Chem.	2010.0	CHEMBL1257215	>	>	IC50	nM	5000.0	IC50	uM	5.0
2597	Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(F)(F)F)cc2)C3)n1C	J. Med. Chem.	2010.0	CHEMBL1257336	>	>	IC50	nM	10000.0	IC50	uM	10.0
2598	Inhibition of human CYP3A4	Cn1c(SCCCN2CCC3CC3(c3ccc(C(F)(F)F)cc3)CC2)nnc1-c1ccnnc1	J. Med. Chem.	2010.0	CHEMBL1258034	>	>	IC50	nM	6000.0	IC50	uM	6.0
2599	Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN[C@@H]2CC[C@]3(c4ccc(C(F)(F)F)cc4)CC23)n1C	J. Med. Chem.	2010.0	CHEMBL1258035	>	>	IC50	nM	4000.0	IC50	uM	4.0
2600	Inhibition of human CYP3A4	CCOc1ccc2c(c1)Oc1cc(OCC)ccc1C21OC(=O)c2ccccc21	J. Med. Chem.	2010.0	CHEMBL1257567	=	=	IC50	nM	1000.0	IC50	uM	1.0
2601	Inhibition of human CYP3A4	c1ccc(COc2ccc3cccnc3c2)cc1	J. Med. Chem.	2010.0	CHEMBL1081779	=	=	IC50	nM	25000.0	IC50	uM	25.0
2602	Inhibition of CYP3A4 by competitive inhibition assay	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	110.0	IC50	uM	0.11
2603	Inhibition of CYP3A4 in presence of NADPH	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	4.0	IC50	uM	0.004
2604	Inhibition of CYP3A4	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	46.0	IC50	uM	0.046
2605	Inhibition of CYP3A4 using midazolam as substrate	COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269671	=	=	IC50	nM	4800.0	IC50	uM	4.8
2606	Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	=	=	IC50	nM	7400.0	IC50	uM	7.4
2607	Inhibition of CYP3A4 using midazolam as substrate	COCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269672	=	=	IC50	nM	3200.0	IC50	uM	3.2
2608	Inhibition of CYP3A4 using midazolam as substrate	CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269673	=	=	IC50	nM	14000.0	IC50	uM	14.0
2609	Inhibition of CYP3A4 using midazolam as substrate	CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269674	=	=	IC50	nM	15000.0	IC50	uM	15.0
2610	Inhibition of CYP3A4 using midazolam as substrate	CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269675	=	=	IC50	nM	14000.0	IC50	uM	14.0
2611	Inhibition of CYP3A4 using midazolam as substrate	CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269676	=	=	IC50	nM	15000.0	IC50	uM	15.0
2612	Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269680	=	=	IC50	nM	7300.0	IC50	uM	7.3
2613	Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269681	=	=	IC50	nM	3100.0	IC50	uM	3.1
2614	Inhibition of CYP3A4 using midazolam as substrate	CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269682	=	=	IC50	nM	2400.0	IC50	uM	2.4
2615	Inhibition of CYP3A4 using midazolam as substrate	CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269683	=	=	IC50	nM	2900.0	IC50	uM	2.9
2616	Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269684	=	=	IC50	nM	2800.0	IC50	uM	2.8
2617	Inhibition of CYP3A4 using midazolam as substrate	CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269686	=	=	IC50	nM	2100.0	IC50	uM	2.1
2618	Inhibition of CYP3A4 using midazolam as substrate	CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269687	=	=	IC50	nM	5100.0	IC50	uM	5.1
2619	Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269692	=	=	IC50	nM	4000.0	IC50	uM	4.0
2620	Inhibition of CYP3A4 using midazolam as substrate	COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269696	=	=	IC50	nM	3500.0	IC50	uM	3.5
2621	Inhibition of CYP3A4 using midazolam as substrate	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c(Cl)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269697	=	=	IC50	nM	5900.0	IC50	uM	5.9
2622	Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	=	=	IC50	nM	11000.0	IC50	uM	11.0
2623	Inhibition of CYP3A4 using testosterone as substrate	COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269671	=	=	IC50	nM	8100.0	IC50	uM	8.1
2624	Inhibition of CYP3A4 using testosterone as substrate	CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269673	=	=	IC50	nM	16000.0	IC50	uM	16.0
2625	Inhibition of CYP3A4 using testosterone as substrate	CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269674	=	=	IC50	nM	17000.0	IC50	uM	17.0
2626	Inhibition of CYP3A4 using testosterone as substrate	CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269675	=	=	IC50	nM	17000.0	IC50	uM	17.0
2627	Inhibition of CYP3A4 using testosterone as substrate	CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269676	=	=	IC50	nM	18000.0	IC50	uM	18.0
2628	Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269680	=	=	IC50	nM	9900.0	IC50	uM	9.9
2629	Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269681	=	=	IC50	nM	4800.0	IC50	uM	4.8
2630	Inhibition of CYP3A4 using testosterone as substrate	CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269682	=	=	IC50	nM	6000.0	IC50	uM	6.0
2631	Inhibition of CYP3A4 using testosterone as substrate	CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269683	=	=	IC50	nM	8900.0	IC50	uM	8.9
2632	Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269684	=	=	IC50	nM	4500.0	IC50	uM	4.5
2633	Inhibition of CYP3A4 using testosterone as substrate	CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269686	=	=	IC50	nM	7100.0	IC50	uM	7.1
2634	Inhibition of CYP3A4 using testosterone as substrate	CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269687	=	=	IC50	nM	8400.0	IC50	uM	8.4
2635	Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269692	=	=	IC50	nM	7900.0	IC50	uM	7.9
2636	Inhibition of CYP3A4 using testosterone as substrate	COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269696	=	=	IC50	nM	6500.0	IC50	uM	6.5
2637	Inhibition of CYP3A4	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	>	>	IC50	nM	7000.0	IC50	uM	7.0
2638	Inhibition of CYP3A4	Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)N(Cc4cccc(Cl)c4Cl)C4CC4)CNCC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087637	=	=	IC50	nM	800.0	IC50	uM	0.8
2639	Inhibition of CYP3A4	CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270269	=	=	IC50	nM	35000.0	IC50	uM	35.0
2640	Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL445162	=	=	IC50	nM	2600.0	IC50	uM	2.6
2641	Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	Clc1ccc2c(c1Nc1ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n1)OCO2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL468970	=	=	IC50	nM	900.0	IC50	uM	0.9
2642	Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269858	=	=	IC50	nM	5000.0	IC50	uM	5.0
2643	Inhibition of CYP3A4	CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270738	>	>	IC50	nM	30000.0	IC50	uM	30.0
2644	Inhibition of CYP3A4	O=C(Nc1ccc(-n2nc(-c3cccnc3)cc2C(F)(F)F)cn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271608	>	>	IC50	nM	30.0	IC50	nM	30.0
2645	Inhibition of human recombinant CYP3A4	CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12	J. Med. Chem.	2010.0	CHEMBL1236391	>	>	IC50	nM	10000.0	IC50	uM	10.0
2646	Inhibition of human CYP3A4	CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1cccc3oc(N4CCOCC4)nc13)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084761	>	>	IC50	nM	50000.0	IC50	uM	50.0
2647	Inhibition of human CYP3A4	O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271520	>	>	IC50	nM	100000.0	IC50	uM	100.0
2648	Inhibition of human CYP3A4	COc1ccccc1-c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272016	>	>	IC50	nM	50000.0	IC50	uM	50.0
2649	Inhibition of human CYP3A4	COc1ccccc1-c1nc2c(C(=O)N[C@H]3C[C@@H]4CCC[C@H](C3)N4C)cccc2o1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084777	=	=	IC50	nM	1100.0	IC50	uM	1.1
2650	Inhibition of human CYP3A4	O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272072	>	>	IC50	nM	100000.0	IC50	uM	100.0
2651	Inhibition of human CYP3A4	CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1cccc3oc(C4CC4)nc13)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084778	>	>	IC50	nM	50000.0	IC50	uM	50.0
2652	Inhibition of human CYP3A4	Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL46	=	=	IC50	nM	11000.0	IC50	uM	11.0
2653	Inhibition of human CYP3A4	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
2654	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC2C3CC4CC(C3)CC2C4)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270215	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2655	Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270910	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2656	Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271218	=	=	IC50	nM	3300.0	IC50	nM	3300.0
2657	Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271320	=	=	IC50	nM	7200.0	IC50	nM	7200.0
2658	Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4cccc(C(F)(F)F)n4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271427	=	=	IC50	nM	4800.0	IC50	nM	4800.0
2659	Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@H](OC(=O)N1CC[C@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271428	=	=	IC50	nM	8500.0	IC50	nM	8500.0
2660	Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269894	=	=	IC50	nM	10300.0	IC50	nM	10300.0
2661	Inhibition of CYP3A4	N#Cc1cccnc1N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269895	=	=	IC50	nM	17100.0	IC50	nM	17100.0
2662	Inhibition of CYP3A4	N#Cc1ccc(N[C@@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270001	=	=	IC50	nM	14200.0	IC50	nM	14200.0
2663	Inhibition of CYP3A4	N#Cc1cccnc1N[C@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270002	=	=	IC50	nM	18600.0	IC50	nM	18600.0
2664	Inhibition of CYP3A4	N#Cc1ccc(N[C@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270110	=	=	IC50	nM	26600.0	IC50	nM	26600.0
2665	Inhibition of CYP3A4	OC1C2CC3CC(C2)CC1C3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269176	>	>	IC50	nM	30000.0	IC50	nM	30000.0
2666	Inhibition of CYP3A4	COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272135	>	>	IC50	nM	25000.0	IC50	uM	25.0
2667	Inhibition of CYP3A4	CC#Cc1cccc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270934	<	<	IC50	nM	100.0	IC50	uM	0.1
2668	Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2cccc(C#CC3CC3)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271246	=	=	IC50	nM	100.0	IC50	uM	0.1
2669	Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CC3CC3)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270335	=	=	IC50	nM	10000.0	IC50	uM	10.0
2670	Inhibition of CYP3A4	Cc1cc([C@]2(c3ccc(F)c(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270432	=	=	IC50	nM	4100.0	IC50	uM	4.1
2671	Inhibition of CYP3A4	Cc1cc([C@]2(c3cccc(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270630	=	=	IC50	nM	100.0	IC50	uM	0.1
2672	Inhibition of CYP3A4	CCCC#Cc1cc([C@@]2(c3ccc(OC(F)F)c(C)c3)N=C(N)N(C)C2=O)ccc1F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270834	=	=	IC50	nM	3400.0	IC50	uM	3.4
2673	Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CCCCF)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270835	=	=	IC50	nM	900.0	IC50	uM	0.9
2674	Inhibition of CYP3A4	CC#Cc1cc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)ccc1F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270936	=	=	IC50	nM	1000.0	IC50	uM	1.0
2675	Inhibition of CYP3A4	CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271930	>	>	IC50	nM	20000.0	IC50	uM	20.0
2676	Inhibition of CYP3A4 by CYPEX bactosome P450 inhibition assay	Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271489	>	>	IC50	nM	5000.0	IC50	uM	5.0
2677	Inhibition of CYP3A4 using DEF substrate by CYPEX bactosome P450 inhibition assay	Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271489	=	=	IC50	nM	2000.0	IC50	uM	2.0
2678	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CCC(C3)N4)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271544	=	=	IC50	nM	0.5	IC50	nM	0.5
2679	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271600	=	=	IC50	nM	13.6	IC50	nM	13.6
2680	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCC(CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271601	=	=	IC50	nM	13.8	IC50	nM	13.8
2681	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271651	=	=	IC50	nM	30.0	IC50	nM	30.0
2682	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CNCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271652	=	=	IC50	nM	6.4	IC50	nM	6.4
2683	Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271703	=	=	IC50	nM	0.3	IC50	nM	0.3
2684	Inhibition of CYP3A4 after 30 mins	CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCN(C(C)(C)CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271704	=	=	IC50	nM	23.8	IC50	nM	23.8
2685	Inhibition of CYP3A4 after 30 mins	CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCC(CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271762	=	=	IC50	nM	7.1	IC50	nM	7.1
2686	Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCC(CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271763	=	=	IC50	nM	5.5	IC50	nM	5.5
2687	Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCC(N4CCCCC4)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271821	=	=	IC50	nM	1.5	IC50	nM	1.5
2688	Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCN(C(C)(C)CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271822	=	=	IC50	nM	0.5	IC50	nM	0.5
2689	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271879	=	=	IC50	nM	0.8	IC50	nM	0.8
2690	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271880	=	=	IC50	nM	2.3	IC50	nM	2.3
2691	Inhibition of CYP3A4 after 30 mins	CC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271935	>	>	IC50	nM	30.0	IC50	nM	30.0
2692	Inhibition of CYP3A4 after 30 mins	CCNC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271991	>	>	IC50	nM	30.0	IC50	nM	30.0
2693	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CC1CN2CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272045	=	=	IC50	nM	3.2	IC50	nM	3.2
2694	Inhibition of CYP3A4 after 30 mins	C[C@H]1CN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)C[C@@H](C)N1CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272046	=	=	IC50	nM	2.0	IC50	nM	2.0
2695	Inhibition of CYP3A4 after 30 mins	CN1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272097	=	=	IC50	nM	1.4	IC50	nM	1.4
2696	Inhibition of CYP3A4 after 30 mins	CC[C@H]1CN(C(C)=O)[C@H](C)CN1C(=O)OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272098	>	>	IC50	nM	30.0	IC50	nM	30.0
2697	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272152	>	>	IC50	nM	30.0	IC50	nM	30.0
2698	Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272153	=	=	IC50	nM	11.3	IC50	nM	11.3
2699	Inhibition of CYP3A4 after 30 mins	CN1CCC12CCN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)CC2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272207	=	=	IC50	nM	30.0	IC50	nM	30.0
2700	Inhibition of CYP3A4 after 30 mins	O=C1CC2(CCN(C(=O)OC3([C@H]4COC[C@@H](CC5CC5)N4S(=O)(=O)c4ccc(Cl)cc4)CC3)CC2)N1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272208	>	>	IC50	nM	30.0	IC50	nM	30.0
2701	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL393941	=	=	IC50	nM	400.0	IC50	uM	0.4
2702	Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL399507	=	=	IC50	nM	19500.0	IC50	uM	19.5
2703	Inhibition of CYP3A4	Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2	Eur. J. Med. Chem.	2010.0	CHEMBL1276654	=	=	IC50	nM	1600.0	IC50	uM	1.6
2704	Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@@H]2CNC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1	J. Med. Chem.	2010.0	CHEMBL509903	>	>	IC50	nM	10000.0	IC50	uM	10.0
2705	Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2	J. Med. Chem.	2010.0	CHEMBL391463	>	>	IC50	nM	30000.0	IC50	uM	30.0
2706	Inhibition of human CYP3A4	CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1	J. Med. Chem.	2010.0	CHEMBL1277677	=	=	IC50	nM	1100.0	IC50	uM	1.1
2707	Inhibition of human CYP3A4	Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1	J. Med. Chem.	2010.0	CHEMBL1276946	=	=	IC50	nM	20900.0	IC50	uM	20.9
2708	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1277312	>	>	IC50	nM	10000.0	IC50	uM	10.0
2709	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277126	>	>	IC50	nM	10000.0	IC50	uM	10.0
2710	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1276948	>	>	IC50	nM	10000.0	IC50	uM	10.0
2711	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2	J. Med. Chem.	2010.0	CHEMBL1276947	>	>	IC50	nM	10000.0	IC50	uM	10.0
2712	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1(F)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277678	>	>	IC50	nM	10000.0	IC50	uM	10.0
2713	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277770	>	>	IC50	nM	10000.0	IC50	uM	10.0
2714	Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1277935	>	>	IC50	nM	10000.0	IC50	uM	10.0
2715	Inhibition of CYP3A4	Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290746	>	>	IC50	nM	13000.0	IC50	uM	13.0
2716	Inhibition of CYP3A4	CN(O)C(=O)c1cc2c(CN3CCC[C@H]3C(N)=O)cn(Cc3ccc(F)cc3)c2cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289313	>	>	IC50	nM	30000.0	IC50	uM	30.0
2717	Inhibition of CYP3A4	COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL214957	=	=	IC50	nM	1600.0	IC50	uM	1.6
2718	Inhibition of CYP3A4	CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)C2CCC3(c4ccc(C#N)cc4)CC23)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289614	<	<	IC50	nM	50.0	IC50	uM	0.05
2719	Inhibition of CYP3A4	O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290041	=	=	IC50	nM	2000.0	IC50	uM	2.0
2720	Inhibition of CYP3A4	O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290150	=	=	IC50	nM	1700.0	IC50	uM	1.7
2721	Inhibition of CYP3A4	O=C(c1ccccc1N1Cn2c(ccc2-c2ccccc2)C1=O)N1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290004	>	>	IC50	nM	5000.0	IC50	uM	5.0
2722	Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289283	=	=	IC50	nM	10000.0	IC50	uM	10.0
2723	Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290155	=	=	IC50	nM	68000.0	IC50	uM	68.0
2724	Inhibition of CYP3A4	CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290264	=	=	IC50	nM	67000.0	IC50	uM	67.0
2725	Inhibition of CYP3A4	Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289395	=	=	IC50	nM	12000.0	IC50	uM	12.0
2726	Inhibition of CYP3A4	CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289396	=	=	IC50	nM	24000.0	IC50	uM	24.0
2727	Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289283	=	=	IC50	nM	10000.0	IC50	uM	10.0
2728	Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289515	=	=	IC50	nM	7700.0	IC50	uM	7.7
2729	Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289053	=	=	IC50	nM	38000.0	IC50	uM	38.0
2730	Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(C)c1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288260	=	=	IC50	nM	10200.0	IC50	uM	10.2
2731	Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2c1c(=O)n(C)c(=O)n2C.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288261	=	=	IC50	nM	20200.0	IC50	uM	20.2
2732	Inhibition of CYP3A4 in human liver microsomes after 10 mins	CCn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1C#N.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288288	=	=	IC50	nM	9400.0	IC50	uM	9.4
2733	Inhibition of CYP3A4 in human liver microsomes after 10 mins	CN(C)C(=O)Cn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1Cl.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288289	=	=	IC50	nM	13400.0	IC50	uM	13.4
2734	Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(CCCO)c1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287844	=	=	IC50	nM	7700.0	IC50	uM	7.7
2735	Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2ncn(C)c(=O)c21.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287901	=	=	IC50	nM	11900.0	IC50	uM	11.9
2736	Inhibition of human CYP3A4	COc1cccc2c(C(=O)N3CCN4CCCC[C@H]4C3)cn(CC3CCCCC3)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287846	=	=	IC50	nM	6000.0	IC50	uM	6.0
2737	Inhibition of CYP3A4 in human liver microsomes using midazolam as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
2738	Inhibition of human recombinant CYP3A4	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	67000.0	IC50	uM	67.0
2739	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
2740	Inhibition of CYP3A4 in human liver microsomes using nifedipine as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
2741	Inhibition of human CYP3A4	CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1	Antimicrob. Agents Chemother.	2009.0	CHEMBL264241	>	>	IC50	nM	17500.0	IC50	uM	17.5
2742	Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12	J. Med. Chem.	2010.0	CHEMBL221959	>	>	IC50	nM	52000.0	IC50	uM	52.0
2743	Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-n3ccnc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL411095	<	<	IC50	nM	100.0	IC50	uM	0.1
2744	Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3ccncc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631858	=	=	IC50	nM	200.0	IC50	uM	0.2
2745	Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3cccnc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631876	=	=	IC50	nM	1800.0	IC50	uM	1.8
2746	Inhibition of CYP3A4	Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)ccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631859	=	=	IC50	nM	1900.0	IC50	uM	1.9
2747	Inhibition of CYP3A4	Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)cc(C)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1629855	=	=	IC50	nM	4800.0	IC50	uM	4.8
2748	Inhibition of CYP3A4	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(Cl)cc2C1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631007	>	>	IC50	nM	38000.0	IC50	uM	38.0
2749	Inhibition of CYP3A4	NC(=O)c1cc(C(N)=O)n(-c2cccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)c2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631095	>	>	IC50	nM	100000.0	IC50	uM	100.0
2750	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
2751	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641808	>	>	IC50	nM	50000.0	IC50	uM	50.0
2752	Inhibition of CYP3A4	C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641811	>	>	IC50	nM	50000.0	IC50	uM	50.0
2753	Inhibition of human CYP3A4	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643880	=	=	IC50	nM	9300.0	IC50	uM	9.3
2754	Inhibition of human CYP3A4	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
2755	Inhibition of human CYP3A4	O=C1c2cccc3[nH]nc(c23)CN1[C@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643881	<	<	IC50	nM	10000.0	IC50	uM	10.0
2756	Inhibition of CYP3A4	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642258	=	=	IC50	nM	2000.0	IC50	uM	2.0
2757	Inhibition of human CYP3A4	Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643883	<	<	IC50	nM	10000.0	IC50	uM	10.0
2758	Inhibition of CYP3A4	O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1644183	=	=	IC50	nM	39000.0	IC50	uM	39.0
2759	Inhibition of CYP3A4	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem.	2011.0	CHEMBL809	=	=	IC50	nM	800.0	IC50	uM	0.8
2760	Inhibition of CYP3A4	CN[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642894	>	>	IC50	nM	25000.0	IC50	uM	25.0
2761	Inhibition of CYP3A4	CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642895	>	>	IC50	nM	25000.0	IC50	uM	25.0
2762	Inhibition of CYP3A4	CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642896	>	>	IC50	nM	25000.0	IC50	uM	25.0
2763	Inhibition of CYP3A4	CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642897	=	=	IC50	nM	17100.0	IC50	uM	17.1
2764	Inhibition of CYP3A4	CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642906	=	=	IC50	nM	20100.0	IC50	uM	20.1
2765	Inhibition of CYP3A4	CNC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642907	>	>	IC50	nM	25000.0	IC50	uM	25.0
2766	Inhibition of CYP3A4	CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642908	>	>	IC50	nM	25000.0	IC50	uM	25.0
2767	Inhibition of CYP3A4	NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642912	>	>	IC50	nM	25000.0	IC50	uM	25.0
2768	Inhibition of CYP3A4	NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642913	>	>	IC50	nM	25000.0	IC50	uM	25.0
2769	Inhibition of CYP3A4	CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)NC(C)(C)C)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643735	>	>	IC50	nM	10000.0	IC50	uM	10.0
2770	Inhibition of CYP3A4	N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643512	>	>	IC50	nM	25000.0	IC50	uM	25.0
2771	Inhibition of CYP3A4	CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643511	>	>	IC50	nM	25000.0	IC50	uM	25.0
2772	Inhibition of CYP3A4	CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643513	>	>	IC50	nM	25000.0	IC50	uM	25.0
2773	Inhibition of CYP3A4	CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643514	>	>	IC50	nM	25000.0	IC50	uM	25.0
2774	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
2775	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)cc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643773	>	>	IC50	nM	50000.0	IC50	uM	50.0
2776	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)c(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643780	>	>	IC50	nM	50000.0	IC50	uM	50.0
2777	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3cccc(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643783	>	>	IC50	nM	50000.0	IC50	uM	50.0
2778	Inhibition of CYP3A4	O=C(O)Cc1c2n(c3ccccc13)C[C@H](N(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(F)cc1)CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643789	>	>	IC50	nM	50000.0	IC50	uM	50.0
2779	Inhibition of CYP3A4	Cc1ccccc1/C(=C\CCN1CCC[C@@H](C(=O)O)C1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641613	>	>	IC50	nM	10000.0	IC50	uM	10.0
2780	Inhibition of human CYP3A4	CC(C)c1ccc(S(=O)(=O)n2cc(N3CCN(C)CC3)c3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642412	=	=	IC50	nM	5540.0	IC50	uM	5.54
2781	Inhibition of human CYP3A4	CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642413	=	=	IC50	nM	4770.0	IC50	uM	4.77
2782	Inhibition of human CYP3A4	CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccc(Br)cc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642419	=	=	IC50	nM	4610.0	IC50	uM	4.61
2783	Inhibition of CYP3A4	FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1	J. Med. Chem.	2011.0	CHEMBL1650511	>	>	IC50	nM	10000.0	IC50	uM	10.0
2784	Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651534	=	=	IC50	nM	30000.0	IC50	uM	30.0
2785	Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651533	=	=	IC50	nM	23500.0	IC50	uM	23.5
2786	Inhibition of CYP3A4 uisng testosterone substrate	Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651532	=	=	IC50	nM	3000.0	IC50	uM	3.0
2787	Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651525	=	=	IC50	nM	800.0	IC50	uM	0.8
2788	Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651534	=	=	IC50	nM	30000.0	IC50	uM	30.0
2789	Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651533	=	=	IC50	nM	30000.0	IC50	uM	30.0
2790	Inhibition of CYP3A4 uisng midazolam substrate	Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651532	=	=	IC50	nM	11800.0	IC50	uM	11.8
2791	Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651525	=	=	IC50	nM	4300.0	IC50	uM	4.3
2792	Inhibition of human CYP3A4 by fluorescence assay	CC(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649675	<=	<=	IC50	nM	1000.0	IC50	uM	1.0
2793	Inhibition of human CYP3A4 by fluorescence assay	CN1CCc2c(C(F)(F)F)nn(-c3ccc(CN4CCCC4=O)cc3)c2C1	J. Med. Chem.	2011.0	CHEMBL1649685	>	>	IC50	nM	10000.0	IC50	uM	10.0
2794	Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649684	>	>	IC50	nM	10000.0	IC50	uM	10.0
2795	Inhibition of human CYP3A4 by fluorescence assay	O=C(c1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1)N1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649683	>	>	IC50	nM	10000.0	IC50	uM	10.0
2796	Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1c(F)cc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1F	J. Med. Chem.	2011.0	CHEMBL1649682	>	>	IC50	nM	10000.0	IC50	uM	10.0
2797	Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649681	>	>	IC50	nM	8000.0	IC50	uM	8.0
2798	Inhibition of human CYP3A4 by fluorescence assay	O=C(c1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1)N1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649656	>	>	IC50	nM	10000.0	IC50	uM	10.0
2799	Inhibition of human CYP3A4 by fluorescence assay	O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1649667	=	=	IC50	nM	6000.0	IC50	uM	6.0
2800	Inhibition of human CYP3A4 by fluorescence assay	O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649665	=	=	IC50	nM	700.0	IC50	uM	0.7
2801	Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL381751	>	>	IC50	nM	5000.0	IC50	uM	5.0
2802	Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL466624	>	>	IC50	nM	5000.0	IC50	uM	5.0
2803	Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](F)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL443705	>	>	IC50	nM	5000.0	IC50	uM	5.0
2804	Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL468092	>	>	IC50	nM	5000.0	IC50	uM	5.0
2805	Inhibition of human cytochrome P450 3A4	Cc1nc(N)c2ncn([C@@H]3O[C@H](CN(C)C/C=C\CN)[C@@H](O)[C@H]3O)c2n1	Antimicrob. Agents Chemother.	2009.0	CHEMBL467047	>	>	IC50	nM	5000.0	IC50	uM	5.0
2806	Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL469227	=	=	IC50	nM	2770.0	IC50	uM	2.77
2807	Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL1650645	=	=	IC50	nM	220.0	IC50	uM	0.22
2808	Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL1650652	=	=	IC50	nM	40.0	IC50	uM	0.04
2809	Inhibition of human CYP3A4	Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1	J. Med. Chem.	2011.0	CHEMBL1650654	=	=	IC50	nM	1070.0	IC50	uM	1.07
2810	Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	uM	0.05
2811	Inhibition of CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)ncc(F)c1=O	J. Med. Chem.	2011.0	CHEMBL1650404	<	<	IC50	nM	10000.0	IC50	uM	10.0
2812	Inhibition of CYP3A4	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	J. Med. Chem.	2011.0	CHEMBL376359	<	<	IC50	nM	10000.0	IC50	uM	10.0
2813	Inhibition of CYP3A4	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	J. Med. Chem.	2011.0	CHEMBL1650443	<	<	IC50	nM	10000.0	IC50	uM	10.0
2814	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL559251	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2815	Inhibition of CYP3A4	CCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669405	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2816	Inhibition of CYP3A4	CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669406	=	=	IC50	nM	4038.0	IC50	nM	4038.0
2817	Inhibition of CYP3A4	CN(CCF)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669407	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2818	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL556506	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2819	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCF)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669408	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2820	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CC#N)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669409	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2821	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCC#N)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669410	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2822	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCC(F)(F)F)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669411	>	>	IC50	nM	5000.0	IC50	nM	5000.0
2823	Inhibition of CYP3A4	c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669412	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2824	Inhibition of CYP3A4	c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669413	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2825	Inhibition of CYP3A4	FC1CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669414	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2826	Inhibition of CYP3A4	FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669415	=	=	IC50	nM	3871.0	IC50	nM	3871.0
2827	Inhibition of CYP3A4	FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669416	=	=	IC50	nM	1405.0	IC50	nM	1405.0
2828	Inhibition of CYP3A4	FC1CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669417	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2829	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669418	=	=	IC50	nM	2751.0	IC50	nM	2751.0
2830	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669419	=	=	IC50	nM	1826.0	IC50	nM	1826.0
2831	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669420	=	=	IC50	nM	2820.0	IC50	nM	2820.0
2832	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669421	=	=	IC50	nM	4840.0	IC50	nM	4840.0
2833	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669422	=	=	IC50	nM	4416.0	IC50	nM	4416.0
2834	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669423	=	=	IC50	nM	1535.0	IC50	nM	1535.0
2835	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669424	=	=	IC50	nM	4783.0	IC50	nM	4783.0
2836	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669425	=	=	IC50	nM	1281.0	IC50	nM	1281.0
2837	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2cnccn2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669426	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2838	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CC2CCOCC2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669427	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2839	Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1F)nc2[C@H]1CC[C@H](C(=O)Nc2nc3ccccc3[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1667948	>	>	IC50	nM	20000.0	IC50	uM	20.0
2840	Inhibition of CYP3A4	CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL537424	=	=	IC50	nM	19700.0	IC50	uM	19.7
2841	Inhibition of CYP3A4	CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL536743	=	=	IC50	nM	9300.0	IC50	uM	9.3
2842	Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL559168	>	>	IC50	nM	30000.0	IC50	uM	30.0
2843	Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL536754	>	>	IC50	nM	30000.0	IC50	uM	30.0
2844	Inhibition of CYP3A4	CCCCN1C(=O)[C@H](CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1170878	=	=	IC50	nM	24900.0	IC50	uM	24.9
2845	Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668019	>	>	IC50	nM	30000.0	IC50	uM	30.0
2846	Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668020	>	>	IC50	nM	30000.0	IC50	uM	30.0
2847	Inhibition of CYP3A4	CCCCN1C(=O)[C@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668021	>	>	IC50	nM	30000.0	IC50	uM	30.0
2848	Inhibition of CYP3A4	CCCCN1C(=O)[C@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668022	>	>	IC50	nM	30000.0	IC50	uM	30.0
2849	Inhibition of human CYP3A4	CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668898	>	>	IC50	nM	50000.0	IC50	uM	50.0
2850	Inhibition of human CYP3A4 by time-dependent inhibition assay	CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668898	=	=	IC50	nM	2.0	IC50	uM	0.002
2851	Inhibition of CYP3A4	CCOC(=O)c1sc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668909	=	=	IC50	nM	50.0	IC50	nM	50.0
2852	Inhibition of CYP3A4	CCOC(=O)c1oc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1667925	=	=	IC50	nM	8300.0	IC50	nM	8300.0
2853	Inhibition of CYP3A4	O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642362	=	=	IC50	nM	4500.0	IC50	uM	4.5
2854	Inhibition of CYP3A4	O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668238	=	=	IC50	nM	7600.0	IC50	uM	7.6
2855	Inhibition of CYP3A4	O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668239	=	=	IC50	nM	33000.0	IC50	uM	33.0
2856	Inhibition of CYP3A4	O=C(N[C@H]1CC[C@H](C(=O)O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668240	>	>	IC50	nM	50000.0	IC50	uM	50.0
2857	Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615153	=	=	IC50	nM	37000.0	IC50	uM	37.0
2858	Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615152	=	=	IC50	nM	39000.0	IC50	uM	39.0
2859	Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668243	=	=	IC50	nM	23000.0	IC50	uM	23.0
2860	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615150	>	>	IC50	nM	50000.0	IC50	uM	50.0
2861	Inhibition of CYP3A4	O=C(Nc1ccc(OC2(C(=O)O)CC2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668249	>	>	IC50	nM	50000.0	IC50	uM	50.0
2862	Inhibition of CYP3A4	O=C(Nc1ccc(-c2nnn[nH]2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668257	=	=	IC50	nM	7700.0	IC50	uM	7.7
2863	Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668259	=	=	IC50	nM	49000.0	IC50	uM	49.0
2864	Inhibition of CYP3A4	COc1ccc(-c2nc3cc(F)c(F)cc3n2[C@H](C(=O)N[C@H]2CC[C@H](C(=O)O)CC2)C2CCCCC2)c(OC)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668261	>	>	IC50	nM	50000.0	IC50	uM	50.0
2865	Inhibition of human CYP3A4	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	J. Nat. Prod.	2011.0	CHEMBL98745	=	=	Ki	nM	630.0	Ki	uM	0.63
2866	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2COc3ccccc3[C@@H]2O)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668108	=	=	IC50	nM	99500.0	IC50	uM	99.5
2867	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2OC[C@H]([C@@H](O)c3ccc(O)c(OC)c3)[C@@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668112	=	=	IC50	nM	66500.0	IC50	uM	66.5
2868	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@@H](CO)[C@@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL399512	>	>	IC50	nM	100000.0	IC50	uM	100.0
2869	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(O)c3)[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668114	=	=	IC50	nM	85600.0	IC50	uM	85.6
2870	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	J. Nat. Prod.	2011.0	CHEMBL368347	=	=	IC50	nM	47300.0	IC50	uM	47.3
2871	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(OC)c3)[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL518421	=	=	IC50	nM	25600.0	IC50	uM	25.6
2872	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@@H]2Oc3cc(CCCO)ccc3O[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668115	=	=	IC50	nM	54200.0	IC50	uM	54.2
2873	Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@H]3C(=O)OC[C@H]23)ccc1O	J. Nat. Prod.	2011.0	CHEMBL463246	=	=	IC50	nM	200.0	IC50	uM	0.2
2874	Inhibition of CYP3A4 after 30 mins by fluorometric assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2011.0	CHEMBL157101	=	=	IC50	nM	7.8	IC50	uM	0.0078
2875	Inhibition of recombinant CYP3A4 after 30 mins	CC(C)(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671922	>	>	IC50	nM	40000.0	IC50	uM	40.0
2876	Inhibition of recombinant CYP3A4 after 30 mins	CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671921	>	>	IC50	nM	40000.0	IC50	uM	40.0
2877	Inhibition of recombinant CYP3A4 after 30 mins	CCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671918	>	>	IC50	nM	40000.0	IC50	uM	40.0
2878	Inhibition of recombinant CYP3A4 after 30 mins	CCCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671917	>	>	IC50	nM	40000.0	IC50	uM	40.0
2879	Inhibition of recombinant CYP3A4 after 30 mins	CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O	J. Med. Chem.	2011.0	CHEMBL431770	>	>	IC50	nM	40000.0	IC50	uM	40.0
2880	Inhibition of recombinant CYP3A4 after 30 mins	CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)Nc2nccs2)cc1F	J. Med. Chem.	2011.0	CHEMBL1671936	>	>	IC50	nM	40000.0	IC50	uM	40.0
2881	Inhibition of recombinant CYP3A4 after 30 mins	Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671916	=	=	IC50	nM	1400.0	IC50	uM	1.4
2882	Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(Cl)c1	J. Med. Chem.	2011.0	CHEMBL1671964	=	=	IC50	nM	2500.0	IC50	uM	2.5
2883	Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1671965	>	>	IC50	nM	10000.0	IC50	uM	10.0
2884	Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Br	J. Med. Chem.	2011.0	CHEMBL1671967	=	=	IC50	nM	3800.0	IC50	uM	3.8
2885	Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(C(F)(F)F)c1	J. Med. Chem.	2011.0	CHEMBL1671969	=	=	IC50	nM	9800.0	IC50	uM	9.8
2886	Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1671971	>	>	IC50	nM	10000.0	IC50	uM	10.0
2887	Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccccc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1671972	=	=	IC50	nM	1900.0	IC50	uM	1.9
2888	Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)c2ccccc12	J. Med. Chem.	2011.0	CHEMBL1671981	=	=	IC50	nM	4500.0	IC50	uM	4.5
2889	Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c2ccccc12	J. Med. Chem.	2011.0	CHEMBL1671982	=	=	IC50	nM	800.0	IC50	uM	0.8
2890	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672611	=	=	IC50	nM	25000.0	IC50	uM	25.0
2891	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672621	=	=	IC50	nM	5000.0	IC50	uM	5.0
2892	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672622	=	=	IC50	nM	1000.0	IC50	uM	1.0
2893	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672627	=	=	IC50	nM	5000.0	IC50	uM	5.0
2894	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2c(F)cncc2F)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672629	>	>	IC50	nM	25000.0	IC50	uM	25.0
2895	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672630	=	=	IC50	nM	1000.0	IC50	uM	1.0
2896	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2ncco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672632	>	>	IC50	nM	25000.0	IC50	uM	25.0
2897	Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672633	=	=	IC50	nM	5000.0	IC50	uM	5.0
2898	Inhibition of human CYP3A4	O=c1cc(CCCC2CC2)c2c(=O)[nH]c(C(F)F)nc2o1	ACS Med. Chem. Lett.	2011.0	CHEMBL1671877	>	>	IC50	nM	50000.0	IC50	uM	50.0
2899	Inhibition of CYP3A4 in human liver microsome	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL655	>	>	IC50	nM	33000.0	IC50	nM	33000.0
2900	Inhibition of CYP3A4 in human liver microsome	CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1487	=	=	IC50	nM	5100.0	IC50	nM	5100.0
2901	Inhibition of CYP3A4 in human liver microsome	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL193	=	=	IC50	nM	11000.0	IC50	nM	11000.0
2902	Inhibition of human CYP3A4	CC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682888	=	=	IC50	nM	1400.0	IC50	nM	1400.0
2903	Inhibition of human CYP3A4	COC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682891	=	=	IC50	nM	1400.0	IC50	nM	1400.0
2904	Inhibition of human CYP3A4	CCCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682895	=	=	IC50	nM	3400.0	IC50	nM	3400.0
2905	Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682893	=	=	IC50	nM	3600.0	IC50	nM	3600.0
2906	Inhibition of human CYP3A4	CNC(=O)c1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1C	Bioorg. Med. Chem.	2011.0	CHEMBL1682899	=	=	IC50	nM	3600.0	IC50	nM	3600.0
2907	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc(C(N)=O)ccc2c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682892	=	=	IC50	nM	3700.0	IC50	nM	3700.0
2908	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc3c(cc2c1)CN(C)C3=O)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682903	=	=	IC50	nM	5400.0	IC50	nM	5400.0
2909	Inhibition of human CYP3A4	CCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682894	=	=	IC50	nM	5700.0	IC50	nM	5700.0
2910	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	=	=	IC50	nM	6700.0	IC50	nM	6700.0
2911	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	=	=	IC50	nM	7400.0	IC50	nM	7400.0
2912	Inhibition of human CYP3A4	CC(C)NC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682896	=	=	IC50	nM	9300.0	IC50	nM	9300.0
2913	Inhibition of human CYP3A4	COc1ccc2cc([C@](O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682887	<	<	IC50	nM	1000.0	IC50	nM	1000.0
2914	Inhibition of human CYP3A4	CC(=O)Nc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682889	<	<	IC50	nM	1000.0	IC50	nM	1000.0
2915	Inhibition of human CYP3A4	CNC(=O)Nc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682890	<	<	IC50	nM	1000.0	IC50	nM	1000.0
2916	Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1682897	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2917	Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1C	Bioorg. Med. Chem.	2011.0	CHEMBL1682898	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2918	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682901	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2919	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc3c(cc2c1)CNC3=O)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682902	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2920	Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2921	Inhibition of human CYP3A4	CC(C)[C@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682904	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2922	Inhibition of human CYP3A4	CC(C)[C@@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682905	>	>	IC50	nM	10000.0	IC50	nM	10000.0
2923	Inhibition of CYP3A4	C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683443	=	=	IC50	nM	1.4	IC50	nM	1.4
2924	Inhibition of CYP3A4	C[C@@H](C[C@@H](CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683444	<	<	IC50	nM	0.1	IC50	nM	0.1
2925	Inhibition of CYP3A4	C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683445	>	>	IC50	nM	10.0	IC50	nM	10.0
2926	Inhibition of CYP3A4	C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615186	>	>	IC50	nM	10.0	IC50	nM	10.0
2927	Inhibition of CYP3A4	C[C@H]1CN(c2ncc(C(=O)NCc3ccc(F)c(F)c3)cc2Cl)CCN1C1CCN(Cc2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1681849	>	>	IC50	nM	10000.0	IC50	uM	10.0
2928	Inhibition of CYP3A4	CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684057	>	>	IC50	nM	25000.0	IC50	uM	25.0
2929	Inhibition of CYP3A4	CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684058	>	>	IC50	nM	25000.0	IC50	uM	25.0
2930	Inhibition of CYP3A4	CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684059	>	>	IC50	nM	5000.0	IC50	uM	5.0
2931	Inhibition of CYP3A4	N[C@H]1CN(c2ncnc(N3CCC(F)(F)C3)n2)C[C@@H]1N1CC(F)(F)CCC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683571	>	>	IC50	nM	15000.0	IC50	uM	15.0
2932	Inhibition of CYP3A4	Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683577	>	>	IC50	nM	30000.0	IC50	uM	30.0
2933	Inhibition of CYP3A4	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1614766	>	>	IC50	nM	100000.0	IC50	uM	100.0
2934	Inhibition of CYP3A4	Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1682999	=	=	IC50	nM	7300.0	IC50	uM	7.3
2935	Inhibition of CYP3A4	Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683000	>	>	IC50	nM	50000.0	IC50	uM	50.0
2936	Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH	Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1682999	=	=	IC50	nM	2700.0	IC50	uM	2.7
2937	Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH	Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683000	>	>	IC50	nM	50000.0	IC50	uM	50.0
2938	Inhibition of human CYP3A4	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683074	>	>	IC50	nM	25000.0	IC50	uM	25.0
2939	Inhibition of CYP3A4	CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C	ACS Med. Chem. Lett.	2010.0	CHEMBL1688243	>	>	IC50	nM	25000.0	IC50	uM	25.0
2940	Inhibition of CYP3A4	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c3c(N)ncnn32)C1	ACS Med. Chem. Lett.	2010.0	CHEMBL1667935	>	>	IC50	nM	25000.0	IC50	uM	25.0
2941	Mechanism based inhibition of human cytochrome P450 3A4	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL513494	=	=	Ki	nM	59000.0	KI	uM	59.0
2942	Mechanism based inhibition of human cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Curr. Drug Metab.	2005.0	CHEMBL163	=	=	Ki	nM	100.0	KI	uM	0.1
2943	Mechanism based inhibition of human cytochrome P450 3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Curr. Drug Metab.	2005.0	CHEMBL1741	=	=	Ki	nM	5490.0	KI	uM	5.49
2944	Mechanism based inhibition of human cytochrome P450 3A4	CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC	Curr. Drug Metab.	2005.0	CHEMBL481	=	=	Ki	nM	24000.0	KI	uM	24.0
2945	Mechanism based inhibition of human cytochrome P450 3A4	CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC	Curr. Drug Metab.	2005.0	CHEMBL837	=	=	Ki	nM	26000.0	KI	uM	26.0
2946	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL479701	=	=	Ki	nM	82.0	KI	uM	0.082
2947	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL469916	=	=	Ki	nM	54.0	KI	uM	0.054
2948	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL486597	=	=	Ki	nM	142.0	KI	uM	0.142
2949	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL242011	=	=	Ki	nM	373.0	KI	uM	0.373
2950	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL471067	=	=	Ki	nM	177.0	KI	uM	0.177
2951	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	CC1(C)O[C@H]2CC(=O)OC[C@@]23[C@H]1CC(=O)[C@]1(C)[C@@H]3CC[C@@]2(C)[C@H](c3ccoc3)OC(=O)[C@H]3O[C@]321	Curr. Drug Metab.	2005.0	CHEMBL517449	=	=	Ki	nM	23200.0	KI	uM	23.2
2952	Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12	Curr. Drug Metab.	2005.0	CHEMBL85139	=	=	Ki	nM	107700.0	KI	uM	107.7
2953	Mechanism based inhibition of human cytochrome P450 3A4 measured by BFC hydroxylation	COc1cc(C2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3OC2CO)ccc1O	Curr. Drug Metab.	2005.0	CHEMBL9509	=	=	Ki	nM	32000.0	KI	uM	32.0
2954	Mechanism based inhibition of human cytochrome P450 3A4 measured by DBF fluorescence	CC(O)CCC(=O)c1ccoc1	Curr. Drug Metab.	2005.0	CHEMBL1743358	=	=	Ki	nM	20000.0	KI	uM	20.0
2955	Mechanism based inhibition of human cytochrome P450 3A4 measured by N-demethylation of erythromycin	COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@](C)(O)[C@H]2OC(=O)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL404875	=	=	Ki	nM	399.0	KI	uM	0.399
2956	Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam 1'-hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL1743350	=	=	Ki	nM	12000.0	KI	uM	12.0
2957	Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam hydroxylase activity	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Curr. Drug Metab.	2005.0	CHEMBL23	=	=	Ki	nM	2200.0	KI	uM	2.2
2958	Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL513494	=	=	Ki	nM	5560.0	KI	uM	5.56
2959	Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C=C(C)C(CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12)OC(C)(C)C(O)CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL1743356	=	=	Ki	nM	310.0	KI	uM	0.31
2960	Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(OC(C)(C)C(O)CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL1743357	=	=	Ki	nM	130.0	KI	uM	0.13
2961	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC(C)CN(CC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNCc1cccc(F)c1)S(=O)(=O)c1cccc(N)c1	Curr. Drug Metab.	2005.0	CHEMBL1743352	=	=	Ki	nM	240.0	KI	uM	0.24
2962	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cnc3occc3c2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Curr. Drug Metab.	2005.0	CHEMBL2062137	=	=	Ki	nM	7500.0	KI	uM	7.5
2963	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C	Curr. Drug Metab.	2005.0	CHEMBL691	=	=	Ki	nM	18000.0	KI	uM	18.0
2964	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	Curr. Drug Metab.	2005.0	CHEMBL1276308	=	=	Ki	nM	4700.0	KI	uM	4.7
2965	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	C=C(C)N1c2ccccc2SC1c1cc(OC)ccc1OCCCN(C)CCOc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL1743364	=	=	Ki	nM	250.0	KI	uM	0.25
2966	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CNCCCC(C#N)(c1ccc(OC)c(OC)c1)C(C)C	Curr. Drug Metab.	2005.0	CHEMBL1743342	=	=	Ki	nM	7930.0	KI	uM	7.93
2967	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Curr. Drug Metab.	2005.0	CHEMBL23	=	=	Ki	nM	500.0	KI	uM	0.5
2968	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1	Curr. Drug Metab.	2005.0	CHEMBL165	=	=	Ki	nM	20000.0	KI	uM	20.0
2969	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL83	=	=	Ki	nM	200.0	KI	uM	0.2
2970	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL1743350	=	=	Ki	nM	2600.0	KI	uM	2.6
2971	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Curr. Drug Metab.	2005.0	CHEMBL139	=	=	Ki	nM	1640000.0	KI	uM	1640.0
2972	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL81	=	=	Ki	nM	9900.0	KI	uM	9.9
2973	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	COc1cc(C2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3OC2CO)ccc1O	Curr. Drug Metab.	2005.0	CHEMBL9509	=	=	Ki	nM	132000.0	KI	uM	132.0
2974	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation and erythromycin N-demethylation	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL1078442	=	=	Ki	nM	7700.0	KI	uM	7.7
2975	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	2110.0	KI	uM	2.11
2976	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL197	=	=	Ki	nM	5100.0	KI	uM	5.1
2977	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL36148	=	=	Ki	nM	1390.0	KI	uM	1.39
2978	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	5890.0	KI	uM	5.89
2979	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL197	=	=	Ki	nM	6460.0	KI	uM	6.46
2980	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL36148	=	=	Ki	nM	2970.0	KI	uM	2.97
2981	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone beta-hydroxylation	COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2cc3c(cc2CCN1C)OCO3	Curr. Drug Metab.	2005.0	CHEMBL1256919	=	=	Ki	nM	110000.0	KI	uM	110.0
2982	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Curr. Drug Metab.	2005.0	CHEMBL116	=	=	Ki	nM	260.0	KI	uM	0.26
2983	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Curr. Drug Metab.	2005.0	CHEMBL115	=	=	Ki	nM	480.0	KI	uM	0.48
2984	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	Curr. Drug Metab.	2005.0	CHEMBL729	=	=	Ki	nM	410.0	KI	uM	0.41
2985	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	Curr. Drug Metab.	2005.0	CHEMBL729	=	=	Ki	nM	1000.0	KI	uM	1.0
2986	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Curr. Drug Metab.	2005.0	CHEMBL584	=	=	Ki	nM	480.0	KI	uM	0.48
2987	Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	Curr. Drug Metab.	2005.0	CHEMBL114	=	=	Ki	nM	170.0	KI	uM	0.17
2988	Mechanism based inhibition of human cytochrome P450 3A4 using expressed CYP3A4 cDNA	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	10300.0	KI	uM	10.3
2989	Mechanism based inhibition of human cytochrome P450 3A4 was evaluated using S-mephenytoin	NNC(=O)c1ccncc1	Curr. Drug Metab.	2005.0	CHEMBL64	=	=	Ki	nM	36000.0	KI	uM	36.0
2990	Inhibition of CYP3A4	Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760794	=	=	IC50	nM	10000.0	IC50	uM	10.0
2991	Inhibition of CYP3A4	Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760809	=	=	IC50	nM	36000.0	IC50	uM	36.0
2992	Inhibition of CYP3A4	C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1738841	>	>	IC50	nM	15000.0	IC50	uM	15.0
2993	Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)CN3CCS(=O)(=O)CC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762427	>	>	IC50	nM	30000.0	IC50	uM	30.0
2994	Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)C3CCOCC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762293	>	>	IC50	nM	30000.0	IC50	uM	30.0
2995	Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)N3CCS(=O)(=O)CC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762429	>	>	IC50	nM	30000.0	IC50	uM	30.0
2996	Inhibition of CYP3A4 using 7-benzyloxyquinoline as a substrate	CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762808	>	>	IC50	nM	100000.0	IC50	uM	100.0
2997	Inhibition of CYP3A4 using dibenzylfluorescein as a substrate	CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762808	>	>	IC50	nM	100000.0	IC50	uM	100.0
2998	Inhibition of CYP3A4	CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760005	<	>	IC50	nM	3162.28	pIC50		5.5
2999	Inhibition of CYP3A4	CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760428	<	>	IC50	nM	3162.28	pIC50		5.5
3000	Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccccc3)n[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760200	>	>	IC50	nM	15000.0	IC50	uM	15.0
3001	Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760338	=	=	IC50	nM	8000.0	IC50	uM	8.0
3002	Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760205	=	=	IC50	nM	12000.0	IC50	uM	12.0
3003	Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760206	=	=	IC50	nM	20000.0	IC50	uM	20.0
3004	Inhibition of CYP3A4	CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL10188	=	=	IC50	nM	4000.0	IC50	uM	4.0
3005	Inhibition of CYP3A4	CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL346178	=	=	IC50	nM	1000.0	IC50	uM	1.0
3006	Inhibition of CYP3A4	CCN(C(C)=O)c1ccc(OC)c2nc(NC(=O)c3ccnn3C)sc12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1170367	>	>	IC50	nM	50000.0	IC50	uM	50.0
3007	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761518	=	=	IC50	nM	19600.0	IC50	uM	19.6
3008	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761519	=	=	IC50	nM	21600.0	IC50	uM	21.6
3009	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761520	=	=	IC50	nM	22700.0	IC50	uM	22.7
3010	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761521	=	=	IC50	nM	27600.0	IC50	uM	27.6
3011	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761522	=	=	IC50	nM	6300.0	IC50	uM	6.3
3012	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761523	>	>	IC50	nM	50000.0	IC50	uM	50.0
3013	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761524	=	=	IC50	nM	19300.0	IC50	uM	19.3
3014	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761525	>	>	IC50	nM	50000.0	IC50	uM	50.0
3015	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761530	>	>	IC50	nM	50000.0	IC50	uM	50.0
3016	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761531	>	>	IC50	nM	50000.0	IC50	uM	50.0
3017	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761532	>	>	IC50	nM	50000.0	IC50	uM	50.0
3018	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761533	>	>	IC50	nM	50000.0	IC50	uM	50.0
3019	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761534	>	>	IC50	nM	50000.0	IC50	uM	50.0
3020	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761535	>	>	IC50	nM	50000.0	IC50	uM	50.0
3021	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761536	>	>	IC50	nM	50000.0	IC50	uM	50.0
3022	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761673	>	>	IC50	nM	50000.0	IC50	uM	50.0
3023	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761674	>	>	IC50	nM	50000.0	IC50	uM	50.0
3024	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761518	=	=	IC50	nM	1400.0	IC50	uM	1.4
3025	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761519	=	=	IC50	nM	2400.0	IC50	uM	2.4
3026	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761520	=	=	IC50	nM	1400.0	IC50	uM	1.4
3027	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761521	=	=	IC50	nM	1600.0	IC50	uM	1.6
3028	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761522	=	=	IC50	nM	2400.0	IC50	uM	2.4
3029	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761523	=	=	IC50	nM	5600.0	IC50	uM	5.6
3030	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761524	=	=	IC50	nM	1400.0	IC50	uM	1.4
3031	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761525	>	>	IC50	nM	50000.0	IC50	uM	50.0
3032	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761530	>	>	IC50	nM	50000.0	IC50	uM	50.0
3033	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761531	>	>	IC50	nM	50000.0	IC50	uM	50.0
3034	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761532	>	>	IC50	nM	50000.0	IC50	uM	50.0
3035	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761533	>	>	IC50	nM	50000.0	IC50	uM	50.0
3036	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761534	>	>	IC50	nM	50000.0	IC50	uM	50.0
3037	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761535	>	>	IC50	nM	50000.0	IC50	uM	50.0
3038	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761536	>	>	IC50	nM	50000.0	IC50	uM	50.0
3039	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761673	>	>	IC50	nM	50000.0	IC50	uM	50.0
3040	Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761674	>	>	IC50	nM	50000.0	IC50	uM	50.0
3041	Inhibition of CYP3A4	CC1COc2ccccc2N1C(=O)N1CCC(c2c[nH]cn2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761843	<	<	IC50	nM	1000.0	IC50	uM	1.0
3042	Inhibition of CYP3A4	O=C(N1CCC(c2c[nH]cn2)CC1)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761844	<	<	IC50	nM	1000.0	IC50	uM	1.0
3043	Inhibition of CYP3A4	O=C(N1CCC(c2cn[nH]c2)CC1)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761848	>	>	IC50	nM	10000.0	IC50	uM	10.0
3044	Inhibition of CYP3A4	Cn1cc(C2CCN(C(=O)N3CCCc4ccccc43)CC2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761849	>	>	IC50	nM	10000.0	IC50	uM	10.0
3045	Inhibition of human CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
3046	Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1	J. Med. Chem.	2011.0	CHEMBL1766005	=	=	IC50	nM	8000.0	IC50	uM	8.0
3047	Inhibition of CYP3A4 in human liver microsomes	C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C	J. Med. Chem.	2011.0	CHEMBL517438	=	=	IC50	nM	11000.0	IC50	uM	11.0
3048	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccccc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766169	=	=	IC50	nM	1200.0	IC50	nM	1200.0
3049	Inhibition of human CYP3A4 after 30 mins	COc1ccc(-c2cccc(C(O)(c3c[nH]cn3)C(C)C)c2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1765101	=	=	IC50	nM	2000.0	IC50	nM	2000.0
3050	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccc(F)cc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766170	=	=	IC50	nM	2100.0	IC50	nM	2100.0
3051	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccc(Cl)cc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766171	=	=	IC50	nM	2400.0	IC50	nM	2400.0
3052	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccccc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766172	=	=	IC50	nM	3700.0	IC50	nM	3700.0
3053	Inhibition of human CYP3A4 after 30 mins	COc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1766173	=	=	IC50	nM	4900.0	IC50	nM	4900.0
3054	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccc(F)cc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766174	=	=	IC50	nM	5300.0	IC50	nM	5300.0
3055	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccc(Cl)cc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766175	=	=	IC50	nM	7600.0	IC50	nM	7600.0
3056	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766176	=	=	IC50	nM	7100.0	IC50	nM	7100.0
3057	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1766177	=	=	IC50	nM	1000.0	IC50	nM	1000.0
3058	Inhibition of human CYP3A4 after 30 mins	CNC(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766178	=	=	IC50	nM	8100.0	IC50	nM	8100.0
3059	Inhibition of human CYP3A4 after 30 mins	CNS(=O)(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766179	=	=	IC50	nM	3300.0	IC50	nM	3300.0
3060	Inhibition of human CYP3A4 after 30 mins	CNC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766180	=	=	IC50	nM	5500.0	IC50	nM	5500.0
3061	Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccccn2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766181	=	=	IC50	nM	5200.0	IC50	nM	5200.0
3062	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766182	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3063	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(C)(O)c3c[nH]cn3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766183	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3064	Inhibition of human CYP3A4 after 30 mins	CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766184	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3065	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C3CC3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766185	=	=	IC50	nM	5500.0	IC50	nM	5500.0
3066	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)c3c[nH]cn3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766186	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3067	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@](O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766187	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3068	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766188	=	=	IC50	nM	6700.0	IC50	nM	6700.0
3069	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@](O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3070	Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3071	Inhibition of human CYP3A4 after 30 mins	CC[C@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3072	Inhibition of human CYP3A4 after 30 mins	CC[C@@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766192	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3073	Inhibition of human CYP3A4 after 30 mins	COc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766193	<	<	IC50	nM	1000.0	IC50	nM	1000.0
3074	Inhibition of CYP3A4	Nc1ncc(-c2ccccc2)nc1C(=O)Nc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1766759	>	>	IC50	nM	100000.0	IC50	uM	100.0
3075	Inhibition of CYP3A4	Nc1ncc(-c2cccnc2)nc1C(=O)Nc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1765107	=	=	IC50	nM	2000.0	IC50	uM	2.0
3076	Inhibition of CYP3A4	O=C(Nc1ccc(C2CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC2)cc1)c1nc(-c2ccccc2)oc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1766811	>	>	IC50	nM	50000.0	IC50	uM	50.0
3077	Inhibition of human CYP3A4	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21	J. Med. Chem.	2011.0	CHEMBL1230122	>	>	IC50	nM	40000.0	IC50	uM	40.0
3078	Inhibition of human CYP3A4	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21	J. Med. Chem.	2011.0	CHEMBL1090089	>	>	IC50	nM	29000.0	IC50	uM	29.0
3079	Inhibition of CYP3A4 in human liver microsomes	O=C1CC(=O)N(CCc2ccccc2)C(=O)N1CCc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1412368	>	>	IC50	nM	50000.0	IC50	uM	50.0
3080	Inhibition of CYP3A4	O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1	J. Med. Chem.	2011.0	CHEMBL1767164	=	=	IC50	nM	300.0	IC50	uM	0.3
3081	Inhibition of CYP3A4	c1ccc(Cc2ncc3c(n2)CCNCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1770373	>	>	IC50	nM	30000.0	IC50	nM	30000.0
3082	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NC13CC(C1)C3)C2	J. Med. Chem.	2011.0	CHEMBL1774924	=	=	IC50	nM	1100.0	IC50	uM	1.1
3083	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774926	=	=	IC50	nM	1900.0	IC50	uM	1.9
3084	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)c2C1	J. Med. Chem.	2011.0	CHEMBL1738805	=	=	IC50	nM	3300.0	IC50	uM	3.3
3085	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)n1)CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774930	=	=	IC50	nM	800.0	IC50	uM	0.8
3086	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774931	=	=	IC50	nM	1400.0	IC50	uM	1.4
3087	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)c2C1	J. Med. Chem.	2011.0	CHEMBL1774932	=	=	IC50	nM	600.0	IC50	uM	0.6
3088	Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774933	=	=	IC50	nM	4700.0	IC50	uM	4.7
3089	Inhibition of CYP3A4	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774933	>	>	IC50	nM	30000.0	IC50	uM	30.0
3090	Inhibition of CYP3A4	Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778587	=	=	IC50	nM	8700.0	IC50	uM	8.7
3091	Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778481	=	=	IC50	nM	8900.0	IC50	uM	8.9
3092	Inhibition of human CYP3A4	COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823817	>	>	IC50	nM	30000.0	IC50	uM	30.0
3093	Inhibition of CYP3A4	COc1ccc(CN2CCN(C(=O)C[C@H](N)Cc3cc(F)c(F)cc3F)CC2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779699	=	=	IC50	nM	1075.0	IC50	nM	1075.0
3094	Inhibition of CYP3A4	Cc1c(Nc2ccc(C#N)cc2Cl)ncnc1O[C@@H]1C[C@@H]2CC[C@H](C1)N2S(=O)(=O)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL3084389	>	>	IC50	nM	20000.0	IC50	uM	20.0
3095	Inhibition of CYP3A4	CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777861	>	>	IC50	nM	50000.0	IC50	uM	50.0
3096	Inhibition of CYP3A4	CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777855	>	>	IC50	nM	50000.0	IC50	uM	50.0
3097	Inhibition of CYP3A4	CC#C[C@@H](c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)[C@H]1OC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777878	>	>	IC50	nM	50000.0	IC50	uM	50.0
3098	Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777958	>	>	IC50	nM	30000.0	IC50	uM	30.0
3099	Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777976	>	>	IC50	nM	30000.0	IC50	uM	30.0
3100	Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777979	=	=	IC50	nM	2200.0	IC50	uM	2.2
3101	Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777958	>	>	IC50	nM	30000.0	IC50	uM	30.0
3102	Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777976	>	>	IC50	nM	30000.0	IC50	uM	30.0
3103	Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777979	>	>	IC50	nM	30000.0	IC50	uM	30.0
3104	Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
3105	Inhibition of CYP3A4	C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778387	>	>	IC50	nM	50000.0	IC50	uM	50.0
3106	Inhibition of CYP3A4	CN(C(=O)C1(c2ccc(F)cc2)CCCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778388	=	=	IC50	nM	37000.0	IC50	uM	37.0
3107	Inhibition of CYP3A4	CN(C(=O)Cc1ccc(F)cc1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778506	>	>	IC50	nM	50000.0	IC50	uM	50.0
3108	Inhibition of CYP3A4	CN(C(=O)C1(c2ccc(F)cc2)CCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778524	>	>	IC50	nM	50000.0	IC50	uM	50.0
3109	Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC2CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779003	>	>	IC50	nM	20000.0	IC50	uM	20.0
3110	Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNCC2CC2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778865	>	>	IC50	nM	20000.0	IC50	uM	20.0
3111	Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC(=O)c2cnccn2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779012	>	>	IC50	nM	20000.0	IC50	uM	20.0
3112	Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779013	>	>	IC50	nM	20000.0	IC50	uM	20.0
3113	Iinhibition of CYP3A4	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL17350	>	>	IC50	nM	20000.0	IC50	uM	20.0
3114	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)ccc2OCC(=O)O)c(C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778639	>	>	IC50	nM	50000.0	IC50	uM	50.0
3115	Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C(=O)C3CCC3)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784345	>	>	IC50	nM	10000.0	IC50	uM	10.0
3116	Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCC(F)(F)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784346	>	>	IC50	nM	10000.0	IC50	uM	10.0
3117	Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCS(=O)(=O)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784347	>	>	IC50	nM	10000.0	IC50	uM	10.0
3118	Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCOC(C)(C)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784350	>	>	IC50	nM	10000.0	IC50	uM	10.0
3119	Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784351	>	>	IC50	nM	10000.0	IC50	uM	10.0
3120	Inhibition of CYP3A4	CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784368	=	=	IC50	nM	1000.0	IC50	uM	1.0
3121	Inhibition of CYP3A4	CC(C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784354	>	>	IC50	nM	10000.0	IC50	uM	10.0
3122	Inhibition of CYP3A4	O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784355	=	=	IC50	nM	1900.0	IC50	uM	1.9
3123	Inhibition of CYP3A4	CN1CCC(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)(N(O)C=O)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784356	>	>	IC50	nM	10000.0	IC50	uM	10.0
3124	Inhibition of CYP3A4	O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCOCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784357	>	>	IC50	nM	10000.0	IC50	uM	10.0
3125	Inhibition of CYP3A4	CCc1c(C)nc(-c2ccc(F)s2)nc1Nc1ccc(CC(=O)O)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1782308	>	>	IC50	nM	10000.0	IC50	uM	10.0
3126	Inhibition of CYP3A4	CCc1c(C)nc(-c2ccc(Cl)s2)nc1Nc1ccc(CC(=O)O)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1782306	>	>	IC50	nM	10000.0	IC50	uM	10.0
3127	Inhibition of CYP3A4 in human liver microsomes	O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782521	>	>	IC50	nM	10000.0	IC50	uM	10.0
3128	Inhibition of CYP3A4 in human liver microsomes	N[C@H]1CC[C@@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782530	>	>	IC50	nM	10000.0	IC50	uM	10.0
3129	Inhibition of CYP3A4 in human liver microsomes	N[C@H]1CC[C@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782531	>	>	IC50	nM	10000.0	IC50	uM	10.0
3130	Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1	J. Med. Chem.	2009.0	CHEMBL1232887	<	>	IC50	nM	100000.0	pIC50		4.0
3131	Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1	J. Med. Chem.	2009.0	CHEMBL1784172	<	>	IC50	nM	63095.73	pIC50		4.2
3132	Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1	J. Med. Chem.	2009.0	CHEMBL1088752	<=	>=	IC50	nM	79432.82	pIC50		4.1
3133	Inhibition of CYP3A4	O=C(NCc1ccncc1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796296	>	<	IC50	nM	10000.0	pIC50		5.0
3134	Inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796298	<	>	IC50	nM	10000.0	pIC50		5.0
3135	Time dependent inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796298	<	>	IC50	nM	50118.72	pIC50		4.3
3136	Reversible inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	6500.0	IC50	nM	6500.0
3137	Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	16000.0	IC50	nM	16000.0
3138	Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	20000.0	IC50	nM	20000.0
3139	Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CC(F)(F)C3)nc3nccnc32)c2cccc(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801062	=	=	EC50	nM	23000.0	EC50	uM	23.0
3140	Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2ccc(F)c(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801504	>	>	EC50	nM	100000.0	EC50	uM	100.0
3141	Inhibition of human CYP3A4	CC(C)Cc1nc2nccnc2n1Cc1cc(=O)[nH]c2c(F)c(F)ccc12	J. Med. Chem.	2010.0	CHEMBL1801506	>	>	EC50	nM	60000.0	EC50	uM	60.0
3142	Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2cccc(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801060	>	>	EC50	nM	60000.0	EC50	uM	60.0
3143	Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc5cc(F)ccc5n4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801250	=	=	IC50	nM	10000.0	IC50	uM	10.0
3144	Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc(Cl)cc4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801238	>	>	IC50	nM	50000.0	IC50	uM	50.0
3145	Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc5ccccc5c4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801233	>	>	IC50	nM	50000.0	IC50	uM	50.0
3146	Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NS(=O)(=O)c4ccc5ccccc5c4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801172	=	=	IC50	nM	10000.0	IC50	uM	10.0
3147	Inhibition of CYP3A4	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1	J. Med. Chem.	2011.0	CHEMBL1822792	=	=	IC50	nM	7100.0	IC50	uM	7.1
3148	Inhibition of CYP3A4	CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1	J. Med. Chem.	2011.0	CHEMBL1803004	>	>	IC50	nM	50000.0	IC50	uM	50.0
3149	Inhibition of CYP3A4 using diethoxyflourescein as a substrate	Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1801364	=	=	IC50	nM	5500.0	IC50	uM	5.5
3150	Inhibition of CYP3A4	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1800911	>	>	IC50	nM	25000.0	IC50	uM	25.0
3151	Inhibition of CYP 3A4	CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1	J. Med. Chem.	2011.0	CHEMBL1800774	>	>	IC50	nM	8900.0	IC50	uM	8.9
3152	Inhibition of CYP 3A4	CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1	J. Med. Chem.	2011.0	CHEMBL1800137	>	>	IC50	nM	8900.0	IC50	uM	8.9
3153	Inhibition of CYP 3A4	NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1	J. Med. Chem.	2011.0	CHEMBL601821	>	>	IC50	nM	10000.0	IC50	uM	10.0
3154	Inhibition of CYP3A4	CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808424	=	=	IC50	nM	14700.0	IC50	uM	14.7
3155	Inhibition of CYP3A4	Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1807440	=	=	IC50	nM	470.0	IC50	nM	470.0
3156	Inhibition of CYP3A4	O=C(CCCCCCC(=O)Nc1ccccc1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL98	>	>	IC50	nM	10000.0	IC50	uM	10.0
3157	Inhibition of CYP3A4	O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL408513	>	>	IC50	nM	10000.0	IC50	uM	10.0
3158	Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL27759	=	=	IC50	nM	730.0	IC50	uM	0.73
3159	Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL272980	=	=	IC50	nM	570.0	IC50	uM	0.57
3160	Inhibition of CYP3A4	O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL356066	=	=	IC50	nM	14000.0	IC50	uM	14.0
3161	Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(C(=O)Cc1ccccc1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808624	>	>	IC50	nM	50000.0	IC50	uM	50.0
3162	Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(S(=O)(=O)c1cccs1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808631	>	>	IC50	nM	50000.0	IC50	uM	50.0
3163	Inhibition of CYP3A4	COc1ccc(S(=O)(=O)N2Cc3ccc(/C=C/C(=O)NO)cc3C2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808640	>	>	IC50	nM	50000.0	IC50	uM	50.0
3164	Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCC1CCCCC1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808643	>	>	IC50	nM	50000.0	IC50	uM	50.0
3165	Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCc1c[nH]c3ccccc13)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808644	>	>	IC50	nM	10000.0	IC50	uM	10.0
3166	Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCc1cnn3ccccc13)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808645	>	>	IC50	nM	50000.0	IC50	uM	50.0
3167	Inhibition of CYP3A4	Cc1[nH]c2ccccc2c1CCN1Cc2ccc(/C=C/C(=O)NO)cc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1088949	>	>	IC50	nM	10000.0	IC50	uM	10.0
3168	Inhibition of CYP3A4	CCCCN1C(=O)C(C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1813459	=	=	IC50	nM	9300.0	IC50	uM	9.3
3169	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813314	=	=	IC50	nM	6500.0	IC50	uM	6.5
3170	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813315	=	=	IC50	nM	5280.0	IC50	uM	5.28
3171	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813471	=	=	IC50	nM	8390.0	IC50	uM	8.39
3172	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813472	=	=	IC50	nM	12800.0	IC50	uM	12.8
3173	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813316	>	>	IC50	nM	5000.0	IC50	uM	5.0
3174	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813317	>	>	IC50	nM	5000.0	IC50	uM	5.0
3175	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813478	=	=	IC50	nM	12700.0	IC50	uM	12.7
3176	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813484	>	>	IC50	nM	25000.0	IC50	uM	25.0
3177	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813474	=	=	IC50	nM	9170.0	IC50	uM	9.17
3178	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813475	>	>	IC50	nM	5000.0	IC50	uM	5.0
3179	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1	J. Med. Chem.	2011.0	CHEMBL1813476	=	=	IC50	nM	2650.0	IC50	uM	2.65
3180	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1	J. Med. Chem.	2011.0	CHEMBL1813477	=	=	IC50	nM	10700.0	IC50	uM	10.7
3181	Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090176	>	>	IC50	nM	10000.0	IC50	uM	10.0
3182	Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090526	>	>	IC50	nM	10000.0	IC50	uM	10.0
3183	Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092662	>	>	IC50	nM	10000.0	IC50	uM	10.0
3184	Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL556506	>	>	IC50	nM	10000.0	IC50	uM	10.0
3185	Inhibition of CYP3A4	C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL564144	>	>	IC50	nM	10000.0	IC50	uM	10.0
3186	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1.Cl	J. Med. Chem.	2011.0	CHEMBL1813067	>	>	IC50	nM	30000.0	IC50	uM	30.0
3187	Inhibition of CYP3A4	C[C@@]12CN(C(=O)Nc3ccnn3-c3ccccc3)CCN1C(=O)N([C@H]1C[C@@H]1c1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1813114	>	>	IC50	nM	40000.0	IC50	uM	40.0
3188	Inhibition of CYP3A4	CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)c2cc(-c3cccc(CN)c3)nc3ccccc23)CC1	Bioorg. Med. Chem.	2011.0	CHEMBL1818291	=	=	IC50	nM	2400.0	IC50	uM	2.4
3189	Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818445	>	>	IC50	nM	6000.0	IC50	uM	6.0
3190	Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818451	>	>	IC50	nM	10000.0	IC50	uM	10.0
3191	Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	Bioorg. Med. Chem.	2011.0	CHEMBL1818452	>	>	IC50	nM	10000.0	IC50	uM	10.0
3192	Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818455	>	>	IC50	nM	8000.0	IC50	uM	8.0
3193	Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818543	>	>	IC50	nM	25000.0	IC50	uM	25.0
3194	Inhibition of CYP3A4 in human liver microsomes pre-incubated for 15 mins by LC/MS/MS analysis	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819089	=	=	Ki	nM	0.026	Ki	nM	0.026
3195	Inhibition of CYP3A4 in human liver microsomes pre-incubated for 15 mins by LC/MS/MS analysis	CC[C@@]1(N)CCCN(c2cc3c(c(=O)n(C)c(=O)n3C)n2Cc2cc(F)ccc2C#N)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1819091	=	=	Ki	nM	0.022	Ki	nM	0.022
3196	Inhibition of CYP3A4	Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819090	>	>	IC50	nM	50000.0	IC50	uM	50.0
3197	Inhibition of CYP3A4	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819089	=	=	IC50	nM	1600.0	IC50	uM	1.6
3198	Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin	CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825089	=	=	IC50	nM	40.0	IC50	uM	0.04
3199	Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline	CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825089	=	=	IC50	nM	40.0	IC50	uM	0.04
3200	Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin	CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825096	>	>	IC50	nM	10000.0	IC50	uM	10.0
3201	Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline	CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825096	>	>	IC50	nM	10000.0	IC50	uM	10.0
3202	Inhibition of CYP3A4 using DEF substrate	CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1821837	=	=	IC50	nM	45000.0	IC50	uM	45.0
3203	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1821837	>	>	IC50	nM	100000.0	IC50	uM	100.0
3204	Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1.Cl.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3217170	>	>	IC50	nM	20000.0	IC50	uM	20.0
3205	Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1.Cl.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215850	>	>	IC50	nM	20000.0	IC50	uM	20.0
3206	Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215864	>	>	IC50	nM	20000.0	IC50	uM	20.0
3207	Inhibition of CYP3A4	Cn1nc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)ccc1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823410	>	>	IC50	nM	30000.0	IC50	uM	30.0
3208	Inhibition of CYP3A4	O=C(Nc1ccccc1Cl)N1CCN(c2nc(-c3ccc4ccccc4n3)no2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823591	>	>	IC50	nM	25000.0	IC50	uM	25.0
3209	Inhibition of CYP3A4	COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12	J. Med. Chem.	2011.0	CHEMBL1822515	=	=	IC50	nM	9400.0	IC50	uM	9.4
3210	Inhibition of CYP3A4	CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1821735	=	=	IC50	nM	14600.0	IC50	uM	14.6
3211	Inhibition of CYP3A4	COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1	J. Med. Chem.	2011.0	CHEMBL1822525	>	>	IC50	nM	12000.0	IC50	uM	12.0
3212	Inhibition of CYP3A4	c1cc([C@H]2CC[C@H](N3CCOCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824241	=	=	IC50	nM	66200.0	IC50	uM	66.2
3213	Inhibition of CYP3A4	c1cc([C@H]2CC[C@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824235	=	=	IC50	nM	48000.0	IC50	uM	48.0
3214	Inhibition of CYP3A4	c1cc([C@H]2CC[C@@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824234	=	=	IC50	nM	41700.0	IC50	uM	41.7
3215	Inhibition of CYP3A4	CN(C)[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824231	=	=	IC50	nM	42600.0	IC50	uM	42.6
3216	Inhibition of CYP3A4	CN(C)[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824230	=	=	IC50	nM	50000.0	IC50	uM	50.0
3217	Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1	J. Med. Chem.	2011.0	CHEMBL1766005	<	<	IC50	nM	100.0	IC50	uM	0.1
3218	Inhibition of CYP3A4 in human liver microsomes	C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C	J. Med. Chem.	2011.0	CHEMBL517438	=	=	IC50	nM	350.0	IC50	uM	0.35
3219	Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1	J. Med. Chem.	2011.0	CHEMBL1831092	=	=	IC50	nM	330.0	IC50	uM	0.33
3220	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(-c3ncccn3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829472	>	>	IC50	nM	30000.0	IC50	uM	30.0
3221	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829477	>	>	IC50	nM	30000.0	IC50	uM	30.0
3222	Inhibition of CYP3A4	C[C@H](COc1ccc(-c2ccc(=O)n(C)n2)cc1)CN1CCC[C@H]1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829485	>	>	IC50	nM	30000.0	IC50	uM	30.0
3223	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829777	>	>	IC50	nM	30000.0	IC50	uM	30.0
3224	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829769	>	>	IC50	nM	30000.0	IC50	uM	30.0
3225	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829764	>	>	IC50	nM	30000.0	IC50	uM	30.0
3226	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829768	=	=	IC50	nM	21000.0	IC50	uM	21.0
3227	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829759	=	=	IC50	nM	14000.0	IC50	uM	14.0
3228	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(N)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829776	=	=	IC50	nM	12000.0	IC50	uM	12.0
3229	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829763	=	=	IC50	nM	12000.0	IC50	uM	12.0
3230	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829761	=	=	IC50	nM	11000.0	IC50	uM	11.0
3231	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829775	=	=	IC50	nM	9000.0	IC50	uM	9.0
3232	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2F)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829765	=	=	IC50	nM	6000.0	IC50	uM	6.0
3233	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829767	=	=	IC50	nM	8000.0	IC50	uM	8.0
3234	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829782	=	=	IC50	nM	7000.0	IC50	uM	7.0
3235	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2cccc(F)c2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829766	=	=	IC50	nM	7000.0	IC50	uM	7.0
3236	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829772	=	=	IC50	nM	5000.0	IC50	uM	5.0
3237	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829780	=	=	IC50	nM	4000.0	IC50	uM	4.0
3238	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCN)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829770	=	=	IC50	nM	3000.0	IC50	uM	3.0
3239	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CC[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829762	=	=	IC50	nM	1500.0	IC50	uM	1.5
3240	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CNC(=O)NCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1	J. Med. Chem.	2011.0	CHEMBL1829773	=	=	IC50	nM	1000.0	IC50	uM	1.0
3241	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CNC(=O)NCCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1	J. Med. Chem.	2011.0	CHEMBL1829781	=	=	IC50	nM	600.0	IC50	uM	0.6
3242	Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCN)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829779	=	=	IC50	nM	2000.0	IC50	uM	2.0
3243	Inhibition of human recombinant CYP3A4	Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1	J. Med. Chem.	2011.0	CHEMBL1829433	>	>	IC50	nM	10000.0	IC50	uM	10.0
3244	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215861	=	=	IC50	nM	2730.0	IC50	uM	2.73
3245	Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215861	>	>	IC50	nM	25000.0	IC50	uM	25.0
3246	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21	J. Med. Chem.	2011.0	CHEMBL1830397	=	=	IC50	nM	2280.0	IC50	uM	2.28
3247	Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21	J. Med. Chem.	2011.0	CHEMBL1830397	>	>	IC50	nM	25000.0	IC50	uM	25.0
3248	Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C	J. Med. Chem.	2011.0	CHEMBL1830424	=	=	IC50	nM	330.0	IC50	uM	0.33
3249	Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C	J. Med. Chem.	2011.0	CHEMBL1830424	>	>	IC50	nM	25000.0	IC50	uM	25.0
3250	Inhibition of CYP3A4	CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837037	>	>	IC50	nM	30000.0	IC50	uM	30.0
3251	Inhibition of CYP3A4	COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837038	>	>	IC50	nM	30000.0	IC50	uM	30.0
3252	Inhibition of CYP3A4	CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837040	>	>	IC50	nM	30000.0	IC50	uM	30.0
3253	Inhibition of CYP3A4	CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837041	>	>	IC50	nM	30000.0	IC50	uM	30.0
3254	Inhibition of CYP3A4	CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1836317	=	=	IC50	nM	4100.0	IC50	uM	4.1
3255	Inhibition of CYP 3A4	CCN/C(=N\S(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1	J. Med. Chem.	2011.0	CHEMBL1834345	<	>	IC50	nM	10000.0	pIC50		5.0
3256	Inhibition of CYP3A4	Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1834793	=	=	IC50	nM	6800.0	IC50	uM	6.8
3257	Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc1ccc(-c2cncc(F)c2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2011.0	CHEMBL1835487	=	=	IC50	nM	140.0	IC50	uM	0.14
3258	Inhibition of CYP3A4 using vivid red as substrate	Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2	J. Med. Chem.	2011.0	CHEMBL1836215	=	=	IC50	nM	15300.0	IC50	uM	15.3
3259	Inhibition of CYP3A4 using vivid green as substrate	Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2	J. Med. Chem.	2011.0	CHEMBL1836215	=	=	IC50	nM	8400.0	IC50	uM	8.4
3260	Inhibition of CYP3A4 using BFC as substrate	CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142316	=	=	IC50	nM	74800.0	IC50	uM	74.8
3261	Inhibition of CYP3A4 using BFC as substrate	Cl.Cl.N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3142317	=	=	IC50	nM	100000.0	IC50	uM	100.0
3262	Inhibition of CYP3A4 using BQ as substrate	CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142316	>	>	IC50	nM	100000.0	IC50	uM	100.0
3263	Inhibition of CYP3A4 using BQ as substrate	Cl.Cl.N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3142317	>	>	IC50	nM	100000.0	IC50	uM	100.0
3264	Inhibition of human CYP3A4	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1834184	>	>	IC50	nM	10000.0	IC50	uM	10.0
3265	Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834663	=	=	IC50	nM	2500.0	IC50	uM	2.5
3266	Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834662	>	>	IC50	nM	10000.0	IC50	uM	10.0
3267	Inhibition of CYP3A4 using DBF as substrate	CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1834661	=	=	IC50	nM	6000.0	IC50	uM	6.0
3268	Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834660	>	>	IC50	nM	10000.0	IC50	uM	10.0
3269	Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834659	=	=	IC50	nM	2500.0	IC50	uM	2.5
3270	Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834658	>	>	IC50	nM	10000.0	IC50	uM	10.0
3271	Inhibition of CYP3A4 using DBF as substrate	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O	J. Med. Chem.	2011.0	CHEMBL1834657	>	>	IC50	nM	10000.0	IC50	uM	10.0
3272	Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834663	<	<	IC50	nM	100.0	IC50	uM	0.1
3273	Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834662	=	=	IC50	nM	500.0	IC50	uM	0.5
3274	Inhibition of CYP3A4 using BFC as substrate	CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1834661	=	=	IC50	nM	1200.0	IC50	uM	1.2
3275	Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834660	=	=	IC50	nM	1000.0	IC50	uM	1.0
3276	Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834659	>	>	IC50	nM	10000.0	IC50	uM	10.0
3277	Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834658	=	=	IC50	nM	1100.0	IC50	uM	1.1
3278	Inhibition of CYP3A4 using BFC as substrate	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O	J. Med. Chem.	2011.0	CHEMBL1834657	>	>	IC50	nM	10000.0	IC50	uM	10.0
3279	Inhibition of CYP3A4	NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12	J. Med. Chem.	2011.0	CHEMBL1835153	>	>	IC50	nM	75000.0	IC50	uM	75.0
3280	Inhibition of CYP3A4	CC(C)n1nc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)c2sccc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835772	>	>	IC50	nM	30000.0	IC50	uM	30.0
3281	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835782	>	>	IC50	nM	30000.0	IC50	uM	30.0
3282	Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835783	>	>	IC50	nM	30000.0	IC50	uM	30.0
3283	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NN(C)C(=O)C3CCCC23)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835784	>	>	IC50	nM	30000.0	IC50	uM	30.0
3284	Inhibition of CYP3A4	CN1N=C(c2ccc(OCCCN3CCCCC3)cc2)C2CCCC2C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835785	>	>	IC50	nM	30000.0	IC50	uM	30.0
3285	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835786	>	>	IC50	nM	30000.0	IC50	uM	30.0
3286	Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCCC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835787	>	>	IC50	nM	30000.0	IC50	uM	30.0
3287	Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2ccccc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835706	>	>	IC50	nM	30000.0	IC50	uM	30.0
3288	Inhibition of CYP3A4	Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835918	<	>	IC50	nM	10000.0	pIC50		5.0
3289	Time dependent inhibition of CYP3A4	Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835918	<	>	IC50	nM	50118.72	pIC50		4.3
3290	Inhibition of CYP3A4	Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL29609	=	=	IC50	nM	6309.57	pIC50		5.2
3291	Time dependent inhibition of CYP3A4	Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL29609	<	>	IC50	nM	50118.72	pIC50		4.3
3292	Mechanism based inhibition of human cytochrome P450 CYP3A4 measured by 7BFC O-debenzylation	CC1(C)C=Cc2c(ccc3c2OC[C@@H](c2ccc(O)cc2O)C3)O1	Curr. Drug Metab.	2005.0	CHEMBL480477	=	=	Ki	nM	7000.0	ki	uM	7.0
3293	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1			CHEMBL1016	=	=	IC50	nM	9000.0	IC50	uM	9.0
3294	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL493	=	=	IC50	nM	2000.0	IC50	uM	2.0
3295	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL1403281	=	=	IC50	nM	600.0	IC50	uM	0.6
3296	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1			CHEMBL116	=	=	IC50	nM	1000.0	IC50	uM	1.0
3297	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]			CHEMBL64894	=	=	IC50	nM	3633.7	IC50	uM	3.6337
3298	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1			CHEMBL808	=	=	IC50	nM	50.0	IC50	uM	0.05
3299	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL1385840	=	=	IC50	nM	500.0	IC50	uM	0.5
3300	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O			CHEMBL252556	=	=	IC50	nM	7000.0	IC50	uM	7.0
3301	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21			CHEMBL442	=	=	IC50	nM	1000.0	IC50	uM	1.0
3302	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC			CHEMBL1729	=	=	IC50	nM	300.0	IC50	uM	0.3
3303	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O			CHEMBL12131	=	=	IC50	nM	5000.0	IC50	uM	5.0
3304	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O			CHEMBL1255837	=	=	IC50	nM	3000.0	IC50	uM	3.0
3305	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1			CHEMBL104	=	=	IC50	nM	16.0	IC50	uM	0.016
3306	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21			CHEMBL1732	=	=	IC50	nM	5000.0	IC50	uM	5.0
3307	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1			CHEMBL23	=	=	IC50	nM	1836.6	IC50	uM	1.8366
3308	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O			CHEMBL3545252	=	=	IC50	nM	2000.0	IC50	uM	2.0
3309	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	NNCCc1ccccc1			CHEMBL1089	=	=	IC50	nM	2000.0	IC50	uM	2.0
3310	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC			CHEMBL61	=	=	IC50	nM	600.0	IC50	uM	0.6
3311	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1			CHEMBL1262	=	=	IC50	nM	90.0	IC50	uM	0.09
3312	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C			CHEMBL584	=	=	IC50	nM	2000.0	IC50	uM	2.0
3313	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	NNc1ccccc1			CHEMBL456807	=	=	IC50	nM	900.0	IC50	uM	0.9
3314	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CNCCCC12CCC(c3ccccc31)c1ccccc12			CHEMBL21731	=	=	IC50	nM	4322.0	IC50	uM	4.322
3315	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O			CHEMBL64391	=	=	IC50	nM	900.0	IC50	uM	0.9
3316	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1			CHEMBL91	=	=	IC50	nM	100.0	IC50	uM	0.1
3317	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS			CHEMBL1221512	=	=	IC50	nM	3000.0	IC50	uM	3.0
3318	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O			CHEMBL115	=	=	IC50	nM	400.0	IC50	uM	0.4
3319	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1			CHEMBL60889	=	=	IC50	nM	700.0	IC50	uM	0.7
3320	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C(=O)c1cccnc1)c1cccnc1			CHEMBL934	=	=	IC50	nM	800.0	IC50	uM	0.8
3321	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1			CHEMBL157101	=	=	IC50	nM	16.0	IC50	uM	0.016
3322	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C			CHEMBL460291	=	=	IC50	nM	900.0	IC50	uM	0.9
3323	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2			CHEMBL553025	=	=	IC50	nM	1000.0	IC50	uM	1.0
3324	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C			CHEMBL413	=	=	IC50	nM	2000.0	IC50	uM	2.0
3325	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC			CHEMBL269732	=	=	IC50	nM	1000.0	IC50	uM	1.0
3326	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1			CHEMBL1221	=	=	IC50	nM	70.0	IC50	uM	0.07
3327	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1			CHEMBL165	=	=	IC50	nM	600.0	IC50	uM	0.6
3328	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc(N)[nH]c2nc(-c3ccc(F)cc3)c(-c3ccncc3)c1-2			CHEMBL115769	=	=	IC50	nM	1000.0	IC50	uM	1.0
3329	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1			CHEMBL163	=	=	IC50	nM	16.0	IC50	uM	0.016
3330	DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1			CHEMBL84	=	=	IC50	nM	1521.1	IC50	uM	1.5211
3331	Inhibition of human CYP3A4	Cc1nnc(-c2ccc(C)c(-c3ccc4c(c3)NC(=O)C43CCOCC3)c2)[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911194	>	>	IC50	nM	25000.0	IC50	uM	25.0
3332	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910126	=	=	IC50	nM	7000.0	IC50	uM	7.0
3333	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)Nc1ccnn1C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910125	>	>	IC50	nM	17000.0	IC50	uM	17.0
3334	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCOCC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910124	>	>	IC50	nM	17000.0	IC50	uM	17.0
3335	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCCC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910123	>	>	IC50	nM	17000.0	IC50	uM	17.0
3336	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(C)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910122	>	>	IC50	nM	17000.0	IC50	uM	17.0
3337	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(S(C)(=O)=O)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910121	>	>	IC50	nM	17000.0	IC50	uM	17.0
3338	Inhibition of CYP3A4 up to 40 uM	CC(=O)N1CCN(C(=O)CN2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910120	>	>	IC50	nM	17000.0	IC50	uM	17.0
3339	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCC(C(N)=O)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910119	>	>	IC50	nM	17000.0	IC50	uM	17.0
3340	Inhibition of CYP3A4 up to 40 uM	CCN(CC)C(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910118	>	>	IC50	nM	17000.0	IC50	uM	17.0
3341	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N(C)C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910117	>	>	IC50	nM	17000.0	IC50	uM	17.0
3342	Inhibition of CYP3A4 up to 40 uM	CNC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910116	>	>	IC50	nM	17000.0	IC50	uM	17.0
3343	Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(N)=O)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910115	>	>	IC50	nM	17000.0	IC50	uM	17.0
3344	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911827	=	=	IC50	nM	12000.0	IC50	nM	12000.0
3345	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN(C)[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911826	=	=	IC50	nM	7200.0	IC50	nM	7200.0
3346	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN(C)C1CN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911825	=	=	IC50	nM	5400.0	IC50	nM	5400.0
3347	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCC2(C)CC2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911824	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3348	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCC(C)(C)C)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911823	=	=	IC50	nM	12000.0	IC50	nM	12000.0
3349	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccnc(Cl)c2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911822	=	=	IC50	nM	11000.0	IC50	nM	11000.0
3350	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccncc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911821	=	=	IC50	nM	2000.0	IC50	nM	2000.0
3351	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	Cc1ncc(COC[C@@H](NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C(=O)N2CCN(C)CC2)o1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911820	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3352	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccc(F)cc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911819	=	=	IC50	nM	6300.0	IC50	nM	6300.0
3353	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccc3c(c2)OCCO3)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911818	=	=	IC50	nM	3300.0	IC50	nM	3300.0
3354	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN[C@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911828	=	=	IC50	nM	9000.0	IC50	nM	9000.0
3355	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	O=C(N[C@H](COCc1ccccc1)C(=O)N[C@@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911829	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3356	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	O=C(N[C@H](COCc1ccccc1)C(=O)N[C@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911830	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3357	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911817	=	=	IC50	nM	13500.0	IC50	nM	13500.0
3358	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909987	=	=	IC50	nM	340.0	IC50	uM	0.34
3359	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909986	=	=	IC50	nM	730.0	IC50	uM	0.73
3360	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909985	=	=	IC50	nM	1400.0	IC50	uM	1.4
3361	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COCCN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910114	=	=	IC50	nM	22000.0	IC50	uM	22.0
3362	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CCO)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910113	>	>	IC50	nM	40000.0	IC50	uM	40.0
3363	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)O)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910112	>	>	IC50	nM	40000.0	IC50	uM	40.0
3364	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910111	=	=	IC50	nM	17000.0	IC50	uM	17.0
3365	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910110	>	>	IC50	nM	40000.0	IC50	uM	40.0
3366	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CNC2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909647	>	>	IC50	nM	40000.0	IC50	uM	40.0
3367	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(C#N)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910108	=	=	IC50	nM	670.0	IC50	uM	0.67
3368	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(F)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910107	=	=	IC50	nM	1400.0	IC50	uM	1.4
3369	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(Cl)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909994	=	=	IC50	nM	390.0	IC50	uM	0.39
3370	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909992	=	=	IC50	nM	270.0	IC50	uM	0.27
3371	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	1500.0	IC50	uM	1.5
3372	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	1300.0	IC50	uM	1.3
3373	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	2200.0	IC50	uM	2.2
3374	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909989	=	=	IC50	nM	2500.0	IC50	uM	2.5
3375	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909988	=	=	IC50	nM	1200.0	IC50	uM	1.2
3376	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909987	=	=	IC50	nM	770.0	IC50	uM	0.77
3377	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909986	=	=	IC50	nM	1100.0	IC50	uM	1.1
3378	Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909985	=	=	IC50	nM	2800.0	IC50	uM	2.8
3379	Inhibition of CYP3A4	COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910294	=	=	IC50	nM	900.0	IC50	uM	0.9
3380	Inhibition of CYP3A4	CN(C)S(=O)(=O)NCCCCCNc1nc(-c2ccccn2)cs1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909725	>	>	IC50	nM	7000.0	IC50	uM	7.0
3381	Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)cc2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915563	<	<	IC50	nM	200.0	IC50	uM	0.2
3382	Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)c(OC)c2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915564	<	<	IC50	nM	200.0	IC50	uM	0.2
3383	Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)cc2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915565	=	=	IC50	nM	1200.0	IC50	uM	1.2
3384	Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)c(OC)c2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915566	=	=	IC50	nM	2200.0	IC50	uM	2.2
3385	Inhibition of human CYP3A4	CN(C)CCN1C(=O)CCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216770	>	>	IC50	nM	100000.0	IC50	uM	100.0
3386	Inhibition of human CYP3A4	CN(C)CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216313	>	>	IC50	nM	100000.0	IC50	uM	100.0
3387	Inhibition of human CYP3A4	CN1CCC[C@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142403	>	>	IC50	nM	100000.0	IC50	uM	100.0
3388	Inhibition of human CYP3A4	CN1CCC[C@@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216112	>	>	IC50	nM	100000.0	IC50	uM	100.0
3389	Inhibition of human CYP3A4	Cl.Cl.N=C(Nc1ccc2c(c1)CCCN2C1CCNCC1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3217198	>	>	IC50	nM	100000.0	IC50	uM	100.0
3390	Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)Nc2c(C(=O)N[C@@H](C)C(C)(C)C)c(C)nn2-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916282	<	>	IC50	nM	10000.0	pIC50		5.0
3391	Inhibition of CYP3A4	Cc1nn(-c2ccc(F)cc2)c(NS(=O)(=O)c2ccc(C#N)cc2)c1C(=O)N[C@@H](C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916288	<	>	IC50	nM	10000.0	pIC50		5.0
3392	Inhibition of CYP3A4	CCOC(=O)N1CCC(N2CCC[C@@H](NC(=O)c3ccccc3C)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916224	>	>	IC50	nM	25000.0	IC50	uM	25.0
3393	Inhibition of human CYP3A4	COc1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2ccccc2)[C@@H]1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916686	>	>	IC50	nM	30000.0	IC50	uM	30.0
3394	Inhibition of human CYP3A4	COC(=O)N(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916697	>	>	IC50	nM	30000.0	IC50	uM	30.0
3395	Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916700	=	=	IC50	nM	18000.0	IC50	uM	18.0
3396	Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OC	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916704	>	>	IC50	nM	30000.0	IC50	uM	30.0
3397	Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916708	=	=	IC50	nM	21000.0	IC50	uM	21.0
3398	Inhibition of CYP3A4	N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)CCN4C(=O)CCC(=O)O)no2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916399	>	>	IC50	nM	50000.0	IC50	uM	50.0
3399	Inhibition of CYP3A4	O=C(O)CCC(=O)N1CCc2cc(-c3noc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916559	>	>	IC50	nM	50000.0	IC50	uM	50.0
3400	Inhibition of CYP3A4	CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1914489	>	>	IC50	nM	10000.0	IC50	uM	10.0
3401	Inhibition of CYP3A4	C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(C)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1917464	>	>	IC50	nM	30000.0	IC50	uM	30.0
3402	Inhibition of CYP3A4	C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(-c3ccc(F)cc3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1917468	>	>	IC50	nM	30000.0	IC50	uM	30.0
3403	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923729	>	>	IC50	nM	30000.0	IC50	uM	30.0
3404	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2S(=O)(=O)c3ccccc3S2(=O)=O)cc1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1921855	>	>	IC50	nM	30000.0	IC50	uM	30.0
3405	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)[C@H]3[C@H]4C=C[C@H](C4)[C@H]3C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1921961	>	>	IC50	nM	30000.0	IC50	uM	30.0
3406	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)CC3(CCCCC3)C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1705230	>	>	IC50	nM	30000.0	IC50	uM	30.0
3407	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1698322	>	>	IC50	nM	30000.0	IC50	uM	30.0
3408	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	COc1cc(NC(=O)c2ccccn2)ccc1Cl	J. Med. Chem.	2011.0	CHEMBL562551	>	>	IC50	nM	30000.0	IC50	uM	30.0
3409	Inhibition of CYP3A4	CNC(=O)c1ccc2cc([C@](O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921975	=	=	IC50	nM	7800.0	IC50	nM	7800.0
3410	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682893	=	=	IC50	nM	3600.0	IC50	nM	3600.0
3411	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921977	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3412	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3(O)c4cncn4CC3(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921978	=	=	IC50	nM	3200.0	IC50	nM	3200.0
3413	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921979	<	<	IC50	nM	1000.0	IC50	nM	1000.0
3414	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C(C)(O)c3cncn3C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921980	=	=	IC50	nM	6900.0	IC50	nM	6900.0
3415	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921981	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3416	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CCNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3417	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	O=C(NC1CC1)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921983	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3418	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CC(C)NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921984	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3419	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3420	Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc([C@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921985	>	>	IC50	nM	10000.0	IC50	nM	10000.0
3421	Inhibition of human B-lymphoblastoid cell microsomal CYP3A4 assessed as testosterone 6beta-hydroxylation preincubated for 5 mins with substrate	CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921976	>	>	IC50	nM	30000.0	IC50	nM	30000.0
3422	Inhibition of CYP3A4	CNc1nc2[nH]c(-c3cccc(CNC(=O)COC)n3)cc2c2c1ncn2C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923983	>	>	IC50	nM	40000.0	IC50	uM	40.0
3423	Inhibition of human CYP3A4	CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1	J. Med. Chem.	2011.0	CHEMBL1922660	>	>	IC50	nM	50.0	IC50	nM	50.0
3424	Inhibition of human CYP3A4	Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1922662	=	=	IC50	nM	8.5	IC50	nM	8.5
3425	Inhibition of human CYP3A4	Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1922663	=	=	IC50	nM	5.5	IC50	nM	5.5
3426	Inhibition of human CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1229205	=	=	IC50	nM	8.8	IC50	nM	8.8
3427	Inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910292	=	=	IC50	nM	900.0	IC50	uM	0.9
3428	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccccc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910286	=	=	IC50	nM	2600.0	IC50	uM	2.6
3429	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923106	=	=	IC50	nM	6000.0	IC50	uM	6.0
3430	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)c2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923107	=	=	IC50	nM	7200.0	IC50	uM	7.2
3431	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCCc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923108	=	=	IC50	nM	6400.0	IC50	uM	6.4
3432	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC=Cc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923109	=	=	IC50	nM	1100.0	IC50	uM	1.1
3433	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)Cc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923110	=	=	IC50	nM	5600.0	IC50	uM	5.6
3434	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923111	=	=	IC50	nM	13000.0	IC50	uM	13.0
3435	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccccc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923112	=	=	IC50	nM	5000.0	IC50	uM	5.0
3436	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923113	=	=	IC50	nM	5600.0	IC50	uM	5.6
3437	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccc(Cl)cc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923114	=	=	IC50	nM	1900.0	IC50	uM	1.9
3438	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cc(Cl)ccc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923115	=	=	IC50	nM	1600.0	IC50	uM	1.6
3439	Reversible inhibition of CYP3A4	Cc1cccc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923116	=	=	IC50	nM	5000.0	IC50	uM	5.0
3440	Reversible inhibition of CYP3A4	Cc1c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923117	=	=	IC50	nM	2300.0	IC50	uM	2.3
3441	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(C(F)(F)F)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923118	=	=	IC50	nM	3600.0	IC50	uM	3.6
3442	Reversible inhibition of CYP3A4	COCCCc1cc(C)c(C)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923119	=	=	IC50	nM	3500.0	IC50	uM	3.5
3443	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923120	=	=	IC50	nM	6000.0	IC50	uM	6.0
3444	Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c2ccccc2c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923121	=	=	IC50	nM	1600.0	IC50	uM	1.6
3445	Reversible inhibition of CYP3A4	COCCCc1cccc2cccc(CN(C(=O)[C@H]3CNCC[C@@]34OCc3cc(F)c(F)cc34)C3CC3)c12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923122	=	=	IC50	nM	15000.0	IC50	uM	15.0
3446	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1nccc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923123	=	=	IC50	nM	9300.0	IC50	uM	9.3
3447	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccnc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923124	=	=	IC50	nM	31000.0	IC50	uM	31.0
3448	Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2cccnc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923125	=	=	IC50	nM	8900.0	IC50	uM	8.9
3449	Reversible inhibition of CYP3A4	O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2cccc(C(F)(F)F)c2Cl)C2CC2)c2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923126	=	=	IC50	nM	700.0	IC50	uM	0.7
3450	Reversible inhibition of CYP3A4	COCCCc1cc(CCCN2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923127	=	=	IC50	nM	2600.0	IC50	uM	2.6
3451	Reversible inhibition of CYP3A4	CCN(CC)CCCc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923128	=	=	IC50	nM	5800.0	IC50	uM	5.8
3452	Reversible inhibition of CYP3A4	COCCCc1cc(CCCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923129	=	=	IC50	nM	2200.0	IC50	uM	2.2
3453	Reversible inhibition of CYP3A4	COCCCc1cc(CCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923130	=	=	IC50	nM	2000.0	IC50	uM	2.0
3454	Reversible inhibition of CYP3A4	COCCCc1cc(CCCN2CCS(=O)(=O)CC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923131	=	=	IC50	nM	2400.0	IC50	uM	2.4
3455	Reversible inhibition of CYP3A4	COCCCc1cc(CCC(=O)N2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923132	=	=	IC50	nM	2800.0	IC50	uM	2.8
3456	Inhibition of human CYP3A4	C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O	J. Med. Chem.	2011.0	CHEMBL1923502	=	=	IC50	nM	2400.0	IC50	uM	2.4
3457	Inhibition of human CYP3A4	C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCN[C@@H](C2CC2)C(=O)N1C	J. Med. Chem.	2011.0	CHEMBL1923642	=	=	IC50	nM	1200.0	IC50	uM	1.2
3458	Inhibition of CYP3A4	CCCCC[C@@H](Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1922933	>	>	IC50	nM	11000.0	IC50	nM	11000.0
3459	Inhibition of CYP3A4	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1929238	=	=	IC50	nM	550.0	IC50	uM	0.55
3460	Inhibition of CYP3A4	Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1.Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1929387	>	>	IC50	nM	10000.0	IC50	uM	10.0
3461	Inhibition of human CYP3A4	CC(C)(C)CC(c1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1)N1CCC(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1928243	>	>	IC50	nM	10000.0	IC50	uM	10.0
3462	Inhibition of human recombinant CYP3A4 by mass spectrophotometry	Cl.O=c1c2c3n(c(=O)cc2[nH]n1-c1ccccc1Cl)CCCN(Cc1ccccc1)C3	Bioorg. Med. Chem.	2011.0	CHEMBL1927147	>	>	IC50	nM	25000.0	IC50	uM	25.0
3463	Inhibition of human recombinant CYP3A4	COc1ccc(-c2sc(/N=C/c3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC	Eur. J. Med. Chem.	2012.0	CHEMBL1928092	=	=	IC50	nM	33200.0	IC50	uM	33.2
3464	Inhibition of human recombinant CYP3A4	COc1ccc(-c2sc(/N=C/c3ccc(-c4ccccc4)cc3)c(C#N)c2C)cc1OC	Eur. J. Med. Chem.	2012.0	CHEMBL1928095	>	>	IC50	nM	100000.0	IC50	uM	100.0
3465	Inhibition of CYP3A4	CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935416	>	>	IC50	nM	30000.0	IC50	uM	30.0
3466	Inhibition of CYP3A4	CN1CCC[C@@H](c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1095819	>	>	IC50	nM	5000.0	IC50	uM	5.0
3467	Inhibition of CYP3A4	Cc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935441	>	>	IC50	nM	20000.0	IC50	uM	20.0
3468	Inhibition of CYP3A4	Fc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935442	>	>	IC50	nM	20000.0	IC50	uM	20.0
3469	Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935443	=	=	IC50	nM	4900.0	IC50	uM	4.9
3470	Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935443	=	=	IC50	nM	7600.0	IC50	uM	7.6
3471	Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	7500.0	IC50	uM	7.5
3472	Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	7800.0	IC50	uM	7.8
3473	Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	9500.0	IC50	uM	9.5
3474	Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935445	=	=	IC50	nM	16700.0	IC50	uM	16.7
3475	Inhibition of CYP3A4	Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935446	=	=	IC50	nM	15600.0	IC50	uM	15.6
3476	Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935445	=	=	IC50	nM	10600.0	IC50	uM	10.6
3477	Inhibition of CYP3A4	COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935447	=	=	IC50	nM	5800.0	IC50	uM	5.8
3478	Inhibition of CYP3A4	COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935448	=	=	IC50	nM	15800.0	IC50	uM	15.8
3479	Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
3480	Inhibition of CYP3A4	O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935601	>	>	IC50	nM	30000.0	IC50	uM	30.0
3481	Inhibition of CYP3A4	COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934523	>	>	IC50	nM	40000.0	IC50	uM	40.0
3482	Inhibition of CYP3A4	CO[C@H]1CC[C@@H](n2nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c2NS(=O)(=O)c2ccc(C)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934424	<	>	IC50	nM	10000.0	pIC50		5.0
3483	Inhibition of CYP3A4	Cc1nn(C2CCOCC2)c(NS(=O)(=O)c2ccc(C3CC3)cc2)c1C(=O)N[C@@H](C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934426	<	>	IC50	nM	10000.0	pIC50		5.0
3484	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935100	>	>	IC50	nM	11000.0	IC50	uM	11.0
3485	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935114	>	>	IC50	nM	30000.0	IC50	uM	30.0
3486	Inhibition of CYP3A4	CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935111	>	>	IC50	nM	30000.0	IC50	uM	30.0
3487	Inhibition of CYP3A4	CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935111	>	>	IC50	nM	30000.0	IC50	uM	30.0
3488	Inhibition of CYP3A4	Cc1cc(=O)[nH]nc1-c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1829475	>	>	IC50	nM	30000.0	IC50	uM	30.0
3489	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins by fluorimetry	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1	J. Med. Chem.	2011.0	CHEMBL1939876	>	>	IC50	nM	30000.0	IC50	uM	30.0
3490	Inhibition of CYP3A4	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(F)c(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1939559	>	>	IC50	nM	10000.0	IC50	uM	10.0
3491	Inhibition of CYP3A4	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(C(F)(F)F)c(F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1939560	>	>	IC50	nM	10000.0	IC50	uM	10.0
3492	Inhibition of CYP3A4	O=C(NC1CCCS(=O)(=O)C1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940315	>	>	IC50	nM	10000.0	IC50	uM	10.0
3493	Inhibition of CYP3A4	CN1CCC(NC(=O)c2ccc(Oc3ccc(C#C[C@]4(O)CN5CCC4CC5)cc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940308	>	>	IC50	nM	10000.0	IC50	uM	10.0
3494	Inhibition of CYP3A4	CNC(=O)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940296	<	>	IC50	nM	10000.0	pIC50		5.0
3495	Inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1796298	<	>	IC50	nM	10000.0	pIC50		5.0
3496	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1	J. Med. Chem.	2012.0	CHEMBL1944698	>	>	IC50	nM	25000.0	IC50	uM	25.0
3497	Inhibition of CYP3A4	COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1	J. Med. Chem.	2011.0	CHEMBL1947144	=	=	IC50	nM	22000.0	IC50	uM	22.0
3498	Inhibition of CYP3A4	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1cc2nnc(-c3c(F)cccc3Cl)n2n(C)c1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945721	=	=	IC50	nM	25800.0	IC50	uM	25.8
3499	Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2nnc(-c3c(F)cccc3Cl)n21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945723	>	>	IC50	nM	27000.0	IC50	uM	27.0
3500	Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2nnc(-c3c(F)cccc3Cl)n21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945726	=	=	IC50	nM	11800.0	IC50	uM	11.8
3501	Inhibition of CYP3A4	O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950643	>	>	IC50	nM	30000.0	IC50	uM	30.0
3502	Inhibition of CYP3A4	CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950743	>	>	IC50	nM	30000.0	IC50	uM	30.0
3503	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951055	>	>	IC50	nM	30000.0	IC50	uM	30.0
3504	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951320	=	=	IC50	nM	310.0	IC50	uM	0.31
3505	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951321	=	=	IC50	nM	210.0	IC50	uM	0.21
3506	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951322	=	=	IC50	nM	600.0	IC50	uM	0.6
3507	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951323	=	=	IC50	nM	710.0	IC50	uM	0.71
3508	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951324	=	=	IC50	nM	480.0	IC50	uM	0.48
3509	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951325	=	=	IC50	nM	92.0	IC50	uM	0.092
3510	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951326	=	=	IC50	nM	1200.0	IC50	uM	1.2
3511	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951327	=	=	IC50	nM	1500.0	IC50	uM	1.5
3512	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc([N+](=O)[O-])c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951328	=	=	IC50	nM	61.0	IC50	uM	0.061
3513	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951329	=	=	IC50	nM	82.0	IC50	uM	0.082
3514	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COc1ccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951330	=	=	IC50	nM	200.0	IC50	uM	0.2
3515	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951331	=	=	IC50	nM	26.0	IC50	uM	0.026
3516	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCOC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951332	=	=	IC50	nM	44.0	IC50	uM	0.044
3517	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951334	=	=	IC50	nM	98.0	IC50	uM	0.098
3518	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951335	=	=	IC50	nM	55.0	IC50	uM	0.055
3519	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951336	=	=	IC50	nM	90.0	IC50	uM	0.09
3520	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CN(C)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951337	=	=	IC50	nM	110.0	IC50	uM	0.11
3521	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCN(CC)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951338	=	=	IC50	nM	47.0	IC50	uM	0.047
3522	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)N(C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951339	=	=	IC50	nM	60.0	IC50	uM	0.06
3523	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951340	=	=	IC50	nM	53.0	IC50	uM	0.053
3524	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951341	=	=	IC50	nM	70.0	IC50	uM	0.07
3525	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951342	=	=	IC50	nM	79.0	IC50	uM	0.079
3526	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951343	=	=	IC50	nM	290.0	IC50	uM	0.29
3527	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951344	=	=	IC50	nM	560.0	IC50	uM	0.56
3528	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4c3ccn4C)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951345	=	=	IC50	nM	2900.0	IC50	uM	2.9
3529	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951346	=	=	IC50	nM	22000.0	IC50	uM	22.0
3530	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951347	=	=	IC50	nM	4600.0	IC50	uM	4.6
3531	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(Cl)c34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951348	=	=	IC50	nM	14000.0	IC50	uM	14.0
3532	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951350	=	=	IC50	nM	26000.0	IC50	uM	26.0
3533	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951443	=	=	IC50	nM	130.0	IC50	uM	0.13
3534	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951444	=	=	IC50	nM	11.0	IC50	uM	0.011
3535	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccc(O)cc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951445	=	=	IC50	nM	30.0	IC50	uM	0.03
3536	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Nc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951446	=	=	IC50	nM	200.0	IC50	uM	0.2
3537	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COc1cccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951447	=	=	IC50	nM	48.0	IC50	uM	0.048
3538	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951448	=	=	IC50	nM	1700.0	IC50	uM	1.7
3539	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951449	=	=	IC50	nM	220.0	IC50	uM	0.22
3540	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951450	=	=	IC50	nM	360.0	IC50	uM	0.36
3541	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(NCc1ccc(F)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951451	=	=	IC50	nM	280.0	IC50	nM	280.0
3542	Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(NCc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951452	=	=	IC50	nM	270.0	IC50	nM	270.0
3543	Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis	CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951453	=	=	IC50	nM	4700.0	IC50	uM	4.7
3544	Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis	CCCOc1sc(C(=O)N2[C@H]3CC[C@H]2CC(c2cc(CN)ccc2F)C3)c(C)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951454	=	=	IC50	nM	5300.0	IC50	uM	5.3
3545	Inhibition of CYP3A4	COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1.CS(=O)(=O)O	ACS Med. Chem. Lett.	2011.0	CHEMBL1951778	>	>	IC50	nM	25000.0	IC50	uM	25.0
3546	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3nccc4ccccc34)c(=O)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951432	=	=	IC50	nM	1700.0	IC50	uM	1.7
3547	Inhibition of CYP3A4	Cn1c(=O)n(Cc2nccc3ccccc23)c(=O)c2c1c(C#N)c(N1CCC[C@H](N)C1)n2Cc1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951596	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3548	Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3Cc3ccccc3)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951595	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3549	Inhibition of CYP3A4	Cn1c(=O)c2c(c(C#N)c(N3CCC[C@H](N)C3)n2Cc2ccccc2)n(C)c1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951597	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3550	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951599	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3551	Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3CC=C(C)C)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951598	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3552	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951600	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3553	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1ncccc1C#N)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951602	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3554	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1cnc3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951601	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3555	Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCNCC4)n3CC=C(C)C)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951607	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3556	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951609	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3557	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951608	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3558	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1cn3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951610	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3559	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949693	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3560	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951611	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3561	Inhibition of CYP3A4	CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951612	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
3562	Inhibition of CYP3A4	CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951614	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
3563	Inhibition of CYP3A4	CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951914	=	=	IC50	nM	9000.0	IC50	uM	9.0
3564	Inhibition of human CYP3A4 by luminescent assay	COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1952142	=	=	IC50	nM	4500.0	IC50	uM	4.5
3565	Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3ccnc4ccccc34)c(=O)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951431	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
3566	Inhibition of CYP3A4	O=C(N1CCCCC1)N1CC(O[C@@H](c2ccc(Cl)cc2)c2cccnc2Cl)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL555563	>	>	IC50	nM	10000.0	IC50	uM	10.0
3567	Inhibition of CYP3A4	CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950351	>	>	IC50	nM	20000.0	IC50	uM	20.0
3568	Inhibition of CYP 3A4	COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949930	>	>	IC50	nM	5900.0	IC50	uM	5.9
3569	Reversible inhibition of CYP3A4	Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3[nH]nc(C)c23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950091	=	=	IC50	nM	7900.0	IC50	uM	7.9
3570	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950090	=	=	IC50	nM	300.0	IC50	uM	0.3
3571	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950089	=	=	IC50	nM	7400.0	IC50	uM	7.4
3572	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950088	>	>	IC50	nM	20000.0	IC50	uM	20.0
3573	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950087	=	=	IC50	nM	1800.0	IC50	uM	1.8
3574	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950086	=	=	IC50	nM	1100.0	IC50	uM	1.1
3575	Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950085	=	=	IC50	nM	300.0	IC50	uM	0.3
3576	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950084	=	=	IC50	nM	300.0	IC50	uM	0.3
3577	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950082	=	=	IC50	nM	7100.0	IC50	uM	7.1
3578	Reversible inhibition of CYP3A4	COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950081	=	=	IC50	nM	300.0	IC50	uM	0.3
3579	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950080	=	=	IC50	nM	800.0	IC50	uM	0.8
3580	Reversible inhibition of CYP3A4	COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950078	<	<	IC50	nM	200.0	IC50	uM	0.2
3581	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncs3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949942	<	<	IC50	nM	200.0	IC50	uM	0.2
3582	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949941	=	=	IC50	nM	1200.0	IC50	uM	1.2
3583	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949940	=	=	IC50	nM	4400.0	IC50	uM	4.4
3584	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949939	=	=	IC50	nM	600.0	IC50	uM	0.6
3585	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949938	=	=	IC50	nM	4600.0	IC50	uM	4.6
3586	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cccnc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949937	<	<	IC50	nM	200.0	IC50	uM	0.2
3587	Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949936	=	=	IC50	nM	2900.0	IC50	uM	2.9
3588	Time dependent inhibition of CYP3A4	Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3[nH]nc(C)c23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950091	>	>	IC50	nM	20000.0	IC50	uM	20.0
3589	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950090	=	=	IC50	nM	800.0	IC50	uM	0.8
3590	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950089	=	=	IC50	nM	1000.0	IC50	uM	1.0
3591	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950088	>	>	IC50	nM	20000.0	IC50	uM	20.0
3592	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950087	=	=	IC50	nM	12200.0	IC50	uM	12.2
3593	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950086	=	=	IC50	nM	2100.0	IC50	uM	2.1
3594	Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950085	=	=	IC50	nM	500.0	IC50	uM	0.5
3595	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950084	=	=	IC50	nM	12000.0	IC50	uM	12.0
3596	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950082	=	=	IC50	nM	14200.0	IC50	uM	14.2
3597	Time dependent inhibition of CYP3A4	COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950081	=	=	IC50	nM	12900.0	IC50	uM	12.9
3598	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950080	=	=	IC50	nM	20000.0	IC50	uM	20.0
3599	Time dependent inhibition of CYP3A4	COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950078	=	=	IC50	nM	1200.0	IC50	uM	1.2
3600	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncs3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949942	=	=	IC50	nM	700.0	IC50	uM	0.7
3601	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949941	=	=	IC50	nM	4900.0	IC50	uM	4.9
3602	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949940	=	=	IC50	nM	7800.0	IC50	uM	7.8
3603	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949939	=	=	IC50	nM	4200.0	IC50	uM	4.2
3604	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949938	=	=	IC50	nM	10600.0	IC50	uM	10.6
3605	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cccnc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949937	=	=	IC50	nM	2700.0	IC50	uM	2.7
3606	Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949936	=	=	IC50	nM	3000.0	IC50	uM	3.0
3607	Inhibition of human CYP3A4	CN1CC=C(c2c[nH]c3ccc(NC(=N)c4ccco4)cc23)CC1.Cl.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL3216551	>	>	IC50	nM	100000.0	IC50	uM	100.0
3608	Inhibition of CYP3A4 in human liver microsomes	O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957816	>	>	IC50	nM	40000.0	IC50	uM	40.0
3609	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1	J. Med. Chem.	2012.0	CHEMBL1945843	>	>	IC50	nM	30000.0	IC50	uM	30.0
3610	Inhibition of recombinant CYP3A4	FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1955989	=	=	IC50	nM	3500.0	IC50	uM	3.5
3611	Inhibition of CYP3A4 in human liver microsomes	FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1955989	>	>	IC50	nM	30000.0	IC50	uM	30.0
3612	Inhibition of CYP3A4 in human microsome	NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1956397	=	=	IC50	nM	139000.0	IC50	uM	139.0
3613	Inhibition of CYP3A4 in human microsome	NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1956397	=	=	IC50	nM	159000.0	IC50	uM	159.0
3614	Inhibition of CYP3A4 after 30 mins by fluorescence assay	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1079119	=	=	IC50	nM	810.0	IC50	uM	0.81
3615	Inhibition of CYP3A4 after 30 mins by fluorescence assay	C/C(=C\COc1c(CCC(=O)O)c(O)cc2occc12)CCC(O)C(C)(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957148	>	>	IC50	nM	172000.0	IC50	uM	172.0
3616	Inhibition of CYP3A4	Nc1cncc(Nc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010816	>	>	IC50	nM	27000.0	IC50	uM	27.0
3617	Inhibition of CYP3A4	COc1ccc(-c2nc(C(=O)NCc3ccc(F)cc3F)c([C@H](C)N)o2)c2ccc(C(F)(F)F)nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2012228	>	>	IC50	nM	8000.0	IC50	uM	8.0
3618	Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2012951	>	>	IC50	nM	10000.0	IC50	uM	10.0
3619	Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2012958	>	>	IC50	nM	10000.0	IC50	uM	10.0
3620	Inhibition of CYP3A4	CC(C)S(=O)(=O)NC[C@H]1CC[C@H](NC(=O)CN2CCc3cc(Cl)ccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013012	=	=	IC50	nM	700.0	IC50	uM	0.7
3621	Inhibition of CYP3A4 by HTRF assay	CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL2010836	>	>	IC50	nM	25000.0	IC50	uM	25.0
3622	Inhibition of CYP3A4	CS(=O)(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013045	>	>	IC50	nM	30000.0	IC50	uM	30.0
3623	Inhibition of CYP3A4	O=S(=O)(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013050	>	>	IC50	nM	30000.0	IC50	uM	30.0
3624	Inhibition of CYP3A4	CC(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013051	>	>	IC50	nM	30000.0	IC50	uM	30.0
3625	Inhibition of CYP3A4	CC(C)C(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013052	>	>	IC50	nM	30000.0	IC50	uM	30.0
3626	Inhibition of CYP3A4	O=C(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013053	>	>	IC50	nM	30000.0	IC50	uM	30.0
3627	Inhibition of CYP3A4	CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3	J. Med. Chem.	2012.0	CHEMBL2010872	>	>	IC50	nM	30000.0	IC50	uM	30.0
3628	Inhibition of CYP3A4 co-incubated with substrate	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F	J. Med. Chem.	2012.0	CHEMBL2011266	>	>	IC50	nM	20000.0	IC50	uM	20.0
3629	Inhibition of CYP3A4 preincubated prior to substrate addition	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F	J. Med. Chem.	2012.0	CHEMBL2011266	>	>	IC50	nM	20000.0	IC50	uM	20.0
3630	Inhibition of CYP3A4	Oc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013195	>	>	IC50	nM	30000.0	IC50	uM	30.0
3631	Inhibition of CYP3A4	c1ccc(-c2nc3c(CN4CCCCC4)cccc3[nH]2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010880	>	>	IC50	nM	50000.0	IC50	uM	50.0
3632	Inhibition of CYP3A4	Fc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010883	>	>	IC50	nM	30000.0	IC50	uM	30.0
3633	Inhibition of CYP3A4 in human liver microsomes co-incubated with testosterone	O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938681	>	>	IC50	nM	20000.0	IC50	uM	20.0
3634	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins prior to substrate addition	O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938681	>	>	IC50	nM	20000.0	IC50	uM	20.0
3635	Inhibition of CYP3A4	COc1nc(C(=O)N[C@H]2COc3ccc(Cl)c(F)c32)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2018331	>	>	IC50	nM	30000.0	IC50	uM	30.0
3636	Inhibition of human CYP3A4	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938952	>	>	IC50	nM	30000.0	IC50	uM	30.0
3637	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1	J. Med. Chem.	2012.0	CHEMBL2018481	=	=	IC50	nM	7146.0	IC50	nM	7146.0
3638	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1	J. Med. Chem.	2012.0	CHEMBL2018482	=	=	IC50	nM	301.0	IC50	nM	301.0
3639	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018484	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3640	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018485	=	=	IC50	nM	12605.0	IC50	nM	12605.0
3641	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018486	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3642	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1ccnn1	J. Med. Chem.	2012.0	CHEMBL2018571	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3643	Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1nccn1	J. Med. Chem.	2012.0	CHEMBL2018573	>	>	IC50	nM	20000.0	IC50	nM	20000.0
3644	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018906	>	>	IC50	nM	50000.0	IC50	uM	50.0
3645	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018905	=	=	IC50	nM	27100.0	IC50	uM	27.1
3646	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018903	>	>	IC50	nM	50000.0	IC50	uM	50.0
3647	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018904	=	=	IC50	nM	26300.0	IC50	uM	26.3
3648	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018907	=	=	IC50	nM	5330.0	IC50	uM	5.33
3649	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018908	=	=	IC50	nM	15700.0	IC50	uM	15.7
3650	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC(C)C)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018909	>	>	IC50	nM	50000.0	IC50	uM	50.0
3651	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC(C)(C)C)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018910	>	>	IC50	nM	50000.0	IC50	uM	50.0
3652	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC3CC3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018911	=	=	IC50	nM	16400.0	IC50	uM	16.4
3653	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC3CCCCC3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018912	=	=	IC50	nM	6230.0	IC50	uM	6.23
3654	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCCCO)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018913	=	=	IC50	nM	5490.0	IC50	uM	5.49
3655	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCCCC(=O)O)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018914	>	>	IC50	nM	50000.0	IC50	uM	50.0
3656	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccccc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018915	>	>	IC50	nM	80.0	IC50	uM	0.08
3657	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018916	=	=	IC50	nM	8860.0	IC50	uM	8.86
3658	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(C)C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018917	=	=	IC50	nM	8340.0	IC50	uM	8.34
3659	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(C)(C)C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018918	=	=	IC50	nM	12300.0	IC50	uM	12.3
3660	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(Cl)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018919	=	=	IC50	nM	4860.0	IC50	uM	4.86
3661	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(Br)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018920	=	=	IC50	nM	4230.0	IC50	uM	4.23
3662	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(I)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018921	=	=	IC50	nM	4910.0	IC50	uM	4.91
3663	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(=O)O)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018922	>	>	IC50	nM	50000.0	IC50	uM	50.0
3664	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1	J. Med. Chem.	2012.0	CHEMBL488400	=	=	IC50	nM	720.0	IC50	uM	0.72
3665	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3cccc(-c4ccccc4)c3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018923	=	=	IC50	nM	1870.0	IC50	uM	1.87
3666	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1	J. Med. Chem.	2012.0	CHEMBL502335	=	=	IC50	nM	3110.0	IC50	uM	3.11
3667	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc4ccccc4n3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018924	=	=	IC50	nM	2810.0	IC50	uM	2.81
3668	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3cccc(Oc4ccccc4)c3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018925	=	=	IC50	nM	2490.0	IC50	uM	2.49
3669	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(OCc4ccccc4)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018926	=	=	IC50	nM	3560.0	IC50	uM	3.56
3670	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019022	=	=	IC50	nM	4010.0	IC50	uM	4.01
3671	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCOc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019023	=	=	IC50	nM	400.0	IC50	uM	0.4
3672	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	c1ccc(CSc2nc3ccccc3[nH]2)nc1	J. Med. Chem.	2012.0	CHEMBL296580	>	>	IC50	nM	3750.0	IC50	uM	3.75
3673	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	Cc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019024	=	=	IC50	nM	3610.0	IC50	uM	3.61
3674	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	FC(F)Oc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019025	=	=	IC50	nM	10700.0	IC50	uM	10.7
3675	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	Nc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019026	=	=	IC50	nM	520.0	IC50	uM	0.52
3676	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957676	=	=	IC50	nM	20000.0	IC50	uM	20.0
3677	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Br)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016935	=	=	IC50	nM	3000.0	IC50	uM	3.0
3678	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016936	=	=	IC50	nM	8000.0	IC50	uM	8.0
3679	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Cl)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016937	=	=	IC50	nM	7000.0	IC50	uM	7.0
3680	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2ccccc2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016938	=	=	IC50	nM	18000.0	IC50	uM	18.0
3681	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc(Cl)c2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017097	=	=	IC50	nM	19000.0	IC50	uM	19.0
3682	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	Cc1cccc(-c2noc([C@H]3CNCC[C@]3(O)c3ccc(F)c(F)c3)c2Br)c1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017098	=	=	IC50	nM	20000.0	IC50	uM	20.0
3683	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2c(Cl)cccc2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017099	=	=	IC50	nM	15000.0	IC50	uM	15.0
3684	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc3ccccc23)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017100	>	>	IC50	nM	50000.0	IC50	uM	50.0
3685	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1noc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017101	=	=	IC50	nM	45000.0	IC50	uM	45.0
3686	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017102	=	=	IC50	nM	33000.0	IC50	uM	33.0
3687	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)on1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017103	=	=	IC50	nM	17000.0	IC50	uM	17.0
3688	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1cc(F)ccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017104	=	=	IC50	nM	45000.0	IC50	uM	45.0
3689	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1cc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017105	=	=	IC50	nM	32000.0	IC50	uM	32.0
3690	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017106	>	>	IC50	nM	50000.0	IC50	uM	50.0
3691	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017107	=	=	IC50	nM	8000.0	IC50	uM	8.0
3692	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017108	>	>	IC50	nM	50000.0	IC50	uM	50.0
3693	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017109	=	=	IC50	nM	13000.0	IC50	uM	13.0
3694	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CO[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1noc(-c2ccccc2CCNC(C)=O)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017110	=	=	IC50	nM	28000.0	IC50	uM	28.0
3695	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(C(N)=O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017111	=	=	IC50	nM	36000.0	IC50	uM	36.0
3696	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(OCC(O)CO)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017112	>	>	IC50	nM	50000.0	IC50	uM	50.0
3697	Inhibition of CYP3A4	COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1	J. Med. Chem.	2012.0	CHEMBL1552719	=	=	IC50	nM	1700.0	IC50	uM	1.7
3698	Inhibition of CYP3A4	Oc1nc(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2	J. Med. Chem.	2012.0	CHEMBL1086580	>	>	IC50	nM	50000.0	IC50	uM	50.0
3699	Inhibition of CYP3A4	COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1	J. Med. Chem.	2012.0	CHEMBL1867804	=	=	IC50	nM	5300.0	IC50	uM	5.3
3700	Inhibition of CYP3A4	COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1	J. Med. Chem.	2012.0	CHEMBL1898239	=	=	IC50	nM	5700.0	IC50	uM	5.7
3701	Inhibition of CYP3A4	Fc1ccc(-c2nnc(SCc3nc(-c4ccccc4)no3)n2-c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2016639	>	>	IC50	nM	50000.0	IC50	uM	50.0
3702	Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	COC[C@H](C)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2noc(-c3ccccc3CCNC(C)=O)c2Br)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017113	=	=	IC50	nM	29000.0	IC50	uM	29.0
3703	Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017089	=	=	IC50	nM	17000.0	IC50	uM	17.0
3704	Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017091	>	>	IC50	nM	33000.0	IC50	uM	33.0
3705	Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017268	=	=	IC50	nM	2000.0	IC50	uM	2.0
3706	Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017269	=	=	IC50	nM	13000.0	IC50	uM	13.0
3707	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017273	=	=	IC50	nM	4700.0	IC50	uM	4.7
3708	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017274	=	=	IC50	nM	1900.0	IC50	uM	1.9
3709	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017275	=	=	IC50	nM	1900.0	IC50	uM	1.9
3710	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017276	=	=	IC50	nM	3100.0	IC50	uM	3.1
3711	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017279	=	=	IC50	nM	1500.0	IC50	uM	1.5
3712	Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017280	=	=	IC50	nM	1800.0	IC50	uM	1.8
3713	Inhibition of CYP3A4	COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017281	=	=	IC50	nM	3900.0	IC50	uM	3.9
3714	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017283	=	=	IC50	nM	1700.0	IC50	uM	1.7
3715	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017284	=	=	IC50	nM	2000.0	IC50	uM	2.0
3716	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017285	=	=	IC50	nM	3700.0	IC50	uM	3.7
3717	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017286	=	=	IC50	nM	12900.0	IC50	uM	12.9
3718	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017287	=	=	IC50	nM	2000.0	IC50	uM	2.0
3719	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017288	=	=	IC50	nM	1500.0	IC50	uM	1.5
3720	Inhibition of CYP3A4	CC[C@H](c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017290	=	=	IC50	nM	2400.0	IC50	uM	2.4
3721	Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
3722	Inhibition of CYP3A4	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1970317	=	=	IC50	nM	7900.0	IC50	uM	7.9
3723	Inhibition of CYP3A4	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1980297	>	>	IC50	nM	30000.0	IC50	uM	30.0
3724	Inhibition of CYP3A4 preincubated for 15 mins	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1970317	=	=	IC50	nM	2700.0	IC50	uM	2.7
3725	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](C[C@H]1CCCOC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2024248	=	=	IC50	nM	28000.0	IC50	nM	28000.0
3726	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](CC1CCOCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2023124	>	>	IC50	nM	30000.0	IC50	nM	30000.0
3727	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@@H](NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)[C@@H](O)C1CCCCC1	ACS Med. Chem. Lett.	2011.0	CHEMBL2023123	=	=	IC50	nM	7100.0	IC50	nM	7100.0
3728	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)C[C@H]1CCCOC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1276678	>	>	IC50	nM	30000.0	IC50	nM	30000.0
3729	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	COCCCC[C@@](O)(c1cccc(Cl)c1F)[C@@H]1CCCN(C(=O)NC[C@@H](N)CC2CCCCC2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2024249	=	=	IC50	nM	2910.0	IC50	nM	2910.0
3730	Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](CC1CCCCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL591578	=	=	IC50	nM	4600.0	IC50	nM	4600.0
3731	Inhibition of human CYP3A4	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl	ACS Med. Chem. Lett.	2011.0	CHEMBL119385	>	>	IC50	nM	40000.0	IC50	uM	40.0
3732	Inhibition of CYP3A4	CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023802	>	>	IC50	nM	8600.0	IC50	uM	8.6
3733	Inhibition of CYP3A4	COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1.O=S(=O)(O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023803	>	>	IC50	nM	10000.0	IC50	uM	10.0
3734	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022495	=	=	IC50	nM	48000.0	IC50	uM	48.0
3735	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022495	=	=	IC50	nM	76000.0	IC50	uM	76.0
3736	Inhibition of CYP3A4	Cc1n[nH]c(C(=O)O)c1Cc1cccc(-c2ccc(F)cc2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2022570	>	>	IC50	nM	10000.0	IC50	uM	10.0
3737	Inhibition of CYP3A4	Cc1n[nH]c(C(=O)O)c1Cc1cc2ccccc2s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2022571	>	>	IC50	nM	10000.0	IC50	uM	10.0
3738	Inhibition of CYP3A4 using diethoxyfluorescein as substrate	O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022739	>	>	IC50	nM	100000.0	IC50	uM	100.0
3739	Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022739	=	=	IC50	nM	64000.0	IC50	uM	64.0
3740	Inhibition of CYP3A4	Cc1cccc(C(CC[C@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022995	>	>	IC50	nM	25000.0	IC50	uM	25.0
3741	Inhibition of CYP3A4	Cc1cccc(C(CC[C@@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022996	>	>	IC50	nM	25000.0	IC50	uM	25.0
3742	Inhibition of CYP3A4	Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022997	=	=	IC50	nM	5500.0	IC50	uM	5.5
3743	Inhibition of CYP3A4	Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1	J. Med. Chem.	2012.0	CHEMBL228814	=	=	IC50	nM	4100.0	IC50	uM	4.1
3744	Inhibition of CYP3A4	O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2029422	>	>	IC50	nM	30000.0	IC50	uM	30.0
3745	Inhibition of human CYP3A4	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC	J. Med. Chem.	2012.0	CHEMBL2029988	>	>	IC50	nM	10000.0	IC50	uM	10.0
3746	Inhibition of CYP3A4	O=c1[nH]c([C@@H]2CCCN2)nc2c1oc1ccc(Cl)cc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2030402	>	>	IC50	nM	50000.0	IC50	uM	50.0
3747	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc2c(c1)CCc1cc(=O)n(C)nc1-2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2031470	>	>	IC50	nM	30000.0	IC50	uM	30.0
3748	Inhibition of CYP3A4	O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036757	=	=	IC50	nM	1600.0	IC50	uM	1.6
3749	Inhibition of CYP3A4	CN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl	J. Med. Chem.	2012.0	CHEMBL2036268	=	=	IC50	nM	57300.0	IC50	uM	57.3
3750	Inhibition of CYP3A4	CCN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl	J. Med. Chem.	2012.0	CHEMBL2036270	=	=	IC50	nM	23100.0	IC50	uM	23.1
3751	Inhibition of CYP3A4	CNC1CCCC(c2c[nH]c3ccc(NC(=N)c4cccs4)cc23)C1.Cl	J. Med. Chem.	2012.0	CHEMBL2036273	=	=	IC50	nM	100000.0	IC50	uM	100.0
3752	Inhibition of CYP3A4	CC(C)C1(c2ccc(-c3ccc4ccccc4c3)[nH]c2=O)OC(=O)NC1=O	ACS Med. Chem. Lett.	2010.0	CHEMBL1770317	<	>	IC50	nM	50118.72	pIC50		4.3
3753	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1cccc(C(F)(F)F)c1)c1cccc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036208	>	>	IC50	nM	10000.0	IC50	uM	10.0
3754	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cccc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036209	>	>	IC50	nM	10000.0	IC50	uM	10.0
3755	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036210	>	>	IC50	nM	10000.0	IC50	uM	10.0
3756	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036211	>	>	IC50	nM	10000.0	IC50	uM	10.0
3757	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1cccc(OC(F)(F)F)c1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036212	>	>	IC50	nM	10000.0	IC50	uM	10.0
3758	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036213	>	>	IC50	nM	10000.0	IC50	uM	10.0
3759	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036214	>	>	IC50	nM	10000.0	IC50	uM	10.0
3760	Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(Cl)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036215	>	>	IC50	nM	10000.0	IC50	uM	10.0
3761	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951055	>	>	IC50	nM	30000.0	IC50	uM	30.0
3762	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCN(C(=O)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036635	>	>	IC50	nM	30000.0	IC50	uM	30.0
3763	Inhibition of CYP3A4	COC(=O)N1CCN(CC(=O)c2ccc(OCCCN3CCC[C@H]3C)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036653	>	>	IC50	nM	30000.0	IC50	uM	30.0
3764	Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCC(F)(F)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036643	>	>	IC50	nM	30000.0	IC50	uM	30.0
3765	Inhibition of CYP3A4	O=c1[nH]c(CN2CC[C@@H](O)C2)nc2c1oc1ccc(Br)cc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2030386	>	>	IC50	nM	20000.0	IC50	uM	20.0
3766	Inhibition of human CYP3A4	CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1	ACS Med. Chem. Lett.	2012.0	CHEMBL2036958	>	>	IC50	nM	50000.0	IC50	uM	50.0
3767	Inhibition of CYP3A4	COCn1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O	Bioorg. Med. Chem.	2012.0	CHEMBL2037608	>	>	IC50	nM	30000.0	IC50	uM	30.0
3768	Inhibition of CYP3A4	C[C@H](COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCC[C@H]1C	Bioorg. Med. Chem.	2012.0	CHEMBL2037604	>	>	IC50	nM	30000.0	IC50	uM	30.0
3769	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C	J. Med. Chem.	2012.0	CHEMBL2037511	>	>	IC50	nM	100000.0	IC50	uM	100.0
3770	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2012.0	CHEMBL377414	=	=	IC50	nM	31000.0	IC50	uM	31.0
3771	Inhibition of human CYP3A4 using diethoxyfluorescein as substrate	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C	J. Med. Chem.	2012.0	CHEMBL2037511	>	>	IC50	nM	100000.0	IC50	uM	100.0
3772	Inhibition of human CYP3A4 using diethoxyfluorescein as substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2012.0	CHEMBL377414	=	=	IC50	nM	5000.0	IC50	uM	5.0
3773	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2	J. Med. Chem.	2012.0	CHEMBL2035053	=	=	IC50	nM	970.0	IC50	uM	0.97
3774	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035183	>	>	IC50	nM	10000.0	IC50	uM	10.0
3775	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035185	>	>	IC50	nM	10000.0	IC50	uM	10.0
3776	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035186	>	>	IC50	nM	10000.0	IC50	uM	10.0
3777	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by fluorescence detection assay	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035185	>	>	IC50	nM	10000.0	IC50	uM	10.0
3778	Inhibition of CYP3A4	O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036730	>	>	IC50	nM	30000.0	IC50	uM	30.0
3779	Inhibition of CYP3A4	CN1C(=O)N(Cc2cc(Cl)ccc2F)C(=O)[C@]12C(=O)N(CC(=O)O)c1ccc(Cl)cc12	ACS Med. Chem. Lett.	2011.0	CHEMBL2042239	>	>	IC50	nM	10000.0	IC50	uM	10.0
3780	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis	O=C(O)/C(O)=C/C(=O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O	ACS Med. Chem. Lett.	2011.0	CHEMBL2043144	>	>	IC50	nM	200000.0	IC50	uM	200.0
3781	Inhibition of CYP3A4 in human liver microsomes using triazolam as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis	O=C(O)/C(O)=C/C(=O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O	ACS Med. Chem. Lett.	2011.0	CHEMBL2043144	>	>	IC50	nM	200000.0	IC50	uM	200.0
3782	Inhibition of CYP3A4	CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1	ACS Med. Chem. Lett.	2012.0	CHEMBL2043437	>	>	IC50	nM	30000.0	IC50	uM	30.0
3783	Inhibition of human CYP3A4 in liver microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL157101	=	=	IC50	nM	70.0	IC50	uM	0.07
3784	Inhibition of human CYP3A4 in liver microsomes	CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL105592	=	=	IC50	nM	140.0	IC50	uM	0.14
3785	Inhibition of human CYP3A4 in liver microsomes	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL163	=	=	IC50	nM	100.0	IC50	uM	0.1
3786	Reversible inhibition of human CYP3A4 in liver microsomes by Dixon and Cornish-Bowden plot analysis	CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL105592	=	=	Ki	nM	80.0	Ki	uM	0.08
3787	Inhibition of CYP3A4	NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1	Eur. J. Med. Chem.	2012.0	CHEMBL2043240	=	=	IC50	nM	40000.0	IC50	uM	40.0
3788	Inhibition of CYP3A4	NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1	Eur. J. Med. Chem.	2012.0	CHEMBL2043240	=	=	IC50	nM	32000.0	IC50	uM	32.0
3789	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043011	>	>	IC50	nM	10000.0	IC50	uM	10.0
3790	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043168	>	>	IC50	nM	50000.0	IC50	uM	50.0
3791	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043169	>	>	IC50	nM	50000.0	IC50	uM	50.0
3792	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043170	>	>	IC50	nM	50000.0	IC50	uM	50.0
3793	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4Cl)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043171	>	>	IC50	nM	50000.0	IC50	uM	50.0
3794	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043172	>	>	IC50	nM	50000.0	IC50	uM	50.0
3795	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043324	>	>	IC50	nM	50000.0	IC50	uM	50.0
3796	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043325	>	>	IC50	nM	50000.0	IC50	uM	50.0
3797	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043326	>	>	IC50	nM	50000.0	IC50	uM	50.0
3798	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043327	=	=	IC50	nM	40000.0	IC50	uM	40.0
3799	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043328	>	>	IC50	nM	50000.0	IC50	uM	50.0
3800	Inhibition of CYP3A4	COCc1nc(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1	J. Med. Chem.	2012.0	CHEMBL2040894	>	>	IC50	nM	50000.0	IC50	uM	50.0
3801	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2040895	>	>	IC50	nM	50000.0	IC50	uM	50.0
3802	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2040896	>	>	IC50	nM	50000.0	IC50	uM	50.0
3803	Inhibition of CYP3A4	Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1	J. Med. Chem.	2012.0	CHEMBL2040897	>	>	IC50	nM	50000.0	IC50	uM	50.0
3804	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041010	>	>	IC50	nM	50000.0	IC50	uM	50.0
3805	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041164	>	>	IC50	nM	50000.0	IC50	uM	50.0
3806	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4coc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041165	>	>	IC50	nM	50000.0	IC50	uM	50.0
3807	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3cnc(O)nc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041167	>	>	IC50	nM	50000.0	IC50	uM	50.0
3808	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041168	>	>	IC50	nM	50000.0	IC50	uM	50.0
3809	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041169	>	>	IC50	nM	50000.0	IC50	uM	50.0
3810	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041170	>	>	IC50	nM	50000.0	IC50	uM	50.0
3811	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041171	>	>	IC50	nM	50000.0	IC50	uM	50.0
3812	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041172	>	>	IC50	nM	50000.0	IC50	uM	50.0
3813	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041173	>	>	IC50	nM	50000.0	IC50	uM	50.0
3814	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041174	=	=	IC50	nM	18000.0	IC50	uM	18.0
3815	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041175	>	>	IC50	nM	50000.0	IC50	uM	50.0
3816	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041176	>	>	IC50	nM	50000.0	IC50	uM	50.0
3817	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041177	>	>	IC50	nM	50000.0	IC50	uM	50.0
3818	Inhibition of CYP3A4	CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1	J. Med. Chem.	2012.0	CHEMBL2041178	>	>	IC50	nM	50000.0	IC50	uM	50.0
3819	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041179	>	>	IC50	nM	50000.0	IC50	uM	50.0
3820	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041180	>	>	IC50	nM	50000.0	IC50	uM	50.0
3821	Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041181	>	>	IC50	nM	50000.0	IC50	uM	50.0
3822	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(O)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1	J. Med. Chem.	2012.0	CHEMBL2040854	>	>	IC50	nM	50000.0	IC50	uM	50.0
3823	Inhibition of CYP3A4	Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041182	>	>	IC50	nM	50000.0	IC50	uM	50.0
3824	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041183	>	>	IC50	nM	50000.0	IC50	uM	50.0
3825	Inhibition of CYP3A4	Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1	J. Med. Chem.	2012.0	CHEMBL2041184	>	>	IC50	nM	50000.0	IC50	uM	50.0
3826	Inhibition of CYP3A4	COc1nccnc1N1C(=O)N(c2ccc(-c3ccc(C(=O)O)cc3C)cc2)C(=O)C12CCN(Cc1ncccc1C)CC2	J. Med. Chem.	2012.0	CHEMBL2041185	>	>	IC50	nM	50000.0	IC50	uM	50.0
3827	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041186	>	>	IC50	nM	50000.0	IC50	uM	50.0
3828	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1	J. Med. Chem.	2012.0	CHEMBL2041187	>	>	IC50	nM	10000.0	IC50	uM	10.0
3829	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041188	>	>	IC50	nM	50000.0	IC50	uM	50.0
3830	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1	J. Med. Chem.	2012.0	CHEMBL2041189	>	>	IC50	nM	50000.0	IC50	uM	50.0
3831	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041190	>	>	IC50	nM	50000.0	IC50	uM	50.0
3832	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1	J. Med. Chem.	2012.0	CHEMBL2041191	>	>	IC50	nM	50000.0	IC50	uM	50.0
3833	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1	J. Med. Chem.	2012.0	CHEMBL2041192	>	>	IC50	nM	50000.0	IC50	uM	50.0
3834	Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041193	>	>	IC50	nM	50000.0	IC50	uM	50.0
3835	Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043004	=	=	IC50	nM	69000.0	IC50	uM	69.0
3836	Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048183	=	=	IC50	nM	37000.0	IC50	uM	37.0
3837	Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048187	=	=	IC50	nM	10000.0	IC50	uM	10.0
3838	Inhibition of CYP3A4 using midazolam as substrate	CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048199	=	=	IC50	nM	4000.0	IC50	uM	4.0
3839	Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048204	=	=	IC50	nM	5000.0	IC50	uM	5.0
3840	Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048183	>	>	IC50	nM	50000.0	IC50	uM	50.0
3841	Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048187	=	=	IC50	nM	15000.0	IC50	uM	15.0
3842	Inhibition of CYP3A4 using testosterone as substrate	CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048199	=	=	IC50	nM	7000.0	IC50	uM	7.0
3843	Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048204	=	=	IC50	nM	13000.0	IC50	uM	13.0
3844	Inhibition of CYP3A4 in human liver microsomes	Cc1csc(N(C)C(=O)CSc2ccc(-c3ccccc3)nn2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048846	>	>	IC50	nM	30000.0	IC50	uM	30.0
3845	Inhibition of CYP3A4 in human liver microsomes	Cc1csc(N(C(=O)CSc2ccc(-c3ccccc3)nn2)C2CC2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048855	>	>	IC50	nM	30000.0	IC50	uM	30.0
3846	Inhibition of CYP3A4	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1	ACS Med. Chem. Lett.	2012.0	CHEMBL2048028	>	>	IC50	nM	20000.0	IC50	uM	20.0
3847	Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
3848	Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Cl)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4Cl)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2047188	=	=	IC50	nM	13800.0	IC50	uM	13.8
3849	Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(F)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4F)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2047191	=	=	IC50	nM	3100.0	IC50	uM	3.1
3850	Inhibition of CYP3A4	CC(C)(C)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048047	=	=	IC50	nM	300.0	IC50	uM	0.3
3851	Inhibition of CYP3A4	CC(C)(C)c1ccnc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048057	=	=	IC50	nM	400.0	IC50	uM	0.4
3852	Inhibition of CYP3A4	CC(C)(O)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048058	=	=	IC50	nM	2100.0	IC50	uM	2.1
3853	Inhibition of CYP3A4	CC(C)(CO)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048059	=	=	IC50	nM	800.0	IC50	uM	0.8
3854	Inhibition of CYP3A4	CC1(C)OCc2ccc(CN[C@H]3CS(=O)(=O)C[C@@H](Cc4cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c4)[C@@H]3O)cc21	J. Med. Chem.	2012.0	CHEMBL2048060	=	=	IC50	nM	700.0	IC50	uM	0.7
3855	Inhibition of CYP3A4	Nc1c(F)cc(C[C@@H]2CS(=O)(=O)C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc1OC(C(F)(F)F)C(F)(F)F	J. Med. Chem.	2012.0	CHEMBL2048061	=	=	IC50	nM	9200.0	IC50	uM	9.2
3856	Inhibition of CYP3A4	CC(C)(C)Cn1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)cn1	J. Med. Chem.	2012.0	CHEMBL2048062	=	=	IC50	nM	6700.0	IC50	uM	6.7
3857	Inhibition of CYP3A4	CC(C)(C)Cc1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)no1	J. Med. Chem.	2012.0	CHEMBL2048063	=	=	IC50	nM	400.0	IC50	uM	0.4
3858	Inhibition of CYP3A4	N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)cc3n4CCC3CC(=O)O)no2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048293	>	>	IC50	nM	30000.0	IC50	uM	30.0
3859	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048485	>	>	IC50	nM	50000.0	IC50	uM	50.0
3860	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048486	>	>	IC50	nM	50000.0	IC50	uM	50.0
3861	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048487	=	=	IC50	nM	76000.0	IC50	uM	76.0
3862	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048490	>	>	IC50	nM	50000.0	IC50	uM	50.0
3863	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048492	=	=	IC50	nM	36600.0	IC50	uM	36.6
3864	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048496	=	=	IC50	nM	25700.0	IC50	uM	25.7
3865	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048497	=	=	IC50	nM	29000.0	IC50	uM	29.0
3866	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048485	>	>	IC50	nM	50000.0	IC50	uM	50.0
3867	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048486	>	>	IC50	nM	50000.0	IC50	uM	50.0
3868	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048487	=	=	IC50	nM	33000.0	IC50	uM	33.0
3869	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048490	>	>	IC50	nM	50000.0	IC50	uM	50.0
3870	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048492	>	>	IC50	nM	50000.0	IC50	uM	50.0
3871	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048496	=	=	IC50	nM	40300.0	IC50	uM	40.3
3872	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048497	>	>	IC50	nM	50000.0	IC50	uM	50.0
3873	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)sc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059114	=	=	IC50	nM	19.0	IC50	uM	0.019
3874	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cccnc3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058906	=	=	IC50	nM	22.0	IC50	uM	0.022
3875	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058665	=	=	IC50	nM	22.0	IC50	uM	0.022
3876	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059115	=	=	IC50	nM	23.0	IC50	uM	0.023
3877	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccc(F)cc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058900	=	=	IC50	nM	23.0	IC50	uM	0.023
3878	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccccc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058905	=	=	IC50	nM	24.0	IC50	uM	0.024
3879	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccncc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058664	=	=	IC50	nM	24.0	IC50	uM	0.024
3880	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057522	=	=	IC50	nM	26.0	IC50	uM	0.026
3881	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC3CCCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057523	=	=	IC50	nM	26.0	IC50	uM	0.026
3882	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057527	=	=	IC50	nM	27.0	IC50	uM	0.027
3883	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057518	=	=	IC50	nM	28.0	IC50	uM	0.028
3884	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCC(F)(F)CC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057791	=	=	IC50	nM	30.0	IC50	uM	0.03
3885	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057792	=	=	IC50	nM	30.0	IC50	uM	0.03
3886	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058910	=	=	IC50	nM	31.0	IC50	uM	0.031
3887	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057790	=	=	IC50	nM	31.0	IC50	uM	0.031
3888	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059117	=	=	IC50	nM	33.0	IC50	uM	0.033
3889	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(C(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058663	=	=	IC50	nM	37.0	IC50	uM	0.037
3890	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)C)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057788	=	=	IC50	nM	37.0	IC50	uM	0.037
3891	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCOCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059120	=	=	IC50	nM	38.0	IC50	uM	0.038
3892	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCNc1nc2ccc(C(=O)N(CC#C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057787	=	=	IC50	nM	38.0	IC50	uM	0.038
3893	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057786	=	=	IC50	nM	39.0	IC50	uM	0.039
3894	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057524	=	=	IC50	nM	40.0	IC50	uM	0.04
3895	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057517	=	=	IC50	nM	41.0	IC50	uM	0.041
3896	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058901	=	=	IC50	nM	42.0	IC50	uM	0.042
3897	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccc4c(c3)OCO4)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058903	=	=	IC50	nM	44.0	IC50	uM	0.044
3898	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058904	=	=	IC50	nM	52.0	IC50	uM	0.052
3899	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059119	=	=	IC50	nM	53.0	IC50	uM	0.053
3900	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncoc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057528	=	=	IC50	nM	55.0	IC50	uM	0.055
3901	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057521	=	=	IC50	nM	60.0	IC50	uM	0.06
3902	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3cccnc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057794	=	=	IC50	nM	69.0	IC50	uM	0.069
3903	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CC)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057520	=	=	IC50	nM	79.0	IC50	uM	0.079
3904	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057514	=	=	IC50	nM	84.0	IC50	uM	0.084
3905	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1cccnc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059116	=	=	IC50	nM	90.0	IC50	uM	0.09
3906	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCN(C)CC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059123	=	=	IC50	nM	92.0	IC50	uM	0.092
3907	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCNc1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057789	=	=	IC50	nM	97.0	IC50	uM	0.097
3908	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059126	=	=	IC50	nM	110.0	IC50	uM	0.11
3909	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059127	=	=	IC50	nM	120.0	IC50	uM	0.12
3910	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059122	=	=	IC50	nM	130.0	IC50	uM	0.13
3911	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN3CCOCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058909	=	=	IC50	nM	140.0	IC50	uM	0.14
3912	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN3CCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059121	=	=	IC50	nM	140.0	IC50	uM	0.14
3913	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057525	=	=	IC50	nM	140.0	IC50	uM	0.14
3914	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057516	=	=	IC50	nM	180.0	IC50	uM	0.18
3915	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccncc3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058907	=	=	IC50	nM	200.0	IC50	uM	0.2
3916	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059124	=	=	IC50	nM	200.0	IC50	uM	0.2
3917	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057515	=	=	IC50	nM	200.0	IC50	uM	0.2
3918	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CN(C)CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059125	=	=	IC50	nM	230.0	IC50	uM	0.23
3919	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058908	=	=	IC50	nM	410.0	IC50	uM	0.41
3920	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NC3CCN(C)CC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058902	=	=	IC50	nM	2700.0	IC50	uM	2.7
3921	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	CC(C)C[C@@H](NC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)C(=O)N1CCC(N2CCCCC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059786	=	=	IC50	nM	16000.0	IC50	uM	16.0
3922	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059790	>	>	IC50	nM	40000.0	IC50	uM	40.0
3923	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1cc(Br)c(O)c(Br)c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059794	=	=	IC50	nM	2400.0	IC50	uM	2.4
3924	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059798	=	=	IC50	nM	30.0	IC50	uM	0.03
3925	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059799	=	=	IC50	nM	30.0	IC50	uM	0.03
3926	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059800	=	=	IC50	nM	1300.0	IC50	uM	1.3
3927	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059801	>	>	IC50	nM	40000.0	IC50	uM	40.0
3928	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	Cn1cc(C[C@@H](NC(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059802	=	=	IC50	nM	100.0	IC50	uM	0.1
3929	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059803	=	=	IC50	nM	2500.0	IC50	uM	2.5
3930	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059804	=	=	IC50	nM	17000.0	IC50	uM	17.0
3931	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059852	=	=	IC50	nM	7300.0	IC50	uM	7.3
3932	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059853	=	=	IC50	nM	30000.0	IC50	uM	30.0
3933	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C1Cc2cc(C[C@@H](NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059877	=	=	IC50	nM	11000.0	IC50	uM	11.0
3934	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2[nH]nnc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059878	=	=	IC50	nM	23000.0	IC50	uM	23.0
3935	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059880	=	=	IC50	nM	84.0	IC50	uM	0.084
3936	Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence detection assay	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059880	=	=	IC50	nM	870.0	IC50	uM	0.87
3937	Inhibition of CYP3A4	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC2(CC1)N=C(c1ccccc1)NC2=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059900	<	<	IC50	nM	1000.0	IC50	uM	1.0
3938	Inhibition of CYP3A4	O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)O1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059905	<	<	IC50	nM	1000.0	IC50	uM	1.0
3939	Inhibition of CYP3A4	O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059906	=	=	IC50	nM	100.0	IC50	uM	0.1
3940	Inhibition of CYP3A4	CCc1c(CCCC(=O)O)cccc1-c1noc(-c2ccc(OC(C)C)c(C#N)c2)n1	J. Med. Chem.	2012.0	CHEMBL2059515	<	>	IC50	nM	10000.0	pIC50		5.0
3941	Inhibition of CYP3A4	CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)s1	J. Med. Chem.	2012.0	CHEMBL2059516	<	>	IC50	nM	10000.0	pIC50		5.0
3942	Inhibition of CYP3A4	CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2057282	<	>	IC50	nM	10000.0	pIC50		5.0
3943	Inhibition of CYP3A4	CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(CC(C)C)c(C#N)c2)n1	J. Med. Chem.	2012.0	CHEMBL2057285	<	>	IC50	nM	10000.0	pIC50		5.0
3944	Inhibition of human CYP3A4	CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN	J. Med. Chem.	2012.0	CHEMBL2058833	>	>	IC50	nM	6000.0	IC50	uM	6.0
3945	Inhibition of CPY3A4	O=C(C1CN(S(=O)(=O)c2cccc3cnccc23)C1)N1CC2CN(c3ccncc3)CC2C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057776	<	<	IC50	nM	2500.0	IC50	uM	2.5
3946	Inhibition of CYP3A4	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1	J. Med. Chem.	2012.0	CHEMBL2062808	=	=	IC50	nM	200.0	IC50	uM	0.2
3947	Inhibition of CYP3A4	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2062804	=	=	IC50	nM	11000.0	IC50	uM	11.0
3948	Inhibition of CYP3A4	CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2062809	=	=	IC50	nM	24000.0	IC50	uM	24.0
3949	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064417	>	>	IC50	nM	40000.0	IC50	uM	40.0
3950	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064413	=	=	IC50	nM	19000.0	IC50	uM	19.0
3951	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064412	>	>	IC50	nM	40000.0	IC50	uM	40.0
3952	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064352	>	>	IC50	nM	40000.0	IC50	uM	40.0
3953	Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21	J. Med. Chem.	2012.0	CHEMBL2064348	>	>	IC50	nM	40000.0	IC50	uM	40.0
3954	Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21	J. Med. Chem.	2012.0	CHEMBL2064347	>	>	IC50	nM	40000.0	IC50	uM	40.0
3955	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064346	>	>	IC50	nM	40000.0	IC50	uM	40.0
3956	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064344	>	>	IC50	nM	40000.0	IC50	uM	40.0
3957	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064343	>	>	IC50	nM	40000.0	IC50	uM	40.0
3958	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064341	>	>	IC50	nM	40000.0	IC50	uM	40.0
3959	Inhibition of human recombinant CPY3A4	CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21	J. Med. Chem.	2012.0	CHEMBL2064340	>	>	IC50	nM	40000.0	IC50	uM	40.0
3960	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Cl)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064336	>	>	IC50	nM	40000.0	IC50	uM	40.0
3961	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Br)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064335	>	>	IC50	nM	40000.0	IC50	uM	40.0
3962	Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21	J. Med. Chem.	2012.0	CHEMBL2064333	>	>	IC50	nM	40000.0	IC50	uM	40.0
3963	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064331	>	>	IC50	nM	40000.0	IC50	uM	40.0
3964	Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21	J. Med. Chem.	2012.0	CHEMBL2064330	>	>	IC50	nM	40000.0	IC50	uM	40.0
3965	Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064418	>	>	IC50	nM	40000.0	IC50	uM	40.0
3966	Inhibition of CYP3A4	O=C(O)c1cc(NC(=O)[C@H](Cc2ccccc2)NCc2cscn2)cc(-c2ccncc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069579	>	>	IC50	nM	30000.0	IC50	uM	30.0
3967	Inhibition of CYP3A4	Cc1cc(-c2c[nH]c(=O)c(NC(=O)[C@H](Cc3ccccc3)NCc3cscn3)c2)ccn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069588	>	>	IC50	nM	30000.0	IC50	uM	30.0
3968	Inhibition of CYP3A4	Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069398	>	>	IC50	nM	11000.0	IC50	uM	11.0
3969	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL1504335	>	>	IC50	nM	20000.0	IC50	uM	20.0
3970	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2069921	>	>	IC50	nM	20000.0	IC50	uM	20.0
3971	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1	J. Med. Chem.	2012.0	CHEMBL2069806	>	>	IC50	nM	20000.0	IC50	uM	20.0
3972	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1	J. Med. Chem.	2012.0	CHEMBL2069805	>	>	IC50	nM	20000.0	IC50	uM	20.0
3973	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1cc(-c2nnc(C3CCCCC3)o2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069804	>	>	IC50	nM	20000.0	IC50	uM	20.0
3974	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1cc(-c2noc(C3CCCCC3)n2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069803	=	=	IC50	nM	10200.0	IC50	uM	10.2
3975	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1	J. Med. Chem.	2012.0	CHEMBL2069802	>	>	IC50	nM	20000.0	IC50	uM	20.0
3976	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1	J. Med. Chem.	2012.0	CHEMBL2069801	=	=	IC50	nM	14600.0	IC50	uM	14.6
3977	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069800	>	>	IC50	nM	20000.0	IC50	uM	20.0
3978	Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069799	=	=	IC50	nM	14200.0	IC50	uM	14.2
3979	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccccc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069838	=	=	IC50	nM	1000.0	IC50	uM	1.0
3980	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069839	=	=	IC50	nM	1000.0	IC50	uM	1.0
3981	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069840	=	=	IC50	nM	1000.0	IC50	uM	1.0
3982	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(OC(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069841	=	=	IC50	nM	1000.0	IC50	uM	1.0
3983	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069842	=	=	IC50	nM	1000.0	IC50	uM	1.0
3984	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(S(N)(=O)=O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069843	=	=	IC50	nM	1000.0	IC50	uM	1.0
3985	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069844	=	=	IC50	nM	1000.0	IC50	uM	1.0
3986	Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2cccc(C(=O)O)c2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069845	=	=	IC50	nM	1000.0	IC50	uM	1.0
3987	Inhibition of CYP3A4	CN1CCN(c2ccc(C(=O)N3CCN(C(=O)C[C@H](N)Cc4cc(F)c(F)cc4F)CC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069846	=	=	IC50	nM	1000.0	IC50	uM	1.0
3988	Inhibition of CYP3A4	N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070937	<	>	IC50	nM	31622.78	pIC50		4.5
3989	Inhibition of CYP3A4	CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)sc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070947	=	=	IC50	nM	630.96	pIC50		6.2
3990	Inhibition of CYP3A4	CC(C)(C#N)c1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070948	=	=	IC50	nM	3981.07	pIC50		5.4
3991	Inhibition of CYP3A4	N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070949	<	>	IC50	nM	31622.78	pIC50		4.5
3992	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cn(-c4ccccc4)ccc3=O)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070162	>	>	IC50	nM	20000.0	IC50	uM	20.0
3993	Inhibition of CYP3A4	O=c1ccc(-c2nc3cc(S(=O)(=O)CC(F)(F)F)ccc3[nH]2)cn1-c1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070161	>	>	IC50	nM	20000.0	IC50	uM	20.0
3994	Inhibition of CYP3A4	O=c1ccc(-c2nc3cc(S(=O)(=O)C(F)(F)F)ccc3[nH]2)cn1-c1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070160	=	=	IC50	nM	5100.0	IC50	uM	5.1
3995	Inhibition of CYP3A4	CC(C)(C)S(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070159	>	>	IC50	nM	20000.0	IC50	uM	20.0
3996	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070158	>	>	IC50	nM	20000.0	IC50	uM	20.0
3997	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccnc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070157	=	=	IC50	nM	8700.0	IC50	uM	8.7
3998	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cncc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070156	=	=	IC50	nM	7800.0	IC50	uM	7.8
3999	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccn3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070155	=	=	IC50	nM	7000.0	IC50	uM	7.0
4000	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)n3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070154	=	=	IC50	nM	7700.0	IC50	uM	7.7
4001	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(C)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069316	=	=	IC50	nM	5700.0	IC50	uM	5.7
4002	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3C)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070153	=	=	IC50	nM	5900.0	IC50	uM	5.9
4003	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3C)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070152	=	=	IC50	nM	5200.0	IC50	uM	5.2
4004	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(Cl)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070151	=	=	IC50	nM	2600.0	IC50	uM	2.6
4005	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3Cl)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070150	=	=	IC50	nM	5000.0	IC50	uM	5.0
4006	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3Cl)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070149	=	=	IC50	nM	3800.0	IC50	uM	3.8
4007	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(F)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070148	=	=	IC50	nM	5600.0	IC50	uM	5.6
4008	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3F)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070147	=	=	IC50	nM	14000.0	IC50	uM	14.0
4009	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3F)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070146	=	=	IC50	nM	6600.0	IC50	uM	6.6
4010	Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070137	=	=	IC50	nM	9000.0	IC50	uM	9.0
4011	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(OC(F)(F)F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070143	=	=	IC50	nM	10000.0	IC50	uM	10.0
4012	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(C(F)(F)F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070142	=	=	IC50	nM	20000.0	IC50	uM	20.0
4013	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(-c4ccccc4)cc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070141	=	=	IC50	nM	2900.0	IC50	uM	2.9
4014	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070140	=	=	IC50	nM	6000.0	IC50	uM	6.0
4015	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3-c3ccccc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070139	=	=	IC50	nM	11000.0	IC50	uM	11.0
4016	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070138	>	>	IC50	nM	20000.0	IC50	uM	20.0
4017	Inhibition of CYP3A4	O=S(=O)(c1ccc2[nH]c(SCc3cccc(Cl)c3)nc2c1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1585484	=	=	IC50	nM	1900.0	IC50	uM	1.9
4018	Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccn(-c4ccccc4)c3=O)nc2c1.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070163	>	>	IC50	nM	20000.0	IC50	uM	20.0
4019	Inhibition of CYP3A4	CCCCCCc1c(O)ccc2c1O[C@]1(C2=O)C(Cl)=C(Cl)C(=O)N1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087639	>	>	IC50	nM	10000.0	IC50	uM	10.0
4020	Inhibition of CYP3A4	CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cc3)nc(NC[C@@H](O)CO)nc21	Eur. J. Med. Chem.	2012.0	CHEMBL2089032	>	>	IC50	nM	5000.0	IC50	uM	5.0
4021	Inhibition of CYP3A4 by high-throughput fluorescence assay	CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)no1	J. Med. Chem.	2012.0	CHEMBL2086690	>	>	IC50	nM	30000.0	IC50	uM	30.0
4022	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4cc(OC)ccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086751	=	=	IC50	nM	5600.0	IC50	uM	5.6
4023	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086753	=	=	IC50	nM	3000.0	IC50	uM	3.0
4024	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(C)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086754	=	=	IC50	nM	12000.0	IC50	uM	12.0
4025	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(OC)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086755	=	=	IC50	nM	9000.0	IC50	uM	9.0
4026	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086756	=	=	IC50	nM	4000.0	IC50	uM	4.0
4027	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086757	=	=	IC50	nM	6000.0	IC50	uM	6.0
4028	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086758	=	=	IC50	nM	25000.0	IC50	uM	25.0
4029	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086759	=	=	IC50	nM	23000.0	IC50	uM	23.0
4030	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086760	>	>	IC50	nM	50000.0	IC50	uM	50.0
4031	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087167	=	=	IC50	nM	25000.0	IC50	uM	25.0
4032	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087168	=	=	IC50	nM	10000.0	IC50	uM	10.0
4033	Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2nc(C)c[nH]2)c2ccccc2F)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087169	=	=	IC50	nM	26000.0	IC50	uM	26.0
4034	Inhibition of CYP3A4	Cn1cc(S(=O)(=O)[C@H]2CC[C@](CNC(=O)c3ccc(Cl)cc3Cl)(CC3CC3)CC2)nn1	ACS Med. Chem. Lett.	2010.0	CHEMBL520648	>	>	IC50	nM	10000.0	IC50	uM	10.0
4035	Inhibition of human CYP3A4	CC1CCN([C@H](c2ccc(F)cc2)c2ccc([C@@H](C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL2146750	>	>	IC50	nM	35000.0	IC50	uM	35.0
4036	Inhibition of CYP3A4	Cl.Cn1c(=O)c2c(nc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2Cl)c2ccc(C(=O)O)cc21	Bioorg. Med. Chem.	2012.0	CHEMBL2147070	>	>	IC50	nM	50000.0	IC50	uM	50.0
4037	Inhibition of CYP3A4-catalyzed midazolam 1'-hydroxylation in human liver microsomes	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1	J. Med. Chem.	2011.0	CHEMBL565612	=	=	Ki	nM	2900.0	Ki	uM	2.9
4038	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@@H]([C@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152522	=	=	IC50	nM	15848.93	pIC50		4.8
4039	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@H]([C@@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152523	=	=	IC50	nM	19952.62	pIC50		4.7
4040	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@@H]([C@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152524	=	=	IC50	nM	12589.25	pIC50		4.9
4041	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@H]([C@@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152525	=	=	IC50	nM	12589.25	pIC50		4.9
4042	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152010	=	=	Ki	nM	3100.0	Ki	uM	3.1
4043	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152011	=	=	Ki	nM	14400.0	Ki	uM	14.4
4044	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152012	=	=	Ki	nM	4100.0	Ki	uM	4.1
4045	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152013	=	=	Ki	nM	3970.0	Ki	uM	3.97
4046	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152014	=	=	Ki	nM	540.0	Ki	uM	0.54
4047	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152015	=	=	Ki	nM	800.0	Ki	uM	0.8
4048	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccncc2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL463976	=	=	Ki	nM	700.0	Ki	uM	0.7
4049	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152016	=	=	Ki	nM	540.0	Ki	uM	0.54
4050	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152017	=	=	Ki	nM	11900.0	Ki	uM	11.9
4051	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152018	=	=	Ki	nM	32900.0	Ki	uM	32.9
4052	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccccn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL513115	=	=	Ki	nM	14500.0	Ki	uM	14.5
4053	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152019	=	=	Ki	nM	3900.0	Ki	uM	3.9
4054	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152020	=	=	Ki	nM	20100.0	Ki	uM	20.1
4055	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152021	=	=	Ki	nM	15930.0	Ki	uM	15.93
4056	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2cnccn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152022	=	=	Ki	nM	6900.0	Ki	uM	6.9
4057	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152023	=	=	Ki	nM	2700.0	Ki	uM	2.7
4058	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152024	=	=	Ki	nM	2200.0	Ki	uM	2.2
4059	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152025	=	=	Ki	nM	8400.0	Ki	uM	8.4
4060	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccncn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152026	=	=	Ki	nM	2200.0	Ki	uM	2.2
4061	Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2151049	=	=	Ki	nM	3000.0	Ki	uM	3.0
4062	Inhibition of CYP3A4	O=C(C1CCC(F)(F)CC1)N1CC(c2nc(-c3cccc(Cl)c3)no2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151497	=	=	IC50	nM	25000000.0	IC50	mM	25.0
4063	Inhibition of CYP3A4	CC1CCCCC1C(=O)N1CC(c2nc(-c3cccc(F)c3)no2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151616	=	=	IC50	nM	25000000.0	IC50	mM	25.0
4064	Inhibition of human CYP3A4 using midazolam as substrate after 15 mins by LC/MS/MS analysis	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N	J. Med. Chem.	2012.0	CHEMBL2152252	>	>	IC50	nM	20000.0	IC50	nM	20000.0
4065	Inhibition of human CYP3A4 using testosterone as substrate after 15 mins by LC/MS/MS analysis	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N	J. Med. Chem.	2012.0	CHEMBL2152252	>	>	IC50	nM	20000.0	IC50	nM	20000.0
4066	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2064419	=	=	IC50	nM	40000.0	IC50	uM	40.0
4067	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151821	=	=	IC50	nM	40000.0	IC50	uM	40.0
4068	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151921	=	=	IC50	nM	40000.0	IC50	uM	40.0
4069	Inhibition of human recombinant CYP3A4	COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151922	=	=	IC50	nM	40000.0	IC50	uM	40.0
4070	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151923	=	=	IC50	nM	40000.0	IC50	uM	40.0
4071	Inhibition of human recombinant CYP3A4	Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151925	=	=	IC50	nM	40000.0	IC50	uM	40.0
4072	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151926	=	=	IC50	nM	40000.0	IC50	uM	40.0
4073	Inhibition of human recombinant CYP3A4	COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151927	=	=	IC50	nM	40000.0	IC50	uM	40.0
4074	Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151048	=	=	IC50	nM	40000.0	IC50	uM	40.0
4075	Inhibition of human recombinant CYP3A4	Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151935	=	=	IC50	nM	40000.0	IC50	uM	40.0
4076	Inhibition of CYP3A4	NC(=O)c1ccccc1Nc1cccc(OCCc2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2152613	>	>	IC50	nM	10000.0	IC50	uM	10.0
4077	Inhibition of CYP3A4 in human liver microsomes	COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O.Cl.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL4299173	>	>	IC50	nM	20000.0	IC50	uM	20.0
4078	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159130	=	=	IC50	nM	1330.0	IC50	uM	1.33
4079	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159131	=	=	IC50	nM	700.0	IC50	uM	0.7
4080	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159136	=	=	IC50	nM	700.0	IC50	uM	0.7
4081	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159135	=	=	IC50	nM	1400.0	IC50	uM	1.4
4082	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159134	=	=	IC50	nM	1100.0	IC50	uM	1.1
4083	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159133	=	=	IC50	nM	1000.0	IC50	uM	1.0
4084	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159132	=	=	IC50	nM	7800.0	IC50	uM	7.8
4085	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159140	=	=	IC50	nM	500.0	IC50	uM	0.5
4086	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159139	=	=	IC50	nM	7900.0	IC50	uM	7.9
4087	Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL529	>	>	IC50	nM	10000.0	IC50	uM	10.0
4088	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159130	>	>	IC50	nM	10000.0	IC50	uM	10.0
4089	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159131	=	=	IC50	nM	8000.0	IC50	uM	8.0
4090	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159136	=	=	IC50	nM	4700.0	IC50	uM	4.7
4091	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159135	>	>	IC50	nM	10000.0	IC50	uM	10.0
4092	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159134	=	=	IC50	nM	9800.0	IC50	uM	9.8
4093	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159133	>	>	IC50	nM	10000.0	IC50	uM	10.0
4094	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159132	>	>	IC50	nM	10000.0	IC50	uM	10.0
4095	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159140	=	=	IC50	nM	5700.0	IC50	uM	5.7
4096	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159139	>	>	IC50	nM	10000.0	IC50	uM	10.0
4097	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)OC)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159138	=	=	IC50	nM	2900.0	IC50	uM	2.9
4098	Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL529	>	>	IC50	nM	10000.0	IC50	uM	10.0
4099	Reversible inhibition of CYP3A4 using midazolam as substrate	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1	J. Med. Chem.	2012.0	CHEMBL2159210	>	>	IC50	nM	10000.0	IC50	uM	10.0
4100	Reversible inhibition of CYP3A4 using testosterone as substrate	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1	J. Med. Chem.	2012.0	CHEMBL2159210	>	>	IC50	nM	10000.0	IC50	uM	10.0
4101	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2159071	=	=	IC50	nM	1600.0	IC50	uM	1.6
4102	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2159071	=	=	IC50	nM	7300.0	IC50	uM	7.3
4103	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159084	=	=	IC50	nM	18000.0	IC50	uM	18.0
4104	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159084	=	=	IC50	nM	19000.0	IC50	uM	19.0
4105	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2158890	=	=	IC50	nM	150.0	IC50	uM	0.15
4106	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159075	=	=	IC50	nM	10000.0	IC50	uM	10.0
4107	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL2158221	>	>	IC50	nM	10000.0	IC50	uM	10.0
4108	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158222	=	=	IC50	nM	1700.0	IC50	uM	1.7
4109	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158224	=	=	IC50	nM	5600.0	IC50	uM	5.6
4110	Inhibition of CYP3A4	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1	J. Med. Chem.	2011.0	CHEMBL2158225	>	>	IC50	nM	10000.0	IC50	uM	10.0
4111	Inhibition of CYP3A4	CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158227	>	>	IC50	nM	10000.0	IC50	uM	10.0
4112	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158228	>	>	IC50	nM	10000.0	IC50	uM	10.0
4113	Inhibition of CYP3A4	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1	J. Med. Chem.	2011.0	CHEMBL2158230	=	=	IC50	nM	3800.0	IC50	uM	3.8
4114	Inhibition of CYP3A4	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL256712	>	>	IC50	nM	10000.0	IC50	uM	10.0
4115	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158231	=	=	IC50	nM	6100.0	IC50	uM	6.1
4116	Inhibition of CYP3A4	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL1908842	=	=	IC50	nM	4800.0	IC50	uM	4.8
4117	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158287	=	=	IC50	nM	8200.0	IC50	uM	8.2
4118	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158288	=	=	IC50	nM	5100.0	IC50	uM	5.1
4119	Inhibition of CYP3A4	CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158289	=	=	IC50	nM	6700.0	IC50	uM	6.7
4120	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158291	=	=	IC50	nM	1900.0	IC50	uM	1.9
4121	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158292	>	>	IC50	nM	10000.0	IC50	uM	10.0
4122	Inhibition of CYP3A4	Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4nc(C#N)c[nH]4)c(C4=CCCCC4)c3)CC2)c1	J. Med. Chem.	2011.0	CHEMBL2158294	=	=	IC50	nM	2300.0	IC50	uM	2.3
4123	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158295	=	=	IC50	nM	1500.0	IC50	uM	1.5
4124	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158297	=	=	IC50	nM	1000.0	IC50	uM	1.0
4125	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158299	=	=	IC50	nM	1800.0	IC50	uM	1.8
4126	Inhibition of CYP3A4	CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158301	>	>	IC50	nM	10000.0	IC50	uM	10.0
4127	Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158302	=	=	IC50	nM	6400.0	IC50	uM	6.4
4128	Inhibition of human CYP3A4 in liver microsomes assessed as testosterone 6beta-hydroxylation after 48 hrs	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	J. Med. Chem.	2012.0	CHEMBL1933349	=	=	IC50	nM	60000.0	IC50	uM	60.0
4129	Inhibition of CYP3A4 using midazolam as substrate	O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1	J. Med. Chem.	2012.0	CHEMBL1939222	>	>	IC50	nM	50000.0	IC50	uM	50.0
4130	Inhibition of CYP3A4 using testosterone as substrate	O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1	J. Med. Chem.	2012.0	CHEMBL1939222	>	>	IC50	nM	50000.0	IC50	uM	50.0
4131	Inhibition of CYP3A4	CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1	J. Med. Chem.	2012.0	CHEMBL2164048	=	=	IC50	nM	3900.0	IC50	uM	3.9
4132	inhibition of CYP3A4	O=S(=O)(NCCO)c1ccc(-c2ccnc3[nH]c(C4CC4)cc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2164422	>	>	IC50	nM	10000.0	IC50	uM	10.0
4133	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2163828	=	=	IC50	nM	2900.0	IC50	nM	2900.0
4134	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2163827	=	=	IC50	nM	2400.0	IC50	nM	2400.0
4135	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163826	=	=	IC50	nM	600.0	IC50	nM	600.0
4136	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163825	=	=	IC50	nM	430.0	IC50	nM	430.0
4137	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1CCCC(NC(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C1	J. Med. Chem.	2012.0	CHEMBL2163824	=	=	IC50	nM	420.0	IC50	nM	420.0
4138	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163823	=	=	IC50	nM	8000.0	IC50	nM	8000.0
4139	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	O=C([C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCC(O)CC1	J. Med. Chem.	2012.0	CHEMBL2163822	=	=	IC50	nM	1300.0	IC50	nM	1300.0
4140	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163839	=	=	IC50	nM	7800.0	IC50	nM	7800.0
4141	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163838	=	=	IC50	nM	1530.0	IC50	nM	1530.0
4142	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	C[C@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1	J. Med. Chem.	2012.0	CHEMBL2163837	=	=	IC50	nM	400.0	IC50	nM	400.0
4143	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	C[C@@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1	J. Med. Chem.	2012.0	CHEMBL2163836	=	=	IC50	nM	450.0	IC50	nM	450.0
4144	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	O=C([C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCNCC1	J. Med. Chem.	2012.0	CHEMBL2163835	<	<	IC50	nM	200.0	IC50	nM	200.0
4145	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163834	=	=	IC50	nM	480.0	IC50	nM	480.0
4146	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163833	=	=	IC50	nM	760.0	IC50	nM	760.0
4147	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163832	=	=	IC50	nM	1030.0	IC50	nM	1030.0
4148	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163831	=	=	IC50	nM	1360.0	IC50	nM	1360.0
4149	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](COCc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163830	=	=	IC50	nM	2200.0	IC50	nM	2200.0
4150	Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163829	=	=	IC50	nM	10000.0	IC50	nM	10000.0
4151	Inhibition of hepatic CYP3A4	CCOc1cc2c(cc1-c1cccnc1)CCC(=O)N2C	J. Med. Chem.	2012.0	CHEMBL2165317	=	=	IC50	nM	90000.0	IC50	uM	90.0
4152	Inhibition of hepatic CYP3A4	COc1cc2c(cc1-c1cccnc1)CCC(=O)N2C	J. Med. Chem.	2012.0	CHEMBL2165315	=	=	IC50	nM	90000.0	IC50	uM	90.0
4153	Inhibition of human CYP3A4	NC(=O)c1cc2cc(Br)c(C(F)(F)F)nc2nc1N	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2163365	>	>	IC50	nM	50000.0	IC50	uM	50.0
4154	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165505	=	=	Ki	nM	78000.0	Ki	uM	78.0
4155	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165504	=	=	Ki	nM	6600.0	Ki	uM	6.6
4156	Inhibition of CYP3A4	Cc1cc(-c2cc(=O)[nH]c(NCc3cccc4ccccc34)n2)ccn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2165175	=	=	IC50	nM	700.0	IC50	uM	0.7
4157	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4COC4)CC3(C)C)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165502	>	>	IC50	nM	10000.0	IC50	uM	10.0
4158	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(C(C)(C)O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165501	>	>	IC50	nM	10000.0	IC50	uM	10.0
4159	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165500	>	>	IC50	nM	10000.0	IC50	uM	10.0
4160	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(C)(C)C(N)=O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165499	>	>	IC50	nM	10000.0	IC50	uM	10.0
4161	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(N(C)C)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165498	>	>	IC50	nM	10000.0	IC50	uM	10.0
4162	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CN(C)C1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165666	=	=	IC50	nM	9100.0	IC50	uM	9.1
4163	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4ccnc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165513	<	<	IC50	nM	100.0	IC50	uM	0.1
4164	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cncc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165512	=	=	IC50	nM	3200.0	IC50	uM	3.2
4165	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4nccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165511	>	>	IC50	nM	10000.0	IC50	uM	10.0
4166	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cn1ccc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc21	J. Med. Chem.	2012.0	CHEMBL2165510	>	>	IC50	nM	10000.0	IC50	uM	10.0
4167	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1cc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2165509	<	<	IC50	nM	100.0	IC50	uM	0.1
4168	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)cc(F)c5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165508	=	=	IC50	nM	600.0	IC50	uM	0.6
4169	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(C#N)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165507	=	=	IC50	nM	1200.0	IC50	uM	1.2
4170	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(F)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165506	=	=	IC50	nM	510.0	IC50	uM	0.51
4171	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165505	=	=	IC50	nM	7000.0	IC50	uM	7.0
4172	Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165504	=	=	IC50	nM	1500.0	IC50	uM	1.5
4173	Inhibition of CYP3A4 in human liver microsomes	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1	J. Med. Chem.	2012.0	CHEMBL2001019	>	>	IC50	nM	30000.0	IC50	uM	30.0
4174	Inhibition of CYP3A4	COc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F	J. Med. Chem.	2012.0	CHEMBL2171396	=	=	IC50	nM	26.0	IC50	nM	26.0
4175	Inhibition of CYP3A4	Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(OCC2CC2)n(-c2ccccc2F)n1	J. Med. Chem.	2012.0	CHEMBL2171398	=	=	IC50	nM	15.0	IC50	nM	15.0
4176	Inhibition of CYP3A4	CCOc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F	J. Med. Chem.	2012.0	CHEMBL2171397	=	=	IC50	nM	15.0	IC50	nM	15.0
4177	Inhibition of CYP3A4	Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(=O)n(-c2ccccc2F)[nH]1	J. Med. Chem.	2012.0	CHEMBL3145341	=	=	IC50	nM	38.0	IC50	nM	38.0
4178	Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate incubated for 30 mins prior to substrate addition measured up to 10 mins by fluorimetry	COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(OC(F)(F)F)cc(-c3cccnc3)c1)CC2	ACS Med. Chem. Lett.	2012.0	CHEMBL586213	>	>	IC50	nM	50000.0	IC50	uM	50.0
4179	Inhibition of human CYP3A4	O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F	J. Med. Chem.	2012.0	CHEMBL2170747	=	=	IC50	nM	54000.0	IC50	uM	54.0
4180	Inhibition of human CYP3A4	Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O	J. Med. Chem.	2012.0	CHEMBL2170754	=	=	IC50	nM	54000.0	IC50	uM	54.0
4181	Inhibition of human CYP3A4	O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1	J. Med. Chem.	2012.0	CHEMBL2170750	=	=	IC50	nM	54000.0	IC50	uM	54.0
4182	Inhibition of human recombinant CYP3A4	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	J. Med. Chem.	2012.0	CHEMBL2170062	>	>	IC50	nM	10000.0	IC50	uM	10.0
4183	Inhibition of CYP3A4 in human liver microsomes	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	J. Med. Chem.	2012.0	CHEMBL2170062	>	>	IC50	nM	10000.0	IC50	uM	10.0
4184	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170610	>	>	IC50	nM	30000.0	IC50	uM	30.0
4185	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170609	=	=	IC50	nM	26000.0	IC50	uM	26.0
4186	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	COCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170608	>	>	IC50	nM	30000.0	IC50	uM	30.0
4187	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170607	=	=	IC50	nM	16000.0	IC50	uM	16.0
4188	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170606	=	=	IC50	nM	400.0	IC50	uM	0.4
4189	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170605	=	=	IC50	nM	13000.0	IC50	uM	13.0
4190	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170618	=	=	IC50	nM	3000.0	IC50	uM	3.0
4191	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170617	=	=	IC50	nM	26000.0	IC50	uM	26.0
4192	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170615	=	=	IC50	nM	24000.0	IC50	uM	24.0
4193	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(O)nc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170639	>	>	IC50	nM	30000.0	IC50	uM	30.0
4194	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(C(N)=O)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170638	=	=	IC50	nM	24500.0	IC50	uM	24.5
4195	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccn3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170637	>	>	IC50	nM	30000.0	IC50	uM	30.0
4196	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3cccnc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170636	>	>	IC50	nM	30000.0	IC50	uM	30.0
4197	Inhibition of CYP3A4 using midazolam as substrate	Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NC[C@@H](CO)C3)ccc1=O	J. Med. Chem.	2012.0	CHEMBL2170294	>	>	IC50	nM	100000.0	IC50	uM	100.0
4198	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccncc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170635	>	>	IC50	nM	30000.0	IC50	uM	30.0
4199	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CS(=O)(=O)c1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1	J. Med. Chem.	2012.0	CHEMBL2170633	>	>	IC50	nM	30000.0	IC50	uM	30.0
4200	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2170632	=	=	IC50	nM	15000.0	IC50	uM	15.0
4201	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1ccccc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170631	>	>	IC50	nM	30000.0	IC50	uM	30.0
4202	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1	J. Med. Chem.	2012.0	CHEMBL2170630	=	=	IC50	nM	22000.0	IC50	uM	22.0
4203	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2170629	=	=	IC50	nM	11000.0	IC50	uM	11.0
4204	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170643	=	=	IC50	nM	6000.0	IC50	uM	6.0
4205	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170642	>	>	IC50	nM	30000.0	IC50	uM	30.0
4206	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2105423	=	=	IC50	nM	7000.0	IC50	uM	7.0
4207	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177588	=	=	IC50	nM	21000.0	IC50	uM	21.0
4208	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177582	=	=	IC50	nM	4000.0	IC50	uM	4.0
4209	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CC(C)(O)CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2178223	=	=	IC50	nM	3000.0	IC50	uM	3.0
4210	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1	J. Med. Chem.	2012.0	CHEMBL2178221	=	=	IC50	nM	2000.0	IC50	uM	2.0
4211	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177587	=	=	IC50	nM	14000.0	IC50	uM	14.0
4212	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	CO[C@H](C)C(=O)N[C@@H](Cc1ccc2c(c1)OCO2)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181880	=	=	IC50	nM	50.0	IC50	nM	50.0
4213	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	C#Cc1ccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)cc1	J. Med. Chem.	2012.0	CHEMBL2181899	=	=	IC50	nM	100.0	IC50	nM	100.0
4214	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1ccc(-c2nccs2)cc1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181898	=	=	IC50	nM	30.0	IC50	nM	30.0
4215	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	CC#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1	J. Med. Chem.	2012.0	CHEMBL2181897	=	=	IC50	nM	30.0	IC50	nM	30.0
4216	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	C#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1	J. Med. Chem.	2012.0	CHEMBL2181896	=	=	IC50	nM	30.0	IC50	nM	30.0
4217	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nc(C)cs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181895	=	=	IC50	nM	100.0	IC50	nM	100.0
4218	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2cscn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181894	=	=	IC50	nM	100.0	IC50	nM	100.0
4219	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2cncs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181893	=	=	IC50	nM	30.0	IC50	nM	30.0
4220	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nccs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181892	=	=	IC50	nM	100.0	IC50	nM	100.0
4221	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nccn2C)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181891	=	=	IC50	nM	50.0	IC50	nM	50.0
4222	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ncco2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181890	=	=	IC50	nM	100.0	IC50	nM	100.0
4223	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ccccn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181889	=	=	IC50	nM	400.0	IC50	nM	400.0
4224	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ccncc2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181888	=	=	IC50	nM	160.0	IC50	nM	160.0
4225	Inhibition of CYP3A4	CNc1ccn2ncc(C(=O)Nc3cc(C)nn3-c3cccc(Cl)c3)c2n1	J. Med. Chem.	2012.0	CHEMBL2178247	>	>	IC50	nM	10000.0	IC50	uM	10.0
4226	Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178807	>	>	IC50	nM	10000.0	IC50	uM	10.0
4227	Time dependent inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cc(Cl)ccc2Cl)n1	J. Med. Chem.	2012.0	CHEMBL2178804	=	=	IC50	nM	5800.0	IC50	uM	5.8
4228	Inhibition of CYP3A4 preincubated with substrate	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178718	=	=	IC50	nM	1900.0	IC50	uM	1.9
4229	Inhibition of CYP3A4 coincubated with substrate	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178718	>	>	IC50	nM	30000.0	IC50	uM	30.0
4230	Inhibition of CYP3A4	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178714	=	=	IC50	nM	6000.0	IC50	uM	6.0
4231	Inhibition of CYP3A4	Cc1nc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3ccc(N)nc23)s1	J. Med. Chem.	2012.0	CHEMBL2178258	=	=	IC50	nM	6700.0	IC50	uM	6.7
4232	Inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178254	>	>	IC50	nM	10000.0	IC50	uM	10.0
4233	Inhibition of CYP3A4	O=C(Nc1c[nH]nc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178253	=	=	IC50	nM	7200.0	IC50	uM	7.2
4234	Inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178252	>	>	IC50	nM	10000.0	IC50	uM	10.0
4235	Inhibition of CYP3A4	Cn1cc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3cccnc23)n1	J. Med. Chem.	2012.0	CHEMBL2178251	>	>	IC50	nM	10000.0	IC50	uM	10.0
4236	Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)cn1	J. Med. Chem.	2012.0	CHEMBL2178250	>	>	IC50	nM	10000.0	IC50	uM	10.0
4237	Inhibition of CYP3A4	O=C(Nc1ccncc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178249	=	=	IC50	nM	200.0	IC50	uM	0.2
4238	Inhibition of CYP3A4	O=C(Nc1cccnc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178248	>	>	IC50	nM	10000.0	IC50	uM	10.0
4239	Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178806	=	=	IC50	nM	4600.0	IC50	uM	4.6
4240	Inhibition of CYP3A4	CS(=O)(=O)c1ccc(F)cc1C(=O)N1CCC(N(C2CC2)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2180905	=	=	IC50	nM	5100.0	IC50	uM	5.1
4241	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)N2CCOc3ccc(Cl)cc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2178742	=	=	IC50	nM	2800.0	IC50	uM	2.8
4242	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2nc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1.O=C(O)[C@H](O)[C@@H](O)C(=O)O	J. Med. Chem.	2012.0	CHEMBL3436346	=	=	IC50	nM	10000.0	IC50	uM	10.0
4243	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2179222	=	=	IC50	nM	10000.0	IC50	uM	10.0
4244	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2179217	=	=	IC50	nM	6460.0	IC50	uM	6.46
4245	Inhibition of CYP3A4	FC(F)(F)c1c(N2CCC(c3ccccc3)CC2)ccn2c(CC3CC3)nnc12	J. Med. Chem.	2012.0	CHEMBL2179319	>	>	IC50	nM	30000.0	IC50	uM	30.0
4246	Inhibition of human recombinant CYP3A4 using benzoylresorufin as substrate after 45 mins by fluorescence assay	N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F	J. Med. Chem.	2012.0	CHEMBL2178422	=	=	IC50	nM	17000.0	IC50	uM	17.0
4247	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence assay	N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F	J. Med. Chem.	2012.0	CHEMBL2178422	=	=	IC50	nM	17000.0	IC50	uM	17.0
4248	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1	J. Med. Chem.	2012.0	CHEMBL2177836	>	>	IC50	nM	10000.0	IC50	uM	10.0
4249	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177831	>	>	IC50	nM	10000.0	IC50	uM	10.0
4250	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177819	>	>	IC50	nM	10000.0	IC50	uM	10.0
4251	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177818	>	>	IC50	nM	10000.0	IC50	uM	10.0
4252	Inhibition of CYP3A4 in human liver microsomes	O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl	J. Med. Chem.	2012.0	CHEMBL1651219	>	>	IC50	nM	25000.0	IC50	uM	25.0
4253	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	J. Med. Chem.	2012.0	CHEMBL2151164	=	=	IC50	nM	2900.0	IC50	uM	2.9
4254	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	J. Med. Chem.	2012.0	CHEMBL2151164	=	=	IC50	nM	8700.0	IC50	uM	8.7
4255	Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect cells using fluorogeinc substrate	CC(C)[C@@H](NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2180528	>	>	IC50	nM	40000.0	IC50	nM	40000.0
4256	Inhibition of CYP3A4	Cc1nc(C)c(-c2ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc2)nc1C(N)=O	J. Med. Chem.	2012.0	CHEMBL2178953	>	>	IC50	nM	30000.0	IC50	uM	30.0
4257	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1	J. Med. Chem.	2011.0	CHEMBL2181313	>	>	IC50	nM	10000.0	IC50	uM	10.0
4258	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2	J. Med. Chem.	2011.0	CHEMBL2181088	=	=	IC50	nM	2500.0	IC50	uM	2.5
4259	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1	J. Med. Chem.	2011.0	CHEMBL2181331	=	=	IC50	nM	370.0	IC50	uM	0.37
4260	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1	J. Med. Chem.	2011.0	CHEMBL2035187	>	>	IC50	nM	5000.0	IC50	uM	5.0
4261	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2	J. Med. Chem.	2011.0	CHEMBL2181329	=	=	IC50	nM	2800.0	IC50	uM	2.8
4262	Inhibition of CYP3A4	Cn1c(-c2ccncc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181629	=	=	IC50	nM	4300.0	IC50	uM	4.3
4263	Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181621	=	=	IC50	nM	10700.0	IC50	uM	10.7
4264	Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181618	=	=	IC50	nM	6300.0	IC50	uM	6.3
4265	Inhibition of CYP3A4	Cn1c(-c2cnccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181643	=	=	IC50	nM	10600.0	IC50	uM	10.6
4266	Inhibition of CYP3A4	COc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)cn1	J. Med. Chem.	2012.0	CHEMBL2181641	=	=	IC50	nM	1500.0	IC50	uM	1.5
4267	Inhibition of CYP3A4	Cn1c(-c2cccc(N)n2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181638	=	=	IC50	nM	7000.0	IC50	uM	7.0
4268	Inhibition of CYP3A4	Cn1c(-c2ccc(F)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181635	=	=	IC50	nM	6700.0	IC50	uM	6.7
4269	Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181634	=	=	IC50	nM	10900.0	IC50	uM	10.9
4270	Inhibition of CYP3A4	Cc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)nc1	J. Med. Chem.	2012.0	CHEMBL2181777	=	=	IC50	nM	5800.0	IC50	uM	5.8
4271	Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181776	=	=	IC50	nM	9500.0	IC50	uM	9.5
4272	Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181775	=	=	IC50	nM	8300.0	IC50	uM	8.3
4273	Inhibition of CYP3A4	Cn1c(-c2ccoc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181765	=	=	IC50	nM	9200.0	IC50	uM	9.2
4274	Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	J. Med. Chem.	2012.0	CHEMBL2181789	=	=	IC50	nM	9400.0	IC50	uM	9.4
4275	Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	J. Med. Chem.	2012.0	CHEMBL2181786	=	=	IC50	nM	7900.0	IC50	uM	7.9
4276	Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	J. Med. Chem.	2012.0	CHEMBL114	=	=	Ki	nM	650.0	Ki	uM	0.65
4277	Time dependent inhibition of CYP3A4 in human liver microsomes	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O	J. Med. Chem.	2012.0	CHEMBL1084546	=	=	Ki	nM	12000.0	Ki	uM	12.0
4278	Time dependent inhibition of CYP3A4	CC(C)(C)NC(=O)C1(C2CCCCC2)CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@H]2CCc3ccccc3[C@H]2N)CC1	J. Med. Chem.	2012.0	CHEMBL433764	=	=	Ki	nM	23000.0	Ki	uM	23.0
4279	Reversible inhibition of CYP3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2012.0	CHEMBL45816	=	=	IC50	nM	300.0	IC50	uM	0.3
4280	Time dependent inhibition of CYP3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2012.0	CHEMBL45816	=	=	Ki	nM	2300.0	Ki	uM	2.3
4281	Inhibition of CYP3A4 in human liver microsomes	O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12	J. Med. Chem.	2012.0	CHEMBL81	=	=	Ki	nM	9900.0	Ki	uM	9.9
4282	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	COc1cc(CC(=O)O)ccc1Oc1ccc2[nH]c(C)cc2c1NS(=O)(=O)c1ccc(Cl)cc1Cl	J. Med. Chem.	2012.0	CHEMBL2181816	=	=	Ki	nM	18000.0	Ki	uM	18.0
4283	Time dependent inhibition of CYP3A4	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1	J. Med. Chem.	2012.0	CHEMBL553	=	=	Ki	nM	6300.0	Ki	uM	6.3
4284	Time dependent inhibition of CYP3A4 in human liver microsomes assessed as quasi-irreversible complex formation	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1	J. Med. Chem.	2012.0	CHEMBL554	=	=	Ki	nM	1700.0	Ki	uM	1.7
4285	Time dependent inhibition of CYP3A4 in human liver microsomes	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1	J. Med. Chem.	2012.0	CHEMBL1421	=	=	Ki	nM	6300.0	Ki	uM	6.3
4286	Inhibition of CYP3A4-mediated midazolam 1'-hydroxylation	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1	J. Med. Chem.	2012.0	CHEMBL941	=	=	Ki	nM	14300.0	Ki	uM	14.3
4287	Time dependent inhibition of CYP3A4	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	Ki	nM	1000.0	Ki	uM	1.0
4288	Time dependent inhibition of CYP3A4 in human liver microsomes	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	IC50	nM	15.0	IC50	uM	0.015
4289	Competitive inhibition of CYP3A4 in human liver microsomes	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	IC50	nM	1500.0	IC50	uM	1.5
4290	Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2012.0	CHEMBL163	=	=	Ki	nM	170.0	Ki	uM	0.17
4291	Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	J. Med. Chem.	2012.0	CHEMBL584	=	=	Ki	nM	1000.0	Ki	uM	1.0
4292	Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	J. Med. Chem.	2012.0	CHEMBL116	=	=	Ki	nM	370.0	Ki	uM	0.37
4293	Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	J. Med. Chem.	2012.0	CHEMBL729	=	=	Ki	nM	1000.0	Ki	uM	1.0
4294	Inhibition of CYP3A4-mediated N-demethylation in human liver microsomes	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	J. Med. Chem.	2012.0	CHEMBL23	=	=	Ki	nM	100.0	Ki	uM	0.1
4295	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
4296	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017288	=	=	IC50	nM	1500.0	IC50	uM	1.5
4297	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017286	=	=	IC50	nM	12900.0	IC50	uM	12.9
4298	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017285	=	=	IC50	nM	3700.0	IC50	uM	3.7
4299	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017283	=	=	IC50	nM	1700.0	IC50	uM	1.7
4300	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017277	=	=	IC50	nM	6100.0	IC50	uM	6.1
4301	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017281	=	=	IC50	nM	3900.0	IC50	uM	3.9
4302	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017273	=	=	IC50	nM	4700.0	IC50	uM	4.7
4303	Inhibition of CYP3A4 using diethoxyfluoresin as substrate	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017269	=	=	IC50	nM	13000.0	IC50	uM	13.0
4304	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl	J. Med. Chem.	2011.0	CHEMBL2204363	=	=	IC50	nM	5500.0	IC50	uM	5.5
4305	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl	J. Med. Chem.	2011.0	CHEMBL2204360	=	=	IC50	nM	10000.0	IC50	uM	10.0
4306	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1	J. Med. Chem.	2011.0	CHEMBL2204359	=	=	IC50	nM	4400.0	IC50	uM	4.4
4307	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1cccc(Sc2ccccc2N2CCNCC2)c1C.Cl	J. Med. Chem.	2011.0	CHEMBL2204357	=	=	IC50	nM	8700.0	IC50	uM	8.7
4308	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl	J. Med. Chem.	2011.0	CHEMBL2204356	=	=	IC50	nM	6100.0	IC50	uM	6.1
4309	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C.Cl	J. Med. Chem.	2011.0	CHEMBL2205054	=	=	IC50	nM	11000.0	IC50	uM	11.0
4310	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl	J. Med. Chem.	2011.0	CHEMBL2205045	=	=	IC50	nM	16000.0	IC50	uM	16.0
4311	Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1	J. Med. Chem.	2011.0	CHEMBL2205043	=	=	IC50	nM	6800.0	IC50	uM	6.8
4312	Inhibition of human liver microsome CYP3A4 by LC-MS-MS analysis	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2207503	>	>	IC50	nM	10000.0	IC50	uM	10.0
4313	Inhibition of CYP3A4	CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C	ACS Med. Chem. Lett.	2012.0	CHEMBL2206278	>	>	IC50	nM	40000.0	IC50	uM	40.0
4314	Inhibition of CYP3A4	CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C	ACS Med. Chem. Lett.	2012.0	CHEMBL2206277	>	>	IC50	nM	40000.0	IC50	uM	40.0
4315	Inhibition of CYP3A4	CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1	ACS Med. Chem. Lett.	2012.0	CHEMBL2203434	>	>	IC50	nM	40000.0	IC50	uM	40.0
4316	Inhibition of cytochrome P450 3A4	O=S(=O)(Nc1cc(Cl)ccc1Cn1ccnn1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207081	=	=	IC50	nM	3981.07	pIC50		5.4
4317	Inhibition of cytochrome P450 3A4	O=S(=O)(Nc1cc(Cl)c(Cl)cc1Cn1ccnn1)c1ccc(Cl)s1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207100	=	=	IC50	nM	5011.87	pIC50		5.3
4318	Inhibition of cytochrome P450 3A4	Cn1nnnc1Cc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207099	=	=	IC50	nM	10000.0	pIC50		5.0
4319	Inhibition of CYP3A4 in human liver microsomes	COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](CO)C3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2204445	>	>	IC50	nM	30000.0	IC50	uM	30.0
4320	Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1	Bioorg. Med. Chem.	2012.0	CHEMBL2205775	=	=	IC50	nM	200.0	IC50	uM	0.2
4321	Inhibition of CYP3A4	Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O	J. Med. Chem.	2012.0	CHEMBL2204469	=	=	IC50	nM	16000.0	IC50	uM	16.0
4322	Inhibition of CYP3A4	CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1[C@@H]1C[C@H]2CC[C@@H]1C2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2206059	>	>	IC50	nM	10000.0	IC50	uM	10.0
4323	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH	CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207388	=	=	IC50	nM	30500.0	IC50	uM	30.5
4324	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH	CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207386	=	=	IC50	nM	35970.0	IC50	uM	35.97
4325	Inhibition of Homo sapiens (human) recombinant CYP3A4 by fluorogenic assay	COc1ccc2c(n1)C1(CO2)C(=O)N(Cc2ccc(C(F)(F)F)o2)c2ccccc21	Med Chem Res	2013.0	CHEMBL2296321	>	>	IC50	nM	10000.0	IC50	uM	10.0
4326	Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry	N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CCN3CCN(CCC(=O)Nc4ccc(cc4)C[C@@H](NS(=O)(=O)Cc4ccccc4)C(=O)N2)CC3)cc1.O=C(O)C(F)(F)F	J. Med. Chem.	2013.0	CHEMBL2315243	>	>	IC50	nM	10000.0	IC50	uM	10.0
4327	Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry	N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CN3CCN(CC3)CC(=O)Nc3ccc(cc3)C[C@@H](NS(=O)(=O)Cc3ccccc3)C(=O)N2)cc1.O=C(O)C(F)(F)F	J. Med. Chem.	2013.0	CHEMBL2315239	>	>	IC50	nM	22000.0	IC50	uM	22.0
4328	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316386	=	=	IC50	nM	5500.0	IC50	uM	5.5
4329	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316385	>	>	IC50	nM	20000.0	IC50	uM	20.0
4330	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2cccnc2C(=O)NCC2CCOCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316383	>	>	IC50	nM	20000.0	IC50	uM	20.0
4331	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1	J. Med. Chem.	2013.0	CHEMBL2316382	=	=	IC50	nM	8800.0	IC50	uM	8.8
4332	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316379	=	=	IC50	nM	610.0	IC50	uM	0.61
4333	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1	J. Med. Chem.	2013.0	CHEMBL2316378	=	=	IC50	nM	360.0	IC50	uM	0.36
4334	Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NOCC[C@@H]3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2312555	>	>	IC50	nM	30000.0	IC50	uM	30.0
4335	Inhibition of human CYP3A4	CO[C@@H]1COCC[C@@H]1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2313764	=	=	IC50	nM	7500.0	IC50	uM	7.5
4336	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(-c2nnc(/C=C/c3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1	J. Med. Chem.	2013.0	CHEMBL2325503	>	>	IC50	nM	25000.0	IC50	uM	25.0
4337	Competitive inhibition of CYP3A4 (unknown origin)	COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2322875	>	>	IC50	nM	10000.0	IC50	uM	10.0
4338	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2323775	=	=	IC50	nM	11580.0	IC50	nM	11580.0
4339	Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(F)cccc3F)CCC(F)(F)CC2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2324491	>	>	IC50	nM	10000.0	IC50	uM	10.0
4340	Inhibition of CYP3A4 (unknown origin)	O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1	J. Med. Chem.	2013.0	CHEMBL1907089	=	=	IC50	nM	17600.0	IC50	uM	17.6
4341	Inhibition of CYP3A4 (unknown origin)	Cc1cccc(N2CNC(=O)C23CCN(C[C@H](C)NC(=O)c2ccc(Br)cc2)CC3)c1	J. Med. Chem.	2013.0	CHEMBL2325485	=	=	IC50	nM	6800.0	IC50	uM	6.8
4342	Inhibition of CYP3A4 (unknown origin)	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2325940	>	>	IC50	nM	20000.0	IC50	uM	20.0
4343	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1	J. Med. Chem.	2013.0	CHEMBL2325697	>	>	IC50	nM	10000.0	IC50	uM	10.0
4344	Inhibition of CYP3A4 (unknown origin)	N#Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338479	=	=	IC50	nM	10.0	IC50	uM	0.01
4345	Inhibition of CYP3A4 (unknown origin)	Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338480	=	=	IC50	nM	1.0	IC50	uM	0.001
4346	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CN(C2COC2)CC3)cc1	J. Med. Chem.	2013.0	CHEMBL2334760	=	=	IC50	nM	2500.0	IC50	uM	2.5
4347	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2S(C)(=O)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334764	=	=	IC50	nM	5000.0	IC50	uM	5.0
4348	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2C2COC2)cc1	J. Med. Chem.	2013.0	CHEMBL2334763	>	>	IC50	nM	10000.0	IC50	uM	10.0
4349	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2S(C)(=O)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334758	=	=	IC50	nM	5000.0	IC50	uM	5.0
4350	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C(C)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334759	=	=	IC50	nM	7300.0	IC50	uM	7.3
4351	Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C2COC2)cc1	J. Med. Chem.	2013.0	CHEMBL2334756	>	>	IC50	nM	10000.0	IC50	uM	10.0
4352	Inhibition of CYP3A4 (unknown origin)	CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2	ACS Med. Chem. Lett.	2013.0	CHEMBL2331648	>	>	IC50	nM	30000.0	IC50	uM	30.0
4353	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL450668	=	=	IC50	nM	26000.0	IC50	uM	26.0
4354	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2nn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336411	>	>	IC50	nM	40000.0	IC50	uM	40.0
4355	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336412	=	=	IC50	nM	18000.0	IC50	uM	18.0
4356	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336413	>	>	IC50	nM	40000.0	IC50	uM	40.0
4357	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336415	=	=	IC50	nM	32000.0	IC50	uM	32.0
4358	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336416	>	>	IC50	nM	40000.0	IC50	uM	40.0
4359	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336417	>	>	IC50	nM	40000.0	IC50	uM	40.0
4360	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336418	=	=	IC50	nM	3500.0	IC50	uM	3.5
4361	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)n[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336419	>	>	IC50	nM	40000.0	IC50	uM	40.0
4362	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336421	=	=	IC50	nM	25000.0	IC50	uM	25.0
4363	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336422	=	=	IC50	nM	13000.0	IC50	uM	13.0
4364	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454791	=	=	IC50	nM	36000.0	IC50	uM	36.0
4365	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336424	=	=	IC50	nM	24000.0	IC50	uM	24.0
4366	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454751	>	>	IC50	nM	40000.0	IC50	uM	40.0
4367	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL450668	=	=	IC50	nM	6700.0	IC50	uM	6.7
4368	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2nn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336411	=	=	IC50	nM	7300.0	IC50	uM	7.3
4369	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336412	=	=	IC50	nM	2300.0	IC50	uM	2.3
4370	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336413	=	=	IC50	nM	5000.0	IC50	uM	5.0
4371	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336415	=	=	IC50	nM	5500.0	IC50	uM	5.5
4372	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336416	=	=	IC50	nM	7200.0	IC50	uM	7.2
4373	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336417	=	=	IC50	nM	17000.0	IC50	uM	17.0
4374	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336418	=	=	IC50	nM	1600.0	IC50	uM	1.6
4375	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)n[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336419	=	=	IC50	nM	6900.0	IC50	uM	6.9
4376	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CC(C)c1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336420	=	=	IC50	nM	370.0	IC50	uM	0.37
4377	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336421	=	=	IC50	nM	450.0	IC50	uM	0.45
4378	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336422	=	=	IC50	nM	180.0	IC50	uM	0.18
4379	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454791	=	=	IC50	nM	6000.0	IC50	uM	6.0
4380	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336424	=	=	IC50	nM	1100.0	IC50	uM	1.1
4381	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454751	=	=	IC50	nM	4000.0	IC50	uM	4.0
4382	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331680	>	>	IC50	nM	10000.0	IC50	uM	10.0
4383	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C(C)C)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331678	>	>	IC50	nM	10000.0	IC50	uM	10.0
4384	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2nccn2C)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331677	>	>	IC50	nM	10000.0	IC50	uM	10.0
4385	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2cc(C)ncn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331676	=	=	IC50	nM	8400.0	IC50	uM	8.4
4386	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ccnc(C)n2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331689	=	=	IC50	nM	3300.0	IC50	uM	3.3
4387	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncc(F)cn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331688	=	=	IC50	nM	1400.0	IC50	uM	1.4
4388	Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncccn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2181522	=	=	IC50	nM	900.0	IC50	uM	0.9
4389	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cccc(OCC2CCN(c3ccc(NC(=O)c4cccc(Oc5ccccc5)c4)cn3)CC2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2334082	=	=	IC50	nM	5000.0	IC50	uM	5.0
4390	Inhibition of human recombinant CYP3A4	CC(C)(C)NC(=O)NCCN1CCC(CO)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2337981	>	>	IC50	nM	10000.0	IC50	uM	10.0
4391	Inhibition of human recombinant CYP3A4	CC(C)CCOc1ccc2c(c1)[C@H]1OCCC[C@H]1[C@@H](C1CCOCC1)N2	J. Med. Chem.	2013.0	CHEMBL2338343	>	>	IC50	nM	5000.0	IC50	uM	5.0
4392	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)NCCC1CCN(c2ncnc3cc(C(N)=O)sc23)CC1	J. Med. Chem.	2013.0	CHEMBL2332055	>	>	IC50	nM	50000.0	IC50	uM	50.0
4393	Inhibition of CYP3A4 (unknown origin)	Cc1cn([C@H]2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2331747	>	>	IC50	nM	20000.0	IC50	uM	20.0
4394	Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332068	=	=	IC50	nM	80000.0	IC50	uM	80.0
4395	Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332065	=	=	IC50	nM	35000.0	IC50	uM	35.0
4396	Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332097	>	>	IC50	nM	100000.0	IC50	uM	100.0
4397	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL1236924	=	=	IC50	nM	25000.0	IC50	uM	25.0
4398	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(F)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338473	=	=	IC50	nM	10000.0	IC50	uM	10.0
4399	Inhibition of CYP3A4 (unknown origin)	CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338475	=	=	IC50	nM	3000.0	IC50	uM	3.0
4400	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338472	=	=	IC50	nM	2600.0	IC50	uM	2.6
4401	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338474	=	=	IC50	nM	2300.0	IC50	uM	2.3
4402	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2331772	=	=	IC50	nM	1200.0	IC50	uM	1.2
4403	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338477	=	=	IC50	nM	1000.0	IC50	uM	1.0
4404	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338484	=	=	IC50	nM	600.0	IC50	uM	0.6
4405	Inhibition of CYP3A4 (unknown origin)	CC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338482	=	=	IC50	nM	360.0	IC50	uM	0.36
4406	Inhibition of CYP3A4 (unknown origin)	CCNC(=O)c1cc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2331785	=	=	IC50	nM	360.0	IC50	uM	0.36
4407	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338481	=	=	IC50	nM	30.0	IC50	uM	0.03
4408	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3ncn4c3CCCC4)nc12	J. Med. Chem.	2013.0	CHEMBL2347996	>	>	IC50	nM	50000.0	IC50	uM	50.0
4409	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(C4CCNCC4)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347994	>	>	IC50	nM	50000.0	IC50	uM	50.0
4410	Inhibition of CYP3A4 (unknown origin)	Cc1ccc2c(-c3cnc4[nH]cc(C(=O)NC(C)(C)CO)c4n3)nn(CCCN(C)C)c2c1	J. Med. Chem.	2013.0	CHEMBL2347993	>	>	IC50	nM	50000.0	IC50	uM	50.0
4411	Inhibition of CYP3A4 (unknown origin)	CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347992	>	>	IC50	nM	50000.0	IC50	uM	50.0
4412	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347991	>	>	IC50	nM	50000.0	IC50	uM	50.0
4413	Inhibition of CYP3A4 (unknown origin)	CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347990	>	>	IC50	nM	50000.0	IC50	uM	50.0
4414	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347989	>	>	IC50	nM	50000.0	IC50	uM	50.0
4415	Inhibition of CYP3A4 (unknown origin)	CN(C)CCCn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21	J. Med. Chem.	2013.0	CHEMBL2347415	>	>	IC50	nM	50000.0	IC50	uM	50.0
4416	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@]4(C)C[C@@H](N)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347414	>	>	IC50	nM	50000.0	IC50	uM	50.0
4417	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC4COCC(N)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347410	>	>	IC50	nM	50000.0	IC50	uM	50.0
4418	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC4(C)CCNCC4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347408	>	>	IC50	nM	50000.0	IC50	uM	50.0
4419	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3n[nH]c4ccc(OC(F)F)cc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347405	>	>	IC50	nM	19000.0	IC50	uM	19.0
4420	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21	J. Med. Chem.	2013.0	CHEMBL2346686	>	>	IC50	nM	19000.0	IC50	uM	19.0
4421	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@H]4C[C@H](O)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2348857	>	>	IC50	nM	50000.0	IC50	uM	50.0
4422	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)CO)c3n2)c2ccc(Cl)cc21	J. Med. Chem.	2013.0	CHEMBL2348856	>	>	IC50	nM	7000.0	IC50	uM	7.0
4423	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2ccc(Cl)cc21	J. Med. Chem.	2013.0	CHEMBL2348853	>	>	IC50	nM	50000.0	IC50	uM	50.0
4424	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc3[nH]cc(C(=O)NC(C)CO)c3n2)cc1OC	J. Med. Chem.	2013.0	CHEMBL2348851	>	>	IC50	nM	50000.0	IC50	uM	50.0
4425	Inhibition of CYP3A4 (unknown origin)	COc1ccc(Nc2nc(-c3cccc(C(=O)Nc4ccc(C(=O)O)cc4)c3)nc3scnc23)cc1OC	J. Med. Chem.	2013.0	CHEMBL2177737	>	>	IC50	nM	50000.0	IC50	uM	50.0
4426	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1	J. Med. Chem.	2013.0	CHEMBL2177736	>	>	IC50	nM	25000.0	IC50	uM	25.0
4427	Inhibition of CYP3A4 (unknown origin)	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2103830	>	>	IC50	nM	50000.0	IC50	uM	50.0
4428	Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cccnc2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347183	=	=	IC50	nM	130.0	IC50	nM	130.0
4429	Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnco2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347184	=	=	IC50	nM	3400.0	IC50	nM	3400.0
4430	Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[nH]2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347185	=	=	IC50	nM	280.0	IC50	nM	280.0
4431	Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL163	=	=	IC50	nM	550.0	IC50	nM	550.0
4432	Inhibition of human CYP3A4	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C[C@@H](C(F)(F)F)OC(N)=N1	J. Med. Chem.	2013.0	CHEMBL2347208	>	>	IC50	nM	25000.0	IC50	uM	25.0
4433	Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347337	=	=	IC50	nM	6900.0	IC50	uM	6.9
4434	Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347328	=	=	IC50	nM	6500.0	IC50	uM	6.5
4435	Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Br)c(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347323	=	=	IC50	nM	1500.0	IC50	uM	1.5
4436	Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347159	=	=	IC50	nM	5100.0	IC50	uM	5.1
4437	Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
4438	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO	Bioorg. Med. Chem.	2013.0	CHEMBL2348780	>	>	IC50	nM	50000.0	IC50	uM	50.0
4439	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2376562	>	>	IC50	nM	30000.0	IC50	uM	30.0
4440	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2375371	=	=	IC50	nM	26000.0	IC50	uM	26.0
4441	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)Nc2ccc(Oc3ccccc3)cc2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2376577	>	>	IC50	nM	30000.0	IC50	uM	30.0
4442	Inhibition of human recombinant CYP3A4	O[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2375587	=	=	IC50	nM	30300.0	IC50	uM	30.3
4443	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2377663	>	>	IC50	nM	20000.0	IC50	uM	20.0
4444	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2377662	>	>	IC50	nM	20000.0	IC50	uM	20.0
4445	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL47955	>	>	IC50	nM	20000.0	IC50	uM	20.0
4446	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL126	>	>	IC50	nM	20000.0	IC50	uM	20.0
4447	Inhibition of CYP3A4 (unknown origin)	N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2382415	>	>	IC50	nM	30000.0	IC50	uM	30.0
4448	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2086687	>	>	IC50	nM	30000.0	IC50	uM	30.0
4449	Inhibition of CYP3A4 (unknown origin)	N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2382414	>	>	IC50	nM	30000.0	IC50	uM	30.0
4450	Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4c(F)c(C#N)ccc43)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381946	=	=	IC50	nM	5400.0	IC50	uM	5.4
4451	Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4cc(C#N)c(F)cc43)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381945	=	=	IC50	nM	7600.0	IC50	uM	7.6
4452	Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](NC(=O)c3ccnc4cc(F)cnc34)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381936	>	>	IC50	nM	27000.0	IC50	uM	27.0
4453	Inhibition of CYP3A4 (unknown origin) by fluorescence detection method	CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380735	=	=	IC50	nM	9950.0	IC50	uM	9.95
4454	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N4CCC(c5cn[nH]c5)C4)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL1761869	<	<	IC50	nM	300.0	IC50	nM	300.0
4455	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380637	>	>	IC50	nM	10000.0	IC50	uM	10.0
4456	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380639	>	>	IC50	nM	10000.0	IC50	uM	10.0
4457	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](OC(N)=O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380640	>	>	IC50	nM	10000.0	IC50	uM	10.0
4458	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380641	>	>	IC50	nM	10000.0	IC50	uM	10.0
4459	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380642	>	>	IC50	nM	30000.0	IC50	uM	30.0
4460	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380643	>	>	IC50	nM	10000.0	IC50	uM	10.0
4461	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380644	>	>	IC50	nM	10000.0	IC50	uM	10.0
4462	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380646	>	>	IC50	nM	30000.0	IC50	uM	30.0
4463	Inhibition of CYP3A4 (unknown origin)	O=C(N[C@H]1C2CC3CC1C[C@](O)(C3)C2)N1CCN(c2ccc(N3CCN(S(=O)(=O)C4CC4)CC3)cn2)c2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380647	>	>	IC50	nM	10000.0	IC50	uM	10.0
4464	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380648	>	>	IC50	nM	50000.0	IC50	uM	50.0
4465	Inhibition of CYP3A4 (unknown origin)	NC(=O)[C@]12CC3CC(C1)[C@@H](NC(=O)N1CCN(c4ccc(N5CCN(S(=O)(=O)C6CC6)CC5)cn4)c4ccccc41)C(C3)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380649	>	>	IC50	nM	30000.0	IC50	uM	30.0
4466	Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381076	=	=	IC50	nM	64000.0	IC50	uM	64.0
4467	Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381074	>	>	IC50	nM	100000.0	IC50	uM	100.0
4468	Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1cc(C)nc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381071	=	=	IC50	nM	7900.0	IC50	uM	7.9
4469	Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381100	>	>	IC50	nM	100000.0	IC50	uM	100.0
4470	Time-dependent inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381116	>	>	IC50	nM	30000.0	IC50	uM	30.0
4471	Inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate by LC-MS/MS analysis	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381116	>	>	IC50	nM	30000.0	IC50	uM	30.0
4472	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins prior to NADPH addition measured after 8 mins by LC/MS/MS analysis	COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1	J. Med. Chem.	2013.0	CHEMBL2385886	>	>	IC50	nM	30000.0	IC50	uM	30.0
4473	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5ccccc5n4CC(=O)O)C3)cc2)cc1	J. Med. Chem.	2013.0	CHEMBL2385904	>	>	IC50	nM	50000.0	IC50	uM	50.0
4474	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1c[nH]c3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2385902	>	>	IC50	nM	50000.0	IC50	uM	50.0
4475	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2385901	>	>	IC50	nM	50000.0	IC50	uM	50.0
4476	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2386081	>	>	IC50	nM	50000.0	IC50	uM	50.0
4477	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2386079	>	>	IC50	nM	50000.0	IC50	uM	50.0
4478	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc(Cl)c1)CC2	J. Med. Chem.	2013.0	CHEMBL2386077	>	>	IC50	nM	50000.0	IC50	uM	50.0
4479	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc(Cl)c1)CC2	J. Med. Chem.	2013.0	CHEMBL2386076	>	>	IC50	nM	50000.0	IC50	uM	50.0
4480	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccs1)CC2	J. Med. Chem.	2013.0	CHEMBL2386075	>	>	IC50	nM	50000.0	IC50	uM	50.0
4481	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2	J. Med. Chem.	2013.0	CHEMBL2385906	>	>	IC50	nM	50000.0	IC50	uM	50.0
4482	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccc(Cl)cc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387588	>	>	IC50	nM	30000.0	IC50	uM	30.0
4483	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccc(Cl)c3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387587	>	>	IC50	nM	30000.0	IC50	uM	30.0
4484	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3Cl)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387507	>	>	IC50	nM	30000.0	IC50	uM	30.0
4485	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)cc1	Bioorg. Med. Chem.	2013.0	CHEMBL2387506	>	>	IC50	nM	30000.0	IC50	uM	30.0
4486	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1cccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2387505	>	>	IC50	nM	30000.0	IC50	uM	30.0
4487	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccccc1-c1ccc2c(c1)[nH]c(=O)c1nc(-c3c(F)cccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387504	>	>	IC50	nM	30000.0	IC50	uM	30.0
4488	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387503	>	>	IC50	nM	30000.0	IC50	uM	30.0
4489	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3[N+](=O)[O-])nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387502	>	>	IC50	nM	30000.0	IC50	uM	30.0
4490	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3C(F)(F)F)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387501	=	=	IC50	nM	7500.0	IC50	uM	7.5
4491	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1cccc(Cl)c1-c1nc2c(=O)[nH]c3cc(-c4ccccc4)ccc3c2[nH]1	Bioorg. Med. Chem.	2013.0	CHEMBL2387500	>	>	IC50	nM	30000.0	IC50	uM	30.0
4492	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccncc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387606	>	>	IC50	nM	30000.0	IC50	uM	30.0
4493	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccnc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387605	=	=	IC50	nM	24000.0	IC50	uM	24.0
4494	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccco3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387604	>	>	IC50	nM	30000.0	IC50	uM	30.0
4495	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccs3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387603	>	>	IC50	nM	30000.0	IC50	uM	30.0
4496	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387602	>	>	IC50	nM	30000.0	IC50	uM	30.0
4497	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(CCc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387601	>	>	IC50	nM	30000.0	IC50	uM	30.0
4498	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Cc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387600	>	>	IC50	nM	30000.0	IC50	uM	30.0
4499	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387599	>	>	IC50	nM	30000.0	IC50	uM	30.0
4500	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387598	>	>	IC50	nM	30000.0	IC50	uM	30.0
4501	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387597	>	>	IC50	nM	30000.0	IC50	uM	30.0
4502	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387596	>	>	IC50	nM	30000.0	IC50	uM	30.0
4503	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387595	>	>	IC50	nM	30000.0	IC50	uM	30.0
4504	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387594	>	>	IC50	nM	30000.0	IC50	uM	30.0
4505	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387593	>	>	IC50	nM	30000.0	IC50	uM	30.0
4506	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccc(Cl)cc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387592	>	>	IC50	nM	30000.0	IC50	uM	30.0
4507	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccc(Br)cc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387591	>	>	IC50	nM	30000.0	IC50	uM	30.0
4508	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Cl)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387590	>	>	IC50	nM	30000.0	IC50	uM	30.0
4509	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387589	>	>	IC50	nM	30000.0	IC50	uM	30.0
4510	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Br)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL1934810	=	=	IC50	nM	24000.0	IC50	uM	24.0
4511	Inhibition of CYP3A4 (unknown origin)	COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2386162	>	>	IC50	nM	10000.0	IC50	uM	10.0
4512	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2386558	>	>	IC50	nM	50000.0	IC50	uM	50.0
4513	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386636	>	>	IC50	nM	10000.0	IC50	uM	10.0
4514	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386635	>	>	IC50	nM	10000.0	IC50	uM	10.0
4515	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386633	>	>	IC50	nM	10000.0	IC50	uM	10.0
4516	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1	J. Med. Chem.	2013.0	CHEMBL2385096	>	>	IC50	nM	10000.0	IC50	uM	10.0
4517	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1	J. Med. Chem.	2013.0	CHEMBL2386629	>	>	IC50	nM	10000.0	IC50	uM	10.0
4518	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1	J. Med. Chem.	2013.0	CHEMBL2386653	>	>	IC50	nM	10000.0	IC50	uM	10.0
4519	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386636	=	=	IC50	nM	6700.0	IC50	uM	6.7
4520	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386635	=	=	IC50	nM	8800.0	IC50	uM	8.8
4521	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386633	=	=	IC50	nM	7900.0	IC50	uM	7.9
4522	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1	J. Med. Chem.	2013.0	CHEMBL2385096	>	>	IC50	nM	10000.0	IC50	uM	10.0
4523	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1	J. Med. Chem.	2013.0	CHEMBL2386629	>	>	IC50	nM	10000.0	IC50	uM	10.0
4524	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1	J. Med. Chem.	2013.0	CHEMBL2386653	>	>	IC50	nM	10000.0	IC50	uM	10.0
4525	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)Nc1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2387312	=	=	IC50	nM	13000.0	IC50	uM	13.0
4526	Inhibition of CYP3A4 (unknown origin)	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2385906	>	>	IC50	nM	50000.0	IC50	uM	50.0
4527	Inhibition of CYP3A4 (unknown origin)	N#C/C(=C\c1cn(CC(=O)O)c2ccccc12)C(=O)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2391518	>	>	IC50	nM	10000.0	IC50	uM	10.0
4528	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2393183	>	>	IC50	nM	10000.0	IC50	uM	10.0
4529	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397199	>	>	IC50	nM	10000.0	IC50	uM	10.0
4530	Inhibition of CYP3A4 (unknown origin)	CC(C)(c1cc(-c2cnc(NC(=O)N3CCC[C@H]3C(N)=O)s2)ccn1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397196	>	>	IC50	nM	10000.0	IC50	uM	10.0
4531	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2CCC2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397194	>	>	IC50	nM	10000.0	IC50	uM	10.0
4532	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)C)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397193	>	>	IC50	nM	10000.0	IC50	uM	10.0
4533	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397192	>	>	IC50	nM	10000.0	IC50	uM	10.0
4534	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2396661	>	>	IC50	nM	10000.0	IC50	uM	10.0
4535	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397187	>	>	IC50	nM	10000.0	IC50	uM	10.0
4536	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397186	>	>	IC50	nM	10000.0	IC50	uM	10.0
4537	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397317	>	>	IC50	nM	30000.0	IC50	uM	30.0
4538	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C(C)(C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397316	=	=	IC50	nM	17000.0	IC50	uM	17.0
4539	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397315	>	>	IC50	nM	30000.0	IC50	uM	30.0
4540	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397314	>	>	IC50	nM	30000.0	IC50	uM	30.0
4541	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)Cc2nc(-c3ccccc3)c(C)o2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397313	=	=	IC50	nM	7700.0	IC50	uM	7.7
4542	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397312	>	>	IC50	nM	30000.0	IC50	uM	30.0
4543	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C2(C)CCCCC2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397311	=	=	IC50	nM	17000.0	IC50	uM	17.0
4544	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@H]2CC[C@@H](C(F)(F)F)CC2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397310	>	>	IC50	nM	30000.0	IC50	uM	30.0
4545	Inhibition of CYP3A4 (unknown origin)	CO[C@H]1CC[C@@H](C(=O)Nc2nc(C)c(-c3ccc(N)nc3)s2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397309	>	>	IC50	nM	30000.0	IC50	uM	30.0
4546	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(=O)N(CC(=O)Nc2ncc(-c3ccc(N)cc3)s2)Cc2ccccc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397308	=	=	IC50	nM	15000.0	IC50	uM	15.0
4547	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1[C@H](C(=O)Nc2ncc(-c3ccc(N)cc3)s2)CC[C@@H]1c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397307	=	=	IC50	nM	980.0	IC50	uM	0.98
4548	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)CN2C(=O)OC[C@H]2C(C)C)sc1-c1ccc(N)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397306	>	>	IC50	nM	30000.0	IC50	uM	30.0
4549	Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)CN(Cc2ccccc2)C(=O)c2ccncc2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397305	=	=	IC50	nM	710.0	IC50	uM	0.71
4550	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397304	=	=	IC50	nM	1800.0	IC50	uM	1.8
4551	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397303	=	=	IC50	nM	500.0	IC50	uM	0.5
4552	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as benzoylresorufin conversion to resorufin metabolites after 45 mins by fluorescence assay	Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397415	=	=	IC50	nM	24000.0	IC50	uM	24.0
4553	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as 7-benzyloxy-4-trifluoromethylcoumarin conversion to 7-hydroxy-4-trifluoromethylcoumarin after 20 mins by fluorescence assay	Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397415	>	>	IC50	nM	40000.0	IC50	uM	40.0
4554	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403551	>	>	IC50	nM	30000.0	IC50	uM	30.0
4555	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403550	>	>	IC50	nM	30000.0	IC50	uM	30.0
4556	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403549	>	>	IC50	nM	30000.0	IC50	uM	30.0
4557	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403548	>	>	IC50	nM	30000.0	IC50	uM	30.0
4558	Inhibition of human CYP3A4	Cc1ccccc1[C@@H]1[C@@H](O[C@H](CO)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H]2CN(C3=NC(=O)CO3)C[C@H]21	J. Med. Chem.	2013.0	CHEMBL2402572	=	=	IC50	nM	15000.0	IC50	uM	15.0
4559	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis	CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4ccc(NC(=O)Nc5cc(C(C)(C)C)nn5-c5cccc(N)c5)cc4)c3c2)CC1	J. Med. Chem.	2013.0	CHEMBL2403820	=	=	IC50	nM	1950.0	IC50	uM	1.95
4560	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4ccccc34)cc2)n(-c2cccc(N)c2)n1	J. Med. Chem.	2013.0	CHEMBL2403816	=	=	IC50	nM	14800.0	IC50	uM	14.8
4561	Inhibition of CP3A4 (unknown origin)	C#CCC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2401818	=	=	IC50	nM	1600.0	IC50	uM	1.6
4562	Inhibition of CP3A4 (unknown origin)	CC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2401834	>	>	IC50	nM	20000.0	IC50	uM	20.0
4563	Inhibition of CYP3A4 (unknown origin)	COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403317	=	=	IC50	nM	18000.0	IC50	uM	18.0
4564	Induction of CYP3A4 (unknown origin)	O=C(O)CC1CCC(c2ccc(-c3nc4cc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)ccc4[nH]3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409564	>	>	EC50	nM	100000.0	EC50	uM	100.0
4565	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC(c2ccc(-c3nc4cc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)ccc4[nH]3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409564	>	>	IC50	nM	100000.0	IC50	uM	100.0
4566	Inhibition of human CYP3A4	O=CN(O)[C@@H](CCCc1ncccn1)CS(=O)(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409667	=	=	IC50	nM	1000.0	IC50	uM	1.0
4567	Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OCc4ccccn4)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409691	>	>	IC50	nM	10000.0	IC50	uM	10.0
4568	Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409710	>	>	IC50	nM	40000.0	IC50	uM	40.0
4569	Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409676	>	>	IC50	nM	10000.0	IC50	uM	10.0
4570	Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409707	>	>	IC50	nM	10000.0	IC50	uM	10.0
4571	Inhibition of CYP3A4 (unknown origin)	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1	ACS Med. Chem. Lett.	2013.0	CHEMBL2408045	>	>	IC50	nM	10000.0	IC50	uM	10.0
4572	Inhibition of CYP3A4 (unknown origin) using vivid green as substrate	Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1	J. Med. Chem.	2013.0	CHEMBL2407717	=	=	IC50	nM	16000.0	IC50	uM	16.0
4573	Inhibition of CYP3A4 (unknown origin) using vivid red as substrate	Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1	J. Med. Chem.	2013.0	CHEMBL2407717	=	=	IC50	nM	25000.0	IC50	uM	25.0
4574	Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2013.0	CHEMBL2407900	=	=	IC50	nM	10000.0	IC50	uM	10.0
4575	Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1	J. Med. Chem.	2013.0	CHEMBL2407899	=	=	IC50	nM	800.0	IC50	uM	0.8
4576	Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1	J. Med. Chem.	2013.0	CHEMBL2407897	=	=	IC50	nM	10000.0	IC50	uM	10.0
4577	Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2013.0	CHEMBL2407749	=	=	IC50	nM	2700.0	IC50	uM	2.7
4578	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CN(C)c1ccc(C(C/C(=N\O)c2ccncc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407936	<	<	IC50	nM	200.0	IC50	uM	0.2
4579	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(-c3cccc(C(=O)O)c3)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407955	>	>	IC50	nM	50000.0	IC50	uM	50.0
4580	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(-c3ccc(C(=O)O)cc3)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407954	>	>	IC50	nM	50000.0	IC50	uM	50.0
4581	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(CC(=O)O)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407953	>	>	IC50	nM	50000.0	IC50	uM	50.0
4582	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(C(=O)O)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407952	>	>	IC50	nM	50000.0	IC50	uM	50.0
4583	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1ccccc1C(C/C(=N\O)c1ccc(=O)n(C)c1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407951	>	>	IC50	nM	50000.0	IC50	uM	50.0
4584	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(Br)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407950	=	=	IC50	nM	5000.0	IC50	uM	5.0
4585	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1ccccc1C(C/C(=N\O)c1ccncc1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407949	<	<	IC50	nM	200.0	IC50	uM	0.2
4586	Inhibition of CYP3A4 (unknown origin)	COCc1c(C(=O)NCc2ccncc2)cnn1-c1ncc(C)c(-c2cccs2)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2409024	=	=	IC50	nM	2900.0	IC50	uM	2.9
4587	Inhibition of CYP3A4 (unknown origin)	CCOCc1c(C(=O)NCc2cncn2C)cnn1-c1ncc(C)c(N2CCCCC2)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2409007	=	=	IC50	nM	1000.0	IC50	uM	1.0
4588	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis	CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1	Bioorg. Med. Chem.	2013.0	CHEMBL2413882	=	=	IC50	nM	1450.0	IC50	uM	1.45
4589	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis	CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C	Bioorg. Med. Chem.	2013.0	CHEMBL2413881	=	=	IC50	nM	6.0	IC50	uM	0.006
4590	Inhibition of CYP3A4 (unknown origin) using nifedipine as substrate	Cc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1	Bioorg. Med. Chem.	2013.0	CHEMBL2413849	>	>	IC50	nM	100000.0	IC50	uM	100.0
4591	Inhibition of CYP3A4 (unknown origin)	COc1nc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415099	>	>	IC50	nM	10000.0	IC50	uM	10.0
4592	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCO[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415098	=	=	IC50	nM	1100.0	IC50	uM	1.1
4593	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415097	=	=	IC50	nM	100.0	IC50	uM	0.1
4594	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415095	=	=	IC50	nM	6940.0	IC50	uM	6.94
4595	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	C[C@@H]1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397347	=	=	IC50	nM	7000.0	IC50	uM	7.0
4596	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)N1CCC2(CCCC2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418359	>	>	IC50	nM	30000.0	IC50	uM	30.0
4597	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418364	=	=	IC50	nM	6200.0	IC50	uM	6.2
4598	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418954	>	>	IC50	nM	25000.0	IC50	uM	25.0
4599	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418948	=	=	IC50	nM	800.0	IC50	uM	0.8
4600	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1nc2ccc(-c3ccc(N)nc3)cc2s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418946	=	=	IC50	nM	50.0	IC50	uM	0.05
4601	Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCN(CCO)CC1)Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)c2sc3ccccc3c12	J. Med. Chem.	2013.0	CHEMBL2420310	>	>	IC50	nM	10000.0	IC50	uM	10.0
4602	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1	J. Med. Chem.	2013.0	CHEMBL1086377	>	>	IC50	nM	10000.0	IC50	uM	10.0
4603	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1	J. Med. Chem.	2013.0	CHEMBL2420425	>	>	IC50	nM	10000.0	IC50	uM	10.0
4604	Inhibition of CYP3A4 (unknown origin)	CCc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1	J. Med. Chem.	2013.0	CHEMBL2420615	<	<	IC50	nM	1000.0	IC50	uM	1.0
4605	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2013.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
4606	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420688	=	=	IC50	nM	1739.0	IC50	nM	1739.0
4607	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420687	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4608	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420686	=	=	IC50	nM	2145.0	IC50	nM	2145.0
4609	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420685	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4610	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420684	=	=	IC50	nM	5046.0	IC50	nM	5046.0
4611	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc(O)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420683	=	=	IC50	nM	6720.0	IC50	nM	6720.0
4612	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420682	=	=	IC50	nM	4196.0	IC50	nM	4196.0
4613	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3ccc(OC)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420681	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4614	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420680	=	=	IC50	nM	3581.0	IC50	nM	3581.0
4615	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420679	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4616	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F	J. Med. Chem.	2013.0	CHEMBL2420678	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4617	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F	J. Med. Chem.	2013.0	CHEMBL2420677	=	=	IC50	nM	1009.0	IC50	nM	1009.0
4618	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(F)c2c1	J. Med. Chem.	2013.0	CHEMBL2420676	=	=	IC50	nM	1262.0	IC50	nM	1262.0
4619	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(F)c2c1	J. Med. Chem.	2013.0	CHEMBL2420675	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4620	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420674	=	=	IC50	nM	1759.0	IC50	nM	1759.0
4621	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL371430	=	=	IC50	nM	3560.0	IC50	nM	3560.0
4622	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl	Eur. J. Med. Chem.	2013.0	CHEMBL2387224	>	>	IC50	nM	10000.0	IC50	uM	10.0
4623	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccncc1)c1c(Cl)cccc1Cl	Eur. J. Med. Chem.	2013.0	CHEMBL1327969	=	=	IC50	nM	4700.0	IC50	uM	4.7
4624	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419495	=	=	IC50	nM	1400.0	IC50	uM	1.4
4625	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C(C)C)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419494	>	>	IC50	nM	2000.0	IC50	uM	2.0
4626	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419493	>	>	IC50	nM	17000.0	IC50	uM	17.0
4627	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(OC)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419492	>	>	IC50	nM	17000.0	IC50	uM	17.0
4628	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419491	=	=	IC50	nM	4500.0	IC50	uM	4.5
4629	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419490	=	=	IC50	nM	20000.0	IC50	uM	20.0
4630	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419487	=	=	IC50	nM	20000.0	IC50	uM	20.0
4631	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419486	>	>	IC50	nM	20000.0	IC50	uM	20.0
4632	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419485	=	=	IC50	nM	3300.0	IC50	uM	3.3
4633	Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccccc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419501	>	>	IC50	nM	50000.0	IC50	uM	50.0
4634	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy trifluoromethylcoumarin as substrate	Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1	J. Med. Chem.	2013.0	CHEMBL2417553	=	=	IC50	nM	1100.0	IC50	uM	1.1
4635	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419525	>	>	IC50	nM	10000.0	IC50	uM	10.0
4636	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419524	>	>	IC50	nM	10000.0	IC50	uM	10.0
4637	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419518	>	>	IC50	nM	10000.0	IC50	uM	10.0
4638	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419516	>	>	IC50	nM	10000.0	IC50	uM	10.0
4639	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
4640	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419505	>	>	IC50	nM	10000.0	IC50	uM	10.0
4641	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419525	>	>	IC50	nM	10000.0	IC50	uM	10.0
4642	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419524	>	>	IC50	nM	10000.0	IC50	uM	10.0
4643	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419518	>	>	IC50	nM	10000.0	IC50	uM	10.0
4644	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419516	>	>	IC50	nM	10000.0	IC50	uM	10.0
4645	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
4646	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419505	>	>	IC50	nM	10000.0	IC50	uM	10.0
4647	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425161	>	>	IC50	nM	10000.0	IC50	uM	10.0
4648	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425160	>	>	IC50	nM	10000.0	IC50	uM	10.0
4649	Inhibition of CYP3A4 (unknown origin)	COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425159	>	>	IC50	nM	10000.0	IC50	uM	10.0
4650	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425158	>	>	IC50	nM	10000.0	IC50	uM	10.0
4651	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425157	>	>	IC50	nM	10000.0	IC50	uM	10.0
4652	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425156	>	>	IC50	nM	10000.0	IC50	uM	10.0
4653	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425155	>	>	IC50	nM	10000.0	IC50	uM	10.0
4654	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425154	>	>	IC50	nM	10000.0	IC50	uM	10.0
4655	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425153	>	>	IC50	nM	10000.0	IC50	uM	10.0
4656	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425152	>	>	IC50	nM	10000.0	IC50	uM	10.0
4657	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425151	>	>	IC50	nM	10000.0	IC50	uM	10.0
4658	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425150	>	>	IC50	nM	10000.0	IC50	uM	10.0
4659	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425149	>	>	IC50	nM	10000.0	IC50	uM	10.0
4660	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425148	>	>	IC50	nM	10000.0	IC50	uM	10.0
4661	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425147	>	>	IC50	nM	10000.0	IC50	uM	10.0
4662	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425146	>	>	IC50	nM	10000.0	IC50	uM	10.0
4663	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425145	>	>	IC50	nM	10000.0	IC50	uM	10.0
4664	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425144	>	>	IC50	nM	10000.0	IC50	uM	10.0
4665	Inhibition of CYP3A (unknown origin)	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL376359	>	>	IC50	nM	30000.0	IC50	uM	30.0
4666	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425886	=	=	IC50	nM	97900.0	IC50	uM	97.9
4667	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Cl)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425889	=	=	IC50	nM	91930.0	IC50	uM	91.93
4668	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Br)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425888	=	=	IC50	nM	79360.0	IC50	uM	79.36
4669	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(F)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425890	=	=	IC50	nM	58280.0	IC50	uM	58.28
4670	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(F)cc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425894	=	=	IC50	nM	54650.0	IC50	uM	54.65
4671	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(C)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425891	=	=	IC50	nM	46240.0	IC50	uM	46.24
4672	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425893	=	=	IC50	nM	46180.0	IC50	uM	46.18
4673	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(OC)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425892	=	=	IC50	nM	42190.0	IC50	uM	42.19
4674	Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2cc(Cl)c3ccccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425895	=	=	IC50	nM	14080.0	IC50	uM	14.08
4675	Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate	CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1	J. Med. Chem.	2013.0	CHEMBL2425952	=	=	IC50	nM	100.0	IC50	uM	0.1
4676	Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate	Cc1nc2cc(/C=C/C(=O)NO)ccc2c(=O)n1CCc1ccccc1	J. Med. Chem.	2013.0	CHEMBL2425958	=	=	IC50	nM	6500.0	IC50	uM	6.5
4677	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccn3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425607	=	=	IC50	nM	1600.0	IC50	uM	1.6
4678	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(CC(C)(C)C)on3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425606	=	=	IC50	nM	1100.0	IC50	uM	1.1
4679	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cnn(CC(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425605	=	=	IC50	nM	3600.0	IC50	uM	3.6
4680	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425604	=	=	IC50	nM	4700.0	IC50	uM	4.7
4681	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425603	=	=	IC50	nM	900.0	IC50	uM	0.9
4682	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)O)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425602	=	=	IC50	nM	2400.0	IC50	uM	2.4
4683	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)CO)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425601	=	=	IC50	nM	1000.0	IC50	uM	1.0
4684	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccc3F)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425600	=	=	IC50	nM	100.0	IC50	uM	0.1
4685	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](N[C@H](C)c3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425599	=	=	IC50	nM	100.0	IC50	uM	0.1
4686	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425618	=	=	IC50	nM	700.0	IC50	uM	0.7
4687	Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])(N[C@H]1C[S@+]([O-])C[C@@H](Cc2cc(F)c(N)c(O[C@H](COC)C(F)(F)F)c2)[C@@H]1O)c1cccc(C(C)(C)C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425617	=	=	IC50	nM	100.0	IC50	uM	0.1
4688	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S+]([O-])C[C@H](N)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425615	>	>	IC50	nM	10000.0	IC50	uM	10.0
4689	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(O)c(N)c(F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425614	>	>	IC50	nM	10000.0	IC50	uM	10.0
4690	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(O[C@H](CO)C(F)(F)F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425613	=	=	IC50	nM	900.0	IC50	uM	0.9
4691	Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425612	=	=	IC50	nM	200.0	IC50	uM	0.2
4692	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(OCC(F)(F)F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425611	=	=	IC50	nM	300.0	IC50	uM	0.3
4693	Inhibition of CYP3A4 (unknown origin)	COc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425610	=	=	IC50	nM	300.0	IC50	uM	0.3
4694	Inhibition of human CYP3A4	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21	J. Med. Chem.	2013.0	CHEMBL1232461	>=	>=	IC50	nM	33000.0	IC50	uM	33.0
4695	Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2ccncc2)cc1NC(=O)[C@H](Cc1ccccc1)NCC(=O)O	ACS Med. Chem. Lett.	2013.0	CHEMBL2430983	>	>	IC50	nM	30000.0	IC50	uM	30.0
4696	Inhibition of human CYP3A4	CC1(NC(=O)c2ccc(C#Cc3cccc(F)c3)cn2)COC1	J. Med. Chem.	2013.0	CHEMBL2431173	>	>	IC50	nM	30000.0	IC50	uM	30.0
4697	Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431365	>	>	IC50	nM	50000.0	IC50	uM	50.0
4698	Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431456	=	=	IC50	nM	340.0	IC50	uM	0.34
4699	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431365	>	>	IC50	nM	50000.0	IC50	uM	50.0
4700	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431463	=	=	IC50	nM	40.0	IC50	uM	0.04
4701	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431462	=	=	IC50	nM	1100.0	IC50	uM	1.1
4702	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(CCN2CCC(NS(C)(=O)=O)CC2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431460	>	>	IC50	nM	50000.0	IC50	uM	50.0
4703	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431457	>	>	IC50	nM	50000.0	IC50	uM	50.0
4704	Inhibition of CYP3A4 in human liver microsomes	Cn1c2c(c3ccccc31)CCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436632	>	>	IC50	nM	30000.0	IC50	uM	30.0
4705	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccc(F)cc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436630	>	>	IC50	nM	30000.0	IC50	uM	30.0
4706	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436629	>	>	IC50	nM	30000.0	IC50	uM	30.0
4707	Inhibition of CYP3A4 in human liver microsomes	N#Cc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436628	>	>	IC50	nM	30000.0	IC50	uM	30.0
4708	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436627	>	>	IC50	nM	30000.0	IC50	uM	30.0
4709	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCNc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436626	>	>	IC50	nM	30000.0	IC50	uM	30.0
4710	Inhibition of CYP3A4 in human liver microsomes	COc1ccc2c(c1)CCCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436625	>	>	IC50	nM	30000.0	IC50	uM	30.0
4711	Inhibition of CYP3A4 in human liver microsomes	COc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CCC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436624	>	>	IC50	nM	30000.0	IC50	uM	30.0
4712	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCCc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436623	>	>	IC50	nM	30000.0	IC50	uM	30.0
4713	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5CC4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436622	>	>	IC50	nM	30000.0	IC50	uM	30.0
4714	Inhibition of CYP3A4 in human liver microsomes	Cc1nnc2n1-c1sccc1C(=O)N(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436621	>	>	IC50	nM	30000.0	IC50	uM	30.0
4715	Inhibition of CYP3A4 in human liver microsomes	Cc1nnc2n1-c1sccc1CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436620	>	>	IC50	nM	30000.0	IC50	uM	30.0
4716	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4c5ccccc5Sc5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436617	>	>	IC50	nM	30000.0	IC50	uM	30.0
4717	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436616	=	=	IC50	nM	18000.0	IC50	uM	18.0
4718	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436633	=	=	IC50	nM	18000.0	IC50	uM	18.0
4719	Inhibition of CYP3A4 (unknown origin)	CCc1nc(N[C@@H]2CCC[C@@H]2C#N)c2cc[nH]c(=O)c2n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436945	>	>	IC50	nM	10000.0	IC50	uM	10.0
4720	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436976	>	>	IC50	nM	30000.0	IC50	uM	30.0
4721	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436982	>	>	IC50	nM	30000.0	IC50	uM	30.0
4722	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436980	>	>	IC50	nM	30000.0	IC50	uM	30.0
4723	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2436983	=	=	IC50	nM	21800.0	IC50	uM	21.8
4724	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL2436978	=	=	IC50	nM	16200.0	IC50	uM	16.2
4725	Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2436981	=	=	IC50	nM	4200.0	IC50	uM	4.2
4726	Inhibition of CYP3A4 (unknown origin)	CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435856	>	>	IC50	nM	73000.0	IC50	uM	73.0
4727	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)C[C@H]4c4ccccc4)CC3)cn2)cc1	J. Med. Chem.	2013.0	CHEMBL2434978	>	>	IC50	nM	60000.0	IC50	uM	60.0
4728	Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435852	>	>	IC50	nM	40000.0	IC50	uM	40.0
4729	Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435858	>	>	IC50	nM	26000.0	IC50	uM	26.0
4730	Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2cccc(Cl)c2)CC1	J. Med. Chem.	2013.0	CHEMBL2435853	>	>	IC50	nM	100000.0	IC50	uM	100.0
4731	Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=S)OC)OC3=O)cc2F)CCN1	Eur. J. Med. Chem.	2013.0	CHEMBL2437199	>	>	IC50	nM	20000.0	IC50	uM	20.0
4732	Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)C(F)F)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2437330	>	>	IC50	nM	20000.0	IC50	uM	20.0
4733	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2cccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436321	=	=	IC50	nM	1800.0	IC50	uM	1.8
4734	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cnccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437433	>	>	IC50	nM	30000.0	IC50	uM	30.0
4735	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ncccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437432	>	>	IC50	nM	30000.0	IC50	uM	30.0
4736	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437431	>	>	IC50	nM	30000.0	IC50	uM	30.0
4737	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cc(F)cc(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437430	>	>	IC50	nM	30000.0	IC50	uM	30.0
4738	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccc(F)c(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437429	>	>	IC50	nM	30000.0	IC50	uM	30.0
4739	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CCCCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437428	>	>	IC50	nM	30000.0	IC50	uM	30.0
4740	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(C5CCCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437427	=	=	IC50	nM	22000.0	IC50	uM	22.0
4741	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437426	=	=	IC50	nM	30000.0	IC50	uM	30.0
4742	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437425	>	>	IC50	nM	30000.0	IC50	uM	30.0
4743	Inhibition of CYP3A4 in human liver microsomes	CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccc(F)cc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437424	>	>	IC50	nM	30000.0	IC50	uM	30.0
4744	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437423	=	=	IC50	nM	30000.0	IC50	uM	30.0
4745	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437422	>	>	IC50	nM	30000.0	IC50	uM	30.0
4746	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437421	=	=	IC50	nM	30000.0	IC50	uM	30.0
4747	Inhibition of CYP3A4 in human liver microsomes	COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437420	>	>	IC50	nM	30000.0	IC50	uM	30.0
4748	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437417	>	>	IC50	nM	30000.0	IC50	uM	30.0
4749	Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)[nH]c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437416	>	>	IC50	nM	30000.0	IC50	uM	30.0
4750	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436222	=	=	Ki	nM	83300.0	Ki	uM	83.3
4751	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436225	=	=	Ki	nM	50000.0	Ki	uM	50.0
4752	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436224	=	=	Ki	nM	50000.0	Ki	uM	50.0
4753	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436223	=	=	Ki	nM	50000.0	Ki	uM	50.0
4754	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436224	>	>	IC50	nM	50000.0	IC50	uM	50.0
4755	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436223	>	>	IC50	nM	50000.0	IC50	uM	50.0
4756	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(C)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436221	>	>	IC50	nM	50000.0	IC50	uM	50.0
4757	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436220	=	=	IC50	nM	38000.0	IC50	uM	38.0
4758	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436222	=	=	IC50	nM	37000.0	IC50	uM	37.0
4759	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436219	=	=	IC50	nM	32000.0	IC50	uM	32.0
4760	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436225	=	=	IC50	nM	18000.0	IC50	uM	18.0
4761	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436226	=	=	Ki	nM	16700.0	Ki	uM	16.7
4762	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436226	=	=	IC50	nM	16000.0	IC50	uM	16.0
4763	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2ccccc2)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436324	=	=	IC50	nM	15000.0	IC50	uM	15.0
4764	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(N)cc2)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436208	=	=	IC50	nM	10200.0	IC50	uM	10.2
4765	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436215	=	=	IC50	nM	10000.0	IC50	uM	10.0
4766	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436218	=	=	IC50	nM	9700.0	IC50	uM	9.7
4767	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436219	=	=	Ki	nM	8500.0	Ki	uM	8.5
4768	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436218	=	=	Ki	nM	7100.0	Ki	uM	7.1
4769	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3cc(Br)ccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436216	=	=	IC50	nM	4800.0	IC50	uM	4.8
4770	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(CCc2ccccc2)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436325	=	=	IC50	nM	3300.0	IC50	uM	3.3
4771	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(C)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436214	=	=	IC50	nM	3200.0	IC50	uM	3.2
4772	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)Cc2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436210	=	=	IC50	nM	2800.0	IC50	uM	2.8
4773	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)C2CCOCC2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436213	=	=	IC50	nM	2300.0	IC50	uM	2.3
4774	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436220	=	=	Ki	nM	2100.0	Ki	uM	2.1
4775	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(S(C)(=O)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436205	=	=	IC50	nM	2000.0	IC50	uM	2.0
4776	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)o2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436212	=	=	IC50	nM	1900.0	IC50	uM	1.9
4777	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C(C)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436206	=	=	IC50	nM	1800.0	IC50	uM	1.8
4778	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2	J. Med. Chem.	2013.0	CHEMBL2436227	=	=	IC50	nM	1800.0	IC50	uM	1.8
4779	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3c(Br)cccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436217	=	=	IC50	nM	1700.0	IC50	uM	1.7
4780	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cnccn2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436211	=	=	IC50	nM	1600.0	IC50	uM	1.6
4781	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(F)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436331	=	=	IC50	nM	1500.0	IC50	uM	1.5
4782	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436328	=	=	IC50	nM	1500.0	IC50	uM	1.5
4783	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436334	=	=	IC50	nM	1400.0	IC50	uM	1.4
4784	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(C)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436327	=	=	IC50	nM	1300.0	IC50	uM	1.3
4785	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436209	=	=	IC50	nM	1200.0	IC50	uM	1.2
4786	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccc(F)c2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436332	=	=	IC50	nM	1200.0	IC50	uM	1.2
4787	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436330	=	=	IC50	nM	1200.0	IC50	uM	1.2
4788	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436329	=	=	IC50	nM	1100.0	IC50	uM	1.1
4789	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2	J. Med. Chem.	2013.0	CHEMBL2436227	=	=	Ki	nM	1000.0	Ki	uM	1.0
4790	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2F)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436333	=	=	IC50	nM	860.0	IC50	uM	0.86
4791	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441346	=	=	IC50	nM	20500.0	IC50	uM	20.5
4792	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441342	=	=	IC50	nM	7400.0	IC50	uM	7.4
4793	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441340	=	=	IC50	nM	19700.0	IC50	uM	19.7
4794	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2171124	=	=	IC50	nM	10000.0	IC50	uM	10.0
4795	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441346	>	>	IC50	nM	25000.0	IC50	uM	25.0
4796	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441342	=	=	IC50	nM	9090.0	IC50	uM	9.09
4797	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441340	>	>	IC50	nM	25000.0	IC50	uM	25.0
4798	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2171124	=	=	IC50	nM	13000.0	IC50	uM	13.0
4799	Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis	CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441567	>	>	IC50	nM	10000.0	IC50	uM	10.0
4800	Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis	CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441565	>	>	IC50	nM	10000.0	IC50	uM	10.0
4801	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCCC1)C2	J. Med. Chem.	2013.0	CHEMBL2441955	=	=	IC50	nM	8200.0	IC50	uM	8.2
4802	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCC1)C2	J. Med. Chem.	2013.0	CHEMBL2441954	=	=	IC50	nM	23000.0	IC50	uM	23.0
4803	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCCN(C)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441953	=	=	IC50	nM	5500.0	IC50	uM	5.5
4804	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2	J. Med. Chem.	2013.0	CHEMBL2441952	=	=	IC50	nM	13000.0	IC50	uM	13.0
4805	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2	J. Med. Chem.	2013.0	CHEMBL2441952	=	=	IC50	nM	36000.0	IC50	uM	36.0
4806	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CNC(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441951	>	>	IC50	nM	40000.0	IC50	uM	40.0
4807	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(N)=O)C2	J. Med. Chem.	2013.0	CHEMBL2441950	>	>	IC50	nM	40000.0	IC50	uM	40.0
4808	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)[C@@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441848	=	=	IC50	nM	9600.0	IC50	uM	9.6
4809	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)CCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441847	=	=	IC50	nM	8300.0	IC50	uM	8.3
4810	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441846	=	=	IC50	nM	6600.0	IC50	uM	6.6
4811	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CCC(=O)O)C2	J. Med. Chem.	2013.0	CHEMBL2441845	>	>	IC50	nM	40000.0	IC50	uM	40.0
4812	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)O)C2	J. Med. Chem.	2013.0	CHEMBL2441844	>	>	IC50	nM	40000.0	IC50	uM	40.0
4813	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCOC(=O)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441843	=	=	IC50	nM	6400.0	IC50	uM	6.4
4814	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)NC2	J. Med. Chem.	2013.0	CHEMBL2441842	>	>	IC50	nM	40000.0	IC50	uM	40.0
4815	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1S(=O)(=O)C1CC1)C2	J. Med. Chem.	2013.0	CHEMBL2441841	=	=	IC50	nM	3000.0	IC50	uM	3.0
4816	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1)C2	J. Med. Chem.	2013.0	CHEMBL2441840	=	=	IC50	nM	40000.0	IC50	uM	40.0
4817	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCO1)C2	J. Med. Chem.	2013.0	CHEMBL2441839	=	=	IC50	nM	15000.0	IC50	uM	15.0
4818	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@H]1CCCO1)C2	J. Med. Chem.	2013.0	CHEMBL2441838	=	=	IC50	nM	14000.0	IC50	uM	14.0
4819	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441837	=	=	IC50	nM	13000.0	IC50	uM	13.0
4820	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441837	=	=	IC50	nM	13000.0	IC50	uM	13.0
4821	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	14000.0	IC50	uM	14.0
4822	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	29000.0	IC50	uM	29.0
4823	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	23000.0	IC50	uM	23.0
4824	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1cc(CN2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)no1	J. Med. Chem.	2013.0	CHEMBL2441835	=	=	IC50	nM	4700.0	IC50	uM	4.7
4825	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ncco1)C2	J. Med. Chem.	2013.0	CHEMBL2441834	=	=	IC50	nM	7700.0	IC50	uM	7.7
4826	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccn(C)n1)C2	J. Med. Chem.	2013.0	CHEMBL2441833	=	=	IC50	nM	7900.0	IC50	uM	7.9
4827	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccccc1)C2	J. Med. Chem.	2013.0	CHEMBL2441832	=	=	IC50	nM	900.0	IC50	uM	0.9
4828	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(c1ccn(C)n1)C2	J. Med. Chem.	2013.0	CHEMBL2441831	=	=	IC50	nM	11000.0	IC50	uM	11.0
4829	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	800.0	IC50	uM	0.8
4830	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	3400.0	IC50	uM	3.4
4831	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	800.0	IC50	uM	0.8
4832	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccc(N2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)cc1	J. Med. Chem.	2013.0	CHEMBL2441829	=	=	IC50	nM	900.0	IC50	uM	0.9
4833	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	N#Cc1cncc(Oc2cc(Cl)cc(C(=O)Nc3ccc(F)cn3)c2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440639	=	=	IC50	nM	1700.0	IC50	uM	1.7
4834	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncc(F)c3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440638	=	=	IC50	nM	700.0	IC50	uM	0.7
4835	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncc(F)c2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440637	=	=	IC50	nM	1300.0	IC50	uM	1.3
4836	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440626	=	=	IC50	nM	4300.0	IC50	uM	4.3
4837	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1cccc(Cl)n1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440625	=	=	IC50	nM	1900.0	IC50	uM	1.9
4838	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1cccc(F)n1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440624	<	<	IC50	nM	100.0	IC50	uM	0.1
4839	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440663	=	=	IC50	nM	6200.0	IC50	uM	6.2
4840	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1csc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440660	=	=	IC50	nM	2200.0	IC50	uM	2.2
4841	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440659	=	=	IC50	nM	22300.0	IC50	uM	22.3
4842	Inhibition of human CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1	Bioorg. Med. Chem.	2013.0	CHEMBL2442750	>	>	IC50	nM	100000.0	IC50	uM	100.0
4843	Inhibition of CYP2D6 (unknown origin) coincubated with substrate	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	>	>	IC50	nM	20000.0	IC50	uM	20.0
4844	Inhibition of CYP2D6 (unknown origin) coincubated with substrate	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
4845	Inhibition of CYP3A4 (unknown origin) coincubated with substrate	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	>	>	IC50	nM	20000.0	IC50	uM	20.0
4846	Inhibition of CYP3A4 (unknown origin) coincubated with substrate	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
4847	Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	=	=	IC50	nM	5000.0	IC50	uM	5.0
4848	Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
4849	DNDI: CYP Inhibition	Cl.OC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1			CHEMBL2448692	=	=	IC50	nM	700.0	IC50	uM	0.7
4850	DNDI: CYP Inhibition	O=c1c2ccccc2nc(-c2ccc(-c3ccccc3)cc2)n1Cc1cccnc1			CHEMBL2448693	>	>	IC50	nM	20000.0	IC50	uM	20.0
4851	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCOC(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448694	>	>	IC50	nM	20000.0	IC50	uM	20.0
4852	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(NC(=O)CN(C)C2CCN(C)CC2)c(Cl)c1.Cl			CHEMBL2448695	=	=	IC50	nM	19000.0	IC50	uM	19.0
4853	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)c2ccc3c(c2)CCNC3)c1			CHEMBL2448696	=	=	IC50	nM	5830.0	IC50	uM	5.83
4854	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCOC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1.O=CO			CHEMBL2448697	<	<	IC50	nM	250.0	IC50	uM	0.25
4855	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(CC)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448698	=	=	IC50	nM	20000.0	IC50	uM	20.0
4856	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448699	>	>	IC50	nM	20000.0	IC50	uM	20.0
4857	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)CNC2CCCN(C)C2)c1.O=CO			CHEMBL2448700	=	=	IC50	nM	16300.0	IC50	uM	16.3
4858	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448701	>	>	IC50	nM	20000.0	IC50	uM	20.0
4859	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(NCCc1cnc[nH]1)c1ccc2cc(Br)ccc2c1			CHEMBL2448703	=	=	IC50	nM	3280.0	IC50	uM	3.28
4860	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448704	=	=	IC50	nM	18000.0	IC50	uM	18.0
4861	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1			CHEMBL2448705	=	=	IC50	nM	16000.0	IC50	uM	16.0
4862	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN(CC(O)COc1ccc2cc(Br)ccc2c1)C1CCCCC1			CHEMBL2448706	>	>	IC50	nM	10000.0	IC50	uM	10.0
4863	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(C)N(C)CC(O)COc1ccc2cc(Br)ccc2c1			CHEMBL2448707	>	>	IC50	nM	20000.0	IC50	uM	20.0
4864	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448708	=	=	IC50	nM	1000.0	IC50	uM	1.0
4865	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1			CHEMBL2448709	=	=	IC50	nM	44400.0	IC50	uM	44.4
4866	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448711	=	=	IC50	nM	1400.0	IC50	uM	1.4
4867	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448712	=	=	IC50	nM	4500.0	IC50	uM	4.5
4868	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN(C)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448713	=	=	IC50	nM	10000.0	IC50	uM	10.0
4869	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448714	<	<	IC50	nM	250.0	IC50	uM	0.25
4870	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448715	=	=	IC50	nM	790.0	IC50	uM	0.79
4871	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448716	=	=	IC50	nM	1000.0	IC50	uM	1.0
4872	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3cccs3)nc2)c1			CHEMBL2448717	=	=	IC50	nM	1400.0	IC50	uM	1.4
4873	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)nc2)c1			CHEMBL2448689	=	=	IC50	nM	4000.0	IC50	uM	4.0
4874	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)cc2)c1			CHEMBL2448718	=	=	IC50	nM	3000.0	IC50	uM	3.0
4875	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccn3)s2)c1			CHEMBL2448719	=	=	IC50	nM	2000.0	IC50	uM	2.0
4876	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448720	=	=	IC50	nM	1120.0	IC50	uM	1.12
4877	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnn(-c3ccccn3)c2)c1			CHEMBL2448721	=	=	IC50	nM	1400.0	IC50	uM	1.4
4878	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448722	=	=	IC50	nM	2900.0	IC50	uM	2.9
4879	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448722	=	=	IC50	nM	1520.0	IC50	uM	1.52
4880	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCS(=O)(=O)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448723	=	=	IC50	nM	1040.0	IC50	uM	1.04
4881	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1			CHEMBL2448724	=	=	IC50	nM	2000.0	IC50	uM	2.0
4882	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1			CHEMBL2448725	>	>	IC50	nM	10000.0	IC50	uM	10.0
4883	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448727	=	=	IC50	nM	775.0	IC50	uM	0.775
4884	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448728	=	=	IC50	nM	1110.0	IC50	uM	1.11
4885	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2sc(-c3ccccc3)nc2C)c1			CHEMBL2448729	<	<	IC50	nM	1000.0	IC50	uM	1.0
4886	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cl.NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448730	<	<	IC50	nM	1000.0	IC50	uM	1.0
4887	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cl.NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448730	=	=	IC50	nM	1010.0	IC50	uM	1.01
4888	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448733	=	=	IC50	nM	1000.0	IC50	uM	1.0
4889	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448734	=	=	IC50	nM	470.0	IC50	uM	0.47
4890	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448735	=	=	IC50	nM	1500.0	IC50	uM	1.5
4891	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccn3)s2)c1			CHEMBL2448736	=	=	IC50	nM	3000.0	IC50	uM	3.0
4892	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448737	>	>	IC50	nM	10000.0	IC50	uM	10.0
4893	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)cn2)c1			CHEMBL2448738	=	=	IC50	nM	8000.0	IC50	uM	8.0
4894	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448739	<	<	IC50	nM	1000.0	IC50	uM	1.0
4895	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1c[nH]cn1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448740	=	=	IC50	nM	4000.0	IC50	uM	4.0
4896	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448741	=	=	IC50	nM	612.0	IC50	uM	0.612
4897	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1c[nH]cn1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448742	>	>	IC50	nM	10000.0	IC50	uM	10.0
4898	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cnc[nH]1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448743	=	=	IC50	nM	576.0	IC50	uM	0.576
4899	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	NCC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448744	=	=	IC50	nM	13040.0	IC50	uM	13.04
4900	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1c[nH]cn1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448745	<	<	IC50	nM	1000.0	IC50	uM	1.0
4901	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(C)Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448747	<	<	IC50	nM	1000.0	IC50	uM	1.0
4902	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1c[nH]cn1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448748	=	=	IC50	nM	4000.0	IC50	uM	4.0
4903	DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cncc(-c3ccccc3)n2)c1			CHEMBL2448752	<	<	IC50	nM	1000.0	IC50	uM	1.0
4904	Inhibition of CYP3A4 (unknown origin)	Cc1csc(C(C)(O)c2nnc(NC(=O)Cc3c(F)cccc3F)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088176	>	>	IC50	nM	50000.0	IC50	uM	50.0
4905	Inhibition of CYP3A4 (unknown origin)	Cc1csc(C(C)(O)c2nnc(Nc3ncn(Cc4c(F)cccc4F)n3)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088175	=	=	IC50	nM	48000.0	IC50	uM	48.0
4906	Inhibition of CYP3A4 (unknown origin)	Cc1csc([C@](C)(O)c2nnc(Nc3ccn(Cc4c(F)cccc4F)n3)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088172	=	=	IC50	nM	1900.0	IC50	uM	1.9
4907	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)[C@@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087343	>	>	IC50	nM	27000.0	IC50	uM	27.0
4908	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087342	>	>	IC50	nM	27000.0	IC50	uM	27.0
4909	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087341	>	>	IC50	nM	27000.0	IC50	uM	27.0
4910	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087340	>	>	IC50	nM	27000.0	IC50	uM	27.0
4911	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087339	>	>	IC50	nM	27000.0	IC50	uM	27.0
4912	Inhibition of CYP3A4 (unknown origin) after 5 mins	CCCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087043	>	>	IC50	nM	27000.0	IC50	uM	27.0
4913	Inhibition of CYP3A4 (unknown origin) after 5 mins	CCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087042	=	=	IC50	nM	12200.0	IC50	uM	12.2
4914	Inhibition of CYP3A4 (unknown origin) after 5 mins	C=Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087041	=	=	IC50	nM	4500.0	IC50	uM	4.5
4915	Inhibition of CYP3A4 (unknown origin) after 5 mins	COc1cc(-c2ccnc(C)c2)ccc1NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087040	=	=	IC50	nM	2200.0	IC50	uM	2.2
4916	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087038	>	>	IC50	nM	27000.0	IC50	uM	27.0
4917	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087037	=	=	IC50	nM	4700.0	IC50	uM	4.7
4918	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087036	=	=	IC50	nM	3500.0	IC50	uM	3.5
4919	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087035	=	=	IC50	nM	16200.0	IC50	uM	16.2
4920	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087355	=	=	IC50	nM	600.0	IC50	uM	0.6
4921	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1nccn1-c1ccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087353	>	>	IC50	nM	27000.0	IC50	uM	27.0
4922	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087352	=	=	IC50	nM	100.0	IC50	uM	0.1
4923	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cc[nH]n2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087351	=	=	IC50	nM	15300.0	IC50	uM	15.3
4924	Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1noc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087350	>	>	IC50	nM	27000.0	IC50	uM	27.0
4925	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087349	=	=	IC50	nM	27000.0	IC50	uM	27.0
4926	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087348	=	=	IC50	nM	13000.0	IC50	uM	13.0
4927	Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087347	=	=	IC50	nM	1600.0	IC50	uM	1.6
4928	Inhibition of CYP3A4 (unknown origin) after 4 hrs	Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087669	>	>	IC50	nM	100000.0	IC50	uM	100.0
4929	Inhibition of CYP3A4 (unknown origin)	Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086045	=	=	IC50	nM	25000.0	IC50	uM	25.0
4930	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis	Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086078	=	=	IC50	nM	18000.0	IC50	uM	18.0
4931	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis	Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086078	=	=	IC50	nM	14000.0	IC50	uM	14.0
4932	Inhibition of recombinant human CYP3A4	Cn1c(NCC(=O)c2ccccc2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091545	>	>	IC50	nM	50000.0	IC50	uM	50.0
4933	Inhibition of recombinant human CYP3A4	COc1cccc([C@H]2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091464	>	>	IC50	nM	50000.0	IC50	uM	50.0
4934	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091536	>	>	IC50	nM	50000.0	IC50	uM	50.0
4935	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091531	>	>	IC50	nM	50000.0	IC50	uM	50.0
4936	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091529	>	>	IC50	nM	50000.0	IC50	uM	50.0
4937	Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091547	>	>	IC50	nM	50000.0	IC50	uM	50.0
4938	Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091546	>	>	IC50	nM	50000.0	IC50	uM	50.0
4939	Inhibition of CYP3A4 in human liver microsomes measured after compound pre-incubation	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092124	>	>	IC50	nM	50000.0	IC50	uM	50.0
4940	Inhibition of CYP3A4 in human liver microsomes measured after concurrent incubation	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092124	>	>	IC50	nM	50000.0	IC50	uM	50.0
4941	Inhibition of human CYP3A4	Nc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092130	>	>	IC50	nM	10000.0	IC50	uM	10.0
4942	Inhibition of human CYP3A4	Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2442495	>	>	IC50	nM	10000.0	IC50	uM	10.0
4943	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093463	=	=	IC50	nM	5800.0	IC50	nM	5800.0
4944	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093462	=	=	IC50	nM	940.0	IC50	nM	940.0
4945	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093461	=	=	IC50	nM	570.0	IC50	nM	570.0
4946	Inhibition of CYP3A4 (unknown origin)	CC(C)(C1CCN(C(=O)c2cc(F)ccc2S(C)(=O)=O)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092198	=	=	IC50	nM	10000.0	IC50	uM	10.0
4947	Inhibition of CYP3A4 (unknown origin)	CC(C)(C1CCN(C(=O)c2ccc(S(C)(=O)=O)cc2OC(F)(F)F)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092197	=	=	IC50	nM	10000.0	IC50	uM	10.0
4948	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ncnc3c2)c(F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092423	>	>	IC50	nM	20000.0	IC50	uM	20.0
4949	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092421	=	=	IC50	nM	15000.0	IC50	uM	15.0
4950	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ncnc4c3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092419	>	>	IC50	nM	20000.0	IC50	uM	20.0
4951	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ccnc4c3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092417	>	>	IC50	nM	20000.0	IC50	uM	20.0
4952	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL126	>	>	IC50	nM	20000.0	IC50	uM	20.0
4953	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis	CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2414256	=	=	IC50	nM	80.0	IC50	uM	0.08
4954	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis	Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL3099819	=	=	IC50	nM	170.0	IC50	uM	0.17
4955	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
4956	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104490	=	=	IC50	nM	4000.0	IC50	uM	4.0
4957	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
4958	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1	J. Med. Chem.	2013.0	CHEMBL3104488	=	=	IC50	nM	7000.0	IC50	uM	7.0
4959	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
4960	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
4961	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
4962	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104479	=	=	IC50	nM	6300.0	IC50	uM	6.3
4963	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104478	=	=	IC50	nM	12000.0	IC50	uM	12.0
4964	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104476	>	>	IC50	nM	20000.0	IC50	uM	20.0
4965	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104473	=	=	IC50	nM	16000.0	IC50	uM	16.0
4966	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104472	>	>	IC50	nM	20000.0	IC50	uM	20.0
4967	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104537	=	=	IC50	nM	5200.0	IC50	uM	5.2
4968	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104534	=	=	IC50	nM	18000.0	IC50	uM	18.0
4969	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C([C@@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104526	=	=	IC50	nM	15000.0	IC50	uM	15.0
4970	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C([C@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104525	=	=	IC50	nM	17000.0	IC50	uM	17.0
4971	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104376	=	=	IC50	nM	16000.0	IC50	uM	16.0
4972	Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104375	>	>	IC50	nM	20000.0	IC50	uM	20.0
4973	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1	J. Med. Chem.	2013.0	CHEMBL3105228	=	=	IC50	nM	16000.0	IC50	uM	16.0
4974	Inhibition of CYP3A4 (unknown origin)	C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O	J. Med. Chem.	2013.0	CHEMBL3104250	=	=	IC50	nM	2610.0	IC50	uM	2.61
4975	Inhibition of CYP3A4 (unknown origin)	c1ccc(-c2ccc(C3(Cc4nnn[nH]4)C4CC5CC(C4)CC3C5)cc2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3103437	>	>	IC50	nM	40000.0	IC50	uM	40.0
4976	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109337	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4977	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109356	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4978	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCNC[C@@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109338	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4979	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109337	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4980	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109340	>	>	IC50	nM	10000.0	IC50	nM	10000.0
4981	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	24.0	IC50	uM	0.024
4982	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	C[C@]12CC[C@@H]3c4ccc(CCBr)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL2203397	=	=	IC50	nM	3900.0	IC50	uM	3.9
4983	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL410242	=	=	IC50	nM	1500.0	IC50	uM	1.5
4984	Inhibition of human CYP3A4	CCOc1ccc(N2CCN(c3noc(C4(NC(C)=O)CCC4)n3)[C@@H](C)C2)c(C)c1	J. Med. Chem.	2013.0	CHEMBL3110076	>	>	IC50	nM	25000.0	IC50	uM	25.0
4985	Inhibition of CYP3A4 (unknown origin)	CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(Cl)c(F)c1)C(=O)c1cn(C)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114787	>	>	IC50	nM	10000.0	IC50	uM	10.0
4986	Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)CC2CC2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114971	>	>	IC50	nM	30000.0	IC50	uM	30.0
4987	Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114968	>	>	IC50	nM	30000.0	IC50	uM	30.0
4988	Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccc(Cl)cc2Cl)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114967	>	>	IC50	nM	30000.0	IC50	uM	30.0
4989	Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL472757	>	>	IC50	nM	10000.0	IC50	uM	10.0
4990	Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)N1CCC(c2ccccc2)([C@H](C)NC(=O)c2ccc(Cl)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114792	>	>	IC50	nM	10000.0	IC50	uM	10.0
4991	Inhibition of CYP3A4 (unknown origin)	Cn1cncc1[C@@](C)(O)C1=Cc2cccnc2[C@@H](N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(Cl)cc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115253	=	=	IC50	nM	300.0	IC50	uM	0.3
4992	Inhibition of CYP3A4 (unknown origin) compound preincubated with substrate	COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112778	=	=	IC50	nM	300.0	IC50	uM	0.3
4993	Inhibition of CYP3A4 (unknown origin) compound co-incubated with substrate	COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112778	=	=	IC50	nM	4900.0	IC50	uM	4.9
4994	Inhibition of CYP3A4 (unknown origin)	COc1cccc(OC)c1C1CCCC(=O)N1Cc1ccc2ccccc2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112601	>	>	IC50	nM	30000.0	IC50	uM	30.0
4995	Inhibition of CYP3A4 (unknown origin) after 10 to 30 mins	Cl.O=C1N[C@H](C(=O)O)Cc2cn(cn2)C/C=C/COc2ccc(Cl)c1c2	ACS Med. Chem. Lett.	2014.0	CHEMBL3115061	>	>	IC50	nM	30000.0	IC50	uM	30.0
4996	Inhibition of recombinant human CYP3A4	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112867	=	=	IC50	nM	40000.0	IC50	uM	40.0
4997	Inhibition of recombinant human CYP3A4	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112866	=	=	IC50	nM	40000.0	IC50	uM	40.0
4998	Inhibition of recombinant human CYP3A4	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112865	=	=	IC50	nM	40000.0	IC50	uM	40.0
4999	Inhibition of recombinant human CYP3A4	CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112864	=	=	IC50	nM	40000.0	IC50	uM	40.0
5000	Inhibition of recombinant human CYP3A4	Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O	J. Med. Chem.	2014.0	CHEMBL3112861	=	=	IC50	nM	40000.0	IC50	uM	40.0
5001	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112858	=	=	IC50	nM	31000.0	IC50	uM	31.0
5002	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112857	=	=	IC50	nM	40000.0	IC50	uM	40.0
5003	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112856	=	=	IC50	nM	11000.0	IC50	uM	11.0
5004	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112855	=	=	IC50	nM	40000.0	IC50	uM	40.0
5005	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21	J. Med. Chem.	2014.0	CHEMBL3112854	=	=	IC50	nM	40000.0	IC50	uM	40.0
5006	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F	J. Med. Chem.	2014.0	CHEMBL3112853	=	=	IC50	nM	40000.0	IC50	uM	40.0
5007	Inhibition of recombinant human CYP3A4	COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112852	=	=	IC50	nM	40000.0	IC50	uM	40.0
5008	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21	J. Med. Chem.	2014.0	CHEMBL3112850	=	=	IC50	nM	40000.0	IC50	uM	40.0
5009	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21	J. Med. Chem.	2014.0	CHEMBL3112849	=	=	IC50	nM	40000.0	IC50	uM	40.0
5010	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21	J. Med. Chem.	2014.0	CHEMBL3112848	=	=	IC50	nM	40000.0	IC50	uM	40.0
5011	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21	J. Med. Chem.	2014.0	CHEMBL3112592	=	=	IC50	nM	40000.0	IC50	uM	40.0
5012	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21	J. Med. Chem.	2014.0	CHEMBL3112847	=	=	IC50	nM	40000.0	IC50	uM	40.0
5013	Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112690	=	=	IC50	nM	40000.0	IC50	uM	40.0
5014	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114739	=	=	IC50	nM	500.0	IC50	uM	0.5
5015	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114739	=	=	IC50	nM	460.0	IC50	uM	0.46
5016	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114738	=	=	IC50	nM	220.0	IC50	uM	0.22
5017	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114737	=	=	IC50	nM	1400.0	IC50	uM	1.4
5018	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114736	=	=	IC50	nM	1100.0	IC50	uM	1.1
5019	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114735	=	=	IC50	nM	270.0	IC50	uM	0.27
5020	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114734	=	=	IC50	nM	350.0	IC50	uM	0.35
5021	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2Cl)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114733	=	=	IC50	nM	340.0	IC50	uM	0.34
5022	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccc(Cl)cc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114732	=	=	IC50	nM	440.0	IC50	uM	0.44
5023	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114731	=	=	IC50	nM	340.0	IC50	uM	0.34
5024	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114730	=	=	IC50	nM	320.0	IC50	uM	0.32
5025	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114729	=	=	IC50	nM	300.0	IC50	uM	0.3
5026	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NC2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112611	=	=	IC50	nM	1670.0	IC50	uM	1.67
5027	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCC(NC(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114728	=	=	IC50	nM	1840.0	IC50	uM	1.84
5028	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114727	=	=	IC50	nM	1260.0	IC50	uM	1.26
5029	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114726	=	=	IC50	nM	300.0	IC50	uM	0.3
5030	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCNNC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114725	=	=	IC50	nM	630.0	IC50	uM	0.63
5031	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114724	=	=	IC50	nM	240.0	IC50	uM	0.24
5032	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114723	=	=	IC50	nM	870.0	IC50	uM	0.87
5033	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114722	=	=	IC50	nM	140.0	IC50	uM	0.14
5034	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H]2OC(C)(C)O[C@@H]2[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114721	=	=	IC50	nM	310.0	IC50	uM	0.31
5035	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](C)CC[C@H](C)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114720	=	=	IC50	nM	510.0	IC50	uM	0.51
5036	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC[C@@H](CC[C@H](CC)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114719	=	=	IC50	nM	190.0	IC50	uM	0.19
5037	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114718	=	=	IC50	nM	130.0	IC50	uM	0.13
5038	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114717	=	=	IC50	nM	130.0	IC50	uM	0.13
5039	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(C)[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114740	=	=	IC50	nM	410.0	IC50	uM	0.41
5040	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)N(C)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114716	=	=	IC50	nM	710.0	IC50	uM	0.71
5041	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](/C=C/[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114715	=	=	IC50	nM	150.0	IC50	uM	0.15
5042	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114714	=	=	IC50	nM	280.0	IC50	uM	0.28
5043	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114713	=	=	IC50	nM	130.0	IC50	uM	0.13
5044	Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL163	=	=	IC50	nM	110.0	IC50	uM	0.11
5045	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114894	=	=	IC50	nM	1800.0	IC50	uM	1.8
5046	Inhibition of CYP3A4 (unknown origin)	CC(C)CC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114886	>	>	IC50	nM	25000.0	IC50	uM	25.0
5047	Inhibition of CYP3A4 (unknown origin)	CC(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114880	>	>	IC50	nM	6000.0	IC50	uM	6.0
5048	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114905	=	=	IC50	nM	3100.0	IC50	uM	3.1
5049	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114896	=	=	IC50	nM	3100.0	IC50	uM	3.1
5050	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115191	=	=	IC50	nM	90.0	IC50	uM	0.09
5051	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115190	=	=	IC50	nM	80.0	IC50	uM	0.08
5052	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115189	=	=	IC50	nM	120.0	IC50	uM	0.12
5053	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115188	=	=	IC50	nM	120.0	IC50	uM	0.12
5054	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115187	=	=	IC50	nM	140.0	IC50	uM	0.14
5055	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cn2cccn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115186	=	=	IC50	nM	100.0	IC50	uM	0.1
5056	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115185	=	=	IC50	nM	110.0	IC50	uM	0.11
5057	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115184	=	=	IC50	nM	120.0	IC50	uM	0.12
5058	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCNS(C)(=O)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115183	=	=	IC50	nM	120.0	IC50	uM	0.12
5059	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115182	=	=	IC50	nM	150.0	IC50	uM	0.15
5060	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115181	=	=	IC50	nM	120.0	IC50	uM	0.12
5061	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115180	=	=	IC50	nM	150.0	IC50	uM	0.15
5062	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2095208	=	=	IC50	nM	150.0	IC50	uM	0.15
5063	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115179	=	=	IC50	nM	140.0	IC50	uM	0.14
5064	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CNCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115178	=	=	IC50	nM	130.0	IC50	uM	0.13
5065	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115177	=	=	IC50	nM	210.0	IC50	uM	0.21
5066	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115176	=	=	IC50	nM	140.0	IC50	uM	0.14
5067	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)NC(CN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115175	=	=	IC50	nM	140.0	IC50	uM	0.14
5068	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115174	=	=	IC50	nM	130.0	IC50	uM	0.13
5069	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115173	=	=	IC50	nM	500.0	IC50	uM	0.5
5070	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](COCc2ccccc2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115172	=	=	IC50	nM	170.0	IC50	uM	0.17
5071	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	COC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115171	=	=	IC50	nM	150.0	IC50	uM	0.15
5072	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115170	=	=	IC50	nM	120.0	IC50	uM	0.12
5073	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CN(Cc1cncs1)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115169	=	=	IC50	nM	170.0	IC50	uM	0.17
5074	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C2CC2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115168	=	=	IC50	nM	110.0	IC50	uM	0.11
5075	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115167	=	=	IC50	nM	150.0	IC50	uM	0.15
5076	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CN(Cc1cncs1)C(=O)NCCC(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115166	=	=	IC50	nM	130.0	IC50	uM	0.13
5077	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cncs1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115165	=	=	IC50	nM	80.0	IC50	uM	0.08
5078	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(Cc1cscn1)C1CC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115164	<	<	IC50	nM	100.0	IC50	uM	0.1
5079	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115163	=	=	IC50	nM	140.0	IC50	uM	0.14
5080	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	Cc1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115162	=	=	IC50	nM	100.0	IC50	uM	0.1
5081	Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)C2CC2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115161	=	=	IC50	nM	210.0	IC50	uM	0.21
5082	Inhibition of human CYP3A4	O=C(Nc1ccc(F)c(-c2nc3cc(-c4ccccc4)cnc3[nH]2)c1)N1CCCC1	J. Med. Chem.	2014.0	CHEMBL3115821	=	=	IC50	nM	1500.0	IC50	uM	1.5
5083	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116157	>	>	IC50	nM	40000.0	IC50	uM	40.0
5084	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116158	=	=	IC50	nM	40000.0	IC50	uM	40.0
5085	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116160	>	>	IC50	nM	40000.0	IC50	uM	40.0
5086	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116154	=	=	IC50	nM	24000.0	IC50	uM	24.0
5087	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116155	=	=	IC50	nM	32000.0	IC50	uM	32.0
5088	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116156	=	=	IC50	nM	40000.0	IC50	uM	40.0
5089	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2152165	=	=	IC50	nM	8800.0	IC50	uM	8.8
5090	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116157	>	>	IC50	nM	40000.0	IC50	uM	40.0
5091	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116158	=	=	IC50	nM	40000.0	IC50	uM	40.0
5092	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116160	>	>	IC50	nM	40000.0	IC50	uM	40.0
5093	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116154	=	=	IC50	nM	19000.0	IC50	uM	19.0
5094	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116155	=	=	IC50	nM	40000.0	IC50	uM	40.0
5095	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116156	=	=	IC50	nM	13000.0	IC50	uM	13.0
5096	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2152165	=	=	IC50	nM	3600.0	IC50	uM	3.6
5097	Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1	J. Med. Chem.	2014.0	CHEMBL3121804	>	>	IC50	nM	10000.0	IC50	uM	10.0
5098	Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ccccn1	J. Med. Chem.	2014.0	CHEMBL3121800	>	>	IC50	nM	10000.0	IC50	uM	10.0
5099	Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1	J. Med. Chem.	2014.0	CHEMBL3120505	>	>	IC50	nM	10000.0	IC50	uM	10.0
5100	Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccc1F	J. Med. Chem.	2014.0	CHEMBL3121798	>	>	IC50	nM	10000.0	IC50	uM	10.0
5101	Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1	J. Med. Chem.	2014.0	CHEMBL3121694	>	>	IC50	nM	10000.0	IC50	uM	10.0
5102	Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1	J. Med. Chem.	2014.0	CHEMBL3121811	>	>	IC50	nM	10000.0	IC50	uM	10.0
5103	Inhibition of CYP3A4 (unknown origin)	O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3121096	>	>	IC50	nM	30000.0	IC50	uM	30.0
5104	Inhibition of CYP3A4 (unknown origin)	O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3121095	>	>	IC50	nM	30000.0	IC50	uM	30.0
5105	Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CC6(CN5C(=O)[C@@H](NC(=O)OC)C(C)C)OCCO6)[nH]4)cc3)cc2)[nH]1)C(C)C	J. Med. Chem.	2014.0	CHEMBL3121951	>	>	IC50	nM	33000.0	IC50	uM	33.0
5106	Inhibition of CYP3A4 (unknown origin)	C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	J. Med. Chem.	2014.0	CHEMBL2403888	=	=	IC50	nM	2000.0	IC50	uM	2.0
5107	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1	J. Med. Chem.	2014.0	CHEMBL3128180	=	=	IC50	nM	41800.0	IC50	uM	41.8
5108	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21	J. Med. Chem.	2014.0	CHEMBL3128188	>	>	IC50	nM	100000.0	IC50	uM	100.0
5109	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21	J. Med. Chem.	2014.0	CHEMBL3128178	>	>	IC50	nM	100000.0	IC50	uM	100.0
5110	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1	J. Med. Chem.	2014.0	CHEMBL1684585	>	>	IC50	nM	100000.0	IC50	uM	100.0
5111	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2014.0	CHEMBL3128194	=	=	IC50	nM	86000.0	IC50	uM	86.0
5112	Inhibition of human recombinant CYP3A4	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125375	=	=	IC50	nM	40.0	IC50	nM	40.0
5113	Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125395	=	=	IC50	nM	40000.0	IC50	uM	40.0
5114	Inhibition of human recombinant CYP3A4	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125394	=	=	IC50	nM	40000.0	IC50	uM	40.0
5115	Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125391	=	=	IC50	nM	40000.0	IC50	uM	40.0
5116	Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125390	=	=	IC50	nM	40000.0	IC50	uM	40.0
5117	Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125389	=	=	IC50	nM	40000.0	IC50	uM	40.0
5118	Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125385	=	=	IC50	nM	40000.0	IC50	uM	40.0
5119	Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125384	=	=	IC50	nM	40000.0	IC50	uM	40.0
5120	Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125384	=	=	IC50	nM	40000.0	IC50	uM	40.0
5121	Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125383	=	=	IC50	nM	40000.0	IC50	uM	40.0
5122	Inhibition of human recombinant CYP3A4	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125381	=	=	IC50	nM	40000.0	IC50	uM	40.0
5123	Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125380	=	=	IC50	nM	40000.0	IC50	uM	40.0
5124	Inhibition of human recombinant CYP3A4	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125379	=	=	IC50	nM	40000.0	IC50	uM	40.0
5125	Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125378	=	=	IC50	nM	40000.0	IC50	uM	40.0
5126	Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125395	=	=	IC50	nM	25000.0	IC50	uM	25.0
5127	Inhibition of CYP3A4 in human liver microsomes after 7 mins by LC/MS/MS analysis	O=C(c1nn2c(C(F)(F)F)cc(C3CC3)cc2c1Cl)N1CCN([C@H]2C[C@@H]3C[C@@H]3[C@@H]2O)C(=O)C1	J. Med. Chem.	2014.0	CHEMBL3125655	>	>	IC50	nM	20000.0	IC50	uM	20.0
5128	Inhibition of human CYP3A4 by fluorescence assay	CCc1cc(C(=O)N[C@@H]2C[C@@H](C(N)=O)N(C(=O)c3coc4ccccc34)C2)n(CC)n1	J. Med. Chem.	2014.0	CHEMBL3125270	>	>	IC50	nM	50000.0	IC50	uM	50.0
5129	Inhibition of human CYP3A4 by fluorescence assay	CCNC(=O)[C@@H]1C[C@@H](NC(=O)c2cc(CC)nn2C)CN1C(=O)c1coc2ccccc12	J. Med. Chem.	2014.0	CHEMBL3125272	>	>	IC50	nM	50000.0	IC50	uM	50.0
5130	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1csc(-n2nc(-c3ccccc3)c3ccc(C(F)(F)F)cc32)n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3127163	>	>	IC50	nM	10000.0	IC50	uM	10.0
5131	Inhibition of human CYP3A4 expressed in Escherichia coli using 7-benzyloxyquinoline as substrate	CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1	J. Med. Chem.	2014.0	CHEMBL3126382	=	=	IC50	nM	3800.0	IC50	uM	3.8
5132	Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein as substrate	CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1	J. Med. Chem.	2014.0	CHEMBL3126382	=	=	IC50	nM	1600.0	IC50	uM	1.6
5133	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127494	=	=	IC50	nM	1800.0	IC50	uM	1.8
5134	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127510	=	=	IC50	nM	1900.0	IC50	uM	1.9
5135	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127509	=	=	IC50	nM	960.0	IC50	uM	0.96
5136	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127507	=	=	IC50	nM	1500.0	IC50	uM	1.5
5137	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127506	=	=	IC50	nM	3000.0	IC50	uM	3.0
5138	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127501	=	=	IC50	nM	890.0	IC50	uM	0.89
5139	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1	J. Med. Chem.	2014.0	CHEMBL3127500	=	=	IC50	nM	890.0	IC50	uM	0.89
5140	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127526	>	>	IC50	nM	10000.0	IC50	uM	10.0
5141	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127525	=	=	IC50	nM	8900.0	IC50	uM	8.9
5142	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127522	=	=	IC50	nM	3500.0	IC50	uM	3.5
5143	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127521	=	=	IC50	nM	680.0	IC50	uM	0.68
5144	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127520	=	=	IC50	nM	1200.0	IC50	uM	1.2
5145	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127494	=	=	IC50	nM	1400.0	IC50	uM	1.4
5146	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127510	=	=	IC50	nM	200.0	IC50	uM	0.2
5147	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127509	=	=	IC50	nM	300.0	IC50	uM	0.3
5148	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127507	=	=	IC50	nM	140.0	IC50	uM	0.14
5149	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127506	=	=	IC50	nM	270.0	IC50	uM	0.27
5150	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127501	=	=	IC50	nM	65.0	IC50	uM	0.065
5151	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1	J. Med. Chem.	2014.0	CHEMBL3127500	=	=	IC50	nM	180.0	IC50	uM	0.18
5152	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127526	>	>	IC50	nM	10000.0	IC50	uM	10.0
5153	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127525	=	=	IC50	nM	2500.0	IC50	uM	2.5
5154	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127522	=	=	IC50	nM	2000.0	IC50	uM	2.0
5155	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127521	=	=	IC50	nM	90.0	IC50	uM	0.09
5156	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127520	=	=	IC50	nM	110.0	IC50	uM	0.11
5157	Inhibition of CYP3A4 (unknown origin)	COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126842	>	>	IC50	nM	40000.0	IC50	uM	40.0
5158	Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)C1CC1(C(=O)N1C3CC1CN(Cc1ccccc1)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126836	=	=	EC50	nM	13000.0	EC50	uM	13.0
5159	Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	CCN1CC2CC(C1)N2C(=O)[C@]12C[C@H]1c1cc(OC)ccc1-c1c(C3CCCCC3)c3ccc(C(=O)NS(=O)(=O)N(C)C)cc3n1C2	J. Med. Chem.	2014.0	CHEMBL3126835	=	=	EC50	nM	9000.0	EC50	uM	9.0
5160	Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126834	=	=	EC50	nM	14000.0	EC50	uM	14.0
5161	Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)C1CC1(C(=O)N1C3CNCC1C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126657	>	>	EC50	nM	40000.0	EC50	uM	40.0
5162	Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2	Eur. J. Med. Chem.	2014.0	CHEMBL3127992	=	=	IC50	nM	2200.0	IC50	uM	2.2
5163	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(Cl)cc2C(F)(F)F)C3=O)cn1	J. Med. Chem.	2014.0	CHEMBL3127906	>	>	IC50	nM	30000.0	IC50	uM	30.0
5164	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(F)cc2C(F)(F)F)C3=O)cn1	J. Med. Chem.	2014.0	CHEMBL3127905	>	>	IC50	nM	30000.0	IC50	uM	30.0
5165	Inhibition of CYP3A4 (unknown origin)	CCC1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)cc(Cl)c2NC1=O	MedChemComm	2013.0	CHEMBL3134098	>	>	IC50	nM	30000.0	IC50	uM	30.0
5166	Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CC[C@@H](Oc2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cn2)CC1	MedChemComm	2013.0	CHEMBL3133005	>	>	IC50	nM	10000.0	IC50	uM	10.0
5167	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	20000.0	IC50	uM	20.0
5168	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	1200.0	IC50	uM	1.2
5169	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	7400.0	IC50	uM	7.4
5170	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	=	=	IC50	nM	7000.0	IC50	uM	7.0
5171	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	>	>	IC50	nM	20000.0	IC50	uM	20.0
5172	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	=	=	IC50	nM	6600.0	IC50	uM	6.6
5173	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	4000.0	IC50	uM	4.0
5174	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	19000.0	IC50	uM	19.0
5175	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	7100.0	IC50	uM	7.1
5176	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
5177	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	=	=	IC50	nM	20000.0	IC50	uM	20.0
5178	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
5179	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
5180	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
5181	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
5182	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
5183	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
5184	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
5185	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
5186	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
5187	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
5188	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
5189	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
5190	DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
5191	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
5192	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
5193	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
5194	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3137390	>	>	IC50	nM	20000.0	IC50	uM	20.0
5195	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3137391	=	=	IC50	nM	18000.0	IC50	uM	18.0
5196	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3137392	=	=	IC50	nM	20000.0	IC50	uM	20.0
5197	DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(Cc2ccccc2C(F)(F)F)CC1			CHEMBL3137394	=	=	IC50	nM	15000.0	IC50	uM	15.0
5198	DNDI: CYP Inhibition	CS(=O)(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137466	=	=	IC50	nM	2600.0	IC50	uM	2.6
5199	DNDI: CYP Inhibition	CC(C)(C)CC(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3104528	=	=	IC50	nM	800.0	IC50	uM	0.8
5200	DNDI: CYP Inhibition	O=C(C1CC1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137467	=	=	IC50	nM	1500.0	IC50	uM	1.5
5201	DNDI: CYP Inhibition	O=C(c1ccccc1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137468	=	=	IC50	nM	1900.0	IC50	uM	1.9
5202	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104479	=	=	IC50	nM	6300.0	IC50	uM	6.3
5203	DNDI: CYP Inhibition	CC(C)(C)C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104529	=	=	IC50	nM	1900.0	IC50	uM	1.9
5204	DNDI: CYP Inhibition	O=C(c1ccccc1C(F)(F)F)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104531	=	=	IC50	nM	1700.0	IC50	uM	1.7
5205	DNDI: CYP Inhibition	Cc1noc(C)c1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137441	=	=	IC50	nM	2100.0	IC50	uM	2.1
5206	DNDI: CYP Inhibition	Cc1ncsc1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137442	=	=	IC50	nM	2900.0	IC50	uM	2.9
5207	DNDI: CYP Inhibition	O=C(c1ccc(F)cc1)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137443	=	=	IC50	nM	4400.0	IC50	uM	4.4
5208	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	>	>	IC50	nM	100000.0	IC50	uM	100.0
5209	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	=	=	IC50	nM		IC50	uM	
5210	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1			CHEMBL3104472	=	=	IC50	nM		IC50	uM	
5211	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1			CHEMBL3137445	>	>	IC50	nM	20000.0	IC50	uM	20.0
5212	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	>	>	IC50	nM	100000.0	IC50	uM	100.0
5213	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM		IC50	uM	
5214	DNDI: CYP Inhibition	FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137448	=	=	IC50	nM		IC50	uM	
5215	DNDI: CYP Inhibition	COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137450	=	=	IC50	nM	15000.0	IC50	uM	15.0
5216	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1			CHEMBL3104532	>	>	IC50	nM	20000.0	IC50	uM	20.0
5217	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1			CHEMBL3137452	=	=	IC50	nM		IC50	uM	
5218	DNDI: CYP Inhibition	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104534	>	>	IC50	nM	20000.0	IC50	uM	20.0
5219	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
5220	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
5221	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	>	>	IC50	nM	100000.0	IC50	uM	100.0
5222	DNDI: CYP Inhibition	Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1			CHEMBL3137455	=	=	IC50	nM		IC50	uM	
5223	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1			CHEMBL3137456	=	=	IC50	nM		IC50	uM	
5224	DNDI: CYP Inhibition	N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104538	=	=	IC50	nM		IC50	uM	
5225	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	=	=	IC50	nM	30200.0	IC50	uM	30.2
5226	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1			CHEMBL3104472	>	>	IC50	nM	20000.0	IC50	uM	20.0
5227	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1			CHEMBL3137445	=	=	IC50	nM	11000.0	IC50	uM	11.0
5228	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM	10700.0	IC50	uM	10.7
5229	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM	18000.0	IC50	uM	18.0
5230	DNDI: CYP Inhibition	FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137448	=	=	IC50	nM	10000.0	IC50	uM	10.0
5231	DNDI: CYP Inhibition	COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137450	=	=	IC50	nM	8000.0	IC50	uM	8.0
5232	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1			CHEMBL3104532	>	>	IC50	nM	20000.0	IC50	uM	20.0
5233	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1			CHEMBL3137452	=	=	IC50	nM	1700.0	IC50	uM	1.7
5234	DNDI: CYP Inhibition	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104534	=	=	IC50	nM	18000.0	IC50	uM	18.0
5235	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM	6000.0	IC50	uM	6.0
5236	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM	12100.0	IC50	uM	12.1
5237	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	>	>	IC50	nM	20000.0	IC50	uM	20.0
5238	DNDI: CYP Inhibition	Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1			CHEMBL3137455	=	=	IC50	nM	700.0	IC50	uM	0.7
5239	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1			CHEMBL3137456	=	=	IC50	nM	1800.0	IC50	uM	1.8
5240	DNDI: CYP Inhibition	N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104538	=	=	IC50	nM	4000.0	IC50	uM	4.0
5241	DNDI: CYP Inhibition	N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104537	=	=	IC50	nM	5200.0	IC50	uM	5.2
5242	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1			CHEMBL3104473	=	=	IC50	nM	16000.0	IC50	uM	16.0
5243	DNDI: CYP Inhibition	Cc1cncc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1			CHEMBL3137458	=	=	IC50	nM	600.0	IC50	uM	0.6
5244	DNDI: CYP Inhibition	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1			CHEMBL3104476	>	>	IC50	nM	20000.0	IC50	uM	20.0
5245	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104478	=	=	IC50	nM	12000.0	IC50	uM	12.0
5246	DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104477	=	=	IC50	nM	2000.0	IC50	uM	2.0
5247	DNDI: CYP Inhibition	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(F)c(F)c3)CC2)cc1			CHEMBL3137459	=	=	IC50	nM	4300.0	IC50	uM	4.3
5248	DNDI: CYP Inhibition	CC(C)(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137460	=	=	IC50	nM	5300.0	IC50	uM	5.3
5249	DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1ccccc1N1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1			CHEMBL3137461	=	=	IC50	nM	2000.0	IC50	uM	2.0
5250	DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1			CHEMBL3137462	=	=	IC50	nM	7000.0	IC50	uM	7.0
5251	DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)c1			CHEMBL3137463	=	=	IC50	nM	6000.0	IC50	uM	6.0
5252	DNDI: CYP Inhibition	CCC(C(C)=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137464	=	=	IC50	nM	10000.0	IC50	uM	10.0
5253	DNDI: CYP Inhibition	CC(=O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137471	=	=	IC50	nM	5000.0	IC50	uM	5.0
5254	DNDI: CYP Inhibition	CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137472	>	>	IC50	nM	20000.0	IC50	uM	20.0
5255	DNDI: CYP Inhibition	CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137472	>	>	IC50	nM	20000.0	IC50	uM	20.0
5256	DNDI: CYP Inhibition	N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137473	>	>	IC50	nM	20000.0	IC50	uM	20.0
5257	DNDI: CYP Inhibition	N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137474	>	>	IC50	nM	20000.0	IC50	uM	20.0
5258	DNDI: CYP Inhibition	Cn1nc(C2CC2)cc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137475	>	>	IC50	nM	20000.0	IC50	uM	20.0
5259	DNDI: CYP Inhibition	CC(C)(O)CN1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1			CHEMBL3137476	>	>	IC50	nM	20000.0	IC50	uM	20.0
5260	DNDI: CYP Inhibition	CCC(C(C)O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137477	=	=	IC50	nM	17000.0	IC50	uM	17.0
5261	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cncnc3)CC2)cc1			CHEMBL3137479	=	=	IC50	nM	16000.0	IC50	uM	16.0
5262	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1			CHEMBL3137480	=	=	IC50	nM	9000.0	IC50	uM	9.0
5263	DNDI: CYP Inhibition	CC(C)C(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137481	>	>	IC50	nM	20000.0	IC50	uM	20.0
5264	DNDI: CYP Inhibition	CC(C)(F)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137482	=	=	IC50	nM	16000.0	IC50	uM	16.0
5265	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(C(c3ccccc3)C(F)(F)F)CC2)cc1			CHEMBL3137483	>	>	IC50	nM	20000.0	IC50	uM	20.0
5266	DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
5267	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218854	=	=	IC50	nM	5300.0	IC50	uM	5.3
5268	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218855	=	=	IC50	nM	8500.0	IC50	uM	8.5
5269	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218856	>	>	IC50	nM	30000.0	IC50	uM	30.0
5270	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218857	>	>	IC50	nM	30000.0	IC50	uM	30.0
5271	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(CN2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218858	>	>	IC50	nM	30000.0	IC50	uM	30.0
5272	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(CN2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218859	>	>	IC50	nM	30000.0	IC50	uM	30.0
5273	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218854	=	=	IC50	nM	5400.0	IC50	uM	5.4
5274	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218855	=	=	IC50	nM	13700.0	IC50	uM	13.7
5275	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218856	=	=	IC50	nM	14200.0	IC50	uM	14.2
5276	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218857	>	>	IC50	nM	30000.0	IC50	uM	30.0
5277	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(CN2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218858	>	>	IC50	nM	30000.0	IC50	uM	30.0
5278	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(CN2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218859	>	>	IC50	nM	30000.0	IC50	uM	30.0
5279	Inhibition of CYP3A4 (unknown origin)	Br.CN(C)Cc1cc2c([nH]c(=O)c3cccc(O)c32)s1	MedChemComm	2011.0	CHEMBL3219283	<	<	IC50	nM	200000.0	IC50	uM	200.0
5280	Inhibition of CYP3A4 (unknown origin)	Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1	MedChemComm	2013.0	CHEMBL3218645	=	=	IC50	nM	680.0	IC50	uM	0.68
5281	Inhibition of CYP3A4 (unknown origin)	COc1cc(OC)cc(-c2nnc([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccccc4)C3=O)o2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3234858	>	>	IC50	nM	50000.0	IC50	uM	50.0
5282	Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccccc1)N1C(=O)O[C@](Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3234863	>	>	IC50	nM	19000.0	IC50	uM	19.0
5283	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCN(C)CC2)nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1	J. Med. Chem.	2014.0	CHEMBL3234564	>	>	IC50	nM	25000.0	IC50	uM	25.0
5284	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(C(F)(F)F)nc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234565	=	=	IC50	nM	2000.0	IC50	uM	2.0
5285	Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)nc(N2CCN(C)CC2)c1F	J. Med. Chem.	2014.0	CHEMBL3234566	=	=	IC50	nM	7600.0	IC50	uM	7.6
5286	Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2CCN(C)CC2)cc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1	J. Med. Chem.	2014.0	CHEMBL3234567	>	>	IC50	nM	25000.0	IC50	uM	25.0
5287	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234568	<	<	IC50	nM	1000.0	IC50	uM	1.0
5288	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cc1	J. Med. Chem.	2014.0	CHEMBL3234569	<	<	IC50	nM	100.0	IC50	uM	0.1
5289	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCN(C5COC5)CC4)nc(C(F)(F)F)n3)C2)cc1	J. Med. Chem.	2014.0	CHEMBL3234570	=	=	IC50	nM	1100.0	IC50	uM	1.1
5290	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234571	=	=	IC50	nM	10000.0	IC50	uM	10.0
5291	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cn1	J. Med. Chem.	2014.0	CHEMBL3234572	<	<	IC50	nM	300.0	IC50	uM	0.3
5292	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4cnc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234573	=	=	IC50	nM	5200.0	IC50	uM	5.2
5293	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234574	=	=	IC50	nM	400.0	IC50	uM	0.4
5294	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234575	=	=	IC50	nM	2200.0	IC50	uM	2.2
5295	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234576	=	=	IC50	nM	700.0	IC50	uM	0.7
5296	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234577	=	=	IC50	nM	3000.0	IC50	uM	3.0
5297	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234578	=	=	IC50	nM	800.0	IC50	uM	0.8
5298	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)nc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234579	=	=	IC50	nM	7800.0	IC50	uM	7.8
5299	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCN2c2cc(-c3ccc([C@H]4CC[C@H](C(=O)O)CC4)cc3)nc(C(F)(F)F)n2)cc1	J. Med. Chem.	2014.0	CHEMBL3234871	>	>	IC50	nM	25000.0	IC50	uM	25.0
5300	Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1cccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)n1	J. Med. Chem.	2014.0	CHEMBL3233058	>	>	IC50	nM	50000.0	IC50	uM	50.0
5301	Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)ccc1F	J. Med. Chem.	2014.0	CHEMBL3237560	>	>	IC50	nM	50000.0	IC50	uM	50.0
5302	Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1ccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)nc1C	J. Med. Chem.	2014.0	CHEMBL3237561	>	>	IC50	nM	50000.0	IC50	uM	50.0
5303	Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)cc1Nc1ccc2c(n1)CCC2	J. Med. Chem.	2014.0	CHEMBL3237564	>	>	IC50	nM	50000.0	IC50	uM	50.0
5304	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3ccc(F)cn3)CC[C@H]2C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3235253	>	>	IC50	nM	50000.0	IC50	uM	50.0
5305	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3cccc(CO)c3)CC[C@H]2C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3235265	=	=	IC50	nM	4000.0	IC50	uM	4.0
5306	Inhibition of CYP3A4 (unknown origin)	c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1	J. Med. Chem.	2014.0	CHEMBL3237442	=	=	IC50	nM	550.0	IC50	uM	0.55
5307	Inhibition of CYP3A4 (unknown origin)	Fc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237443	>	>	IC50	nM	10000.0	IC50	uM	10.0
5308	Inhibition of CYP3A4 (unknown origin)	Clc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237444	>	>	IC50	nM	10000.0	IC50	uM	10.0
5309	Inhibition of CYP3A4 (unknown origin)	Cc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237445	>	>	IC50	nM	10000.0	IC50	uM	10.0
5310	Inhibition of CYP3A4 (unknown origin)	c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2nn1	J. Med. Chem.	2014.0	CHEMBL3237448	>	>	IC50	nM	10000.0	IC50	uM	10.0
5311	Inhibition of CYP3A4 (unknown origin)	C[C@@H](CO)n1c2cnccc2c2cnc(Nc3ccc(N4CCNCC4)cn3)nc21	J. Med. Chem.	2014.0	CHEMBL3237449	>	>	IC50	nM	10000.0	IC50	uM	10.0
5312	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CC[C@H](n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1	J. Med. Chem.	2014.0	CHEMBL3237703	>	>	IC50	nM	10000.0	IC50	uM	10.0
5313	Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1	J. Med. Chem.	2014.0	CHEMBL3237704	=	=	IC50	nM	9500.0	IC50	uM	9.5
5314	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3125527	>	>	IC50	nM	27000.0	IC50	uM	27.0
5315	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2nnn[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236358	=	=	IC50	nM	2500.0	IC50	uM	2.5
5316	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2noc(=O)[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236359	=	=	IC50	nM	1200.0	IC50	uM	1.2
5317	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)NS(=O)(=O)C(F)(F)F)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236360	=	=	IC50	nM	3800.0	IC50	uM	3.8
5318	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3125537	>	>	IC50	nM	27000.0	IC50	uM	27.0
5319	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)C(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236361	>	>	IC50	nM	27000.0	IC50	uM	27.0
5320	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)CO)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236362	=	=	IC50	nM	700.0	IC50	uM	0.7
5321	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236363	=	=	IC50	nM	1300.0	IC50	uM	1.3
5322	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236364	=	=	IC50	nM	1200.0	IC50	uM	1.2
5323	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CS(N)(=O)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236365	=	=	IC50	nM	500.0	IC50	uM	0.5
5324	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236635	>	>	IC50	nM	27000.0	IC50	uM	27.0
5325	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236636	>	>	IC50	nM	27000.0	IC50	uM	27.0
5326	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236637	=	=	IC50	nM	700.0	IC50	uM	0.7
5327	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccc2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236638	=	=	IC50	nM	1700.0	IC50	uM	1.7
5328	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2cc(C(=O)O)ccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236639	>	>	IC50	nM	27000.0	IC50	uM	27.0
5329	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ncc(C(=O)CO)s2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236654	=	=	IC50	nM	800.0	IC50	uM	0.8
5330	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cn(C(C)C)c(=O)c3ccccc23)c2cc(F)ccc2n1CC(=O)O	J. Med. Chem.	2014.0	CHEMBL3236948	>	>	IC50	nM	100000.0	IC50	uM	100.0
5331	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2nc(CC(=O)O)cs2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236640	>	>	IC50	nM	27000.0	IC50	uM	27.0
5332	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1	J. Med. Chem.	2014.0	CHEMBL271202	=	=	IC50	nM	13000.0	IC50	uM	13.0
5333	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3263640	=	=	IC50	nM	9800.0	IC50	uM	9.8
5334	Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3263640	>	>	IC50	nM	40000.0	IC50	uM	40.0
5335	Inhibition of human recombinant CYP3A4	Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260740	=	=	IC50	nM	6600.0	IC50	uM	6.6
5336	Inhibition of human recombinant CYP3A4	Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21	J. Med. Chem.	2013.0	CHEMBL3260741	=	=	IC50	nM	6800.0	IC50	uM	6.8
5337	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260742	=	=	IC50	nM	18000.0	IC50	uM	18.0
5338	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3C)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260744	>	>	IC50	nM	40000.0	IC50	uM	40.0
5339	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccc(C#N)cc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260745	>	>	IC50	nM	40000.0	IC50	uM	40.0
5340	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(C)nc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260753	>	>	IC50	nM	40000.0	IC50	uM	40.0
5341	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260754	=	=	IC50	nM	7000.0	IC50	uM	7.0
5342	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260755	=	=	IC50	nM	3400.0	IC50	uM	3.4
5343	Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(N(C)C)nc3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260756	>	>	IC50	nM	40000.0	IC50	uM	40.0
5344	Inhibition of CYP3A4 in human hepatocytes	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260743	=	=	IC50	nM	3000.0	IC50	uM	3.0
5345	Inhibition of CYP3A4 in human liver microsomes	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260743	=	=	IC50	nM	9100.0	IC50	uM	9.1
5346	Inhibition of CYP3A4 (unknown origin)	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1	J. Med. Chem.	2014.0	CHEMBL3264059	>	>	IC50	nM	25000.0	IC50	uM	25.0
5347	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3264002	>	>	IC50	nM	100000.0	IC50	uM	100.0
5348	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3092195	=	=	IC50	nM	26000.0	IC50	uM	26.0
5349	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3092189	=	=	IC50	nM	13000.0	IC50	uM	13.0
5350	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3263996	>	>	IC50	nM	100000.0	IC50	uM	100.0
5351	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3264002	>	>	IC50	nM	100000.0	IC50	uM	100.0
5352	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3092195	=	=	IC50	nM	11000.0	IC50	uM	11.0
5353	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3092189	=	=	IC50	nM	5600.0	IC50	uM	5.6
5354	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3263996	>	>	IC50	nM	100000.0	IC50	uM	100.0
5355	Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med. Chem. Lett.	2014.0	CHEMBL3259907	=	=	IC50	nM	23000.0	IC50	uM	23.0
5356	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)cc(SC)c1C(=O)N[C@@]1(c2ccccc2)CCCN(C)C1	ACS Med. Chem. Lett.	2014.0	CHEMBL3259928	>	>	IC50	nM	50000.0	IC50	uM	50.0
5357	Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O	J. Med. Chem.	2014.0	CHEMBL3261331	>	>	IC50	nM	50000.0	IC50	uM	50.0
5358	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis	Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1	J. Med. Chem.	2014.0	CHEMBL3260567	>	>	IC50	nM	10000.0	IC50	uM	10.0
5359	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261407	=	=	IC50	nM	10000.0	IC50	uM	10.0
5360	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261425	=	=	IC50	nM	22000.0	IC50	uM	22.0
5361	Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261479	>	>	IC50	nM	50000.0	IC50	uM	50.0
5362	Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261481	>	>	IC50	nM	50000.0	IC50	uM	50.0
5363	Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261482	>	>	IC50	nM	50000.0	IC50	uM	50.0
5364	Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261483	>	>	IC50	nM	50000.0	IC50	uM	50.0
5365	Inhibition of CYP3A4 (unknown origin)	COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261485	>	>	IC50	nM	50000.0	IC50	uM	50.0
5366	Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261486	>	>	IC50	nM	50000.0	IC50	uM	50.0
5367	Inhibition of CYP3A4 (unknown origin)	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
5368	Inhibition of CYP3A4 (unknown origin)	COCCn1cc(-c2c(C)nc3c(N4CCOCC4)nccn23)cn1	J. Med. Chem.	2014.0	CHEMBL3262028	>	>	IC50	nM	10000.0	IC50	uM	10.0
5369	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264599	=	=	IC50	nM	770.0	IC50	uM	0.77
5370	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264604	=	=	IC50	nM	1600.0	IC50	uM	1.6
5371	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cc[nH]n3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264595	=	=	IC50	nM	1800.0	IC50	uM	1.8
5372	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3ccncc3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264602	=	=	IC50	nM	4500.0	IC50	uM	4.5
5373	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cnco3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264600	=	=	IC50	nM	6500.0	IC50	uM	6.5
5374	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cccnc3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264601	=	=	IC50	nM	9400.0	IC50	uM	9.4
5375	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OC(F)F)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264608	=	=	IC50	nM	14000.0	IC50	uM	14.0
5376	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3ccncn3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264603	=	=	IC50	nM	18000.0	IC50	uM	18.0
5377	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264605	=	=	IC50	nM	23000.0	IC50	uM	23.0
5378	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)c(OCC(F)(F)F)cc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264606	=	=	IC50	nM	25000.0	IC50	uM	25.0
5379	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cn[nH]c3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264596	=	=	IC50	nM	27000.0	IC50	uM	27.0
5380	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264597	=	=	IC50	nM	57000.0	IC50	uM	57.0
5381	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(-c3cccs3)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3259868	=	=	IC50	nM	81000.0	IC50	uM	81.0
5382	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3nc[nH]n3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264598	=	=	IC50	nM	100000.0	IC50	uM	100.0
5383	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(-c3cnco3)ccc2c1)c1cnn[nH]1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264607	=	=	IC50	nM	102000.0	IC50	uM	102.0
5384	Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264609	>=	>=	IC50	nM	195000.0	IC50	uM	195.0
5385	Inhibition of CYP3A4 (unknown origin)	COc1ccc(NC(=O)N2CCNC[C@@H]2COc2cccnc2)cc1.Cl	J. Med. Chem.	2014.0	CHEMBL3262163	>	>	IC50	nM	100000.0	IC50	uM	100.0
5386	Inhibition of CYP3A4 (unknown origin)	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1	J. Med. Chem.	2014.0	CHEMBL3265032	>	>	IC50	nM	10000.0	IC50	uM	10.0
5387	Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	280.0	IC50	uM	0.28
5388	Inhibition of CYP3A4 (unknown origin)	Cc1cc2nn(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)c(=O)n2cc1Cl	Bioorg. Med. Chem.	2014.0	CHEMBL3288752	>	>	IC50	nM	11000.0	IC50	uM	11.0
5389	Inhibition of CYP3A4 (unknown origin)	CCN1C(=O)CN(c2ccc(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)cc2)C1=O	Bioorg. Med. Chem.	2014.0	CHEMBL3288755	>	>	IC50	nM	11000.0	IC50	uM	11.0
5390	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291118	=	=	IC50	nM	1250.0	IC50	uM	1.25
5391	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291120	=	=	IC50	nM	1950.0	IC50	uM	1.95
5392	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291124	=	=	IC50	nM	242.0	IC50	uM	0.242
5393	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291127	=	=	IC50	nM	135.0	IC50	uM	0.135
5394	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291394	=	=	IC50	nM	1080.0	IC50	uM	1.08
5395	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291395	=	=	IC50	nM	1890.0	IC50	uM	1.89
5396	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291398	=	=	IC50	nM	4650.0	IC50	uM	4.65
5397	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291118	=	=	IC50	nM	1360.0	IC50	uM	1.36
5398	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291120	=	=	IC50	nM	1900.0	IC50	uM	1.9
5399	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291124	=	=	IC50	nM	216.0	IC50	uM	0.216
5400	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291127	=	=	IC50	nM	44.4	IC50	uM	0.0444
5401	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291394	=	=	IC50	nM	1240.0	IC50	uM	1.24
5402	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291395	=	=	IC50	nM	1630.0	IC50	uM	1.63
5403	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291398	=	=	IC50	nM	4430.0	IC50	uM	4.43
5404	Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1Cc1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291357	=	=	IC50	nM	4800.0	IC50	uM	4.8
5405	Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccc(F)cc2F)n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291346	=	=	IC50	nM	6100.0	IC50	uM	6.1
5406	Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccccc2)n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291340	=	=	IC50	nM	7700.0	IC50	uM	7.7
5407	Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291345	=	=	IC50	nM	22600.0	IC50	uM	22.6
5408	Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1cc(Cl)ccc1Cl)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291348	>	>	IC50	nM	25000.0	IC50	uM	25.0
5409	Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291337	>	>	IC50	nM	50000.0	IC50	uM	50.0
5410	Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1Cl)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291354	>	>	IC50	nM	50000.0	IC50	uM	50.0
5411	Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)N[C@H]3CC[C@H](N)CC3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289023	>	>	IC50	nM	30000.0	IC50	uM	30.0
5412	Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(NC(=O)[C@H]3CC[C@H](N)CC3)cc(Oc3ccc(C(=N)N)cc3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289034	>	>	IC50	nM	30000.0	IC50	uM	30.0
5413	Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)O[C@H]3CC[C@H](N)CC3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289038	>	>	IC50	nM	30000.0	IC50	uM	30.0
5414	Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCCF)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3109801	>	>	IC50	nM	50000.0	IC50	uM	50.0
5415	Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3109802	>	>	IC50	nM	50000.0	IC50	uM	50.0
5416	Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCC(F)F)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3291422	>	>	IC50	nM	50000.0	IC50	uM	50.0
5417	Inhibition of human CYP3A4	Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291423	>	>	IC50	nM	50000.0	IC50	uM	50.0
5418	Inhibition of human CYP3A4	Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC(F)F)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291424	>	>	IC50	nM	50000.0	IC50	uM	50.0
5419	Inhibition of human CYP3A4	COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291427	>	>	IC50	nM	50000.0	IC50	uM	50.0
5420	Inhibition of human CYP3A4	COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291430	>	>	IC50	nM	50000.0	IC50	uM	50.0
5421	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(N2CCC3(CC2)CNC(=O)O3)nc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3286732	>	>	IC50	nM	10000.0	IC50	uM	10.0
5422	Inhibition of CYP3A4 (unknown origin)	Nc1nc2ccc(C(F)(F)F)cc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2014.0	CHEMBL3289803	>	>	IC50	nM	30000.0	IC50	uM	30.0
5423	Inhibition of CYP3A4 (unknown origin)	Nc1nc2cccnc2n1CC(O)c1cccc(Cl)c1Cl	J. Med. Chem.	2014.0	CHEMBL3289805	>	>	IC50	nM	30000.0	IC50	uM	30.0
5424	Inhibition of CYP3A4 (unknown origin)	Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2014.0	CHEMBL3289811	=	=	IC50	nM	2400.0	IC50	uM	2.4
5425	Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1	J. Med. Chem.	2014.0	CHEMBL3289806	=	=	IC50	nM	14100.0	IC50	uM	14.1
5426	Inhibition of CYP3A4 (unknown origin)	CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F	J. Med. Chem.	2014.0	CHEMBL3289813	=	=	IC50	nM	20300.0	IC50	uM	20.3
5427	Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis	CCC(=O)N1CCc2cc(-c3cncc4ccccc34)ccc21	J. Med. Chem.	2014.0	CHEMBL3287179	>	>	IC50	nM	50000.0	IC50	uM	50.0
5428	Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis	CC(=O)N1CCc2cc(-c3cnccc3C)ccc21	J. Med. Chem.	2014.0	CHEMBL3287188	>	>	IC50	nM	50000.0	IC50	uM	50.0
5429	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone conversion to 6-hydroxy testosterone preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis	Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287548	=	=	IC50	nM	50000.0	IC50	uM	50.0
5430	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam conversion to 1'-hydroxy midazolam preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis	Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287548	=	=	IC50	nM	25000.0	IC50	uM	25.0
5431	Inhibition of CYP3A4 (unknown origin)	Cc1noc(C)c1-c1ccc(-c2nc(C)c([C@H](OC(C)(C)C)C(=O)O)c(-c3ccc(Cl)cc3)c2C)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287925	=	=	IC50	nM	17000.0	IC50	uM	17.0
5432	Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med. Chem. Lett.	2014.0	CHEMBL3259907	=	=	IC50	nM	23000.0	IC50	uM	23.0
5433	Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6CCC(N7CCCC7)CC6)cc5)c4)CC3)cn12	J. Med. Chem.	2014.0	CHEMBL3288009	<	>	IC50	nM	1000.0	pIC50		6.0
5434	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CN(Cc2ccc(-c3cccc(Oc4ncc(F)cc4C(=O)N[C@H]4CC[C@@H](NC(=O)c5cc6ccccn6n5)CC4)c3)cc2)C[C@@H](C)N1	J. Med. Chem.	2014.0	CHEMBL3288010	=	=	IC50	nM	398.11	pIC50		6.4
5435	Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6C[C@H](C)N[C@H](C)C6)cc5)c4)CC3)cn12	J. Med. Chem.	2014.0	CHEMBL3288011	<	>	IC50	nM	1000.0	pIC50		6.0
5436	Inhibition of CYP3A4 (unknown origin)	O=c1cc([C@H]2CCN[C@@H](Cc3ccccc3)C2)o[nH]1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287849	>	>	IC50	nM	20000000.0	IC50	mM	20.0
5437	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C[C@H]1C[C@@H](c2cc(=O)[nH]o2)CCN1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287851	>	>	IC50	nM	20000000.0	IC50	mM	20.0
5438	Inhibition of CYP3A4 (unknown origin)	O=c1cc([C@H]2CCN[C@@H](CCc3ccccc3)C2)o[nH]1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287854	>	>	IC50	nM	20000000.0	IC50	mM	20.0
5439	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCCN5C[C@H](C)N[C@H](C)C5)cc4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3288027	<	>	IC50	nM	1000.0	pIC50		6.0
5440	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCN5CCC(N6CCCC6)CC5)cc4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3288028	<	>	IC50	nM	1000.0	pIC50		6.0
5441	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(O)cc4CN4CCOCC4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3287739	=	=	IC50	nM	501.19	pIC50		6.3
5442	Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288447	=	=	IC50	nM	4900.0	IC50	uM	4.9
5443	Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288448	=	=	IC50	nM	2100.0	IC50	uM	2.1
5444	Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288450	>	>	IC50	nM	30000.0	IC50	uM	30.0
5445	Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288451	=	=	IC50	nM	13300.0	IC50	uM	13.3
5446	Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288447	=	=	IC50	nM	300.0	IC50	uM	0.3
5447	Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288448	<	<	IC50	nM	300.0	IC50	uM	0.3
5448	Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288450	=	=	IC50	nM	7500.0	IC50	uM	7.5
5449	Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288451	=	=	IC50	nM	900.0	IC50	uM	0.9
5450	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3109797	>	>	IC50	nM	40000.0	IC50	uM	40.0
5451	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298835	=	=	IC50	nM	2070.0	IC50	uM	2.07
5452	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298836	=	=	IC50	nM	490.0	IC50	uM	0.49
5453	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298837	>	>	IC50	nM	40000.0	IC50	uM	40.0
5454	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298905	=	=	IC50	nM	11540.0	IC50	uM	11.54
5455	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298906	>	>	IC50	nM	40000.0	IC50	uM	40.0
5456	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298907	>	>	IC50	nM	40000.0	IC50	uM	40.0
5457	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298908	>	>	IC50	nM	40000.0	IC50	uM	40.0
5458	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298909	>	>	IC50	nM	100000.0	IC50	uM	100.0
5459	Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298910	>	>	IC50	nM	100000.0	IC50	uM	100.0
5460	Inhibition of CYP3A4 (unknown origin)	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1	Bioorg. Med. Chem.	2013.0	CHEMBL3297762	>	>	IC50	nM	10000.0	IC50	uM	10.0
5461	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298322	=	=	IC50	nM	1900.0	IC50	uM	1.9
5462	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2ncnc3[nH]ccc23)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298431	>	>	IC50	nM	20000.0	IC50	uM	20.0
5463	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2nccc3[nH]ccc23)c(F)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298760	>	>	IC50	nM	20000.0	IC50	uM	20.0
5464	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2nccc3[nH]ccc23)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3297778	>	>	IC50	nM	20000.0	IC50	uM	20.0
5465	Inhibition of human CYP3A4	CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3357391	>	>	IC50	nM	3000.0	IC50	uM	3.0
5466	Inhibition of recombinant CYP3A4 (unknown origin) after 3 mins by LC-MS/MS analysis	COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3354313	=	=	IC50	nM	6710.0	IC50	uM	6.71
5467	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353862	>	>	IC50	nM	50000.0	IC50	uM	50.0
5468	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353863	>	>	IC50	nM	50000.0	IC50	uM	50.0
5469	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCC(=O)N2c2ccc(C(F)(F)F)cc2)on1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353881	>	>	IC50	nM	50000.0	IC50	uM	50.0
5470	Inhibition of human CYP3A4	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCCN2C(=O)N2CCS(=O)(=O)CC2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3354553	>	>	IC50	nM	30000.0	IC50	uM	30.0
5471	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O	ACS Med. Chem. Lett.	2015.0	CHEMBL3355474	>	>	IC50	nM	40000.0	IC50	uM	40.0
5472	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C	ACS Med. Chem. Lett.	2015.0	CHEMBL3355480	>	>	IC50	nM	24000.0	IC50	uM	24.0
5473	Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092460	>	>	IC50	nM	30000.0	IC50	uM	30.0
5474	Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092468	>	>	IC50	nM	30000.0	IC50	uM	30.0
5475	Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3092467	=	=	IC50	nM	26800.0	IC50	uM	26.8
5476	Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092460	=	=	IC50	nM	14500.0	IC50	uM	14.5
5477	Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092468	=	=	IC50	nM	28600.0	IC50	uM	28.6
5478	Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3092467	=	=	IC50	nM	18600.0	IC50	uM	18.6
5479	Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21	ACS Med. Chem. Lett.	2014.0	CHEMBL3358920	>	>	IC50	nM	50000.0	IC50	uM	50.0
5480	Inhibition of CYP3A4 (unknown origin)	C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3359927	>	>	IC50	nM	20000.0	IC50	uM	20.0
5481	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL1254079	=	=	IC50	nM	100.0	IC50	uM	0.1
5482	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358921	=	=	IC50	nM	100.0	IC50	uM	0.1
5483	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358922	=	=	IC50	nM	2000.0	IC50	uM	2.0
5484	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358923	=	=	IC50	nM	600.0	IC50	uM	0.6
5485	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)nc(C)c2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358924	=	=	IC50	nM	200.0	IC50	uM	0.2
5486	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358925	=	=	IC50	nM	3000.0	IC50	uM	3.0
5487	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358926	=	=	IC50	nM	500.0	IC50	uM	0.5
5488	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358927	=	=	IC50	nM	600.0	IC50	uM	0.6
5489	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358928	=	=	IC50	nM	300.0	IC50	uM	0.3
5490	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358929	=	=	IC50	nM	10.0	IC50	uM	0.01
5491	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358930	=	=	IC50	nM	2000.0	IC50	uM	2.0
5492	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358931	=	=	IC50	nM	2000.0	IC50	uM	2.0
5493	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358932	=	=	IC50	nM	100.0	IC50	uM	0.1
5494	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358933	=	=	IC50	nM	100.0	IC50	uM	0.1
5495	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358934	=	=	IC50	nM	100.0	IC50	uM	0.1
5496	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358935	=	=	IC50	nM	200.0	IC50	uM	0.2
5497	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358936	=	=	IC50	nM	4000.0	IC50	uM	4.0
5498	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3352882	=	=	IC50	nM	3000.0	IC50	uM	3.0
5499	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358937	=	=	IC50	nM	10.0	IC50	uM	0.01
5500	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358938	=	=	IC50	nM	500.0	IC50	uM	0.5
5501	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358939	=	=	IC50	nM	2000.0	IC50	uM	2.0
5502	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358940	=	=	IC50	nM	700.0	IC50	uM	0.7
5503	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358941	=	=	IC50	nM	2000.0	IC50	uM	2.0
5504	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358942	>	>	IC50	nM	30000.0	IC50	uM	30.0
5505	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358944	>	>	IC50	nM	30000.0	IC50	uM	30.0
5506	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358945	=	=	IC50	nM	15000.0	IC50	uM	15.0
5507	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358946	=	=	IC50	nM	3000.0	IC50	uM	3.0
5508	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358947	=	=	IC50	nM	15000.0	IC50	uM	15.0
5509	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358948	=	=	IC50	nM	6000.0	IC50	uM	6.0
5510	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358949	=	=	IC50	nM	14000.0	IC50	uM	14.0
5511	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358950	=	=	IC50	nM	26000.0	IC50	uM	26.0
5512	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358951	=	=	IC50	nM	4000.0	IC50	uM	4.0
5513	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1cccc2c1S(=O)(=O)CC2	ACS Med. Chem. Lett.	2014.0	CHEMBL3358952	=	=	IC50	nM	2000.0	IC50	uM	2.0
5514	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358953	=	=	IC50	nM	34000.0	IC50	uM	34.0
5515	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358954	=	=	IC50	nM	8000.0	IC50	uM	8.0
5516	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358921	=	=	IC50	nM	3800.0	IC50	uM	3.8
5517	Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CC[C@@H]2CC(=O)O)cc1C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3359523	>	>	IC50	nM	50000.0	IC50	uM	50.0
5518	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2151164	=	=	IC50	nM	8700.0	IC50	uM	8.7
5519	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2151164	=	=	IC50	nM	2900.0	IC50	uM	2.9
5520	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3353099	=	=	IC50	nM	25400.0	IC50	uM	25.4
5521	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay	COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL502	=	=	IC50	nM	54680.0	IC50	uM	54.68
5522	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL157101	=	=	IC50	nM	200.0	IC50	uM	0.2
5523	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3cccnc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353342	>	>	IC50	nM	1000.0	IC50	uM	1.0
5524	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353348	>	>	IC50	nM	1000.0	IC50	uM	1.0
5525	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	>	>	IC50	nM	1000.0	IC50	uM	1.0
5526	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	>	>	IC50	nM	1000.0	IC50	uM	1.0
5527	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccc(F)cc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353356	>	>	IC50	nM	1000.0	IC50	uM	1.0
5528	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN1CCN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3353359	>	>	IC50	nM	10000.0	IC50	uM	10.0
5529	Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	N#CC1(c2cc(C[C@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310294	>	>	IC50	nM	20000.0	IC50	uM	20.0
5530	Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	N#CC1(c2cc(C[C@@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310295	>	>	IC50	nM	20000.0	IC50	uM	20.0
5531	Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	CS(=O)(=O)NCCc1cc(-c2ccnc3[nH]nc(C(F)(F)F)c23)cc(C2(C#N)CC2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310285	=	=	IC50	nM	7000.0	IC50	uM	7.0
5532	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1175	=	=	IC50	nM	440.0	IC50	uM	0.44
5533	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Clc1ccc(C23CNCC2C3)cc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL528995	=	=	IC50	nM	1300.0	IC50	uM	1.3
5534	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310483	=	=	IC50	nM	600.0	IC50	uM	0.6
5535	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310484	=	=	IC50	nM	710.0	IC50	uM	0.71
5536	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310485	=	=	IC50	nM	510.0	IC50	uM	0.51
5537	Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310486	=	=	IC50	nM	400.0	IC50	uM	0.4
5538	Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330260	=	=	IC50	nM	10000.0	IC50	uM	10.0
5539	Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330410	>	>	IC50	nM	1000.0	IC50	uM	1.0
5540	Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C	Bioorg. Med. Chem.	2014.0	CHEMBL3330409	=	=	IC50	nM	2900.0	IC50	uM	2.9
5541	Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330260	=	=	IC50	nM	1000.0	IC50	uM	1.0
5542	Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330410	=	=	IC50	nM	4000.0	IC50	uM	4.0
5543	Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C	Bioorg. Med. Chem.	2014.0	CHEMBL3330409	=	=	IC50	nM	700.0	IC50	uM	0.7
5544	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310992	=	=	IC50	nM	8000.0	IC50	uM	8.0
5545	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310993	=	=	IC50	nM	32000.0	IC50	uM	32.0
5546	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnc1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310994	=	=	IC50	nM	800.0	IC50	uM	0.8
5547	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ncnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3309278	=	=	IC50	nM	46000.0	IC50	uM	46.0
5548	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	uM	13.0
5549	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccccn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310995	=	=	IC50	nM	136000.0	IC50	uM	136.0
5550	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3358962	=	=	IC50	nM	74000.0	IC50	uM	74.0
5551	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(OCC(F)(F)F)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311221	=	=	IC50	nM	72000.0	IC50	uM	72.0
5552	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311222	=	=	IC50	nM	53000.0	IC50	uM	53.0
5553	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311223	=	=	IC50	nM	16000.0	IC50	uM	16.0
5554	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311224	>	>	IC50	nM	60000.0	IC50	uM	60.0
5555	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311225	=	=	IC50	nM	36000.0	IC50	uM	36.0
5556	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311226	=	=	IC50	nM	54000.0	IC50	uM	54.0
5557	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311227	=	=	IC50	nM	79000.0	IC50	uM	79.0
5558	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311228	=	=	IC50	nM	65000.0	IC50	uM	65.0
5559	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL64391	=	=	IC50	nM	70.0	IC50	uM	0.07
5560	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1397	=	=	IC50	nM	50.0	IC50	uM	0.05
5561	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnc1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3358963	=	=	IC50	nM	51000.0	IC50	uM	51.0
5562	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(S(=O)(=O)N2CCN(c3ncc(C(O)(C(F)(F)F)C(F)(F)F)cc3-c3cccnc3)CC2)cn1	J. Med. Chem.	2014.0	CHEMBL3319549	=	=	IC50	nM	27000.0	IC50	uM	27.0
5563	Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2cc(C(O)(C(F)(F)F)C(F)(F)F)cnc2N2CCN(S(=O)(=O)c3ccc(N)nc3)CC2)cn1	J. Med. Chem.	2014.0	CHEMBL3319533	=	=	IC50	nM	27000.0	IC50	uM	27.0
5564	Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate	COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1	Eur. J. Med. Chem.	2014.0	CHEMBL3329684	>	>	IC50	nM	10000.0	IC50	uM	10.0
5565	Inhibition of CYP3A4 (unknown origin)	CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3315061	>	>	IC50	nM	40000.0	IC50	uM	40.0
5566	Inhibition of CYP3A4 (unknown origin)	CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3315062	=	=	IC50	nM	300.0	IC50	uM	0.3
5567	Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate	O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1	Eur. J. Med. Chem.	2014.0	CHEMBL3322590	>	>	IC50	nM	10000.0	IC50	uM	10.0
5568	Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321845	=	=	IC50	nM	250.0	IC50	uM	0.25
5569	Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)c2cnc(O)nc2Oc2cc(Cl)ccc2Cl)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321846	=	=	IC50	nM	260.0	IC50	uM	0.26
5570	Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321850	=	=	IC50	nM	270.0	IC50	uM	0.27
5571	Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL157101	<	<	IC50	nM	62.0	IC50	uM	0.062
5572	Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	J. Med. Chem.	2014.0	CHEMBL3313972	<	<	IC50	nM	68.0	IC50	nM	68.0
5573	Inhibition of CYP3A4 (unknown origin)	CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)cn2)C2CC2)[C@@H]1O	ACS Med. Chem. Lett.	2014.0	CHEMBL3318957	>	>	IC50	nM	30000.0	IC50	uM	30.0
5574	Inhibition of human CYP3A3	Clc1ccc(C2(c3nnc4c(C5CC5)cccn34)CC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318978	>	>	IC50	nM	20000.0	IC50	uM	20.0
5575	Inhibition of CYP3A4 (unknown origin)	COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318997	=	=	IC50	nM	9400.0	IC50	uM	9.4
5576	Inhibition of CYP3A4 (unknown origin)	COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318998	=	=	IC50	nM	20000.0	IC50	uM	20.0
5577	Inhibition of CYP3A4 in pooled human liver microsomes in presence of NADPH	O=C(Nc1cncc(Oc2cncnc2)n1)c1cc(Cl)ccn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3314850	>	>	IC50	nM	30000.0	IC50	uM	30.0
5578	Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2ccccc2)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318415	>	>	IC50	nM	5000.0	IC50	uM	5.0
5579	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2ccccc2)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318423	>	>	IC50	nM	5000.0	IC50	uM	5.0
5580	Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(Cl)cccc2Cl)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318469	>	>	IC50	nM	5000.0	IC50	uM	5.0
5581	Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(Cl)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318472	>	>	IC50	nM	5000.0	IC50	uM	5.0
5582	Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(C(F)(F)F)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318477	>	>	IC50	nM	5000.0	IC50	uM	5.0
5583	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Cl)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318481	>	>	IC50	nM	5000.0	IC50	uM	5.0
5584	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Br)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318482	>	>	IC50	nM	5000.0	IC50	uM	5.0
5585	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326569	=	=	IC50	nM	1000.0	IC50	uM	1.0
5586	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(F)cc2O1	J. Med. Chem.	2014.0	CHEMBL3326570	=	=	IC50	nM	660.0	IC50	uM	0.66
5587	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(OC(F)(F)F)cc2O1	J. Med. Chem.	2014.0	CHEMBL3326576	=	=	IC50	nM	2200.0	IC50	uM	2.2
5588	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326577	=	=	IC50	nM	2800.0	IC50	uM	2.8
5589	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326578	>	>	IC50	nM	20000.0	IC50	uM	20.0
5590	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1	J. Med. Chem.	2014.0	CHEMBL3326579	>	>	IC50	nM	20000.0	IC50	uM	20.0
5591	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCCC1(CCC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1	J. Med. Chem.	2014.0	CHEMBL3326580	>	>	IC50	nM	20000.0	IC50	uM	20.0
5592	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326581	>	>	IC50	nM	20000.0	IC50	uM	20.0
5593	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(C(F)(F)F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3325460	>	>	IC50	nM	20000.0	IC50	uM	20.0
5594	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(F)c4F)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326582	>	>	IC50	nM	20000.0	IC50	uM	20.0
5595	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c(F)cc(F)cc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326583	>	>	IC50	nM	20000.0	IC50	uM	20.0
5596	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(C(F)(F)F)c4F)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326584	=	=	IC50	nM	18000.0	IC50	uM	18.0
5597	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(OC(F)(F)F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326585	>	>	IC50	nM	20000.0	IC50	uM	20.0
5598	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4ccc(F)cc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326586	=	=	IC50	nM	15000.0	IC50	uM	15.0
5599	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326587	>	>	IC50	nM	20000.0	IC50	uM	20.0
5600	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(Cl)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326588	=	=	IC50	nM	20000.0	IC50	uM	20.0
5601	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(C5CC5)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326589	>	>	IC50	nM	20000.0	IC50	uM	20.0
5602	Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4c(F)cccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326909	>	>	IC50	nM	20000.0	IC50	uM	20.0
5603	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL2407749	=	=	IC50	nM	1000.0	IC50	uM	1.0
5604	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL2407897	=	=	IC50	nM	940.0	IC50	uM	0.94
5605	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL2407900	>	>	IC50	nM	1000.0	IC50	uM	1.0
5606	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C/c1ccc2cn[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353337	=	=	IC50	nM	10000.0	IC50	uM	10.0
5607	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2cn[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353338	>	>	IC50	nM	10000.0	IC50	uM	10.0
5608	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353340	>	>	IC50	nM	1000.0	IC50	uM	1.0
5609	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	2100.0	IC50	uM	2.1
5610	Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	>	>	IC50	nM	10000.0	IC50	uM	10.0
5611	Inhibition of CYP3A4 in human liver microsomes	O=C1NCCc2nc(OCc3cccc(F)c3)ccc21	J. Med. Chem.	2014.0	CHEMBL3298273	>	>	IC50	nM	30000.0	IC50	uM	30.0
5612	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O	J. Med. Chem.	2014.0	CHEMBL2010601	>	>	IC50	nM	20000.0	IC50	uM	20.0
5613	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1515648	>	>	IC50	nM	20000.0	IC50	uM	20.0
5614	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1515648	>	>	IC50	nM	20000.0	IC50	uM	20.0
5615	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F	J. Med. Chem.	2014.0	CHEMBL514794	>	>	IC50	nM	20000.0	IC50	uM	20.0
5616	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F	J. Med. Chem.	2014.0	CHEMBL514794	>	>	IC50	nM	20000.0	IC50	uM	20.0
5617	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21	J. Med. Chem.	2014.0	CHEMBL496942	>	>	IC50	nM	2500.0	IC50	uM	2.5
5618	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21	J. Med. Chem.	2014.0	CHEMBL496942	>	>	IC50	nM	2500.0	IC50	uM	2.5
5619	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325526	=	=	IC50	nM	150.0	IC50	uM	0.15
5620	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	CN1CC[C@H](c2ccc(Cl)cc2)[C@@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325537	=	=	IC50	nM	140.0	IC50	uM	0.14
5621	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325551	>	>	IC50	nM	10000.0	IC50	uM	10.0
5622	Inhibition of CYP3A4 (unknown origin) by high throughput fluorescence assay	C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1	J. Med. Chem.	2014.0	CHEMBL3358006	>	>	IC50	nM	10000.0	IC50	uM	10.0
5623	Inhibition of human liver CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	J. Med. Chem.	2014.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
5624	Inhibition of human liver CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@@H]1c1ncc(C#CC#Cc2ccc(-c3cnc([C@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]3)cc2)[nH]1)C(C)C.Cl	J. Med. Chem.	2014.0	CHEMBL3341815	>	>	IC50	nM	10000.0	IC50	uM	10.0
5625	Inhibition of CYP3A4 (unknown origin)	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2014.0	CHEMBL2181776	>	>	IC50	nM	30000.0	IC50	uM	30.0
5626	Inhibition of CYP3A4 (unknown origin)	CCOc1cc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Cl)cn5)n(C)c4c3)CCC2)ccc1/C=C/C(=O)O	J. Med. Chem.	2014.0	CHEMBL3355225	>	>	IC50	nM	30000.0	IC50	uM	30.0
5627	Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1	J. Med. Chem.	2014.0	CHEMBL3330442	=	=	IC50	nM	85120.0	IC50	uM	85.12
5628	Reversible inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338865	=	=	IC50	nM	17000.0	IC50	uM	17.0
5629	Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2ccccc2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338848	=	=	Ki	nM	5600.0	Ki	uM	5.6
5630	Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338865	=	=	Ki	nM	19400.0	Ki	uM	19.4
5631	Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338866	=	=	Ki	nM	9500.0	Ki	uM	9.5
5632	Inhibition of CYP3A4 (unknown origin)	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(C)[C@@H]([C@@H](C)CN2CCN(CCOC)CC2)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	J. Med. Chem.	2014.0	CHEMBL3344501	>	>	IC50	nM	40000.0	IC50	uM	40.0
5633	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL3353992	=	=	IC50	nM	10000.0	IC50	uM	10.0
5634	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL2177300	=	=	IC50	nM	32000.0	IC50	uM	32.0
5635	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL3353992	=	=	IC50	nM	2000.0	IC50	uM	2.0
5636	Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL2177300	=	=	IC50	nM	21000.0	IC50	uM	21.0
5637	Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@H](F)CN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F	Eur. J. Med. Chem.	2014.0	CHEMBL3330060	=	=	IC50	nM	56490.0	IC50	uM	56.49
5638	Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F	Eur. J. Med. Chem.	2014.0	CHEMBL3330073	=	=	IC50	nM	2250.0	IC50	uM	2.25
5639	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Cl.c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331469	=	=	IC50	nM	1330.0	IC50	uM	1.33
5640	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3331484	=	=	IC50	nM	500.0	IC50	uM	0.5
5641	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl.O=C(O)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3331502	=	=	IC50	nM	32700.0	IC50	uM	32.7
5642	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3331503	=	=	IC50	nM	1100.0	IC50	uM	1.1
5643	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ACS Med. Chem. Lett.	2014.0	CHEMBL1175	=	=	IC50	nM	440.0	IC50	uM	0.44
5644	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331504	=	=	IC50	nM	810.0	IC50	uM	0.81
5645	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331506	=	=	IC50	nM	3640.0	IC50	uM	3.64
5646	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331507	=	=	IC50	nM	500.0	IC50	uM	0.5
5647	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccccc1CN(CC1CNC1)c1ccccc1.O=C(O)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3331508	=	=	IC50	nM	120.0	IC50	uM	0.12
5648	Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med. Chem. Lett.	2014.0	CHEMBL157101	=	=	IC50	nM	2500.0	IC50	uM	2.5
5649	Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	CN(C)C/C=C(\F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	J. Med. Chem.	2014.0	CHEMBL3357641	>	>	IC50	nM	10000.0	IC50	uM	10.0
5650	Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C	J. Med. Chem.	2014.0	CHEMBL3357637	>	>	IC50	nM	10000.0	IC50	uM	10.0
5651	Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1	J. Med. Chem.	2014.0	CHEMBL3357635	>	>	IC50	nM	10000.0	IC50	uM	10.0
5652	Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C	J. Med. Chem.	2014.0	CHEMBL3357634	>	>	IC50	nM	10000.0	IC50	uM	10.0
5653	Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	25.0	IC50	uM	0.025
5654	Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay	C#C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H](N5CCN(C(=O)[C@@H]6CCCN6C(=O)c6ccc7ccccc7n6)CC5)C[C@]4(C)[C@H]3CC[C@@]21C	Bioorg. Med. Chem.	2014.0	CHEMBL3344121	=	=	IC50	nM	3800.0	IC50	uM	3.8
5655	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1	J. Med. Chem.	2014.0	CHEMBL1230001	>	>	IC50	nM	100000.0	IC50	uM	100.0
5656	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359014	=	=	IC50	nM	28000.0	IC50	uM	28.0
5657	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(F)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359017	=	=	IC50	nM	53000.0	IC50	uM	53.0
5658	Inhibition of CYP3A4 (unknown origin)	COc1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1	J. Med. Chem.	2014.0	CHEMBL3359018	=	=	IC50	nM	8000.0	IC50	uM	8.0
5659	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(Cl)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359019	=	=	IC50	nM	50000.0	IC50	uM	50.0
5660	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1	J. Med. Chem.	2014.0	CHEMBL3359020	=	=	IC50	nM	42000.0	IC50	uM	42.0
5661	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cccnc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359021	>	>	IC50	nM	100000.0	IC50	uM	100.0
5662	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cnccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359022	<	<	IC50	nM	46.0	IC50	uM	0.046
5663	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)cn1	J. Med. Chem.	2014.0	CHEMBL3359023	=	=	IC50	nM	1100.0	IC50	uM	1.1
5664	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cnncc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359024	=	=	IC50	nM	12000.0	IC50	uM	12.0
5665	Inhibition of CYP3A4 in human liver microsomes	CCCCOc1cncc(-c2nnc3c(C)nc4ccc(CN5CCOCC5)cc4n23)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331521	>	>	IC50	nM	10000.0	IC50	uM	10.0
5666	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	J. Med. Chem.	2014.0	CHEMBL3301607	>	>	IC50	nM	70000.0	IC50	uM	70.0
5667	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330652	>	>	IC50	nM	10000.0	IC50	uM	10.0
5668	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330650	>	>	IC50	nM	10000.0	IC50	uM	10.0
5669	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2087461	=	=	IC50	nM	9000.0	IC50	uM	9.0
5670	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330649	>	>	IC50	nM	10000.0	IC50	uM	10.0
5671	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330652	>	>	IC50	nM	10000.0	IC50	uM	10.0
5672	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330650	>	>	IC50	nM	10000.0	IC50	uM	10.0
5673	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2087461	=	=	IC50	nM	9000.0	IC50	uM	9.0
5674	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330649	>	>	IC50	nM	10000.0	IC50	uM	10.0
5675	Inhibition of human CYP3A4 by electrospray ionization	c1ccc(CC[C@@H]2CN(Cc3nc4ccccc4[nH]3)CCO2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3335537	>	>	IC50	nM	30000.0	IC50	uM	30.0
5676	Inhibition of human CYP3A4 by electrospray ionization	Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3335556	=	=	IC50	nM	15600.0	IC50	uM	15.6
5677	Inhibition of CYP3A4 (unknown origin)	CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3326224	>=	>=	IC50	nM	5000.0	IC50	uM	5.0
5678	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Oc1nc(SCc2ccc(Cl)cc2)nc2c1CCC2	J. Med. Chem.	2014.0	CHEMBL473326	>	>	IC50	nM	20000.0	IC50	uM	20.0
5679	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Oc1nc(SCc2ccc(Cl)cc2)nc2c1CCC2	J. Med. Chem.	2014.0	CHEMBL473326	>	>	IC50	nM	20000.0	IC50	uM	20.0
5680	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cc1ccc(CSc2nc(O)c3c(n2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1371684	>	>	IC50	nM	20000.0	IC50	uM	20.0
5681	Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cc1ccc(CSc2nc(O)c3c(n2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1371684	>	>	IC50	nM	20000.0	IC50	uM	20.0
5682	Inhibition of CYP3A4 (unknown origin)	CCN1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C	J. Med. Chem.	2014.0	CHEMBL3359270	=	=	IC50	nM	3200.0	IC50	uM	3.2
5683	Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C	J. Med. Chem.	2014.0	CHEMBL3359272	=	=	IC50	nM	10100.0	IC50	uM	10.1
5684	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1	J. Med. Chem.	2015.0	CHEMBL2144409	>	>	IC50	nM	50000.0	IC50	uM	50.0
5685	Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3393730	>	>	IC50	nM	30000.0	IC50	uM	30.0
5686	Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3120454	>	>	IC50	nM	30000.0	IC50	uM	30.0
5687	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394719	>	>	IC50	nM	10000.0	IC50	uM	10.0
5688	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394721	>	>	IC50	nM	10000.0	IC50	uM	10.0
5689	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394722	>	>	IC50	nM	10000.0	IC50	uM	10.0
5690	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394724	>	>	IC50	nM	10000.0	IC50	uM	10.0
5691	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394729	>	>	IC50	nM	10000.0	IC50	uM	10.0
5692	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394730	=	=	IC50	nM	5700.0	IC50	uM	5.7
5693	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394734	>	>	IC50	nM	10000.0	IC50	uM	10.0
5694	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394736	>	>	IC50	nM	10000.0	IC50	uM	10.0
5695	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
5696	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394741	>	>	IC50	nM	10000.0	IC50	uM	10.0
5697	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394719	>	>	IC50	nM	10000.0	IC50	uM	10.0
5698	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394721	>	>	IC50	nM	10000.0	IC50	uM	10.0
5699	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394722	>	>	IC50	nM	10000.0	IC50	uM	10.0
5700	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394724	>	>	IC50	nM	10000.0	IC50	uM	10.0
5701	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394729	>	>	IC50	nM	10000.0	IC50	uM	10.0
5702	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394730	>	>	IC50	nM	10000.0	IC50	uM	10.0
5703	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394734	>	>	IC50	nM	10000.0	IC50	uM	10.0
5704	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394736	>	>	IC50	nM	10000.0	IC50	uM	10.0
5705	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
5706	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394741	>	>	IC50	nM	10000.0	IC50	uM	10.0
5707	Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3394201	>	>	IC50	nM	30000.0	IC50	uM	30.0
5708	Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL2426677	=	=	IC50	nM	2500.0	IC50	uM	2.5
5709	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CC[C@@H](Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394842	=	=	IC50	nM	25400.0	IC50	uM	25.4
5710	Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1nc(-c2ccc(-c3ccc(-c4ccc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)cc3)cc2)c[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394868	>	>	IC50	nM	30000.0	IC50	uM	30.0
5711	Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1	J. Med. Chem.	2015.0	CHEMBL1607077	=	=	IC50	nM	1000.0	IC50	uM	1.0
5712	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(Oc2ccc(C(=O)NCc3ccncc3)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL1427458	=	=	IC50	nM	1000.0	IC50	uM	1.0
5713	Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccc(Cl)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393290	=	=	IC50	nM	1000.0	IC50	uM	1.0
5714	Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccc(F)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393291	=	=	IC50	nM	1000.0	IC50	uM	1.0
5715	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncc2)cc1	J. Med. Chem.	2015.0	CHEMBL1796293	=	=	IC50	nM	1000.0	IC50	uM	1.0
5716	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccccc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393294	>	>	IC50	nM	10000.0	IC50	uM	10.0
5717	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2cccnc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393295	>	>	IC50	nM	10000.0	IC50	uM	10.0
5718	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncn2)cc1	J. Med. Chem.	2015.0	CHEMBL3393063	>	>	IC50	nM	10000.0	IC50	uM	10.0
5719	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393469	=	=	IC50	nM	190.0	IC50	uM	0.19
5720	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CNC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl.O	J. Med. Chem.	2015.0	CHEMBL3393472	=	=	IC50	nM	170.0	IC50	uM	0.17
5721	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)ccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393473	=	=	IC50	nM	12000.0	IC50	uM	12.0
5722	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(F)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393474	=	=	IC50	nM	4500.0	IC50	uM	4.5
5723	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cc(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393475	=	=	IC50	nM	1000.0	IC50	uM	1.0
5724	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)c(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393476	=	=	IC50	nM	8400.0	IC50	uM	8.4
5725	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccc(F)c(F)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393477	=	=	IC50	nM	34000.0	IC50	uM	34.0
5726	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)c(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393478	=	=	IC50	nM	23000.0	IC50	uM	23.0
5727	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(Cl)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393479	=	=	IC50	nM	50.0	IC50	uM	0.05
5728	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(O)cccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393482	=	=	IC50	nM	490.0	IC50	uM	0.49
5729	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(N)cccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393483	=	=	IC50	nM	80.0	IC50	uM	0.08
5730	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CN(C(=O)CN)C1)[C@H]2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl	J. Med. Chem.	2015.0	CHEMBL3393485	=	=	IC50	nM	500.0	IC50	uM	0.5
5731	Inhibition of human recombinant CYP3A4 in liver microsomes by mechanism based inhibition assay	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)[C@H]2c1cccc(Oc2nc3ccccc3[nH]2)c1	J. Med. Chem.	2015.0	CHEMBL3393498	=	=	Ki	nM	990.0	Ki	uM	0.99
5732	Inhibition of human recombinant CYP3A4 in liver microsomes by mechanism based inhibition assay	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	J. Med. Chem.	2015.0	CHEMBL655	=	=	Ki	nM	2470.0	Ki	uM	2.47
5733	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398175	=	=	IC50	nM	12000.0	IC50	uM	12.0
5734	Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using triazolam substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method	O=C(/C=C(\O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398252	>	>	IC50	nM	85000.0	IC50	uM	85.0
5735	Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using testosterone substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method	O=C(/C=C(\O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398252	>	>	IC50	nM	50000.0	IC50	uM	50.0
5736	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2206994	=	=	IC50	nM	12000.0	IC50	uM	12.0
5737	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCOC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2207044	=	=	IC50	nM	1100.0	IC50	uM	1.1
5738	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403817	=	=	IC50	nM	100000.0	IC50	uM	100.0
5739	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403817	=	=	IC50	nM	54000.0	IC50	uM	54.0
5740	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403818	=	=	IC50	nM	12000.0	IC50	uM	12.0
5741	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403818	=	=	IC50	nM	1600.0	IC50	uM	1.6
5742	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403819	=	=	IC50	nM	5300.0	IC50	uM	5.3
5743	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403819	=	=	IC50	nM	2700.0	IC50	uM	2.7
5744	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403820	=	=	IC50	nM	3000.0	IC50	uM	3.0
5745	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403820	=	=	IC50	nM	2700.0	IC50	uM	2.7
5746	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403821	=	=	IC50	nM	4900.0	IC50	uM	4.9
5747	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403821	=	=	IC50	nM	3200.0	IC50	uM	3.2
5748	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403822	=	=	IC50	nM	15000.0	IC50	uM	15.0
5749	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403822	=	=	IC50	nM	16000.0	IC50	uM	16.0
5750	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403823	=	=	IC50	nM	13000.0	IC50	uM	13.0
5751	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403823	=	=	IC50	nM	7700.0	IC50	uM	7.7
5752	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403824	=	=	IC50	nM	6600.0	IC50	uM	6.6
5753	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403824	=	=	IC50	nM	1900.0	IC50	uM	1.9
5754	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403825	=	=	IC50	nM	22000.0	IC50	uM	22.0
5755	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403825	=	=	IC50	nM	7800.0	IC50	uM	7.8
5756	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403826	=	=	IC50	nM	14000.0	IC50	uM	14.0
5757	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403826	=	=	IC50	nM	11000.0	IC50	uM	11.0
5758	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403827	=	=	IC50	nM	17000.0	IC50	uM	17.0
5759	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403827	=	=	IC50	nM	17000.0	IC50	uM	17.0
5760	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403816	=	=	IC50	nM	37000.0	IC50	uM	37.0
5761	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403816	=	=	IC50	nM	25000.0	IC50	uM	25.0
5762	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403815	=	=	IC50	nM	25000.0	IC50	uM	25.0
5763	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403815	=	=	IC50	nM	25000.0	IC50	uM	25.0
5764	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2206994	=	=	IC50	nM	3900.0	IC50	uM	3.9
5765	Inhibition of CYP3A4 (unknown origin)	CC(CCN1CCOCC1)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3402641	>	>	IC50	nM	40000.0	IC50	uM	40.0
5766	Inhibition of human CYP3A4	O=C1N(c2ccc(F)cc2)CCc2nc(COc3ccccc3)cn21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401195	>	>	IC50	nM	20000.0	IC50	uM	20.0
5767	Inhibition of recombinant human CYP3A4	CC(C)C1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401115	>	>	IC50	nM	50000.0	IC50	uM	50.0
5768	Inhibition of recombinant human CYP3A4	CCCCC1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401116	>	>	IC50	nM	50000.0	IC50	uM	50.0
5769	Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(C3CCC3)C2)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401117	>	>	IC50	nM	50000.0	IC50	uM	50.0
5770	Inhibition of recombinant human CYP3A4	C[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401118	>	>	IC50	nM	50000.0	IC50	uM	50.0
5771	Inhibition of recombinant human CYP3A4	C[C@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401121	>	>	IC50	nM	50000.0	IC50	uM	50.0
5772	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3091536	>	>	IC50	nM	50000.0	IC50	uM	50.0
5773	Inhibition of recombinant human CYP3A4	C[C@H]1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@@H]1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401127	=	=	IC50	nM	485000.0	IC50	uM	485.0
5774	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3CCC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401129	=	=	IC50	nM	445000.0	IC50	uM	445.0
5775	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3CCCC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401131	=	=	IC50	nM	418000.0	IC50	uM	418.0
5776	Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3COC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401132	=	=	IC50	nM	545000.0	IC50	uM	545.0
5777	Inhibition of human recombinant CYP3A4 assessed as effect on conversion of beetle D-luciferin derivative into D-luciferin by firefly luciferase based luminescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
5778	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401541	>	>	IC50	nM	30000.0	IC50	uM	30.0
5779	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400450	=	=	IC50	nM	14800.0	IC50	uM	14.8
5780	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400449	=	=	IC50	nM	3400.0	IC50	uM	3.4
5781	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400435	=	=	IC50	nM	2500.0	IC50	uM	2.5
5782	Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401541	=	=	IC50	nM	4400.0	IC50	uM	4.4
5783	Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400450	=	=	IC50	nM	6400.0	IC50	uM	6.4
5784	Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400449	=	=	IC50	nM	3200.0	IC50	uM	3.2
5785	Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400445	=	=	IC50	nM	3100.0	IC50	uM	3.1
5786	Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400435	=	=	IC50	nM	1400.0	IC50	uM	1.4
5787	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)C2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400440	>	>	IC50	nM	10000.0	IC50	uM	10.0
5788	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CC2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400443	>	>	IC50	nM	10000.0	IC50	uM	10.0
5789	Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)CC2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400459	=	=	IC50	nM	10000.0	IC50	uM	10.0
5790	Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403995	=	=	IC50	nM	4000.0	IC50	uM	4.0
5791	Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-n3cccc3)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403987	<=	<=	IC50	nM	200.0	IC50	nM	200.0
5792	Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-c3ccccc3)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403986	<=	<=	IC50	nM	200.0	IC50	nM	200.0
5793	Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(OC)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403984	<=	<=	IC50	nM	200.0	IC50	nM	200.0
5794	Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2csc(C)n2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3187348	>	>	IC50	nM	30000.0	IC50	uM	30.0
5795	Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL1872483	>	>	IC50	nM	30000.0	IC50	uM	30.0
5796	Inhibition of human CYP3A4	CCn1nc(C)c(CNC(=O)c2ccc(OC)c(OC3CCN(C(C)C)CC3)c2)c1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3182315	>	>	IC50	nM	30000.0	IC50	uM	30.0
5797	Inhibition of human CYP3A4	COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3188567	=	=	IC50	nM	28200.0	IC50	uM	28.2
5798	Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3304438	>	>	IC50	nM	30000.0	IC50	uM	30.0
5799	Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3303792	>	>	IC50	nM	30000.0	IC50	uM	30.0
5800	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	5600.0	IC50	uM	5.6
5801	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1	J. Med. Chem.	2015.0	CHEMBL3408940	=	=	IC50	nM	2900.0	IC50	uM	2.9
5802	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408941	=	=	IC50	nM	2800.0	IC50	uM	2.8
5803	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	=	=	IC50	nM	10000.0	IC50	uM	10.0
5804	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353348	=	=	IC50	nM	7500.0	IC50	uM	7.5
5805	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3408942	>	>	IC50	nM	1000.0	IC50	uM	1.0
5806	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408943	=	=	IC50	nM	10000.0	IC50	uM	10.0
5807	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408944	=	=	IC50	nM	5400.0	IC50	uM	5.4
5808	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	=	=	IC50	nM	2700.0	IC50	uM	2.7
5809	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353357	=	=	IC50	nM	6200.0	IC50	uM	6.2
5810	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	=	=	IC50	nM	6400.0	IC50	uM	6.4
5811	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408945	=	=	IC50	nM	6000.0	IC50	uM	6.0
5812	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1	J. Med. Chem.	2015.0	CHEMBL3408946	=	=	IC50	nM	5000.0	IC50	uM	5.0
5813	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408947	=	=	IC50	nM	4600.0	IC50	uM	4.6
5814	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408948	>	>	IC50	nM	1000.0	IC50	uM	1.0
5815	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408951	=	=	IC50	nM	11000.0	IC50	uM	11.0
5816	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408955	=	=	IC50	nM	1600.0	IC50	uM	1.6
5817	Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3408957	=	=	IC50	nM	1600.0	IC50	uM	1.6
5818	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	10000.0	IC50	uM	10.0
5819	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1	J. Med. Chem.	2015.0	CHEMBL3408940	=	=	IC50	nM	300.0	IC50	uM	0.3
5820	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	=	=	IC50	nM	5000.0	IC50	uM	5.0
5821	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3408942	=	=	IC50	nM	2300.0	IC50	uM	2.3
5822	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408943	>	>	IC50	nM	1000.0	IC50	uM	1.0
5823	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408944	>	>	IC50	nM	1000.0	IC50	uM	1.0
5824	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	=	=	IC50	nM	6300.0	IC50	uM	6.3
5825	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353357	=	=	IC50	nM	3000.0	IC50	uM	3.0
5826	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	=	=	IC50	nM	2400.0	IC50	uM	2.4
5827	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408945	=	=	IC50	nM	20000.0	IC50	uM	20.0
5828	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1	J. Med. Chem.	2015.0	CHEMBL3408946	=	=	IC50	nM	5100.0	IC50	uM	5.1
5829	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408947	=	=	IC50	nM	3100.0	IC50	uM	3.1
5830	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408948	=	=	IC50	nM	10000.0	IC50	uM	10.0
5831	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408951	=	=	IC50	nM	450.0	IC50	uM	0.45
5832	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408955	=	=	IC50	nM	10000.0	IC50	uM	10.0
5833	Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3408957	>	>	IC50	nM	1000.0	IC50	uM	1.0
5834	Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4cnccn4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407774	>	>	IC50	nM	10000.0	IC50	uM	10.0
5835	Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccco4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407778	>	>	IC50	nM	10000.0	IC50	uM	10.0
5836	Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407784	>	>	IC50	nM	10000.0	IC50	uM	10.0
5837	Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407785	>	>	IC50	nM	7000.0	IC50	uM	7.0
5838	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407810	=	=	IC50	nM	2500.0	IC50	uM	2.5
5839	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407814	=	=	IC50	nM	70000.0	IC50	uM	70.0
5840	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cc1cncn1-c1nccc(CCNCCCc2cccc(F)c2)n1.Cl	J. Med. Chem.	2015.0	CHEMBL3407821	=	=	IC50	nM	900.0	IC50	uM	0.9
5841	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.Fc1cccc(C[C@@H]2C[C@H]2NCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407822	=	=	IC50	nM	300.0	IC50	uM	0.3
5842	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](C)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3113764	=	=	IC50	nM	8700.0	IC50	uM	8.7
5843	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](Cl)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409853	=	=	IC50	nM	6600.0	IC50	uM	6.6
5844	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409855	=	=	IC50	nM	10000.0	IC50	uM	10.0
5845	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1C1CC(F)(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409857	=	=	IC50	nM	5200.0	IC50	uM	5.2
5846	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409859	=	=	IC50	nM	25000.0	IC50	uM	25.0
5847	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](OC)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409860	=	=	IC50	nM	1400.0	IC50	uM	1.4
5848	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1C1CCC(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409869	=	=	IC50	nM	6900.0	IC50	uM	6.9
5849	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409870	=	=	IC50	nM	8800.0	IC50	uM	8.8
5850	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409872	=	=	IC50	nM	18000.0	IC50	uM	18.0
5851	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409873	=	=	IC50	nM	21000.0	IC50	uM	21.0
5852	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1C1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409875	=	=	IC50	nM	46000.0	IC50	uM	46.0
5853	Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409876	>	>	IC50	nM	50000.0	IC50	uM	50.0
5854	Inhibition of CYP3A4 (unknown origin)	COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409876	>	>	IC50	nM	50000.0	IC50	uM	50.0
5855	Inhibition of CYP3A4 (unknown origin)	O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1[C@H](CO)c1ccc(Cl)c(F)c1	J. Med. Chem.	2015.0	CHEMBL3409588	>	>	IC50	nM	10000.0	IC50	uM	10.0
5856	Inhibition of CYP3A4 (unknown origin)	NC(=O)C1CCN(c2c(Cl)cncc2Cl)CC1	J. Med. Chem.	2015.0	CHEMBL1673059	=	=	IC50	nM	7000.0	IC50	uM	7.0
5857	Inhibition of CYP3A4 (unknown origin)	O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2	J. Med. Chem.	2015.0	CHEMBL3408192	=	=	IC50	nM	2100.0	IC50	uM	2.1
5858	Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method	Cc1nnc2n1-c1c(F)cc(-c3cncc(F)c3)cc1CC2	J. Med. Chem.	2015.0	CHEMBL2331699	>	>	IC50	nM	50000.0	IC50	uM	50.0
5859	Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method	Cc1ccncc1-c1cc(F)c2c(c1)CCc1nnc(C)n1-2	J. Med. Chem.	2015.0	CHEMBL3313969	>	>	IC50	nM	50000.0	IC50	uM	50.0
5860	Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	C[C@]1(Nc2ccc(C(=O)NO)cc2)CCN(c2ccc(Cl)cc2)C1=O	J. Med. Chem.	2015.0	CHEMBL3415629	>	>	IC50	nM	50000.0	IC50	uM	50.0
5861	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CC(C)(O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417511	>	>	IC50	nM	30000.0	IC50	uM	30.0
5862	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417525	>	>	IC50	nM	30000.0	IC50	uM	30.0
5863	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CN(C)CCn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417530	>	>	IC50	nM	30000.0	IC50	uM	30.0
5864	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CC(C)(O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417531	>	>	IC50	nM	30000.0	IC50	uM	30.0
5865	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417504	>	>	IC50	nM	30000.0	IC50	uM	30.0
5866	Inhibition of CYP3A4 (unknown origin)	C[C@H](COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCC[C@H]1C	Eur. J. Med. Chem.	2015.0	CHEMBL3417505	>	>	IC50	nM	30000.0	IC50	uM	30.0
5867	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417585	>	>	IC50	nM	30000.0	IC50	uM	30.0
5868	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417586	>	>	IC50	nM	30000.0	IC50	uM	30.0
5869	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2ccccn2)C1	J. Med. Chem.	2015.0	CHEMBL3421983	>	>	IC50	nM	100000.0	IC50	uM	100.0
5870	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1	J. Med. Chem.	2015.0	CHEMBL3422000	>	>	IC50	nM	100000.0	IC50	uM	100.0
5871	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2cccc(C(F)(F)F)n2)C1	J. Med. Chem.	2015.0	CHEMBL3422004	>	>	IC50	nM	100000.0	IC50	uM	100.0
5872	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422005	=	=	IC50	nM	63000.0	IC50	uM	63.0
5873	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1	J. Med. Chem.	2015.0	CHEMBL3422006	=	=	IC50	nM	67000.0	IC50	uM	67.0
5874	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422007	=	=	IC50	nM	45000.0	IC50	uM	45.0
5875	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422008	=	=	IC50	nM	2000.0	IC50	uM	2.0
5876	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	J. Med. Chem.	2015.0	CHEMBL3422009	=	=	IC50	nM	19000.0	IC50	uM	19.0
5877	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422010	=	=	IC50	nM	50000.0	IC50	uM	50.0
5878	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1	J. Med. Chem.	2015.0	CHEMBL3422012	=	=	IC50	nM	30000.0	IC50	uM	30.0
5879	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(C(F)(F)F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	J. Med. Chem.	2015.0	CHEMBL3422013	>	>	IC50	nM	100000.0	IC50	uM	100.0
5880	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422014	=	=	IC50	nM	35000.0	IC50	uM	35.0
5881	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1	J. Med. Chem.	2015.0	CHEMBL3422015	=	=	IC50	nM	43000.0	IC50	uM	43.0
5882	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422016	=	=	IC50	nM	11000.0	IC50	uM	11.0
5883	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422017	=	=	IC50	nM	55000.0	IC50	uM	55.0
5884	Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422018	=	=	IC50	nM	80000.0	IC50	uM	80.0
5885	Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1	J. Med. Chem.	2015.0	CHEMBL2386285	=	=	IC50	nM	285.0	IC50	nM	285.0
5886	Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1	J. Med. Chem.	2015.0	CHEMBL3422028	=	=	IC50	nM	1880.0	IC50	nM	1880.0
5887	Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1	J. Med. Chem.	2015.0	CHEMBL2386285	=	=	Ki	nM	375.0	Ki	nM	375.0
5888	Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1	J. Med. Chem.	2015.0	CHEMBL3422028	=	=	Ki	nM	1640.0	Ki	nM	1640.0
5889	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422072	=	=	IC50	nM	1500.0	IC50	uM	1.5
5890	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccn5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422073	=	=	IC50	nM	1500.0	IC50	uM	1.5
5891	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CN(C)CC(=O)N1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422074	=	=	IC50	nM	1000.0	IC50	uM	1.0
5892	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CN1[C@H]2CC[C@@H]1C[C@H](Oc1ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc1)C2	J. Med. Chem.	2015.0	CHEMBL3422075	=	=	IC50	nM	2400.0	IC50	uM	2.4
5893	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(O[C@@H]4C[C@@H]5CC[C@H](C4)N5C=O)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422078	=	=	IC50	nM	410.0	IC50	uM	0.41
5894	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccc1F)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422082	=	=	IC50	nM	240.0	IC50	uM	0.24
5895	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1)c1ccccc1Cl	J. Med. Chem.	2015.0	CHEMBL3422083	=	=	IC50	nM	60.0	IC50	uM	0.06
5896	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422085	=	=	IC50	nM	1400.0	IC50	uM	1.4
5897	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422086	=	=	IC50	nM	930.0	IC50	uM	0.93
5898	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422087	=	=	IC50	nM	360.0	IC50	uM	0.36
5899	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422091	=	=	IC50	nM	2100.0	IC50	uM	2.1
5900	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422092	=	=	IC50	nM	1300.0	IC50	uM	1.3
5901	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422093	=	=	IC50	nM	820.0	IC50	uM	0.82
5902	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422094	=	=	IC50	nM	230.0	IC50	uM	0.23
5903	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422095	=	=	IC50	nM	940.0	IC50	uM	0.94
5904	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)C[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422097	=	=	IC50	nM	320.0	IC50	uM	0.32
5905	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422098	=	=	IC50	nM	290.0	IC50	uM	0.29
5906	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422099	=	=	IC50	nM	1300.0	IC50	uM	1.3
5907	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5COC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422102	=	=	IC50	nM	330.0	IC50	uM	0.33
5908	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422091	=	=	IC50	nM	1700.0	IC50	uM	1.7
5909	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422092	=	=	IC50	nM	1400.0	IC50	uM	1.4
5910	Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422093	=	=	IC50	nM	800.0	IC50	uM	0.8
5911	Inhibition of CYP3A4 (unknown origin)	NC1=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3ncco3)C[C@H]2CS1	J. Med. Chem.	2015.0	CHEMBL3422235	>	>	IC50	nM	30000.0	IC50	uM	30.0
5912	Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422236	>	>	IC50	nM	30000.0	IC50	uM	30.0
5913	Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422237	>	>	IC50	nM	30000.0	IC50	uM	30.0
5914	Inhibition of CYP3A4 (unknown origin)	Cn1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1	J. Med. Chem.	2015.0	CHEMBL3422238	>	>	IC50	nM	30000.0	IC50	uM	30.0
5915	Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422241	>	>	IC50	nM	30000.0	IC50	uM	30.0
5916	Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422242	>	>	IC50	nM	30000.0	IC50	uM	30.0
5917	Inhibition of CYP3A4 (unknown origin)	C[C@H]1SC(N)=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3cnn(C)c3)C[C@@H]12	J. Med. Chem.	2015.0	CHEMBL3422243	>	>	IC50	nM	30000.0	IC50	uM	30.0
5918	Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422244	>	>	IC50	nM	30000.0	IC50	uM	30.0
5919	Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422245	>	>	IC50	nM	30000.0	IC50	uM	30.0
5920	Inhibition of CYP3A4 (unknown origin)	Cn1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1	J. Med. Chem.	2015.0	CHEMBL3422246	>	>	IC50	nM	30000.0	IC50	uM	30.0
5921	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL243876	=	=	IC50	nM	27500.0	IC50	uM	27.5
5922	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427272	>	>	IC50	nM	50000.0	IC50	uM	50.0
5923	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427276	>	>	IC50	nM	50000.0	IC50	uM	50.0
5924	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427277	>	>	IC50	nM	50000.0	IC50	uM	50.0
5925	Inhibition of CYP3A4 in human liver microsomes	CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1	J. Med. Chem.	2015.0	CHEMBL2364618	>	>	IC50	nM	25000.0	IC50	uM	25.0
5926	Inhibition of human His-tagged CYP3A4 expressed in Escherichia coli TOPP3 using BFC as substrate after 15 mins by double reciprocal plot analysis in presence of NADPH and cytochrome b5	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12	Drug Metab. Dispos.	2011.0	CHEMBL1614710	=	=	Ki	nM	24000.0	Ki	uM	24.0
5927	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1708	=	=	IC50	nM	24100.0	IC50	uM	24.1
5928	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Drug Metab. Dispos.	2012.0	CHEMBL6966	=	=	IC50	nM	17600.0	IC50	uM	17.6
5929	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1	Drug Metab. Dispos.	2012.0	CHEMBL296419	=	=	IC50	nM	10600.0	IC50	uM	10.6
5930	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL54	=	=	IC50	nM	8200.0	IC50	uM	8.2
5931	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Drug Metab. Dispos.	2012.0	CHEMBL50	=	=	IC50	nM	2110.0	IC50	uM	2.11
5932	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1	Drug Metab. Dispos.	2012.0	CHEMBL172	=	=	IC50	nM	667.0	IC50	uM	0.667
5933	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Drug Metab. Dispos.	2012.0	CHEMBL83	>	>	IC50	nM	30000.0	IC50	uM	30.0
5934	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21	Drug Metab. Dispos.	2012.0	CHEMBL1064	>	>	IC50	nM	30000.0	IC50	uM	30.0
5935	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Drug Metab. Dispos.	2012.0	CHEMBL1423	>	>	IC50	nM	30000.0	IC50	uM	30.0
5936	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cc1ccccc1C(OCCN(C)C)c1ccccc1	Drug Metab. Dispos.	2012.0	CHEMBL900	>	>	IC50	nM	30000.0	IC50	uM	30.0
5937	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2012.0	CHEMBL1484	>	>	IC50	nM	30000.0	IC50	uM	30.0
5938	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1	Drug Metab. Dispos.	2012.0	CHEMBL998	>	>	IC50	nM	30000.0	IC50	uM	30.0
5939	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1	Drug Metab. Dispos.	2012.0	CHEMBL480	>	>	IC50	nM	30000.0	IC50	uM	30.0
5940	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O	Drug Metab. Dispos.	2012.0	CHEMBL1200633	>	>	IC50	nM	30000.0	IC50	uM	30.0
5941	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12	Drug Metab. Dispos.	2012.0	CHEMBL1648	>	>	IC50	nM	30000.0	IC50	uM	30.0
5942	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C	Drug Metab. Dispos.	2012.0	CHEMBL1479	>	>	IC50	nM	30000.0	IC50	uM	30.0
5943	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Drug Metab. Dispos.	2012.0	CHEMBL1008	>	>	IC50	nM	30000.0	IC50	uM	30.0
5944	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	Drug Metab. Dispos.	2012.0	CHEMBL1483	>	>	IC50	nM	30000.0	IC50	uM	30.0
5945	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2012.0	CHEMBL157101	<	<	IC50	nM	100.0	IC50	uM	0.1
5946	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Drug Metab. Dispos.	2012.0	CHEMBL104	<	<	IC50	nM	100.0	IC50	uM	0.1
5947	Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835951	=	=	IC50	nM	4.0	IC50	nM	4.0
5948	Inhibition of CYP3A4 (unknown origin)	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835950	=	=	IC50	nM	4.0	IC50	nM	4.0
5949	Inhibition of CYP3A4 (unknown origin)	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835949	=	=	IC50	nM	4.0	IC50	nM	4.0
5950	Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL454471	=	=	IC50	nM	4.0	IC50	nM	4.0
5951	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O	Drug Metab. Dispos.	2011.0	CHEMBL3526984	=	=	IC50	nM	8220.0	IC50	uM	8.22
5952	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	IC50	nM	9860.0	IC50	uM	9.86
5953	Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	IC50	nM	9720.0	IC50	uM	9.72
5954	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	Ki	nM	4930.0	Ki	uM	4.93
5955	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1	Drug Metab. Dispos.	2013.0	CHEMBL161	>	>	IC50	nM	50000.0	IC50	uM	50.0
5956	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21	Drug Metab. Dispos.	2013.0	CHEMBL71	=	=	IC50	nM	23300.0	IC50	uM	23.3
5957	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Drug Metab. Dispos.	2013.0	CHEMBL6966	=	=	IC50	nM	12000.0	IC50	uM	12.0
5958	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	Clc1ccccc1CN1CCc2sccc2C1	Drug Metab. Dispos.	2013.0	CHEMBL833	=	=	IC50	nM	32700.0	IC50	uM	32.7
5959	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21	Drug Metab. Dispos.	2013.0	CHEMBL809	=	=	IC50	nM	13600.0	IC50	uM	13.6
5960	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1	Drug Metab. Dispos.	2013.0	CHEMBL42	=	=	IC50	nM	46300.0	IC50	uM	46.3
5961	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Drug Metab. Dispos.	2013.0	CHEMBL1008	=	=	IC50	nM	23600.0	IC50	uM	23.6
5962	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1	Drug Metab. Dispos.	2013.0	CHEMBL567	=	=	IC50	nM	13900.0	IC50	uM	13.9
5963	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Drug Metab. Dispos.	2013.0	CHEMBL1451	=	=	IC50	nM	49100.0	IC50	uM	49.1
5964	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCCc1ccc(OCC(O)CNC(C)C)cc1	Drug Metab. Dispos.	2013.0	CHEMBL13	>	>	IC50	nM	50000.0	IC50	uM	50.0
5965	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1	Drug Metab. Dispos.	2013.0	CHEMBL54	=	=	IC50	nM	33100.0	IC50	uM	33.1
5966	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Drug Metab. Dispos.	2013.0	CHEMBL388590	=	=	IC50	nM	29200.0	IC50	uM	29.2
5967	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2013.0	CHEMBL1428	=	=	IC50	nM	1780.0	IC50	uM	1.78
5968	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Drug Metab. Dispos.	2013.0	CHEMBL193	=	=	IC50	nM	5620.0	IC50	uM	5.62
5969	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21	Drug Metab. Dispos.	2013.0	CHEMBL9	>	>	IC50	nM	50000.0	IC50	uM	50.0
5970	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Drug Metab. Dispos.	2013.0	CHEMBL45816	=	=	IC50	nM	470.0	IC50	uM	0.47
5971	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2013.0	CHEMBL1484	=	=	IC50	nM	380.0	IC50	uM	0.38
5972	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Drug Metab. Dispos.	2013.0	CHEMBL682	>	>	IC50	nM	50000.0	IC50	uM	50.0
5973	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1	Drug Metab. Dispos.	2013.0	CHEMBL30008	>	>	IC50	nM	50000.0	IC50	uM	50.0
5974	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1	Drug Metab. Dispos.	2013.0	CHEMBL1017	>	>	IC50	nM	50000.0	IC50	uM	50.0
5975	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Drug Metab. Dispos.	2011.0	CHEMBL45816	=	=	Ki	nM	280.0	Ki	uM	0.28
5976	Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH	CC(C)[C@H]1c2ccc(F)cc2CC[C@]1(O)CCN(C)CCCc1nc2ccccc2[nH]1	Drug Metab. Dispos.	2011.0	CHEMBL3526662	=	=	Ki	nM	820.0	Ki	uM	0.82
5977	Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	IC50	nM	300.0	IC50	uM	0.3
5978	Reversible inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	IC50	nM	690.0	IC50	uM	0.69
5979	Inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity preincubated for 30 mins by LC-MS/MS analysis	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	Ki	nM	120.0	Ki	uM	0.12
5980	Inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5 assessed as decrease in enzyme activity preincubated for 30 mins by LC-MS/MS analysis	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	Ki	nM	170.0	Ki	uM	0.17
5981	Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O	Drug Metab. Dispos.	2011.0	CHEMBL3526984	=	=	IC50	nM	5600.0	IC50	uM	5.6
5982	Inhibition of CYP3A4 activity in human liver microsomes using testosterone as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	49.0	Ki	uM	0.049
5983	Inhibition of CYP3A4 activity in human liver microsomes using testosterone as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	287000.0	Ki	uM	287.0
5984	Inhibition of CYP3A4 activity in human liver microsomes using nifedipine as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	11.0	Ki	uM	0.011
5985	Inhibition of CYP3A4 activity in human liver microsomes using nifedipine as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	403000.0	Ki	uM	403.0
5986	Inhibition of CYP3A4 activity in human liver microsomes using midazolam as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	7.0	Ki	uM	0.007
5987	Inhibition of CYP3A4 activity in human liver microsomes using midazolam as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	58000.0	Ki	uM	58.0
5988	Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	IC50	nM	9.8	IC50	nM	9.8
5989	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>	>	Ki	nM	30000.0	Ki	uM	30.0
5990	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
5991	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL3526979	>	>	Ki	nM	30000.0	Ki	uM	30.0
5992	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>	>	Ki	nM	30000.0	Ki	uM	30.0
5993	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
5994	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL3526979	>	>	Ki	nM	30000.0	Ki	uM	30.0
5995	Inhibition of CYP3A4 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy	CC(C)c1cc2c(c(O)c1O)[C@@]1(C(=O)O)CCCC(C)(C)[C@@H]1CC2	Drug Metab. Dispos.	2012.0	CHEMBL484853	=	=	Ki	nM	4300.0	Ki	uM	4.3
5996	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	IC50	nM	120.0	IC50	uM	0.12
5997	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	IC50	nM	620.0	IC50	uM	0.62
5998	Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	Ki	nM	2660.0	Ki	uM	2.66
5999	Competitive inhibition of recombinant CYP3A4 (unknown origin) expressed in supersomes	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	7600.0	Ki	uM	7.6
6000	Competitive inhibition of CYP3A4 in human liver microsomes	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	300.0	Ki	uM	0.3
6001	Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	890.0	Ki	uM	0.89
6002	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	IC50	nM	1450.0	IC50	uM	1.45
6003	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	IC50	nM	2060.0	IC50	uM	2.06
6004	Induction of CYP3A4 in human hepatocytes after 72 hrs relative to vehicle-treated control	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	EC50	nM	5900.0	EC50	uM	5.9
6005	Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4	Drug Metab. Dispos.	2012.0	CHEMBL252518	>	>	IC50	nM	125000.0	IC50	uM	125.0
6006	Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	IC50	nM	50000.0	IC50	uM	50.0
6007	Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4	Drug Metab. Dispos.	2012.0	CHEMBL252518	>	>	IC50	nM	125000.0	IC50	uM	125.0
6008	Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	IC50	nM	50000.0	IC50	uM	50.0
6009	Competitive inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	Ki	nM	25000.0	Ki(app)	uM	25.0
6010	Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	65000.0	IC50	uM	65.0
6011	Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	33000.0	IC50	uM	33.0
6012	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	>	>	IC50	nM	100000.0	IC50	uM	100.0
6013	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	54000.0	IC50	uM	54.0
6014	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
6015	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
6016	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
6017	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
6018	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
6019	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
6020	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
6021	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
6022	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	8300.0	IC50	uM	8.3
6023	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	740.0	Ki	uM	0.74
6024	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	730.0	Ki	uM	0.73
6025	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	80000.0	IC50	uM	80.0
6026	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	1900.0	Ki	uM	1.9
6027	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	110000.0	IC50	uM	110.0
6028	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	1900.0	Ki	uM	1.9
6029	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	20000.0	IC50	uM	20.0
6030	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	9200.0	IC50	uM	9.2
6031	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	146000.0	IC50	uM	146.0
6032	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	30000.0	IC50	uM	30.0
6033	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	220000.0	IC50	uM	220.0
6034	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	5700.0	IC50	uM	5.7
6035	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	62000.0	IC50	uM	62.0
6036	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	22000.0	IC50	uM	22.0
6037	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	36000.0	IC50	uM	36.0
6038	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	2900.0	IC50	uM	2.9
6039	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	19000.0	IC50	uM	19.0
6040	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	27000.0	IC50	uM	27.0
6041	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	9600.0	IC50	uM	9.6
6042	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	7000.0	IC50	uM	7.0
6043	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100000.0	IC50	uM	100.0
6044	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	650.0	IC50	uM	0.65
6045	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	26000.0	IC50	uM	26.0
6046	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	190000.0	IC50	uM	190.0
6047	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	2100.0	IC50	uM	2.1
6048	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	8000.0	IC50	uM	8.0
6049	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	110000.0	IC50	uM	110.0
6050	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	30000.0	IC50	uM	30.0
6051	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	220000.0	IC50	uM	220.0
6052	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	5200.0	IC50	uM	5.2
6053	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	12000.0	IC50	uM	12.0
6054	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	27.0	IC50	uM	0.027
6055	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	25000.0	IC50	uM	25.0
6056	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	8100.0	IC50	uM	8.1
6057	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	68.0	IC50	uM	0.068
6058	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	2700.0	IC50	uM	2.7
6059	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100.0	IC50	uM	0.1
6060	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	21000.0	IC50	uM	21.0
6061	Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100.0	IC50	uM	0.1
6062	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835955	=	=	IC50	nM	26.0	IC50	nM	26.0
6063	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835954	=	=	IC50	nM	20.0	IC50	nM	20.0
6064	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835953	=	=	IC50	nM	16.0	IC50	nM	16.0
6065	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835952	=	=	IC50	nM	17.0	IC50	nM	17.0
6066	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	O=C(Cn1cncn1)c1ccc(Cl)cc1Cl	Drug Metab. Dispos.	2012.0	CHEMBL2063494	>	>	IC50	nM	15000.0	IC50	uM	15.0
6067	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins by LC-MS/MS method	CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl	J. Med. Chem.	2015.0	CHEMBL3577447	=	=	IC50	nM	6500.0	IC50	uM	6.5
6068	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate incubated for 30 mins by LC-MS/MS method	CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl	J. Med. Chem.	2015.0	CHEMBL3577447	=	=	IC50	nM	15000.0	IC50	uM	15.0
6069	Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1.O=C(O)/C=C\C(=O)O	ACS Med. Chem. Lett.	2015.0	CHEMBL3577955	>	>	IC50	nM	40000.0	IC50	uM	40.0
6070	Inhibition of human recombinant CYP3A4 assessed as remaining enzyme activity by measuring conversion of luciferin-PPXE into D-luciferin by luminescence CYP3A4 P450-Glo assay relative to untreated control	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
6071	Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis	CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2	J. Med. Chem.	2015.0	CHEMBL3582243	=	=	IC50	nM	4780.0	IC50	uM	4.78
6072	Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis	CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O	J. Med. Chem.	2015.0	CHEMBL3582240	=	=	IC50	nM	2535.0	IC50	uM	2.535
6073	Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis	CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2	J. Med. Chem.	2015.0	CHEMBL3582243	=	=	IC50	nM	2740.0	IC50	uM	2.74
6074	Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis	CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O	J. Med. Chem.	2015.0	CHEMBL3582240	=	=	IC50	nM	932.0	IC50	uM	0.932
6075	Inhibition of CYP3A4 (unknown origin)	CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582336	>	>	IC50	nM	10000.0	IC50	uM	10.0
6076	Inhibition of CYP3A4 (unknown origin)	CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl	J. Med. Chem.	2015.0	CHEMBL3581693	>	>	IC50	nM	20000.0	IC50	uM	20.0
6077	Inhibition of CYP3A4 (unknown origin)	Fc1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582472	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6078	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582477	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6079	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582478	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6080	Inhibition of CYP3A4 (unknown origin)	Cc1c(F)cncc1-c1nc2cc(F)c(F)cc2n1C1CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582481	=	=	IC50	nM	8235.0	IC50	nM	8235.0
6081	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581121	=	=	IC50	nM	750.0	IC50	uM	0.75
6082	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581132	=	=	IC50	nM	480.0	IC50	uM	0.48
6083	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581137	=	=	IC50	nM	10000.0	IC50	uM	10.0
6084	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581138	=	=	IC50	nM	2000.0	IC50	uM	2.0
6085	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581139	=	=	IC50	nM	7400.0	IC50	uM	7.4
6086	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581140	=	=	IC50	nM	26000.0	IC50	uM	26.0
6087	Inhibition of CYP3A4 (unknown origin)	CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1	J. Med. Chem.	2015.0	CHEMBL3581141	=	=	IC50	nM	11400.0	IC50	uM	11.4
6088	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581142	=	=	IC50	nM	3500.0	IC50	uM	3.5
6089	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581143	=	=	IC50	nM	8300.0	IC50	uM	8.3
6090	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581144	=	=	IC50	nM	1500.0	IC50	uM	1.5
6091	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581145	=	=	IC50	nM	3600.0	IC50	uM	3.6
6092	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581146	=	=	IC50	nM	3800.0	IC50	uM	3.8
6093	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3580669	>	>	IC50	nM	30000.0	IC50	uM	30.0
6094	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581147	=	=	IC50	nM	5000.0	IC50	uM	5.0
6095	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581148	=	=	IC50	nM	7500.0	IC50	uM	7.5
6096	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581149	=	=	IC50	nM	5600.0	IC50	uM	5.6
6097	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581150	>	>	IC50	nM	15000.0	IC50	uM	15.0
6098	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4c(F)cccc4-n4nccn4)C[C@H]3C2)n1	J. Med. Chem.	2015.0	CHEMBL3586436	>	>	IC50	nM	10000.0	IC50	uM	10.0
6099	Competitive inhibition of CYP3A4 (unknown origin)	Cl.O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1	ACS Med. Chem. Lett.	2015.0	CHEMBL3589557	>	>	IC50	nM	10000.0	IC50	uM	10.0
6100	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)O)nc(N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)n1	J. Med. Chem.	2015.0	CHEMBL3594232	>	>	IC50	nM	34000.0	IC50	uM	34.0
6101	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601185	>	>	IC50	nM	50000.0	IC50	uM	50.0
6102	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601186	>	>	IC50	nM	50000.0	IC50	uM	50.0
6103	Inhibition of CYP3A4 (unknown origin)	COc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601189	>	>	IC50	nM	50000.0	IC50	uM	50.0
6104	Inhibition of CYP3A4 (unknown origin)	OC[C@H]1C[C@@H](Nc2nc(Nc3ccnc(OC4CC4)c3)ncc2-c2ccc3ccccc3n2)[C@H](O)[C@@H]1O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601190	>	>	IC50	nM	50000.0	IC50	uM	50.0
6105	Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601070	>	>	IC50	nM	50000.0	IC50	uM	50.0
6106	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601192	>	>	IC50	nM	50000.0	IC50	uM	50.0
6107	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)c(-c3nc4ccccc4s3)cn2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601196	>	>	IC50	nM	50000.0	IC50	uM	50.0
6108	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601323	=	=	IC50	nM	9400.0	IC50	uM	9.4
6109	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCNC(=O)C4)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601397	=	=	IC50	nM	11300.0	IC50	uM	11.3
6110	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601399	=	=	IC50	nM	5000.0	IC50	uM	5.0
6111	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CC(=O)N(C)C4)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601400	=	=	IC50	nM	13200.0	IC50	uM	13.2
6112	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601401	>	>	IC50	nM	20000.0	IC50	uM	20.0
6113	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601402	>	>	IC50	nM	20000.0	IC50	uM	20.0
6114	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1cnc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601403	>	>	IC50	nM	20000.0	IC50	uM	20.0
6115	Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601398	=	=	IC50	nM	17000.0	IC50	uM	17.0
6116	Inhibition of CYP3A4 (unknown origin)	C[C@H](NC(=O)[C@H]1CCCCN1CCOc1ccccc1)c1ccc(C(=O)O)cc1.Cl	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3115074	>	>	IC50	nM	10000.0	IC50	uM	10.0
6117	Inhibition of CYP3A4 (unknown origin)	COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601377	=	=	IC50	nM	18000.0	IC50	uM	18.0
6118	Inhibition of CYP3A4 (unknown origin)	O=C(c1ccc(F)cc1)N1CCc2nc(COc3cccc(F)c3)oc2C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3605277	>	>	IC50	nM	30000.0	IC50	uM	30.0
6119	Inhibition of CYP3A4 (unknown origin)	O=C(c1n[nH]c2ncccc12)N1CCc2nc(COc3ccccc3)oc2C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3605296	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
6120	Inhibition of human CYP3A4	O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3604174	=	=	IC50	nM	58100.0	IC50	uM	58.1
6121	Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2cccnc2)nc2ccc(C(F)(F)F)cc21	J. Med. Chem.	2015.0	CHEMBL3605542	=	=	IC50	nM	830.0	IC50	uM	0.83
6122	Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C(F)(F)F)cc21	J. Med. Chem.	2015.0	CHEMBL3605557	>	>	IC50	nM	20000.0	IC50	uM	20.0
6123	Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21	J. Med. Chem.	2015.0	CHEMBL3605558	>	>	IC50	nM	20000.0	IC50	uM	20.0
6124	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)ccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604739	=	=	IC50	nM	3981.07	pIC50		5.4
6125	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604734	=	=	IC50	nM	12589.25	pIC50		4.9
6126	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(C)cccc2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604733	=	=	IC50	nM	10000.0	pIC50		5.0
6127	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(Cl)cccc2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604722	=	=	IC50	nM	7943.28	pIC50		5.1
6128	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2cccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604717	=	=	IC50	nM	3981.07	pIC50		5.4
6129	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2ccccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604713	=	=	IC50	nM	12589.25	pIC50		4.9
6130	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(C)cccc2C)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604701	=	=	IC50	nM	10000.0	pIC50		5.0
6131	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1	J. Med. Chem.	2015.0	CHEMBL3603923	<	>	IC50	nM	15848.93	pIC50		4.8
6132	Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	34000.0	IC50	uM	34.0
6133	Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL45816	=	=	IC50	nM	140000.0	IC50	uM	140.0
6134	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1'-hydroxylation by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	3000.0	IC50	uM	3.0
6135	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	5500.0	IC50	uM	5.5
6136	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608740	=	=	IC50	nM	31000.0	IC50	uM	31.0
6137	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608688	>	>	IC50	nM	100000.0	IC50	uM	100.0
6138	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608687	>	>	IC50	nM	100000.0	IC50	uM	100.0
6139	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3(C)C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608686	>	>	IC50	nM	100000.0	IC50	uM	100.0
6140	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608684	>	>	IC50	nM	100000.0	IC50	uM	100.0
6141	Inhibition of CYP3A4 (unknown origin)	CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608683	>	>	IC50	nM	100000.0	IC50	uM	100.0
6142	Inhibition of CYP3A4 (unknown origin)	Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608682	>	>	IC50	nM	100000.0	IC50	uM	100.0
6143	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422018	=	=	IC50	nM	79000.0	IC50	uM	79.0
6144	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608680	=	=	IC50	nM	90000.0	IC50	uM	90.0
6145	Inhibition of CYP3A4 (unknown origin)	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422010	=	=	IC50	nM	50000.0	IC50	uM	50.0
6146	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422009	=	=	IC50	nM	19000.0	IC50	uM	19.0
6147	Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3CCO)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608741	>	>	IC50	nM	100000.0	IC50	uM	100.0
6148	Inhibition of human CYP3A4	CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@@H](Cc1ccc3ccccc3c1)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCC[C@H]1C[C@@H](C(=O)N[C@@H](Cc3ccc4ccccc4c3)C(=O)N[C@H](NS(=O)(=O)C3CC3)Cc3ccc(cc3)OCc3cn2nn3)N(C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)C1)C(C)(C)C	ACS Med. Chem. Lett.	2015.0	CHEMBL3609325	>	>	IC50	nM	20000.0	IC50	uM	20.0
6149	Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2C(F)(F)F)c(C(F)(F)F)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608913	=	=	EC50	nM	4640.0	EC50	uM	4.64
6150	Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2F)c(F)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608915	=	=	EC50	nM	2460.0	EC50	uM	2.46
6151	Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2Cl)c(Cl)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608916	=	=	EC50	nM	3990.0	EC50	uM	3.99
6152	Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2c(c1)C(C)(C)c1cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)ccc1-2)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608920	=	=	EC50	nM	1030.0	EC50	uM	1.03
6153	Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2c(c1)C(F)(F)c1cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)ccc1-2)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608921	=	=	EC50	nM	976.0	EC50	uM	0.976
6154	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3608458	>	>	IC50	nM	40000.0	IC50	uM	40.0
6155	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3608458	=	=	IC50	nM	38800.0	IC50	uM	38.8
6156	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N	ACS Med. Chem. Lett.	2015.0	CHEMBL3612810	>	>	IC50	nM	50000.0	IC50	uM	50.0
6157	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	180.0	IC50	umol/L	0.18
6158	Inhibition of CYP3A4 (unknown origin)	O=C(Cn1cnc([N+](=O)[O-])n1)Nc1cccc(-c2ccccc2)c1	Bioorg. Med. Chem.	2015.0	CHEMBL3612341	>	>	IC50	nM	20000.0	IC50	uM	20.0
6159	Inhibition of CYP3A4 (unknown origin)	O=C(NCCCCNC(=O)c1cccnc1O)c1cc(-c2ccccc2)on1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3618396	>	>	IC50	nM	30000.0	IC50	uM	30.0
6160	Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	COC(=O)C(Cn1ccnc1)NC(=O)c1c(C)nn(-c2ccccc2)c1Cl	Bioorg. Med. Chem.	2015.0	CHEMBL3617983	=	=	IC50	nM	1170.0	IC50	uM	1.17
6161	Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	Cc1nn(-c2ccccc2)c(Cl)c1C(=O)NC(Cn1ccnc1)C(=O)OC(C)C	Bioorg. Med. Chem.	2015.0	CHEMBL3617986	=	=	IC50	nM	4920.0	IC50	uM	4.92
6162	Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1	Bioorg. Med. Chem.	2015.0	CHEMBL389433	=	=	IC50	nM	690.0	IC50	uM	0.69
6163	Inhibition of CYP3A4 in human liver microsomes by cocktail assay	C[C@@H]1CN(c2cccnc2F)C(=O)c2cc(COc3ccc(Cl)cn3)nn21	J. Med. Chem.	2015.0	CHEMBL3617655	>	>	IC50	nM	30000.0	IC50	uM	30.0
6164	Inhibition of human CYP3A4	CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12	ACS Med. Chem. Lett.	2015.0	CHEMBL3623127	>	>	IC50	nM	40000.0	IC50	uM	40.0
6165	Inhibition of CYP3A4 (unknown origin)	COCc1cnc(N2CCC([C@H]3C[C@H]3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622175	=	=	IC50	nM	40000.0	IC50	uM	40.0
6166	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)cc(Nc2nccc(-n3cc(C)c(CN4CC[C@@H](O)C4)c3)n2)c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3622924	=	=	IC50	nM	5100.0	IC50	uM	5.1
6167	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccnc(Nc3cc(C)c(OCCO)c(C)c3)n2)cc1CN1CC[C@@H](O)C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3622939	>	>	IC50	nM	10000.0	IC50	uM	10.0
6168	Inhibition of CYP3A4 (unknown origin)	CC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623823	>	>	IC50	nM	50000.0	IC50	uM	50.0
6169	Inhibition of CYP3A4 (unknown origin)	CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623824	>	>	IC50	nM	50000.0	IC50	uM	50.0
6170	Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623825	>	>	IC50	nM	50000.0	IC50	uM	50.0
6171	Inhibition of CYP3A4 (unknown origin)	CCC(=O)N[C@@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623830	>	>	IC50	nM	50000.0	IC50	uM	50.0
6172	Inhibition of CYP3A4 (unknown origin)	CCC(=O)N[C@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623831	>	>	IC50	nM	20000.0	IC50	uM	20.0
6173	Inhibition of CYP3A4 in human liver microsomes	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3622137	=	=	IC50	nM	3000.0	IC50	uM	3.0
6174	Inhibition of human CYP3A4	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1	J. Med. Chem.	2015.0	CHEMBL3623278	>	>	IC50	nM	10000.0	IC50	uM	10.0
6175	Inhibition of CYP3A4 (unknown origin)	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	J. Med. Chem.	2015.0	CHEMBL3623290	>	>	IC50	nM	50.0	IC50	nM	50.0
6176	Inhibition of CYP3A4 in human liver microsomes	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3545215	=	=	IC50	nM	3000.0	IC50	uM	3.0
6177	Inhibition of human CYP3A4	c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622434	=	=	IC50	nM	36510.0	IC50	nM	36510.0
6178	Inhibition of human CYP3A4	COC(=O)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622437	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6179	Inhibition of human CYP3A4	COC(C)(C)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL2331704	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6180	Inhibition of human CYP3A4	Cc1nnc2n1-c1ccc(-c3cncc([C@](C)(O)C(F)(F)F)c3)cc1CC2	ACS Med. Chem. Lett.	2015.0	CHEMBL3622445	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6181	Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(F)ccc(C)c4c(=O)[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627899	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6182	Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627895	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6183	Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3ccc4[nH]c(C)nc4c3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627897	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6184	Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627896	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6185	Inhibition of CYP3A4 (unknown origin)	COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627894	=	=	IC50	nM	33260.0	IC50	nM	33260.0
6186	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628112	>	>	IC50	nM	30000.0	IC50	uM	30.0
6187	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628113	>	>	IC50	nM	30000.0	IC50	uM	30.0
6188	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628115	>	>	IC50	nM	30000.0	IC50	uM	30.0
6189	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21	J. Med. Chem.	2015.0	CHEMBL521982	>	>	IC50	nM	30000.0	IC50	uM	30.0
6190	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(Nc1ccc(N2C(=O)c3cccc(Cl)c3C2=O)c(Cl)c1)c1ncccc1Cl	J. Med. Chem.	2015.0	CHEMBL3628116	>	>	IC50	nM	30000.0	IC50	uM	30.0
6191	Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C2CCCC2)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL592646	=	=	IC50	nM	260.0	IC50	uM	0.26
6192	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@](C)(NCc1ccc2ncccc2c1)c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628591	=	=	IC50	nM	1200.0	IC50	uM	1.2
6193	Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL600002	=	=	IC50	nM	3800.0	IC50	uM	3.8
6194	Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628942	=	=	IC50	nM	314.0	IC50	uM	0.314
6195	Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C2CCCC2)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628943	=	=	IC50	nM	263.0	IC50	uM	0.263
6196	Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncsc3c2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628934	=	=	IC50	nM	300.0	IC50	uM	0.3
6197	Inhibition of CYP3A4 (unknown origin)	C[C@@](NCc1ccc2ncsc2c1)(c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1)C1CCCC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628939	=	=	IC50	nM	200.0	IC50	uM	0.2
6198	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL372199	=	=	IC50	nM	16600.0	IC50	uM	16.6
6199	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629736	=	=	IC50	nM	11000.0	IC50	uM	11.0
6200	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629738	>	>	IC50	nM	20000.0	IC50	uM	20.0
6201	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21	J. Med. Chem.	2015.0	CHEMBL3629740	>	>	IC50	nM	30000.0	IC50	uM	30.0
6202	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1	J. Med. Chem.	2015.0	CHEMBL3629741	>	>	IC50	nM	20000.0	IC50	uM	20.0
6203	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3629743	>	>	IC50	nM	30000.0	IC50	uM	30.0
6204	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629744	>	>	IC50	nM	20000.0	IC50	uM	20.0
6205	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629745	>	>	IC50	nM	20000.0	IC50	uM	20.0
6206	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL1090209	=	=	IC50	nM	9600.0	IC50	uM	9.6
6207	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3627955	>	>	IC50	nM	30000.0	IC50	uM	30.0
6208	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL372199	=	=	IC50	nM	9300.0	IC50	uM	9.3
6209	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629736	=	=	IC50	nM	11500.0	IC50	uM	11.5
6210	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629738	>	>	IC50	nM	20000.0	IC50	uM	20.0
6211	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21	J. Med. Chem.	2015.0	CHEMBL3629740	>	>	IC50	nM	30000.0	IC50	uM	30.0
6212	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1	J. Med. Chem.	2015.0	CHEMBL3629741	>	>	IC50	nM	20000.0	IC50	uM	20.0
6213	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3629743	>	>	IC50	nM	20000.0	IC50	uM	20.0
6214	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629744	>	>	IC50	nM	20000.0	IC50	uM	20.0
6215	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629745	>	>	IC50	nM	20000.0	IC50	uM	20.0
6216	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL1090209	=	=	IC50	nM	3500.0	IC50	uM	3.5
6217	Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3627955	=	=	IC50	nM	21400.0	IC50	uM	21.4
6218	Inhibition of human recombinant CYP3A4 assessed as conversion of luciferin-PPXE to D-luciferin by luminescence Glo assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
6219	Inhibition of human CYP3A4	COc1ccc2c(O[C@H]3CCN4C(=O)N(C)CCCC/C=C/[C@@H]5C[C@@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)[C@@H]4C3)cc(-c3nc(C(F)(F)F)cs3)nc2c1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634394	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
6220	Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition	O=C(Nc1cc2ncncc2cc1OCc1cccc(Cl)c1)Nc1cccc2ccccc12	Eur. J. Med. Chem.	2015.0	CHEMBL3634101	>	>	IC50	nM	10000.0	IC50	uM	10.0
6221	Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	60.0	IC50	uM	0.06
6222	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)N1[C@H]2CC[C@@H]1C[C@@H](CN1CC[C@@H](N3Cc4ccccc4NC3=O)C1)C2	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3633184	>	>	IC50	nM	2000.0	IC50	uM	2.0
6223	Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method	O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(C(F)(F)F)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3633320	>	>	IC50	nM	20000.0	IC50	uM	20.0
6224	Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method	O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3633321	>	>	IC50	nM	20000.0	IC50	uM	20.0
6225	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL558752	>	>	IC50	nM	40000.0	IC50	uM	40.0
6226	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cnc(-c2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)[nH]1	ACS Med. Chem. Lett.	2015.0	CHEMBL3632724	=	=	IC50	nM	3400.0	IC50	uM	3.4
6227	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cc(C(F)(F)F)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632723	=	=	IC50	nM	26000.0	IC50	uM	26.0
6228	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(F)(F)F)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632722	>	>	IC50	nM	40000.0	IC50	uM	40.0
6229	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cc(C(C)(C)C)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632721	=	=	IC50	nM	3300.0	IC50	uM	3.3
6230	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632720	=	=	IC50	nM	34000.0	IC50	uM	34.0
6231	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632719	=	=	IC50	nM	10000.0	IC50	uM	10.0
6232	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632718	=	=	IC50	nM	7100.0	IC50	uM	7.1
6233	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632717	=	=	IC50	nM	1800.0	IC50	uM	1.8
6234	Reversible inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	J. Med. Chem.	2015.0	CHEMBL3633460	>	>	IC50	nM	100000.0	IC50	uM	100.0
6235	Time-dependent inhibition of CYP3A4 in human liver microsomes	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	J. Med. Chem.	2015.0	CHEMBL3633460	>	>	IC50	nM	100000.0	IC50	uM	100.0
6236	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCCn2nc(COc3ccccc3)cc21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3633943	>	>	IC50	nM	30000.0	IC50	uM	30.0
6237	Inhibition of CYP3A4 (unknown origin)	COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634013	=	=	IC50	nM	8000.0	IC50	uM	8.0
6238	Inhibition of CYP3A4 (unknown origin)	Cc1n[nH]c(C)c1[C@H](C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634015	>	>	IC50	nM	20000.0	IC50	uM	20.0
6239	Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1		2013.0	CHEMBL1650658	=	=	IC50	nM	1070.0	IC50	nM	1070.0
6240	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673964	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6241	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1		2015.0	CHEMBL3669004	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6242	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3673980	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6243	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F		2015.0	CHEMBL3673971	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6244	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673978	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6245	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3673980	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6246	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673935	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6247	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1		2015.0	CHEMBL3669002	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6248	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1		2015.0	CHEMBL3673968	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6249	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1		2015.0	CHEMBL3673948	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6250	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673973	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6251	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673963	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6252	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1		2015.0	CHEMBL3673979	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6253	Inhibition Assay: Inhibition assay using P450 CYP enzymes.	COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1		2013.0	CHEMBL1650646	=	=	IC50	nM	2050.0	IC50	nM	2050.0
6254	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(c1ccc2cc(OC(F)F)ccc2c1)n1ncnn1		2015.0	CHEMBL3682507	>	>	IC50	nM	200000.0	IC50	nM	200000.0
6255	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1		2015.0	CHEMBL3673982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6256	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F		2015.0	CHEMBL3673971	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6257	Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1		2014.0	CHEMBL3680985	=	=	IC50	nM	3800.0	IC50	nM	3800.0
6258	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F		2014.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	nM	13000.0
6259	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3669005	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6260	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1		2015.0	CHEMBL3673972	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6261	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673973	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6262	Inhibition Assay: Inhibition assay using P450 CYP enzymes.	O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1		2013.0	CHEMBL3645217	=	=	IC50	nM	221.0	IC50	nM	221.0
6263	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1		2015.0	CHEMBL3673950	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6264	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1		2015.0	CHEMBL3673953	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6265	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673967	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6266	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12		2015.0	CHEMBL3673958	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6267	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673939	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6268	Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1		2014.0	CHEMBL3680983	=	=	IC50	nM	1400.0	IC50	nM	1400.0
6269	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673939	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6270	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3673934	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6271	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1		2015.0	CHEMBL3673957	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6272	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1		2015.0	CHEMBL3673938	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6273	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673974	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6274	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1		2015.0	CHEMBL3673943	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6275	Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CCOC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12		2013.0	CHEMBL3645215	=	=	IC50	nM	1580.0	IC50	nM	1580.0
6276	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1		2015.0	CHEMBL3673940	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6277	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673974	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6278	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1		2015.0	CHEMBL3673945	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6279	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1		2015.0	CHEMBL3673945	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6280	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1		2015.0	CHEMBL3673940	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6281	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1		2015.0	CHEMBL3673962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6282	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673941	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6283	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673967	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6284	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1		2015.0	CHEMBL3673947	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6285	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	COc1cc2ccc(C(C(C)C)n3ncnn3)cc2cc1OC		2015.0	CHEMBL3682506	>	>	IC50	nM	200000.0	IC50	nM	200000.0
6286	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1		2015.0	CHEMBL3669004	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6287	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673978	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6288	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1		2015.0	CHEMBL3673947	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6289	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(c1ccc2cc(OCC(F)(F)F)ccc2c1)n1ncnn1		2015.0	CHEMBL3682505	>	>	IC50	nM	60000.0	IC50	nM	60000.0
6290	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673944	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6291	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3669001	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6292	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673954	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6293	Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1		2014.0	CHEMBL3680984	=	=	IC50	nM	5800.0	IC50	nM	5800.0
6294	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673935	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6295	Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	COc1cc2cnc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC		2014.0	CHEMBL3689756	=	=	IC50	nM	23000.0	IC50	nM	23000.0
6296	Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1		2014.0	CHEMBL3311224	>	>	IC50	nM	60000.0	IC50	nM	60000.0
6297	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3669001	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6298	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3673934	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6299	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1		2015.0	CHEMBL3673966	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6300	Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1		2014.0	CHEMBL3264605	=	=	IC50	nM	23000.0	IC50	nM	23000.0
6301	Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1		2014.0	CHEMBL3311223	=	=	IC50	nM	16000.0	IC50	nM	16000.0
6302	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1		2015.0	CHEMBL3673957	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6303	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673959	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6304	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		2015.0	CHEMBL3673952	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6305	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673963	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6306	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1		2015.0	CHEMBL3673966	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6307	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673981	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6308	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1		2015.0	CHEMBL3673950	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6309	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673944	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6310	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1		2015.0	CHEMBL3673948	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6311	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	150.0	IC50	nM	150.0
6312	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1		2015.0	CHEMBL3673972	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6313	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1		2015.0	CHEMBL3673937	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6314	Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC		2014.0	CHEMBL3264597	=	=	IC50	nM	57000.0	IC50	nM	57000.0
6315	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1		2014.0	CHEMBL3699081	=	=	IC50	nM	11000.0	IC50	nM	11000.0
6316	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O		2015.0	CHEMBL3673976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6317	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1		2015.0	CHEMBL3673965	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6318	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O		2015.0	CHEMBL3673976	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6319	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1		2015.0	CHEMBL3673968	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6320	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1		2015.0	CHEMBL3673937	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6321	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673936	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6322	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673964	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6323	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3639728	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6324	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1		2015.0	CHEMBL3673965	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6325	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1		2015.0	CHEMBL3669003	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6326	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1		2015.0	CHEMBL3673970	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6327	Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CNC(=O)/C=C/c1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1		2013.0	CHEMBL3645225	=	=	IC50	nM	2250.0	IC50	nM	2250.0
6328	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1		2015.0	CHEMBL3673982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6329	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1		2015.0	CHEMBL3673962	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6330	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1		2015.0	CHEMBL3673960	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6331	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12		2015.0	CHEMBL3673958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6332	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1		2015.0	CHEMBL3673946	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6333	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1		2015.0	CHEMBL3669002	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6334	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1		2015.0	CHEMBL3673970	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6335	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1		2015.0	CHEMBL3673946	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6336	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3669005	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6337	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3639728	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6338	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2014.0	CHEMBL106	=	=	IC50	nM	8000.0	IC50	nM	8000.0
6339	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673981	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6340	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1		2014.0	CHEMBL3699082	=	=	IC50	nM	45000.0	IC50	nM	45000.0
6341	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(O)c1ccc2cc(OCC(F)(F)F)ccc2c1		2015.0	CHEMBL3682508	>	>	IC50	nM	200000.0	IC50	nM	200000.0
6342	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1		2015.0	CHEMBL3673960	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6343	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1		2015.0	CHEMBL3673938	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6344	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673959	>	>	IC50	nM	10000.0	IC50	nM	10000.0
6345	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673936	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6346	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1		2015.0	CHEMBL3673943	=	=	IC50	nM	5000.0	IC50	nM	5000.0
6347	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		2015.0	CHEMBL3673952	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6348	Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1		2015.0	CHEMBL3669003	<	<	IC50	nM	5000.0	IC50	nM	5000.0
6349	Inhibition of CYP3A4 (unknown origin)	Cc1noc([C@H]2C[C@@H]2C(=O)NCc2ccc(-c3cccc(OC(F)(F)F)c3)c3c2CN(C(=O)NC(C)(C)C)CC3)n1	J. Med. Chem.	2015.0	CHEMBL3734797	=	=	IC50	nM	13000.0	IC50	uM	13.0
6350	Inhibition of human CYP3A4 by LC-MS analysis	CC(C)NCC(O)COc1cccc2ccccc12	J. Med. Chem.	2015.0	CHEMBL27	<	>	IC50	nM	10000.0	pIC50		5.0
6351	Inhibition of human CYP3A4 by LC-MS analysis	CB1C=Cc2cccc(OCC(O)CN(C)C)c2N1	J. Med. Chem.	2015.0	CHEMBL3736433	<	>	IC50	nM	10000.0	pIC50		5.0
6352	Inhibition of human CYP3A4 by LC-MS analysis	CB1C=Cc2c(cccc2OCC(O)CN(C)C)N1	J. Med. Chem.	2015.0	CHEMBL3736156	<	>	IC50	nM	10000.0	pIC50		5.0
6353	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NCC2CCN(CC3CCOCC3)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741608	=	=	IC50	nM	25500.0	IC50	uM	25.5
6354	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1CCC(CNC(=O)c2nc(C(C)C)n3ccccc23)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3741821	=	=	IC50	nM	27200.0	IC50	uM	27.2
6355	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(C(C)C)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739521	=	=	IC50	nM	200.0	IC50	uM	0.2
6356	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(CC3CC3)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739470	=	=	IC50	nM	20000.0	IC50	uM	20.0
6357	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1CCC(NC(=O)c2nc(C(C)C)n3ccccc23)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3741776	=	=	IC50	nM	16300.0	IC50	uM	16.3
6358	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(CCF)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3740908	=	=	IC50	nM	27300.0	IC50	uM	27.3
6359	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1C[C@H]2[C@H](CNC(=O)c3nc(C(C)C)n4ccccc34)[C@H]2C1	Eur. J. Med. Chem.	2015.0	CHEMBL3740472	=	=	IC50	nM	0.0	IC50	uM	0.0
6360	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC4CCOCC4)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739647	=	=	IC50	nM	41400.0	IC50	uM	41.4
6361	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COC(=O)N1CCC(CN2C[C@H]3[C@H](CNC(=O)c4nc(C(C)C)n5ccccc45)[C@H]3C2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3740669	=	=	IC50	nM	54300.0	IC50	uM	54.3
6362	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC(C)(C)F)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741595	=	=	IC50	nM	44700.0	IC50	uM	44.7
6363	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC(C)(C)O)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741377	=	=	IC50	nM	18900.0	IC50	uM	18.9
6364	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2C(=O)N(Cc3c(F)cc(F)cc3F)c3ncccc3S2(=O)=O)cnc1OC	MedChemComm	2015.0	CHEMBL3740099	<	>	IC50	nM	10000.0	pIC50		5.0
6365	Inhibition of human CYP3A4 by fluorescence assay	Cc1cc(F)c(-c2ccnn(C)c2=O)cc1NC(=O)C1=CN(C)C(=O)C[C@H]1c1ccc(F)cc1	J. Med. Chem.	2015.0	CHEMBL3740684	>	>	IC50	nM	32000.0	IC50	uM	32.0
6366	Inhibition of human CYP3A4 by fluorescence assay	COC[C@H](O)Cn1c(=O)cnn(-c2ccc(C)c(NC(=O)C3=CN(C)C(=O)C[C@H]3c3ccc(F)cc3)c2)c1=O	J. Med. Chem.	2015.0	CHEMBL3739741	>	>	IC50	nM	50000.0	IC50	uM	50.0
6367	Inhibition of CYP3A4 (unknown origin) assessed as testosterone-6beta hydroxylation	CCn1cc(C(=O)N2CCc3ccsc3C2Cc2ccc(OC)c(OC)c2)c2ccccc21	MedChemComm	2015.0	CHEMBL3742341	=	=	IC50	nM	3000.0	IC50	uM	3.0
6368	Inhibition of CYP3A4 (unknown origin)	CC(C)Cc1cc(O)c(-c2ccccc2)c(=O)[nH]1	Eur. J. Med. Chem.	2015.0	CHEMBL3597017	>	>	IC50	nM	20000.0	IC50	uM	20.0
6369	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)N(C)C2(C(=O)N[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)CC2)cc1F	MedChemComm	2015.0	CHEMBL3741915	>	>	IC50	nM	50000.0	IC50	uM	50.0
6370	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(=O)O)c(C)c1NC(=O)c1cc(-c2cccc(Cl)c2)cc2ccccc12	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3740325	>	>	IC50	nM	10000.0	IC50	uM	10.0
6371	Inhibition of human recombinant CYP3A4 by fluorescence assay	O=C(c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-])N1CCCCC1	Bioorg. Med. Chem.	2015.0	CHEMBL3742347	=	=	IC50	nM	3910.0	IC50	uM	3.91
6372	Inhibition of human recombinant CYP3A4 by fluorescence assay	COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL3742122	=	=	IC50	nM	19500.0	IC50	uM	19.5
6373	Inhibition of human recombinant CYP3A4 by fluorescence assay	COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)c(C)c([N+](=O)[O-])c3s2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL3741545	=	=	IC50	nM	95000.0	IC50	uM	95.0
6374	Inhibition of human recombinant CYP3A4 by fluorescence assay	O=C([C@@H]1COC(c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)=N1)N1CCCC1	Bioorg. Med. Chem.	2015.0	CHEMBL3739863	=	=	IC50	nM	18600.0	IC50	uM	18.6
6375	Inhibition of human recombinant CYP3A4 by fluorescence assay	Cc1c(C(F)(F)F)cc2nc(C3=N[C@H](C(=O)N4CCCC4)CO3)sc2c1[N+](=O)[O-]	Bioorg. Med. Chem.	2015.0	CHEMBL3739831	>	>	IC50	nM	100000.0	IC50	uM	100.0
6376	Inhibition of CYP3A4 (unknown origin)	Cn1cc(CNc2cc(OC[C@H]3C[C@@H]3c3ccccn3)nc3ccnn23)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3695713	>	>	IC50	nM	50000.0	IC50	uM	50.0
6377	Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2cc(C3CC3)nc3ccnn23)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3695718	>	>	IC50	nM	50000.0	IC50	uM	50.0
6378	Inhibition of CYP3A4 (unknown origin)	Cc1c(Cl)nc(OC[C@H]2C[C@@H]2c2ccccn2)nc1NCc1cnn(C)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3665949	=	=	IC50	nM	3800.0	IC50	uM	3.8
6379	Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2nc(C3CC3)nc(Cl)c2C)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3622879	=	=	IC50	nM	17000.0	IC50	uM	17.0
6380	Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3622898	=	=	IC50	nM	900.0	IC50	uM	0.9
6381	Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(COc3ccccc3)nn2CCN1c1ccc(F)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3746457	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
6382	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2cccc(CO)c2)nc1C(=O)Nc1c(C)ccc(C(=O)O)c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3754085	>	>	IC50	nM	10000.0	IC50	uM	10.0
6383	Inhibition of human CYP3A4 after 2 mins by LC-MS/MS analysis	CC(C)N1CCC(Oc2ccc(C(=O)NC3CCN(C(C)C)C3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL3753093	>	>	IC50	nM	45000.0	IC50	uM	45.0
6384	Inhibition of human CYP3A4 after 2 mins by LC-MS/MS analysis	CC(C)N1CCC(NC(=O)c2ccc(OC3CCN(C4CCC4)CC3)cc2)C1	Eur. J. Med. Chem.	2016.0	CHEMBL3754205	>	>	IC50	nM	30000.0	IC50	uM	30.0
6385	Inhibition of CYP3A4 (unknown origin)	CC(C)n1nc(-c2cc(C3CC3)on2)c2c(N)ncnc21	J. Med. Chem.	2016.0	CHEMBL3753341	>	>	IC50	nM	30000.0	IC50	uM	30.0
6386	Inhibition of CYP3A4 (unknown origin)	Cc1ccc2c(c1)C(=O)N(c1ccc(NC(=O)c3occc3C)c(F)c1)C2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758746	>	>	IC50	nM	30000.0	IC50	uM	30.0
6387	Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(C)c3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758305	>	>	IC50	nM	30000.0	IC50	uM	30.0
6388	Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3759901	>	>	IC50	nM	30000.0	IC50	uM	30.0
6389	Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(F)cc3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758435	>	>	IC50	nM	30000.0	IC50	uM	30.0
6390	Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758465	>	>	IC50	nM	30000.0	IC50	uM	30.0
6391	Inhibition of CYP3A4 (unknown origin)	COc1cc(CNC(=O)c2cc(-c3nnn(C[C@H]4CO[C@H](CO)CO4)n3)nc(C)n2)ccc1F	J. Med. Chem.	2016.0	CHEMBL3759468	>	>	IC50	nM	30000.0	IC50	uM	30.0
6392	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1	J. Med. Chem.	2016.0	CHEMBL111201	=	=	IC50	nM	9300.0	IC50	uM	9.3
6393	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1	J. Med. Chem.	2016.0	CHEMBL1684585	>	>	IC50	nM	100000.0	IC50	uM	100.0
6394	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21	J. Med. Chem.	2016.0	CHEMBL3128178	>	>	IC50	nM	100000.0	IC50	uM	100.0
6395	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21	J. Med. Chem.	2016.0	CHEMBL3128188	>	>	IC50	nM	100000.0	IC50	uM	100.0
6396	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3764774	=	=	IC50	nM	96000.0	IC50	uM	96.0
6397	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1ncccc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3764088	>	>	IC50	nM	100000.0	IC50	uM	100.0
6398	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1cccnc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3763594	>	>	IC50	nM	100000.0	IC50	uM	100.0
6399	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21	J. Med. Chem.	2016.0	CHEMBL2107826	>	>	IC50	nM	100000.0	IC50	uM	100.0
6400	Inhibition of CYP3A4 (unknown origin)	Cl.NOCc1ccc(I)cc1	Eur. J. Med. Chem.	2016.0	CHEMBL3763688	=	=	IC50	nM	7200.0	IC50	uM	7.2
6401	Inhibition of CYP3A4 (unknown origin)	Cl.NOCc1cccc(Cl)c1	Eur. J. Med. Chem.	2016.0	CHEMBL3765807	=	=	IC50	nM	15000.0	IC50	uM	15.0
6402	Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765754	>	>	IC50	nM	30000.0	IC50	uM	30.0
6403	Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764557	>	>	IC50	nM	6000.0	IC50	uM	6.0
6404	Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765426	>	>	IC50	nM	30000.0	IC50	uM	30.0
6405	Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764143	>	>	IC50	nM	3000.0	IC50	uM	3.0
6406	Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765754	>	>	IC50	nM	30000.0	IC50	uM	30.0
6407	Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764557	>	>	IC50	nM	6000.0	IC50	uM	6.0
6408	Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765426	>	>	IC50	nM	30000.0	IC50	uM	30.0
6409	Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764143	>	>	IC50	nM	3000.0	IC50	uM	3.0
6410	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	O=C(O)CN(C1(c2ccc(-c3ccccc3OC(F)(F)F)cc2)CCC1)S(=O)(=O)c1ccc(OC(F)F)cc1	Bioorg. Med. Chem.	2016.0	CHEMBL3765022	=	=	IC50	nM	6000.0	IC50	uM	6.0
6411	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)C3(c4cccc(-c5cc(Cl)cc(Cl)c5)c4)CCC3)ccc2O1	Bioorg. Med. Chem.	2016.0	CHEMBL3764017	=	=	IC50	nM	9000.0	IC50	uM	9.0
6412	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)Cc3cccc(-c4ccccc4)c3)ccc2O1	Bioorg. Med. Chem.	2016.0	CHEMBL3764044	=	=	IC50	nM	40000.0	IC50	uM	40.0
6413	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	O=C(O)CN(Cc1cccc(-c2ccccc2OC(F)(F)F)c1)S(=O)(=O)c1ccc(OC(F)F)cc1	Bioorg. Med. Chem.	2016.0	CHEMBL3764377	=	=	IC50	nM	30000.0	IC50	uM	30.0
6414	Inhibition of CYP3A4 (unknown origin)	CC(C)n1ncnc1-c1cn2c(n1)-c1ccc(O[C@@H](C)C(N)=O)cc1OCC2	J. Med. Chem.	2016.0	CHEMBL3771364	>	>	IC50	nM	10000.0	IC50	uM	10.0
6415	Inhibition of human CYP3A4 by VG metabolism assay	Cc1c2c(nn1-c1nnc(-c3ccc(OC(C)C)c(Cl)c3)s1)CCN(CCC(=O)O)C2	J. Med. Chem.	2016.0	CHEMBL3769933	>	>	IC50	nM	50000.0	IC50	uM	50.0
6416	Inhibition of human CYP3A4 by VR metabolism assay	Cc1c2c(nn1-c1nnc(-c3ccc(OC(C)C)c(Cl)c3)s1)CCN(CCC(=O)O)C2	J. Med. Chem.	2016.0	CHEMBL3769933	>	>	IC50	nM	50000.0	IC50	uM	50.0
6417	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1	J. Med. Chem.	2016.0	CHEMBL3771105	=	=	IC50	nM	28120.0	IC50	uM	28.12
6418	Inhibition of CYP3A4 (unknown origin) using testostrone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1	J. Med. Chem.	2016.0	CHEMBL3771105	=	=	IC50	nM	21940.0	IC50	uM	21.94
6419	Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
6420	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)CCc2sc(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769671	=	=	IC50	nM	700.0	IC50	uM	0.7
6421	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1ncn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770314	=	=	IC50	nM	300.0	IC50	uM	0.3
6422	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Clc1cn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771055	=	=	IC50	nM	300.0	IC50	uM	0.3
6423	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(o2)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769445	=	=	IC50	nM	300.0	IC50	uM	0.3
6424	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(n2C)CCc2cc(-n4cnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769523	=	=	IC50	nM	300.0	IC50	uM	0.3
6425	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(n2C)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769470	=	=	IC50	nM	300.0	IC50	uM	0.3
6426	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)CCc2ccc(Cc4ccc(F)cc4)nc2C3=O)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770902	=	=	IC50	nM	300.0	IC50	uM	0.3
6427	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769926	=	=	IC50	nM	150.0	IC50	uM	0.15
6428	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	O=C1Nc2cc(-n3cnc(Cl)c3)ccc2Nc2nc(Cc3ccccc3)ccc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770111	>	>	IC50	nM	13000.0	IC50	uM	13.0
6429	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1ncn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771031	=	=	IC50	nM	2000.0	IC50	uM	2.0
6430	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2cc3c(cc2F)Nc2nc(Cc4ccccc4)ccc2C(=O)N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771295	=	=	IC50	nM	30.0	IC50	uM	0.03
6431	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(C(C)c4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770105	=	=	IC50	nM	200.0	IC50	uM	0.2
6432	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	CC(c1ccccc1)c1ccc2c(n1)Nc1ccc(-n3cnc(Cl)c3)cc1NC2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770272	>	>	IC50	nM	13000.0	IC50	uM	13.0
6433	Inhibition of CYP3A4 (unknown origin)	COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cccc(SC)c2)cc1	J. Med. Chem.	2016.0	CHEMBL3667554	=	=	IC50	nM	8000.0	IC50	uM	8.0
6434	Inhibition of CYP3A4 (unknown origin)	COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cc(C)cc(C)c2)cc1	J. Med. Chem.	2016.0	CHEMBL3597952	=	=	IC50	nM	15000.0	IC50	uM	15.0
6435	Inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC	J. Med. Chem.	2016.0	CHEMBL3338866	=	=	IC50	nM	28000.0	IC50	uM	28.0
6436	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3774588	>	>	IC50	nM	5000.0	IC50	uM	5.0
6437	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774683	>	>	IC50	nM	2000.0	IC50	uM	2.0
6438	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774591	>	>	IC50	nM	1000.0	IC50	uM	1.0
6439	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1	Bioorg. Med. Chem.	2016.0	CHEMBL3775197	>	>	IC50	nM	3000.0	IC50	uM	3.0
6440	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	16000.0	IC50	uM	16.0
6441	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774411	>	>	IC50	nM	20000.0	IC50	uM	20.0
6442	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3775350	>	>	IC50	nM	15000.0	IC50	uM	15.0
6443	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1	Bioorg. Med. Chem.	2016.0	CHEMBL3774649	>	>	IC50	nM	17000.0	IC50	uM	17.0
6444	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775589	>	>	IC50	nM	1000.0	IC50	uM	1.0
6445	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775226	>	>	IC50	nM	3000.0	IC50	uM	3.0
6446	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3774588	>	>	IC50	nM	5000.0	IC50	uM	5.0
6447	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774683	>	>	IC50	nM	2000.0	IC50	uM	2.0
6448	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21	Bioorg. Med. Chem.	2016.0	CHEMBL3775598	>	>	IC50	nM	1000.0	IC50	uM	1.0
6449	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774591	>	>	IC50	nM	1000.0	IC50	uM	1.0
6450	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21	Bioorg. Med. Chem.	2016.0	CHEMBL3775598	>	>	IC50	nM	1000.0	IC50	uM	1.0
6451	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1	Bioorg. Med. Chem.	2016.0	CHEMBL3775197	=	=	IC50	nM	920.0	IC50	uM	0.92
6452	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774411	>	>	IC50	nM	20000.0	IC50	uM	20.0
6453	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	16000.0	IC50	uM	16.0
6454	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	25000.0	IC50	uM	25.0
6455	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3775350	>	>	IC50	nM	15000.0	IC50	uM	15.0
6456	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1	Bioorg. Med. Chem.	2016.0	CHEMBL3774649	>	>	IC50	nM	17000.0	IC50	uM	17.0
6457	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775589	>	>	IC50	nM	1000.0	IC50	uM	1.0
6458	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775226	>	>	IC50	nM	3000.0	IC50	uM	3.0
6459	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	25000.0	IC50	uM	25.0
6460	Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774783	=	=	IC50	nM	980.0	IC50	uM	0.98
6461	Inhibition of human CYP3A4	CCn1c(CCC(=O)Nc2ccc(C)cc2C)nnc1CCC1CCCCC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775930	=	=	IC50	nM	12000.0	IC50	uM	12.0
6462	Inhibition of human CYP3A4	CCn1c(SCC(=O)Nc2cccc3ccccc23)nnc1C1Cc2ccccc2C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775765	=	=	IC50	nM	4000.0	IC50	uM	4.0
6463	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	CC(=O)N1C[C@H](C(=O)Nc2ccc(C)cc2C)[C@@H](c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3774855	>	>	IC50	nM	50000.0	IC50	uM	50.0
6464	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	Cc1ccc(NC(=O)[C@H]2C[C@@H](O)C[C@@H]2c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775807	=	=	IC50	nM	3000.0	IC50	uM	3.0
6465	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	Cc1ccc(NC(=O)CCc2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775828	=	=	IC50	nM	5000.0	IC50	uM	5.0
6466	Inhibition of CYP3A4 (unknown origin)	CN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3774871	=	=	IC50	nM	7040.0	IC50	nM	7040.0
6467	Inhibition of CYP3A4 (unknown origin)	C[N+]1([O-])CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3774852	=	=	IC50	nM	26139.0	IC50	nM	26139.0
6468	Inhibition of CYP3A4 (unknown origin)	O=C(O)CCN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3775464	=	=	IC50	nM	25988.0	IC50	nM	25988.0
6469	Inhibition of CYP3A4 (unknown origin)	CN(C)CC(=O)N1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3775389	=	=	IC50	nM	4778.0	IC50	nM	4778.0
6470	Inhibition of CYP3A4 (unknown origin)	O=C1COc2ccc(CN3c4ccccc4COc4cc(F)ccc43)cc2N1	Bioorg. Med. Chem.	2016.0	CHEMBL3775476	=	=	IC50	nM	5544.0	IC50	nM	5544.0
6471	Inhibition of CYP3A4 (unknown origin)	O=C1COc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc2N1	Bioorg. Med. Chem.	2016.0	CHEMBL3775370	=	=	IC50	nM	6697.0	IC50	nM	6697.0
6472	Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=S)Nc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc21	Bioorg. Med. Chem.	2016.0	CHEMBL3775473	=	=	IC50	nM	363.0	IC50	nM	363.0
6473	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc2n1[C@@H]1C[C@@H]2COCCN2C1	Bioorg. Med. Chem.	2016.0	CHEMBL3775798	=	=	IC50	nM	5810.0	IC50	nM	5810.0
6474	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3775504	>	>	IC50	nM	15000.0	IC50	uM	15.0
6475	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)[C@H]1CC[C@H](Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3775875	>	>	IC50	nM	15000.0	IC50	uM	15.0
6476	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)N1CCC(Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3774827	>	>	IC50	nM	15000.0	IC50	uM	15.0
6477	Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C[C@H]1COC(N)=N1)c1ccccc1	ACS Med. Chem. Lett.	2016.0	CHEMBL3684869	>	>	IC50	nM	50000.0	IC50	uM	50.0
6478	Inhibition of CYP3A4 (unknown origin)	Cc1c(F)cccc1[C@H]1COC(N)=N1	ACS Med. Chem. Lett.	2016.0	CHEMBL3781694	>	>	IC50	nM	50000.0	IC50	uM	50.0
6479	Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL494979	=	=	IC50	nM	29000.0	IC50	uM	29.0
6480	Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL566685	>	>	IC50	nM	50000.0	IC50	uM	50.0
6481	Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1	J. Med. Chem.	2016.0	CHEMBL2029678	=	=	IC50	nM	21000.0	IC50	uM	21.0
6482	Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1	J. Med. Chem.	2016.0	CHEMBL3414926	>	>	IC50	nM	50000.0	IC50	uM	50.0
6483	Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL494979	=	=	IC50	nM	2000.0	IC50	uM	2.0
6484	Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL566685	=	=	IC50	nM	26000.0	IC50	uM	26.0
6485	Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1	J. Med. Chem.	2016.0	CHEMBL2029678	=	=	IC50	nM	1500.0	IC50	uM	1.5
6486	Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1	J. Med. Chem.	2016.0	CHEMBL3414926	>	>	IC50	nM	50000.0	IC50	uM	50.0
6487	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	CC1(C)CCC(Nc2ncnc3c2nn2ccccc32)CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3787247	>	>	IC50	nM	30000.0	IC50	uM	30.0
6488	Inhibition of CYP3A4 (unknown origin)	CC(C)(CN1C(=O)c2ccccc2C1C(=O)NCCCF)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3785768	>	>	IC50	nM	50000.0	IC50	uM	50.0
6489	Inhibition of CYP3A4 (unknown origin)	CCCNC(=O)C1c2ccccc2C(=O)N1CC(C)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3786344	>	>	IC50	nM	50000.0	IC50	uM	50.0
6490	Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3787458	=	=	IC50	nM	28000.0	IC50	uM	28.0
6491	Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1C[C@H]2C[C@H]2N1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3785556	>	>	IC50	nM	100000.0	IC50	uM	100.0
6492	Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3785177	>	>	IC50	nM	100000.0	IC50	uM	100.0
6493	Inhibition of human CYP3A4 by HPLC analysis	CC(C)(C)[C@@H](O)C(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1	MedChemComm	2016.0	CHEMBL3785476	=	=	IC50	nM	47000.0	IC50	uM	47.0
6494	Inhibition of human CYP3A4 by HPLC analysis	CCCC[C@@H](O)C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1	MedChemComm	2016.0	CHEMBL3786799	>	>	IC50	nM	50000.0	IC50	uM	50.0
6495	Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)[C@H](O)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787587	>	>	IC50	nM	50000.0	IC50	uM	50.0
6496	Inhibition of human CYP3A4 by HPLC analysis	CCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3786896	=	=	IC50	nM	8000.0	IC50	uM	8.0
6497	Inhibition of human CYP3A4 by HPLC analysis	CC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3785257	>	>	IC50	nM	20000.0	IC50	uM	20.0
6498	Inhibition of human CYP3A4 by HPLC analysis	CCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787339	=	=	IC50	nM	1800.0	IC50	uM	1.8
6499	Inhibition of human CYP3A4 by HPLC analysis	CCCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787686	=	=	IC50	nM	1200.0	IC50	uM	1.2
6500	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	CC1(C)CCC(C)(C)c2cc(C3(c4ccc(/C=C/C(=O)O)cc4)OCCO3)ccc21	J. Med. Chem.	2016.0	CHEMBL3786581	=	=	IC50	nM	30000.0	IC50	uM	30.0
6501	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	CC1(C)CCC(C)(C)c2cc(C3(c4ccc(CCC(=O)O)cc4)SCCS3)ccc21	J. Med. Chem.	2016.0	CHEMBL3787323	=	=	IC50	nM	7500.0	IC50	uM	7.5
6502	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	Cn1cnc2ncn(Cc3nc(CCc4ccc(Cl)cc4)no3)c(=O)c21	J. Med. Chem.	2016.0	CHEMBL3785736	>	>	IC50	nM	27000.0	IC50	uM	27.0
6503	Inhibition of CYP34A (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2Cc3c(Cl)cccc3C2=O)c(Cl)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3785321	>	>	IC50	nM	30000.0	IC50	uM	30.0
6504	Time-dependent inhibition of CYP3A4 (unknown origin)	Cc1c2cc(-n3ccc(OCc4csc(C(F)(F)F)c4)cc3=O)ccc2nn1C1CC1	Bioorg. Med. Chem.	2016.0	CHEMBL3578244	>	>	IC50	nM	10000.0	IC50	uM	10.0
6505	Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccn5)c4C(F)(F)F)n3)cc2)C1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3794145	>	>	IC50	nM	40000.0	IC50	uM	40.0
6506	Inhibition of CYP3A4 (unknown origin)	Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3692706	>	>	IC50	nM	50000.0	IC50	uM	50.0
6507	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(N2CCC(O)CC2)nc1C(=O)Nc1c(C)cc(C(=O)O)cc1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3686863	>	>	IC50	nM	10000.0	IC50	uM	10.0
6508	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799831	>	>	IC50	nM	30000.0	IC50	uM	30.0
6509	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL521982	>	>	IC50	nM	30000.0	IC50	uM	30.0
6510	Inhibition of CYP3A4 (unknown origin)	N#Cc1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797793	>	>	IC50	nM	30000.0	IC50	uM	30.0
6511	Inhibition of CYP3A4 (unknown origin)	CC(C)c1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799685	>	>	IC50	nM	30000.0	IC50	uM	30.0
6512	Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1	J. Med. Chem.	2016.0	CHEMBL3794064	>	>	IC50	nM	40000.0	IC50	uM	40.0
6513	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cc(F)c(F)c3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640275	=	=	IC50	nM	30000.0	IC50	uM	30.0
6514	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)ccc(F)c3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640286	>	>	IC50	nM	20000.0	IC50	uM	20.0
6515	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640258	>	>	IC50	nM	20000.0	IC50	uM	20.0
6516	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)c(F)cc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640255	>	>	IC50	nM	20000.0	IC50	uM	20.0
6517	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3261082	>	>	IC50	nM	30000.0	IC50	uM	30.0
6518	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640263	=	=	IC50	nM	34100.0	IC50	uM	34.1
6519	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640262	>	>	IC50	nM	30000.0	IC50	uM	30.0
6520	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640259	>	>	IC50	nM	30000.0	IC50	uM	30.0
6521	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3798199	=	=	IC50	nM	18000.0	IC50	uM	18.0
6522	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3798544	=	=	IC50	nM	24000.0	IC50	uM	24.0
6523	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(F)cc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640290	>	>	IC50	nM	30000.0	IC50	uM	30.0
6524	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J. Med. Chem.	2016.0	CHEMBL3800286	=	=	IC50	nM	2000.0	IC50	uM	2.0
6525	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccc3C#N)C[C@H]2C1=O	J. Med. Chem.	2016.0	CHEMBL2178713	>	>	IC50	nM	30000.0	IC50	uM	30.0
6526	Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2016.0	CHEMBL2178718	=	=	IC50	nM	1200.0	IC50	uM	1.2
6527	Inhibition of CYP3A4 (unknown origin)	CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCC(Oc2cccc(C(=O)O)n2)CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797513	>	>	IC50	nM	50000.0	IC50	uM	50.0
6528	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate incubated for 30 mins by fluorescence analysis in presence of NADPH	CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797717	=	=	IC50	nM	1100.0	IC50	uM	1.1
6529	Inhibition of human recombinant CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate incubated for 30 mins by fluorescence analysis in presence of NADPH	CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCNCC3)nc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799529	<	<	IC50	nM	1100.0	IC50	uM	1.1
6530	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	Nc1cccnc1C(=O)Nc1ccc(N2C(=O)c3ccccc3C2=O)c(Cl)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3798234	>	>	IC50	nM	30000.0	IC50	uM	30.0
6531	Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	CCc1cnc(Oc2ccc(NC(=O)c3ncccc3N)cc2Cl)nc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3798517	=	=	IC50	nM	21100.0	IC50	uM	21.1
6532	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect cells using BFC as susbtrate incubated for 45 mins by plate reader analysis in presence of NADP+	COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805852	>	>	IC50	nM	20000.0	IC50	uM	20.0
6533	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect cells using benzyloxyresorufin as susbtrate incubated for 45 mins by plate reader analysis in presence of NADP+	COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805852	>	>	IC50	nM	20000.0	IC50	uM	20.0
6534	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis	Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12	ACS Med. Chem. Lett.	2016.0	CHEMBL3341983	=	=	IC50	nM	77.0	IC50	uM	0.077
6535	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis	Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncccn4)cc3F)cc12	ACS Med. Chem. Lett.	2016.0	CHEMBL3804898	>	>	IC50	nM	10000.0	IC50	uM	10.0
6536	Inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins by fluorimetry	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	280.0	IC50	uM	0.28
6537	Inhibition of CYP3A4 (unknown origin)	Cc1cc2ncc3c(n2n1)CN([C@H]1CC[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3805966	>	>	IC50	nM	50000.0	IC50	uM	50.0
6538	Inhibition of CYP3A4 (unknown origin)	Cc1cc2ncc3c(n2n1)CN([C@H]1CO[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806029	>	>	IC50	nM	50000.0	IC50	uM	50.0
6539	Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3cnc4nnc(C5CC5)n4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806041	>	>	IC50	nM	50000.0	IC50	uM	50.0
6540	Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3nn4cccnc4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806003	>	>	IC50	nM	50000.0	IC50	uM	50.0
6541	Inhibition of CYP3A4 (unknown origin)	Cc1ccn2nc3c(c2n1)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3805400	>	>	IC50	nM	50000.0	IC50	uM	50.0
6542	Inhibition of CYP3A4 (unknown origin)	Cc1ccnc2c3c(nn12)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3804950	>	>	IC50	nM	50000.0	IC50	uM	50.0
6543	Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3nn4nccnc4c3C2)CO[C@@H]1c1cc(F)ccc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806052	>	>	IC50	nM	50000.0	IC50	uM	50.0
6544	Time dependent inhibition of CYP3A4 in human liver microsomes	Cn1c(=O)n(CC(C)(C)C)c2ccc(N3C[C@@H]4CC[C@H]3CN4C(=O)c3ccon3)nc21	ACS Med. Chem. Lett.	2016.0	CHEMBL3806137	=	=	Ki	nM	540.0	Ki	nM	540.0
6545	Inhibition of CYP3A4 (unknown origin)	CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805372	>	>	IC50	nM	50000.0	IC50	uM	50.0
6546	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1cccc(-c2cccc(-c3cn[nH]c3N)c2)c1	J. Med. Chem.	2016.0	CHEMBL3806191	>	>	IC50	nM	25000.0	IC50	uM	25.0
6547	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1cccc(-c2cccc(-c3c(-c4ccc(O)cc4)n[nH]c3N)c2)c1	J. Med. Chem.	2016.0	CHEMBL3806115	=	=	IC50	nM	11300.0	IC50	uM	11.3
6548	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Oc1ccc(CNc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1	J. Med. Chem.	2016.0	CHEMBL3805279	>	>	IC50	nM	25000.0	IC50	uM	25.0
6549	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(C)=O)nc4)cc3)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3805891	=	=	IC50	nM	3200.0	IC50	uM	3.2
6550	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1ccc(-c2ccc(NCC(=O)Nc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2)cn1	J. Med. Chem.	2016.0	CHEMBL3804921	=	=	IC50	nM	2400.0	IC50	uM	2.4
6551	Inhibition of CYP3A4 (unknown origin)	O=C(CNc1ccc(-c2ccc(NC(=O)C3CC3)nc2)cc1)Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1	J. Med. Chem.	2016.0	CHEMBL3805330	=	=	IC50	nM	1100.0	IC50	uM	1.1
6552	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3805771	>	>	IC50	nM	30000.0	IC50	uM	30.0
6553	Inhibition of CYP3A4 (unknown origin)	CN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3F)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3806189	>	>	IC50	nM	30000.0	IC50	uM	30.0
6554	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2016.0	CHEMBL64391	=	=	IC50	nM	50.4	IC50	nM	50.4
6555	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(C)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2016.0	CHEMBL3809786	>	>	IC50	nM	10000.0	IC50	uM	10.0
6556	Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(=O)Nc2ccc(NC(=O)c3ccco3)cc2)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808895	>	>	IC50	nM	30000.0	IC50	uM	30.0
6557	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccn(-c2cn(Cc3cccc(C(F)(F)F)c3)cn2)c(=O)c1)c1cscn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809896	=	=	IC50	nM	1900.0	IC50	uM	1.9
6558	Inhibition of CYP3A4 (unknown origin)	CC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810245	>	>	IC50	nM	30000.0	IC50	uM	30.0
6559	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccn(-c2c[nH]c(C(O)c3cccc(C(F)(F)F)c3)n2)c(=O)c1)c1cscn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809890	>	>	IC50	nM	30000.0	IC50	uM	30.0
6560	Inhibition of CYP3A4 (unknown origin)	CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808805	>	>	IC50	nM	30000.0	IC50	uM	30.0
6561	Inhibition of CYP3A4 (unknown origin)	Cc1cccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810414	>	>	IC50	nM	30000.0	IC50	uM	30.0
6562	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)cc1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809367	>	>	IC50	nM	30000.0	IC50	uM	30.0
6563	Inhibition of CYP3A4 (unknown origin)	CC(C)CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808401	>	>	IC50	nM	30000.0	IC50	uM	30.0
6564	Inhibition of CYP3A4 (unknown origin)	CC(C)OC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810042	>	>	IC50	nM	30000.0	IC50	uM	30.0
6565	Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1	J. Med. Chem.	2016.0	CHEMBL3109945	<	<	IC50	nM	1000.0	IC50	uM	1.0
6566	Inhibition of CYP3A4 (unknown origin)	Cc1sc2ncnc(N3CCC(C(=O)Nc4ccc(S(N)(=O)=O)cc4)CC3)c2c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL1357034	>	>	IC50	nM	20000.0	IC50	uM	20.0
6567	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	J. Med. Chem.	2016.0	CHEMBL3814877	=	=	IC50	nM	210.0	IC50	uM	0.21
6568	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1ccccc1	J. Med. Chem.	2016.0	CHEMBL3814479	=	=	IC50	nM	520.0	IC50	uM	0.52
6569	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)CC1CCCCC1	J. Med. Chem.	2016.0	CHEMBL3814345	=	=	IC50	nM	30000.0	IC50	uM	30.0
6570	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814729	=	=	IC50	nM	1000000.0	IC50	uM	1000.0
6571	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814075	=	=	IC50	nM	75000.0	IC50	uM	75.0
6572	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	NCCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL1256004	=	=	IC50	nM	5000000.0	IC50	uM	5000.0
6573	Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	c1ccncc1	J. Med. Chem.	2016.0	CHEMBL266158	=	=	IC50	nM	4000000.0	IC50	uM	4000.0
6574	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	J. Med. Chem.	2016.0	CHEMBL3814877	=	=	Kd	nM	500.0	Kd	uM	0.5
6575	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1ccccc1	J. Med. Chem.	2016.0	CHEMBL3814479	=	=	Kd	nM	900.0	Kd	uM	0.9
6576	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)CC1CCCCC1	J. Med. Chem.	2016.0	CHEMBL3814345	=	=	Kd	nM	10000.0	Kd	uM	10.0
6577	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814729	=	=	Kd	nM	10000.0	Kd	uM	10.0
6578	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814075	=	=	Kd	nM	105000.0	Kd	uM	105.0
6579	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	NCCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL1256004	=	=	Kd	nM	2500000.0	Kd	uM	2500.0
6580	Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	c1ccncc1	J. Med. Chem.	2016.0	CHEMBL266158	=	=	Kd	nM	4500000.0	Kd	uM	4500.0
6581	Inhibition of recombinant CYP3A4 (unknown origin)	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	J. Med. Chem.	2016.0	CHEMBL3814206	=	=	IC50	nM	29430.0	IC50	nM	29430.0
6582	Inhibition of CYP3A4 in human liver microsomes	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	J. Med. Chem.	2016.0	CHEMBL3814206	=	=	IC50	nM	6600.0	IC50	nM	6600.0
6583	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819185	>	>	IC50	nM	20000.0	IC50	uM	20.0
6584	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccccc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3819606	>	>	IC50	nM	20000.0	IC50	uM	20.0
6585	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818643	=	=	IC50	nM	15500.0	IC50	uM	15.5
6586	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818560	>	>	IC50	nM	20000.0	IC50	uM	20.0
6587	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	COc1ccc(C2(OCC(F)(F)F)Sc3ccccc3-n3c2noc3=O)cc1	J. Med. Chem.	2016.0	CHEMBL3819349	>	>	IC50	nM	20000.0	IC50	uM	20.0
6588	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	4.0	IC50	uM	0.004
6589	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL211204	>	>	IC50	nM	20000.0	IC50	uM	20.0
6590	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3408523	>	>	IC50	nM	20000.0	IC50	uM	20.0
6591	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3408526	>	>	IC50	nM	20000.0	IC50	uM	20.0
6592	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1	J. Med. Chem.	2016.0	CHEMBL3408529	>	>	IC50	nM	20000.0	IC50	uM	20.0
6593	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819185	=	=	IC50	nM	19100.0	IC50	uM	19.1
6594	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccccc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3819606	>	>	IC50	nM	20000.0	IC50	uM	20.0
6595	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818643	=	=	IC50	nM	19400.0	IC50	uM	19.4
6596	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccccc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819226	>	>	IC50	nM	20000.0	IC50	uM	20.0
6597	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818560	>	>	IC50	nM	20000.0	IC50	uM	20.0
6598	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	COc1ccc(C2(OCC(F)(F)F)Sc3ccccc3-n3c2noc3=O)cc1	J. Med. Chem.	2016.0	CHEMBL3819349	>	>	IC50	nM	20000.0	IC50	uM	20.0
6599	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	1.0	IC50	uM	0.001
6600	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL211204	=	=	IC50	nM	19200.0	IC50	uM	19.2
6601	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3408523	>	>	IC50	nM	20000.0	IC50	uM	20.0
6602	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3408526	>	>	IC50	nM	20000.0	IC50	uM	20.0
6603	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1	J. Med. Chem.	2016.0	CHEMBL3408529	>	>	IC50	nM	20000.0	IC50	uM	20.0
6604	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(NC4CCCC4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819637	=	=	IC50	nM	19000.0	IC50	uM	19.0
6605	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819210	=	=	IC50	nM	800.0	IC50	uM	0.8
6606	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4cccc(F)c4F)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3818646	>	>	IC50	nM	20000.0	IC50	uM	20.0
6607	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819019	=	=	IC50	nM	470.0	IC50	uM	0.47
6608	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4ccccc4F)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819328	=	=	IC50	nM	9300.0	IC50	uM	9.3
6609	Inhibition of CYP3A4 (unknown origin)	CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3819521	<	>	IC50	nM	10000.0	pIC50		5.0
6610	Inhibition of CYP3A4 (unknown origin)	CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3819512	<	>	IC50	nM	10000.0	pIC50		5.0
6611	Inhibition of CYP3A4 (unknown origin)	CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3818331	<	>	IC50	nM	10000.0	pIC50		5.0
6612	Inhibition of CYP3A4 (unknown origin)	CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3818179	<	>	IC50	nM	10000.0	pIC50		5.0
6613	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis	Cc1sc2ccccc2c1[C@@H]1C=CN=CN1	MedChemComm	2016.0	CHEMBL3823832	=	=	IC50	nM	11000.0	IC50	uM	11.0
6614	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis	Cc1cc(C2C=CN=CN2)c(C)s1.Cl	MedChemComm	2016.0	CHEMBL3823354	=	=	IC50	nM	19800.0	IC50	uM	19.8
6615	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH using midazolam as substrate measured within 2.5 mins by LC-MS/MS analysis	COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN(C)C	J. Med. Chem.	2016.0	CHEMBL3823478	>	>	IC50	nM	50000.0	IC50	uM	50.0
6616	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH using midazolam as substrate measured within 2.5 mins by LC-MS/MS analysis	COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C	J. Med. Chem.	2016.0	CHEMBL3823101	>	>	IC50	nM	50000.0	IC50	uM	50.0
6617	Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	COc1cccc(-c2nc(OC)c3ccccc3n2)c1	J. Med. Chem.	2016.0	CHEMBL3822473	=	=	IC50	nM	12860.0	IC50	uM	12.86
6618	Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	COc1cccc(-c2nc(SC)c3ccccc3n2)c1	J. Med. Chem.	2016.0	CHEMBL3822867	=	=	IC50	nM	22940.0	IC50	uM	22.94
6619	Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	240.0	IC50	uM	0.24
6620	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823297	<	<	IC50	nM	1000.0	IC50	uM	1.0
6621	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824296	=	=	IC50	nM	4800.0	IC50	uM	4.8
6622	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3823914	>	>	IC50	nM	10000.0	IC50	uM	10.0
6623	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(CCO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824323	>	>	IC50	nM	10000.0	IC50	uM	10.0
6624	Inhibition of CYP3A4 (unknown origin)	CNC(=O)CN1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3823962	>	>	IC50	nM	10000.0	IC50	uM	10.0
6625	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(CC(=O)N(C)C)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823095	>	>	IC50	nM	10000.0	IC50	uM	10.0
6626	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)CO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822587	>	>	IC50	nM	10000.0	IC50	uM	10.0
6627	Inhibition of CYP3A4 (unknown origin)	COCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3822651	>	>	IC50	nM	10000.0	IC50	uM	10.0
6628	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822947	>	>	IC50	nM	10000.0	IC50	uM	10.0
6629	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823030	=	=	IC50	nM	21000.0	IC50	uM	21.0
6630	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)CN)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823154	=	=	IC50	nM	500.0	IC50	uM	0.5
6631	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824103	=	=	IC50	nM	300.0	IC50	uM	0.3
6632	Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822644	=	=	IC50	nM	1000.0	IC50	uM	1.0
6633	Inhibition of CYP3A4 (unknown origin)	CNCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3822976	=	=	IC50	nM	3800.0	IC50	uM	3.8
6634	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nc2ccccc2nc1SCC(=O)NC(=O)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828067	>	>	IC50	nM	33000.0	IC50	uM	33.0
6635	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccccc1NC(=O)NC(=O)CSc1nc2ccccc2nc1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828353	>	>	IC50	nM	33000.0	IC50	uM	33.0
6636	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc(NC(=O)NC(=O)CSc2nc3ccccc3nc2C)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828283	>	>	IC50	nM	33000.0	IC50	uM	33.0
6637	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc(C)c(NC(=O)NC(=O)CSc2nc3ccccc3nc2C)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3827067	>	>	IC50	nM	33000.0	IC50	uM	33.0
6638	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nc2ccccc2nc1SCC(=O)NC(=O)Nc1cccc(F)c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828651	>	>	IC50	nM	33000.0	IC50	uM	33.0
6639	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(CSc1nc2ccccc2nc1C(F)(F)F)NC(=O)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828537	>	>	IC50	nM	33000.0	IC50	uM	33.0
6640	Inhibition of CYP3A4 (unknown origin)	COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F	ACS Med. Chem. Lett.	2016.0	CHEMBL3828718	>	>	IC50	nM	40000.0	IC50	uM	40.0
6641	Inhibition of CYP3A4 in human TC5 cells	COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F	ACS Med. Chem. Lett.	2016.0	CHEMBL3828718	>	>	IC50	nM	150000.0	IC50	uM	150.0
6642	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ccc(F)cn2)ccc1Oc1ccc(CO)c(Cl)c1	MedChemComm	2016.0	CHEMBL3688197	>	>	IC50	nM	30000.0	IC50	uM	30.0
6643	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(Oc2ccc(S(=O)(=O)Nc3ccc(F)cn3)cc2C#N)cc1Cl	MedChemComm	2016.0	CHEMBL3683287	=	=	IC50	nM	17500.0	IC50	uM	17.5
6644	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(C(F)(F)F)nc1)c1ccccc1C(F)(F)F	MedChemComm	2016.0	CHEMBL3924161	>	>	IC50	nM	30000.0	IC50	uM	30.0
6645	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cncc(C(F)(F)F)c1)c1ccccc1C(F)(F)F	MedChemComm	2016.0	CHEMBL3929544	=	=	IC50	nM	620.0	IC50	uM	0.62
6646	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3935692	=	=	IC50	nM	300.0	IC50	uM	0.3
6647	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3913607	>	>	IC50	nM	17000.0	IC50	uM	17.0
6648	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccccc3)C2)n1C	J Med Chem	2016.0	CHEMBL3983937	>	>	IC50	nM	50000.0	IC50	uM	50.0
6649	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3963783	=	=	IC50	nM	3400.0	IC50	uM	3.4
6650	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C	J Med Chem	2016.0	CHEMBL3901587	>	>	IC50	nM	17000.0	IC50	uM	17.0
6651	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	J Med Chem	2016.0	CHEMBL3899125	>	>	IC50	nM	5000.0	IC50	uM	5.0
6652	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(C(N)=O)c1	J Med Chem	2016.0	CHEMBL3970323	>	>	IC50	nM	3000.0	IC50	uM	3.0
6653	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(CC(N)=O)cc1	J Med Chem	2016.0	CHEMBL3981856	>	>	IC50	nM	7000.0	IC50	uM	7.0
6654	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	J Med Chem	2016.0	CHEMBL3941818	>	>	IC50	nM	3000.0	IC50	uM	3.0
6655	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)nnc1-c1cccnc1	J Med Chem	2016.0	CHEMBL3949662	>	>	IC50	nM	7000.0	IC50	uM	7.0
6656	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	CC(=O)NC1CCC(c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)CC1	J Med Chem	2016.0	CHEMBL3912801	>	>	IC50	nM	6000.0	IC50	uM	6.0
6657	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCOCC1	J Med Chem	2016.0	CHEMBL3948167	>	>	IC50	nM	10000.0	IC50	uM	10.0
6658	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3968272	>	>	IC50	nM	2000.0	IC50	uM	2.0
6659	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1C(F)(F)F	J Med Chem	2016.0	CHEMBL3946313	>	>	IC50	nM	6000.0	IC50	uM	6.0
6660	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)nc1	J Med Chem	2016.0	CHEMBL3950254	>	>	IC50	nM	17000.0	IC50	uM	17.0
6661	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1nc(C(N)=O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3941520	>	>	IC50	nM	10000.0	IC50	uM	10.0
6662	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1nc(C(=O)O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3964649	>	>	IC50	nM	38000.0	IC50	uM	38.0
6663	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CCC(=O)N=C1	J Med Chem	2016.0	CHEMBL3964512	>	>	IC50	nM	5000.0	IC50	uM	5.0
6664	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(=O)n(C)c1	J Med Chem	2016.0	CHEMBL3922838	>	>	IC50	nM	9000.0	IC50	uM	9.0
6665	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccn(C)c(=O)c1	J Med Chem	2016.0	CHEMBL3894853	>	>	IC50	nM	17000.0	IC50	uM	17.0
6666	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCNC(=O)C1	J Med Chem	2016.0	CHEMBL3913849	>	>	IC50	nM	21000.0	IC50	uM	21.0
6667	Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1	J Med Chem	2016.0	CHEMBL3963243	>	>	IC50	nM	17000.0	IC50	uM	17.0
6668	Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1	J Med Chem	2016.0	CHEMBL3963243	>	>	IC50	nM	17000.0	IC50	uM	17.0
6669	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL3892579	=	=	IC50	nM	18000.0	IC50	uM	18.0
6670	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL3892579	=	=	IC50	nM	1800.0	IC50	uM	1.8
6671	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3814206	=	=	IC50	nM	29450.0	IC50	nM	29450.0
6672	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3978980	=	=	IC50	nM	7700.0	IC50	nM	7700.0
6673	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3932169	=	=	IC50	nM	3050.0	IC50	nM	3050.0
6674	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3959681	>	>	IC50	nM	30000.0	IC50	nM	30000.0
6675	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3933543	=	=	IC50	nM	12800.0	IC50	nM	12800.0
6676	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1	Bioorg Med Chem Lett	2016.0	CHEMBL3960195	>	>	IC50	nM	30000.0	IC50	nM	30000.0
6677	Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3985591	=	=	IC50	nM	21100.0	IC50	nM	21100.0
6678	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3914727	=	=	IC50	nM	12920.0	IC50	nM	12920.0
6679	Inhibition of CYP3A4 (unknown origin)	COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3972392	=	=	IC50	nM	15400.0	IC50	nM	15400.0
6680	Inhibition of CYP3A4 (unknown origin)	COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F	Bioorg Med Chem Lett	2016.0	CHEMBL3905741	=	=	IC50	nM	2500.0	IC50	nM	2500.0
6681	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3976470	>	>	IC50	nM	30000.0	IC50	nM	30000.0
6682	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL3913348	>	>	IC50	nM	30000.0	IC50	nM	30000.0
6683	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL3940521	>	>	IC50	nM	30000.0	IC50	nM	30000.0
6684	Inhibition of CYP3A4 in human liver microsomes after 5 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	ACS Med Chem Lett	2016.0	CHEMBL3984425	>	>	IC50	nM	20000.0	IC50	uM	20.0
6685	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(C)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3975000	=	=	IC50	nM	4800.0	IC50	uM	4.8
6686	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(OC)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3933716	=	=	IC50	nM	10000.0	IC50	uM	10.0
6687	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3891198	=	=	IC50	nM	18000.0	IC50	uM	18.0
6688	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(N3CCOCC3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3913765	=	=	IC50	nM	11000.0	IC50	uM	11.0
6689	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941754	=	=	IC50	nM	7400.0	IC50	uM	7.4
6690	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(OC(F)(F)F)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3904766	>	>	IC50	nM	30000.0	IC50	uM	30.0
6691	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3932777	>	>	IC50	nM	30000.0	IC50	uM	30.0
6692	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3895821	=	=	IC50	nM	18000.0	IC50	uM	18.0
6693	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3923823	=	=	IC50	nM	7900.0	IC50	uM	7.9
6694	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3984607	=	=	IC50	nM	5800.0	IC50	uM	5.8
6695	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3914795	=	=	IC50	nM	9300.0	IC50	uM	9.3
6696	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3949480	=	=	IC50	nM	8400.0	IC50	uM	8.4
6697	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3939202	=	=	IC50	nM	5400.0	IC50	uM	5.4
6698	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3957699	=	=	IC50	nM	9900.0	IC50	uM	9.9
6699	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3930206	=	=	IC50	nM	16000.0	IC50	uM	16.0
6700	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976743	=	=	IC50	nM	8700.0	IC50	uM	8.7
6701	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905160	=	=	IC50	nM	8300.0	IC50	uM	8.3
6702	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3948762	=	=	IC50	nM	29000.0	IC50	uM	29.0
6703	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905463	=	=	IC50	nM	15000.0	IC50	uM	15.0
6704	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3973340	=	=	IC50	nM	30000.0	IC50	uM	30.0
6705	Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976702	=	=	IC50	nM	4300.0	IC50	uM	4.3
6706	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976702	<	<	IC50	nM	1000.0	IC50	uM	1.0
6707	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(C)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3975000	<	<	IC50	nM	1000.0	IC50	uM	1.0
6708	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(OC)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3933716	<	<	IC50	nM	1000.0	IC50	uM	1.0
6709	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3891198	=	=	IC50	nM	11000.0	IC50	uM	11.0
6710	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(N3CCOCC3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3913765	=	=	IC50	nM	11000.0	IC50	uM	11.0
6711	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941754	<	<	IC50	nM	1000.0	IC50	uM	1.0
6712	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(OC(F)(F)F)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3904766	=	=	IC50	nM	4000.0	IC50	uM	4.0
6713	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3932777	>	>	IC50	nM	30000.0	IC50	uM	30.0
6714	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3895821	>	>	IC50	nM	30000.0	IC50	uM	30.0
6715	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3923823	=	=	IC50	nM	8000.0	IC50	uM	8.0
6716	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3984607	=	=	IC50	nM	15000.0	IC50	uM	15.0
6717	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3914795	=	=	IC50	nM	41000.0	IC50	uM	41.0
6718	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3949480	>	>	IC50	nM	30000.0	IC50	uM	30.0
6719	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3939202	=	=	IC50	nM	13000.0	IC50	uM	13.0
6720	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3957699	>	>	IC50	nM	30000.0	IC50	uM	30.0
6721	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3930206	>	>	IC50	nM	30000.0	IC50	uM	30.0
6722	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976743	=	=	IC50	nM	11000.0	IC50	uM	11.0
6723	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905160	=	=	IC50	nM	27000.0	IC50	uM	27.0
6724	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3977242	=	=	IC50	nM	16000.0	IC50	uM	16.0
6725	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3948762	=	=	IC50	nM	14000.0	IC50	uM	14.0
6726	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905463	=	=	IC50	nM	9800.0	IC50	uM	9.8
6727	Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3973340	=	=	IC50	nM	23000.0	IC50	uM	23.0
6728	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2	J Med Chem	2016.0	CHEMBL2064666	>	>	IC50	nM	10000.0	IC50	uM	10.0
6729	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@H](N1CCN(C)CC1)C2	J Med Chem	2016.0	CHEMBL3936443	>	>	IC50	nM	10000.0	IC50	uM	10.0
6730	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@@H](N1CCN(C)CC1)C2	J Med Chem	2016.0	CHEMBL3980825	>	>	IC50	nM	10000.0	IC50	uM	10.0
6731	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@@H](N2CCN(CCO)CC2)C3)ncc1Cl	J Med Chem	2016.0	CHEMBL3972653	>	>	IC50	nM	5600.0	IC50	uM	5.6
6732	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl	J Med Chem	2016.0	CHEMBL3951811	>	>	IC50	nM	5600.0	IC50	uM	5.6
6733	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by HPLC analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	=	=	IC50	nM	2000.0	IC50	uM	2.0
6734	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	=	=	IC50	nM	2200.0	IC50	uM	2.2
6735	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	9.1	IC50	nM	9.1
6736	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	>	>	IC50	nM	10000.0	IC50	uM	10.0
6737	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	7.4	IC50	nM	7.4
6738	Inhibition of CYP3A4 (unknown origin)	Fc1ccc(N2CCN(Cc3ccn4c(CC5CC5)nnc4c3C(F)(F)F)CC2)c(F)c1	J Med Chem	2016.0	CHEMBL3926416	>	>	IC50	nM	20000.0	IC50	uM	20.0
6739	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O	J Med Chem	2016.0	CHEMBL3900554	=	=	IC50	nM	8500.0	IC50	uM	8.5
6740	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N1CCCC[C@@H](n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cccc(C)c32)C1	J Med Chem	2016.0	CHEMBL3972316	=	=	IC50	nM	3500.0	IC50	uM	3.5
6741	Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12	J Med Chem	2016.0	CHEMBL3951434	=	=	IC50	nM	22200.0	IC50	uM	22.2
6742	Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(NC(=O)c3ccnc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12	J Med Chem	2016.0	CHEMBL3939913	>	>	IC50	nM	25000.0	IC50	uM	25.0
6743	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)Nc2nc3cccc(C)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1	J Med Chem	2016.0	CHEMBL3960167	>	>	IC50	nM	25000.0	IC50	uM	25.0
6744	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1	J Med Chem	2016.0	CHEMBL3787344	>	>	IC50	nM	25000.0	IC50	uM	25.0
6745	Inhibition of human CYP3A4	CC(C)c1cc(CNC(=O)c2ccc(Cl)c(OC3CCN(C)CC3)c2)on1	Bioorg Med Chem Lett	2016.0	CHEMBL3933906	>	>	IC50	nM	30000.0	IC50	uM	30.0
6746	Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3304438	>	>	IC50	nM	30000.0	IC50	uM	30.0
6747	Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH	Cc1nnc(C)n1-c1ccc(O[C@H]2c3cc(Cl)cc(Cl)c3C[C@@H]2N2CC[C@@H](O)C2)c(F)c1	J Med Chem	2016.0	CHEMBL3949677	>	>	IC50	nM	50000.0	IC50	uM	50.0
6748	Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	28.5	IC50	uM	0.0285
6749	Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL1738980	>	>	IC50	nM	50000.0	IC50	uM	50.0
6750	Inhibition of CYP3A4 (unknown origin)	CC(C)c1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL3947458	>	>	IC50	nM	50000.0	IC50	uM	50.0
6751	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1c(N2CCCCC2)nc2ccc(Cl)cc2c1-c1ccccc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941588	>	>	IC50	nM	50000.0	IC50	uM	50.0
6752	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1c(N2CCCCC2)nc2c(Cl)cc(Cl)cc2c1-c1ccccc1	Bioorg Med Chem Lett	2016.0	CHEMBL3971182	>	>	IC50	nM	50000.0	IC50	uM	50.0
6753	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc2c(-c3ccccc3)c(C(=O)O)c(N3CCCCC3)nc12	Bioorg Med Chem Lett	2016.0	CHEMBL3950316	=	=	IC50	nM	16000.0	IC50	uM	16.0
6754	Inhibition of CYP3A4 (unknown origin)	CC(C)c1cccc(-c2c(C(=O)O)c(N(C)C)nc3ccc(Cl)cc23)c1	Bioorg Med Chem Lett	2016.0	CHEMBL3979347	>	>	IC50	nM	50000.0	IC50	uM	50.0
6755	Inhibition of CYP3A4 (unknown origin)	Clc1ccc2nc(N3CCCCC3)c(-c3nnn[nH]3)c(-c3ccccc3)c2c1	Bioorg Med Chem Lett	2016.0	CHEMBL3959018	>	>	IC50	nM	50000.0	IC50	uM	50.0
6756	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1	Bioorg Med Chem Lett	2016.0	CHEMBL3889982	>	>	IC50	nM	50000.0	IC50	uM	50.0
6757	Inhibition of CYP3A4 (unknown origin)	S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1	Bioorg Med Chem Lett	2016.0	CHEMBL3970105	=	=	IC50	nM	15000.0	IC50	uM	15.0
6758	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as suppression of 6beta-hydroxytestosterone formation after 30 mins by LC-MS/MS analysis	CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC(=O)[C@H](CC1CCCCC1)NS(=O)(=O)N[C@@H](CCCCN)C(=O)O)C2.Cl	J Med Chem	2016.0	CHEMBL3982647	>	>	IC50	nM	30000.0	IC50	uM	30.0
6759	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as suppression of 1'-hydroxymidazolam formation after 10 mins by LC-MS/MS analysis	CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC(=O)[C@H](CC1CCCCC1)NS(=O)(=O)N[C@@H](CCCCN)C(=O)O)C2.Cl	J Med Chem	2016.0	CHEMBL3982647	=	=	IC50	nM	12000.0	IC50	uM	12.0
6760	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3940415	=	=	IC50	nM	21800.0	IC50	uM	21.8
6761	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2nnc(N)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3929336	=	=	IC50	nM	9900.0	IC50	uM	9.9
6762	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3968866	=	=	IC50	nM	50000.0	IC50	uM	50.0
6763	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2cc[nH]n2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3939323	=	=	IC50	nM	2400.0	IC50	uM	2.4
6764	Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CN1CCC(C)(C2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CC1	J Med Chem	2016.0	CHEMBL3897162	>	>	IC50	nM	50000.0	IC50	uM	50.0
6765	Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CCS(=O)(=O)CC1	J Med Chem	2016.0	CHEMBL3922315	>	>	IC50	nM	50000.0	IC50	uM	50.0
6766	Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(F)c3)C2)CCS(=O)(=O)CC1	J Med Chem	2016.0	CHEMBL3957888	>	>	IC50	nM	50000.0	IC50	uM	50.0
6767	Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1(C2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CCNCC1.Cl	J Med Chem	2016.0	CHEMBL3899527	>	>	IC50	nM	50000.0	IC50	uM	50.0
6768	Inhibition of CYP3A4 (unknown origin)	COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C3CC3)N(C(=O)[C@@H](NC(=O)O[C@@H]3C[C@@H]4C[C@@H]4C3)C(C)(C)C)C2)c2cc(Cl)ccc12	J Med Chem	2016.0	CHEMBL3941014	=	=	EC50	nM	2000.0	EC50	uM	2.0
6769	Inhibition of CYP3A4 (unknown origin)	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O	J Med Chem	2016.0	CHEMBL3976121	>	>	IC50	nM	30000.0	IC50	uM	30.0
6770	Inhibition of CYP3A4 (unknown origin)	COC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O	J Med Chem	2016.0	CHEMBL3970041	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
6771	Inhibition of CYP3A4 (unknown origin)	C[C@H]1c2ccncc2N(Cc2ccccc2)C[C@@H](C)N1C(=O)NCc1ccccc1	J Med Chem	2016.0	CHEMBL3895005	=	=	IC50	nM	23.0	IC50	nM	23.0
6772	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc(-c3cn(CC(=O)Nc4cccc(Cl)c4Cl)nn3)cc2F)cn1	ACS Med Chem Lett	2016.0	CHEMBL3903475	>	>	IC50	nM	50000.0	IC50	uM	50.0
6773	Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cc1	ACS Med Chem Lett	2016.0	CHEMBL3905835	=	=	IC50	nM	15000.0	IC50	uM	15.0
6774	Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cn1	ACS Med Chem Lett	2016.0	CHEMBL3965469	=	=	IC50	nM	43000.0	IC50	uM	43.0
6775	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1	J Med Chem	2016.0	CHEMBL2420629	>	>	IC50	nM	10000.0	IC50	uM	10.0
6776	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1	J Med Chem	2016.0	CHEMBL2391568	>	>	IC50	nM	10000.0	IC50	uM	10.0
6777	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1	J Med Chem	2016.0	CHEMBL3260358	=	=	IC50	nM	7900.0	IC50	uM	7.9
6778	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J Med Chem	2016.0	CHEMBL3127521	=	=	IC50	nM	90.0	IC50	uM	0.09
6779	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	J Med Chem	2016.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
6780	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	J Med Chem	2016.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
6781	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	N#CN/C(=N\CCCCCCOc1ccc(Cl)cc1)Nc1ccncc1	J Med Chem	2016.0	CHEMBL17289	=	=	IC50	nM	220.0	IC50	uM	0.22
6782	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1	J Med Chem	2016.0	CHEMBL566757	=	=	IC50	nM	1500.0	IC50	uM	1.5
6783	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1	J Med Chem	2016.0	CHEMBL2420629	>	>	IC50	nM	10000.0	IC50	uM	10.0
6784	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1	J Med Chem	2016.0	CHEMBL2391568	>	>	IC50	nM	10000.0	IC50	uM	10.0
6785	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1	J Med Chem	2016.0	CHEMBL3260358	=	=	IC50	nM	9000.0	IC50	uM	9.0
6786	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J Med Chem	2016.0	CHEMBL3127521	=	=	IC50	nM	680.0	IC50	uM	0.68
6787	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	J Med Chem	2016.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
6788	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	J Med Chem	2016.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
6789	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	N#CN/C(=N\CCCCCCOc1ccc(Cl)cc1)Nc1ccncc1	J Med Chem	2016.0	CHEMBL17289	=	=	IC50	nM	320.0	IC50	uM	0.32
6790	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1	J Med Chem	2016.0	CHEMBL566757	=	=	IC50	nM	540.0	IC50	uM	0.54
6791	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CC1(OC(=O)N2CCC3(CC2)C[C@@H]3CNC(=O)N2Cc3ccncc3C2)COC1	J Med Chem	2016.0	CHEMBL3916438	>	>	IC50	nM	10000.0	IC50	uM	10.0
6792	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC1(OC(=O)N2CCC3(CC2)C[C@@H]3CNC(=O)N2Cc3ccncc3C2)COC1	J Med Chem	2016.0	CHEMBL3916438	>	>	IC50	nM	10000.0	IC50	uM	10.0
6793	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3983734	=	=	IC50	nM	158.0	IC50	nM	158.0
6794	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3913908	=	=	IC50	nM	162.0	IC50	nM	162.0
6795	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(C)S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3894912	=	=	IC50	nM	198.0	IC50	nM	198.0
6796	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C1CC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3922888	=	=	IC50	nM	185.0	IC50	nM	185.0
6797	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	COCCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3964421	=	=	IC50	nM	185.0	IC50	nM	185.0
6798	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C1CCOCC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3931836	=	=	IC50	nM	226.0	IC50	nM	226.0
6799	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1)C(F)(F)F	Bioorg Med Chem Lett	2016.0	CHEMBL3938615	=	=	IC50	nM	336.0	IC50	nM	336.0
6800	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C(F)F)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3968178	=	=	IC50	nM	99.0	IC50	nM	99.0
6801	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	N#CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3952032	=	=	IC50	nM	153.0	IC50	nM	153.0
6802	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3980889	=	=	IC50	nM	151.0	IC50	nM	151.0
6803	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(c1cccs1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3960724	=	=	IC50	nM	87.0	IC50	nM	87.0
6804	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	Cn1ccnc1S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3891718	=	=	IC50	nM	145.0	IC50	nM	145.0
6805	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL75	=	=	IC50	nM	136.0	IC50	nM	136.0
6806	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL157101	=	=	IC50	nM	146.0	IC50	nM	146.0
6807	Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL157101	=	=	IC50	nM	133.0	IC50	nM	133.0
6808	Inhibition of CYP3A4 (unknown origin)	O=C(O)CCCOc1ccc(-c2cc(OC(F)(F)F)ccc2Cl)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3968947	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6809	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cc(OC(F)(F)F)ccc2Cl)cc(C)c1OCCCC(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL3909872	=	=	IC50	nM	3280.0	IC50	nM	3280.0
6810	Inhibition of CYP3A4 (unknown origin)	O=C(O)CCc1cc2cc(-c3cc(OC(F)(F)F)ccc3F)ccc2o1	Bioorg Med Chem Lett	2016.0	CHEMBL3896657	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6811	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3966450	=	=	IC50	nM	15100.0	IC50	uM	15.1
6812	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3904067	>	>	IC50	nM	20000.0	IC50	uM	20.0
6813	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3974964	>	>	IC50	nM	20000.0	IC50	uM	20.0
6814	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3892856	>	>	IC50	nM	20000.0	IC50	uM	20.0
6815	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3911925	>	>	IC50	nM	20000.0	IC50	uM	20.0
6816	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3981876	=	=	IC50	nM	2000.0	IC50	uM	2.0
6817	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3902914	=	=	IC50	nM	6100.0	IC50	uM	6.1
6818	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3928270	>	>	IC50	nM	20000.0	IC50	uM	20.0
6819	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CCN1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL3903590	>	>	IC50	nM	20000.0	IC50	uM	20.0
6820	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CNC(C)(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3920870	>	>	IC50	nM	20000.0	IC50	uM	20.0
6821	Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3916230	=	=	IC50	nM	13200.0	IC50	uM	13.2
6822	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3928270	=	=	IC50	nM	9000.0	IC50	uM	9.0
6823	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CCN1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL3903590	>	>	IC50	nM	20000.0	IC50	uM	20.0
6824	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CNC(C)(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3920870	>	>	IC50	nM	20000.0	IC50	uM	20.0
6825	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3916230	=	=	IC50	nM	1000.0	IC50	uM	1.0
6826	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3966450	=	=	IC50	nM	2800.0	IC50	uM	2.8
6827	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3904067	=	=	IC50	nM	8400.0	IC50	uM	8.4
6828	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3974964	=	=	IC50	nM	1400.0	IC50	uM	1.4
6829	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3892856	=	=	IC50	nM	1000.0	IC50	uM	1.0
6830	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3911925	=	=	IC50	nM	1000.0	IC50	uM	1.0
6831	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3981876	=	=	IC50	nM	1000.0	IC50	uM	1.0
6832	Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3902914	=	=	IC50	nM	3700.0	IC50	uM	3.7
6833	Inhibition of CYP3A4 (unknown origin)	Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N	Bioorg Med Chem Lett	2016.0	CHEMBL3933749	>	>	IC50	nM	50000.0	IC50	uM	50.0
6834	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3976597	>	>	IC50	nM	30000.0	IC50	uM	30.0
6835	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3947332	>	>	IC50	nM	30000.0	IC50	uM	30.0
6836	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Eur J Med Chem	2016.0	CHEMBL3940770	>	>	IC50	nM	30000.0	IC50	uM	30.0
6837	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3912780	=	=	IC50	nM	9900.0	IC50	uM	9.9
6838	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3979311	=	=	IC50	nM	30000.0	IC50	uM	30.0
6839	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3909015	>	>	IC50	nM	30000.0	IC50	uM	30.0
6840	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3889928	>	>	IC50	nM	30000.0	IC50	uM	30.0
6841	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3917946	>	>	IC50	nM	30000.0	IC50	uM	30.0
6842	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3898853	=	=	IC50	nM	30000.0	IC50	uM	30.0
6843	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCN(CCO)CC1	Eur J Med Chem	2016.0	CHEMBL3926905	>	>	IC50	nM	30000.0	IC50	uM	30.0
6844	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	C[C@H]1CN(C(C)(C)CO)CCN1C(=O)CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1	Eur J Med Chem	2016.0	CHEMBL3907874	>	>	IC50	nM	30000.0	IC50	uM	30.0
6845	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(CO)CC1	Eur J Med Chem	2016.0	CHEMBL3935840	=	=	IC50	nM	30000.0	IC50	uM	30.0
6846	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3942592	=	=	IC50	nM	21000.0	IC50	uM	21.0
6847	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3972189	=	=	IC50	nM	30000.0	IC50	uM	30.0
6848	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](O)C1	Eur J Med Chem	2016.0	CHEMBL3907872	>	>	IC50	nM	30000.0	IC50	uM	30.0
6849	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](CO)C1	Eur J Med Chem	2016.0	CHEMBL3984859	=	=	IC50	nM	30000.0	IC50	uM	30.0
6850	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3976597	=	=	IC50	nM	1900.0	IC50	uM	1.9
6851	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3947332	=	=	IC50	nM	2000.0	IC50	uM	2.0
6852	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Eur J Med Chem	2016.0	CHEMBL3940770	<	<	IC50	nM	400.0	IC50	uM	0.4
6853	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3912780	<	<	IC50	nM	300.0	IC50	uM	0.3
6854	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3979311	=	=	IC50	nM	4300.0	IC50	uM	4.3
6855	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3909015	=	=	IC50	nM	9000.0	IC50	uM	9.0
6856	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3889928	>	>	IC50	nM	30000.0	IC50	uM	30.0
6857	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3917946	=	=	IC50	nM	1500.0	IC50	uM	1.5
6858	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3898853	=	=	IC50	nM	17000.0	IC50	uM	17.0
6859	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCN(CCO)CC1	Eur J Med Chem	2016.0	CHEMBL3926905	=	=	IC50	nM	6900.0	IC50	uM	6.9
6860	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	C[C@H]1CN(C(C)(C)CO)CCN1C(=O)CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1	Eur J Med Chem	2016.0	CHEMBL3907874	=	=	IC50	nM	2200.0	IC50	uM	2.2
6861	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(CO)CC1	Eur J Med Chem	2016.0	CHEMBL3935840	=	=	IC50	nM	30000.0	IC50	uM	30.0
6862	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3942592	=	=	IC50	nM	8000.0	IC50	uM	8.0
6863	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3972189	=	=	IC50	nM	15000.0	IC50	uM	15.0
6864	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](O)C1	Eur J Med Chem	2016.0	CHEMBL3907872	>	>	IC50	nM	30000.0	IC50	uM	30.0
6865	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](CO)C1	Eur J Med Chem	2016.0	CHEMBL3984859	=	=	IC50	nM	30000.0	IC50	uM	30.0
6866	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(N[C@@H](C)CCCC(C)(C)O)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL1778663	=	=	IC50	nM	9300.0	IC50	uM	9.3
6867	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3966303	=	=	IC50	nM	1400.0	IC50	uM	1.4
6868	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3F)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3903916	=	=	IC50	nM	1600.0	IC50	uM	1.6
6869	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3Cl)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3974799	=	=	IC50	nM	1200.0	IC50	uM	1.2
6870	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3912923	<	<	IC50	nM	400.0	IC50	uM	0.4
6871	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccn3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3922893	=	=	IC50	nM	7200.0	IC50	uM	7.2
6872	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccncc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3921905	<	<	IC50	nM	400.0	IC50	uM	0.4
6873	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1	Bioorg Med Chem Lett	2016.0	CHEMBL3893914	=	=	IC50	nM	4500.0	IC50	uM	4.5
6874	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3C)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3937431	=	=	IC50	nM	1800.0	IC50	uM	1.8
6875	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)c(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3967136	=	=	IC50	nM	1700.0	IC50	uM	1.7
6876	Inhibition of CYP3A4 (unknown origin)	CCc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1	Bioorg Med Chem Lett	2016.0	CHEMBL3928420	=	=	IC50	nM	1600.0	IC50	uM	1.6
6877	Inhibition of hepatic CYP3A4 (unknown origin)	C[C@](O)(c1cncc(-c2nc3ccc(F)cn3c2C2CC2)c1)C(F)(F)F	Bioorg Med Chem Lett	2017.0	CHEMBL3923127	>	>	IC50	nM	25000.0	IC50	uM	25.0
6878	Inhibition of hepatic CYP3A4 (unknown origin)	Fc1cncc(-c2nc3ccc(F)cn3c2C2CC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL3893614	>	>	IC50	nM	50000.0	IC50	nM	50000.0
6879	Inhibition of hepatic CYP3A4 (unknown origin)	Fc1ccc2nc(-c3cncc4ccccc34)c(C3CC3)n2c1	Bioorg Med Chem Lett	2017.0	CHEMBL3948337	=	=	IC50	nM	3500.0	IC50	nM	3500.0
6880	Inhibition of hepatic CYP3A4 (unknown origin)	Fc1cncc(-c2nc3cc(F)c(Cl)cn3c2C2CC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL3951973	>	>	IC50	nM	25000.0	IC50	uM	25.0
6881	Inhibition of hepatic CYP3A4 (unknown origin)	Cc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1	Bioorg Med Chem Lett	2017.0	CHEMBL3924257	=	=	IC50	nM	11000.0	IC50	nM	11000.0
6882	Inhibition of hepatic CYP3A4 (unknown origin)	CCc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1	Bioorg Med Chem Lett	2017.0	CHEMBL3919759	=	=	IC50	nM	2800.0	IC50	nM	2800.0
6883	Inhibition of human CYP3A4	CO[C@H]1C[C@H](Oc2cc(F)c(F)c(-c3ccc4c(c3)CC[C@H](CCC(=O)O)O4)n2)C1	ACS Med Chem Lett	2017.0	CHEMBL3980898	>	>	IC50	nM	50000.0	IC50	uM	50.0
6884	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3963788	>	>	IC50	nM	30000.0	IC50	uM	30.0
6885	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3915634	>	>	IC50	nM	30000.0	IC50	uM	30.0
6886	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(F)(F)(F)(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3942511	>	>	IC50	nM	30000.0	IC50	uM	30.0
6887	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method	CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2F)cc1	Bioorg Med Chem	2017.0	CHEMBL3984743	=	=	IC50	nM	155.0	IC50	uM	0.155
6888	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method	CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(-c2ccccc2F)cc1	Bioorg Med Chem	2017.0	CHEMBL3892576	=	=	IC50	nM	227.0	IC50	uM	0.227
6889	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Bioorg Med Chem	2017.0	CHEMBL64391	=	=	IC50	nM	32.6	IC50	nM	32.6
6890	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2017.0	CHEMBL157101	=	=	IC50	nM	31.7	IC50	nM	31.7
6891	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation at 1 to 25 uM by UPLC-MS/MS analysis	C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL3910904	>	>	IC50	nM	25000.0	IC50	uM	25.0
6892	Inhibition of human CYP3A4 using BFC as substrate	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	J Med Chem	2016.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
6893	Inhibition of human CYP3A4 using BZR as substrate	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	J Med Chem	2016.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
6894	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3918722	>	>	IC50	nM	10000.0	IC50	uM	10.0
6895	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3971789	>	>	IC50	nM	10000.0	IC50	uM	10.0
6896	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3903656	>	>	IC50	nM	10000.0	IC50	uM	10.0
6897	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3957835	>	>	IC50	nM	10000.0	IC50	uM	10.0
6898	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3941703	>	>	IC50	nM	10000.0	IC50	uM	10.0
6899	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3939013	>	>	IC50	nM	10000.0	IC50	uM	10.0
6900	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3986998	>	>	IC50	nM	10000.0	IC50	uM	10.0
6901	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3948750	>	>	IC50	nM	10000.0	IC50	uM	10.0
6902	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2ccccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3899101	>	>	IC50	nM	10000.0	IC50	uM	10.0
6903	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3896422	=	=	IC50	nM	5000.0	IC50	uM	5.0
6904	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3981313	=	=	IC50	nM	5000.0	IC50	uM	5.0
6905	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3934437	>	>	IC50	nM	10000.0	IC50	uM	10.0
6906	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3951586	>	>	IC50	nM	10000.0	IC50	uM	10.0
6907	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3949599	=	=	IC50	nM	5000.0	IC50	uM	5.0
6908	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3956565	=	=	IC50	nM	5000.0	IC50	uM	5.0
6909	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3904681	>	>	IC50	nM	10000.0	IC50	uM	10.0
6910	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3968497	>	>	IC50	nM	10000.0	IC50	uM	10.0
6911	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3966021	>	>	IC50	nM	10000.0	IC50	uM	10.0
6912	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3928847	>	>	IC50	nM	10000.0	IC50	uM	10.0
6913	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3926189	>	>	IC50	nM	10000.0	IC50	uM	10.0
6914	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3890797	>	>	IC50	nM	10000.0	IC50	uM	10.0
6915	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3979607	>	>	IC50	nM	10000.0	IC50	uM	10.0
6916	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5ccccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3895266	>	>	IC50	nM	10000.0	IC50	uM	10.0
6917	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cc(F)ccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3904980	>	>	IC50	nM	10000.0	IC50	uM	10.0
6918	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5c(F)cccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3940360	>	>	IC50	nM	10000.0	IC50	uM	10.0
6919	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cccc(F)c5)c4F)c3c2)cn1		2012.0	CHEMBL3942988	>	>	IC50	nM	10000.0	IC50	uM	10.0
6920	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3916725	>	>	IC50	nM	10000.0	IC50	uM	10.0
6921	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3919462	>	>	IC50	nM	10000.0	IC50	uM	10.0
6922	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3954395	=	=	IC50	nM	5000.0	IC50	uM	5.0
6923	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3956999	>	>	IC50	nM	10000.0	IC50	uM	10.0
6924	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3944290	>	>	IC50	nM	10000.0	IC50	uM	10.0
6925	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3931676	>	>	IC50	nM	10000.0	IC50	uM	10.0
6926	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3977421	<	<	IC50	nM	5000.0	IC50	uM	5.0
6927	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3968167	<	<	IC50	nM	5000.0	IC50	uM	5.0
6928	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3967303	=	=	IC50	nM	5000.0	IC50	uM	5.0
6929	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3914107	=	=	IC50	nM	5000.0	IC50	uM	5.0
6930	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3893235	>	>	IC50	nM	10000.0	IC50	uM	10.0
6931	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3890467	=	=	IC50	nM	5000.0	IC50	uM	5.0
6932	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3980636	>	>	IC50	nM	10000.0	IC50	uM	10.0
6933	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NCC)nc4)cc23)c1F		2012.0	CHEMBL3928507	>	>	IC50	nM	10000.0	IC50	uM	10.0
6934	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)nc4)cc23)c1F		2012.0	CHEMBL3912374	>	>	IC50	nM	10000.0	IC50	uM	10.0
6935	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(F)nc4)cc23)c1F		2012.0	CHEMBL3964025	>	>	IC50	nM	10000.0	IC50	uM	10.0
6936	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F		2012.0	CHEMBL3921859	=	=	IC50	nM	5000.0	IC50	uM	5.0
6937	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NS(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3979361	>	>	IC50	nM	10000.0	IC50	uM	10.0
6938	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)cc23)c1F		2012.0	CHEMBL3981784	>	>	IC50	nM	10000.0	IC50	uM	10.0
6939	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F		2012.0	CHEMBL3904645	>	>	IC50	nM	10000.0	IC50	uM	10.0
6940	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F		2012.0	CHEMBL3907402	>	>	IC50	nM	10000.0	IC50	uM	10.0
6941	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cn[nH]c4)cc23)c1F		2012.0	CHEMBL3968460	>	>	IC50	nM	10000.0	IC50	uM	10.0
6942	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(CCN5CCOCC5)c4)cc23)c1F		2012.0	CHEMBL3952336	<	<	IC50	nM	5000.0	IC50	uM	5.0
6943	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN(C)C)nc4)cc23)c1F		2012.0	CHEMBL3954978	>	>	IC50	nM	10000.0	IC50	uM	10.0
6944	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC)nc4)cc23)c1F		2012.0	CHEMBL3971807	>	>	IC50	nM	10000.0	IC50	uM	10.0
6945	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC5CC5)nc4)cc23)c1F		2012.0	CHEMBL3969082	>	>	IC50	nM	10000.0	IC50	uM	10.0
6946	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3981425	>	>	IC50	nM	10000.0	IC50	uM	10.0
6947	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3979042	>	>	IC50	nM	10000.0	IC50	uM	10.0
6948	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N(C)C)cc4)cc23)c1F		2012.0	CHEMBL3935100	>	>	IC50	nM	10000.0	IC50	uM	10.0
6949	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(SC)nc4)cc23)c1F		2012.0	CHEMBL3932389	>	>	IC50	nM	10000.0	IC50	uM	10.0
6950	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3968095	>	>	IC50	nM	10000.0	IC50	uM	10.0
6951	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(SC)nc4)cc23)c1F		2012.0	CHEMBL3985076	>	>	IC50	nM	10000.0	IC50	uM	10.0
6952	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(Cc5ccccc5)c4)cc23)c1F		2012.0	CHEMBL3913674	>	>	IC50	nM	10000.0	IC50	uM	10.0
6953	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccnc(F)c4)cc23)c1F		2012.0	CHEMBL3920821	>	>	IC50	nM	10000.0	IC50	uM	10.0
6954	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F		2012.0	CHEMBL3904333	=	=	IC50	nM	5000.0	IC50	uM	5.0
6955	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3907089	>	>	IC50	nM	10000.0	IC50	uM	10.0
6956	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3942381	<	<	IC50	nM	5000.0	IC50	uM	5.0
6957	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3945059	>	>	IC50	nM	10000.0	IC50	uM	10.0
6958	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3911079	>	>	IC50	nM	10000.0	IC50	uM	10.0
6959	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(C)nc4)cc23)c1F		2012.0	CHEMBL3899027	>	>	IC50	nM	10000.0	IC50	uM	10.0
6960	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C)nc4)cc23)c1F		2012.0	CHEMBL3933168	>	>	IC50	nM	10000.0	IC50	uM	10.0
6961	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)c1F		2012.0	CHEMBL3896589	>	>	IC50	nM	10000.0	IC50	uM	10.0
6962	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)CC)cc4)cc23)c1F		2012.0	CHEMBL3899285	>	>	IC50	nM	10000.0	IC50	uM	10.0
6963	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3928075	=	=	IC50	nM	5000.0	IC50	uM	5.0
6964	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F		2012.0	CHEMBL3949992	>	>	IC50	nM	10000.0	IC50	uM	10.0
6965	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)C(C)C)cc4)cc23)c1F		2012.0	CHEMBL3947313	>	>	IC50	nM	10000.0	IC50	uM	10.0
6966	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)CCC)c4F)c3c2)cn1		2012.0	CHEMBL3897700	>	>	IC50	nM	10000.0	IC50	uM	10.0
6967	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(CCCOC)cc4)cc23)c1F		2012.0	CHEMBL3985717	>	>	IC50	nM	10000.0	IC50	uM	10.0
6968	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cccc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3935744	>	>	IC50	nM	10000.0	IC50	uM	10.0
6969	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3955478	>	>	IC50	nM	10000.0	IC50	uM	10.0
6970	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3919966	>	>	IC50	nM	10000.0	IC50	uM	10.0
6971	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3917210	>	>	IC50	nM	10000.0	IC50	uM	10.0
6972	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3958968	>	>	IC50	nM	10000.0	IC50	uM	10.0
6973	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3941565	>	>	IC50	nM	10000.0	IC50	uM	10.0
6974	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3896039	<	<	IC50	nM	5000.0	IC50	uM	5.0
6975	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F		2012.0	CHEMBL3945707	=	=	IC50	nM	5000.0	IC50	uM	5.0
6976	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1		2012.0	CHEMBL3948349	<	<	IC50	nM	5000.0	IC50	uM	5.0
6977	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4)cc23)c1F		2012.0	CHEMBL3917962	>	>	IC50	nM	10000.0	IC50	uM	10.0
6978	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3923610	>	>	IC50	nM	10000.0	IC50	uM	10.0
6979	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3918722	>	>	IC50	nM	10000.0	IC50	uM	10.0
6980	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3971789	>	>	IC50	nM	10000.0	IC50	uM	10.0
6981	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3903656	>	>	IC50	nM	10000.0	IC50	uM	10.0
6982	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3957835	>	>	IC50	nM	10000.0	IC50	uM	10.0
6983	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3941703	>	>	IC50	nM	10000.0	IC50	uM	10.0
6984	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3939013	>	>	IC50	nM	10000.0	IC50	uM	10.0
6985	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3986998	>	>	IC50	nM	10000.0	IC50	uM	10.0
6986	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3948750	=	=	IC50	nM	5000.0	IC50	uM	5.0
6987	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2ccccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3899101	>	>	IC50	nM	10000.0	IC50	uM	10.0
6988	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3896422	>	>	IC50	nM	10000.0	IC50	uM	10.0
6989	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3981313	>	>	IC50	nM	10000.0	IC50	uM	10.0
6990	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3934437	>	>	IC50	nM	10000.0	IC50	uM	10.0
6991	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3951586	>	>	IC50	nM	10000.0	IC50	uM	10.0
6992	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3949599	=	=	IC50	nM	5000.0	IC50	uM	5.0
6993	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3956565	<	<	IC50	nM	5000.0	IC50	uM	5.0
6994	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3904681	>	>	IC50	nM	10000.0	IC50	uM	10.0
6995	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3968497	>	>	IC50	nM	10000.0	IC50	uM	10.0
6996	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3966021	>	>	IC50	nM	10000.0	IC50	uM	10.0
6997	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3928847	>	>	IC50	nM	10000.0	IC50	uM	10.0
6998	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3926189	>	>	IC50	nM	10000.0	IC50	uM	10.0
6999	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3890797	>	>	IC50	nM	10000.0	IC50	uM	10.0
7000	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3979607	>	>	IC50	nM	10000.0	IC50	uM	10.0
7001	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5ccccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3895266	>	>	IC50	nM	10000.0	IC50	uM	10.0
7002	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cc(F)ccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3904980	>	>	IC50	nM	10000.0	IC50	uM	10.0
7003	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5c(F)cccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3940360	>	>	IC50	nM	10000.0	IC50	uM	10.0
7004	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cccc(F)c5)c4F)c3c2)cn1		2012.0	CHEMBL3942988	>	>	IC50	nM	10000.0	IC50	uM	10.0
7005	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3916725	>	>	IC50	nM	10000.0	IC50	uM	10.0
7006	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3919462	>	>	IC50	nM	10000.0	IC50	uM	10.0
7007	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3954395	>	>	IC50	nM	10000.0	IC50	uM	10.0
7008	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3956999	>	>	IC50	nM	10000.0	IC50	uM	10.0
7009	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3944290	>	>	IC50	nM	10000.0	IC50	uM	10.0
7010	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3931676	>	>	IC50	nM	10000.0	IC50	uM	10.0
7011	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3977421	<	<	IC50	nM	5000.0	IC50	uM	5.0
7012	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3968167	<	<	IC50	nM	5000.0	IC50	uM	5.0
7013	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3967303	<	<	IC50	nM	5000.0	IC50	uM	5.0
7014	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3914107	<	<	IC50	nM	5000.0	IC50	uM	5.0
7015	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3893235	>	>	IC50	nM	10000.0	IC50	uM	10.0
7016	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3890467	=	=	IC50	nM	5000.0	IC50	uM	5.0
7017	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3980636	>	>	IC50	nM	10000.0	IC50	uM	10.0
7018	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NCC)nc4)cc23)c1F		2012.0	CHEMBL3928507	>	>	IC50	nM	10000.0	IC50	uM	10.0
7019	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)nc4)cc23)c1F		2012.0	CHEMBL3912374	>	>	IC50	nM	10000.0	IC50	uM	10.0
7020	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(F)nc4)cc23)c1F		2012.0	CHEMBL3964025	>	>	IC50	nM	10000.0	IC50	uM	10.0
7021	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F		2012.0	CHEMBL3921859	<	<	IC50	nM	5000.0	IC50	uM	5.0
7022	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NS(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3979361	>	>	IC50	nM	10000.0	IC50	uM	10.0
7023	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)cc23)c1F		2012.0	CHEMBL3981784	>	>	IC50	nM	10000.0	IC50	uM	10.0
7024	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F		2012.0	CHEMBL3904645	=	=	IC50	nM	5000.0	IC50	uM	5.0
7025	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F		2012.0	CHEMBL3907402	=	=	IC50	nM	5000.0	IC50	uM	5.0
7026	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cn[nH]c4)cc23)c1F		2012.0	CHEMBL3968460	<	<	IC50	nM	5000.0	IC50	uM	5.0
7027	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(CCN5CCOCC5)c4)cc23)c1F		2012.0	CHEMBL3952336	>	>	IC50	nM	10000.0	IC50	uM	10.0
7028	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN(C)C)nc4)cc23)c1F		2012.0	CHEMBL3954978	<	<	IC50	nM	5000.0	IC50	uM	5.0
7029	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC)nc4)cc23)c1F		2012.0	CHEMBL3971807	>	>	IC50	nM	10000.0	IC50	uM	10.0
7030	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC5CC5)nc4)cc23)c1F		2012.0	CHEMBL3969082	>	>	IC50	nM	10000.0	IC50	uM	10.0
7031	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3981425	>	>	IC50	nM	10000.0	IC50	uM	10.0
7032	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3979042	>	>	IC50	nM	10000.0	IC50	uM	10.0
7033	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N(C)C)cc4)cc23)c1F		2012.0	CHEMBL3935100	>	>	IC50	nM	10000.0	IC50	uM	10.0
7034	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(SC)nc4)cc23)c1F		2012.0	CHEMBL3932389	>	>	IC50	nM	10000.0	IC50	uM	10.0
7035	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3968095	>	>	IC50	nM	10000.0	IC50	uM	10.0
7036	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(SC)nc4)cc23)c1F		2012.0	CHEMBL3985076	<	<	IC50	nM	5000.0	IC50	uM	5.0
7037	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(Cc5ccccc5)c4)cc23)c1F		2012.0	CHEMBL3913674	>	>	IC50	nM	10000.0	IC50	uM	10.0
7038	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccnc(F)c4)cc23)c1F		2012.0	CHEMBL3920821	>	>	IC50	nM	10000.0	IC50	uM	10.0
7039	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F		2012.0	CHEMBL3904333	>	>	IC50	nM	10000.0	IC50	uM	10.0
7040	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3907089	>	>	IC50	nM	10000.0	IC50	uM	10.0
7041	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3942381	>	>	IC50	nM	10000.0	IC50	uM	10.0
7042	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3945059	>	>	IC50	nM	10000.0	IC50	uM	10.0
7043	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3911079	>	>	IC50	nM	10000.0	IC50	uM	10.0
7044	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(C)nc4)cc23)c1F		2012.0	CHEMBL3899027	>	>	IC50	nM	10000.0	IC50	uM	10.0
7045	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C)nc4)cc23)c1F		2012.0	CHEMBL3933168	>	>	IC50	nM	10000.0	IC50	uM	10.0
7046	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)c1F		2012.0	CHEMBL3896589	>	>	IC50	nM	10000.0	IC50	uM	10.0
7047	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)CC)cc4)cc23)c1F		2012.0	CHEMBL3899285	>	>	IC50	nM	10000.0	IC50	uM	10.0
7048	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3928075	>	>	IC50	nM	10000.0	IC50	uM	10.0
7049	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F		2012.0	CHEMBL3949992	=	=	IC50	nM	5000.0	IC50	uM	5.0
7050	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)C(C)C)cc4)cc23)c1F		2012.0	CHEMBL3947313	>	>	IC50	nM	10000.0	IC50	uM	10.0
7051	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)CCC)c4F)c3c2)cn1		2012.0	CHEMBL3897700	>	>	IC50	nM	10000.0	IC50	uM	10.0
7052	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(CCCOC)cc4)cc23)c1F		2012.0	CHEMBL3985717	>	>	IC50	nM	10000.0	IC50	uM	10.0
7053	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cccc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3935744	>	>	IC50	nM	10000.0	IC50	uM	10.0
7054	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3955478	>	>	IC50	nM	10000.0	IC50	uM	10.0
7055	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3919966	>	>	IC50	nM	10000.0	IC50	uM	10.0
7056	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3917210	>	>	IC50	nM	10000.0	IC50	uM	10.0
7057	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3958968	>	>	IC50	nM	10000.0	IC50	uM	10.0
7058	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3941565	>	>	IC50	nM	10000.0	IC50	uM	10.0
7059	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3896039	=	=	IC50	nM	5000.0	IC50	uM	5.0
7060	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F		2012.0	CHEMBL3945707	=	=	IC50	nM	5000.0	IC50	uM	5.0
7061	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1		2012.0	CHEMBL3948349	=	=	IC50	nM	5000.0	IC50	uM	5.0
7062	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4)cc23)c1F		2012.0	CHEMBL3917962	>	>	IC50	nM	10000.0	IC50	uM	10.0
7063	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3923610	>	>	IC50	nM	10000.0	IC50	uM	10.0
7064	Inhibition of CYP3A4 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		2013.0	CHEMBL3544960	>	>	IC50	nM	10000.0	IC50	uM	10.0
7065	Inhibition of CYP3A4 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay	NC[C@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		2013.0	CHEMBL3942454	>	>	IC50	nM	10000.0	IC50	uM	10.0
7066	Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C)nc34)CC2)no1		2016.0	CHEMBL2207501	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7067	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3645534	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7068	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645512	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7069	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1nc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3645513	=	=	IC50	nM	32700.0	IC50	nM	32700.0
7070	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645515	=	=	IC50	nM	15600.0	IC50	nM	15600.0
7071	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O		2013.0	CHEMBL3645516	=	=	IC50	nM	31000.0	IC50	nM	31000.0
7072	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(=O)n(C)nc1-c1ccc([C@H](C)N2CC[C@](CC(C)(C)O)(c3ccccc3)OC2=O)cc1		2013.0	CHEMBL3645517	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7073	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645518	=	=	IC50	nM	5700.0	IC50	nM	5700.0
7074	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645519	=	=	IC50	nM	15700.0	IC50	nM	15700.0
7075	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL1829763	=	=	IC50	nM	7400.0	IC50	nM	7400.0
7076	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL1829768	=	=	IC50	nM	9900.0	IC50	nM	9900.0
7077	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645523	=	=	IC50	nM	4400.0	IC50	nM	4400.0
7078	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL1829759	=	=	IC50	nM	5300.0	IC50	nM	5300.0
7079	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL1829761	=	=	IC50	nM	7000.0	IC50	nM	7000.0
7080	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645524	=	=	IC50	nM	14100.0	IC50	nM	14100.0
7081	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645525	=	=	IC50	nM	4900.0	IC50	nM	4900.0
7082	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645526	=	=	IC50	nM	4400.0	IC50	nM	4400.0
7083	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645527	=	=	IC50	nM	19700.0	IC50	nM	19700.0
7084	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645528	=	=	IC50	nM	3100.0	IC50	nM	3100.0
7085	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664694	=	=	IC50	nM	44000.0	IC50	nM	44000.0
7086	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664695	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7087	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664696	=	=	IC50	nM	29000.0	IC50	nM	29000.0
7088	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3664643	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7089	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664706	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7090	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664707	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7091	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664646	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7092	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3664710	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7093	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664711	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7094	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664712	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7095	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664715	=	=	IC50	nM	48000.0	IC50	nM	48000.0
7096	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3664651	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7097	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664717	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7098	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3664657	=	=	IC50	nM	32000.0	IC50	nM	32000.0
7099	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3639635	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7100	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664659	=	=	IC50	nM	48000.0	IC50	nM	48000.0
7101	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664660	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7102	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664661	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7103	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664662	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7104	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC)(c2ccccc2)OC1=O		2013.0	CHEMBL3664665	=	=	IC50	nM	8000.0	IC50	nM	8000.0
7105	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(C)n1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664718	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7106	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn(C)c1=O		2013.0	CHEMBL3664667	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7107	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664668	=	=	IC50	nM	48000.0	IC50	nM	48000.0
7108	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(=O)n1C		2013.0	CHEMBL3664670	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7109	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664671	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7110	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664672	=	=	IC50	nM	18000.0	IC50	nM	18000.0
7111	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664673	=	=	IC50	nM	28000.0	IC50	nM	28000.0
7112	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(C)n1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664674	=	=	IC50	nM	43000.0	IC50	nM	43000.0
7113	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664675	=	=	IC50	nM	23000.0	IC50	nM	23000.0
7114	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O		2013.0	CHEMBL3664676	=	=	IC50	nM	28000.0	IC50	nM	28000.0
7115	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C#CC(C)(C)C[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1		2013.0	CHEMBL3664719	=	=	IC50	nM	6000.0	IC50	nM	6000.0
7116	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1c(C)cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664677	=	=	IC50	nM	41000.0	IC50	nM	41000.0
7117	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664679	=	=	IC50	nM	23000.0	IC50	nM	23000.0
7118	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664680	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7119	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)n(C)c3)cc2)C(=O)O1		2013.0	CHEMBL3664681	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7120	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1		2013.0	CHEMBL3664682	=	=	IC50	nM	47000.0	IC50	nM	47000.0
7121	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2cc(=O)n(C)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664683	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7122	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CC(C)(C)O)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664684	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7123	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COCC(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664685	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7124	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(CO)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664686	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7125	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC(C)(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664687	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7126	Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664689	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7127	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	58720.0	IC50	nM	58720.0
7128	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	15330.0	IC50	nM	15330.0
7129	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL178090	=	=	IC50	nM	47170.0	IC50	nM	47170.0
7130	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC#Cc1cccnc1		2013.0	CHEMBL360541	=	=	IC50	nM	365000.0	IC50	nM	365000.0
7131	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC#Cc1cccnc1		2013.0	CHEMBL360541	=	=	IC50	nM	128000.0	IC50	nM	128000.0
7132	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccsc1-c1cccnc1		2013.0	CHEMBL179669	=	=	IC50	nM	5990.0	IC50	nM	5990.0
7133	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cn1cnc(-c2cccnc2)c1		2013.0	CHEMBL360999	=	=	IC50	nM	261900.0	IC50	nM	261900.0
7134	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-n2ccnc2)c1		2013.0	CHEMBL179477	=	=	IC50	nM	109000.0	IC50	nM	109000.0
7135	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccsc1-c1ccc(F)nc1		2013.0	CHEMBL179621	=	=	IC50	nM	39080.0	IC50	nM	39080.0
7136	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-c2ccsc2)c1		2013.0	CHEMBL361153	=	=	IC50	nM	55910.0	IC50	nM	55910.0
7137	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1nccn1-c1cccnc1		2013.0	CHEMBL368883	=	=	IC50	nM	152000.0	IC50	nM	152000.0
7138	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-c2c[nH]cn2)c1		2013.0	CHEMBL178516	=	=	IC50	nM	139900.0	IC50	nM	139900.0
7139	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1cscc1-c1cccnc1		2013.0	CHEMBL179704	<	<	IC50	nM	25000.0	IC50	nM	25000.0
7140	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL3640786	=	=	IC50	nM	12980.0	IC50	nM	12980.0
7141	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Nc1ccc(-c2cccnc2)s1		2013.0	CHEMBL3640762	=	=	IC50	nM	1590.0	IC50	nM	1590.0
7142	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-n2ccnc2)c1		2013.0	CHEMBL179477	=	=	IC50	nM	77540.0	IC50	nM	77540.0
7143	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
7144	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=Cc1ccc(-c2cccnc2)s1		2013.0	CHEMBL179398	=	=	IC50	nM	23930.0	IC50	nM	23930.0
7145	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Fc1ccc(-c2ccsc2)cn1		2013.0	CHEMBL179005	=	=	IC50	nM	114000.0	IC50	nM	114000.0
7146	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC1CCC(c2cccnc2)O1		2013.0	CHEMBL3640764	=	=	IC50	nM	64710.0	IC50	nM	64710.0
7147	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	56990.0	IC50	nM	56990.0
7148	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	CC(=O)c1ccc(-c2cccnc2)s1		2013.0	CHEMBL362702	=	=	IC50	nM	26900.0	IC50	nM	26900.0
7149	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
7150	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cnc(-c2cccnc2)nc1		2013.0	CHEMBL178878	>	>	IC50	nM	400000.0	IC50	nM	400000.0
7151	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1cscc1-c1ccc(F)nc1		2013.0	CHEMBL425519	=	=	IC50	nM	114000.0	IC50	nM	114000.0
7152	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccc(-c2cccnc2)nc1		2013.0	CHEMBL179589	=	=	IC50	nM	84230.0	IC50	nM	84230.0
7153	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	CN1CCCC1c1cccnc1		2013.0	CHEMBL440464	=	=	IC50	nM	142400.0	IC50	nM	142400.0
7154	Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
7155	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7156	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7157	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7158	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7159	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL3646210	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7160	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL3646210	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7161	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL2004290	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7162	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL2004290	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7163	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL3646211	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7164	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL3646211	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7165	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL1969102	=	=	IC50	nM	300.0	IC50	nM	300.0
7166	Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL1969102	=	=	IC50	nM	760.0	IC50	nM	760.0
7167	Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	150.0	IC50	nM	150.0
7168	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699315	=	=	IC50	nM	14700.0	IC50	nM	14700.0
7169	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699316	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7170	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699317	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7171	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCSCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699318	=	=	IC50	nM	1760.0	IC50	nM	1760.0
7172	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C(C)=O)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699319	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7173	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699320	=	=	IC50	nM	7040.0	IC50	nM	7040.0
7174	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCOCC7)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699321	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7175	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccccc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699322	=	=	IC50	nM	2130.0	IC50	nM	2130.0
7176	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(C(N)=O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699323	=	=	IC50	nM	15970.0	IC50	nM	15970.0
7177	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699324	=	=	IC50	nM	8070.0	IC50	nM	8070.0
7178	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699325	=	=	IC50	nM	7630.0	IC50	nM	7630.0
7179	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699326	=	=	IC50	nM	2420.0	IC50	nM	2420.0
7180	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OCc7ccccc7)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699327	=	=	IC50	nM	17200.0	IC50	nM	17200.0
7181	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699328	=	=	IC50	nM	6530.0	IC50	nM	6530.0
7182	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699329	=	=	IC50	nM	19500.0	IC50	nM	19500.0
7183	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OCCCC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699330	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7184	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccc(N7CCN(c8ccc(OC)cc8)CC7)cc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699331	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7185	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC(C)C)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699332	=	=	IC50	nM	13700.0	IC50	nM	13700.0
7186	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NC6CCC(NC(=O)OC(C)(C)C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699333	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7187	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NNC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699334	=	=	IC50	nM	3410.0	IC50	nM	3410.0
7188	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(c7ccccn7)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699335	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7189	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699336	=	=	IC50	nM	2510.0	IC50	nM	2510.0
7190	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699337	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7191	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699338	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7192	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699339	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7193	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(C)C)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699340	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7194	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCCCCC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699341	=	=	IC50	nM	21700.0	IC50	nM	21700.0
7195	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(CN(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699342	=	=	IC50	nM	2260.0	IC50	nM	2260.0
7196	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(NC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699343	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7197	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699344	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7198	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702672	=	=	IC50	nM	2190.0	IC50	nM	2190.0
7199	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702673	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7200	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCNCCC(C)=O)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3640015	=	=	IC50	nM	2780.0	IC50	nM	2780.0
7201	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702674	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7202	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702675	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7203	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCCc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702676	=	=	IC50	nM	10500.0	IC50	nM	10500.0
7204	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702677	=	=	IC50	nM	9480.0	IC50	nM	9480.0
7205	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699316	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7206	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702678	=	=	IC50	nM	7800.0	IC50	nM	7800.0
7207	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ncccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702679	=	=	IC50	nM	8520.0	IC50	nM	8520.0
7208	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6cnccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702680	=	=	IC50	nM	4610.0	IC50	nM	4610.0
7209	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699317	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7210	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702681	=	=	IC50	nM	10200.0	IC50	nM	10200.0
7211	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702682	=	=	IC50	nM	6960.0	IC50	nM	6960.0
7212	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702683	=	=	IC50	nM	6510.0	IC50	nM	6510.0
7213	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702684	=	=	IC50	nM	20390.0	IC50	nM	20390.0
7214	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCC(C)(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702685	=	=	IC50	nM	2190.0	IC50	nM	2190.0
7215	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702686	=	=	IC50	nM	6400.0	IC50	nM	6400.0
7216	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702687	=	=	IC50	nM	2920.0	IC50	nM	2920.0
7217	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N(C)C)o5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702688	=	=	IC50	nM	3420.0	IC50	nM	3420.0
7218	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCOC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702694	=	=	IC50	nM	9120.0	IC50	nM	9120.0
7219	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702695	=	=	IC50	nM	11300.0	IC50	nM	11300.0
7220	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702696	=	=	IC50	nM	9300.0	IC50	nM	9300.0
7221	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702697	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7222	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702698	=	=	IC50	nM	10900.0	IC50	nM	10900.0
7223	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(C)(=O)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702699	=	=	IC50	nM	11200.0	IC50	nM	11200.0
7224	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(=O)(=O)CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702700	=	=	IC50	nM	2820.0	IC50	nM	2820.0
7225	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702701	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7226	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702702	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7227	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCNCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702703	=	=	IC50	nM	8170.0	IC50	nM	8170.0
7228	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702704	=	=	IC50	nM	5530.0	IC50	nM	5530.0
7229	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702705	=	=	IC50	nM	6090.0	IC50	nM	6090.0
7230	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(c6ccccn6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702706	=	=	IC50	nM	2480.0	IC50	nM	2480.0
7231	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702707	=	=	IC50	nM	3630.0	IC50	nM	3630.0
7232	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCCC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702708	=	=	IC50	nM	6600.0	IC50	nM	6600.0
7233	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(C)=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702709	=	=	IC50	nM	15000.0	IC50	nM	15000.0
7234	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702710	=	=	IC50	nM	3980.0	IC50	nM	3980.0
7235	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(=O)OC(C)(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702711	=	=	IC50	nM	2200.0	IC50	nM	2200.0
7236	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702712	=	=	IC50	nM	12100.0	IC50	nM	12100.0
7237	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702713	=	=	IC50	nM	5040.0	IC50	nM	5040.0
7238	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702714	=	=	IC50	nM	10700.0	IC50	nM	10700.0
7239	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(OC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702715	=	=	IC50	nM	3300.0	IC50	nM	3300.0
7240	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)OCC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702716	=	=	IC50	nM	3860.0	IC50	nM	3860.0
7241	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)N(C)CCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702717	=	=	IC50	nM	4970.0	IC50	nM	4970.0
7242	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702718	=	=	IC50	nM	7650.0	IC50	nM	7650.0
7243	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702719	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7244	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702720	=	=	IC50	nM	6020.0	IC50	nM	6020.0
7245	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702721	=	=	IC50	nM	2230.0	IC50	nM	2230.0
7246	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702722	=	=	IC50	nM	8550.0	IC50	nM	8550.0
7247	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702723	=	=	IC50	nM	2110.0	IC50	nM	2110.0
7248	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC6CCN(C)C6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702724	=	=	IC50	nM	2450.0	IC50	nM	2450.0
7249	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC6CN(C)CC65)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702725	=	=	IC50	nM	4490.0	IC50	nM	4490.0
7250	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(O)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702726	=	=	IC50	nM	18300.0	IC50	nM	18300.0
7251	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCN(C)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702727	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7252	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCOCC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702728	=	=	IC50	nM	5990.0	IC50	nM	5990.0
7253	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCC(OC)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702729	=	=	IC50	nM	11800.0	IC50	nM	11800.0
7254	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702689	=	=	IC50	nM	3900.0	IC50	nM	3900.0
7255	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702690	=	=	IC50	nM	12200.0	IC50	nM	12200.0
7256	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702691	=	=	IC50	nM	8040.0	IC50	nM	8040.0
7257	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702692	=	=	IC50	nM	2240.0	IC50	nM	2240.0
7258	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702693	=	=	IC50	nM	6820.0	IC50	nM	6820.0
7259	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702730	=	=	IC50	nM	3160.0	IC50	nM	3160.0
7260	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702731	=	=	IC50	nM	2510.0	IC50	nM	2510.0
7261	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702732	=	=	IC50	nM	16180.0	IC50	nM	16180.0
7262	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702733	=	=	IC50	nM	3680.0	IC50	nM	3680.0
7263	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702734	=	=	IC50	nM	3840.0	IC50	nM	3840.0
7264	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCOCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702735	=	=	IC50	nM	16360.0	IC50	nM	16360.0
7265	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC5(CO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702736	=	=	IC50	nM	2530.0	IC50	nM	2530.0
7266	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702737	=	=	IC50	nM	2010.0	IC50	nM	2010.0
7267	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702738	=	=	IC50	nM	7870.0	IC50	nM	7870.0
7268	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(CC)CC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702739	=	=	IC50	nM	3640.0	IC50	nM	3640.0
7269	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702740	=	=	IC50	nM	17890.0	IC50	nM	17890.0
7270	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(CCO)CCNCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702741	=	=	IC50	nM	2890.0	IC50	nM	2890.0
7271	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N[C@H](C)C(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702742	=	=	IC50	nM	10890.0	IC50	nM	10890.0
7272	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702743	=	=	IC50	nM	3580.0	IC50	nM	3580.0
7273	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702744	=	=	IC50	nM	3460.0	IC50	nM	3460.0
7274	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)O)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702745	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7275	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702746	=	=	IC50	nM	8500.0	IC50	nM	8500.0
7276	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702747	=	=	IC50	nM	2860.0	IC50	nM	2860.0
7277	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702748	=	=	IC50	nM	11510.0	IC50	nM	11510.0
7278	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702749	=	=	IC50	nM	7800.0	IC50	nM	7800.0
7279	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702750	=	=	IC50	nM	1100.0	IC50	nM	1100.0
7280	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702751	=	=	IC50	nM	2540.0	IC50	nM	2540.0
7281	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702752	=	=	IC50	nM	5040.0	IC50	nM	5040.0
7282	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCn5ccnc5C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702753	=	=	IC50	nM	2480.0	IC50	nM	2480.0
7283	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702754	=	=	IC50	nM	2050.0	IC50	nM	2050.0
7284	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccnc(N(C)C)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702755	=	=	IC50	nM	2180.0	IC50	nM	2180.0
7285	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)NC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702756	=	=	IC50	nM	2330.0	IC50	nM	2330.0
7286	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702757	=	=	IC50	nM	6150.0	IC50	nM	6150.0
7287	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702758	=	=	IC50	nM	17440.0	IC50	nM	17440.0
7288	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702759	=	=	IC50	nM	4780.0	IC50	nM	4780.0
7289	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702760	=	=	IC50	nM	22290.0	IC50	nM	22290.0
7290	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(C6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702761	=	=	IC50	nM	2390.0	IC50	nM	2390.0
7291	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNc5ccccc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702762	=	=	IC50	nM	6800.0	IC50	nM	6800.0
7292	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)OC(C)(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702763	=	=	IC50	nM	5650.0	IC50	nM	5650.0
7293	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702764	=	=	IC50	nM	9710.0	IC50	nM	9710.0
7294	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702765	=	=	IC50	nM	5120.0	IC50	nM	5120.0
7295	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702766	=	=	IC50	nM	6870.0	IC50	nM	6870.0
7296	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702767	=	=	IC50	nM	6150.0	IC50	nM	6150.0
7297	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702768	=	=	IC50	nM	9650.0	IC50	nM	9650.0
7298	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(F)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702769	=	=	IC50	nM	2970.0	IC50	nM	2970.0
7299	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702770	=	=	IC50	nM	2610.0	IC50	nM	2610.0
7300	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(OC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702771	=	=	IC50	nM	2160.0	IC50	nM	2160.0
7301	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702772	=	=	IC50	nM	19100.0	IC50	nM	19100.0
7302	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(CCO)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3640016	=	=	IC50	nM	7400.0	IC50	nM	7400.0
7303	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCOC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702773	=	=	IC50	nM	7620.0	IC50	nM	7620.0
7304	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702774	=	=	IC50	nM	10100.0	IC50	nM	10100.0
7305	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702775	=	=	IC50	nM	13030.0	IC50	nM	13030.0
7306	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702776	=	=	IC50	nM	6750.0	IC50	nM	6750.0
7307	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)CCO)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702777	=	=	IC50	nM	3450.0	IC50	nM	3450.0
7308	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCC(O)CO)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702778	=	=	IC50	nM	2550.0	IC50	nM	2550.0
7309	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702779	=	=	IC50	nM	2380.0	IC50	nM	2380.0
7310	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702780	=	=	IC50	nM	6750.0	IC50	nM	6750.0
7311	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN(CC)CC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702781	=	=	IC50	nM	4530.0	IC50	nM	4530.0
7312	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C(C)C)C(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702782	=	=	IC50	nM	4050.0	IC50	nM	4050.0
7313	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(CCN(CC)CC)CCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702783	=	=	IC50	nM	5350.0	IC50	nM	5350.0
7314	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702784	=	=	IC50	nM	2530.0	IC50	nM	2530.0
7315	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702785	=	=	IC50	nM	2320.0	IC50	nM	2320.0
7316	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCC(O)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702786	=	=	IC50	nM	5800.0	IC50	nM	5800.0
7317	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702787	=	=	IC50	nM	7670.0	IC50	nM	7670.0
7318	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCCN6CCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702788	=	=	IC50	nM	2570.0	IC50	nM	2570.0
7319	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699315	=	=	IC50	nM	12240.0	IC50	nM	12240.0
7320	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCOCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702789	=	=	IC50	nM	21060.0	IC50	nM	21060.0
7321	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702790	=	=	IC50	nM	6950.0	IC50	nM	6950.0
7322	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(OC)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702791	=	=	IC50	nM	2210.0	IC50	nM	2210.0
7323	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCNCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702792	=	=	IC50	nM	2730.0	IC50	nM	2730.0
7324	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702793	=	=	IC50	nM	7600.0	IC50	nM	7600.0
7325	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CC)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702794	=	=	IC50	nM	5730.0	IC50	nM	5730.0
7326	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702795	=	=	IC50	nM	6940.0	IC50	nM	6940.0
7327	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCO)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702796	=	=	IC50	nM	6040.0	IC50	nM	6040.0
7328	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702797	=	=	IC50	nM	6120.0	IC50	nM	6120.0
7329	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5cnc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702798	=	=	IC50	nM	3670.0	IC50	nM	3670.0
7330	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702799	=	=	IC50	nM	4190.0	IC50	nM	4190.0
7331	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702800	=	=	IC50	nM	6940.0	IC50	nM	6940.0
7332	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CCCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702801	=	=	IC50	nM	17240.0	IC50	nM	17240.0
7333	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702802	=	=	IC50	nM	3970.0	IC50	nM	3970.0
7334	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NC6CC(C)(C)N(C)C(C)(C)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702803	=	=	IC50	nM	7100.0	IC50	nM	7100.0
7335	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702804	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7336	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702805	=	=	IC50	nM	3290.0	IC50	nM	3290.0
7337	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702806	=	=	IC50	nM	2370.0	IC50	nM	2370.0
7338	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCN(C)CC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702807	=	=	IC50	nM	6320.0	IC50	nM	6320.0
7339	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccc(C(F)(F)F)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702808	=	=	IC50	nM	23670.0	IC50	nM	23670.0
7340	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccccc7OC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702809	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7341	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(Cc7ccc(OC)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702810	=	=	IC50	nM	21520.0	IC50	nM	21520.0
7342	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(O)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702811	=	=	IC50	nM	4870.0	IC50	nM	4870.0
7343	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCN(C)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702812	=	=	IC50	nM	4100.0	IC50	nM	4100.0
7344	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCC(OC)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702813	=	=	IC50	nM	2560.0	IC50	nM	2560.0
7345	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC7CCN(C)C7C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702814	=	=	IC50	nM	7640.0	IC50	nM	7640.0
7346	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7(CCN(CC)C7)C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702815	=	=	IC50	nM	3910.0	IC50	nM	3910.0
7347	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7CCCN7C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702816	=	=	IC50	nM	4600.0	IC50	nM	4600.0
7348	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702817	=	=	IC50	nM	11240.0	IC50	nM	11240.0
7349	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702818	=	=	IC50	nM	6400.0	IC50	nM	6400.0
7350	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc6c(c5)OCCO6)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702819	=	=	IC50	nM	2630.0	IC50	nM	2630.0
7351	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702820	=	=	IC50	nM	3850.0	IC50	nM	3850.0
7352	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C#N)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702821	=	=	IC50	nM	9330.0	IC50	nM	9330.0
7353	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(-c5ccc(S(C)(=O)=O)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702822	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7354	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)OCC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702823	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7355	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)c6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702824	>	>	IC50	nM	25000.0	IC50	nM	25000.0
7356	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc6ccccc6c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702825	=	=	IC50	nM	2090.0	IC50	nM	2090.0
7357	Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702826	=	=	IC50	nM	6410.0	IC50	nM	6410.0
7358	Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1		2015.0	CHEMBL3125537	=	=	IC50	nM	0.0962	IC50	nM	0.0962
7359	Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)c(F)c1		2015.0	CHEMBL3407554	=	=	IC50	nM	0.102	IC50	nM	0.102
7360	Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)cc3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O		2015.0	CHEMBL3407558	=	=	IC50	nM	0.0503	IC50	nM	0.0503
7361	Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1		2015.0	CHEMBL3236364	=	=	IC50	nM	1.83	IC50	nM	1.83
7362	Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)c(F)c3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O		2015.0	CHEMBL3407575	=	=	IC50	nM	0.33	IC50	nM	0.33
7363	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672572	=	=	IC50	nM	160.0	IC50	nM	160.0
7364	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672573	=	=	IC50	nM	170.0	IC50	nM	170.0
7365	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672574	=	=	IC50	nM	120.0	IC50	nM	120.0
7366	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672575	=	=	IC50	nM	200.0	IC50	nM	200.0
7367	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672576	=	=	IC50	nM	160.0	IC50	nM	160.0
7368	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1		2015.0	CHEMBL3672577	=	=	IC50	nM	190.0	IC50	nM	190.0
7369	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1		2015.0	CHEMBL3672585	=	=	IC50	nM	150.0	IC50	nM	150.0
7370	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3639714	=	=	IC50	nM	140.0	IC50	nM	140.0
7371	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672578	=	=	IC50	nM	190.0	IC50	nM	190.0
7372	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672586	=	=	IC50	nM	170.0	IC50	nM	170.0
7373	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672587	=	=	IC50	nM	150.0	IC50	nM	150.0
7374	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672579	=	=	IC50	nM	120.0	IC50	nM	120.0
7375	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672580	<	<	IC50	nM	100.0	IC50	nM	100.0
7376	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672581	<	<	IC50	nM	100.0	IC50	nM	100.0
7377	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672582	=	=	IC50	nM	130.0	IC50	nM	130.0
7378	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672583	=	=	IC50	nM	110.0	IC50	nM	110.0
7379	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672584	=	=	IC50	nM	190.0	IC50	nM	190.0
7380	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672572	=	=	IC50	nM	230.0	IC50	nM	230.0
7381	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672573	=	=	IC50	nM	240.0	IC50	nM	240.0
7382	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672574	=	=	IC50	nM	300.0	IC50	nM	300.0
7383	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672575	=	=	IC50	nM	300.0	IC50	nM	300.0
7384	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672576	=	=	IC50	nM	260.0	IC50	nM	260.0
7385	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1		2015.0	CHEMBL3672577	=	=	IC50	nM	340.0	IC50	nM	340.0
7386	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1		2015.0	CHEMBL3672585	=	=	IC50	nM	340.0	IC50	nM	340.0
7387	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3639714	=	=	IC50	nM	300.0	IC50	nM	300.0
7388	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672578	=	=	IC50	nM	310.0	IC50	nM	310.0
7389	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672586	=	=	IC50	nM	360.0	IC50	nM	360.0
7390	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672587	=	=	IC50	nM	330.0	IC50	nM	330.0
7391	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672579	=	=	IC50	nM	350.0	IC50	nM	350.0
7392	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672580	=	=	IC50	nM	150.0	IC50	nM	150.0
7393	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672581	=	=	IC50	nM	370.0	IC50	nM	370.0
7394	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672582	=	=	IC50	nM	260.0	IC50	nM	260.0
7395	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672583	=	=	IC50	nM	250.0	IC50	nM	250.0
7396	Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672584	=	=	IC50	nM	370.0	IC50	nM	370.0
7397	Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	12.0	IC50	nM	12.0
7398	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	8800.0	IC50	nM	8800.0
7399	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	47500.0	IC50	nM	47500.0
7400	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	52500.0	IC50	nM	52500.0
7401	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	58800.0	IC50	nM	58800.0
7402	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(Cn2ccnc2)cc1		2015.0	CHEMBL14192	=	=	IC50	nM	77500.0	IC50	nM	77500.0
7403	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2nc[nH]c2-c2ccccc2)cc1		2015.0	CHEMBL224554	=	=	IC50	nM	100000.0	IC50	nM	100000.0
7404	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	Cc1nccn1Cc1ccccc1		2015.0	CHEMBL1269154	=	=	IC50	nM	307500.0	IC50	nM	307500.0
7405	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL104	>	>	IC50	nM	500000.0	IC50	nM	500000.0
7406	null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	500000.0	IC50	nM	500000.0
7407	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1		2015.0	CHEMBL389433	<	<	IC50	nM	100.0	IC50	nM	100.0
7408	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	100.0	IC50	nM	100.0
7409	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	500.0	IC50	nM	500.0
7410	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL104	=	=	IC50	nM	300.0	IC50	nM	300.0
7411	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	1000.0	IC50	nM	1000.0
7412	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	1500.0	IC50	nM	1500.0
7413	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C=CN(C=N)C(c1ccccc1)c1ccc(-c2ccccc2)cc1		2015.0	CHEMBL3961189	=	=	IC50	nM	800.0	IC50	nM	800.0
7414	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL528463	=	=	IC50	nM	800.0	IC50	nM	800.0
7415	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(C)(C(=O)c1cccnc1)c1cccnc1		2015.0	CHEMBL934	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7416	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2		2015.0	CHEMBL1201131	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7417	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
7418	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
7419	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7420	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCN(CC)C(=O)/C=C/C=C/c1ccc2c(c1)OCO2		2015.0	CHEMBL3889591	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7421	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NCCCn1ccnc1		2015.0	CHEMBL3984871	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7422	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1		2015.0	CHEMBL25105	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7423	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1nc(Cc2ccccc2)nc2nc[nH]c12		2015.0	CHEMBL3913781	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7424	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N[C@@H](Cc1c[nH]cn1)C(=O)O		2015.0	CHEMBL17962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7425	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CN/C(=N/CCSCc1nc[nH]c1C)NC#N		2015.0	CHEMBL30	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7426	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3		2015.0	CHEMBL40583	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7427	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		2015.0	CHEMBL261454	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7428	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1cccc(C)c1N(C(=O)CCl)C(C)CCO		2015.0	CHEMBL3963505	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7429	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1nc(C)c[nH]1		2015.0	CHEMBL1367804	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7430	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ncnc2[nH]cnc12		2015.0	CHEMBL140037	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7431	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7432	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O		2015.0	CHEMBL54976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7433	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc2[nH]cnc2c1		2015.0	CHEMBL306226	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7434	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7435	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2nc3ccccc3[nH]2)cc1		2015.0	CHEMBL153535	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7436	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1ccnc1		2015.0	CHEMBL543	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7437	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O		2015.0	CHEMBL8	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7438	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCOC(=O)[C@H](C)[C@@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@H](C)[C@@H](O[C@H](OC(C)C)[C@H](O)CN(C)C)[C@](C)(O)C[C@@H](C)C(O)[C@H](C)[C@@H](O)[C@H](C)O		2015.0	CHEMBL4111332	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7439	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C=Cn1ccnc1		2015.0	CHEMBL3929571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7440	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccccc1-c1nc2ccccc2[nH]1		2015.0	CHEMBL473162	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7441	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1nc[nH]n1		2015.0	CHEMBL232801	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7442	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1		2015.0	CHEMBL1987518	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7443	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	COc1ccc([C@@H]2Sc3ccccc3N(C(C)N(C)C)C(=O)[C@@H]2OC(C)=O)cc1		2015.0	CHEMBL4107351	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7444	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1c[nH]cn1		2015.0	CHEMBL540	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7445	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1ncc[nH]1		2015.0	CHEMBL293391	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7446	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)CC[C@@H](N)C(=O)O		2015.0	CHEMBL1232207	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7447	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCc1nc(Cl)cn1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1		2015.0	CHEMBL3913946	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7448	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl		2015.0	CHEMBL2272118	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7449	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N=C(N)NCCC[C@H](N)C(=O)O		2015.0	CHEMBL1485	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7450	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=c1ncnc2[nH][nH]cc1-2		2015.0	CHEMBL1467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7451	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(NC(=O)[C@@H](N)CCC(=O)O)c1ncc[nH]1		2015.0	CHEMBL3928334	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7452	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=C(n1ccnc1)n1ccnc1		2015.0	CHEMBL3903881	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7453	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1ncc[nH]1		2015.0	CHEMBL303797	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7454	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1c(=O)c2nc[nH]c2n(C)c1=O		2015.0	CHEMBL190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7455	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)n1ccnc1		2015.0	CHEMBL1592087	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7456	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)C[C@H](N)C(=O)O		2015.0	CHEMBL58832	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7457	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCc1nc(C=O)c(Cl)[nH]1		2015.0	CHEMBL3933368	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7458	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)/C=C/C1=C(C)CCCC1(C)C		2015.0	CHEMBL559945	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7459	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC1=N[C@H](C(=O)O)CCN1		2015.0	CHEMBL1230264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7460	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)C(C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O		2015.0	CHEMBL3184688	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7461	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1		2015.0	CHEMBL623	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7462	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)N1c2ccccc2C=Cc2ccccc21		2015.0	CHEMBL108	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7463	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21		2015.0	CHEMBL327919	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7464	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1nc(CC2CCCNC2)c[nH]1		2015.0	CHEMBL151467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7465	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)O[C@@H]1[C@H](C)[C@@H](CO)/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H]1C		2015.0	CHEMBL4111819	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7466	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C		2015.0	CHEMBL160	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7467	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCC[C@H](NC)[C@@H](O)[C@@H](O)OCCC[C@](C)(O)C1O[C@H]([C@H](CC)OCC[C@H](OC)[C@@H](O)[C@H](C)O)C(O)OC[C@H](C)[C@H](OC(C)O)[C@H]1C		2015.0	CHEMBL3923392	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7468	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1cc[nH]c1=S		2015.0	CHEMBL1515	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7469	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21		2015.0	CHEMBL5	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7470	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1ncnc2[nH]cnc12		2015.0	CHEMBL226345	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7471	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1coc(-c2nc3ccccc3[nH]2)c1		2015.0	CHEMBL201094	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7472	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1coc(CNc2ncnc3[nH]cnc23)c1		2015.0	CHEMBL228792	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7473	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	8800.0	IC50	nM	8800.0
7474	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	47500.0	IC50	nM	47500.0
7475	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	52500.0	IC50	nM	52500.0
7476	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	58800.0	IC50	nM	58800.0
7477	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(Cn2ccnc2)cc1		2015.0	CHEMBL14192	=	=	IC50	nM	77500.0	IC50	nM	77500.0
7478	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2nc[nH]c2-c2ccccc2)cc1		2015.0	CHEMBL224554	=	=	IC50	nM	100000.0	IC50	nM	100000.0
7479	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	Cc1nccn1Cc1ccccc1		2015.0	CHEMBL1269154	=	=	IC50	nM	307500.0	IC50	nM	307500.0
7480	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	ClC1CC=CC=C1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL3952468	>	>	IC50	nM	500000.0	IC50	nM	500000.0
7481	In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	500000.0	IC50	nM	500000.0
7482	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1		2015.0	CHEMBL389433	<	<	IC50	nM	100.0	IC50	nM	100.0
7483	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	100.0	IC50	nM	100.0
7484	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	500.0	IC50	nM	500.0
7485	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	ClC1CC=CC=C1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL3952468	=	=	IC50	nM	300.0	IC50	nM	300.0
7486	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	1000.0	IC50	nM	1000.0
7487	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	1500.0	IC50	nM	1500.0
7488	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1		2015.0	CHEMBL277535	=	=	IC50	nM	800.0	IC50	nM	800.0
7489	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL528463	=	=	IC50	nM	800.0	IC50	nM	800.0
7490	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(C)(C(=O)c1cccnc1)c1cccnc1		2015.0	CHEMBL934	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7491	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2		2015.0	CHEMBL1201131	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7492	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
7493	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
7494	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7495	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCN(CC)C(=O)/C=C/C=C/c1ccc2c(c1)OCO2		2015.0	CHEMBL3889591	=	=	IC50	nM	10000.0	IC50	nM	10000.0
7496	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NCCCn1ccnc1		2015.0	CHEMBL3984871	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7497	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1		2015.0	CHEMBL25105	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7498	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1nc(Cc2ccccc2)nc2nc[nH]c12		2015.0	CHEMBL3913781	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7499	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N[C@@H](Cc1c[nH]cn1)C(=O)O		2015.0	CHEMBL17962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7500	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CN/C(=N/CCSCc1nc[nH]c1C)NC#N		2015.0	CHEMBL30	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7501	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3		2015.0	CHEMBL40583	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7502	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		2015.0	CHEMBL261454	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7503	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1cccc(C)c1N(C(=O)CCl)[C@@H](C)COC		2015.0	CHEMBL2251445	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7504	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1nc(C)c[nH]1		2015.0	CHEMBL1367804	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7505	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ncnc2[nH]cnc12		2015.0	CHEMBL140037	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7506	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7507	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O		2015.0	CHEMBL54976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7508	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc2[nH]cnc2c1		2015.0	CHEMBL306226	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7509	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7510	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2nc3ccccc3[nH]2)cc1		2015.0	CHEMBL153535	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7511	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1ccnc1		2015.0	CHEMBL543	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7512	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O		2015.0	CHEMBL8	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7513	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](C)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O		2015.0	CHEMBL1237043	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7514	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	C=Cn1ccnc1		2015.0	CHEMBL3929571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7515	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccccc1-c1nc2ccccc2[nH]1		2015.0	CHEMBL473162	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7516	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1nc[nH]n1		2015.0	CHEMBL232801	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7517	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1		2015.0	CHEMBL1987518	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7518	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCOO[C@H]1C(=O)N(CCN(C)C)c2ccccc2S[C@H]1c1ccc(OC)cc1		2015.0	CHEMBL4106906	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7519	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1c[nH]cn1		2015.0	CHEMBL540	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7520	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1ncc[nH]1		2015.0	CHEMBL293391	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7521	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7522	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCc1nc(Cl)c(COC(c2ccccc2)(c2ccccc2)c2ccccc2)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1		2015.0	CHEMBL3968740	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7523	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl		2015.0	CHEMBL2272118	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7524	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N=C(N)NCCC[C@H](N)C(=O)O		2015.0	CHEMBL1485	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7525	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=c1ncnc2[nH][nH]cc1-2		2015.0	CHEMBL1467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7526	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(NC(=O)[C@@H](N)CCC(=O)O)c1ncc[nH]1		2015.0	CHEMBL3928334	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7527	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=C(n1ccnc1)n1ccnc1		2015.0	CHEMBL3903881	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7528	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1ncc[nH]1		2015.0	CHEMBL303797	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7529	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1c(=O)c2nc[nH]c2n(C)c1=O		2015.0	CHEMBL190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7530	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)n1ccnc1		2015.0	CHEMBL1592087	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7531	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)C[C@H](N)C(=O)O		2015.0	CHEMBL58832	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7532	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCc1nc(C=O)c(Cl)[nH]1		2015.0	CHEMBL3933368	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7533	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)/C=C/C1=C(C)CCCC1(C)C		2015.0	CHEMBL559945	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7534	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC1=N[C@H](C(=O)O)CCN1		2015.0	CHEMBL1230264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7535	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC[C@@H]1OC(=O)[C@@H](C)[C@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@@H](C)O2)C(C)[C@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@@](C)(OC)C[C@H](C)C(=O)[C@@H](C)[C@H](O)[C@@]1(C)O		2015.0	CHEMBL3937847	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7536	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1		2015.0	CHEMBL623	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7537	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)N1c2ccccc2C=Cc2ccccc21		2015.0	CHEMBL108	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7538	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21		2015.0	CHEMBL327919	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7539	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1nc(CC2CCCNC2)c[nH]1		2015.0	CHEMBL151467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7540	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)O[C@@H]1[C@H](C)[C@@H](CO)/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H]1C		2015.0	CHEMBL4111819	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7541	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C		2015.0	CHEMBL4108227	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7542	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCC[C@@H]([C@@H](OC(C)=O)[C@@H](O)OCCCC(C)(O)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)COC(=O)[C@H](C)[C@H](CC)OCC[C@H](OC)[C@@H](OC(C)=O)[C@H](C)O)N(C)C		2015.0	CHEMBL3930201	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7543	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1cc[nH]c1=S		2015.0	CHEMBL1515	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7544	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21		2015.0	CHEMBL5	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7545	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1ncnc2[nH]cnc12		2015.0	CHEMBL226345	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7546	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1coc(-c2nc3ccccc3[nH]2)c1		2015.0	CHEMBL201094	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7547	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1coc(CNc2ncnc3[nH]cnc23)c1		2015.0	CHEMBL228792	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7548	Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.	COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC		2015.0	CHEMBL3264599	=	=	IC50	nM	770.0	IC50	nM	770.0
7549	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3964719	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7550	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1		2015.0	CHEMBL3929240	=	=	IC50	nM	43000.0	IC50	nM	43000.0
7551	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ccccn1		2015.0	CHEMBL3906541	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7552	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cccnc1		2015.0	CHEMBL3920320	=	=	IC50	nM	1200.0	IC50	nM	1200.0
7553	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1		2015.0	CHEMBL3919273	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7554	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cnccn1		2015.0	CHEMBL3922632	=	=	IC50	nM	26000.0	IC50	nM	26000.0
7555	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cccnn1		2015.0	CHEMBL3937551	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7556	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1		2015.0	CHEMBL3912376	=	=	IC50	nM	3200.0	IC50	nM	3200.0
7557	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncco1		2015.0	CHEMBL3946411	=	=	IC50	nM	8400.0	IC50	nM	8400.0
7558	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3951681	=	=	IC50	nM	43000.0	IC50	nM	43000.0
7559	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3901346	=	=	IC50	nM	30000.0	IC50	nM	30000.0
7560	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-n1cccn1		2015.0	CHEMBL3936446	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7561	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3ccnn3)c2)c1		2015.0	CHEMBL3974746	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7562	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1		2015.0	CHEMBL3932552	=	=	IC50	nM	43000.0	IC50	nM	43000.0
7563	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3922611	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7564	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1		2015.0	CHEMBL3962055	=	=	IC50	nM	39000.0	IC50	nM	39000.0
7565	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1		2015.0	CHEMBL3982154	=	=	IC50	nM	32000.0	IC50	nM	32000.0
7566	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1		2015.0	CHEMBL3943785	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7567	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1F		2015.0	CHEMBL3921296	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7568	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3962710	=	=	IC50	nM	41000.0	IC50	nM	41000.0
7569	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cncn3)c2)c1		2015.0	CHEMBL3933744	=	=	IC50	nM	6000.0	IC50	nM	6000.0
7570	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ccccn3)c2)c1		2015.0	CHEMBL3957752	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7571	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3969984	=	=	IC50	nM	24000.0	IC50	nM	24000.0
7572	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3892369	=	=	IC50	nM	31000.0	IC50	nM	31000.0
7573	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ccncc3)c2)c1		2015.0	CHEMBL3967139	=	=	IC50	nM	300.0	IC50	nM	300.0
7574	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1F		2015.0	CHEMBL3981412	=	=	IC50	nM	39000.0	IC50	nM	39000.0
7575	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3952666	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7576	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	N#Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3945071	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7577	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3949919	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7578	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1F		2015.0	CHEMBL3890222	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7579	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1OC		2015.0	CHEMBL3917412	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7580	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3913869	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7581	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3960556	=	=	IC50	nM	36000.0	IC50	nM	36000.0
7582	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3942262	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7583	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccc(C)n3)c2)c1		2015.0	CHEMBL3947571	=	=	IC50	nM	18000.0	IC50	nM	18000.0
7584	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncco2)c1		2015.0	CHEMBL3956147	=	=	IC50	nM	5100.0	IC50	nM	5100.0
7585	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccs3)c2)c1		2015.0	CHEMBL3941085	=	=	IC50	nM	1200.0	IC50	nM	1200.0
7586	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1		2015.0	CHEMBL3967251	=	=	IC50	nM	2000.0	IC50	nM	2000.0
7587	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3cccnn3)c2)c1		2015.0	CHEMBL3950355	=	=	IC50	nM	6000.0	IC50	nM	6000.0
7588	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1		2015.0	CHEMBL3926167	=	=	IC50	nM	9600.0	IC50	nM	9600.0
7589	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1F		2015.0	CHEMBL3941635	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7590	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3913644	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7591	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1		2015.0	CHEMBL3936154	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7592	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)n1		2015.0	CHEMBL3932799	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7593	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)n1		2015.0	CHEMBL3954973	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7594	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(F)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3927349	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7595	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3942815	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7596	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3968722	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7597	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2cc(C)ccc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3959904	=	=	IC50	nM	42000.0	IC50	nM	42000.0
7598	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3975507	=	=	IC50	nM	32000.0	IC50	nM	32000.0
7599	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(C)cc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3947761	=	=	IC50	nM	41000.0	IC50	nM	41000.0
7600	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(F)cc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3977023	=	=	IC50	nM	42000.0	IC50	nM	42000.0
7601	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3938981	=	=	IC50	nM	29000.0	IC50	nM	29000.0
7602	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3933467	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7603	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c1		2015.0	CHEMBL4115063	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7604	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-n1nccn1		2015.0	CHEMBL3972999	=	=	IC50	nM	36000.0	IC50	nM	36000.0
7605	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3895130	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7606	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1COC[C@@H](Cc2cccc(-n3nccn3)c2)N1C(=O)c1ccccc1-n1nccn1		2015.0	CHEMBL3951941	=	=	IC50	nM	24000.0	IC50	nM	24000.0
7607	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2[C@@H](C)COC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3936704	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7608	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2[C@@H](C)COC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3909876	=	=	IC50	nM	6800.0	IC50	nM	6800.0
7609	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C)c(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3915231	=	=	IC50	nM	15000.0	IC50	nM	15000.0
7610	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3959470	=	=	IC50	nM	7500.0	IC50	nM	7500.0
7611	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3946888	=	=	IC50	nM	16000.0	IC50	nM	16000.0
7612	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1F		2015.0	CHEMBL3968942	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7613	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3895786	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7614	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1-n1nccn1		2015.0	CHEMBL3932131	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7615	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3909701	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7616	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3963262	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7617	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3938822	=	=	IC50	nM	15000.0	IC50	nM	15000.0
7618	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1ccc(Cl)c(-c2ncon2)c1		2015.0	CHEMBL3936592	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7619	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)c(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3901849	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7620	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3952970	=	=	IC50	nM	44000.0	IC50	nM	44000.0
7621	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3930115	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7622	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3944222	=	=	IC50	nM	30000.0	IC50	nM	30000.0
7623	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3916290	=	=	IC50	nM	49000.0	IC50	nM	49000.0
7624	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3946474	=	=	IC50	nM	28000.0	IC50	nM	28000.0
7625	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3943141	=	=	IC50	nM	11000.0	IC50	nM	11000.0
7626	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3910117	=	=	IC50	nM	9700.0	IC50	nM	9700.0
7627	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3953726	=	=	IC50	nM	9600.0	IC50	nM	9600.0
7628	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3976034	=	=	IC50	nM	13000.0	IC50	nM	13000.0
7629	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3915416	=	=	IC50	nM	9700.0	IC50	nM	9700.0
7630	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@@]2(C)Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3914317	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7631	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1Cl		2015.0	CHEMBL3901878	=	=	IC50	nM	13000.0	IC50	nM	13000.0
7632	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3904485	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7633	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3982996	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7634	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3916665	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7635	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3922707	=	=	IC50	nM	46000.0	IC50	nM	46000.0
7636	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3894723	=	=	IC50	nM	43000.0	IC50	nM	43000.0
7637	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3931654	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7638	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1-n1nccn1		2015.0	CHEMBL3900153	=	=	IC50	nM	40000.0	IC50	nM	40000.0
7639	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3937108	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7640	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3909195	=	=	IC50	nM	26000.0	IC50	nM	26000.0
7641	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3946019	=	=	IC50	nM	35000.0	IC50	nM	35000.0
7642	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3921658	=	=	IC50	nM	24000.0	IC50	nM	24000.0
7643	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3914896	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7644	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3984705	=	=	IC50	nM	23000.0	IC50	nM	23000.0
7645	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3940721	=	=	IC50	nM	23000.0	IC50	nM	23000.0
7646	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c1		2015.0	CHEMBL3936519	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7647	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1		2015.0	CHEMBL3936920	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7648	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccccc1-n1nccn1		2015.0	CHEMBL3978573	=	=	IC50	nM	18000.0	IC50	nM	18000.0
7649	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1-n1nccn1		2015.0	CHEMBL3954756	=	=	IC50	nM	18000.0	IC50	nM	18000.0
7650	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c(-n2nccn2)c1		2015.0	CHEMBL3963023	=	=	IC50	nM	27000.0	IC50	nM	27000.0
7651	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1		2015.0	CHEMBL3939510	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7652	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1		2015.0	CHEMBL3965827	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7653	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3950474	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7654	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3977521	=	=	IC50	nM	30000.0	IC50	nM	30000.0
7655	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3968141	=	=	IC50	nM	26000.0	IC50	nM	26000.0
7656	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3912674	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7657	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3957620	=	=	IC50	nM	35000.0	IC50	nM	35000.0
7658	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F		2015.0	CHEMBL3907193	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7659	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F		2015.0	CHEMBL3974582	=	=	IC50	nM	37000.0	IC50	nM	37000.0
7660	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1C		2015.0	CHEMBL3902291	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7661	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3924060	=	=	IC50	nM	30000.0	IC50	nM	30000.0
7662	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3961204	=	=	IC50	nM	7400.0	IC50	nM	7400.0
7663	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1Cl		2015.0	CHEMBL3933736	=	=	IC50	nM	13000.0	IC50	nM	13000.0
7664	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3ccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3939249	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7665	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2cc(C)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3977273	=	=	IC50	nM	9200.0	IC50	nM	9200.0
7666	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3909380	=	=	IC50	nM	9100.0	IC50	nM	9100.0
7667	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2ccc(C)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3956556	=	=	IC50	nM	9600.0	IC50	nM	9600.0
7668	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(F)cc(-n2nccn2)c1		2015.0	CHEMBL3932544	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7669	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(F)cc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3971116	=	=	IC50	nM	40000.0	IC50	nM	40000.0
7670	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1		2015.0	CHEMBL3909223	=	=	IC50	nM	28000.0	IC50	nM	28000.0
7671	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3962902	=	=	IC50	nM	31000.0	IC50	nM	31000.0
7672	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3901113	=	=	IC50	nM	32000.0	IC50	nM	32000.0
7673	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3925326	=	=	IC50	nM	15000.0	IC50	nM	15000.0
7674	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3949593	=	=	IC50	nM	18000.0	IC50	nM	18000.0
7675	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3940958	=	=	IC50	nM	24000.0	IC50	nM	24000.0
7676	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1		2015.0	CHEMBL3970504	=	=	IC50	nM	30000.0	IC50	nM	30000.0
7677	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3939766	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7678	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3932708	=	=	IC50	nM	40000.0	IC50	nM	40000.0
7679	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3901217	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7680	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3923760	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7681	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3895759	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7682	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCO[C@@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3922678	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7683	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3910286	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7684	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3907310	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7685	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCO[C@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3957175	=	=	IC50	nM	8500.0	IC50	nM	8500.0
7686	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1C		2015.0	CHEMBL3985846	=	=	IC50	nM	29000.0	IC50	nM	29000.0
7687	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3942007	=	=	IC50	nM	9800.0	IC50	nM	9800.0
7688	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3897210	=	=	IC50	nM	13000.0	IC50	nM	13000.0
7689	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3943170	=	=	IC50	nM	23000.0	IC50	nM	23000.0
7690	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3972733	=	=	IC50	nM	21000.0	IC50	nM	21000.0
7691	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c1		2015.0	CHEMBL3948499	=	=	IC50	nM	50000.0	IC50	nM	50000.0
7692	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3980766	=	=	IC50	nM	35000.0	IC50	nM	35000.0
7693	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3967125	=	=	IC50	nM	22000.0	IC50	nM	22000.0
7694	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3946045	=	=	IC50	nM	24000.0	IC50	nM	24000.0
7695	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)cc1C		2015.0	CHEMBL3968480	=	=	IC50	nM	29000.0	IC50	nM	29000.0
7696	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3954732	=	=	IC50	nM	36000.0	IC50	nM	36000.0
7697	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3930630	=	=	IC50	nM	36000.0	IC50	nM	36000.0
7698	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(C(F)(F)F)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3931693	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7699	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2F)c(-n2nccn2)c1		2015.0	CHEMBL3964366	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7700	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3940700	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7701	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3909224	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7702	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3938386	=	=	IC50	nM	19000.0	IC50	nM	19000.0
7703	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3910447	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7704	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c1		2015.0	CHEMBL3923356	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7705	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c(-n2nccn2)c1		2015.0	CHEMBL3947667	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7706	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2cccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1		2015.0	CHEMBL3910932	=	=	IC50	nM	26000.0	IC50	nM	26000.0
7707	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccc(Cl)cc1-n1nccn1		2015.0	CHEMBL3938872	=	=	IC50	nM	14000.0	IC50	nM	14000.0
7708	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1		2015.0	CHEMBL3901915	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7709	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1		2015.0	CHEMBL3907374	=	=	IC50	nM	600.0	IC50	nM	600.0
7710	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3905808	=	=	IC50	nM	5500.0	IC50	nM	5500.0
7711	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3917550	=	=	IC50	nM	3300.0	IC50	nM	3300.0
7712	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCCC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3905303	=	=	IC50	nM	6100.0	IC50	nM	6100.0
7713	CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCCC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3981385	=	=	IC50	nM	7700.0	IC50	nM	7700.0
7714	Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever	CCCCCCCCCCCC(=O)OCC(CCP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC		2015.0	CHEMBL4107005	=	=	IC50	nM	13600.0	IC50	nM	13600.0
7715	Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.	CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC		2015.0	CHEMBL4106421	=	=	IC50	nM	13600.0	IC50	nM	13600.0
7716	Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	12.0	IC50	nM	12.0
7717	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	CCOC(=O)/C=C/c1ccc(C(F)(F)C(O)(Cn2cnnn2)c2ccc(F)cc2F)nc1		2015.0	CHEMBL3891460	=	=	IC50	nM	83000.0	IC50	nM	83000.0
7718	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(/C=C/COCC(F)(F)F)cn1		2015.0	CHEMBL3954501	=	=	IC50	nM	81000.0	IC50	nM	81000.0
7719	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)nc2)cn1		2015.0	CHEMBL3918756	=	=	IC50	nM	17000.0	IC50	nM	17000.0
7720	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)nc2)cn1		2015.0	CHEMBL3945322	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7721	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	8000.0	IC50	nM	8000.0
7722	Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	nM	13000.0
7723	Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.	C[C@@]1(c2cc(Nc3cc(Cl)cc4cc(Cl)cnc34)ccc2F)COCC(N)=N1		2016.0	CHEMBL3969614	=	=	IC50	nM	33000.0	IC50	nM	33000.0
7724	Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.	Cn1nc(Nc2ccc(F)c([C@@]3(C)COCC(N)=N3)c2)c2ccc(Cl)cc21		2016.0	CHEMBL4111354	=	=	IC50	nM	25000.0	IC50	nM	25000.0
7725	CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4107824	=	=	IC50	nM	23800.0	IC50	nM	23800.0
7726	CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4106646	=	=	IC50	nM	16200.0	IC50	nM	16200.0
7727	CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4107824	=	=	IC50	nM	11900.0	IC50	nM	11900.0
7728	CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4106646	=	=	IC50	nM	11800.0	IC50	nM	11800.0
7729	In Vitro CYP Inhibition Assay: P450 enzyme inhibition was measured using human cDNA-expressed CYP3A4, 2D6, 2C19, 2C9, and 1A2 recombinant enzymes and fluorogenic substrates (coumarin analogues) that are converted to fluorescent products. The analogues utilized for each isoenzyme are as follows: 7-benzyloxy-trifluoromethylcoumarin, (BFC) for 3A4; 3-[2-(N,N-diethyl-N-methyl amino)ethyl]7-methoxy-4-methylcoumarin, (AMMC) for 2D6; 3-cyano-7-ethoxycoumarin, (CEC) for 2C19 and 1 A2; and 7-methoxy-4-trifluoro-methylcoumarin, (MFC) for 2C9. These substrates were utilized at a single concentration (either 50 uM or 75 uM) at or near the apparent Km for each substrate. Fluorescence intensity was measured using a Wallac 1420 Victor3 Multi-label Counter Model (PerkinElmer, Wellesley, Mass.), with an excitation wavelength filter of 405 nm, and an emission filter of 460 nm (535 nm for the 3A4 and 2C9 substrates). Compound stocks (10 mM in a 4:1 ratio of acetonitrile:DMSO) were tested in this study using an 8-point dose response curve in duplicate (ranging from 0.15 uM-20.0 uM). The concentration of acetonitrile was kept constant at 0.4%, and the reaction was carried out at 37° C. for 30 minutes.	C[C@](O)(COc1ccc(Cl)c(F)c1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1		2016.0	CHEMBL512283	>	>	IC50	nM	20000.0	IC50	nM	20000.0
7730	CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3545241	=	=	IC50	nM	10900.0	IC50	nM	10900.0
7731	CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc([C@@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3939800	=	=	IC50	nM	10500.0	IC50	nM	10500.0
7732	CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc([C@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3962269	=	=	IC50	nM	14800.0	IC50	nM	14800.0
7733	Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.26%) are incubated with human liver microsomes (0.1 mg/mL) and NADPH (1 mM) in the presence of the probe substrate midazolam (2.5 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.	OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2		2016.0	CHEMBL1188	=	=	IC50	nM	2700.0	IC50	nM	2700.0
7734	Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.275%) are incubated with human liver microsomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probe substrate testosterone (50 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.	C[C@]12CC[C@H]3[C@@H](C[C@@H](O)C4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O		2016.0	CHEMBL2074878	=	=	IC50	nM	10500.0	IC50	nM	10500.0
7735	Inhibitory Assay: The cytochrome P450 inhibitory potentials of compounds for human recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A were determined using Vivid CYP450 blue screening kits (Invitrogen, USA). All of the procedures were performed according the instruction provided by the manufacturer. Briefly, serials of diluted compounds were incubated the vivid CYP450 reaction systems including CYP450 BACULOSOMES with different recombinant human CYP450 isozymes and the appropriate vivid CYP450 substrates, and rabbit NADPH-P450 reductase, and the regeneration system. Ketoconazole was used as reference CYP450 inhibitor. After 30 minutes incubation at room temperature, the fluorescence was measured with an excitation at 400 nm and an emission at 460 nm using Envision 2104 multi-label Reader (Perkin Elmer, USA).	COc1ccc(C2(c3ccc(OC)cc3)NC(=N)N(C3CCCCC3)C2=O)cc1		2016.0	CHEMBL3109542	=	=	IC50	nM	449.0	IC50	nM	449.0
7736	CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.	O=CN(C[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C(=O)c1ccc(Cl)s1		2016.0	CHEMBL3975957	=	=	IC50	nM	5700.0	IC50	nM	5700.0
7737	CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.	Cc1ccc(C(=O)NC[C@H]2CN(c3ccc(N4CCOCC4=O)cc3)C(=O)O2)s1		2016.0	CHEMBL370614	=	=	IC50	nM	9700.0	IC50	nM	9700.0
7738	Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ccnc3[nH]ncc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL3951306	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7739	Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL2178573	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7740	Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	COC1=C(C(=O)c2ncc(C)cc2NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)C2C=CNC2N=C1		2016.0	CHEMBL3944846	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7741	Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL2178573	=	=	IC50	nM	20000.0	IC50	nM	20000.0
7742	Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cn1cc(-c2nc3c(N4CCN(Cc5cccnc5)CC4)c(Br)cnc3[nH]2)cn1		2016.0	CHEMBL3898132	<	<	IC50	nM	1000.0	IC50	nM	1000.0
7743	Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)c(C)c1-c1nc2c(N3CCN(Cc4cccnc4)CC3)c(Br)cnc2[nH]1		2016.0	CHEMBL3891461	<	<	IC50	nM	1000.0	IC50	nM	1000.0
7744	Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1		2016.0	CHEMBL2207503	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7745	Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ncon4)CC3)c(Cl)cnc2[nH]1		2016.0	CHEMBL2207500	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7746	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccccc12		2016.0	CHEMBL3926686	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7747	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12		2016.0	CHEMBL3915393	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7748	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3942519	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7749	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)ccc12		2016.0	CHEMBL3951269	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7750	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(F)cc12		2016.0	CHEMBL3927059	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7751	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(F)c12		2016.0	CHEMBL3926432	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7752	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)ccc12		2016.0	CHEMBL3900133	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7753	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(O)cc12		2016.0	CHEMBL3930161	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7754	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12		2016.0	CHEMBL3905553	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7755	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3942519	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7756	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1		2016.0	CHEMBL3947939	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7757	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12		2016.0	CHEMBL3941986	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7758	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1		2016.0	CHEMBL3960725	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7759	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3945113	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7760	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Br)ccc12		2016.0	CHEMBL3934554	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7761	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Br)cc12		2016.0	CHEMBL3957026	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7762	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Br)c12		2016.0	CHEMBL3899367	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7763	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2c(Cl)cccc12		2016.0	CHEMBL3889611	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7764	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)ccc12		2016.0	CHEMBL3951766	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7765	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12		2016.0	CHEMBL3915393	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7766	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	N#Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3923510	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7767	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)(F)F)ccc12		2016.0	CHEMBL3906058	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7768	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc3c(cc12)OCCO3		2016.0	CHEMBL3930595	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7769	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)F)ccc12		2016.0	CHEMBL3932173	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7770	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1F		2016.0	CHEMBL3907721	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7771	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cc(F)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3923223	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7772	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1C		2016.0	CHEMBL3962437	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7773	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Cl)c12		2016.0	CHEMBL3910483	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7774	Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3895257	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7775	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3969361	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7776	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3980571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7777	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Cl		2016.0	CHEMBL3917789	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7778	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1OC		2016.0	CHEMBL3892761	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7779	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)cc(Br)c12		2016.0	CHEMBL3961768	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7780	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)cc(Br)c12		2016.0	CHEMBL3916144	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7781	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1c(F)ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3891650	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7782	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(F)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3907175	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7783	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3984048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7784	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Cl)c12		2016.0	CHEMBL3910048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7785	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Br		2016.0	CHEMBL3977772	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7786	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3967401	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7787	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3906051	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7788	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Cl)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3920876	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7789	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)c(F)cc12		2016.0	CHEMBL3908841	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7790	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)c(F)cc12		2016.0	CHEMBL3979166	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7791	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Br)c12		2016.0	CHEMBL3941189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7792	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3945612	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7793	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1O		2016.0	CHEMBL3898625	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7794	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1C		2016.0	CHEMBL3973221	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7795	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1F		2016.0	CHEMBL3939590	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7796	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)c(F)cc12		2016.0	CHEMBL3944958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7797	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C#N)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3923319	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7798	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(O)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3918191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7799	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3969361	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7800	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3980571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7801	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Cl		2016.0	CHEMBL3917789	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7802	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1OC		2016.0	CHEMBL3892761	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7803	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)cc(Br)c12		2016.0	CHEMBL3961768	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7804	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)cc(Br)c12		2016.0	CHEMBL3916144	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7805	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1c(F)ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3891650	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7806	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(F)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3907175	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7807	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3984048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7808	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Cl)c12		2016.0	CHEMBL3910048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7809	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Br		2016.0	CHEMBL3977772	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7810	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3967401	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7811	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3906051	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7812	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Cl)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3920876	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7813	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)c(F)cc12		2016.0	CHEMBL3908841	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7814	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)c(F)cc12		2016.0	CHEMBL3979166	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7815	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Br)c12		2016.0	CHEMBL3941189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7816	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3945612	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7817	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1O		2016.0	CHEMBL3898625	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7818	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1C		2016.0	CHEMBL3973221	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7819	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1F		2016.0	CHEMBL3939590	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7820	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)c(F)cc12		2016.0	CHEMBL3944958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7821	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C#N)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3923319	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7822	"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(O)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3918191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
7823	Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.	CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1		2016.0	CHEMBL3921669	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7824	Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.	CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21		2016.0	CHEMBL3985847	=	=	IC50	nM	39000.0	IC50	nM	39000.0
7825	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3ncccc3c2)n1		2016.0	CHEMBL3925961	=	=	IC50	nM	3700.0	IC50	nM	3700.0
7826	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3nc(C)ccc3c2)n1		2016.0	CHEMBL3910478	=	=	IC50	nM	2100.0	IC50	nM	2100.0
7827	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3934839	=	=	IC50	nM	4000.0	IC50	nM	4000.0
7828	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc(-c3ccon3)cc2)n1		2016.0	CHEMBL3969750	=	=	IC50	nM	2300.0	IC50	nM	2300.0
7829	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(c2)OCC(=O)N3C)n1		2016.0	CHEMBL3947193	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7830	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1		2016.0	CHEMBL3970302	=	=	IC50	nM	3000.0	IC50	nM	3000.0
7831	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3895473	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7832	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3911035	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7833	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnn(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3981054	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7834	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cncn3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3905467	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7835	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3973040	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7836	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3896543	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7837	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3967713	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7838	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3928571	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7839	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3964219	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7840	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3930510	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7841	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1		2016.0	CHEMBL3958007	=	=	IC50	nM	46000.0	IC50	nM	46000.0
7842	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3935923	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7843	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3969059	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7844	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3929505	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7845	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(Cl)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3974300	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7846	Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3ccccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3956933	>	>	IC50	nM	50000.0	IC50	nM	50000.0
7847	Inhibition of CYP3A4 (unknown origin)	CCC(C)(C)C(=O)N(O)Cc1ccccc1	J Med Chem	2017.0	CHEMBL4092421	>	>	IC50	nM	3500.0	IC50	uM	3.5
7848	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cccc(C2=NC(C(F)(F)F)(C(F)(F)F)c3c(n(-c4ccc(Cl)cc4)c(=O)[nH]c3=O)N2)c1	J Med Chem	2017.0	CHEMBL4095693	=	=	IC50	nM	16440.0	IC50	uM	16.44
7849	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)N=C(c1cccc([N+](=O)[O-])c1)N2	J Med Chem	2017.0	CHEMBL4079193	>	>	IC50	nM	30000.0	IC50	uM	30.0
7850	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)NC(c1ccc(Cl)cc1)=N2	J Med Chem	2017.0	CHEMBL1341270	>	>	IC50	nM	30000.0	IC50	uM	30.0
7851	Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4074778	>	<	IC50	nM	10000.0	pIC50		5.0
7852	Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3cc(F)c(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4066163	>	<	IC50	nM	10000.0	pIC50		5.0
7853	Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3cc(F)c(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4078098	>	<	IC50	nM	10000.0	pIC50		5.0
7854	Inhibition of CYP3A4 (unknown origin)	COCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3cc(F)c(CC(=O)N4CCC4)c(F)c3)CC2)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4093284	>	>	IC50	nM	50000.0	IC50	uM	50.0
7855	Inhibition of CYP3A4 (unknown origin)	NCc1ccnc(Cl)c1	ACS Med Chem Lett	2017.0	CHEMBL4068784	>	>	IC50	nM	30000.0	IC50	uM	30.0
7856	Inhibition of human CYP3A4 expressed in baculovirus-infected insect cells using Luciferin-PFBE as substrate in presence of NADPH by P450-Glo luminescence assay	COc1cccc(/C=C/C(=O)c2cc(OC)c(OC)cc2O)c1	Eur J Med Chem	2017.0	CHEMBL4071093	=	=	IC50	nM	27400.0	IC50	uM	27.4
7857	Inhibition of human CYP3A4 expressed in baculovirus-infected insect cells using Luciferin-PFBE as substrate in presence of NADPH by P450-Glo luminescence assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	Eur J Med Chem	2017.0	CHEMBL55	>	>	IC50	nM	100000.0	IC50	uM	100.0
7858	Inhibition of human CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F	ACS Med Chem Lett	2017.0	CHEMBL3137332	>	>	IC50	nM	100000.0	IC50	uM	100.0
7859	Inhibition of CYP3A4 (unknown origin)	O=C(COc1ccc(-n2ccnc2)cc1)Nc1ccc(-c2ccccc2)cc1	J Med Chem	2015.0	CHEMBL4097104	=	=	IC50	nM	20.0	IC50	uM	0.02
7860	Inhibition of CYP3A4 (unknown origin)	O=C(COc1ccc(-c2cnco2)cc1)Nc1ccc(-c2ccccc2)cc1	J Med Chem	2015.0	CHEMBL4063419	>	>	IC50	nM	20000.0	IC50	uM	20.0
7861	Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(OCC(=O)Nc2ccc(-c3ccccc3)cc2)cc1	J Med Chem	2015.0	CHEMBL4070649	=	=	IC50	nM	5200.0	IC50	uM	5.2
7862	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1ccc(OCC(=O)Nc2ccc(-c3ccccc3)cc2)cc1	J Med Chem	2015.0	CHEMBL4099279	>	>	IC50	nM	20000.0	IC50	uM	20.0
7863	Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2ccccc2)cn1	J Med Chem	2015.0	CHEMBL4080842	>	>	IC50	nM	20000.0	IC50	uM	20.0
7864	Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)nc1	J Med Chem	2015.0	CHEMBL4098880	>	>	IC50	nM	20000.0	IC50	uM	20.0
7865	Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)cn1	J Med Chem	2015.0	CHEMBL4088716	>	>	IC50	nM	20000.0	IC50	uM	20.0
7866	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	CC(C)(C)c1ccccc1Oc1ccc(-c2cccc(C(=O)O)c2)cc1NC(=O)Nc1ccc(OC(F)(F)F)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4097275	>	>	IC50	nM	5000.0	IC50	uM	5.0
7867	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3cccc(C)c3)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060679	>	>	IC50	nM	3000.0	IC50	uM	3.0
7868	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3C)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4082553	>	>	IC50	nM	3000.0	IC50	uM	3.0
7869	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3Cl)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060089	>	>	IC50	nM	3000.0	IC50	uM	3.0
7870	Inhibition of CYP3A4 (unknown origin) using BZR as substrate	CC(C)(C)c1ccccc1Oc1ccc(-c2cccc(C(=O)O)c2)cc1NC(=O)Nc1ccc(OC(F)(F)F)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4097275	>	>	IC50	nM	5000.0	IC50	uM	5.0
7871	Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3cccc(C)c3)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060679	>	>	IC50	nM	3000.0	IC50	uM	3.0
7872	Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3C)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4082553	>	>	IC50	nM	3000.0	IC50	uM	3.0
7873	Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3Cl)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060089	>	>	IC50	nM	3000.0	IC50	uM	3.0
7874	Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(F)cc1	Bioorg Med Chem	2017.0	CHEMBL4070447	=	=	IC50	nM	74.0	IC50	uM	0.074
7875	Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1	Bioorg Med Chem	2017.0	CHEMBL4097622	=	=	IC50	nM	70.0	IC50	uM	0.07
7876	Inhibition of human CYP3A4	CCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1	Bioorg Med Chem	2017.0	CHEMBL4092343	=	=	IC50	nM	11900.0	IC50	uM	11.9
7877	Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(OCc2ccc(Cl)cc2)cc1	Bioorg Med Chem	2017.0	CHEMBL4089012	=	=	IC50	nM	179.0	IC50	uM	0.179
7878	Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(F)cc1C(F)(F)F)c1ccc(OCc2ccc(Cl)cc2)cc1	Bioorg Med Chem	2017.0	CHEMBL4065918	=	=	IC50	nM	10.0	IC50	uM	0.01
7879	Inhibition of human CYP3A4	CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)cc1.Cl	Bioorg Med Chem	2017.0	CHEMBL4095951	=	=	IC50	nM	15.0	IC50	uM	0.015
7880	Inhibition of human CYP3A4	CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3cccnc3C(F)(F)F)cc2)cc1.Cl	Bioorg Med Chem	2017.0	CHEMBL4080366	=	=	IC50	nM	144.0	IC50	uM	0.144
7881	Inhibition of human CYP3A4	Cc1cc(C)cc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)c1.Cl	Bioorg Med Chem	2017.0	CHEMBL4088945	=	=	IC50	nM	3.0	IC50	uM	0.003
7882	Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	74400.0	IC50	uM	74.4
7883	Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	32400.0	IC50	uM	32.4
7884	Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	31000.0	IC50	uM	31.0
7885	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by HPLC-MS/MS method	CCCCCc1ccc(NC(=O)COc2cc(C)nc3ccc(OC)cc23)cc1	Eur J Med Chem	2017.0	CHEMBL4094462	>	>	IC50	nM	30000.0	IC50	uM	30.0
7886	Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	15.0	IC50	uM	0.015
7887	Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	18.0	IC50	uM	0.018
7888	Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	ACS Med Chem Lett	2017.0	CHEMBL4101807	=	=	IC50	nM	81900.0	IC50	uM	81.9
7889	Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	ACS Med Chem Lett	2017.0	CHEMBL4101807	=	=	IC50	nM	12500.0	IC50	uM	12.5
7890	Inhibition of recombinant human CYP3A4 using fluorogenic substrate BFC preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	ACS Med Chem Lett	2017.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
7891	Inhibition of recombinant human CYP3A4 using fluorogenic substrate BFC preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1cn(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cn1	ACS Med Chem Lett	2017.0	CHEMBL4084621	>	>	IC50	nM	30000.0	IC50	uM	30.0
7892	Inhibition of recombinant human CYP3A4 using fluorogenic substrate BZR preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	ACS Med Chem Lett	2017.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
7893	Inhibition of recombinant human CYP3A4 using fluorogenic substrate BZR preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1cn(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cn1	ACS Med Chem Lett	2017.0	CHEMBL4084621	>	>	IC50	nM	30000.0	IC50	uM	30.0
7894	Inhibition of CYP3A4 (unknown origin)	O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1	J Med Chem	2017.0	CHEMBL3301604	>	>	IC50	nM	50000.0	IC50	uM	50.0
7895	Inhibition of CYP3A4 (unknown origin)	O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2cccc(F)c2)CC1	J Med Chem	2017.0	CHEMBL3933704	>	>	IC50	nM	50000.0	IC50	uM	50.0
7896	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	Cc1nc(NC2CCCC2)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cn2)n1	J Med Chem	2017.0	CHEMBL4081497	>	>	IC50	nM	25000.0	IC50	uM	25.0
7897	Inhibition of microsomal CYP3A4 (unknown origin) using midazolam as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl	Eur J Med Chem	2017.0	CHEMBL4093614	>	>	IC50	nM	33000.0	IC50	uM	33.0
7898	Inhibition of microsomal CYP3A4 (unknown origin) using testosterone as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl	Eur J Med Chem	2017.0	CHEMBL4093614	>	>	IC50	nM	33000.0	IC50	uM	33.0
7899	Inhibition of CYP3A4 in human liver microsomes	N#Cc1cccc(S(=O)(=O)c2cnc3cc(F)ccc3c2-c2ccc(Cl)cc2)c1	J Med Chem	2017.0	CHEMBL3765114	>	>	IC50	nM	10000.0	IC50	uM	10.0
7900	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CN1CCN(Cc2cn(S(=O)(=O)c3ccccc3)c3ccccc23)CC1.Cl.Cl	J Med Chem	2017.0	CHEMBL4062687	>	>	IC50	nM	10000.0	IC50	uM	10.0
7901	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CN1CCN(Cc2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1	J Med Chem	2017.0	CHEMBL4070284	=	=	IC50	nM	1820.0	IC50	uM	1.82
7902	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)c1ccc(S(=O)(=O)n2cc(CN3CCN(C)CC3)c3cc(F)ccc32)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4093699	=	=	IC50	nM	1400.0	IC50	uM	1.4
7903	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1cccc2c1c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4085003	=	=	IC50	nM	7100.0	IC50	uM	7.1
7904	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O	J Med Chem	2017.0	CHEMBL4082473	=	=	IC50	nM	1500.0	IC50	uM	1.5
7905	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.CS(=O)(=O)O.CS(=O)(=O)O	J Med Chem	2017.0	CHEMBL4100484	=	=	IC50	nM	1850.0	IC50	uM	1.85
7906	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(F)cc1.CS(=O)(=O)O.CS(=O)(=O)O	J Med Chem	2017.0	CHEMBL4073586	=	=	IC50	nM	1710.0	IC50	uM	1.71
7907	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4101284	=	=	IC50	nM	2200.0	IC50	uM	2.2
7908	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O	J Med Chem	2017.0	CHEMBL4082473	=	=	IC50	nM	2640.0	IC50	uM	2.64
7909	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(C(=O)/C=C/c2cccnc2)c(OC)c1	Eur J Med Chem	2017.0	CHEMBL427692	=	=	IC50	nM	11000.0	IC50	uM	11.0
7910	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc(Cl)c1	Eur J Med Chem	2017.0	CHEMBL4065284	=	=	IC50	nM	12500.0	IC50	uM	12.5
7911	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc(Br)c1	Eur J Med Chem	2017.0	CHEMBL4084977	=	=	IC50	nM	14000.0	IC50	uM	14.0
7912	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1	Eur J Med Chem	2017.0	CHEMBL4063333	=	=	IC50	nM	28000.0	IC50	uM	28.0
7913	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc2cc(C(=O)/C=C/c3cccnc3)ccc2c1	Eur J Med Chem	2017.0	CHEMBL4092737	=	=	IC50	nM	10600.0	IC50	uM	10.6
7914	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4071959	=	=	IC50	nM	6000.0	IC50	uM	6.0
7915	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1ccc2ccc3ccccc3c2c1	Eur J Med Chem	2017.0	CHEMBL4080095	=	=	IC50	nM	26000.0	IC50	uM	26.0
7916	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL1413330	=	=	IC50	nM	12000.0	IC50	uM	12.0
7917	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2cccnc2)c1	Eur J Med Chem	2017.0	CHEMBL4099058	=	=	IC50	nM	1280.0	IC50	uM	1.28
7918	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4072091	=	=	IC50	nM	1520.0	IC50	uM	1.52
7919	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2cccnc2)cc1OC	Eur J Med Chem	2017.0	CHEMBL4063471	=	=	IC50	nM	53000.0	IC50	uM	53.0
7920	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2cccnc2)c(OC)c1OC	Eur J Med Chem	2017.0	CHEMBL2237709	=	=	IC50	nM	11800.0	IC50	uM	11.8
7921	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(Cl)c(Cl)c1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4068333	=	=	IC50	nM	15000.0	IC50	uM	15.0
7922	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2ccccc2c1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4059677	=	=	IC50	nM	18000.0	IC50	uM	18.0
7923	Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4087973	=	=	IC50	nM	11100.0	IC50	uM	11.1
7924	Inhibition of CYP3A4 (unknown origin)	COc1nc(C2=NOC[C@H](c3cc4ccccc4o3)N2)ccc1-n1cnc(C)c1	J Med Chem	2017.0	CHEMBL4101809	=	=	IC50	nM	25000.0	IC50	uM	25.0
7925	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccc(Cl)cc2)CC1	J Med Chem	2017.0	CHEMBL4094887	=	=	IC50	nM	280.0	IC50	uM	0.28
7926	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4102633	=	=	IC50	nM	430.0	IC50	uM	0.43
7927	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4062566	=	=	IC50	nM	680.0	IC50	uM	0.68
7928	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4098912	=	=	IC50	nM	270.0	IC50	uM	0.27
7929	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4098978	=	=	IC50	nM	580.0	IC50	uM	0.58
7930	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4072007	=	=	IC50	nM	450.0	IC50	uM	0.45
7931	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1ncns1)c1cc(F)c(OCC[C@]2(c3ccccc3)CC[C@H](NC3CC3)CC2)cc1F	J Med Chem	2017.0	CHEMBL4063378	=	=	IC50	nM	90.0	IC50	uM	0.09
7932	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4101437	=	=	IC50	nM	6700.0	IC50	uM	6.7
7933	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4077266	=	=	IC50	nM	9800.0	IC50	uM	9.8
7934	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@@H](N)CC1	J Med Chem	2017.0	CHEMBL4093720	=	=	IC50	nM	780.0	IC50	uM	0.78
7935	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@H](N)CC1	J Med Chem	2017.0	CHEMBL4087898	=	=	IC50	nM	3000.0	IC50	uM	3.0
7936	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4060154	=	=	IC50	nM	20000.0	IC50	uM	20.0
7937	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4080712	=	=	IC50	nM	9000.0	IC50	uM	9.0
7938	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4076627	=	=	IC50	nM	2300.0	IC50	uM	2.3
7939	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4078268	=	=	IC50	nM	20000.0	IC50	uM	20.0
7940	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNCC2)cc1F	J Med Chem	2017.0	CHEMBL4096299	=	=	IC50	nM	20000.0	IC50	uM	20.0
7941	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4078252	=	=	IC50	nM	6700.0	IC50	uM	6.7
7942	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1ncns1)c1cc(Cl)c(NCCC2CCCCN2)cc1F	J Med Chem	2017.0	CHEMBL4088581	=	=	IC50	nM	5900.0	IC50	uM	5.9
7943	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCN2)cc1F	J Med Chem	2017.0	CHEMBL4076444	=	=	IC50	nM	20000.0	IC50	uM	20.0
7944	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN1CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4091922	=	=	IC50	nM	20000.0	IC50	uM	20.0
7945	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNC2)cc1F	J Med Chem	2017.0	CHEMBL4071098	=	=	IC50	nM	20000.0	IC50	uM	20.0
7946	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CNC2)cc1F	J Med Chem	2017.0	CHEMBL4103940	=	=	IC50	nM	20000.0	IC50	uM	20.0
7947	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4085278	=	=	IC50	nM	20000.0	IC50	uM	20.0
7948	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4062380	=	=	IC50	nM	20000.0	IC50	uM	20.0
7949	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNCCO2)cc1F	J Med Chem	2017.0	CHEMBL4089010	=	=	IC50	nM	20000.0	IC50	uM	20.0
7950	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCN(O)C2)cc1F	J Med Chem	2017.0	CHEMBL4096711	=	=	IC50	nM	7900.0	IC50	uM	7.9
7951	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCN(O)C2)cc1F	J Med Chem	2017.0	CHEMBL4072107	=	=	IC50	nM	17000.0	IC50	uM	17.0
7952	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNC2)cc1F	J Med Chem	2017.0	CHEMBL4071551	=	=	IC50	nM	20000.0	IC50	uM	20.0
7953	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN1C(C)(C)CC(Nc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1(C)C	J Med Chem	2017.0	CHEMBL4064193	=	=	IC50	nM	20000.0	IC50	uM	20.0
7954	Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2(CN3CCCC3)CC2)cc1F	J Med Chem	2017.0	CHEMBL4092078	=	=	IC50	nM	20000.0	IC50	uM	20.0
7955	Inhibition of human CYP3A4	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1	J Med Chem	2017.0	CHEMBL4098877	>	>	IC50	nM	50000.0	IC50	uM	50.0
7956	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	Cc1ccc(-c2ccc(C(=O)NC(CN)c3ncc(CO)s3)[nH]2)cc1F	J Med Chem	2017.0	CHEMBL4075766	>	>	IC50	nM	25000.0	IC50	uM	25.0
7957	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	NCC(NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1ncc(CO)s1	J Med Chem	2017.0	CHEMBL4083672	>	>	IC50	nM	25000.0	IC50	uM	25.0
7958	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	Cc1nc(C(NC(=O)c2ccc(-c3ccc(Cl)cc3)[nH]2)C2CCCCN2)sc1CO	J Med Chem	2017.0	CHEMBL4096918	>	>	IC50	nM	25000.0	IC50	uM	25.0
7959	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2017.0	CHEMBL3301620	>	>	IC50	nM	25000.0	IC50	uM	25.0
7960	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	7100.0	IC50	uM	7.1
7961	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	21800.0	IC50	uM	21.8
7962	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	24900.0	IC50	uM	24.9
7963	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	20800.0	IC50	uM	20.8
7964	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	73400.0	IC50	uM	73.4
7965	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	37400.0	IC50	uM	37.4
7966	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	32000.0	IC50	uM	32.0
7967	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	42900.0	IC50	uM	42.9
7968	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	21800.0	IC50	uM	21.8
7969	Inhibition of CYP3A4 in human liver microsomes assessed as enzyme-mediated metabolite formation using midazolam as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
7970	Inhibition of CYP3A4 in human liver microsomes assessed as enzyme-mediated metabolite formation using testosterone as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	=	=	IC50	nM	30000.0	IC50	uM	30.0
7971	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
7972	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
7973	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	8300.0	IC50	uM	8.3
7974	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 5 mins	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	65200.0	IC50	uM	65.2
7975	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	4000.0	IC50	uM	4.0
7976	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	8100.0	IC50	uM	8.1
7977	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	11600.0	IC50	uM	11.6
7978	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	10500.0	IC50	uM	10.5
7979	Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	8700.0	IC50	uM	8.7
7980	Inhibition of CYP3A4 (unknown origin)	COC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Cl	J Med Chem	2017.0	CHEMBL4064672	>	>	IC50	nM	50000.0	IC50	uM	50.0
7981	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)ccc1-c1ncnc2cc(S(=O)(=O)Nc3nccs3)ccc12	J Med Chem	2017.0	CHEMBL3687538	>	>	IC50	nM	50000.0	IC50	uM	50.0
7982	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3692139	=	=	IC50	nM	7200.0	IC50	uM	7.2
7983	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3682789	=	=	IC50	nM	1300.0	IC50	uM	1.3
7984	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3687606	>	>	IC50	nM	27000.0	IC50	uM	27.0
7985	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncccn3)ccc12	J Med Chem	2017.0	CHEMBL4078593	>	>	IC50	nM	27000.0	IC50	uM	27.0
7986	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3cccnn3)ccc12	J Med Chem	2017.0	CHEMBL4096614	>	>	IC50	nM	27000.0	IC50	uM	27.0
7987	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncns3)ccc12	J Med Chem	2017.0	CHEMBL3687604	>	>	IC50	nM	27000.0	IC50	uM	27.0
7988	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ccon3)ccc12	J Med Chem	2017.0	CHEMBL3687608	>	>	IC50	nM	27000.0	IC50	uM	27.0
7989	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncco3)ccc12	J Med Chem	2017.0	CHEMBL4092695	>	>	IC50	nM	27000.0	IC50	uM	27.0
7990	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncon3)ccc12	J Med Chem	2017.0	CHEMBL4071917	>	>	IC50	nM	27000.0	IC50	uM	27.0
7991	Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(C(F)(F)F)c2)c(F)cc1-c1nccc2cc(S(=O)(=O)Nc3ccon3)ccc12	J Med Chem	2017.0	CHEMBL4060568	>	>	IC50	nM	15000.0	IC50	uM	15.0
7992	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949600	=	=	IC50	nM	45000.0	IC50	uM	45.0
7993	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949474	=	=	IC50	nM	2200.0	IC50	uM	2.2
7994	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3956563	=	=	IC50	nM	2800.0	IC50	uM	2.8
7995	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21	J Med Chem	2017.0	CHEMBL3953660	=	=	IC50	nM	4600.0	IC50	uM	4.6
7996	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3941727	=	=	IC50	nM	32000.0	IC50	uM	32.0
7997	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(OC(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3921528	>	>	IC50	nM	50000.0	IC50	uM	50.0
7998	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cc(OC)c(-n3c(=O)ccc4cc(S(=O)(=O)Nc5ncccn5)ccc43)cc2F)ccc1Cl	J Med Chem	2017.0	CHEMBL3937744	>	>	IC50	nM	50000.0	IC50	uM	50.0
7999	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3979498	>	>	IC50	nM	50000.0	IC50	uM	50.0
8000	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(F)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3961163	>	>	IC50	nM	50000.0	IC50	uM	50.0
8001	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949600	>	>	IC50	nM	50000.0	IC50	uM	50.0
8002	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949474	>	>	IC50	nM	50000.0	IC50	uM	50.0
8003	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3956563	>	>	IC50	nM	50000.0	IC50	uM	50.0
8004	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21	J Med Chem	2017.0	CHEMBL3953660	=	=	IC50	nM	3600.0	IC50	uM	3.6
8005	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3941727	>	>	IC50	nM	50000.0	IC50	uM	50.0
8006	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(OC(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3921528	>	>	IC50	nM	50000.0	IC50	uM	50.0
8007	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cc(OC)c(-n3c(=O)ccc4cc(S(=O)(=O)Nc5ncccn5)ccc43)cc2F)ccc1Cl	J Med Chem	2017.0	CHEMBL3937744	>	>	IC50	nM	50000.0	IC50	uM	50.0
8008	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3979498	>	>	IC50	nM	50000.0	IC50	uM	50.0
8009	Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(F)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3961163	>	>	IC50	nM	50000.0	IC50	uM	50.0
8010	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cn[nH]c12	Bioorg Med Chem Lett	2017.0	CHEMBL4084771	=	=	IC50	nM	3162.28	pIC50		5.5
8011	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(F)ccc2F)cc1Nc1ccnc2cn[nH]c12	Bioorg Med Chem Lett	2017.0	CHEMBL4102696	=	=	IC50	nM	1584.89	pIC50		5.8
8012	Inhibition of CYP3A4 (unknown origin)	COc1cccc2nccc(Nc3cc(-c4nc(C)ccc4F)ncc3C)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4094958	=	=	IC50	nM	6309.57	pIC50		5.2
8013	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cnn(CC(N)=O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4072325	=	=	IC50	nM	12589.25	pIC50		4.9
8014	Inhibition of CYP3A4 (unknown origin)	NC(=O)Cn1cc2nccc(Nc3ccnc(-c4cc(Cl)ccc4F)c3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4067488	=	=	IC50	nM	12589.25	pIC50		4.9
8015	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cn(CC(N)=O)nc12	Bioorg Med Chem Lett	2017.0	CHEMBL4069101	<	>	IC50	nM	50118.72	pIC50		4.3
8016	Inhibition of CYP3A4 (unknown origin)	NC(=O)n1cc(NC(=O)N2CCC[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21	J Med Chem	2017.0	CHEMBL3908849	>	>	IC50	nM	30000.0	IC50	uM	30.0
8017	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1nn(CC(=O)N2[C@H](C(=O)Nc3cccc(Br)n3)C[C@H]3C[C@H]32)c2ccccc12	J Med Chem	2017.0	CHEMBL3683753	=	=	IC50	nM	17000.0	IC50	uM	17.0
8018	Inhibition of CYP3A4 in human microsomes in presence of NADPH	O=c1c2ccccc2oc2c(Cc3ccc4c(c3)OCO4)[nH]c(-c3nccs3)c12	J Med Chem	2017.0	CHEMBL4099219	>	>	IC50	nM	25000.0	IC50	uM	25.0
8019	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(Br)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL2058057	>	>	IC50	nM	10000.0	IC50	uM	10.0
8020	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1O	Eur J Med Chem	2017.0	CHEMBL3289112	>	>	IC50	nM	10000.0	IC50	uM	10.0
8021	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1O	Eur J Med Chem	2017.0	CHEMBL4081914	>	>	IC50	nM	10000.0	IC50	uM	10.0
8022	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	C#CCOc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1	Eur J Med Chem	2017.0	CHEMBL4074105	>	>	IC50	nM	10000.0	IC50	uM	10.0
8023	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(Oc3ccc(Cl)cc3Cl)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4100866	>	>	IC50	nM	10000.0	IC50	uM	10.0
8024	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(OCc3ccc(F)cc3F)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4084413	>	>	IC50	nM	10000.0	IC50	uM	10.0
8025	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Eur J Med Chem	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
8026	Inhibition of CYP3A4 (unknown origin)	O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4060768	>	>	IC50	nM	30000.0	IC50	uM	30.0
8027	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)c(F)c12	J Med Chem	2017.0	CHEMBL4093031	>	>	IC50	nM	13000.0	IC50	uM	13.0
8028	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4104000	=	=	IC50	nM	11400.0	IC50	uM	11.4
8029	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccncc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4086080	=	=	IC50	nM	73.0	IC50	uM	0.073
8030	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5cccnc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4096241	=	=	IC50	nM	63.0	IC50	uM	0.063
8031	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccn5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4078188	=	=	IC50	nM	4100.0	IC50	uM	4.1
8032	Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4088517	=	=	IC50	nM	2100.0	IC50	uM	2.1
8033	Inhibition of CYP3A4 (unknown origin)	O=C(CC1(c2ccccc2)C2CC3CC1CC(C2)C3O)N1CC(O)C1	J Med Chem	2017.0	CHEMBL4080667	>	>	IC50	nM	40000.0	IC50	uM	40.0
8034	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C(=O)C1(C)C	J Med Chem	2017.0	CHEMBL4059848	>	>	IC50	nM	20000.0	IC50	uM	20.0
8035	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C	J Med Chem	2017.0	CHEMBL4064666	>	>	IC50	nM	20000.0	IC50	uM	20.0
8036	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate preincubated with compound followed by substrate addition	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
8037	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
8038	Inhibition of human liver microsomes CYP3A4 using midazolam as substrate preincubated with compound followed by substrate addition	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
8039	Inhibition of human liver microsomes CYP3A4 using midazolam as substrate	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
8040	Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	O=C(NC1CCCCCC1)c1cc2c(Cl)cc(Cl)cc2[nH]1	J Med Chem	2017.0	CHEMBL4090593	<=	<=	IC50	nM	20000.0	IC50	uM	20.0
8041	Inhibition of human CYP3A4 using ketoconazole as substrate	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)(Cl)[C@@H]1O)Oc1ccccc1	J Med Chem	2017.0	CHEMBL4081718	=	=	IC50	nM	6800.0	IC50	uM	6.8
8042	Inhibition of human CYP3A4 using ketoconazole as substrate	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	J Med Chem	2017.0	CHEMBL1259059	=	=	IC50	nM	8400.0	IC50	uM	8.4
8043	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4102132	>	>	IC50	nM	50000.0	IC50	uM	50.0
8044	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1ncc(F)s1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4079748	=	=	IC50	nM	37500.0	IC50	uM	37.5
8045	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nc(Cl)cs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4090203	=	=	IC50	nM	40100.0	IC50	uM	40.1
8046	Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4061793	>	>	IC50	nM	50000.0	IC50	uM	50.0
8047	Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis	CC1(C)CN2CCC[C@]2(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4062780	>	>	IC50	nM	50000.0	IC50	uM	50.0
8048	Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	COc1ccc(CNc2c3c(nc4ccccc24)CCCC3)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4076034	=	=	IC50	nM	3700.0	IC50	uM	3.7
8049	Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	COc1ccc(CNc2c3c(nc4cc(Cl)ccc24)CCCC3)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4070182	=	=	IC50	nM	13800.0	IC50	uM	13.8
8050	Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	Clc1ccc2c(NCc3ccccn3)c3c(nc2c1)CCCC3	Bioorg Med Chem Lett	2017.0	CHEMBL4075061	=	=	IC50	nM	9100.0	IC50	uM	9.1
8051	Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	200.0	IC50	uM	0.2
8052	Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	Nc1c2c(nc3ccccc13)CCCC2	Bioorg Med Chem Lett	2017.0	CHEMBL95	=	=	IC50	nM	96900.0	IC50	uM	96.9
8053	Inhibition of CYP3A4 in liver microsomes (unknown origin) assessed as formation of 1-hydroxymidazolam from midazolam in presence of NADPH by LC-MS/MS analysis	Cc1ncn(-c2ccc(C(=O)N[C@H]3[C@H]4CC[C@H]3N(c3ncc(Cl)c5cnoc35)C4)c(Cl)c2)n1	Bioorg Med Chem Lett	2017.0	CHEMBL4096341	>	>	IC50	nM	10000.0	IC50	uM	10.0
8054	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4068896	=	=	IC50	nM	3000.0	IC50	uM	3.0
8055	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4089245	=	=	IC50	nM	6900.0	IC50	uM	6.9
8056	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4077859	=	=	IC50	nM	13300.0	IC50	uM	13.3
8057	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1	J Med Chem	2018.0	CHEMBL4065122	>	>	IC50	nM	5000.0	IC50	uM	5.0
8058	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	O=[N+]([O-])c1cn2c(n1)OC[C@H](Oc1ccc(OC(F)(F)F)cc1)C2	J Med Chem	2018.0	CHEMBL4078293	>	>	IC50	nM	40000.0	IC50	uM	40.0
8059	Inhibition of CYP3A4 (unknown origin)	C[C@H]1[C@@H](C)OC(C)(C)C(=O)N1c1cc(-c2cc(C(F)(F)F)c3c(N)ncnn23)ccc1C#N	Bioorg Med Chem Lett	2017.0	CHEMBL4091875	>	>	IC50	nM	20000.0	IC50	uM	20.0
8060	Inhibition of human hepatic CYP3A4	COc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1	Eur J Med Chem	2017.0	CHEMBL4063960	=	=	IC50	nM	6526.0	IC50	nM	6526.0
8061	Inhibition of human hepatic CYP3A4	Fc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1	Eur J Med Chem	2017.0	CHEMBL4091726	=	=	IC50	nM	9032.0	IC50	nM	9032.0
8062	Inhibition of human hepatic CYP3A4	Cc1ccncc1CN1CCc2c(sc3ccc(F)cc23)C1	Eur J Med Chem	2017.0	CHEMBL4059780	=	=	IC50	nM	8561.0	IC50	nM	8561.0
8063	Inhibition of human hepatic CYP3A4	Oc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3	Eur J Med Chem	2017.0	CHEMBL4064141	=	=	IC50	nM	5282.0	IC50	nM	5282.0
8064	Inhibition of human hepatic CYP3A4	Fc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3	Eur J Med Chem	2017.0	CHEMBL4101612	=	=	IC50	nM	7897.0	IC50	nM	7897.0
8065	Inhibition of human hepatic CYP3A4	Fc1ccc2sc3c(c2c1)CCN(Cc1c[nH]cn1)C3	Eur J Med Chem	2017.0	CHEMBL4068802	=	=	IC50	nM	685.0	IC50	nM	685.0
8066	Inhibition of human hepatic CYP3A4	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	Eur J Med Chem	2017.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
8067	Reversible inhibition of CYP3A4 in human liver microsomes	Cc1ccc(Oc2nc3cc(-c4ccc(-c5ccccc5)cc4)c(Cl)cc3[nH]2)cc1C(=O)O	J Med Chem	2017.0	CHEMBL4082745	>	>	IC50	nM	50000.0	IC50(app)	uM	50.0
8068	Inhibition of CYP3A4 (unknown origin)	CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1	J Med Chem	2018.0	CHEMBL4075348	>	>	EC50	nM	100000.0	EC50	uM	100.0
8069	Inhibition of CYP3A4 in human liver microsomes	c1nc(N[C@H]2CC[C@H](N3CCOCC3)CC2)c2c(C3CCOCC3)c[nH]c2n1	J Med Chem	2017.0	CHEMBL4064608	>	>	IC50	nM	30000.0	IC50	uM	30.0
8070	Inhibition of CYP3A4 (unknown origin)	COc1cc(C)[nH]c(=O)c1CN1CCc2c(Cl)cc([C@H](OC)C3COC3)c(Cl)c2C1=O	J Med Chem	2018.0	CHEMBL4080228	>	>	IC50	nM	30000.0	IC50	uM	30.0
8071	Inhibition of human CYP3A4	CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc3nc(-c4c(C)cccc4C)nn3c2)cc1	J Med Chem	2018.0	CHEMBL3927519	>	>	IC50	nM	60000.0	IC50	uM	60.0
8072	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl	J Med Chem	2018.0	CHEMBL4086008	=	=	IC50	nM	10000.0	IC50	uM	10.0
8073	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	80000.0	IC50	uM	80.0
8074	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl	J Med Chem	2018.0	CHEMBL4086008	=	=	IC50	nM	10000.0	IC50	uM	10.0
8075	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	80000.0	IC50	uM	80.0
8076	Inhibition of CYP3A4 (unknown origin) expressed in baculosomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	40.0	IC50	uM	0.04
8077	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(=O)NC(c2nc(C(=O)Nc3ccccc3C(=O)c3ccccc3)cs2)C(C)C)cc(OC)c1OC	J Med Chem	2018.0	CHEMBL4076355	=	=	IC50	nM	8230.0	IC50	uM	8.23
8078	Inhibition of human liver microsomal CYP3A4	Cc1cc(NC2CCN(C(=O)CCNCC(=O)O)CC2)nc(NCc2cn(CCCNCCCNC3CCCCC3)nn2)n1	J Med Chem	2018.0	CHEMBL4064397	>	>	IC50	nM	100000.0	IC50	uM	100.0
8079	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by LC-MS/MS analysis	OC12CC3CC(C1)CC(NCc1cc(C4CC4)on1)(C3)C2	J Med Chem	2018.0	CHEMBL4077296	>	>	IC50	nM	100000.0	IC50	uM	100.0
8080	Inhibition of recombinant human CYP3A4 expressed in baculosomes expression system using fluorogenic-BOMCC as substrate by fluorescent homogeneous assay	N#Cc1c(-c2cccs2)nc(SCc2cccc(CC(=O)O)c2)[nH]c1=O	J Med Chem	2018.0	CHEMBL4071212	>	>	IC50	nM	10000.0	IC50	uM	10.0
8081	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	CCOC(=O)C1=C(CN2CCO[C@H](CCC(=O)O)C2)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Br	J Med Chem	2018.0	CHEMBL4085181	>	>	IC50	nM	10000.0	IC50	uM	10.0
8082	Inhibition of CYP3A4 (unknown origin) using BQ as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1100.0	IC50	uM	1.1
8083	Inhibition of CYP3A4 (unknown origin) using DBF as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1200.0	IC50	uM	1.2
8084	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1400.0	IC50	uM	1.4
8085	Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc([C@](C)(O)C(F)(F)F)c2)c2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL4098297	>	>	IC50	nM	50000.0	IC50	nM	50000.0
8086	Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc([C@@](C)(O)C(F)(F)F)c2)c2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL4080256	>	>	IC50	nM	50000.0	IC50	nM	50000.0
8087	Inhibition of hepatic CYP3A4 (unknown origin)	C[C@](O)(c1cncc(-n2nc(C(F)(F)F)c3ccccc32)c1)C(F)(F)F	Bioorg Med Chem Lett	2017.0	CHEMBL4071689	>	>	IC50	nM	50000.0	IC50	nM	50000.0
8088	Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc(C(C)(C)O)c2)c2cccc(F)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4080420	>	>	IC50	nM	50000.0	IC50	nM	50000.0
8089	Inhibition of hepatic CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-n2ncc3c(C(F)(F)F)cccc32)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4067000	=	=	IC50	nM	43000.0	IC50	nM	43000.0
8090	Time dependent inhibition of CYP3A4 (unknown origin) in absence of NADPH	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
8091	Time dependent inhibition of CYP3A4 (unknown origin) in presence of NADPH	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
8092	Inhibition of CYP3A4 (unknown origin)	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
8093	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccncc4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4070692	=	=	IC50	nM	340.0	IC50	uM	0.34
8094	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccnc(F)c4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4094439	=	=	IC50	nM	24000.0	IC50	uM	24.0
8095	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccc(F)nc4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4102040	=	=	IC50	nM	25000.0	IC50	uM	25.0
8096	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4cccnc4F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4091821	>	>	IC50	nM	30000.0	IC50	uM	30.0
8097	Induction of CYP3A4 in cryopreserved human hepatocytes measured after 48 hrs	Cc1nnc2sc(C(=O)NCc3ccc(-c4cccnc4F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4091821	>	>	EC50	nM	50000.0	EC50	uM	50.0
8098	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	O=C(N/N=C/c1ccc2no[n+]([O-])c2c1)c1ccncc1	J Med Chem	2017.0	CHEMBL2338421	>	>	IC50	nM	20000.0	IC50	uM	20.0
8099	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 30 mins by LC-MS/MS analysis	N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1	J Med Chem	2017.0	CHEMBL4095003	=	=	IC50	nM	1300.0	IC50	uM	1.3
8100	Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by addition of NADPH generating system measured after 20 mins by LC-MS/MS analysis	COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1	J Med Chem	2018.0	CHEMBL4066961	>	>	IC50	nM	50000.0	IC50	uM	50.0
8101	Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1cccc(C(F)(F)F)c1F	J Med Chem	2018.0	CHEMBL3919664	>	>	IC50	nM	10000.0	IC50	uM	10.0
8102	Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1ccnc(C(F)(F)F)c1F	J Med Chem	2018.0	CHEMBL3914857	>	>	IC50	nM	10000.0	IC50	uM	10.0
8103	Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	Cc1c(C(=O)N2Cc3nnn(-c4ncc(F)cn4)c3C[C@@H]2C)ccnc1C(F)(F)F	J Med Chem	2018.0	CHEMBL3936866	>	>	IC50	nM	10000.0	IC50	uM	10.0
8104	Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc(Cl)cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4084418	=	=	IC50	nM	94600.0	IC50	uM	94.6
8105	Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc(Br)cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4062734	=	=	IC50	nM	137800.0	IC50	uM	137.8
8106	Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc([N+](=O)[O-])cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4099918	=	=	IC50	nM	155700.0	IC50	uM	155.7
8107	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NC3CN(c4cccc(F)c4F)C3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4062319	=	=	IC50	nM	11000.0	IC50	uM	11.0
8108	Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NC3CN(c4ccc(C(F)(F)F)nc4)C3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4083081	>	>	IC50	nM	30000.0	IC50	uM	30.0
8109	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4102254	>	>	IC50	nM	30000.0	IC50	uM	30.0
8110	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3645526	=	=	IC50	nM	3500.0	IC50	uM	3.5
8111	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4099792	>	>	IC50	nM	30000.0	IC50	uM	30.0
8112	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4100755	=	=	IC50	nM	27000.0	IC50	uM	27.0
8113	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4076820	>	>	IC50	nM	30000.0	IC50	uM	30.0
8114	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4079355	=	=	IC50	nM	6600.0	IC50	uM	6.6
8115	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4103620	=	=	IC50	nM	10000.0	IC50	uM	10.0
8116	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccccn2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4060843	=	=	IC50	nM	23000.0	IC50	uM	23.0
8117	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2cccnc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4070571	=	=	IC50	nM	2100.0	IC50	uM	2.1
8118	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccncc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4101787	=	=	IC50	nM	1800.0	IC50	uM	1.8
8119	Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CCCO)(c4ccccc4)OC3=O)cc2)cc(C)n1	Bioorg Med Chem	2017.0	CHEMBL4075665	>	>	IC50	nM	30000.0	IC50	uM	30.0
8120	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2cncc(F)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4075869	=	=	IC50	nM	11000.0	IC50	uM	11.0
8121	Inhibition of recombinant CYP3A4 (unknown origin)	COc1ccc(-c2ccc([C@H](C)N3CC[C@](CCCO)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4066654	>	>	IC50	nM	30000.0	IC50	uM	30.0
8122	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664710	=	=	IC50	nM	10500.0	IC50	uM	10.5
8123	Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)n1	Bioorg Med Chem	2017.0	CHEMBL4072112	>	>	IC50	nM	50000.0	IC50	uM	50.0
8124	Inhibition of recombinant CYP3A4 (unknown origin)	COc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4069717	=	=	IC50	nM	11600.0	IC50	uM	11.6
8125	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(F)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4096179	=	=	IC50	nM	24100.0	IC50	uM	24.1
8126	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(C#N)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4090128	=	=	IC50	nM	12700.0	IC50	uM	12.7
8127	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(C(N)=O)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4076599	>	>	IC50	nM	50000.0	IC50	uM	50.0
8128	Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cnc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4064441	>	>	IC50	nM	50000.0	IC50	uM	50.0
8129	Inhibition of recombinant CYP3A4 (unknown origin)	Cc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn1	Bioorg Med Chem	2017.0	CHEMBL4075178	>	>	IC50	nM	50000.0	IC50	uM	50.0
8130	Inhibition of recombinant CYP3A4 (unknown origin)	Cc1ncc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4105041	>	>	IC50	nM	50000.0	IC50	uM	50.0
8131	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664715	=	=	IC50	nM	48000.0	IC50	uM	48.0
8132	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664717	>	>	IC50	nM	50000.0	IC50	uM	50.0
8133	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4063121	>	>	IC50	nM	50000.0	IC50	uM	50.0
8134	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc3ncnn3c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3660140	=	=	IC50	nM	10000.0	IC50	uM	10.0
8135	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N1CCC(c2ccc(NC(=O)N3Cc4ccccc4C3)cc2)CC1	Bioorg Med Chem Lett	2017.0	CHEMBL4082366	=	=	IC50	nM	16000.0	IC50	uM	16.0
8136	Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H]1CCOC1)c1ccc(NC(=O)N2Cc3ccccc3C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL3929298	>	>	IC50	nM	20000.0	IC50	uM	20.0
8137	Competitive inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2nc(CCC(F)(F)F)c(-c3cc(C(=O)NC(C)(C)c4ncon4)c(=O)n(C)c3)cc12	ACS Med Chem Lett	2017.0	CHEMBL4061621	=	=	IC50	nM	440.0	IC50	uM	0.44
8138	Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cncn2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL4104608	=	=	IC50	nM	1000.0	IC50	uM	1.0
8139	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin as substrate measured after 45 mins in presence of NADPH by spectrofluorometric method	O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12	Eur J Med Chem	2017.0	CHEMBL8260	=	=	IC50	nM	9200.0	IC50	uM	9.2
8140	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL4103707	>	>	IC50	nM	30000.0	IC50	uM	30.0
8141	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL4076771	>	>	IC50	nM	30000.0	IC50	uM	30.0
8142	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	CCc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL2386772	>	>	IC50	nM	30000.0	IC50	uM	30.0
8143	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cccc(F)n2)n1	J Med Chem	2017.0	CHEMBL4095685	>	>	IC50	nM	30000.0	IC50	uM	30.0
8144	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cccc(F)n2)n1	J Med Chem	2017.0	CHEMBL4077672	=	=	IC50	nM	8000.0	IC50	uM	8.0
8145	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	>	>	IC50	nM	30000.0	IC50	uM	30.0
8146	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386849	=	=	IC50	nM	4300.0	IC50	uM	4.3
8147	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(Cl)cn2)n1	J Med Chem	2017.0	CHEMBL4082854	=	=	IC50	nM	16400.0	IC50	uM	16.4
8148	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(Cl)cn2)n1	J Med Chem	2017.0	CHEMBL4100830	=	=	IC50	nM	2000.0	IC50	uM	2.0
8149	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cc(F)ccn2)n1	J Med Chem	2017.0	CHEMBL4090661	>	>	IC50	nM	30000.0	IC50	uM	30.0
8150	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cc(F)ccn2)n1	J Med Chem	2017.0	CHEMBL4062697	=	=	IC50	nM	27400.0	IC50	uM	27.4
8151	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cnc(C)nc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386771	>	>	IC50	nM	30000.0	IC50	uM	30.0
8152	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(Cl)c2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL4096818	=	=	IC50	nM	3800.0	IC50	uM	3.8
8153	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	=	=	IC50	nM	133000.0	IC50	uM	133.0
8154	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	>	>	IC50	nM	200000.0	IC50	uM	200.0
8155	Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3nccs3)cc1)CCC2	J Med Chem	2017.0	CHEMBL4094309	=	=	IC50	nM	5200.0	IC50	uM	5.2
8156	Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cccnc3)nn1)CCC2	J Med Chem	2017.0	CHEMBL4104257	=	=	IC50	nM	6200.0	IC50	uM	6.2
8157	Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1	J Med Chem	2017.0	CHEMBL4087906	=	=	IC50	nM	2100.0	IC50	uM	2.1
8158	Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cncc(F)c3)nn1)CCC2	J Med Chem	2017.0	CHEMBL4066589	=	=	IC50	nM	7100.0	IC50	uM	7.1
8159	Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cncc(F)c2)nn1	J Med Chem	2017.0	CHEMBL4095609	=	=	IC50	nM	16000.0	IC50	uM	16.0
8160	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ccc(NC(=O)CN3CCCC4=C3C(=O)N(C)C4=O)nn2)cn1	J Med Chem	2017.0	CHEMBL4075204	>	>	IC50	nM	30000.0	IC50	uM	30.0
8161	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ccc(NC(=O)CN3CCCC4=C3C(=O)N(C3CC3)C4=O)nn2)cn1	J Med Chem	2017.0	CHEMBL4103356	=	=	IC50	nM	8000.0	IC50	uM	8.0
8162	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N	J Med Chem	2017.0	CHEMBL2324753	=	=	IC50	nM	556.0	IC50	nM	556.0
8163	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ncns2)cc1F	J Med Chem	2017.0	CHEMBL2325350	<	<	IC50	nM	30.0	IC50	nM	30.0
8164	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl	J Med Chem	2017.0	CHEMBL2324755	=	=	IC50	nM	11068.0	IC50	nM	11068.0
8165	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2cscn2)cc1C#N	J Med Chem	2017.0	CHEMBL2322421	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8166	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2324405	=	=	IC50	nM	26588.0	IC50	nM	26588.0
8167	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl	J Med Chem	2017.0	CHEMBL2324391	=	=	IC50	nM	1058.0	IC50	nM	1058.0
8168	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccn[nH]1	J Med Chem	2017.0	CHEMBL2324742	=	=	IC50	nM	400.0	IC50	nM	400.0
8169	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1	J Med Chem	2017.0	CHEMBL2325330	=	=	IC50	nM	505.0	IC50	nM	505.0
8170	Inhibition of CYP3A4 (unknown origin)	Cc1[nH]ncc1-c1cc(C(F)(F)F)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N	J Med Chem	2017.0	CHEMBL2325619	=	=	IC50	nM	737.0	IC50	nM	737.0
8171	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1N	J Med Chem	2017.0	CHEMBL2325038	=	=	IC50	nM	827.0	IC50	nM	827.0
8172	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccnc(N)c1	J Med Chem	2017.0	CHEMBL2325013	=	=	IC50	nM	205.0	IC50	nM	205.0
8173	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccncn1	J Med Chem	2017.0	CHEMBL2323074	=	=	IC50	nM	910.0	IC50	nM	910.0
8174	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1cccnn1	J Med Chem	2017.0	CHEMBL2323073	=	=	IC50	nM	616.0	IC50	nM	616.0
8175	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccnnc1	J Med Chem	2017.0	CHEMBL2325021	=	=	IC50	nM	1271.0	IC50	nM	1271.0
8176	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1nncs1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F	J Med Chem	2017.0	CHEMBL2324776	>	>	IC50	nM	11248.0	IC50	nM	11248.0
8177	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cscn1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F	J Med Chem	2017.0	CHEMBL2324396	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8178	Inhibition of CYP3A4 (unknown origin)	Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl	J Med Chem	2017.0	CHEMBL2325627	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8179	Inhibition of CYP3A4 (unknown origin)	Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2325601	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8180	Inhibition of CYP3A4 (unknown origin)	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2325014	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8181	Inhibition of CYP3A4 (unknown origin)	CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325622	=	=	IC50	nM	427.0	IC50	nM	427.0
8182	Inhibition of CYP3A4 (unknown origin)	CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2ccc(S(=O)(=O)Nc3cscn3)cc2C#N)C1	J Med Chem	2017.0	CHEMBL2324748	=	=	IC50	nM	12239.0	IC50	nM	12239.0
8183	Inhibition of CYP3A4 (unknown origin)	CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325317	=	=	IC50	nM	15124.0	IC50	nM	15124.0
8184	Inhibition of CYP3A4 (unknown origin)	CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325020	>	>	IC50	nM	30000.0	IC50	nM	30000.0
8185	Inhibition of CYP3A4 (unknown origin)	C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1	J Med Chem	2017.0	CHEMBL4105630	>	>	IC50	nM	30000.0	IC50	uM	30.0
8186	Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1ccc(/C=C/c2cc(O)c(O)c(O)c2)cc1	J Med Chem	2017.0	CHEMBL4062993	=	=	IC50	nM	36200.0	IC50	uM	36.2
8187	Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1cc(O)c(O)cc1-c1cc2ccccc2o1	J Med Chem	2017.0	CHEMBL4090305	=	=	IC50	nM	11200.0	IC50	uM	11.2
8188	Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1cc(O)c2oc(-c3cc(O)c(O)c(O)c3)cc2c1	J Med Chem	2017.0	CHEMBL3409195	=	=	IC50	nM	21700.0	IC50	uM	21.7
8189	Inhibition of CYP3A4 in human liver microsomes	Oc1ccc(-c2cc3cc(Br)cc(O)c3o2)cc1O	J Med Chem	2017.0	CHEMBL3409192	=	=	IC50	nM	23500.0	IC50	uM	23.5
8190	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4061793	>	>	IC50	nM	20000.0	IC50	uM	20.0
8191	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCO[C@H]2OCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4104727	>	>	IC50	nM	20000.0	IC50	uM	20.0
8192	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCC[C@@]2(O)CCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4071736	=	=	IC50	nM	6300.0	IC50	uM	6.3
8193	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CC4CC(CC(O)(C4)C2)C3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4061129	=	=	IC50	nM	6300.0	IC50	uM	6.3
8194	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4101414	>	>	IC50	nM	20000.0	IC50	uM	20.0
8195	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCCC2CCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4073353	>	>	IC50	nM	20000.0	IC50	uM	20.0
8196	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2OCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4083744	>	>	IC50	nM	20000.0	IC50	uM	20.0
8197	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOCC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4102647	>	>	IC50	nM	20000.0	IC50	uM	20.0
8198	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCOCC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4064762	>	>	IC50	nM	20000.0	IC50	uM	20.0
8199	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4092463	>	>	IC50	nM	20000.0	IC50	uM	20.0
8200	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2COCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4087220	>	>	IC50	nM	20000.0	IC50	uM	20.0
8201	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4065798	>	>	IC50	nM	20000.0	IC50	uM	20.0
8202	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4072883	>	>	IC50	nM	20000.0	IC50	uM	20.0
8203	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CC(C)(C)[C@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem	2017.0	CHEMBL4064295	=	=	IC50	nM	4900.0	IC50	uM	4.9
8204	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CC(C)(C)[C@@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem	2017.0	CHEMBL4084268	=	=	IC50	nM	5500.0	IC50	uM	5.5
8205	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCO[C@@H]2c2ccccc2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4102233	=	=	IC50	nM	3600.0	IC50	uM	3.6
8206	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4094490	>	>	IC50	nM	20000.0	IC50	uM	20.0
8207	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=C1CCCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem	2017.0	CHEMBL4102624	>	>	IC50	nM	20000.0	IC50	uM	20.0
8208	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@H](O)C2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4084685	>	>	IC50	nM	20000.0	IC50	uM	20.0
8209	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@@H](O)C2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4094879	>	>	IC50	nM	20000.0	IC50	uM	20.0
8210	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCC3(C2)OCCO3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4074392	=	=	IC50	nM	16500.0	IC50	uM	16.5
8211	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4073324	>	>	IC50	nM	20000.0	IC50	uM	20.0
8212	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CON=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4100176	=	=	IC50	nM	13700.0	IC50	uM	13.7
8213	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@H](O)CC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4092435	>	>	IC50	nM	20000.0	IC50	uM	20.0
8214	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@@H](O)CC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4068484	>	>	IC50	nM	20000.0	IC50	uM	20.0
8215	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S1(=O)CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4075332	>	>	IC50	nM	20000.0	IC50	uM	20.0
8216	Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S1(=O)CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem	2017.0	CHEMBL4082252	>	>	IC50	nM	20000.0	IC50	uM	20.0
8217	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1ccccc1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4060556	>	>	IC50	nM	50000.0	IC50	uM	50.0
8218	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4102181	>	>	IC50	nM	50000.0	IC50	uM	50.0
8219	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4087545	>	>	IC50	nM	50000.0	IC50	uM	50.0
8220	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4098822	>	>	IC50	nM	40000.0	IC50	uM	40.0
8221	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4086461	>	>	IC50	nM	30000.0	IC50	uM	30.0
8222	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4104355	>	>	IC50	nM	30000.0	IC50	uM	30.0
8223	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4086461	>	>	IC50	nM	30000.0	IC50	uM	30.0
8224	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4104355	=	=	IC50	nM	21000.0	IC50	uM	21.0
8225	Inhibition of human CYP3A4	CCCCc1cc(OC2CCN(CCCCNS(=O)(=O)CC)CC2)c2ncccc2c1.Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4088036	=	=	IC50	nM	4000.0	IC50	uM	4.0
8226	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	N#Cc1cncc(Oc2cc(C(=O)Nc3ccc(F)cn3)c3ncnn3c2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4089606	=	=	IC50	nM	10600.0	IC50	uM	10.6
8227	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cnc(F)c(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4081733	=	=	IC50	nM	23000.0	IC50	uM	23.0
8228	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2F)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4092008	>	>	IC50	nM	30000.0	IC50	uM	30.0
8229	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncnc2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4085919	>	>	IC50	nM	30000.0	IC50	uM	30.0
8230	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4089114	>	>	IC50	nM	30000.0	IC50	uM	30.0
8231	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2cnnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4071447	=	=	IC50	nM	17800.0	IC50	uM	17.8
8232	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4104546	=	=	IC50	nM	2000.0	IC50	uM	2.0
8233	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4080316	=	=	IC50	nM	1900.0	IC50	uM	1.9
8234	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ccnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4066902	=	=	IC50	nM	3900.0	IC50	uM	3.9
8235	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)n1	Bioorg Med Chem Lett	2017.0	CHEMBL4088174	=	=	IC50	nM	2100.0	IC50	uM	2.1
8236	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1cccc(F)n1)c1cc(Oc2cncc(F)c2)cn2ccnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4077770	=	=	IC50	nM	2300.0	IC50	uM	2.3
8237	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1	Bioorg Med Chem Lett	2017.0	CHEMBL2386849	=	=	IC50	nM	4300.0	IC50	uM	4.3
8238	Inhibition of CYP3A4 (unknown origin)	CN1[C@H]2CC[C@@H]1Cc1sc(NC(=O)Nc3ccc(Cl)cc3)c(C(N)=O)c12.Cl	J Med Chem	2018.0	CHEMBL4096279	=	=	IC50	nM	46000.0	IC50	uM	46.0
8239	Inhibition of human CYP3A4 using fluorogenic substrate preincubated with co-factor for 10 mins followed by enzyme-substrate addition by fluorometric method	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(/C=C/c4c(Cl)cccc4Cl)oc23)[C@H](O)C1	J Med Chem	2018.0	CHEMBL4079206	>	>	IC50	nM	20000.0	IC50	uM	20.0
8240	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1	J Med Chem	2018.0	CHEMBL3917415	=	=	IC50	nM	43000.0	IC50	uM	43.0
8241	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1	J Med Chem	2018.0	CHEMBL4104507	>	>	IC50	nM	50000.0	IC50	uM	50.0
8242	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)nc3)n2)CC1	J Med Chem	2018.0	CHEMBL4060895	=	=	IC50	nM	47000.0	IC50	uM	47.0
8243	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3cccnc3)n2)CC1	J Med Chem	2018.0	CHEMBL4081213	=	=	IC50	nM	8000.0	IC50	uM	8.0
8244	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	Cn1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1	J Med Chem	2018.0	CHEMBL4093444	>	>	IC50	nM	50000.0	IC50	uM	50.0
8245	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	CC(C)(C)n1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1	J Med Chem	2018.0	CHEMBL4065483	>	>	IC50	nM	50000.0	IC50	uM	50.0
8246	Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1	J Med Chem	2018.0	CHEMBL4073014	>	>	IC50	nM	50000.0	IC50	uM	50.0
8247	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2	J Med Chem	2017.0	CHEMBL4100640	=	=	IC50	nM	6400.0	IC50	uM	6.4
8248	Inhibition of CYP3A4 (unknown origin)	O=C(O)CN1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2	J Med Chem	2017.0	CHEMBL4105361	>	>	IC50	nM	50000.0	IC50	uM	50.0
8249	Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4069786	>	>	IC50	nM	50000.0	IC50	uM	50.0
8250	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
8251	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	>	>	IC50	nM	50000.0	IC50	uM	50.0
8252	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1	J Med Chem	2017.0	CHEMBL4082282	>	>	IC50	nM	50000.0	IC50	uM	50.0
8253	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4087688	>	>	IC50	nM	50000.0	IC50	uM	50.0
8254	Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4066339	>	>	IC50	nM	50000.0	IC50	uM	50.0
8255	Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4079801	>	>	IC50	nM	50000.0	IC50	uM	50.0
8256	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
8257	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
8258	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	=	=	IC50	nM	19500.0	IC50	uM	19.5
8259	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	=	=	IC50	nM	13300.0	IC50	uM	13.3
8260	Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1	J Med Chem	2017.0	CHEMBL4082282	>	>	IC50	nM	50000.0	IC50	uM	50.0
8261	Inhibition of CYP3A4 (unknown origin)	Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1	J Med Chem	2017.0	CHEMBL4068611	=	=	IC50	nM	1300.0	IC50	uM	1.3
8262	Inhibition of CYP3A4 (unknown origin)	Cc1cn2cc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)nc2c(C)n1	J Med Chem	2017.0	CHEMBL4081789	>	>	IC50	nM	50000.0	IC50	uM	50.0
8263	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	O=[N+]([O-])c1cn2c(n1)O[C@@H](COc1ccc(-c3ccc(F)cc3)nc1)CC2	J Med Chem	2017.0	CHEMBL4069220	>	>	IC50	nM	100000.0	IC50	uM	100.0
8264	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	C[C@]1(COc2ccc(OC(F)(F)F)cc2)Cn2cc([N+](=O)[O-])nc2O1	J Med Chem	2017.0	CHEMBL218974	>	>	IC50	nM	25000.0	IC50	uM	25.0
8265	Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC-MS/MS analysis	Cl.NCc1ccnc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)c1	J Med Chem	2017.0	CHEMBL4063337	=	=	IC50	nM	30000.0	IC50	uM	30.0
8266	Inhibition of CYP3A4 (unknown origin)	COc1ccc(F)c(-c2ccc(Cc3ccc(N4C[C@H](C(F)(F)F)C[C@@H]4CC(=O)O)cc3)c(C)c2)c1	J Med Chem	2017.0	CHEMBL4083365	=	=	IC50	nM	1700.0	IC50	uM	1.7
8267	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3cc(F)ccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4094806	>	>	IC50	nM	10000.0	IC50	uM	10.0
8268	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3cnccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4074304	=	=	IC50	nM	2300.0	IC50	uM	2.3
8269	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3ncccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4068397	>	>	IC50	nM	10000.0	IC50	uM	10.0
8270	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	Cc1ccnc(-n2nnc3c2CCN(C(=O)c2cccc(C(F)(F)F)c2Cl)[C@@H]3C)n1	J Med Chem	2017.0	CHEMBL4095741	>	>	IC50	nM	10000.0	IC50	uM	10.0
8271	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4079239	>	>	IC50	nM	10000.0	IC50	uM	10.0
8272	Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N	Bioorg Med Chem Lett	2017.0	CHEMBL4096145	=	=	IC50	nM	3000.0	IC50	uM	3.0
8273	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4080797	=	=	IC50	nM	11000.0	IC50	uM	11.0
8274	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4068343	=	=	IC50	nM	100000.0	IC50	uM	100.0
8275	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4068343	=	=	IC50	nM	198000.0	IC50	uM	198.0
8276	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(Cl)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4087982	>	>	IC50	nM	200000.0	IC50	uM	200.0
8277	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(C(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4059686	>	>	IC50	nM	200000.0	IC50	uM	200.0
8278	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2cccc(F)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4100049	>	>	IC50	nM	200000.0	IC50	uM	200.0
8279	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2cccc(Cl)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4073194	>	>	IC50	nM	200000.0	IC50	uM	200.0
8280	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCC(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4063185	=	=	IC50	nM	60000.0	IC50	uM	60.0
8281	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(NCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4096118	=	=	IC50	nM	10000.0	IC50	uM	10.0
8282	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Bioorg Med Chem Lett	2017.0	CHEMBL1397	=	=	IC50	nM	75.0	IC50	uM	0.075
8283	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL106	=	=	IC50	nM	32000.0	IC50	uM	32.0
8284	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL3311228	=	=	IC50	nM	65000.0	IC50	uM	65.0
8285	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(OC(F)(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4080531	>	>	IC50	nM	200000.0	IC50	uM	200.0
8286	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(C(F)(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4097031	>	>	IC50	nM	200000.0	IC50	uM	200.0
8287	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	CNC(=O)c1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4069838	=	=	IC50	nM	122000.0	IC50	uM	122.0
8288	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4063357	>	>	IC50	nM	200000.0	IC50	uM	200.0
8289	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(CC(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4064340	>	>	IC50	nM	200000.0	IC50	uM	200.0
8290	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(CC(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4064340	>	>	IC50	nM	200000.0	IC50	uM	200.0
8291	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4077246	>	>	IC50	nM	200000.0	IC50	uM	200.0
8292	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4077246	>	>	IC50	nM	200000.0	IC50	uM	200.0
8293	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1cccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4067180	>	>	IC50	nM	200000.0	IC50	uM	200.0
8294	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4073979	>	>	IC50	nM	200000.0	IC50	uM	200.0
8295	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4073979	>	>	IC50	nM	200000.0	IC50	uM	200.0
8296	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)c(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4102268	>	>	IC50	nM	200000.0	IC50	uM	200.0
8297	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(Cl)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4084305	>	>	IC50	nM	200000.0	IC50	uM	200.0
8298	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4cc(F)ccc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4075382	>	>	IC50	nM	200000.0	IC50	uM	200.0
8299	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(OCc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4086421	>	>	IC50	nM	200000.0	IC50	uM	200.0
8300	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1586994	>	>	IC50	nM	20000.0	IC50	uM	20.0
8301	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(OC)c1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299166	>	>	IC50	nM	20000.0	IC50	uM	20.0
8302	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cc([N+](=O)[O-])ccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299167	>	>	IC50	nM	20000.0	IC50	uM	20.0
8303	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2236657	>	>	IC50	nM	20000.0	IC50	uM	20.0
8304	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1477453	>	>	IC50	nM	20000.0	IC50	uM	20.0
8305	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2299353	>	>	IC50	nM	20000.0	IC50	uM	20.0
8306	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/C=C/c1ccccc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4065261	>	>	IC50	nM	20000.0	IC50	uM	20.0
8307	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4086703	>	>	IC50	nM	20000.0	IC50	uM	20.0
8308	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1F)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081406	>	>	IC50	nM	20000.0	IC50	uM	20.0
8309	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4105559	>	>	IC50	nM	20000.0	IC50	uM	20.0
8310	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL3745717	>	>	IC50	nM	20000.0	IC50	uM	20.0
8311	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	CN(C)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2299165	>	>	IC50	nM	20000.0	IC50	uM	20.0
8312	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2299354	>	>	IC50	nM	20000.0	IC50	uM	20.0
8313	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1335197	>	>	IC50	nM	20000.0	IC50	uM	20.0
8314	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccc(Br)c1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4061752	>	>	IC50	nM	20000.0	IC50	uM	20.0
8315	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1Br	Bioorg Med Chem Lett	2017.0	CHEMBL4089828	>	>	IC50	nM	20000.0	IC50	uM	20.0
8316	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	CCc1ccc(/C=C/C(=O)c2ccc[nH]2)o1	Bioorg Med Chem Lett	2017.0	CHEMBL4076533	>	>	IC50	nM	20000.0	IC50	uM	20.0
8317	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4090207	>	>	IC50	nM	20000.0	IC50	uM	20.0
8318	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081017	>	>	IC50	nM	20000.0	IC50	uM	20.0
8319	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(O)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4105268	>	>	IC50	nM	20000.0	IC50	uM	20.0
8320	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1c2ccccc2cc2ccccc12)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4070384	>	>	IC50	nM	20000.0	IC50	uM	20.0
8321	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccc(Cl)c1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL3735451	>	>	IC50	nM	20000.0	IC50	uM	20.0
8322	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(Br)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299352	>	>	IC50	nM	20000.0	IC50	uM	20.0
8323	Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	20000.0	IC50	uM	20.0
8324	Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4105559	>	>	IC50	nM	10000.0	IC50	uM	10.0
8325	Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1335197	>	>	IC50	nM	10000.0	IC50	uM	10.0
8326	Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081017	>	>	IC50	nM	20000.0	IC50	uM	20.0
8327	Inhibition of recombinant human CYP3A4	CC(C)N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4064440	>	>	IC50	nM	50000.0	IC50	uM	50.0
8328	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(Cc2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4082198	>	>	IC50	nM	50000.0	IC50	uM	50.0
8329	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL3719193	>	>	IC50	nM	50000.0	IC50	uM	50.0
8330	Inhibition of recombinant human CYP3A4	Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4102920	=	=	IC50	nM	1400.0	IC50	uM	1.4
8331	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2cccc(F)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4095848	>	>	IC50	nM	50000.0	IC50	uM	50.0
8332	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccc(F)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4076060	>	>	IC50	nM	50000.0	IC50	uM	50.0
8333	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccc(Cl)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4077048	>	>	IC50	nM	50000.0	IC50	uM	50.0
8334	Inhibition of recombinant human CYP3A4	COc1ccccc1N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4065818	>	>	IC50	nM	50000.0	IC50	uM	50.0
8335	Inhibition of recombinant human CYP3A4	COc1cccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4063206	=	=	IC50	nM	9600.0	IC50	uM	9.6
8336	Inhibition of recombinant human CYP3A4	COc1ccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4084855	=	=	IC50	nM	25000.0	IC50	uM	25.0
8337	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2cccc(C#N)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4074586	>	>	IC50	nM	50000.0	IC50	uM	50.0
8338	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccncc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4065956	>	>	IC50	nM	50000.0	IC50	uM	50.0
8339	Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccccn2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4093930	>	>	IC50	nM	50000.0	IC50	uM	50.0
8340	Inhibition of recombinant human CYP3A4	COc1ccccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4085821	>	>	IC50	nM	50000.0	IC50	uM	50.0
8341	Inhibition of recombinant human CYP3A4	COc1cccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)c1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4061578	>	>	IC50	nM	50000.0	IC50	uM	50.0
8342	Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	53000.0	IC50	uM	53.0
8343	Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	50000.0	IC50	uM	50.0
8344	Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	50000.0	IC50	uM	50.0
8345	Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4076186	>	>	IC50	nM	50000.0	IC50	uM	50.0
8346	Inhibition of CYP3A4 in human liver microsomes	COc1ccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)cc1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4078436	>	>	IC50	nM	53000.0	IC50	uM	53.0
8347	Inhibition of CYP3A4 (unknown origin)	CNC(=O)N1CCc2c(c(N3CCCc4cc(-c5cnn(C)c5)c(C(F)F)cc43)nn2C2CCOCC2)C1	J Med Chem	2017.0	CHEMBL4097025	>	>	IC50	nM	10000.0	IC50	uM	10.0
8348	Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1	J Med Chem	2017.0	CHEMBL4086143	>	>	IC50	nM	100000.0	IC50	uM	100.0
8349	Inhibition of CYP3A4 (unknown origin)	O=C1C[C@H](c2c[nH]c3ccccc23)C(=O)N1	J Med Chem	2017.0	CHEMBL4087106	>	>	IC50	nM	10000.0	IC50	uM	10.0
8350	Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
8351	Inhibition of CYP3A4 (unknown origin)	c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccn2)nc1	J Med Chem	2018.0	CHEMBL4086739	=	=	IC50	nM	6010.0	IC50	uM	6.01
8352	Inhibition of CYP3A4 (unknown origin)	c1cncc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2cccnc2)c1	J Med Chem	2018.0	CHEMBL4081338	=	=	IC50	nM	1290.0	IC50	uM	1.29
8353	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCN(Cc1ccncc1)Cc1ccncc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4105591	=	=	IC50	nM	622.0	IC50	uM	0.622
8354	Inhibition of CYP3A4 (unknown origin)	c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccc2)cc1	J Med Chem	2018.0	CHEMBL4082134	=	=	IC50	nM	2240.0	IC50	uM	2.24
8355	Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)nc1	J Med Chem	2018.0	CHEMBL3091683	=	=	IC50	nM	4500.0	IC50	uM	4.5
8356	Inhibition of CYP3A4 (unknown origin)	c1cncc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1	J Med Chem	2018.0	CHEMBL4071612	=	=	IC50	nM	8450.0	IC50	uM	8.45
8357	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCc1ccncc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4092405	=	=	IC50	nM	4500.0	IC50	uM	4.5
8358	Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1	J Med Chem	2018.0	CHEMBL4062981	=	=	IC50	nM	6150.0	IC50	uM	6.15
8359	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCCCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4084652	=	=	IC50	nM	2780.0	IC50	uM	2.78
8360	Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4101106	=	=	IC50	nM	19200.0	IC50	uM	19.2
8361	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCOCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4074366	>	>	IC50	nM	20000.0	IC50	uM	20.0
8362	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCNCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4076841	>	>	IC50	nM	20000.0	IC50	uM	20.0
8363	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCSCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4065751	>	>	IC50	nM	20000.0	IC50	uM	20.0
8364	Inhibition of CYP3A4 (unknown origin)	O=S1(=O)CCC(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4070843	>	>	IC50	nM	20000.0	IC50	uM	20.0
8365	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4097946	=	=	IC50	nM	11700.0	IC50	uM	11.7
8366	Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4062223	=	=	IC50	nM	11300.0	IC50	uM	11.3
8367	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCOCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4090235	>	>	IC50	nM	20000.0	IC50	uM	20.0
8368	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCNCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4089307	>	>	IC50	nM	20000.0	IC50	uM	20.0
8369	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCSCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4068122	>	>	IC50	nM	20000.0	IC50	uM	20.0
8370	Inhibition of CYP3A4 (unknown origin)	O=S1(=O)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4081436	>	>	IC50	nM	20000.0	IC50	uM	20.0
8371	Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4059462	=	=	IC50	nM	12900.0	IC50	uM	12.9
8372	Inhibition of CYP3A4 (unknown origin)	NCc1ccccc1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4084920	=	=	IC50	nM	15200.0	IC50	uM	15.2
8373	Inhibition of CYP3A4 (unknown origin)	NCc1cccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1	J Med Chem	2018.0	CHEMBL4075694	=	=	IC50	nM	4630.0	IC50	uM	4.63
8374	Inhibition of CYP3A4 (unknown origin)	NCc1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1	J Med Chem	2018.0	CHEMBL4078260	=	=	IC50	nM	7440.0	IC50	uM	7.44
8375	Inhibition of CYP3A4 (unknown origin)	NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4096305	=	=	IC50	nM	12700.0	IC50	uM	12.7
8376	Inhibition of CYP3A4 (unknown origin)	NC/C=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4086147	=	=	IC50	nM	9290.0	IC50	uM	9.29
8377	Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4104056	=	=	IC50	nM	10800.0	IC50	uM	10.8
8378	Inhibition of CYP3A4 (unknown origin)	CC(C)(CN)CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4104948	>	>	IC50	nM	20000.0	IC50	uM	20.0
8379	Inhibition of CYP3A4 (unknown origin)	CC(C)(N)CCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4080718	>	>	IC50	nM	20000.0	IC50	uM	20.0
8380	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4059622	=	=	IC50	nM	994.0	IC50	uM	0.994
8381	Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1	J Med Chem	2018.0	CHEMBL4088588	=	=	IC50	nM	200.0	IC50	uM	0.2
8382	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4089531	=	=	IC50	nM	442.0	IC50	uM	0.442
8383	Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1	J Med Chem	2018.0	CHEMBL4061381	=	=	IC50	nM	334.0	IC50	uM	0.334
8384	Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)nc1	J Med Chem	2018.0	CHEMBL4072645	=	=	IC50	nM	109.0	IC50	uM	0.109
8385	Inhibition of CYP3A4 (unknown origin)	c1cncc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)c1	J Med Chem	2018.0	CHEMBL4099550	=	=	IC50	nM	58.0	IC50	uM	0.058
8386	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCc3ccncc3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4083122	=	=	IC50	nM	59.0	IC50	uM	0.059
8387	Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCC1CCOCC1	J Med Chem	2018.0	CHEMBL4070320	>	>	IC50	nM	20000.0	IC50	uM	20.0
8388	Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4094123	=	=	IC50	nM	839.0	IC50	uM	0.839
8389	Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCOCC1	J Med Chem	2018.0	CHEMBL4075205	=	=	IC50	nM	7730.0	IC50	uM	7.73
8390	Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4098635	=	=	IC50	nM	990.0	IC50	uM	0.99
8391	Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccccn1	J Med Chem	2018.0	CHEMBL4081958	=	=	IC50	nM	1560.0	IC50	uM	1.56
8392	Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1cccnc1	J Med Chem	2018.0	CHEMBL4066459	=	=	IC50	nM	1250.0	IC50	uM	1.25
8393	Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccncc1	J Med Chem	2018.0	CHEMBL4090772	=	=	IC50	nM	350.0	IC50	uM	0.35
8394	Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNCC1CCOCC1	J Med Chem	2018.0	CHEMBL4073818	>	>	IC50	nM	20000.0	IC50	uM	20.0
8395	Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCC(F)(F)CC1	J Med Chem	2018.0	CHEMBL4094400	=	=	IC50	nM	5580.0	IC50	uM	5.58
8396	Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCOCC1	J Med Chem	2018.0	CHEMBL4065224	=	=	IC50	nM	17700.0	IC50	uM	17.7
8397	Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCC(C)(C)CCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4086662	=	=	IC50	nM	7830.0	IC50	uM	7.83
8398	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1	Eur J Med Chem	2017.0	CHEMBL4127941	=	=	IC50	nM	5810.0	IC50	uM	5.81
8399	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1	Eur J Med Chem	2017.0	CHEMBL4126548	=	=	IC50	nM	8380.0	IC50	uM	8.38
8400	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2017.0	CHEMBL157101	=	=	IC50	nM	35.9	IC50	uM	0.0359
8401	Inhibition of CYP3A4 (unknown origin) by CYP3A4 P450-Glo assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
8402	Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCOc3ncnc(N)c3C2=O)cc(C)c1C#CC(C)(C)CC(=O)O	Bioorg Med Chem Lett	2018.0	CHEMBL4126331	=	=	IC50	nM	45500.0	IC50	uM	45.5
8403	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CCn1ncc2c1CC[C@@H](Nc1nc3c(-c4ccc(F)cc4C)cccn3n1)C2	Bioorg Med Chem	2018.0	CHEMBL4127978	>	>	IC50	nM	50000.0	IC50	uM	50.0
8404	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	c1cc(C2CCC3(CC2)OOC2(OO3)C3CC4CC(C3)CC2C4)ccc1CN1CCOCC1	Bioorg Med Chem	2018.0	CHEMBL4127539	>	>	IC50	nM	20000.0	IC50	uM	20.0
8405	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	22.0	IC50	uM	0.022
8406	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	c1cc(C2CCC3(CC2)OOC2(OO3)C3CC4CC(C3)CC2C4)ccc1CN1CCOCC1	Bioorg Med Chem	2018.0	CHEMBL4127539	>	>	IC50	nM	20000.0	IC50	uM	20.0
8407	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	13.0	IC50	uM	0.013
8408	Inhibition of human CYP3A4	Cn1cc(-c2ccc(-c3ccc(C4=NC5(CC5)C(=O)N4C[C@@H]4CCN(C(=O)C5CC5)C4)cc3)cc2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4125752	>	>	IC50	nM	10000.0	IC50	uM	10.0
8409	Inhibition of human CYP3A4	CC1(C)OCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4126289	>	>	IC50	nM	40000.0	IC50	uM	40.0
8410	Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL75	=	=	IC50	nM	146.0	IC50	nM	146.0
8411	Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4129721	=	=	IC50	nM	695.0	IC50	nM	695.0
8412	Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CCS(=O)(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4126284	=	=	IC50	nM	243.0	IC50	nM	243.0
8413	Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1)C(F)(F)F	Bioorg Med Chem Lett	2018.0	CHEMBL4128368	=	=	IC50	nM	9360.0	IC50	nM	9360.0
8414	Inhibition of CYP3A4 (unknown origin)	O=C(c1ccc(-n2nnc3cccnc32)cc1)N(c1ncccc1Cl)[C@@H]1CCCNC1	J Med Chem	2018.0	CHEMBL4109308	>	>	IC50	nM	30000.0	IC50	uM	30.0
8415	Inhibition of CYP3A4 (unknown origin)	Cc1cncc(-c2ccc(C(=O)N(c3ncccc3Cl)[C@@H]3CCCNC3)cc2)n1	J Med Chem	2018.0	CHEMBL4127458	>	>	IC50	nM	30000.0	IC50	uM	30.0
8416	Inhibition of human CYP3A4 (unknown origin)	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1	J Med Chem	2018.0	CHEMBL4127317	=	=	IC50	nM	23900.0	IC50	uM	23.9
8417	Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by NADPH/substrate addition measured after 20 mins by LC-MS/MS analysis	Cc1cccc2c(Nc3cccc(-c4nc5c(C(N)=O)cccc5[nH]4)c3)c3ccccc3nc12	Eur J Med Chem	2017.0	CHEMBL4175440	=	=	IC50	nM	6800.0	IC50	uM	6.8
8418	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CC2COC2)c2cnccc12	Eur J Med Chem	2017.0	CHEMBL4177457	>	>	IC50	nM	100000.0	IC50	uM	100.0
8419	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	CC(COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL4164219	>	>	IC50	nM	30000.0	IC50	uM	30.0
8420	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@H](COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL4172540	>	>	IC50	nM	30000.0	IC50	uM	30.0
8421	Reversible inhibition of recombinant human CYP3A4 by fluorescence-based assay	C[C@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C(N)CO[C@H]1C(F)(F)F	J Med Chem	2018.0	CHEMBL4165225	>	>	IC50	nM	30000.0	IC50	uM	30.0
8422	Inhibition of CYP3A4 (unknown origin)	CN(C)CCNC(=O)[C@H]1c2ccccc2C[C@@H]1NC(=O)c1cc2ccccc2[nH]1	J Med Chem	2018.0	CHEMBL4164328	<	>	IC50	nM	19952.62	pIC50		4.7
8423	Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL3301620	>=	>=	IC50	nM	1000.0	IC50	uM	1.0
8424	Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cncn2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL4104608	>	>	IC50	nM	40000.0	IC50	uM	40.0
8425	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1	ACS Med Chem Lett	2017.0	CHEMBL2361777	>	>	IC50	nM	30000.0	IC50	uM	30.0
8426	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4165248	>	>	IC50	nM	30000.0	IC50	uM	30.0
8427	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1	ACS Med Chem Lett	2017.0	CHEMBL4168668	>	>	IC50	nM	30000.0	IC50	uM	30.0
8428	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1F	ACS Med Chem Lett	2017.0	CHEMBL4160748	>	>	IC50	nM	30000.0	IC50	uM	30.0
8429	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4172016	>	>	IC50	nM	30000.0	IC50	uM	30.0
8430	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21	ACS Med Chem Lett	2017.0	CHEMBL4175981	>	>	IC50	nM	50000.0	IC50	uM	50.0
8431	Inhibition of CYP3A4 in human liver microsomes using midozolam as substrate by LC-MS/MS analysis	Cl.O=C(O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12	ACS Med Chem Lett	2017.0	CHEMBL4166742	>	>	IC50	nM	100000.0	IC50	uM	100.0
8432	Inhibition of CYP3A4 (unknown origin)	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C(F)(F)F)C1=O	ACS Med Chem Lett	2018.0	CHEMBL4174931	=	=	IC50	nM	24000.0	IC50	uM	24.0
8433	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4096305	=	=	IC50	nM	13000.0	IC50	uM	13.0
8434	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC/C=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4086147	=	=	IC50	nM	9300.0	IC50	uM	9.3
8435	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1=C(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CCCC1	ACS Med Chem Lett	2018.0	CHEMBL4167521	=	=	IC50	nM	11000.0	IC50	uM	11.0
8436	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CN	ACS Med Chem Lett	2018.0	CHEMBL4159607	>	>	IC50	nM	20000.0	IC50	uM	20.0
8437	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(=C/CN)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4164075	>	>	IC50	nM	20000.0	IC50	uM	20.0
8438	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(\F)CN	ACS Med Chem Lett	2018.0	CHEMBL4174727	=	=	IC50	nM	13000.0	IC50	uM	13.0
8439	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(/F)CN	ACS Med Chem Lett	2018.0	CHEMBL4169450	=	=	IC50	nM	1800.0	IC50	uM	1.8
8440	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN)=C(\F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4161528	=	=	IC50	nM	15000.0	IC50	uM	15.0
8441	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN)=C(/F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4175500	=	=	IC50	nM	2400.0	IC50	uM	2.4
8442	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	FC1(F)CCC(NC/C=C\CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4164874	=	=	IC50	nM	12000.0	IC50	uM	12.0
8443	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC(=O)NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4160401	=	=	IC50	nM	19000.0	IC50	uM	19.0
8444	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1CC1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4163770	>	>	IC50	nM	20000.0	IC50	uM	20.0
8445	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1CC1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4163770	>	>	IC50	nM	20000.0	IC50	uM	20.0
8446	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4171643	=	=	IC50	nM	10000.0	IC50	uM	10.0
8447	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4167221	=	=	IC50	nM	12000.0	IC50	uM	12.0
8448	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@H](N(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4175088	>	>	IC50	nM	20000.0	IC50	uM	20.0
8449	Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@@H](N(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4161850	>	>	IC50	nM	20000.0	IC50	uM	20.0
8450	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(O)C[C@]1(CC(F)(F)F)CCc2cc(-c3cnc(NC(=O)Nc4ccc(F)c(F)c4)cn3)ccc2C1=O	ACS Med Chem Lett	2018.0	CHEMBL4173715	>	>	IC50	nM	10000.0	IC50	uM	10.0
8451	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NC(=O)c2cccc(S(=O)(=O)N[C@H]3CCOC3)c2)ccc1F	J Med Chem	2018.0	CHEMBL4159471	>	>	IC50	nM	10000.0	IC50	uM	10.0
8452	Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	65.0	IC50	uM	0.065
8453	Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	COc1cc(-c2nc(SCC(=O)NC(=O)Nc3ccccn3)nc(Nc3cccc(Cl)c3)c2C#N)cc(OC)c1OC	J Med Chem	2018.0	CHEMBL4161738	=	=	IC50	nM	17243.0	IC50	uM	17.243
8454	Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2018.0	CHEMBL6966	=	=	IC50	nM	8193.0	IC50	uM	8.193
8455	Inhibition of CYP3A4 (unknown origin) after 2 hrs by firefly luciferase-luminescence based P450-glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	100.0	IC50	uM	0.1
8456	Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-c1ccccc1	ACS Med Chem Lett	2018.0	CHEMBL4166415	>	>	IC50	nM	10000.0	IC50	uM	10.0
8457	Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-c1ccsc1	ACS Med Chem Lett	2018.0	CHEMBL4173485	>	>	IC50	nM	10000.0	IC50	uM	10.0
8458	Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-n1cccn1	ACS Med Chem Lett	2018.0	CHEMBL4168975	>	>	IC50	nM	10000.0	IC50	uM	10.0
8459	Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-n1cc(F)cn1	ACS Med Chem Lett	2018.0	CHEMBL4166624	>	>	IC50	nM	10000.0	IC50	uM	10.0
8460	Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL3091687	>	>	IC50	nM	12000.0	IC50	uM	12.0
8461	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4159410	>	>	IC50	nM	12000.0	IC50	uM	12.0
8462	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCC1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4164702	>	>	IC50	nM	12000.0	IC50	uM	12.0
8463	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4166456	>	>	IC50	nM	12000.0	IC50	uM	12.0
8464	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167058	>	>	IC50	nM	12000.0	IC50	uM	12.0
8465	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4159150	>	>	IC50	nM	12000.0	IC50	uM	12.0
8466	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC[C@@H]1CCCNC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4163611	>	>	IC50	nM	12000.0	IC50	uM	12.0
8467	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC[C@H]1CCCNC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4174290	>	>	IC50	nM	12000.0	IC50	uM	12.0
8468	Inhibition of CYP3A4 (unknown origin)	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL518924	>	>	IC50	nM	6670.0	IC50	uM	6.67
8469	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4170857	>	>	IC50	nM	20000.0	IC50	uM	20.0
8470	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CN[C@@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4175350	>	>	IC50	nM	20000.0	IC50	uM	20.0
8471	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CN[C@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167467	>	>	IC50	nM	20000.0	IC50	uM	20.0
8472	Inhibition of CYP3A4 (unknown origin)	c1cnc(CN(CCCN2CCNCC2)[C@H]2CCCc3cccnc32)nc1	ACS Med Chem Lett	2018.0	CHEMBL4162125	>	>	IC50	nM	20000.0	IC50	uM	20.0
8473	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1cc2ccccc2cn1	ACS Med Chem Lett	2018.0	CHEMBL4172802	>	>	IC50	nM	20000.0	IC50	uM	20.0
8474	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2[nH]1	ACS Med Chem Lett	2018.0	CHEMBL4161613	=	=	IC50	nM	12700.0	IC50	uM	12.7
8475	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2s1	ACS Med Chem Lett	2018.0	CHEMBL4172234	=	=	IC50	nM	9400.0	IC50	uM	9.4
8476	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4165032	>	>	IC50	nM	20000.0	IC50	uM	20.0
8477	Inhibition of CYP3A4 (unknown origin)	CCN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4175653	>	>	IC50	nM	20000.0	IC50	uM	20.0
8478	Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4159991	>	>	IC50	nM	20000.0	IC50	uM	20.0
8479	Inhibition of CYP3A4 (unknown origin)	NC(=O)N1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4160551	>	>	IC50	nM	20000.0	IC50	uM	20.0
8480	Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCN1CCN(C3CC3)CC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167654	>	>	IC50	nM	20000.0	IC50	uM	20.0
8481	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2C)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4170141	>	>	IC50	nM	20000.0	IC50	uM	20.0
8482	Inhibition of CYP3A4 in human liver microsomes using BFC/BZR as substrate	Cc1ccc(CN2CC[C@@H](N3CC[C@@H](c4ccc(O)cc4)[C@H](F)C3)C2=O)cc1	ACS Med Chem Lett	2018.0	CHEMBL3892956	>	>	IC50	nM	18000.0	IC50	uM	18.0
8483	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F	J Med Chem	2018.0	CHEMBL4166144	>	>	IC50	nM	10000.0	IC50	uM	10.0
8484	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F	J Med Chem	2018.0	CHEMBL4176771	>	>	IC50	nM	10000.0	IC50	uM	10.0
8485	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1	J Med Chem	2018.0	CHEMBL4166594	>	>	IC50	nM	10000.0	IC50	uM	10.0
8486	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1	J Med Chem	2018.0	CHEMBL4174909	>	>	IC50	nM	10000.0	IC50	uM	10.0
8487	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cccnc1	J Med Chem	2018.0	CHEMBL4171558	=	=	IC50	nM	4000.0	IC50	uM	4.0
8488	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccc(C#CCN)cn1.Cl.Cl	J Med Chem	2018.0	CHEMBL4164781	>	>	IC50	nM	50000.0	IC50	uM	50.0
8489	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4173088	=	=	IC50	nM	5600.0	IC50	uM	5.6
8490	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4175429	>	>	IC50	nM	50000.0	IC50	uM	50.0
8491	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4167560	>	>	IC50	nM	50000.0	IC50	uM	50.0
8492	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4171984	>	>	IC50	nM	50000.0	IC50	uM	50.0
8493	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccccc1	J Med Chem	2018.0	CHEMBL4164113	=	=	IC50	nM	39000.0	IC50	uM	39.0
8494	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccco1	J Med Chem	2018.0	CHEMBL4163694	=	=	IC50	nM	11000.0	IC50	uM	11.0
8495	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccoc1	J Med Chem	2018.0	CHEMBL4174365	=	=	IC50	nM	6400.0	IC50	uM	6.4
8496	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCC#Cc1cnccc1-c1ccncc1	J Med Chem	2018.0	CHEMBL4160326	>	>	IC50	nM	25000.0	IC50	uM	25.0
8497	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCC#Cc1cnccc1-c1cccnc1	J Med Chem	2018.0	CHEMBL4170930	=	=	IC50	nM	92000.0	IC50	uM	92.0
8498	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCC#Cc1cnccc1-c1cncnc1	J Med Chem	2018.0	CHEMBL4161777	>	>	IC50	nM	25000.0	IC50	uM	25.0
8499	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4172417	=	=	IC50	nM	29000.0	IC50	uM	29.0
8500	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4173133	=	=	IC50	nM	181000.0	IC50	uM	181.0
8501	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4162449	>	>	IC50	nM	25000.0	IC50	uM	25.0
8502	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4169721	=	=	IC50	nM	4900.0	IC50	uM	4.9
8503	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)o1	J Med Chem	2018.0	CHEMBL4159065	=	=	IC50	nM	5200.0	IC50	uM	5.2
8504	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)o1	J Med Chem	2018.0	CHEMBL4161400	=	=	IC50	nM	29000.0	IC50	uM	29.0
8505	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)o1	J Med Chem	2018.0	CHEMBL4169324	=	=	IC50	nM	24000.0	IC50	uM	24.0
8506	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)o1	J Med Chem	2018.0	CHEMBL4176506	=	=	IC50	nM	39000.0	IC50	uM	39.0
8507	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)o1	J Med Chem	2018.0	CHEMBL4165895	=	=	IC50	nM	90000.0	IC50	uM	90.0
8508	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)o1	J Med Chem	2018.0	CHEMBL4168256	>	>	IC50	nM	25000.0	IC50	uM	25.0
8509	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4176100	=	=	IC50	nM	37000.0	IC50	uM	37.0
8510	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4161819	=	=	IC50	nM	13000.0	IC50	uM	13.0
8511	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4172462	>	>	IC50	nM	25000.0	IC50	uM	25.0
8512	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4165249	=	=	IC50	nM	4300.0	IC50	uM	4.3
8513	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)s1	J Med Chem	2018.0	CHEMBL4175869	=	=	IC50	nM	5300.0	IC50	uM	5.3
8514	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)s1	J Med Chem	2018.0	CHEMBL4168669	=	=	IC50	nM	7000.0	IC50	uM	7.0
8515	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)s1	J Med Chem	2018.0	CHEMBL4160749	=	=	IC50	nM	5200.0	IC50	uM	5.2
8516	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)s1	J Med Chem	2018.0	CHEMBL4172017	=	=	IC50	nM	214000.0	IC50	uM	214.0
8517	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)s1	J Med Chem	2018.0	CHEMBL4164142	=	=	IC50	nM	42000.0	IC50	uM	42.0
8518	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)s1	J Med Chem	2018.0	CHEMBL4165094	=	=	IC50	nM	39000.0	IC50	uM	39.0
8519	Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	Oc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)NCC2	J Med Chem	2018.0	CHEMBL4167229	>	>	IC50	nM	10000.0	IC50	uM	10.0
8520	Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	CCCS(=O)(=O)NCCOc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)NCC2	J Med Chem	2018.0	CHEMBL3643445	=	=	IC50	nM	620.0	IC50	uM	0.62
8521	Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	CCCS(=O)(=O)NCCOc1ccc2c(c1)[C@@H](Cc1ccc(Cl)c(Cl)c1)[C@@H](N)CC2	J Med Chem	2018.0	CHEMBL4176494	>	>	IC50	nM	10000.0	IC50	uM	10.0
8522	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2018.0	CHEMBL1276308	=	=	IC50	nM	9500.0	IC50	uM	9.5
8523	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1	J Med Chem	2018.0	CHEMBL4163069	=	=	IC50	nM	2900.0	IC50	uM	2.9
8524	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1	J Med Chem	2018.0	CHEMBL4161754	=	=	IC50	nM	1600.0	IC50	uM	1.6
8525	Inhibition of human CYP3A4	CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1	J Med Chem	2018.0	CHEMBL3960662	>	>	IC50	nM	30000.0	IC50	uM	30.0
8526	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1	Eur J Med Chem	2018.0	CHEMBL4160587	=	=	IC50	nM	3030.0	IC50	uM	3.03
8527	Inhibition of human CYP3A4	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
8528	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4172669	>	>	IC50	nM	20000.0	IC50	uM	20.0
8529	Inhibition of human CYP3A4	CN(C[C@@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4162011	>	>	IC50	nM	20000.0	IC50	uM	20.0
8530	Inhibition of human CYP3A4	CCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4169280	>	>	IC50	nM	20000.0	IC50	uM	20.0
8531	Inhibition of human CYP3A4	CCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4177130	>	>	IC50	nM	20000.0	IC50	uM	20.0
8532	Inhibition of human CYP3A4	c1cnc2c(c1)CCC[C@@H]2N(CC1CC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4165854	>	>	IC50	nM	20000.0	IC50	uM	20.0
8533	Inhibition of human CYP3A4	CC(C)N(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4173777	>	>	IC50	nM	20000.0	IC50	uM	20.0
8534	Inhibition of human CYP3A4	c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4176285	=	=	IC50	nM	1780.0	IC50	uM	1.78
8535	Inhibition of human CYP3A4	FC1(F)CCC(CN(C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4168418	=	=	IC50	nM	5620.0	IC50	uM	5.62
8536	Inhibition of human CYP3A4	OCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4172898	>	>	IC50	nM	20000.0	IC50	uM	20.0
8537	Inhibition of human CYP3A4	COCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4176403	>	>	IC50	nM	20000.0	IC50	uM	20.0
8538	Inhibition of human CYP3A4	Cc1cccnc1CN(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4169504	=	=	IC50	nM	1420.0	IC50	uM	1.42
8539	Inhibition of human CYP3A4	Cc1cnc(CN(C)C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)c(C)c1	J Med Chem	2018.0	CHEMBL4161589	>	>	IC50	nM	20000.0	IC50	uM	20.0
8540	Inhibition of human CYP3A4	Cc1ccc(CN(C)C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)nc1	J Med Chem	2018.0	CHEMBL4166081	>	>	IC50	nM	20000.0	IC50	uM	20.0
8541	Inhibition of human CYP3A4	Cc1cnc2c(c1)CCC[C@@H]2N(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4176701	>	>	IC50	nM	20000.0	IC50	uM	20.0
8542	Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN2CCC[C@H]4CCc5cccnc5[C@H]42)NC3)CC1	J Med Chem	2018.0	CHEMBL4171365	>	>	IC50	nM	20000.0	IC50	uM	20.0
8543	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2C[C@H]3C[C@@H]2CN3)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4163467	>	>	IC50	nM	20000.0	IC50	uM	20.0
8544	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3C[C@H]2CN3)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4175596	>	>	IC50	nM	20000.0	IC50	uM	20.0
8545	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNC(C)(C)C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4164970	>	>	IC50	nM	20000.0	IC50	uM	20.0
8546	Inhibition of human CYP3A4	C[C@H]1CN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C[C@@H](C)N1	J Med Chem	2018.0	CHEMBL4160496	>	>	IC50	nM	20000.0	IC50	uM	20.0
8547	Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4168391	>	>	IC50	nM	20000.0	IC50	uM	20.0
8548	Inhibition of human CYP3A4	CCN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4163874	>	>	IC50	nM	20000.0	IC50	uM	20.0
8549	Inhibition of human CYP3A4	CC(C)N1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4171755	>	>	IC50	nM	20000.0	IC50	uM	20.0
8550	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(C3CC3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4167324	=	=	IC50	nM	4230.0	IC50	uM	4.23
8551	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(C3COC3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4175201	>	>	IC50	nM	20000.0	IC50	uM	20.0
8552	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3cccc(C(F)(F)F)c3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4161949	=	=	IC50	nM	2210.0	IC50	uM	2.21
8553	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4169875	=	=	IC50	nM	3160.0	IC50	uM	3.16
8554	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3ncccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4167145	=	=	IC50	nM	3350.0	IC50	uM	3.35
8555	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(Cc3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4159234	=	=	IC50	nM	6790.0	IC50	uM	6.79
8556	Inhibition of human CYP3A4	C[C@H]1CN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C[C@@H](C)N1C	J Med Chem	2018.0	CHEMBL4170542	>	>	IC50	nM	20000.0	IC50	uM	20.0
8557	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN3CCC[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4162609	>	>	IC50	nM	20000.0	IC50	uM	20.0
8558	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN3CCC[C@H]3C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4173977	>	>	IC50	nM	20000.0	IC50	uM	20.0
8559	Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1C)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4166059	>	>	IC50	nM	20000.0	IC50	uM	20.0
8560	Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)N(C)C3)CC1	J Med Chem	2018.0	CHEMBL4177338	>	>	IC50	nM	20000.0	IC50	uM	20.0
8561	Inhibition of of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis	N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)[C@@H](O)C(F)(F)S3(=O)=O)c1	J Med Chem	2018.0	CHEMBL4175320	=	=	IC50	nM	13300.0	IC50	uM	13.3
8562	Inhibition of of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2	J Med Chem	2018.0	CHEMBL4173075	>	>	IC50	nM	50000.0	IC50	uM	50.0
8563	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br	Bioorg Med Chem	2017.0	CHEMBL3742114	>	>	IC50	nM	20000.0	IC50	uM	20.0
8564	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214937	=	=	IC50	nM	34.0	IC50	nM	34.0
8565	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3C[C@H](O)[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210026	=	=	IC50	nM	250.0	IC50	nM	250.0
8566	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCN)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4202424	=	=	IC50	nM	240.0	IC50	nM	240.0
8567	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CN)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4216413	=	=	IC50	nM	440.0	IC50	nM	440.0
8568	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207648	=	=	IC50	nM	560.0	IC50	nM	560.0
8569	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4204601	=	=	IC50	nM	90.0	IC50	nM	90.0
8570	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](NC)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207673	=	=	IC50	nM	49.0	IC50	nM	49.0
8571	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4211388	=	=	IC50	nM	140.0	IC50	nM	140.0
8572	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212859	=	=	IC50	nM	840.0	IC50	nM	840.0
8573	Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(CNC)OC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210995	=	=	IC50	nM	480.0	IC50	nM	480.0
8574	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated conversion of midazolam to 1-hydroxymidazolam measured after 5 mins by LC-MS analysis	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207648	=	=	IC50	nM	20000.0	IC50	nM	20000.0
8575	Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1-c1ccnc(CNCCC2CCNCC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4217988	=	=	IC50	nM	1150.0	IC50	uM	1.15
8576	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4076061	>	>	IC50	nM	50000.0	IC50	uM	50.0
8577	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4203948	=	=	IC50	nM	43400.0	IC50	uM	43.4
8578	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4210866	=	=	IC50	nM	33000.0	IC50	uM	33.0
8579	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4206499	>	>	IC50	nM	50000.0	IC50	uM	50.0
8580	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4209130	>	>	IC50	nM	50000.0	IC50	uM	50.0
8581	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CSc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4204264	=	=	IC50	nM	5100.0	IC50	uM	5.1
8582	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4216985	=	=	IC50	nM	21600.0	IC50	uM	21.6
8583	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4212007	=	=	IC50	nM	16500.0	IC50	uM	16.5
8584	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL376488	>	>	IC50	nM	50000.0	IC50	uM	50.0
8585	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cc(C)c(C)s1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4206467	=	=	IC50	nM	10000.0	IC50	uM	10.0
8586	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cccnc1N(C)C)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4205718	>	>	IC50	nM	50000.0	IC50	uM	50.0
8587	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccc(N(C)C)nc1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4204414	>	>	IC50	nM	10000.0	IC50	uM	10.0
8588	Inhibition of CYP3A4 (unknown origin) after 20 mins	CCSc1ccc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4212501	=	=	IC50	nM	10000.0	IC50	uM	10.0
8589	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cncc(C)c1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4206931	=	=	IC50	nM	4600.0	IC50	uM	4.6
8590	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1cc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cnc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218132	>	>	IC50	nM	10000.0	IC50	uM	10.0
8591	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(C)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4213428	>	>	IC50	nM	10000.0	IC50	uM	10.0
8592	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(OC(F)F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4216673	>	>	IC50	nM	10000.0	IC50	uM	10.0
8593	Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(C#N)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210920	>	>	IC50	nM	10000.0	IC50	uM	10.0
8594	Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1	J Med Chem	2017.0	CHEMBL4217292	=	=	IC50	nM	46000.0	IC50	uM	46.0
8595	Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCC(F)(F)F	J Med Chem	2017.0	CHEMBL4208907	=	=	IC50	nM	46000.0	IC50	uM	46.0
8596	Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCCC(F)(F)F	J Med Chem	2017.0	CHEMBL4204573	=	=	IC50	nM	23000.0	IC50	uM	23.0
8597	Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OC(F)(F)F	J Med Chem	2017.0	CHEMBL4212176	=	=	IC50	nM	17000.0	IC50	uM	17.0
8598	Inhibition of human CYP3A4	N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1	J Med Chem	2017.0	CHEMBL4217292	=	=	IC50	nM	51000.0	IC50	uM	51.0
8599	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4211876	>	>	IC50	nM	10000.0	IC50	uM	10.0
8600	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
8601	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4202990	>	>	IC50	nM	10000.0	IC50	uM	10.0
8602	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218749	>	>	IC50	nM	20000.0	IC50	uM	20.0
8603	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4202990	>	>	IC50	nM	20000.0	IC50	uM	20.0
8604	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4209004	>	>	IC50	nM	20000.0	IC50	uM	20.0
8605	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccncc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212722	>	>	IC50	nM	20000.0	IC50	uM	20.0
8606	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2237704	>	>	IC50	nM	20000.0	IC50	uM	20.0
8607	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4210776	>	>	IC50	nM	20000.0	IC50	uM	20.0
8608	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=C(/C=C/c1cccc2ccccc12)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL1568243	>	>	IC50	nM	20000.0	IC50	uM	20.0
8609	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214111	>	>	IC50	nM	20000.0	IC50	uM	20.0
8610	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2237710	>	>	IC50	nM	20000.0	IC50	uM	20.0
8611	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4213815	>	>	IC50	nM	20000.0	IC50	uM	20.0
8612	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4211876	>	>	IC50	nM	20000.0	IC50	uM	20.0
8613	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4205073	>	>	IC50	nM	20000.0	IC50	uM	20.0
8614	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4210137	>	>	IC50	nM	20000.0	IC50	uM	20.0
8615	Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	20000.0	IC50	uM	20.0
8616	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccncc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212722	>	>	IC50	nM	10000.0	IC50	uM	10.0
8617	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2237704	>	>	IC50	nM	10000.0	IC50	uM	10.0
8618	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4210776	>	>	IC50	nM	10000.0	IC50	uM	10.0
8619	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1cccc2ccccc12)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL1568243	>	>	IC50	nM	10000.0	IC50	uM	10.0
8620	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214111	>	>	IC50	nM	10000.0	IC50	uM	10.0
8621	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2237710	>	>	IC50	nM	10000.0	IC50	uM	10.0
8622	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4213815	>	>	IC50	nM	10000.0	IC50	uM	10.0
8623	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4209004	>	>	IC50	nM	10000.0	IC50	uM	10.0
8624	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4210137	>	>	IC50	nM	10000.0	IC50	uM	10.0
8625	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218749	>	>	IC50	nM	10000.0	IC50	uM	10.0
8626	Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4205073	>	>	IC50	nM	10000.0	IC50	uM	10.0
8627	Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ccnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4210894	>	>	IC50	nM	30000.0	IC50	uM	30.0
8628	Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ncnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4218256	>	>	IC50	nM	30000.0	IC50	uM	30.0
8629	Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1	J Med Chem	2018.0	CHEMBL4203118	=	=	IC50	nM	15000.0	IC50	uM	15.0
8630	Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ccnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4210894	>	>	IC50	nM	30000.0	IC50	uM	30.0
8631	Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ncnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4218256	>	>	IC50	nM	30000.0	IC50	uM	30.0
8632	Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1	J Med Chem	2018.0	CHEMBL4203118	=	=	IC50	nM	13000.0	IC50	uM	13.0
8633	Inhibition of CYP3A4 (unknown origin)	CCN(CC)[C@@H](C)CNC(=O)c1cc(-c2cnn3ccc(-c4cccs4)nc23)nc(N2CC(OC)C2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4215300	>	>	IC50	nM	25000.0	IC50	uM	25.0
8634	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	CC(C)(C)Cn1ncn(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)c1=O	Bioorg Med Chem Lett	2018.0	CHEMBL4210924	=	=	IC50	nM	50000.0	IC50	uM	50.0
8635	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4211628	=	=	IC50	nM	50000.0	IC50	uM	50.0
8636	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCC1	Bioorg Med Chem Lett	2018.0	CHEMBL4206432	=	=	IC50	nM	50000.0	IC50	uM	50.0
8637	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCCC1	Bioorg Med Chem Lett	2018.0	CHEMBL4214518	=	=	IC50	nM	50000.0	IC50	uM	50.0
8638	Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL50	>	>	IC50	nM	20000.0	IC50	uM	20.0
8639	Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	CC(C)=CCc1cc(C2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)ccc1O	Bioorg Med Chem Lett	2017.0	CHEMBL4078418	>	>	IC50	nM	20000.0	IC50	uM	20.0
8640	Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
8641	Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL50	>	>	IC50	nM	20000.0	IC50	uM	20.0
8642	Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	CC(C)=CCc1cc(C2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)ccc1O	Bioorg Med Chem Lett	2017.0	CHEMBL4078418	>	>	IC50	nM	20000.0	IC50	uM	20.0
8643	Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
8644	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCOc1c(Cl)cc(C(=O)Nc2ccc(C(=O)O)c(C)c2)cc1OC(C)C	Bioorg Med Chem	2018.0	CHEMBL4202767	>	>	IC50	nM	25000.0	IC50	uM	25.0
8645	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl	Bioorg Med Chem	2018.0	CHEMBL107430	=	=	IC50	nM	25000.0	IC50	uM	25.0
8646	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccccc3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4208231	>	>	IC50	nM	10000.0	IC50	uM	10.0
8647	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccc(CO)cc3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4213155	>	>	IC50	nM	10000.0	IC50	uM	10.0
8648	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccccn3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4218074	>	>	IC50	nM	10000.0	IC50	uM	10.0
8649	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3cccnc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4206363	=	=	IC50	nM	6700.0	IC50	uM	6.7
8650	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3nccc(OC)c3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4205861	=	=	IC50	nM	9900.0	IC50	uM	9.9
8651	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4210732	>	>	IC50	nM	10000.0	IC50	uM	10.0
8652	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NC(C)C)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4209289	>	>	IC50	nM	10000.0	IC50	uM	10.0
8653	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NCc3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4213687	>	>	IC50	nM	10000.0	IC50	uM	10.0
8654	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N(C)Cc3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4218623	=	=	IC50	nM	8500.0	IC50	uM	8.5
8655	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N[C@H](C)c3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4202404	>	>	IC50	nM	10000.0	IC50	uM	10.0
8656	Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N[C@@H](C)c3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4207296	>	>	IC50	nM	10000.0	IC50	uM	10.0
8657	Inhibition of CYP3A4 (unknown origin)	CNc1ccc(C(N)=O)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4218848	>	>	IC50	nM	20000.0	IC50	uM	20.0
8658	Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3cccc(OC4CC4)c3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4079324	>	>	IC50	nM	30000.0	IC50	uM	30.0
8659	Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3ccsc3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4217112	>	>	IC50	nM	30000.0	IC50	uM	30.0
8660	Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3cccc(S(=O)(=O)C4CC4)c3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4105066	>	>	IC50	nM	30000.0	IC50	uM	30.0
8661	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(OCCCCC[C@H]2CC[C@]3(CC2)COC(C)(C)C3)cc1	Bioorg Med Chem Lett	2018.0	CHEMBL4205617	>	>	IC50	nM	10000.0	IC50	uM	10.0
8662	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1	J Med Chem	2018.0	CHEMBL4211649	>	>	IC50	nM	20000.0	IC50	uM	20.0
8663	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4c3)cc2)CC1	J Med Chem	2018.0	CHEMBL4204438	=	=	IC50	nM	3900.0	IC50	uM	3.9
8664	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCNCC5)cc4)nn23)cc1	J Med Chem	2018.0	CHEMBL4208772	=	=	IC50	nM	5600.0	IC50	uM	5.6
8665	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)nn23)cc1	J Med Chem	2018.0	CHEMBL4203889	>	>	IC50	nM	20000.0	IC50	uM	20.0
8666	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4n3)cc2)CC1	J Med Chem	2018.0	CHEMBL4213168	>	>	IC50	nM	20000.0	IC50	uM	20.0
8667	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN(C)C1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1	J Med Chem	2018.0	CHEMBL4208246	>	>	IC50	nM	20000.0	IC50	uM	20.0
8668	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3cnc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1	J Med Chem	2018.0	CHEMBL4213819	>	>	IC50	nM	20000.0	IC50	uM	20.0
8669	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1	J Med Chem	2018.0	CHEMBL4216991	>	>	IC50	nM	20000.0	IC50	uM	20.0
8670	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	NC(=O)c1ccc(-c2cn3c(-c4ccc(O)cc4)cnc3cn2)cc1	J Med Chem	2018.0	CHEMBL4212480	>	>	IC50	nM	20000.0	IC50	uM	20.0
8671	Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1-n1cnc3ccc(-c4ccnc5[nH]ccc45)cc31)CNC2	J Med Chem	2018.0	CHEMBL4213984	=	=	IC50	nM	3600.0	IC50	uM	3.6
8672	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins in presence of NADPH-regeneration system by LC-MS/MS method	COCCCN1CCC(c2nnc(-c3cccc4cc(C(C)C)nn34)o2)CC1	J Med Chem	2018.0	CHEMBL4215911	>	>	IC50	nM	10000.0	IC50	uM	10.0
8673	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins in presence of NADPH-regeneration system by LC-MS/MS method	CC(C)c1cc2cccc(-c3nnc(C4CCN(CC5CCOCC5)CC4)o3)n2n1	J Med Chem	2018.0	CHEMBL4205936	>	>	IC50	nM	10000.0	IC50	uM	10.0
8674	Inhibition of CYP3A4 (unknown origin)	CCN(CC)CC.NC(=O)c1ccc(-c2cc(C(=O)O)cc(-n3cc(-c4ccc(C(F)(F)F)cc4)nn3)c2)cc1	J Med Chem	2018.0	CHEMBL4211068	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
8675	Inhibition of human CYP3A4 using midazolam as substrate	CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1	J Med Chem	2018.0	CHEMBL4206892	>	>	IC50	nM	10000.0	IC50	uM	10.0
8676	Inhibition of human CYP3A4 using midazolam as substrate	CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2-c2ccc(C3(C#N)CC3)cc2)CC1	J Med Chem	2018.0	CHEMBL4206272	>	>	IC50	nM	10000.0	IC50	uM	10.0
8677	Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J Med Chem	2018.0	CHEMBL254328	=	=	IC50	nM	230.0	IC50	uM	0.23
8678	Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins	C[C@]12CC[C@H]3[C@@H](C/C(=N/O)[C@H]4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J Med Chem	2018.0	CHEMBL4214976	=	=	IC50	nM	8570.0	IC50	uM	8.57
8679	Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H](Cc1ccccc1)N1CCC(O)(C(F)(F)F)CC1)C1(c2ccc(Cl)cc2)CCCC1	MedChemComm	2016.0	CHEMBL4208555	=	=	IC50	nM	2164.0	IC50	nM	2164.0
8680	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccc(N2CCN(CCn3c(=O)n(C)c4c3nc(N)n3nc(-c5nccs5)nc43)CC2)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4215754	>	>	IC50	nM	10000.0	IC50	uM	10.0
8681	Inhibition of CYP3A4 (unknown origin)	COc1ccc(N2C(=O)CN(Cc3ccccc3)C2=S)cc1Cl	ACS Med Chem Lett	2017.0	CHEMBL2094291	=	=	IC50	nM	4015.0	IC50	nM	4015.0
8682	Inhibition of CYP3A4 (unknown origin)	CN(C)c1ccc(N2C(=O)CN(Cc3ccc(F)cc3)C2=S)cc1Cl	ACS Med Chem Lett	2017.0	CHEMBL4204461	=	=	IC50	nM	1279.0	IC50	nM	1279.0
8683	Inhibition of CYP3A4 (unknown origin)	COc1cc(N2C(=O)CN(Cc3ccc(F)cc3Cl)C2=S)ccc1N(C)C	ACS Med Chem Lett	2017.0	CHEMBL4210886	=	=	IC50	nM	7760.0	IC50	nM	7760.0
8684	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL75	=	=	IC50	nM	29.6	IC50	nM	29.6
8685	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	Cc1csc(NC(=O)c2cc(C(F)(F)c3cncnc3)cc3cccnc23)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4205817	=	=	IC50	nM	5900.0	IC50	uM	5.9
8686	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL2386850	>	>	IC50	nM	30000.0	IC50	uM	30.0
8687	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2018.0	CHEMBL4089114	>	>	IC50	nM	30000.0	IC50	uM	30.0
8688	Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=C(CF)OC(N)=N1	J Med Chem	2018.0	CHEMBL4213486	>	>	IC50	nM	20000.0	IC50	uM	20.0
8689	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210484	>	>	IC50	nM	10000.0	IC50	uM	10.0
8690	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4211012	>	>	IC50	nM	10000.0	IC50	uM	10.0
8691	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cccc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)c1	J Med Chem	2018.0	CHEMBL4206122	>	>	IC50	nM	10000.0	IC50	uM	10.0
8692	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4206639	>	>	IC50	nM	10000.0	IC50	uM	10.0
8693	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1	J Med Chem	2018.0	CHEMBL4218366	>	>	IC50	nM	10000.0	IC50	uM	10.0
8694	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4218894	>	>	IC50	nM	10000.0	IC50	uM	10.0
8695	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1	J Med Chem	2018.0	CHEMBL4213968	>	>	IC50	nM	10000.0	IC50	uM	10.0
8696	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1	J Med Chem	2018.0	CHEMBL4216391	>	>	IC50	nM	10000.0	IC50	uM	10.0
8697	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4211426	>	>	IC50	nM	10000.0	IC50	uM	10.0
8698	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4205471	>	>	IC50	nM	10000.0	IC50	uM	10.0
8699	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4210353	>	>	IC50	nM	10000.0	IC50	uM	10.0
8700	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2N2CCC(F)(F)CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4217712	>	>	IC50	nM	10000.0	IC50	uM	10.0
8701	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4205995	>	>	IC50	nM	10000.0	IC50	uM	10.0
8702	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4214250	>	>	IC50	nM	10000.0	IC50	uM	10.0
8703	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2-c2cccc(F)c2)C3)ccn1	J Med Chem	2018.0	CHEMBL4202565	>	>	IC50	nM	10000.0	IC50	uM	10.0
8704	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4209849	>	>	IC50	nM	10000.0	IC50	uM	10.0
8705	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4214756	>	>	IC50	nM	10000.0	IC50	uM	10.0
8706	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccnc(C)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4206403	>	>	IC50	nM	10000.0	IC50	uM	10.0
8707	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)S(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4211293	>	>	IC50	nM	10000.0	IC50	uM	10.0
8708	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210589	>	>	IC50	nM	10000.0	IC50	uM	10.0
8709	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4205726	>	>	IC50	nM	10000.0	IC50	uM	10.0
8710	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1	J Med Chem	2018.0	CHEMBL4215015	>	>	IC50	nM	10000.0	IC50	uM	10.0
8711	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210095	>	>	IC50	nM	10000.0	IC50	uM	10.0
8712	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1	J Med Chem	2018.0	CHEMBL4202824	>	>	IC50	nM	10000.0	IC50	uM	10.0
8713	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1	J Med Chem	2018.0	CHEMBL4214486	>	>	IC50	nM	10000.0	IC50	uM	10.0
8714	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C)C3)ccn1	J Med Chem	2018.0	CHEMBL4207171	>	>	IC50	nM	10000.0	IC50	uM	10.0
8715	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OCC2CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4218903	>	>	IC50	nM	10000.0	IC50	uM	10.0
8716	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2N2CCC(F)(F)CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4211535	>	>	IC50	nM	10000.0	IC50	uM	10.0
8717	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	N#Cc1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4206650	>	>	IC50	nM	10000.0	IC50	uM	10.0
8718	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2-c2cccc(F)c2)C3)ccn1	J Med Chem	2018.0	CHEMBL4212425	>	>	IC50	nM	10000.0	IC50	uM	10.0
8719	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4c3cnn4C)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4211181	>	>	IC50	nM	20000.0	IC50	uM	20.0
8720	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	Cc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4206816	=	=	IC50	nM	900.0	IC50	uM	0.9
8721	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4217096	>	>	IC50	nM	20000.0	IC50	uM	20.0
8722	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4c3ncn4C)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4209793	>	>	IC50	nM	20000.0	IC50	uM	20.0
8723	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4205416	=	=	IC50	nM	1600.0	IC50	uM	1.6
8724	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5ccccc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4210308	>	>	IC50	nM	20000.0	IC50	uM	20.0
8725	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4215340	>	>	IC50	nM	20000.0	IC50	uM	20.0
8726	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)cc1	J Med Chem	2018.0	CHEMBL4203041	>	>	IC50	nM	20000.0	IC50	uM	20.0
8727	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)c(C)n1	J Med Chem	2018.0	CHEMBL4207928	>	>	IC50	nM	20000.0	IC50	uM	20.0
8728	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sccc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4215244	>	>	IC50	nM	20000.0	IC50	uM	20.0
8729	Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sncc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4203566	>	>	IC50	nM	20000.0	IC50	uM	20.0
8730	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	Eur J Med Chem	2018.0	CHEMBL55	>	>	IC50	nM	100000.0	IC50	uM	100.0
8731	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1	Eur J Med Chem	2018.0	CHEMBL110	=	=	IC50	nM	98200.0	IC50	uM	98.2
8732	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C	Eur J Med Chem	2018.0	CHEMBL125	>	>	IC50	nM	100000.0	IC50	uM	100.0
8733	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2	Eur J Med Chem	2018.0	CHEMBL267345	>	>	IC50	nM	100000.0	IC50	uM	100.0
8734	Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH/substrate addition by LC-MS/MS analysis	CCN1CCC(N2CCc3nc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)ccc3C2)CC1	Eur J Med Chem	2018.0	CHEMBL4203179	>	>	IC50	nM	50000.0	IC50	uM	50.0
8735	Inhibition of recombinant human CYP3A4	CC(CC(=O)O)c1cccc(-n2c(C(N)=O)cc3ccc(OC(F)(F)F)cc32)n1	ACS Med Chem Lett	2018.0	CHEMBL4215835	>	>	IC50	nM	20000.0	IC50	uM	20.0
8736	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate pretreated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS analysis	C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1	ACS Med Chem Lett	2018.0	CHEMBL4211915	>	>	IC50	nM	10000.0	IC50	uM	10.0
8737	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS analysis	C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1	ACS Med Chem Lett	2018.0	CHEMBL4211915	>	>	IC50	nM	10000.0	IC50	uM	10.0
8738	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3590107	=	=	IC50	nM	7800000.0	IC50	mM	7.8
8739	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3645235	>	>	IC50	nM	30000000.0	IC50	mM	30.0
8740	Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4213970	>	>	IC50	nM	5000.0	IC50	uM	5.0
8741	Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3590107	=	=	IC50	nM	5700000.0	IC50	mM	5.7
8742	Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3645235	=	=	IC50	nM	2000000.0	IC50	mM	2.0
8743	Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc5c(c4)OCO5)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4218701	=	=	IC50	nM	300.0	IC50	uM	0.3
8744	Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4213970	=	=	IC50	nM	1700.0	IC50	uM	1.7
8745	Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1	ACS Med Chem Lett	2018.0	CHEMBL4217549	>	>	IC50	nM	30000.0	IC50	uM	30.0
8746	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1	ACS Med Chem Lett	2018.0	CHEMBL4218854	>	>	IC50	nM	30000.0	IC50	uM	30.0
8747	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1	J Med Chem	2018.0	CHEMBL4208229	>	>	IC50	nM	20000.0	IC50	uM	20.0
8748	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	COCCNc1cc(O)c2c(=O)c3c(-c4nccs4)[nH]c(Cc4ccc5c(c4)OCO5)c3oc2c1	J Med Chem	2018.0	CHEMBL4218772	>	>	IC50	nM	10000.0	IC50	uM	10.0
8749	Inhibition of CYP3A4 (unknown origin)	COc1cncc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)c1	J Med Chem	2018.0	CHEMBL4205724	=	=	IC50	nM	50.0	IC50	uM	0.05
8750	Inhibition of CYP3A4 (unknown origin)	COc1cccc(NC(C(=O)c2c[nH]c3ccccc23)c2nc3ccccc3o2)c1	J Med Chem	2018.0	CHEMBL4203720	>	>	IC50	nM	10000.0	IC50	uM	10.0
8751	Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OCCO)c1	J Med Chem	2018.0	CHEMBL4203293	>	>	IC50	nM	10000.0	IC50	uM	10.0
8752	Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
8753	Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
8754	Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
8755	Inhibition of recombinant human CYP3A4 using Luciferin-BE as substrate in presence of NADPH by P450-Glo luminescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2017.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
8756	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2018.0	CHEMBL376488	>	>	IC50	nM	50000.0	IC50	uM	50.0
8757	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2c1CCC2	Bioorg Med Chem	2018.0	CHEMBL4227597	>	>	IC50	nM	10000.0	IC50	uM	10.0
8758	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4224771	>	>	IC50	nM	10000.0	IC50	uM	10.0
8759	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4229114	>	>	IC50	nM	10000.0	IC50	uM	10.0
8760	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccnc1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4229127	=	=	IC50	nM	7800.0	IC50	uM	7.8
8761	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4228130	>	>	IC50	nM	10000.0	IC50	uM	10.0
8762	Inhibition of CYP3A4 in human liver microsomes after 20 mins	CCOc1cc([C@H](c2cc3cc(Br)ccc3cc2OC)[C@@](O)(CCN(C)C)c2cccc3ccoc23)cc(OCC)n1	Bioorg Med Chem	2018.0	CHEMBL4227669	>	>	IC50	nM	10000.0	IC50	uM	10.0
8763	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1ccc2occc2c1	Bioorg Med Chem	2018.0	CHEMBL4226478	=	=	IC50	nM	9700.0	IC50	uM	9.7
8764	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1ccc2occc2c1	Bioorg Med Chem	2018.0	CHEMBL4226743	=	=	IC50	nM	6900.0	IC50	uM	6.9
8765	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cc2ccccc2o1	Bioorg Med Chem	2018.0	CHEMBL4227540	>	>	IC50	nM	10000.0	IC50	uM	10.0
8766	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cc2ccccc2o1	Bioorg Med Chem	2018.0	CHEMBL4226688	>	>	IC50	nM	10000.0	IC50	uM	10.0
8767	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2c1OCC2	Bioorg Med Chem	2018.0	CHEMBL4225886	>	>	IC50	nM	10000.0	IC50	uM	10.0
8768	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2	Bioorg Med Chem	2018.0	CHEMBL4225434	>	>	IC50	nM	10000.0	IC50	uM	10.0
8769	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2	Bioorg Med Chem	2018.0	CHEMBL4228918	>	>	IC50	nM	10000.0	IC50	uM	10.0
8770	Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCCO2	Bioorg Med Chem	2018.0	CHEMBL4228396	>	>	IC50	nM	10000.0	IC50	uM	10.0
8771	Inhibition of CYP3A4 in human liver microsomes	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4227082	>	>	IC50	nM	20000.0	IC50	uM	20.0
8772	Inhibition of CYP3A4 in human liver microsomes	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4225923	>	>	IC50	nM	20000.0	IC50	uM	20.0
8773	Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	Bioorg Med Chem	2018.0	CHEMBL3604734	=	=	IC50	nM	12589.25	pIC50		4.9
8774	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2n[nH]cc2CN1C1=NC(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2N1	Bioorg Med Chem	2018.0	CHEMBL4227839	=	=	IC50	nM	158.49	pIC50		6.8
8775	Inhibition of CYP3A4 (unknown origin)	Cc1n[nH]c2c1CN(C1=NC(NCc3c(F)cccc3C(F)(F)F)c3cccc(C(N)=O)c3N1)C2	Bioorg Med Chem	2018.0	CHEMBL4226243	=	=	IC50	nM	630.96	pIC50		6.2
8776	Inhibition of human recombinant CYP3A4 using DEF substrate	CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)cc1)C2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4224936	>	>	IC50	nM	100000.0	IC50	uM	100.0
8777	Inhibition of human recombinant CYP3A4 using 7BQ substrate	CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)cc1)C2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4224936	>	>	IC50	nM	100000.0	IC50	uM	100.0
8778	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1CCc1ccccc1-2	Bioorg Med Chem	2018.0	CHEMBL4227117	=	=	IC50	nM	7270.0	IC50	uM	7.27
8779	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1ccc1ccccc12	Bioorg Med Chem	2018.0	CHEMBL4227911	=	=	IC50	nM	14600.0	IC50	uM	14.6
8780	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	34.5	IC50	uM	0.0345
8781	Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4226756	>	>	IC50	nM	20000.0	IC50	uM	20.0
8782	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225651	>	>	IC50	nM	20000.0	IC50	uM	20.0
8783	Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(Oc2ncc(/C=C/[C@H](C)NC(C)=O)s2)cc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226491	>	>	IC50	nM	20000.0	IC50	uM	20.0
8784	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225397	>	>	IC50	nM	20000.0	IC50	uM	20.0
8785	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4226229	>	>	IC50	nM	20000.0	IC50	uM	20.0
8786	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1nnc(Oc2ccc(OCC3CC3)cc2Cl)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225124	>	>	IC50	nM	20000.0	IC50	uM	20.0
8787	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)n1C	Bioorg Med Chem Lett	2018.0	CHEMBL4225976	>	>	IC50	nM	20000.0	IC50	uM	20.0
8788	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224858	=	=	IC50	nM	16000.0	IC50	uM	16.0
8789	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4226182	>	>	IC50	nM	20000.0	IC50	uM	20.0
8790	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nn1	Bioorg Med Chem Lett	2018.0	CHEMBL4227288	=	=	IC50	nM	18000.0	IC50	uM	18.0
8791	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226442	>	>	IC50	nM	20000.0	IC50	uM	20.0
8792	Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(Oc2ccc(/C=C/[C@H](C)NC(C)=O)cn2)c(Cl)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4227033	>	>	IC50	nM	20000.0	IC50	uM	20.0
8793	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCCF)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226186	>	>	IC50	nM	20000.0	IC50	uM	20.0
8794	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC(F)F)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224836	>	>	IC50	nM	20000.0	IC50	uM	20.0
8795	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4225924	>	>	IC50	nM	20000.0	IC50	uM	20.0
8796	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2cc3sc(C)nc3cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226500	>	>	IC50	nM	20000.0	IC50	uM	20.0
8797	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4225659	=	=	IC50	nM	19000.0	IC50	uM	19.0
8798	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)(C)O)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224749	>	>	IC50	nM	20000.0	IC50	uM	20.0
8799	Inhibition of CYP3A4 (unknown origin)	CCOc1nc2ccc(Oc3ccc(/C=C/[C@H](C)NC(C)=O)cn3)c(Cl)c2s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225405	>	>	IC50	nM	20000.0	IC50	uM	20.0
8800	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3sc(C(C)C)nc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4228805	>	>	IC50	nM	20000.0	IC50	uM	20.0
8801	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2C(F)(F)F)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226825	=	=	IC50	nM	17000.0	IC50	uM	17.0
8802	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2F)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4229067	>	>	IC50	nM	20000.0	IC50	uM	20.0
8803	Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection	O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1	Eur J Med Chem	2018.0	CHEMBL4239823	=	=	IC50	nM	10000.0	IC50	uM	10.0
8804	Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection	O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1	Eur J Med Chem	2018.0	CHEMBL4246655	=	=	IC50	nM	23000.0	IC50	uM	23.0
8805	Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL3581140	=	=	IC50	nM	26000.0	IC50	uM	26.0
8806	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4248883	=	=	IC50	nM	2000.0	IC50	uM	2.0
8807	Inhibition of CYP3A4 (unknown origin)	N#Cc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4239032	=	=	IC50	nM	2500.0	IC50	uM	2.5
8808	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4237255	=	=	IC50	nM	6400.0	IC50	uM	6.4
8809	Inhibition of CYP3A4 (unknown origin)	CN(C)S(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4240458	=	=	IC50	nM	2300.0	IC50	uM	2.3
8810	Inhibition of CYP3A4 (unknown origin)	CCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4243123	=	=	IC50	nM	9300.0	IC50	uM	9.3
8811	Inhibition of CYP3A4 (unknown origin)	CCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4240605	=	=	IC50	nM	5700.0	IC50	uM	5.7
8812	Inhibition of CYP3A4 (unknown origin)	CC(C)NS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4249070	=	=	IC50	nM	2600.0	IC50	uM	2.6
8813	Inhibition of CYP3A4 (unknown origin)	COCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4241959	=	=	IC50	nM	3400.0	IC50	uM	3.4
8814	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4249925	=	=	IC50	nM	8300.0	IC50	uM	8.3
8815	Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4250547	=	=	IC50	nM	5900.0	IC50	uM	5.9
8816	Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4241305	=	=	IC50	nM	3600.0	IC50	uM	3.6
8817	Inhibition of CYP3A4 (unknown origin)	CC(C)S(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4244717	=	=	IC50	nM	4900.0	IC50	uM	4.9
8818	Inhibition of CYP3A4 (unknown origin)	CCCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4243658	=	=	IC50	nM	3700.0	IC50	uM	3.7
8819	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4238696	=	=	IC50	nM	14900.0	IC50	uM	14.9
8820	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4245197	=	=	IC50	nM	17500.0	IC50	uM	17.5
8821	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4245242	=	=	IC50	nM	20800.0	IC50	uM	20.8
8822	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4242191	=	=	IC50	nM	12600.0	IC50	uM	12.6
8823	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4248525	=	=	IC50	nM	19600.0	IC50	uM	19.6
8824	Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	[2H]/C(c1nc[nH]c1C(C)(C)C)=c1/[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O	Bioorg Med Chem	2018.0	CHEMBL4063810	>	>	IC50	nM	50000.0	IC50	uM	50.0
8825	Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O	Bioorg Med Chem	2018.0	CHEMBL1096380	>	>	IC50	nM	50000.0	IC50	uM	50.0
8826	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Bioorg Med Chem Lett	2018.0	CHEMBL1873475	=	=	IC50	nM	11000.0	IC50	uM	11.0
8827	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1	J Med Chem	2018.0	CHEMBL4244935	>	>	IC50	nM	25000.0	IC50	uM	25.0
8828	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc([C@H](CCN2[C@H]3CC[C@@H]2C[C@@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1	J Med Chem	2018.0	CHEMBL4248282	=	=	IC50	nM	10900.0	IC50	uM	10.9
8829	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4242114	=	=	IC50	nM	12300.0	IC50	uM	12.3
8830	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4238063	>	>	IC50	nM	25000.0	IC50	uM	25.0
8831	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1	J Med Chem	2018.0	CHEMBL4249798	>	>	IC50	nM	25000.0	IC50	uM	25.0
8832	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1	J Med Chem	2018.0	CHEMBL4244935	>	>	IC50	nM	25000.0	IC50	uM	25.0
8833	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1ccc([C@H](CCN2[C@H]3CC[C@@H]2C[C@@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1	J Med Chem	2018.0	CHEMBL4248282	=	=	IC50	nM	23400.0	IC50	uM	23.4
8834	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4242114	=	=	IC50	nM	21700.0	IC50	uM	21.7
8835	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4238063	>	>	IC50	nM	25000.0	IC50	uM	25.0
8836	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1	J Med Chem	2018.0	CHEMBL4249798	>	>	IC50	nM	25000.0	IC50	uM	25.0
8837	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(C[C@@]24C[C@@H]2C(C)(C)Oc2ccc(C(F)(F)F)cc24)C3=O)cn1	MedChemComm	2017.0	CHEMBL4280986	=	=	IC50	nM	16300.0	IC50	uM	16.3
8838	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	CS(=O)(=O)Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12	J Med Chem	2018.0	CHEMBL4279238	>	>	IC50	nM	10000.0	IC50	uM	10.0
8839	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	O=S(=O)(Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12)C1CC1	J Med Chem	2018.0	CHEMBL4290579	>	>	IC50	nM	10000.0	IC50	uM	10.0
8840	Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	CS(=O)(=O)Nc1nnc2cc(COc3cc(Cl)cc(Cl)c3)c(C3CC3)cn12	J Med Chem	2018.0	CHEMBL4285790	>	>	IC50	nM	10000.0	IC50	uM	10.0
8841	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4129721	=	=	IC50	nM	695.0	IC50	nM	695.0
8842	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(C1CC1)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4126996	=	=	IC50	nM	636.0	IC50	nM	636.0
8843	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(c1cccc(OC(F)(F)F)c1)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1			CHEMBL4288256	=	=	IC50	nM	873.0	IC50	nM	873.0
8844	Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4126284	=	=	IC50	nM	243.0	IC50	nM	243.0
8845	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1)C(F)(F)F			CHEMBL4128368	=	=	IC50	nM	9360.0	IC50	nM	9360.0
8846	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)CNC(=O)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1			CHEMBL4291002	=	=	IC50	nM	1670.0	IC50	nM	1670.0
8847	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(CO[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)OC3)cc2)CC1			CHEMBL4289930	=	=	IC50	nM	109.0	IC50	nM	109.0
8848	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1ccc2c(c1OC)C(OC)N(C)c1c-2ccc2cc3c(cc12)OCO3	MedChemComm	2018.0	CHEMBL4294195	>	>	IC50	nM	10000.0	IC50	uM	10.0
8849	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	Nc1nccc(-c2c[nH]c3ccc(Br)cc23)n1	MedChemComm	2018.0	CHEMBL44541	>	>	IC50	nM	10000.0	IC50	uM	10.0
8850	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c(-c2ccccc2)oc2c(ccc3ccoc32)c1=O	MedChemComm	2018.0	CHEMBL4282750	>	>	IC50	nM	10000.0	IC50	uM	10.0
8851	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2occc2c(OC)c2c(=O)cc(C)oc12	MedChemComm	2018.0	CHEMBL44746	>	>	IC50	nM	10000.0	IC50	uM	10.0
8852	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1ccc(-c2cc(=O)c3c(O)c(OC)c(OC)cc3o2)cc1OC	MedChemComm	2018.0	CHEMBL226508	>	>	IC50	nM	10000.0	IC50	uM	10.0
8853	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c(C(=O)CC(=O)c2ccccc2)ccc2occc12	MedChemComm	2018.0	CHEMBL4285296	>	>	IC50	nM	10000.0	IC50	uM	10.0
8854	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2cc2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL24171	>	>	IC50	nM	10000.0	IC50	uM	10.0
8855	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2c(OCC=C(C)C)c2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL452751	>	>	IC50	nM	10000.0	IC50	uM	10.0
8856	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2c(OC)c2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL140796	>	>	IC50	nM	10000.0	IC50	uM	10.0
8857	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	CC1=CC(=O)c2c(O)cccc2C1=O	MedChemComm	2018.0	CHEMBL295316	>	>	IC50	nM	10000.0	IC50	uM	10.0
8858	Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	O=C1C=CC(=O)c2c(O)ccc(O)c21	MedChemComm	2018.0	CHEMBL274056	>	>	IC50	nM	10000.0	IC50	uM	10.0
8859	Inhibition of recombinant human CYP3A4 by bioluminescence method	CCCCn1c(=O)c2c(nc3n2CCCN3CCc2ccc(OCC(=O)NCCCN(CC)CC)cc2)n(CCCC)c1=O	MedChemComm	2018.0	CHEMBL4291015	=	=	IC50	nM	230.0	IC50	uM	0.23
8860	Inhibition of recombinant human CYP3A4 by bioluminescence method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	MedChemComm	2018.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
8861	Inhibition of human liver microsome CYP3A4 expressed in baculosomes using fluorogenic-DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J Med Chem	2018.0	CHEMBL4284306	>	>	EC50	nM	20000.0	EC50	uM	20.0
8862	Inhibition of CYP3A4 (unknown origin)	Nc1nc(OCc2ccccc2)c2[nH]nnc2n1	MedChemComm	2017.0	CHEMBL333928	=	=	IC50	nM	14000.0	IC50	uM	14.0
8863	Inhibition of CYP3A4 (unknown origin) using luciferin-IPA as substrate preincubated for 10 mins followed by NADPH regeneration system addition and measured after 10 to 30 mins by Promega P450-GloScreening assay	OCC1CCCC(c2ccc(O)cc2)CC1	Eur J Med Chem	2018.0	CHEMBL4293810	=	=	IC50	nM	33000.0	IC50	uM	33.0
8864	Inhibition of CYP3A4 (unknown origin)	CC#C[C@@H](CC(=O)O)c1ccc(OC[C@H]2COc3ccc(Cl)cc3O2)cc1	Bioorg Med Chem	2018.0	CHEMBL4288001	>	>	IC50	nM	100000.0	IC50	uM	100.0
8865	Inhibition of CYP3A4 (unknown origin)	Cn1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)cn1	J Med Chem	2018.0	CHEMBL4285867	>	>	IC50	nM	10000.0	IC50	uM	10.0
8866	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)on1	J Med Chem	2018.0	CHEMBL4283898	>	>	IC50	nM	25000.0	IC50	uM	25.0
8867	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4281098	=	=	IC50	nM	1200.0	IC50	uM	1.2
8868	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccncc3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4280894	=	=	IC50	nM	100.0	IC50	uM	0.1
8869	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4281098	=	=	IC50	nM	2000.0	IC50	uM	2.0
8870	Inhibition of CYP3A4 (unknown origin)	CCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1csc(C)n1)CC2	Bioorg Med Chem Lett	2018.0	CHEMBL4276988	>	>	IC50	nM	10000.0	IC50	uM	10.0
8871	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C)CC(C(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4292052	>	>	IC50	nM	20000.0	IC50	uM	20.0
8872	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(Br)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4281073	>	>	IC50	nM	20000.0	IC50	uM	20.0
8873	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(Cl)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4295138	>	>	IC50	nM	20000.0	IC50	uM	20.0
8874	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(OC(F)(F)F)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4287884	>	>	IC50	nM	20000.0	IC50	uM	20.0
8875	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C)CC(C(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4292052	>	>	IC50	nM	20000.0	IC50	uM	20.0
8876	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(Br)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4281073	>	>	IC50	nM	20000.0	IC50	uM	20.0
8877	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(Cl)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4295138	>	>	IC50	nM	20000.0	IC50	uM	20.0
8878	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(OC(F)(F)F)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4287884	>	>	IC50	nM	20000.0	IC50	uM	20.0
8879	Inhibition of CYP3A4 (unknown origin)	CCCCc1ccccc1NCc1ccc(C(=O)Nc2nc(CC(=O)O)cs2)s1	Eur J Med Chem	2018.0	CHEMBL4276719	>	>	IC50	nM	50000.0	IC50	uM	50.0
8880	Inhibition of CYP3A4 (unknown origin)	COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1[C@H](C(C)C)C2	J Med Chem	2018.0	CHEMBL4283853	>	>	IC50	nM	50000.0	IC50	uM	50.0
8881	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1	J Med Chem	2018.0	CHEMBL3648329	>	>	IC50	nM	10000.0	IC50	uM	10.0
8882	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1	J Med Chem	2018.0	CHEMBL4291436	>	>	IC50	nM	10000.0	IC50	uM	10.0
8883	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1	J Med Chem	2018.0	CHEMBL4281240	>	>	IC50	nM	10000.0	IC50	uM	10.0
8884	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1	J Med Chem	2018.0	CHEMBL4285417	>	>	IC50	nM	10000.0	IC50	uM	10.0
8885	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1	J Med Chem	2018.0	CHEMBL2325697	>	>	IC50	nM	10000.0	IC50	uM	10.0
8886	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 30 mins in presence of NADPH measured by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178718	>	>	IC50	nM	30000.0	IC50	uM	30.0
8887	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F	J Med Chem	2018.0	CHEMBL4293298	=	=	IC50	nM	11000.0	IC50	uM	11.0
8888	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F	J Med Chem	2018.0	CHEMBL4288838	=	=	IC50	nM	13000.0	IC50	uM	13.0
8889	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCOCC4)n3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4278154	>	>	IC50	nM	30000.0	IC50	uM	30.0
8890	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCCC4)n3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4285940	>	>	IC50	nM	30000.0	IC50	uM	30.0
8891	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4278011	=	=	IC50	nM	1200.0	IC50	uM	1.2
8892	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4294236	=	=	IC50	nM	700.0	IC50	uM	0.7
8893	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL3800286	=	=	IC50	nM	1300.0	IC50	uM	1.3
8894	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4279084	=	=	IC50	nM	900.0	IC50	uM	0.9
8895	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4289763	=	=	IC50	nM	600.0	IC50	uM	0.6
8896	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178717	>	>	IC50	nM	30000.0	IC50	uM	30.0
8897	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cc3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178150	>	>	IC50	nM	30000.0	IC50	uM	30.0
8898	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178714	=	=	IC50	nM	6400.0	IC50	uM	6.4
8899	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(Br)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4282976	=	=	IC50	nM	900.0	IC50	uM	0.9
8900	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(Cl)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4280271	=	=	IC50	nM	1200.0	IC50	uM	1.2
8901	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(F)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4291347	=	=	IC50	nM	1000.0	IC50	uM	1.0
8902	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1cc(C#N)cc(-c2csc([C@]34CN(c5ncc(F)cn5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1	J Med Chem	2018.0	CHEMBL4278329	=	=	IC50	nM	1600.0	IC50	uM	1.6
8903	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4288644	=	=	IC50	nM	1600.0	IC50	uM	1.6
8904	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4ccc(Cl)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4294969	=	=	IC50	nM	5500.0	IC50	uM	5.5
8905	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4ccc(F)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4286732	=	=	IC50	nM	5700.0	IC50	uM	5.7
8906	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178718	=	=	IC50	nM	1200.0	IC50	uM	1.2
8907	Inhibition of human CYP3A4	CCOc1cc(CN2CCC3(CC2)CC(=O)N(c2ccc(C(=O)O)cc2)C3)cc(OCC)c1-c1ccc(F)cc1.O=C(O)C(F)(F)F	ACS Med Chem Lett	2018.0	CHEMBL4282052	>	>	IC50	nM	50000.0	IC50	uM	50.0
8908	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cc(-c2[nH]c3cccnc3c2-c2cccc(C(F)F)n2)ccn1	ACS Med Chem Lett	2018.0	CHEMBL4284170	>	>	IC50	nM	20000.0	IC50	uM	20.0
8909	Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])Oc1ccc(-c2c(-c3ccnc(NC(C)=O)c3)[nH]c3cccnc23)nc1	ACS Med Chem Lett	2018.0	CHEMBL4280731	>	>	IC50	nM	20000.0	IC50	uM	20.0
8910	Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3921520	>	>	IC50	nM	10000.0	IC50	uM	10.0
8911	Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(/C=C/c2ccc(C(F)(F)F)cc2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3962890	>	>	IC50	nM	10000.0	IC50	uM	10.0
8912	Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3945880	>	>	IC50	nM	10000.0	IC50	uM	10.0
8913	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccccc1N1C(=O)CSC1c1cccc(C(=O)NCCc2ccc(Br)cc2)c1	J Med Chem	2019.0	CHEMBL3261573	=	=	IC50	nM	19540.0	IC50	uM	19.54
8914	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc(-c2nc(C)nn2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1	J Med Chem	2019.0	CHEMBL4528087	=	=	IC50	nM	36880.0	IC50	uM	36.88
8915	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	CCc1nc(-c2ncc(OC)cn2)n(-c2cccc(C(=O)NCCCCc3ccccc3)c2)n1	J Med Chem	2019.0	CHEMBL4582168	>	>	IC50	nM	50000.0	IC50	uM	50.0
8916	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc(-n2nc(C)nc2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1	J Med Chem	2019.0	CHEMBL4587127	=	=	IC50	nM	37690.0	IC50	uM	37.69
8917	Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay	N#Cc1ccc2nnc(C(=O)N3CCC(c4ccccc4C(F)(F)F)CC3)n2c1	J Med Chem	2019.0	CHEMBL4463039	=	=	IC50	nM	50000.0	IC50	uM	50.0
8918	Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay	N#Cc1ccc2nnc(C(=O)N3CCC(c4cccc(F)c4C(F)(F)F)CC3)n2c1	J Med Chem	2019.0	CHEMBL3954871	=	=	IC50	nM	74000.0	IC50	uM	74.0
8919	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins followed by substrate addition further incubated for 10 mins by LC-MS/MS analysis	Cc1cc(Cc2cc(-c3ccc(Br)cc3)on2)cc(C)c1OC(C)(C)C(=O)O	ACS Med Chem Lett	2019.0	CHEMBL4470753	>	>	IC50	nM	50000.0	IC50	uM	50.0
8920	Inhibition of CYP3A4 (unknown origin)	CC(C)(F)CN1[C@@H]2CCC[C@@]1(c1c(F)cc(/C=C/C(=O)O)cc1F)c1[nH]c3ccccc3c1C2	ACS Med Chem Lett	2019.0	CHEMBL4452972	>	>	IC50	nM	30000.0	IC50	uM	30.0
8921	Inhibition of CYP3A4 (unknown origin)	Fc1cc(Cl)ccc1-c1ccc(Cn2nnc3ccccc32)cn1	J Med Chem	2018.0	CHEMBL4483344	>	>	IC50	nM	10000.0	IC50	uM	10.0
8922	Inhibition of CYP3A4 (unknown origin)	FC(F)(F)c1cccc2c1nnn2CC1CC1	J Med Chem	2018.0	CHEMBL4460927	>	>	IC50	nM	10000.0	IC50	uM	10.0
8923	Inhibition of recombinant human CYP3A4	O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1	J Med Chem	2018.0	CHEMBL3945728	>	>	IC50	nM	50000.0	IC50	uM	50.0
8924	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 8 mins by LC-MS/MS analysis	O=C(NC1CC(F)(F)C1)c1nsc2cc(Nc3n[nH]c4cccnc34)ccc12	J Med Chem	2018.0	CHEMBL4588443	>	>	IC50	nM	30000.0	IC50	uM	30.0
8925	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn5c6cccc(F)c6cc5c4n3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4590062	>	>	IC50	nM	50000.0	IC50	uM	50.0
8926	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)-c3cc5c(F)cccc5n3CN4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4435877	>	>	IC50	nM	50000.0	IC50	uM	50.0
8927	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ccn5c6cccc(F)c6cc5c4n3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL3901713	>	>	IC50	nM	50000.0	IC50	uM	50.0
8928	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)-c3cc5c(F)cccc5n3CC4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL3947779	>	>	IC50	nM	50000.0	IC50	uM	50.0
8929	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(C)CC4)c3)c2c1	J Med Chem	2019.0	CHEMBL463783	=	=	IC50	nM	1000.0	IC50	uM	1.0
8930	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(CCN(C)C)CC4)c3)c2c1	J Med Chem	2019.0	CHEMBL4470176	>	>	IC50	nM	1000.0	IC50	uM	1.0
8931	Inhibition of human CYP3A4 preincubated for 5 mins followed by NADPH addition and measured after 30 mins by luminescence based microplate reader analysis	Oc1ccc(-c2ccc(CNCCc3c[nH]c4ncc(F)cc34)o2)cc1	Eur J Med Chem	2020.0	CHEMBL4442855	=	=	IC50	nM	7800.0	IC50	uM	7.8
8932	Inhibition of human CYP3A4 preincubated for 5 mins followed by NADPH addition and measured after 30 mins by luminescence based microplate reader analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	100.0	IC50	uM	0.1
8933	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured for 15 mins by LC-MS/MS analysis	C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5CC6(CC6)OC5=O)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12	J Med Chem	2019.0	CHEMBL4533341	>	>	IC50	nM	25000.0	IC50	uM	25.0
8934	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured for 15 mins by LC-MS/MS analysis	C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5CC6(CC6)OC5=O)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12	J Med Chem	2019.0	CHEMBL4533341	>	>	IC50	nM	25000.0	IC50	uM	25.0
8935	Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	IC50	nM	7500.0	IC50	uM	7.5
8936	Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	IC50	nM	3800.0	IC50	uM	3.8
8937	Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	IC50	nM	6300.0	IC50	uM	6.3
8938	Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	IC50	nM	4900.0	IC50	uM	4.9
8939	Time dependent inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	Ki	nM	1120.0	Ki	uM	1.12
8940	Time dependent inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	Ki	nM	1160.0	Ki	uM	1.16
8941	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cn3)C[C@@]2(O)CN)cc1F	J Med Chem	2019.0	CHEMBL4550510	=	=	IC50	nM	12000.0	IC50	uM	12.0
8942	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C[C@@]2(O)CN)cc1F	J Med Chem	2019.0	CHEMBL4517101	=	=	IC50	nM	1600.0	IC50	uM	1.6
8943	Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F	J Med Chem	2019.0	CHEMBL4557670	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
8944	Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by fluorescence method	C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F	J Med Chem	2019.0	CHEMBL4557670	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
8945	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4537998	>	>	IC50	nM	20000.0	IC50	uM	20.0
8946	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1	J Med Chem	2019.0	CHEMBL4458424	>	>	IC50	nM	20000.0	IC50	uM	20.0
8947	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate treated prior to substrate addition by LC-MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4537998	>	>	IC50	nM	20000.0	IC50	uM	20.0
8948	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate treated prior to substrate addition by LC-MS/MS analysis	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1	J Med Chem	2019.0	CHEMBL4458424	>	>	IC50	nM	20000.0	IC50	uM	20.0
8949	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4447631	>	>	IC50	nM	100000.0	IC50	uM	100.0
8950	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4560698	>	>	IC50	nM	100000.0	IC50	uM	100.0
8951	Inhibition of CYP3A4 (unknown origin)	CCCCN(C)C1CCN(c2ccc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)cc2F)CC1	J Med Chem	2019.0	CHEMBL4436572	>	>	IC50	nM	100000.0	IC50	uM	100.0
8952	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCN4CCN(C)CC4)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4461809	>	>	IC50	nM	100000.0	IC50	uM	100.0
8953	Inhibition of CYP3A4 in pooled human liver microsomes pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	17.0	IC50	uM	0.017
8954	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1	J Med Chem	2019.0	CHEMBL4521594	>	>	IC50	nM	20000.0	IC50	uM	20.0
8955	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3(N)CC3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4590564	>	>	IC50	nM	50000.0	IC50	uM	50.0
8956	Inhibition of CYP3A4 (unknown origin)	CN1CC(C#CC#Cc2cc3n(c2)C(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C3)C1	J Med Chem	2020.0	CHEMBL4520045	>	>	IC50	nM	50000.0	IC50	uM	50.0
8957	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCF)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4457739	>	>	IC50	nM	50000.0	IC50	uM	50.0
8958	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCO)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4437135	>	>	IC50	nM	50000.0	IC50	uM	50.0
8959	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4438243	>	>	IC50	nM	50000.0	IC50	uM	50.0
8960	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@@H]3C[C@@]3(F)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL3754389	>	>	IC50	nM	50000.0	IC50	uM	50.0
8961	Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3[C@@H](O)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4456704	>	>	IC50	nM	50000.0	IC50	uM	50.0
8962	Inhibition of human recombinant CYP3A4 expressed in supersomes assessed as decrease in formation of D-luciferin using luciferin-IPA as substrate incubated for 10 mins in presence of NADPH by P450-Glo luminescence assay	CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C	J Med Chem	2020.0	CHEMBL1159650	=	=	IC50	nM	206.0	IC50	uM	0.206
8963	Inhibition of CYP3A4 in CRISPR/Cas9-mediated CYP3A5 knock-out and doxycycline-induced CYP3A4 overexpressing human AsPC1 cells assessed as decrease in 1-hydroxymidazolam formation using midazolam as substrate pretreated with doxycycline for 24 hrs followed by incubation with compound for 24 hrs by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	117.0	IC50	uM	0.117
8964	Binding affinity to His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli DH5alpha assessed as type 2 spectral shift by measuring dissociation constant by UV-vis spectrophotometric titration analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	Kd	nM	900.0	Kd	uM	0.9
8965	Inhibition of recombinant human CYP3A4 using 7-benzyloxyquinoline fluorescent substrate in presence of NADPH-generating system after 15 mins	O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1	J Med Chem	2018.0	CHEMBL3707245	>	>	IC50	nM	20000.0	IC50	uM	20.0
8966	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL2006299	=	=	IC50	nM	850.0	IC50	uM	0.85
8967	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4454552	=	=	IC50	nM	80.0	IC50	uM	0.08
8968	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4476761	=	=	IC50	nM	80.0	IC50	uM	0.08
8969	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1	J Med Chem	2018.0	CHEMBL4522042	=	=	IC50	nM	80.0	IC50	uM	0.08
8970	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4436040	=	=	IC50	nM	2000.0	IC50	uM	2.0
8971	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4448806	=	=	IC50	nM	80.0	IC50	uM	0.08
8972	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1	J Med Chem	2018.0	CHEMBL4474946	=	=	IC50	nM	11900.0	IC50	uM	11.9
8973	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1	J Med Chem	2018.0	CHEMBL4459800	>	>	IC50	nM	20000.0	IC50	uM	20.0
8974	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1	J Med Chem	2018.0	CHEMBL4472858	=	=	IC50	nM	6400.0	IC50	uM	6.4
8975	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1	J Med Chem	2018.0	CHEMBL4460511	=	=	IC50	nM	19600.0	IC50	uM	19.6
8976	Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1	J Med Chem	2018.0	CHEMBL4584824	=	=	IC50	nM	16700.0	IC50	uM	16.7
8977	Inhibition of human CYP3A4	CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12	ACS Med Chem Lett	2018.0	CHEMBL4301600	>	>	IC50	nM	30000.0	IC50	uM	30.0
8978	Inhibition of CYP3A4 (unknown origin)	Cc1nn(-c2ccccc2)nc1COc1cc(N)nc2[nH]nnc12	ACS Med Chem Lett	2018.0	CHEMBL4586955	=	=	IC50	nM	370.0	IC50	nM	370.0
8979	Inhibition of CYP3A4 (unknown origin)	Cc1c(COc2cc(N)nc3[nH]nnc23)cccc1-c1ccn(C)n1	ACS Med Chem Lett	2018.0	CHEMBL4466985	=	=	IC50	nM	1500.0	IC50	nM	1500.0
8980	Inhibition of CYP3A4 (unknown origin)	Nc1cc(OCc2cc(-c3cccc(F)c3)ccc2Cl)c2nn[nH]c2n1	ACS Med Chem Lett	2018.0	CHEMBL4582838	=	=	IC50	nM	60.0	IC50	nM	60.0
8981	Inhibition of CYP3A4 (unknown origin)	O=C(O)CNC(=O)c1c(O)c2c(n(Cc3ccc(C(F)(F)F)cc3)c1=O)COC2	ACS Med Chem Lett	2018.0	CHEMBL4577928	>	>	IC50	nM	50000.0	IC50	uM	50.0
8982	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL1397	=	=	IC50	nM	150.0	IC50	uM	0.15
8983	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL64391	=	=	IC50	nM	40.0	IC50	uM	0.04
8984	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](C)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL4450683	>	>	IC50	nM	20000.0	IC50	uM	20.0
8985	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC1(c2ccc(Cl)cc2Cl)OCC(COc2ccc(N3CCN(c4ccc(-n5cnn(CCC(=O)O)c5=O)cc4)CC3)cc2)O1	Eur J Med Chem	2019.0	CHEMBL4587117	>	>	IC50	nM	20000.0	IC50	uM	20.0
8986	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)c1cccc(C(=O)Nc2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](C)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1	Eur J Med Chem	2019.0	CHEMBL4540110	>	>	IC50	nM	20000.0	IC50	uM	20.0
8987	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1	J Med Chem	2019.0	CHEMBL4445670	>	>	IC50	nM	20000.0	IC50	uM	20.0
8988	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with compound and measured by LC-MS/MS analysis	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1	J Med Chem	2019.0	CHEMBL4445670	>	>	IC50	nM	20000.0	IC50	uM	20.0
8989	Inhibition of CYP3A4 (unknown origin)	CC1(C)C[C@]2(CC[C@H](Nc3cc(Nc4ccc(S(C)(=O)=O)cc4F)ncn3)CC2)CO1	Bioorg Med Chem Lett	2019.0	CHEMBL4591100	>	>	IC50	nM	50000.0	IC50	uM	50.0
8990	Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(-c2ccc(CCCc3nn(-c4ccc(C(F)(F)F)cc4)c(=O)n3-c3ccccc3F)cc2)cc1CC(=O)O	Bioorg Med Chem Lett	2019.0	CHEMBL4449687	>	>	IC50	nM	30000.0	IC50	uM	30.0
8991	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cc(CNC(=O)c2cncc3c2cnn3-c2ccc(F)cc2)ccn1	Bioorg Med Chem Lett	2019.0	CHEMBL4441094	>	>	IC50	nM	30000.0	IC50	uM	30.0
8992	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1	Bioorg Med Chem Lett	2019.0	CHEMBL4456123	>	>	IC50	nM	30000.0	IC50	uM	30.0
8993	Inhibition of CYP3A4 (unknown origin)	CC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4464625	=	=	IC50	nM	17000.0	IC50	uM	17.0
8994	Competitive inhibition of CYP3A4 (unknown origin)	CC1=C(c2cccc(O)c2)[C@H](c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21	ACS Med Chem Lett	2019.0	CHEMBL4447340	>	>	IC50	nM	10000.0	IC50	uM	10.0
8995	Inhibition of recombinant CYP3A4 (unknown origin) using BFC substrate	O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1	J Med Chem	2019.0	CHEMBL4463581	>	>	IC50	nM	20000.0	IC50	uM	20.0
8996	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccc(-c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cnccc23)c(F)c1	ACS Med Chem Lett	2020.0	CHEMBL4456513	=	=	IC50	nM	4800.0	IC50	uM	4.8
8997	Inhibition of human CYP3A4 using sorafenib as substrate by LC/MS/MS analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1	ACS Med Chem Lett	2020.0	CHEMBL4463663	=	=	IC50	nM	27840.0	IC50	uM	27.84
8998	Inhibition of recombinant CYP3A4 (unknown origin)	N#Cc1cnc2ccc(-c3c(-c4ccc(F)c(Cl)c4)ncn3CCO)nn12	ACS Med Chem Lett	2020.0	CHEMBL4514379	>	>	IC50	nM	20000.0	IC50	uM	20.0
8999	Inhibition of CYP3A4 (unknown origin)	NS(=O)(=O)CC(=O)NCCSc1nonc1/C(=N/O)Nc1cccc(Cl)c1	ACS Med Chem Lett	2020.0	CHEMBL4585089	>	>	IC50	nM	10000.0	IC50	uM	10.0
9000	Inhibition of CYP3A4 (unknown origin)	NS(=O)(=O)NCC(=O)NCCSc1nonc1/C(=N/O)Nc1ccc(F)c(C(F)F)c1	ACS Med Chem Lett	2020.0	CHEMBL4549976	>	>	IC50	nM	10000.0	IC50	uM	10.0
9001	Inhibition of CYP3A4 in human liver microsomes	Cc1cc(-c2cnc3ccn(CC(=O)N4CCC4)c3c2)ccc1F	ACS Med Chem Lett	2019.0	CHEMBL4443868	>	>	IC50	nM	10000.0	IC50	uM	10.0
9002	Inhibition of CYP3A4 in human liver microsomes	Cc1cc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)ccc1F	ACS Med Chem Lett	2019.0	CHEMBL4302264	>	>	IC50	nM	10000.0	IC50	uM	10.0
9003	Inhibition of CYP3A4 in human liver microsomes	Cc1nnc(Cn2ccc3ncc(-c4ccc(F)c(C)c4)cc32)o1	ACS Med Chem Lett	2019.0	CHEMBL4590530	>	>	IC50	nM	10000.0	IC50	uM	10.0
9004	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4571666	>	>	IC50	nM	10000.0	IC50	uM	10.0
9005	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)n3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4462073	>	>	IC50	nM	10000.0	IC50	uM	10.0
9006	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(Cl)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4451099	>	>	IC50	nM	10000.0	IC50	uM	10.0
9007	Inhibition of CYP3A4 in human liver microsomes	Cc1cccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1	ACS Med Chem Lett	2019.0	CHEMBL4474982	>	>	IC50	nM	10000.0	IC50	uM	10.0
9008	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(Cl)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4593473	>	>	IC50	nM	10000.0	IC50	uM	10.0
9009	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(C(F)F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4547576	>	>	IC50	nM	10000.0	IC50	uM	10.0
9010	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4591770	>	>	IC50	nM	10000.0	IC50	uM	10.0
9011	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(C(F)(F)F)s3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4531750	>	>	IC50	nM	10000.0	IC50	uM	10.0
9012	Inhibition of CYP3A4 in human liver microsomes	Cc1ccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)s1	ACS Med Chem Lett	2019.0	CHEMBL4575739	>	>	IC50	nM	10000.0	IC50	uM	10.0
9013	Inhibition of CYP3A4 in human liver microsomes	Cc1csc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1	ACS Med Chem Lett	2019.0	CHEMBL4529810	>	>	IC50	nM	10000.0	IC50	uM	10.0
9014	Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(Cl)s3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4211247	>	>	IC50	nM	10000.0	IC50	uM	10.0
9015	Inhibition of CYP3A4 (unknown origin)	O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1	ACS Med Chem Lett	2019.0	CHEMBL3934548	>	>	IC50	nM	20000.0	IC50	uM	20.0
9016	Inhibition of CYP3A4 (unknown origin)	C#CCOc1cnc(C(=O)Nc2cc(F)c(F)c([C@@]3(C)N=C(N)S[C@@]4(COC)C[C@H]43)c2)cn1	J Med Chem	2020.0	CHEMBL4560579	=	=	IC50	nM	27000.0	IC50	uM	27.0
9017	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis	C[C@H]1CN(c2cc(F)c3c(c2)N(C)C(=O)C32CCN(c3nc4c(c(=O)[nH]3)CCCN4C)CC2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4449082	>	>	IC50	nM	10000.0	IC50	uM	10.0
9018	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CC[C@@H]([C@H]2c3ccccc3-c3cncn32)[C@H](O)C1	ACS Med Chem Lett	2020.0	CHEMBL4542307	>	>	IC50	nM	10000.0	IC50	uM	10.0
9019	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1CCOC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4540245	=	=	IC50	nM	650.0	IC50	uM	0.65
9020	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1COCC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4548068	=	=	IC50	nM	600.0	IC50	uM	0.6
9021	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2cnccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4447185	=	=	IC50	nM	2400.0	IC50	uM	2.4
9022	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4577396	=	=	IC50	nM	840.0	IC50	uM	0.84
9023	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccncc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4437257	<	<	IC50	nM	100.0	IC50	uM	0.1
9024	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4520696	=	=	IC50	nM	6000.0	IC50	uM	6.0
9025	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O	ACS Med Chem Lett	2020.0	CHEMBL4539108	=	=	IC50	nM	2800.0	IC50	uM	2.8
9026	Inhibition of CYP3A4 (unknown origin)	CP(C)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4589215	=	=	IC50	nM	1600.0	IC50	uM	1.6
9027	Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4541824	=	=	IC50	nM	3300.0	IC50	uM	3.3
9028	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4544695	=	=	IC50	nM	3600.0	IC50	uM	3.6
9029	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2nncn2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4529817	>	>	IC50	nM	10000.0	IC50	uM	10.0
9030	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2nonc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4590789	=	=	IC50	nM	8200.0	IC50	uM	8.2
9031	Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccnn2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4439294	>	>	IC50	nM	10000.0	IC50	uM	10.0
9032	Inhibition of CYP3A4 (unknown origin)	Cn1ncc2c1CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O	ACS Med Chem Lett	2020.0	CHEMBL4440730	=	=	IC50	nM	3300.0	IC50	uM	3.3
9033	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4459487	=	=	IC50	nM	5140.0	IC50	uM	5.14
9034	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3C2CC2)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4466824	=	=	IC50	nM	14900.0	IC50	uM	14.9
9035	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OCC#Cc2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4537107	=	=	IC50	nM	7320.0	IC50	uM	7.32
9036	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	60.0	IC50	uM	0.06
9037	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL1136	=	=	IC50	nM	11800.0	IC50	uM	11.8
9038	Inhibition of CYP3A4 (unknown origin)	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL3989904	=	=	IC50	nM	2700.0	IC50	uM	2.7
9039	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL1136	=	=	IC50	nM	11800.0	IC50	uM	11.8
9040	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC[C@H]1OC(=O)[C@H](C)[C@@H](OC(=O)NCCCc2cccnc2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4474918	=	=	IC50	nM	2500.0	IC50	uM	2.5
9041	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	60.0	IC50	uM	0.06
9042	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454027	>	>	IC50	nM	100000.0	IC50	uM	100.0
9043	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4570491	=	=	IC50	nM	38000.0	IC50	uM	38.0
9044	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4520100	=	=	IC50	nM	37000.0	IC50	uM	37.0
9045	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(F)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4475634	>	>	IC50	nM	100000.0	IC50	uM	100.0
9046	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2ccccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4476185	>	>	IC50	nM	50000.0	IC50	uM	50.0
9047	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4446695	>	>	IC50	nM	50000.0	IC50	uM	50.0
9048	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4567440	=	=	IC50	nM	16300.0	IC50	uM	16.3
9049	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4455132	=	=	IC50	nM	26000.0	IC50	uM	26.0
9050	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4578385	=	=	IC50	nM	46000.0	IC50	uM	46.0
9051	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454027	=	=	IC50	nM	15500.0	IC50	uM	15.5
9052	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(Cl)c(-c3ccccc3OC(F)(F)F)c(Cl)c2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL3609407	>	>	IC50	nM	50000.0	IC50	uM	50.0
9053	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4570491	>	>	IC50	nM	50000.0	IC50	uM	50.0
9054	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4520100	>	>	IC50	nM	50000.0	IC50	uM	50.0
9055	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4446695	=	=	IC50	nM	49000.0	IC50	uM	49.0
9056	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2F)c2ncccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4592447	>	>	IC50	nM	50000.0	IC50	uM	50.0
9057	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4567440	=	=	IC50	nM	13900.0	IC50	uM	13.9
9058	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4455132	=	=	IC50	nM	30800.0	IC50	uM	30.8
9059	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccnc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4438970	>	>	IC50	nM	50000.0	IC50	uM	50.0
9060	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2c(F)cccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4466120	=	=	IC50	nM	27200.0	IC50	uM	27.2
9061	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4452714	=	=	IC50	nM	8340.0	IC50	uM	8.34
9062	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4577020	=	=	IC50	nM	16400.0	IC50	uM	16.4
9063	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccnc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4556521	>	>	IC50	nM	50000.0	IC50	uM	50.0
9064	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4578385	=	=	IC50	nM	44700.0	IC50	uM	44.7
9065	Inhibition of CYP3A4 (unknown origin)	O=C(NCCCCN1CCN(c2cc(Cl)cc(Cl)c2)CC1)c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4583609	>	>	IC50	nM	10000.0	IC50	nM	10000.0
9066	Inhibition of CYP3A4 (unknown origin)	N#Cc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4437341	>	>	IC50	nM	10000.0	IC50	nM	10000.0
9067	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1cc(-c2ccc3c([C@@H]4C[C@H]5C[C@H]5C[C@H]4C(=O)Nc4cn(C)nc4C(N)=O)noc3c2)n[nH]1	J Med Chem	2019.0	CHEMBL4562028	=	=	IC50	nM	3162.28	pIC50		5.5
9068	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cn1cc(NC(=O)[C@@H]2C[C@@H]3C[C@@H]3C[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c(C(F)(F)F)n1	J Med Chem	2019.0	CHEMBL4470157	=	=	IC50	nM	3981.07	pIC50		5.4
9069	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cn(C)nc3C(N)=O)c(F)c2)[nH]n1	J Med Chem	2019.0	CHEMBL4442899	=	=	IC50	nM	6309.57	pIC50		5.2
9070	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cn1cc(NC(=O)[C@@H]2CCCC[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c(C(F)(F)F)n1	J Med Chem	2019.0	CHEMBL4463314	=	=	IC50	nM	19952.62	pIC50		4.7
9071	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1noc(C)c1NC(=O)[C@@H]1CCCC[C@H]1C(=O)c1ccc(-c2cc[nH]n2)cc1	J Med Chem	2019.0	CHEMBL4472275	=	=	IC50	nM	3981.07	pIC50		5.4
9072	Inhibition of CYP3A4 (unknown origin)	CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21	J Med Chem	2019.0	CHEMBL3647536	>	>	IC50	nM	50000.0	IC50	uM	50.0
9073	Inhibition of CYP3A4 (unknown origin)	CCn1cnc2c(-c3ccc(F)c(-c4cc5c(cc4OC)C(=O)N(C)C5)c3)cnnc21	J Med Chem	2019.0	CHEMBL4545044	>	>	IC50	nM	30000.0	IC50	uM	30.0
9074	Inhibition of CYP3A4 (unknown origin)	CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1	J Med Chem	2019.0	CHEMBL3989870	>	>	IC50	nM	30000.0	IC50	uM	30.0
9075	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL157101	=	=	IC50	nM	182.6	IC50	uM	0.1826
9076	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Eur J Med Chem	2019.0	CHEMBL104	=	=	IC50	nM	67.0	IC50	uM	0.067
9077	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Eur J Med Chem	2019.0	CHEMBL106	=	=	IC50	nM	23969.8	IC50	uM	23.9698
9078	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Eur J Med Chem	2019.0	CHEMBL638	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
9079	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL1397	=	=	IC50	nM	672.1	IC50	uM	0.6721
9080	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4437301	=	=	IC50	nM	1022.3	IC50	uM	1.0223
9081	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4543140	=	=	IC50	nM	1312.3	IC50	uM	1.3123
9082	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4441984	=	=	IC50	nM	351.2	IC50	uM	0.3512
9083	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4470695	=	=	IC50	nM	127.2	IC50	uM	0.1272
9084	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4471515	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
9085	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4518317	=	=	IC50	nM	332.0	IC50	uM	0.332
9086	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4465284	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
9087	Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4582292	=	=	IC50	nM	251.5	IC50	uM	0.2515
9088	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL1213603	>	>	IC50	nM	50000.0	IC50	uM	50.0
9089	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](COC)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4570378	>	>	IC50	nM	50000.0	IC50	uM	50.0
9090	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](OC)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4577980	>	>	IC50	nM	50000.0	IC50	uM	50.0
9091	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2OC)S1	J Med Chem	2019.0	CHEMBL4519186	>	>	IC50	nM	50000.0	IC50	uM	50.0
9092	Inhibition of CYP3A4 (unknown origin)	CCN(C)C1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4483089	>	>	IC50	nM	50000.0	IC50	uM	50.0
9093	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](C)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4110677	>	>	IC50	nM	50000.0	IC50	uM	50.0
9094	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@@H]2[C@@H](O)C[C@@H](CO)O[C@@H]2S1	J Med Chem	2019.0	CHEMBL4520749	>	>	IC50	nM	50000.0	IC50	uM	50.0
9095	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@@H]2C[C@H](O)[C@@H](CO)O[C@@H]2S1	J Med Chem	2019.0	CHEMBL4107048	>	>	IC50	nM	50000.0	IC50	uM	50.0
9096	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CF)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4543991	>	>	IC50	nM	50000.0	IC50	uM	50.0
9097	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)C(F)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4554360	>	>	IC50	nM	50000.0	IC50	uM	50.0
9098	Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2F)S1	J Med Chem	2019.0	CHEMBL4448352	>	>	IC50	nM	50000.0	IC50	uM	50.0
9099	Inhibition of CYP3A4 (unknown origin) using midazolam substrate	CC(C)(C)OC(=O)n1c2c(c3ccccc31)C[C@H]1C(=O)N3C[C@@H](CC(=O)O)C[C@H]3[C@@H]2N1C(=O)CC1CCC(F)(F)CC1	J Med Chem	2020.0	CHEMBL4588734	>	>	IC50	nM	50000.0	IC50	uM	50.0
9100	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC(C)(C)OC(=O)n1c2c(c3ccccc31)C[C@H]1C(=O)N3C[C@@H](CC(=O)O)C[C@H]3[C@@H]2N1C(=O)CC1CCC(F)(F)CC1	J Med Chem	2020.0	CHEMBL4588734	>	>	IC50	nM	50000.0	IC50	uM	50.0
9101	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CCCNC1CN(c2ccnc(N)n2)C1.O.O=C(O)/C=C/C(=O)O	J Med Chem	2019.0	CHEMBL4441731	>	>	IC50	nM	25000.0	IC50	uM	25.0
9102	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C	J Med Chem	2020.0	CHEMBL4483575	>=	>=	IC50	nM	5000.0	IC50	uM	5.0
9103	Inhibition of CYP3A4 (unknown origin) in absence of cofactor	O=C(CCSc1nc2cc(Cl)ccc2o1)N1CCCC1	J Med Chem	2020.0	CHEMBL4566791	<	>	IC50	nM	39810.72	pIC50		4.4
9104	Inhibition of CYP3A4 (unknown origin) in presence of cofactor	O=C(CCSc1nc2cc(Cl)ccc2o1)N1CCCC1	J Med Chem	2020.0	CHEMBL4566791	<	>	IC50	nM	39810.72	pIC50		4.4
9105	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2sccc12	J Med Chem	2020.0	CHEMBL4526732	=	=	IC50	nM	7950.0	IC50	uM	7.95
9106	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12	J Med Chem	2020.0	CHEMBL4094163	=	=	IC50	nM	5920.0	IC50	uM	5.92
9107	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1	J Med Chem	2020.0	CHEMBL175691	=	=	IC50	nM	2170.0	IC50	uM	2.17
9108	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	36.6	IC50	uM	0.0366
9109	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4459856	=	=	IC50	nM	8400.0	IC50	uM	8.4
9110	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4471614	=	=	IC50	nM	350.0	IC50	uM	0.35
9111	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1	ACS Med Chem Lett	2019.0	CHEMBL4445809	=	=	IC50	nM	4570.0	IC50	uM	4.57
9112	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1	ACS Med Chem Lett	2019.0	CHEMBL4443301	=	=	IC50	nM	210.0	IC50	uM	0.21
9113	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC([C@H]4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4522927	>	>	IC50	nM	30000.0	IC50	uM	30.0
9114	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4459856	=	=	IC50	nM	6080.0	IC50	uM	6.08
9115	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4471614	=	=	IC50	nM	950.0	IC50	uM	0.95
9116	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1	ACS Med Chem Lett	2019.0	CHEMBL4445809	=	=	IC50	nM	2600.0	IC50	uM	2.6
9117	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1	ACS Med Chem Lett	2019.0	CHEMBL4443301	=	=	IC50	nM	440.0	IC50	uM	0.44
9118	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC([C@H]4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4522927	>	>	IC50	nM	30000.0	IC50	uM	30.0
9119	Inhibition of CYP3A4 (unknown origin)	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	ACS Med Chem Lett	2019.0	CHEMBL3989951	=	=	IC50	nM	2800.0	IC50	uM	2.8
9120	Inhibition of CYP3A4 (unknown origin)	CON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1	Eur J Med Chem	2019.0	CHEMBL4475126	>	>	IC50	nM	10000.0	IC50	uM	10.0
9121	Inhibition of CYP3A4 (unknown origin)	CCON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1	Eur J Med Chem	2019.0	CHEMBL4571987	>	>	IC50	nM	10000.0	IC50	uM	10.0
9122	Inhibition of CYP3A4 (unknown origin)	O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12	Eur J Med Chem	2019.0	CHEMBL3330226	>	>	IC50	nM	10000.0	IC50	uM	10.0
9123	Inhibition of CYP3A4 (unknown origin)	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C	ACS Med Chem Lett	2019.0	CHEMBL3109802	>	>	IC50	nM	50000.0	IC50	uM	50.0
9124	Inhibition of CYP3A4 (unknown origin)	COc1ncnc(Cn2cnc3c(C(=O)NCCF)cccc32)c1C	ACS Med Chem Lett	2019.0	CHEMBL4473847	>	>	IC50	nM	50000.0	IC50	uM	50.0
9125	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(=O)NCCF)c2ncn(Cc3ncnc(N(C)C)c3C)c2c1	ACS Med Chem Lett	2019.0	CHEMBL4515785	>	>	IC50	nM	50000.0	IC50	uM	50.0
9126	Inhibition of CYP3A4 (unknown origin)	COc1ccc(Cl)cc1NCC1C(c2ccc(S(N)(=O)=O)cc2)C1(C)C	ACS Med Chem Lett	2019.0	CHEMBL4541269	>	>	IC50	nM	10000.0	IC50	uM	10.0
9127	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1	Eur J Med Chem	2019.0	CHEMBL4436895	>	>	IC50	nM	5000.0	IC50	uM	5.0
9128	Inhibition of human recombinant CYP3A4 using midazolam as substrate	COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1	ACS Med Chem Lett	2019.0	CHEMBL4591825	>	>	IC50	nM	30000.0	IC50	uM	30.0
9129	Inhibition of human recombinant CYP3A4 using testosterone as substrate	COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1	ACS Med Chem Lett	2019.0	CHEMBL4591825	=	=	IC50	nM	20000.0	IC50	uM	20.0
9130	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CN(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)CC[C@@H]1N1CCC[C@H]1CO	J Med Chem	2019.0	CHEMBL4558456	>	>	IC50	nM	10000.0	IC50	uM	10.0
9131	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CC(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)=CC[C@@H]1N1CCC[C@H]1CO	J Med Chem	2019.0	CHEMBL4459231	>	>	IC50	nM	10000.0	IC50	uM	10.0
9132	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2ccccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL3629569	=	=	IC50	nM	170.0	IC50	uM	0.17
9133	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(=O)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4566253	=	=	IC50	nM	5000.0	IC50	uM	5.0
9134	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(C1CCCCC1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4461262	=	=	IC50	nM	700.0	IC50	uM	0.7
9135	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4537319	=	=	IC50	nM	130.0	IC50	uM	0.13
9136	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccc(F)cc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4542242	=	=	IC50	nM	60.0	IC50	uM	0.06
9137	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccncc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4559452	=	=	IC50	nM	3800.0	IC50	uM	3.8
9138	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1cncnc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4473619	=	=	IC50	nM	8600.0	IC50	uM	8.6
9139	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Nc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4577440	=	=	IC50	nM	510.0	IC50	uM	0.51
9140	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(F)cccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL3753837	=	=	IC50	nM	2000.0	IC50	uM	2.0
9141	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(Cl)cccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL4552010	=	=	IC50	nM	1700.0	IC50	uM	1.7
9142	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2cc(Cl)ccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL4546052	=	=	IC50	nM	10.0	IC50	uM	0.01
9143	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2ccccc2-c2cncn21)C1CCC(F)(F)CC1	J Med Chem	2019.0	CHEMBL4570289	=	=	IC50	nM	1200.0	IC50	uM	1.2
9144	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(F)cccc2-c2cncn21)C1CCC(F)(F)CC1	J Med Chem	2019.0	CHEMBL4576829	=	=	IC50	nM	2600.0	IC50	uM	2.6
9145	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4543526	=	=	IC50	nM	10900.0	IC50	uM	10.9
9146	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(N[C@H]1CC[C@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1	J Med Chem	2019.0	CHEMBL4450473	=	=	IC50	nM	1200.0	IC50	uM	1.2
9147	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(N[C@H]1CC[C@@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1	J Med Chem	2019.0	CHEMBL4550278	=	=	IC50	nM	1100.0	IC50	uM	1.1
9148	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4517185	=	=	IC50	nM	3300.0	IC50	uM	3.3
9149	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@@H](O)CC1	J Med Chem	2019.0	CHEMBL4530496	=	=	IC50	nM	3100.0	IC50	uM	3.1
9150	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL4446572	=	=	IC50	nM	5600.0	IC50	uM	5.6
9151	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL3989951	=	=	IC50	nM	5700.0	IC50	uM	5.7
9152	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL3989951	=	=	IC50	nM	15000.0	IC50	uM	15.0
9153	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)S(=O)(=O)c1cc2c(Nc3ccc4scnc4c3)ncnc2cc1OCCOP(=O)(O)O.[CaH2]	J Med Chem	2019.0	CHEMBL4516875	>	>	IC50	nM	30000.0	IC50	uM	30.0
9154	Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	MedChemComm	2018.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
9155	Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	Cn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12	MedChemComm	2018.0	CHEMBL4474827	=	=	IC50	nM	3530.0	IC50	uM	3.53
9156	Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	CCn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12	MedChemComm	2018.0	CHEMBL4469847	=	=	IC50	nM	310.0	IC50	uM	0.31
9157	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	C[C@H]1CN(c2n[nH]c3nc(N[C@H]4CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC4)ncc23)CCO1	J Med Chem	2019.0	CHEMBL4563818	<	>	IC50	nM	39810.72	pIC50		4.4
9158	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	COc1ccccc1-c1n[nH]c2nc(N[C@H]3CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC3)nc(OC)c12	J Med Chem	2019.0	CHEMBL4516798	=	=	IC50	nM	6309.57	pIC50		5.2
9159	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	COc1nc(N[C@H]2CC[C@H](NS(=O)(=O)CCC(C)C)CC2)nc2[nH]nc(N3CCOC[C@H]3C)c12	J Med Chem	2019.0	CHEMBL4572962	<	>	IC50	nM	39810.72	pIC50		4.4
9160	Inhibition of human CYP3A4 using midazolam as substrate	O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc21	J Med Chem	2019.0	CHEMBL2012686	>	>	IC50	nM	25000.0	IC50	uM	25.0
9161	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH	Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(C(N)=O)cc3)CC2)nc2c1COC2	J Med Chem	2019.0	CHEMBL4514678	>	>	IC50	nM	50000.0	IC50	uM	50.0
9162	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	36.6	IC50	uM	0.0366
9163	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis	Cl.Cl.O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1	J Med Chem	2019.0	CHEMBL4593911	>	>	IC50	nM	45000.0	IC50	uM	45.0
9164	Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F	J Med Chem	2019.0	CHEMBL4448852	=	=	IC50	nM	13000.0	IC50	uM	13.0
9165	Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(F)F	J Med Chem	2019.0	CHEMBL4436187	>	>	IC50	nM	30000.0	IC50	uM	30.0
9166	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1	J Med Chem	2019.0	CHEMBL4453186	=	=	IC50	nM	20500.0	IC50	uM	20.5
9167	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	18.3	IC50	uM	0.0183
9168	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1	J Med Chem	2019.0	CHEMBL4453186	=	=	IC50	nM	7820.0	IC50	uM	7.82
9169	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	56.3	IC50	uM	0.0563
9170	Inhibition of CYP3A4 (unknown origin)	OCc1cccc(-c2ccc3nc(-c4ccc(Cl)cc4)cn3c2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4576867	>	>	IC50	nM	10000.0	IC50	uM	10.0
9171	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccccc1)c1cn2cc(-c3ccccn3)ccc2n1	Bioorg Med Chem Lett	2019.0	CHEMBL4472621	>	>	IC50	nM	10000.0	IC50	uM	10.0
9172	Inhibition of human recombinant CYP3A4 preincubated for 10 mins followed by NADPH addition and measured after 10 to 30 mins by P450-Glo luminescence assay	OC[C@H]1CC[C@H](c2ccc(O)cc2)CC1	J Med Chem	2018.0	CHEMBL4526434	=	=	EC50	nM	89000.0	EC50	uM	89.0
9173	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL4593464	=	=	IC50	nM	0.4	IC50	nM	0.4
9174	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ccc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4557596	>	>	IC50	nM	12.5	IC50	nM	12.5
9175	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Cc1cc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cnc1N	Bioorg Med Chem Lett	2019.0	CHEMBL4474161	>	>	IC50	nM	12.5	IC50	nM	12.5
9176	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ncc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4438972	>	>	IC50	nM	12.5	IC50	nM	12.5
9177	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL4593464	=	=	IC50	nM	2.4	IC50	nM	2.4
9178	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ccc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4557596	>	>	IC50	nM	12.5	IC50	nM	12.5
9179	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Cc1cc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cnc1N	Bioorg Med Chem Lett	2019.0	CHEMBL4474161	>	>	IC50	nM	12.5	IC50	nM	12.5
9180	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ncc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4438972	>	>	IC50	nM	12.5	IC50	nM	12.5
9181	Inhibition of human CYP3A4 using atorvastatin as substrate	COCCN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL4448579	=	=	IC50	nM	10000.0	pIC50		5.0
9182	Inhibition of human CYP3A4 using atorvastatin as substrate	O=C(Nc1ccnnc1)c1cc(N2CCOCC2)ccc1OCc1ccccc1	Bioorg Med Chem Lett	2019.0	CHEMBL4457647	=	=	IC50	nM	6309.57	pIC50		5.2
9183	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12	Bioorg Med Chem Lett	2019.0	CHEMBL4455896	=	=	IC50	nM	310.0	IC50	uM	0.31
9184	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1	Bioorg Med Chem Lett	2019.0	CHEMBL4483816	>	>	IC50	nM	20000.0	IC50	uM	20.0
9185	Inhibition of CYP3A4 in human liver microsomes	CC(C)COc1ncc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2019.0	CHEMBL4279180	>	>	IC50	nM	40000.0	IC50	uM	40.0
9186	Inhibition of CYP3A4 in human liver microsomes	CC(C)COc1ccc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)c(F)cc23)cn1	J Med Chem	2019.0	CHEMBL4550045	=	=	IC50	nM	15000.0	IC50	uM	15.0
9187	Inhibition of human CYP3A4	CCc1sc2ncnc(N[C@H](Cc3ccccc3)C(=O)O)c2c1-c1ccc(OCCN2CCN(C)CC2)c(Cl)c1C	J Med Chem	2019.0	CHEMBL4451346	=	=	IC50	nM	5200.0	IC50	uM	5.2
9188	Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	J Med Chem	2019.0	CHEMBL4435170	>	>	IC50	nM	40000.0	IC50	uM	40.0
9189	Induction of CYP3A4 (unknown origin) by PXR-transactivation assay	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	J Med Chem	2019.0	CHEMBL4435170	>	>	EC50	nM	40000.0	EC50	uM	40.0
9190	Inhibition of CYP3A4 (unknown origin)	CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN	J Med Chem	2019.0	CHEMBL2058833	=	=	Ki	nM	156.0	Ki	nM	156.0
9191	Inhibition of CYP3A4 (unknown origin)	Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1	J Med Chem	2019.0	CHEMBL303933	=	=	Ki	nM	90.0	Ki	nM	90.0
9192	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using coumarin based substrate by fluorescence assay	COc1cc(N(CC2CC2)c2ccc(Cl)c3ccccc23)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O	J Med Chem	2019.0	CHEMBL4454609	>	>	IC50	nM	20000.0	IC50	uM	20.0
9193	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using coumarin based substrate by fluorescence assay	COc1nc(N(CC(C)(C)F)c2cc(Cl)c(F)cc2F)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O	J Med Chem	2019.0	CHEMBL3961833	>	>	IC50	nM	30000.0	IC50	uM	30.0
9194	Inhibition of human CYP3A4	C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	J Med Chem	2020.0	CHEMBL1294	=	=	IC50	nM	28000.0	IC50	uM	28.0
9195	Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@@H]2CCC[C@@H]3CCCC[C@H]32)c2cccc(OCC(=O)O)c2)cc1OC	J Med Chem	2020.0	CHEMBL4454363	=	=	IC50	nM	8400.0	IC50	uM	8.4
9196	Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@H](c2cc(OC)c(OC)c(OC)c2)C2CCCCC2)c2cccc(OCN3CCOCC3)c2)cc1OC	J Med Chem	2020.0	CHEMBL4560373	<	<	IC50	nM	1000.0	IC50	uM	1.0
9197	Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4537673	>	>	IC50	nM	20000.0	IC50	uM	20.0
9198	Inhibition of CYP3A4 (unknown origin) measured under preincubated conditions	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4537673	>	>	IC50	nM	20000.0	IC50	uM	20.0
9199	Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(-c2cccnc2)ccc1C(N)=O	J Med Chem	2020.0	CHEMBL4450463	>	>	IC50	nM	30000.0	IC50	uM	30.0
9200	Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(-c2cncc(-c3cnn(C4COC4)c3)c2)ccc1C(N)=O	J Med Chem	2020.0	CHEMBL4587832	>	>	IC50	nM	30000.0	IC50	uM	30.0
9201	Inhibition of CYP3A4 (unknown origin)	Cc1[nH]ncc1-c1cncc(-c2ccc(C(N)=O)c(OC(C)C)c2)c1	J Med Chem	2020.0	CHEMBL4569209	>	>	IC50	nM	30000.0	IC50	uM	30.0
9202	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cncc(-c3ccc(C(N)=O)c(OC(C)C)c3)c2)cnn1C	J Med Chem	2020.0	CHEMBL4440223	>	>	IC50	nM	30000.0	IC50	uM	30.0
9203	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate in presence of NADPH incubated for 10 mins	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)c(F)c2)nc2ccsc12	J Med Chem	2020.0	CHEMBL4442726	>	>	IC50	nM	50000.0	IC50	uM	50.0
9204	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate in presence of NADPH incubated for 10 mins	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	37.5	IC50	uM	0.0375
9205	Inhibition of CYP3A4 in human liver microsomes	Cc1c(O)c(O)cc[n+]1[C@@H](CO)Cc1ccccc1.[Cl-]	J Med Chem	2020.0	CHEMBL4467408	>	>	IC50	nM	200000.0	IC50	uM	200.0
9206	Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	O=c1cc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12	Eur J Med Chem	2018.0	CHEMBL4586075	>	>	IC50	nM	50000.0	IC50	uM	50.0
9207	Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cc3)[C@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4456312	=	=	IC50	nM	100.0	IC50	uM	0.1
9208	Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4547537	=	=	IC50	nM	300.0	IC50	uM	0.3
9209	Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4461475	=	=	IC50	nM	4000.0	IC50	uM	4.0
9210	Inhibition of CYP3A4 in human liver microsomes using [14C]-erythromycin as substrate preincubated for 2 mins in presence of NADPH followed by substrate addition and measured after 5 mins by liquid scintillation counting method	C[C@@H](Nc1nc2c(cnn2C2CCCC2)c(=O)[nH]1)C(=O)N1CC[C@H](F)C1	J Med Chem	2019.0	CHEMBL4580164	>	>	IC50	nM	10000.0	IC50	uM	10.0
9211	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL97797	=	=	IC50	nM	10000.0	IC50	uM	10.0
9212	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OC(F)(F)F)cc2s1	J Med Chem	2019.0	CHEMBL744	>	>	IC50	nM	25000.0	IC50	uM	25.0
9213	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL2386433	=	=	IC50	nM	10000.0	IC50	uM	10.0
9214	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4465714	<	<	IC50	nM	10000.0	IC50	uM	10.0
9215	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(COc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4468228	=	=	IC50	nM	10000.0	IC50	uM	10.0
9216	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(COc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4540341	=	=	IC50	nM	10000.0	IC50	uM	10.0
9217	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(COc3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4566383	>	>	IC50	nM	25000.0	IC50	uM	25.0
9218	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CSc1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL4592124	>	>	IC50	nM	25000.0	IC50	uM	25.0
9219	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SC(F)(F)F)cc2s1	J Med Chem	2019.0	CHEMBL95463	>	>	IC50	nM	25000.0	IC50	uM	25.0
9220	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4475811	=	=	IC50	nM	10000.0	IC50	uM	10.0
9221	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4439011	<	<	IC50	nM	10000.0	IC50	uM	10.0
9222	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CSc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4564287	<	<	IC50	nM	10000.0	IC50	uM	10.0
9223	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CSc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4577695	<	<	IC50	nM	10000.0	IC50	uM	10.0
9224	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CSc3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4441552	<	<	IC50	nM	10000.0	IC50	uM	10.0
9225	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1	J Med Chem	2019.0	CHEMBL4562350	<	<	IC50	nM	10000.0	IC50	uM	10.0
9226	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CS(=O)(=O)c1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL432942	>	>	IC50	nM	25000.0	IC50	uM	25.0
9227	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(S(=O)(=O)Cc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4440584	>	>	IC50	nM	25000.0	IC50	uM	25.0
9228	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(S(=O)(=O)Cc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4581441	=	=	IC50	nM	10000.0	IC50	uM	10.0
9229	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4464690	<	<	IC50	nM	10000.0	IC50	uM	10.0
9230	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4446494	=	=	IC50	nM	10000.0	IC50	uM	10.0
9231	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CS(=O)(=O)c3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4476655	<	<	IC50	nM	10000.0	IC50	uM	10.0
9232	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4469761	>	>	IC50	nM	25000.0	IC50	uM	25.0
9233	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4458858	<	<	IC50	nM	10000.0	IC50	uM	10.0
9234	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4561783	>	>	IC50	nM	25000.0	IC50	uM	25.0
9235	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4579215	>	>	IC50	nM	25000.0	IC50	uM	25.0
9236	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CNC(=O)c3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4452155	>	>	IC50	nM	25000.0	IC50	uM	25.0
9237	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1	J Med Chem	2019.0	CHEMBL4581650	<	<	IC50	nM	10000.0	IC50	uM	10.0
9238	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1cc(CNC(=O)c2ccc3nc(N)sc3c2)cc(OC)c1OC	J Med Chem	2019.0	CHEMBL4554726	>	>	IC50	nM	25000.0	IC50	uM	25.0
9239	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3[N+](=O)[O-])cc2s1	J Med Chem	2019.0	CHEMBL4582026	<	<	IC50	nM	10000.0	IC50	uM	10.0
9240	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3N)cc2s1	J Med Chem	2019.0	CHEMBL4460492	=	=	IC50	nM	10000.0	IC50	uM	10.0
9241	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NC(c3ccccc3)c3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4435791	<	<	IC50	nM	10000.0	IC50	uM	10.0
9242	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc3nc(N)sc3c2)CC1	J Med Chem	2019.0	CHEMBL4545398	=	=	IC50	nM	10000.0	IC50	uM	10.0
9243	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCCc3cccs3)cc2s1	J Med Chem	2019.0	CHEMBL4554707	>	>	IC50	nM	25000.0	IC50	uM	25.0
9244	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2s1	J Med Chem	2019.0	CHEMBL4528355	>	>	IC50	nM	25000.0	IC50	uM	25.0
9245	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4444333	<	<	IC50	nM	10000.0	IC50	uM	10.0
9246	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)N(CCO)Cc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4452773	=	=	IC50	nM	10000.0	IC50	uM	10.0
9247	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1ccc(CN(Cc2ccc(Cl)c(Cl)c2)C(=O)c2ccc3nc(N)sc3c2)cc1OC	J Med Chem	2019.0	CHEMBL4462566	<	<	IC50	nM	10000.0	IC50	uM	10.0
9248	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(O)cc(C(=O)NCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4552119	<	<	IC50	nM	10000.0	IC50	uM	10.0
9249	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(O)cc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4549839	>	>	IC50	nM	25000.0	IC50	uM	25.0
9250	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4583705	<	<	IC50	nM	10000.0	IC50	uM	10.0
9251	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)NCc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4453795	<	<	IC50	nM	10000.0	IC50	uM	10.0
9252	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)NCc3ccccc3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4456198	<	<	IC50	nM	10000.0	IC50	uM	10.0
9253	Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	J Med Chem	2019.0	CHEMBL55	>	>	IC50	nM	25000.0	IC50	uM	25.0
9254	Inhibition of CYP3A4 (unknown origin)	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1	Bioorg Med Chem Lett	2019.0	CHEMBL4457447	>	>	IC50	nM	50000.0	IC50	uM	50.0
9255	Inhibition of CYP3A4 (unknown origin) using midazolam	COc1c(C#N)ccc2[nH]c(-c3cn4c(n3)[C@H](c3cccc(F)c3C)OCC4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4451760	>	>	IC50	nM	10000.0	IC50	uM	10.0
9256	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1	Bioorg Med Chem	2019.0	CHEMBL4555459	=	=	IC50	nM	1000.0	IC50	uM	1.0
9257	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1	Bioorg Med Chem	2019.0	CHEMBL4564973	>	>	IC50	nM	5000.0	IC50	uM	5.0
9258	Inhibition of CYP3A4 (unknown origin)	CC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL3965066	>	>	IC50	nM	10000.0	IC50	uM	10.0
9259	Inhibition of CYP3A4 (unknown origin)	O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)CC2	Bioorg Med Chem Lett	2019.0	CHEMBL3964587	>	>	IC50	nM	10000.0	IC50	uM	10.0
9260	Inhibition of CYP3A4 (unknown origin)	C[C@@H](O[C@H]1CC[C@]2(CCC(F)(F)CO2)CC1)c1nc(-c2cc(F)c(CS(C)(=O)=O)c(F)c2)no1	Bioorg Med Chem Lett	2019.0	CHEMBL4548931	>	>	IC50	nM	50000.0	IC50	uM	50.0
9261	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	=	=	IC50	nM	7100.0	IC50	uM	7.1
9262	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	=	=	IC50	nM	8900.0	IC50	uM	8.9
9263	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	=	=	IC50	nM	2000.0	IC50	uM	2.0
9264	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	=	=	IC50	nM	4200.0	IC50	uM	4.2
9265	Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
9266	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	>	>	IC50	nM	33000.0	IC50	uM	33.0
9267	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	>	>	IC50	nM	33000.0	IC50	uM	33.0
9268	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	>	>	IC50	nM	33000.0	IC50	uM	33.0
9269	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	>	>	IC50	nM	33000.0	IC50	uM	33.0
9270	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
9271	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	=	=	IC50	nM	28000.0	IC50	uM	28.0
9272	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	>	>	IC50	nM	33000.0	IC50	uM	33.0
9273	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	>	>	IC50	nM	33000.0	IC50	uM	33.0
9274	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	=	=	IC50	nM	8100.0	IC50	uM	8.1
9275	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
9276	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3C(=O)NOC(C)(C)C)cc2)[nH]n1	J Med Chem	2019.0	CHEMBL4563459	>	>	IC50	nM	20000.0	IC50	uM	20.0
9277	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3S(N)(=O)=O)cc2)n[nH]1	J Med Chem	2019.0	CHEMBL4474619	>	>	IC50	nM	20000.0	IC50	uM	20.0
9278	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn4c3C(=O)NCC4)cc2)n[nH]1	J Med Chem	2019.0	CHEMBL4542281	>	>	IC50	nM	20000.0	IC50	uM	20.0
9279	Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
9280	Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay	CCn1cncc1-c1c[nH]c2ccc(I)c(F)c12	Eur J Med Chem	2019.0	CHEMBL4452569	=	=	IC50	nM	100.0	IC50	uM	0.1
9281	Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	CCc1cc(Cc2ccc(CC(N)=O)cc2)nc(-c2cccc(Cl)c2)n1	J Med Chem	2019.0	CHEMBL4573171	=	=	IC50	nM	5900.0	IC50	uM	5.9
9282	Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1	J Med Chem	2019.0	CHEMBL4541964	=	=	IC50	nM	15000.0	IC50	uM	15.0
9283	Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	CCc1cc(Cc2ccc(CC(=O)NCCO)cc2)nc(-c2cccc(Cl)c2)n1	J Med Chem	2019.0	CHEMBL4593524	=	=	IC50	nM	3100.0	IC50	uM	3.1
9284	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCC2)ccc1C	J Med Chem	2019.0	CHEMBL4465111	>	>	IC50	nM	10000.0	IC50	uM	10.0
9285	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCCC2)ccc1C	J Med Chem	2019.0	CHEMBL4540948	>	>	IC50	nM	10000.0	IC50	uM	10.0
9286	Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCOCC2)ccc1C	J Med Chem	2019.0	CHEMBL4464752	>	>	IC50	nM	10000.0	IC50	uM	10.0
9287	Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1COC1)c1nc2ccc(-c3ccc(F)nc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4446981	>	>	IC50	nM	18000.0	IC50	uM	18.0
9288	Inhibition of CYP3A4 (unknown origin)	CN1CCN(C(=O)c2ccc(-c3ccc4nc(C(C#N)C(=O)NCC(=O)NC5CC5)sc4c3)cc2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL4438345	>	>	IC50	nM	18000.0	IC50	uM	18.0
9289	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1cccc(-c2ccc3nc(C(C#N)C(=O)NCC(=O)NC4CC4)sc3c2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4557424	>	>	IC50	nM	18000.0	IC50	uM	18.0
9290	Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4545633	>	>	IC50	nM	18000.0	IC50	uM	18.0
9291	Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccccc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4587475	>	>	IC50	nM	18000.0	IC50	uM	18.0
9292	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cnn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)c2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4513792	>	>	IC50	nM	10000.0	IC50	uM	10.0
9293	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)nc2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4589676	>	>	IC50	nM	10000.0	IC50	uM	10.0
9294	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc2c(cnn2[C@@H](CC(C)C)c2ccc(C(=O)NCCC(=O)O)cc2)cc1-c1ccc(C(F)(F)F)cc1Cl	Bioorg Med Chem Lett	2019.0	CHEMBL4468579	>	>	IC50	nM	10000.0	IC50	uM	10.0
9295	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1c(-c2ccc(C(F)(F)F)cc2Cl)ccc2nn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4582082	>	>	IC50	nM	10000.0	IC50	uM	10.0
9296	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cnn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)c2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4513792	>	>	IC50	nM	10000.0	IC50	uM	10.0
9297	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)nc2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4589676	>	>	IC50	nM	10000.0	IC50	uM	10.0
9298	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc2c(cnn2[C@@H](CC(C)C)c2ccc(C(=O)NCCC(=O)O)cc2)cc1-c1ccc(C(F)(F)F)cc1Cl	Bioorg Med Chem Lett	2019.0	CHEMBL4468579	>	>	IC50	nM	10000.0	IC50	uM	10.0
9299	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1c(-c2ccc(C(F)(F)F)cc2Cl)ccc2nn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4582082	>	>	IC50	nM	10000.0	IC50	uM	10.0
9300	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccncc1)c1cn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cnn(C3CCNCC3)c12	Bioorg Med Chem Lett	2019.0	CHEMBL4452711	=	=	IC50	nM	7000.0	IC50	uM	7.0
9301	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccc(C)c2oc(-c3nc(-c4ccc(C(=O)O)cc4)no3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4459692	>	>	IC50	nM	25000.0	IC50	uM	25.0
9302	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2ccc(O)cc2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4540811	=	=	IC50	nM	6470.0	IC50	uM	6.47
9303	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2ccc(Br)o2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4575355	=	=	IC50	nM	1400.0	IC50	uM	1.4
9304	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2cc(Br)cs2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4591977	<	<	IC50	nM	1000.0	IC50	uM	1.0
9305	Inhibition of human CYP3A4	CC(C)(C)N1CCC(NC(=O)c2ccc(C(F)(F)F)cc2Cl)CC1	J Med Chem	2020.0	CHEMBL4435674	>	>	IC50	nM	100000.0	IC50	uM	100.0
9306	Inhibition of human CYP3A4	COc1c(OCCCCCCC(=O)O)cc2oc3cc4c(c(O)c3c(=O)c2c1CC=C(C)C)C=CC(C)(C)O4	J Med Chem	2020.0	CHEMBL4471352	>	>	IC50	nM	10000.0	IC50	uM	10.0
9307	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	CCS(=O)(=O)Cc1cnc(Oc2ccc(F)cc2F)c(-c2cc(C)c3c(=O)[nH]ccn23)c1	J Med Chem	2020.0	CHEMBL4440098	>	>	IC50	nM	20000.0	IC50	uM	20.0
9308	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	CCS(=O)(=O)Cc1cnc(Oc2ccc(F)cc2F)c(-c2cc(C)c3c(=O)[nH]ccn23)c1	J Med Chem	2020.0	CHEMBL4440098	>	>	IC50	nM	20000.0	IC50	uM	20.0
9309	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4438144	>	>	IC50	nM	40000.0	IC50	uM	40.0
9310	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4467828	=	=	IC50	nM	19700.0	IC50	uM	19.7
9311	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2ccc3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4581829	>	>	IC50	nM	40000.0	IC50	uM	40.0
9312	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	Nc1nn(-c2ccc3cn[nH]c3c2)c2cc(-c3ccnn3Cc3ccc(Cl)cc3Cl)cnc12	J Med Chem	2020.0	CHEMBL4527606	=	=	IC50	nM	4200.0	IC50	uM	4.2
9313	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	Clc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4454039	=	=	IC50	nM	35500.0	IC50	uM	35.5
9314	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4516795	>	>	IC50	nM	40000.0	IC50	uM	40.0
9315	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc3c(cn2)nnn3-c2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1	J Med Chem	2020.0	CHEMBL4454426	>	>	IC50	nM	40000.0	IC50	uM	40.0
9316	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	O=c1[nH]c2ccc(-n3nnc4cnc(-c5ccnn5Cc5ccc(Cl)cc5Cl)cc43)cc2[nH]1	J Med Chem	2020.0	CHEMBL4527142	=	=	IC50	nM	4200.0	IC50	uM	4.2
9317	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	O=c1[nH]c2ccc(-n3nnc4c(Cl)cc(-c5ccnn5Cc5ccc(Cl)cn5)cc43)cc2[nH]1	J Med Chem	2020.0	CHEMBL4522718	>	>	IC50	nM	40000.0	IC50	uM	40.0
9318	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4456158	>	>	IC50	nM	40000.0	IC50	uM	40.0
9319	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1cc(CCNc2nc(C#Cc3ccccc3)nc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@@H]3C[C@@H]32)ccc1O	J Med Chem	2020.0	CHEMBL4571380	=	=	IC50	nM	2230.0	IC50	uM	2.23
9320	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCN(C)CC4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4575655	>	>	IC50	nM	30000.0	IC50	uM	30.0
9321	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4548795	>	>	IC50	nM	30000.0	IC50	uM	30.0
9322	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4C[C@H](C)N(C)[C@H](C)C4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4434717	>	>	IC50	nM	30000.0	IC50	uM	30.0
9323	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1	J Med Chem	2019.0	CHEMBL4163069	=	=	IC50	nM	2900.0	IC50	uM	2.9
9324	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2019.0	CHEMBL4571052	>	>	IC50	nM	10000.0	IC50	uM	10.0
9325	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2019.0	CHEMBL1276308	=	=	IC50	nM	9500.0	IC50	uM	9.5
9326	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4541056	>	>	IC50	nM	25000.0	IC50	uM	25.0
9327	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4439536	>	>	IC50	nM	25000.0	IC50	uM	25.0
9328	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4540185	>	>	IC50	nM	25000.0	IC50	uM	25.0
9329	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4552727	>	>	IC50	nM	25000.0	IC50	uM	25.0
9330	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4444464	>	>	IC50	nM	25000.0	IC50	uM	25.0
9331	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4469631	=	=	IC50	nM	4690.0	IC50	uM	4.69
9332	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4571655	>	>	IC50	nM	25000.0	IC50	uM	25.0
9333	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4457730	>	>	IC50	nM	25000.0	IC50	uM	25.0
9334	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4441045	>	>	IC50	nM	25000.0	IC50	uM	25.0
9335	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4575553	>	>	IC50	nM	25000.0	IC50	uM	25.0
9336	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4561577	>	>	IC50	nM	25000.0	IC50	uM	25.0
9337	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4556614	>	>	IC50	nM	25000.0	IC50	uM	25.0
9338	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4451769	>	>	IC50	nM	25000.0	IC50	uM	25.0
9339	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4456070	>	>	IC50	nM	25000.0	IC50	uM	25.0
9340	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4586676	>	>	IC50	nM	25000.0	IC50	uM	25.0
9341	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4532502	>	>	IC50	nM	25000.0	IC50	uM	25.0
9342	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4448916	=	=	IC50	nM	3110.0	IC50	uM	3.11
9343	Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4483695	=	=	IC50	nM	3040.0	IC50	uM	3.04
9344	Inhibition of CYP3A4 in liver microsomes (unknown origin) using ketoconazole as substrate preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	Cc1cc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)ccc1-c1cnc(NC2CC2)c2nccn12	Eur J Med Chem	2019.0	CHEMBL4586372	=	=	IC50	nM	3520.0	IC50	uM	3.52
9345	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-c2cc(C(c3ccc(Cl)cc3)n3ccnc3)c[nH]2)cc1	J Med Chem	2019.0	CHEMBL4468270	=	=	IC50	nM	1400.0	IC50	uM	1.4
9346	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Cn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4569370	=	=	IC50	nM	1100.0	IC50	uM	1.1
9347	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	C=CCn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4551139	=	=	IC50	nM	900.0	IC50	uM	0.9
9348	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-n2ccc(C(c3ccc(Cl)cc3Cl)n3ccnc3)c2)cc1	J Med Chem	2019.0	CHEMBL4438726	=	=	IC50	nM	900.0	IC50	uM	0.9
9349	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-c2c[nH]cc2C(c2ccc(Cl)cc2Cl)n2ccnc2)cc1	J Med Chem	2019.0	CHEMBL315874	=	=	IC50	nM	800.0	IC50	uM	0.8
9350	Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	400.0	IC50	uM	0.4
9351	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)N(C)C(C)c3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4548820	=	=	IC50	nM	4000.0	IC50	uM	4.0
9352	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCN(C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1)C(C)C	J Med Chem	2019.0	CHEMBL4451661	=	=	IC50	nM	15400.0	IC50	uM	15.4
9353	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)N(C)C(C)C)C2)n1	J Med Chem	2019.0	CHEMBL4464022	>	>	IC50	nM	20000.0	IC50	uM	20.0
9354	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCN(C(=O)N1CC/C(=C\C#Cc2cccc(C)n2)C1)C(C)C	J Med Chem	2019.0	CHEMBL4441964	>	>	IC50	nM	20000.0	IC50	uM	20.0
9355	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCCC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4590911	>	>	IC50	nM	20000.0	IC50	uM	20.0
9356	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4483689	>	>	IC50	nM	20000.0	IC50	uM	20.0
9357	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1ccccc1C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4568857	=	=	IC50	nM	13800.0	IC50	uM	13.8
9358	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1	J Med Chem	2019.0	CHEMBL4567923	=	=	IC50	nM	4600.0	IC50	uM	4.6
9359	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1	J Med Chem	2019.0	CHEMBL4460573	=	=	IC50	nM	6100.0	IC50	uM	6.1
9360	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3cccc(F)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4456792	>	>	IC50	nM	20000.0	IC50	uM	20.0
9361	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3cccc(Cl)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4535926	>	>	IC50	nM	20000.0	IC50	uM	20.0
9362	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	O=C(c1cccc(Cl)c1)N1CCC(=CC#Cc2cccc(Cl)n2)CC1	J Med Chem	2019.0	CHEMBL4455843	=	=	IC50	nM	2300.0	IC50	uM	2.3
9363	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)c3cccc(Cl)c3)C2)n1	J Med Chem	2019.0	CHEMBL4448788	=	=	IC50	nM	12900.0	IC50	uM	12.9
9364	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)c3ccco3)C2)n1	J Med Chem	2019.0	CHEMBL4542890	>	>	IC50	nM	20000.0	IC50	uM	20.0
9365	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCS(=O)(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4453683	=	=	IC50	nM	17200.0	IC50	uM	17.2
9366	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3cccc(Br)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4520868	=	=	IC50	nM	3300.0	IC50	uM	3.3
9367	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1	J Med Chem	2019.0	CHEMBL4452522	=	=	IC50	nM	1900.0	IC50	uM	1.9
9368	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1	J Med Chem	2019.0	CHEMBL4592284	=	=	IC50	nM	1900.0	IC50	uM	1.9
9369	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3ccc(C#N)cc3)CC2)n1	J Med Chem	2019.0	CHEMBL4513498	=	=	IC50	nM	5000.0	IC50	uM	5.0
9370	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	>	>	IC50	nM	20000.0	IC50	uM	20.0
9371	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCCCN(C)C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4443478	=	=	IC50	nM	13400.0	IC50	uM	13.4
9372	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C#N)c2)CC1	J Med Chem	2019.0	CHEMBL4439229	>	>	IC50	nM	20000.0	IC50	uM	20.0
9373	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(Cl)c2)CC1	J Med Chem	2019.0	CHEMBL4472693	=	=	IC50	nM	12800.0	IC50	uM	12.8
9374	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(F)c2)CC1	J Med Chem	2019.0	CHEMBL4475143	=	=	IC50	nM	4200.0	IC50	uM	4.2
9375	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C)c2)CC1	J Med Chem	2019.0	CHEMBL4446275	=	=	IC50	nM	5400.0	IC50	uM	5.4
9376	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OCCc3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4539036	=	=	IC50	nM	3700.0	IC50	uM	3.7
9377	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OCc3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4548205	=	=	IC50	nM	7700.0	IC50	uM	7.7
9378	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OC(C)(C)C)CC2)n1	J Med Chem	2019.0	CHEMBL4448804	>	>	IC50	nM	2000.0	IC50	uM	2.0
9379	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4441707	>	>	IC50	nM	20000.0	IC50	uM	20.0
9380	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2ccccn2)CC1	J Med Chem	2019.0	CHEMBL4472416	>	>	IC50	nM	20000.0	IC50	uM	20.0
9381	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4544729	>	>	IC50	nM	20000.0	IC50	uM	20.0
9382	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC/C(=C/C#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4539998	=	=	IC50	nM	9700.0	IC50	uM	9.7
9383	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC/C(=C\C#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4551786	>	>	IC50	nM	20000.0	IC50	uM	20.0
9384	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC2(CC(=CC#Cc3cccc(C)n3)C2)C1	J Med Chem	2019.0	CHEMBL4551238	=	=	IC50	nM	17200.0	IC50	uM	17.2
9385	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC(=CC#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4464549	>	>	IC50	nM	20000.0	IC50	uM	20.0
9386	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(c3ncccc3[N+](=O)[O-])CC2)n1	J Med Chem	2019.0	CHEMBL3597594	=	=	IC50	nM	4500.0	IC50	uM	4.5
9387	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1nc(C#Cc2cccnc2)cs1	J Med Chem	2019.0	CHEMBL292065	>	>	IC50	nM	100000.0	IC50	uM	100.0
9388	Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#Cc2ccccc2)n1	J Med Chem	2019.0	CHEMBL66654	>	>	IC50	nM	100000.0	IC50	uM	100.0
9389	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1OCC2(CCN(c3nc(N)c(Sc4cccc(Cl)c4Cl)c(=O)n3C)CC2)[C@@H]1N	J Med Chem	2019.0	CHEMBL4546378	>	>	IC50	nM	50000.0	IC50	uM	50.0
9390	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(NC6CC6)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N	J Med Chem	2019.0	CHEMBL4439006	>	>	IC50	nM	50000.0	IC50	uM	50.0
9391	Inhibition of CYP3A4 in human liver microsomes at 1 uM using midazolam as substrate by LC-MS/MS analysis	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1	J Med Chem	2019.0	CHEMBL3936761	=	=	IC50	nM	14300.0	IC50	uM	14.3
9392	Inhibition of CYP3A4 in human liver microsomes at 1 uM using testosterone as substrate by LC-MS/MS analysis	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1	J Med Chem	2019.0	CHEMBL3936761	=	=	IC50	nM	60600.0	IC50	uM	60.6
9393	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC1(C)CCN1Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1	J Med Chem	2019.0	CHEMBL4460028	=	=	IC50	nM	50000.0	IC50	uM	50.0
9394	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)C(C)(C)C	J Med Chem	2019.0	CHEMBL4471825	=	=	IC50	nM	50000.0	IC50	uM	50.0
9395	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(C)N(C)Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1	J Med Chem	2019.0	CHEMBL4435054	=	=	IC50	nM	38000.0	IC50	uM	38.0
9396	Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCOCC(=O)O	J Med Chem	2019.0	CHEMBL4473988	>	>	IC50	nM	50000.0	IC50	uM	50.0
9397	Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCc1nnn[nH]1	J Med Chem	2019.0	CHEMBL4463477	=	=	IC50	nM	4700.0	IC50	uM	4.7
9398	Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCC(=O)O	J Med Chem	2019.0	CHEMBL1802692	>	>	IC50	nM	50000.0	IC50	uM	50.0
9399	Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	40.0	IC50	uM	0.04
9400	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	Cn1c(Sc2ccc(C(=O)NO)cc2)nnc1-c1cccs1	J Med Chem	2019.0	CHEMBL4537736	=	=	IC50	nM	26600.0	IC50	uM	26.6
9401	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NO)c1ccc(Cn2nnnc2-c2cccs2)cc1	J Med Chem	2019.0	CHEMBL4448410	=	=	IC50	nM	47400.0	IC50	uM	47.4
9402	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCc1ccc(-c2cccnc2)s1			CHEMBL359657	=	=	IC50	nM	58700.0	IC50	uM	58.7
9403	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCc1ccc(-c2cccnc2)o1			CHEMBL178090	=	=	IC50	nM	47100.0	IC50	uM	47.1
9404	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCC#Cc1cccnc1			CHEMBL360541	=	=	IC50	nM	365000.0	IC50	uM	365.0
9405	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccsc1-c1cccnc1			CHEMBL179669	=	=	IC50	nM	750.0	IC50	uM	0.75
9406	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cn1cnc(-c2cccnc2)c1			CHEMBL360999	=	=	IC50	nM	261900.0	IC50	uM	261.9
9407	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CNCc1ccc(-c2cccnc2)s1			CHEMBL369285	>	>	IC50	nM	400000.0	IC50	uM	400.0
9408	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccsc1-c1ccc(F)nc1			CHEMBL179621	=	=	IC50	nM	39080.0	IC50	uM	39.08
9409	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2ccsc2)c1			CHEMBL361153	=	=	IC50	nM	55900.0	IC50	uM	55.9
9410	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1ccc(Cn2cnc(-c3cccnc3)c2)cc1			CHEMBL178780	=	=	IC50	nM	75100.0	IC50	uM	75.1
9411	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1nccn1-c1cccnc1			CHEMBL368883	=	=	IC50	nM	152000.0	IC50	uM	152.0
9412	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2c[nH]cn2)c1			CHEMBL178516	=	=	IC50	nM	140000.0	IC50	uM	140.0
9413	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1cscc1-c1cccnc1			CHEMBL179704	<	<	IC50	nM	25000.0	IC50	uM	25.0
9414	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C/c1ccc(-c2cccnc2)s1			CHEMBL178534	=	=	IC50	nM	12980.0	IC50	uM	12.98
9415	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CCn1cnc(-c2cccnc2)c1			CHEMBL361364	=	=	IC50	nM	79200.0	IC50	uM	79.2
9416	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Nc1ccc(-c2cccnc2)s1			CHEMBL3640762	=	=	IC50	nM	1590.0	IC50	uM	1.59
9417	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-n2ccnc2)c1			CHEMBL179477	=	=	IC50	nM	77540.0	IC50	uM	77.54
9418	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O=Cc1ccc(-c2cccnc2)s1			CHEMBL179398	=	=	IC50	nM	23930.0	IC50	uM	23.93
9419	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Fc1ccc(-c2ccsc2)cn1			CHEMBL179005	=	=	IC50	nM	114000.0	IC50	uM	114.0
9420	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NC[C@@H]1CC[C@@H](c2cccnc2)O1			CHEMBL4443442	=	=	IC50	nM	64710.0	IC50	uM	64.71
9421	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2cccnc2)c1			CHEMBL179763	>	>	IC50	nM	400000.0	IC50	uM	400.0
9422	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1			CHEMBL178711	>=	>=	IC50	nM	56990.0	IC50	uM	56.99
9423	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CC(=O)c1ccc(-c2cccnc2)s1			CHEMBL362702	=	=	IC50	nM	26900.0	IC50	uM	26.9
9424	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C/c1ccc(-c2cccnc2)o1			CHEMBL178547	>	>	IC50	nM	400000.0	IC50	uM	400.0
9425	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cnc(-c2cccnc2)nc1			CHEMBL178878	>	>	IC50	nM	400000.0	IC50	uM	400.0
9426	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1cscc1-c1ccc(F)nc1			CHEMBL425519	=	=	IC50	nM	114000.0	IC50	uM	114.0
9427	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccc(-c2cccnc2)nc1			CHEMBL179589	=	=	IC50	nM	84230.0	IC50	uM	84.23
9428	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN1CCC[C@H]1c1cccnc1			CHEMBL3	=	=	IC50	nM	142400.0	IC50	uM	142.4
9429	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN(C)Cc1ccc(-c2cccnc2)o1			CHEMBL360998	=	=	IC50	nM	294000.0	IC50	uM	294.0
9430	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C\c1ccc(-c2cccnc2)o1			CHEMBL178330	>	>	IC50	nM	400000.0	IC50	uM	400.0
9431	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN(C)Cc1ccc(-c2cccnc2)s1			CHEMBL361969	=	=	IC50	nM	219000.0	IC50	uM	219.0
9432	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O=Cc1ccc(-c2cccnc2)o1			CHEMBL178708	=	=	IC50	nM	2200.0	IC50	uM	2.2
9433	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CC(=O)SCc1ccc(-c2cccnc2)o1			CHEMBL386124	=	=	IC50	nM	2900.0	IC50	uM	2.9
9434	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	SCc1ccc(-c2cccnc2)o1			CHEMBL214784	=	=	IC50	nM	6100.0	IC50	uM	6.1
9435	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CSCc1ccc(-c2cccnc2)o1			CHEMBL214990	=	=	IC50	nM	14800.0	IC50	uM	14.8
9436	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	ON=Cc1ccc(-c2cccnc2)o1			CHEMBL4466954	=	=	IC50	nM	51900.0	IC50	uM	51.9
9437	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cc1csc2c1c(=O)n(CCc1ccccc1)c(=O)n2CC1CCCO1	Eur J Med Chem	2019.0	CHEMBL4451942	=	=	IC50	nM	16000.0	IC50	10'-6 mol/L	16.0
9438	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCn1c(=O)c2c(C)c(C(=O)N3CCC(O)CC3)sc2n(CCC(F)(F)F)c1=O	Eur J Med Chem	2019.0	CHEMBL4522981	>	>	IC50	nM	20000.0	IC50	10'-6 mol/L	20.0
9439	Inhibition of CYP3A4 in human liver microsomes by HPLC-MS/MS analysis	O=c1[nH]c(CNC(CO)CO)c(I)c(=O)[nH]1	J Med Chem	2019.0	CHEMBL4455140	>	>	IC50	nM	100000.0	IC50	uM	100.0
9440	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1	J Med Chem	2019.0	CHEMBL4592045	>	>	IC50	nM	30000.0	IC50	uM	30.0
9441	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis relative to control	CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1	J Med Chem	2019.0	CHEMBL4592045	>	>	IC50	nM	30000.0	IC50	uM	30.0
9442	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1[C@@H]1C(C(=O)C(C)C)=C([O-])C(=O)N1c1ccc(-c2ccsc2)cc1.[Na+]	Bioorg Med Chem Lett	2019.0	CHEMBL4439812	>	>	IC50	nM	20000.0	IC50	uM	20.0
9443	Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC[S+](C)[O-]	Bioorg Med Chem Lett	2019.0	CHEMBL4437131	>	>	IC50	nM	20000.0	IC50	uM	20.0
9444	Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4537290	>	>	IC50	nM	20000.0	IC50	uM	20.0
9445	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1C(C(=O)C(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454941	>	>	IC50	nM	20000.0	IC50	uM	20.0
9446	Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4459015	>	>	IC50	nM	20000.0	IC50	uM	20.0
9447	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC(=O)O	Bioorg Med Chem Lett	2019.0	CHEMBL4445659	>	>	IC50	nM	20000.0	IC50	uM	20.0
9448	Inhibition of CYP3A4 (unknown origin)	C[S+]([O-])CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4459391	>	>	IC50	nM	20000.0	IC50	uM	20.0
9449	Inhibition of CYP3A4 (unknown origin)	CN(C)CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4572081	>	>	IC50	nM	20000.0	IC50	uM	20.0
9450	Inhibition of CYP3A4 (unknown origin)	COCCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4592312	>	>	IC50	nM	20000.0	IC50	uM	20.0
9451	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4457637	>	>	IC50	nM	20000.0	IC50	uM	20.0
9452	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3cccs3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4465467	>	>	IC50	nM	20000.0	IC50	uM	20.0
9453	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4466252	>	>	IC50	nM	20000.0	IC50	uM	20.0
9454	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccoc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4562022	>	>	IC50	nM	20000.0	IC50	uM	20.0
9455	Inhibition of CYP3A4 (unknown origin)	Cc1noc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)n1	Bioorg Med Chem Lett	2019.0	CHEMBL4526549	>	>	IC50	nM	20000.0	IC50	uM	20.0
9456	Inhibition of CYP3A4 (unknown origin)	Cc1nc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)no1	Bioorg Med Chem Lett	2019.0	CHEMBL4456152	>	>	IC50	nM	20000.0	IC50	uM	20.0
9457	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)on1	Bioorg Med Chem Lett	2019.0	CHEMBL4459785	>	>	IC50	nM	20000.0	IC50	uM	20.0
9458	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccon3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4565775	>	>	IC50	nM	20000.0	IC50	uM	20.0
9459	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2nccc(-c3ccn([C@H](CO)c4ccc(Cl)c(F)c4)c(=O)c3)n2)ccn1	J Med Chem	2016.0	CHEMBL4571067	=	=	IC50	nM	340.0	IC50	uM	0.34
9460	Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CCCN(C[C@@H](O)c2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1	J Med Chem	2016.0	CHEMBL4458575	>	>	IC50	nM	40000.0	IC50	uM	40.0
9461	Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis	COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1ccc2cccnc2c1	ACS Med Chem Lett	2016.0	CHEMBL4447846	=	=	IC50	nM	20000.0	IC50	uM	20.0
9462	Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis	COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cncc2ccccc12	ACS Med Chem Lett	2016.0	CHEMBL4469309	=	=	IC50	nM	26000.0	IC50	uM	26.0
9463	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)ccn1	J Med Chem	2016.0	CHEMBL2408789	=	=	IC50	nM	3900.0	IC50	nM	3900.0
9464	Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3cnn(C)c3)c2cn1)c1ccccc1	J Med Chem	2016.0	CHEMBL3654680	=	=	IC50	nM	380.0	IC50	nM	380.0
9465	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)cc(C)n1	J Med Chem	2016.0	CHEMBL3654682	=	=	IC50	nM	780.0	IC50	nM	780.0
9466	Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3ccnc(F)c3)c2cn1)c1ccccc1	J Med Chem	2016.0	CHEMBL3663084	=	=	IC50	nM	29000.0	IC50	nM	29000.0
9467	Inhibition of human CYP3A4	CC1=C(CC(=O)NCc2cc(Cl)ccc2CN)C(=O)N(NCc2ccccc2)CC1	J Med Chem	2016.0	CHEMBL4455063	=	=	IC50	nM	13000.0	IC50	uM	13.0
9468	Inhibition of human CYP3A4	CC1=C(CC(=O)NCc2cc(Cl)ccc2CN)C(=O)N(NCc2cccc(C(=O)O)c2)CC1	J Med Chem	2016.0	CHEMBL4443619	>	>	IC50	nM	50000.0	IC50	uM	50.0
9469	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4461070	>	>	IC50	nM	200000.0	IC50	uM	200.0
9470	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1	J Med Chem	2016.0	CHEMBL4436706	=	=	IC50	nM	34000.0	IC50	uM	34.0
9471	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	CCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1	J Med Chem	2016.0	CHEMBL4462907	=	=	IC50	nM	4000.0	IC50	uM	4.0
9472	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5cccc(F)c5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4537541	=	=	IC50	nM	1800.0	IC50	uM	1.8
9473	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4551712	=	=	IC50	nM	2700.0	IC50	uM	2.7
9474	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4466644	=	=	IC50	nM	2900.0	IC50	uM	2.9
9475	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCOCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4593634	>	>	IC50	nM	40000.0	IC50	uM	40.0
9476	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4513820	=	=	IC50	nM	200.0	IC50	uM	0.2
9477	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5ccccc5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4541666	=	=	IC50	nM	7900.0	IC50	uM	7.9
9478	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4460814	=	=	IC50	nM	31000.0	IC50	uM	31.0
9479	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4451715	=	=	IC50	nM	14000.0	IC50	uM	14.0
9480	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5cccc(F)c5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4472923	=	=	IC50	nM	2000.0	IC50	uM	2.0
9481	Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	CCCCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1	J Med Chem	2016.0	CHEMBL4472716	=	=	IC50	nM	8700.0	IC50	uM	8.7
9482	Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1cccc(C(F)(F)F)c1Cl)C2	Bioorg Med Chem Lett	2016.0	CHEMBL3674077	=	=	IC50	nM	3300.0	IC50	uM	3.3
9483	Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1ccc(Cl)cc1F)C2	Bioorg Med Chem Lett	2016.0	CHEMBL3674106	>	>	IC50	nM	10000.0	IC50	uM	10.0
9484	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4098822	>	>	IC50	nM	40000.0	IC50	uM	40.0
9485	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis	O=C(c1ccccc1)N1CCn2nc(-c3ccccn3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4554361	>	>	IC50	nM	50000.0	IC50	uM	50.0
9486	Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCCN4CCOCC4)cc(Oc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4541788	=	=	IC50	nM	780.0	IC50	uM	0.78
9487	Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCC4CCOCC4)cc(N[C@@H](C4CC4)C(C)(C)O)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4542474	=	=	IC50	nM	3000.0	IC50	uM	3.0
9488	Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCC4CC4)cc(N[C@@H]4CCCC[C@H]4O)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4444859	=	=	IC50	nM	2000.0	IC50	uM	2.0
9489	Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4469414	=	=	IC50	nM	510.0	IC50	uM	0.51
9490	Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of DBF as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4469414	=	=	IC50	nM	14000.0	IC50	uM	14.0
9491	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(NC(=O)Cc3cnc(-c4ccnc(F)c4)c(C)c3)nc2)CC1	ACS Med Chem Lett	2016.0	CHEMBL4546441	>	>	IC50	nM	10000.0	IC50	uM	10.0
9492	Inhibition of CYP3A4 (unknown origin)	COc1ccc2nc(NC(=O)Cc3ccc(-c4ccncc4)cc3)sc2c1	ACS Med Chem Lett	2016.0	CHEMBL4537314	=	=	IC50	nM	800.0	IC50	uM	0.8
9493	Reversible inhibition of human CYP3A4	Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O	ACS Med Chem Lett	2016.0	CHEMBL3696475	>	>	IC50	nM	50000.0	IC50	uM	50.0
9494	Inhibition of CYP3A4 (unknown origin)	Fc1ccccc1-c1cc(Nc2ccncc2)c2cc[nH]c2n1	Bioorg Med Chem Lett	2016.0	CHEMBL4576833	=	=	IC50	nM	2511.89	pIC50		5.6
9495	Inhibition of CYP3A4 (unknown origin)	CCn1c(=O)n(-c2cc(-c3cc(Cl)ccc3F)ncc2C)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4569690	>	<	IC50	nM	1584.89	pIC50		5.8
9496	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4564126	<	>	IC50	nM	50118.72	pIC50		4.3
9497	Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(C)c2cnccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4515962	=	=	IC50	nM	1584.89	pIC50		5.8
9498	Inhibition of CYP3A4 (unknown origin)	Cn1c(=O)n(-c2cc(-c3cc(Cl)ccc3F)nc3[nH]ccc23)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4474551	=	=	IC50	nM	1000.0	pIC50		6.0
9499	Inhibition of CYP3A4 (unknown origin)	Cn1c(=O)n(-c2cc(-c3ccc(F)cc3F)nc3[nH]ccc23)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4513488	=	=	IC50	nM	3981.07	pIC50		5.4
9500	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cnccc2n1-c1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4470706	=	=	IC50	nM	3162.28	pIC50		5.5
9501	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cnccc2n1-c1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4555703	<	>	IC50	nM	50118.72	pIC50		4.3
9502	Inhibition of CYP3A4 (unknown origin)	CC(C)(N)CNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4468495	<	>	IC50	nM	50118.72	pIC50		4.3
9503	Inhibition of CYP3A4 (unknown origin)	CNCCNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4470980	<	>	IC50	nM	50118.72	pIC50		4.3
9504	Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1cnccc1Nc1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4467267	<	>	IC50	nM	50118.72	pIC50		4.3
9505	Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4443611	<	>	IC50	nM	50118.72	pIC50		4.3
9506	Inhibition of CYP3A4 (unknown origin)	O=C(NC1CC1)c1cnccc1Nc1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4483492	=	=	IC50	nM	15848.93	pIC50		4.8
9507	Inhibition of CYP3A4 (unknown origin)	O=C(NC1CC1)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4452818	<	>	IC50	nM	50118.72	pIC50		4.3
9508	Inhibition of CYP3A4 (unknown origin)	Fc1cc(F)c(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)cc1Cl	Bioorg Med Chem Lett	2016.0	CHEMBL4437930	<	>	IC50	nM	794.33	pIC50		6.1
9509	Inhibition of CYP3A4 (unknown origin)	Cc1cccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)n1	Bioorg Med Chem Lett	2016.0	CHEMBL4572312	=	=	IC50	nM	25118.86	pIC50		4.6
9510	Inhibition of CYP3A4 (unknown origin)	Fc1ccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)cc1F	Bioorg Med Chem Lett	2016.0	CHEMBL4526347	=	=	IC50	nM	1995.26	pIC50		5.7
9511	Inhibition of CYP3A4 (unknown origin)	Fc1ccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)c(F)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4446613	=	=	IC50	nM	1258.93	pIC50		5.9
9512	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1	J Med Chem	2016.0	CHEMBL4303596	>	>	IC50	nM	27000.0	IC50	uM	27.0
9513	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL3403678	>	>	IC50	nM	27000.0	IC50	uM	27.0
9514	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(N)=O)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4555334	=	=	IC50	nM	13000.0	IC50	uM	13.0
9515	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4516601	=	=	IC50	nM	14000.0	IC50	uM	14.0
9516	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N(C)C)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4570159	=	=	IC50	nM	19000.0	IC50	uM	19.0
9517	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4464055	>	>	IC50	nM	27000.0	IC50	uM	27.0
9518	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(C)NC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4461539	=	=	IC50	nM	13000.0	IC50	uM	13.0
9519	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCS(=O)(=O)CC2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4449366	>	>	IC50	nM	27000.0	IC50	uM	27.0
9520	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4449576	>	>	IC50	nM	27000.0	IC50	uM	27.0
9521	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4542785	>	>	IC50	nM	27000.0	IC50	uM	27.0
9522	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNCCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4438514	>	>	IC50	nM	27000.0	IC50	uM	27.0
9523	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4470291	>	>	IC50	nM	27000.0	IC50	uM	27.0
9524	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4572863	>	>	IC50	nM	27000.0	IC50	uM	27.0
9525	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL4442808	>	>	IC50	nM	27000.0	IC50	uM	27.0
9526	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL4594095	>	>	IC50	nM	27000.0	IC50	uM	27.0
9527	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNCCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4525494	>	>	IC50	nM	27000.0	IC50	uM	27.0
9528	Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2cccc(F)c12	J Med Chem	2016.0	CHEMBL4443843	>	>	IC50	nM	27000.0	IC50	uM	27.0
9529	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C(C)(C)C)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(F)c2)cs1	Bioorg Med Chem Lett	2016.0	CHEMBL4438330	=	=	IC50	nM	16000.0	IC50	uM	16.0
9530	Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2016.0	CHEMBL4462738	=	=	IC50	nM	30700.0	IC50	uM	30.7
9531	Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl	J Med Chem	2016.0	CHEMBL4470763	>	>	IC50	nM	50000.0	IC50	uM	50.0
9532	Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1	J Med Chem	2016.0	CHEMBL4469805	>	>	IC50	nM	50000.0	IC50	uM	50.0
9533	Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2016.0	CHEMBL4462738	=	=	IC50	nM	18400.0	IC50	uM	18.4
9534	Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl	J Med Chem	2016.0	CHEMBL4470763	=	=	IC50	nM	48600.0	IC50	uM	48.6
9535	Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1	J Med Chem	2016.0	CHEMBL4469805	>	>	IC50	nM	50000.0	IC50	uM	50.0
9536	Inhibition of human liver microsomes CYP3A4 after 30 mins in presence of NADPH	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O	J Med Chem	2016.0	CHEMBL3918580	>	>	IC50	nM	40000.0	IC50	uM	40.0
9537	Inhibition of CYP3A4 (unknown origin)	CC(NC(=O)c1ccc(C(F)(F)F)cc1Cl)C1(N2CCN(S(=O)(=O)c3cn(C)nn3)CC2)CCC(F)(F)CC1.Cl	J Med Chem	2016.0	CHEMBL4448986	>	>	IC50	nM	7200.0	IC50	uM	7.2
9538	Inhibition of recombinant human CYP3A4 preincubated for 10 mins followed by addition of BFC as substrate measured after 45 mins	C[C@@]1(c2ccc(F)cc2F)C[C@@H](c2cncnc2)SC(N)=N1	J Med Chem	2016.0	CHEMBL4444341	>	>	IC50	nM	20000.0	IC50	uM	20.0
9539	Inhibition of CYP3A4 (unknown origin)	Cc1nc(C(=O)N[C@H]2CC[C@H](C)CC2)c(C)c(-c2ccc3c(c2C)N(C)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med Chem Lett	2016.0	CHEMBL4545710	>	>	IC50	nM	30000.0	IC50	uM	30.0
9540	Inhibition of human recombinant CYP3A4	NC(=O)c1ccc(Cc2ccccc2)cc1-c1cccc(CCC(=O)O)c1	ACS Med Chem Lett	2016.0	CHEMBL4457557	>	>	IC50	nM	20000.0	IC50	uM	20.0
9541	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	O=c1c(O)c(-c2cccc(O)c2)oc2ccc(O)cc12	J Med Chem	2016.0	CHEMBL4464764	>	>	IC50	nM	10000.0	IC50	uM	10.0
9542	Inhibition of CYP3A4 in human liver microsomes using substrate preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	COC(=O)C1=C(CN2CC(F)(F)C[C@H]2C(=O)O)NC(c2nccs2)=N[C@@]1(C)c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL4541225	>	>	IC50	nM	30000.0	IC50	uM	30.0
9543	Inhibition of recombinant human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cell microsomes using CYP/Luciferin as substrate pre-incubated for 30 mins followed by NADPH regeneration mixture addition and measured after 30 mins by Promega P450-Glo assay	COc1ccc2c(=O)c(O)c(-c3ccc4c(c3)OCO4)oc2c1	ACS Med Chem Lett	2019.0	CHEMBL4450031	=	=	IC50	nM	6000.0	IC50	uM	6.0
9544	Inhibition of CYP3A4 (unknown origin)	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Bioorg Med Chem Lett	2019.0	CHEMBL106	=	=	IC50	nM	25000.0	IC50	uM	25.0
9545	Inhibition of CYP3A4 (unknown origin)	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL104	=	=	IC50	nM	50.0	IC50	uM	0.05
9546	Inhibition of CYP3A4 (unknown origin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Bioorg Med Chem Lett	2019.0	CHEMBL91	=	=	IC50	nM	850.0	IC50	uM	0.85
9547	Inhibition of CYP3A4 (unknown origin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL808	=	=	IC50	nM	430.0	IC50	uM	0.43
9548	Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL75	=	=	IC50	nM	200.0	IC50	uM	0.2
9549	Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4443920	=	=	IC50	nM	4050.0	IC50	uM	4.05
9550	Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)cc1F	Bioorg Med Chem Lett	2019.0	CHEMBL4514676	=	=	IC50	nM	42.9	IC50	uM	0.0429
9551	Inhibition of CYP3A4 (unknown origin)	C[C@H]1NC(=O)c2cc(-c3cccc4c(=O)n(C)c(NC(C)(C)C)nc34)[nH]c21	J Med Chem	2016.0	CHEMBL3979678	>	>	IC50	nM	50000.0	IC50	uM	50.0
9552	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1	J Med Chem	2016.0	CHEMBL4513257	>	>	IC50	nM	10000.0	IC50	uM	10.0
9553	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)c1.Cl	J Med Chem	2016.0	CHEMBL4546484	>	>	IC50	nM	20000.0	IC50	uM	20.0
9554	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1	J Med Chem	2016.0	CHEMBL4523032	=	=	IC50	nM	20000.0	IC50	uM	20.0
9555	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl	J Med Chem	2016.0	CHEMBL4519558	>	>	IC50	nM	10000.0	IC50	uM	10.0
9556	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1	J Med Chem	2016.0	CHEMBL4574111	>	>	IC50	nM	20000.0	IC50	uM	20.0
9557	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1	J Med Chem	2016.0	CHEMBL4544109	=	=	IC50	nM	18000.0	IC50	uM	18.0
9558	Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCc4ccccc4C3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL548646	=	=	IC50	nM	100.0	IC50	uM	0.1
9559	Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL4584780	=	=	IC50	nM	100.0	IC50	uM	0.1
9560	Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCC(CN4CCOCC4)CC3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL4569641	=	=	IC50	nM	100.0	IC50	uM	0.1
9561	Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	Cc1cc(-c2nc(-c3cccnc3)cc(N3CCC(N4CCOCC4)CC3)n2)cc(C)n1	J Med Chem	2016.0	CHEMBL4570567	=	=	IC50	nM	40000.0	IC50	uM	40.0
9562	Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	COc1ccc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1	J Med Chem	2016.0	CHEMBL4557930	=	=	IC50	nM	14000.0	IC50	uM	14.0
9563	Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	CSc1ncc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1	J Med Chem	2016.0	CHEMBL4528799	=	=	IC50	nM	17600.0	IC50	uM	17.6
9564	Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	COc1nn2cc(-c3c(CO)n(Cc4ccccc4Cl)c4ccc(OC(F)(F)F)cc34)nc2s1	J Med Chem	2016.0	CHEMBL4566669	>	>	IC50	nM	30000.0	IC50	uM	30.0
9565	Inhibition of recombinant CYP3A4 (unknown origin)	O=C(O)c1ccc(-c2c(/C=C/c3ccc4ccccc4n3)nc3c(N4CCOCC4)ccnn23)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3919436	>	>	IC50	nM	10000.0	IC50	uM	10.0
9566	Time-dependent inhibition of human CYP3A4 using midazolam as substrate	CC(C)(C)Cc1cc(-c2onc([C@@H](CCC(=O)[O-])CC(=O)Nc3ccc(Cl)cc3Cl)c2C2CC2)no1.[Na+]	J Med Chem	2019.0	CHEMBL4537625	>	>	IC50	nM	50000.0	IC50	uM	50.0
9567	Time-dependent inhibition of human CYP3A4 using testosterone as substrate	CC(C)(C)Cc1cc(-c2onc([C@@H](CCC(=O)[O-])CC(=O)Nc3ccc(Cl)cc3Cl)c2C2CC2)no1.[Na+]	J Med Chem	2019.0	CHEMBL4537625	>	>	IC50	nM	50000.0	IC50	uM	50.0
9568	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2019.0	CHEMBL376488	>	>	IC50	nM	40000.0	IC50	uM	40.0
9569	Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc3c2OCO3)n1	Bioorg Med Chem	2019.0	CHEMBL4563167	=	=	IC50	nM	7600.0	IC50	uM	7.6
9570	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1C	Bioorg Med Chem	2019.0	CHEMBL4574868	>	>	IC50	nM	10000.0	IC50	uM	10.0
9571	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc2c1OCO2)C(O)(CCN(C)C)c1cccnc1C	Bioorg Med Chem	2019.0	CHEMBL4515667	>	>	IC50	nM	10000.0	IC50	uM	10.0
9572	Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(c2cc3cc(Br)ccc3nc2OC)C(O)(CCN(C)C)c2ccc(C)nc2)c1F	Bioorg Med Chem	2019.0	CHEMBL4558224	>	>	IC50	nM	10000.0	IC50	uM	10.0
9573	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4535649	>	>	IC50	nM	10000.0	IC50	uM	10.0
9574	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(C#N)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4575859	>	>	IC50	nM	10000.0	IC50	uM	10.0
9575	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc2c1OCO2)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4515863	>	>	IC50	nM	10000.0	IC50	uM	10.0
9576	Inhibition of CYP3A4 (unknown origin)	COc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cnc1OC	Bioorg Med Chem	2019.0	CHEMBL4521403	>	>	IC50	nM	10000.0	IC50	uM	10.0
9577	Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(c2cc3cc(C#N)ccc3nc2OC)C(O)(CCN(C)C)c2cc(C)nc(C)c2)c1F	Bioorg Med Chem	2019.0	CHEMBL4522585	>	>	IC50	nM	10000.0	IC50	uM	10.0
9578	Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2019.0	CHEMBL376488	>	>	IC50	nM	40000.0	IC50	uM	40.0
9579	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4529465	>	>	IC50	nM	10000.0	IC50	uM	10.0
9580	Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OCC)n1	Bioorg Med Chem	2019.0	CHEMBL4565089	>	>	IC50	nM	10000.0	IC50	uM	10.0
9581	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4519972	>	>	IC50	nM	10000.0	IC50	uM	10.0
9582	Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OCC)n1	Bioorg Med Chem	2019.0	CHEMBL4532620	>	>	IC50	nM	10000.0	IC50	uM	10.0
9583	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCO3)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4543900	>	>	IC50	nM	10000.0	IC50	uM	10.0
9584	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCCO3)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4519008	>	>	IC50	nM	10000.0	IC50	uM	10.0
9585	Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@H](c2cccnc2OC)c2cc3cc(Br)ccc3nc2OC)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4574425	>	>	IC50	nM	10000.0	IC50	uM	10.0
9586	Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@H](c2cc3cc(C#N)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cc(OC)nc(OC)c2)cc(N(C)C)n1	Bioorg Med Chem	2019.0	CHEMBL4580150	>	>	IC50	nM	10000.0	IC50	uM	10.0
9587	Inhibition of CYP3A4 (unknown origin)	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C	Bioorg Med Chem Lett	2020.0	CHEMBL4634634	>	>	IC50	nM	50000.0	IC50	uM	50.0
9588	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2C[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4643942	>	>	IC50	nM	45000.0	IC50	uM	45.0
9589	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ncccc1OC[C@@H]1C[C@H]2C[C@H]2N1	J Med Chem	2020.0	CHEMBL4645127	>	>	IC50	nM	45000.0	IC50	uM	45.0
9590	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1cncc(OC[C@@H]2C[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4638732	>	>	IC50	nM	45000.0	IC50	uM	45.0
9591	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642118	>	>	IC50	nM	45000.0	IC50	uM	45.0
9592	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Fc1ccc(OC[C@@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642865	>	>	IC50	nM	45000.0	IC50	uM	45.0
9593	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@H]2C[C@@H]3C[C@@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4641810	>	>	IC50	nM	45000.0	IC50	uM	45.0
9594	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)c1	J Med Chem	2020.0	CHEMBL4643543	=	=	IC50	nM	31900.0	IC50	uM	31.9
9595	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4645367	>	>	IC50	nM	45000.0	IC50	uM	45.0
9596	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4649507	>	>	IC50	nM	45000.0	IC50	uM	45.0
9597	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@H]2NC[C@@H]3C[C@H]23)c1	J Med Chem	2020.0	CHEMBL4636163	=	=	IC50	nM	21100.0	IC50	uM	21.1
9598	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1cncc(OC[C@H]2NC[C@@H]3C[C@H]23)c1	J Med Chem	2020.0	CHEMBL4647198	>	>	IC50	nM	45000.0	IC50	uM	45.0
9599	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2CC[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642287	>	>	IC50	nM	45000.0	IC50	uM	45.0
9600	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2CC[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4641432	>	>	IC50	nM	45000.0	IC50	uM	45.0
9601	Inhibition of CYP3A4 I (unknown origin)	C[C@H]1CN(C(=O)Nc2cc(-c3cn([C@H]4CC[C@@](C)(O)CC4)c4cnccc34)ccn2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4640031	>	>	IC50	nM	25000.0	IC50	uM	25.0
9602	Inhibition of CYP3A4 I (unknown origin)	CCN1CCN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)CC1	J Med Chem	2020.0	CHEMBL4636064	>	>	IC50	nM	25000.0	IC50	uM	25.0
9603	Inhibition of CYP3A4 II (unknown origin)	C[C@H]1CN(C(=O)Nc2cc(-c3cn([C@H]4CC[C@@](C)(O)CC4)c4cnccc34)ccn2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4640031	>	>	IC50	nM	25000.0	IC50	uM	25.0
9604	Inhibition of CYP3A4 II (unknown origin)	CCN1CCN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)CC1	J Med Chem	2020.0	CHEMBL4636064	>	>	IC50	nM	25000.0	IC50	uM	25.0
9605	Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1	J Med Chem	2020.0	CHEMBL4647703	=	=	IC50	nM	31400.0	IC50	uM	31.4
9606	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(C)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4643577	>	>	IC50	nM	10000.0	IC50	uM	10.0
9607	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(C)cc1C(=O)Nc1cccc(-c2cncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4641666	=	=	IC50	nM	5900.0	IC50	uM	5.9
9608	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(-c2cnccn2)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4632672	=	=	IC50	nM	8800.0	IC50	uM	8.8
9609	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCC4C=NNC4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4640297	=	=	IC50	nM	5580.0	IC50	uM	5.58
9610	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	COCCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5cccnn45)c3)cc2C2CC2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4637502	=	=	IC50	nM	13500.0	IC50	uM	13.5
9611	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4642144	=	=	IC50	nM	13400.0	IC50	uM	13.4
9612	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(C3CC3)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4632471	=	=	IC50	nM	11700.0	IC50	uM	11.7
9613	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3Cc4cn[nH]c4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4638981	=	=	IC50	nM	7280.0	IC50	uM	7.28
9614	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3Cc4ccc(O)cc4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4633367	=	=	IC50	nM	4610.0	IC50	uM	4.61
9615	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1	ACS Med Chem Lett	2020.0	CHEMBL255863	=	=	IC50	nM	580.0	IC50	uM	0.58
9616	Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL1171837	=	=	IC50	nM	11400.0	IC50	uM	11.4
9617	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates incubated for 15 to 30 mins by by LC-MS/MS analysis	CC(C)CCNC1=CC(=O)c2ccccc2C1=O	J Med Chem	2020.0	CHEMBL4642567	>	>	IC50	nM	100000.0	IC50	uM	100.0
9618	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins by LC-MS/MS analysis	O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1	J Med Chem	2020.0	CHEMBL4640366	=	=	IC50	nM	5560.0	IC50	uM	5.56
9619	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	Nc1ncnc2c1c(Oc1cc(C(F)(F)F)ccn1)nn2C1CC1	J Med Chem	2020.0	CHEMBL4634455	=	=	EC50	nM	50000.0	EC50	uM	50.0
9620	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	Nc1ncnc2c1c(Oc1cc(C(F)(F)F)ccn1)nn2[C@@H]1CCCC[C@H]1O	J Med Chem	2020.0	CHEMBL4646408	=	=	EC50	nM	50000.0	EC50	uM	50.0
9621	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	N#Cc1ccnc(Oc2nn([C@H]3C[C@H](F)C3)c3ncnc(N)c23)c1	J Med Chem	2020.0	CHEMBL4642579	=	=	EC50	nM	50000.0	EC50	uM	50.0
9622	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1	Bioorg Med Chem	2020.0	CHEMBL473417	>	>	IC50	nM	20000.0	IC50	uM	20.0
9623	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)c(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1	Bioorg Med Chem	2020.0	CHEMBL4632769	>	>	IC50	nM	20000.0	IC50	uM	20.0
9624	Inhibition of CYP3A4 (unknown origin)	Cc1c(C(F)(F)F)oc2ncnc(SCC(=O)N3CC(=O)N(C)C3)c12	Bioorg Med Chem Lett	2020.0	CHEMBL4633059	>	>	IC50	nM	30000.0	IC50	uM	30.0
9625	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)Cc1nn(CNC(=O)CCCN2CCN(c3cccc(C)c3C)CC2)c(=O)c2c(F)cccc12	Bioorg Med Chem Lett	2020.0	CHEMBL4635232	>	>	IC50	nM	10000.0	IC50	uM	10.0
9626	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)Cc1nn(CNC(=O)CCCN2CCN(c3cccc(C)c3C)CC2)c(=O)c2cc(F)ccc12	Bioorg Med Chem Lett	2020.0	CHEMBL4646426	>	>	IC50	nM	10000.0	IC50	uM	10.0
9627	Inhibition of CYP3A4 (unknown origin)	CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1	Bioorg Med Chem Lett	2020.0	CHEMBL41	>	>	IC50	nM	10000.0	IC50	uM	10.0
9628	Inhibition of CYP3A4 (unknown origin)	CCn1nnc2c(C)c([C@@H](CC(=O)O)c3ccc4c(c3)CN(C(=O)c3c(C)c(C)cc(C)c3C)CC4)ccc21	Bioorg Med Chem Lett	2020.0	CHEMBL4643134	>	>	IC50	nM	10000.0	IC50	uM	10.0
9629	Inhibition of human CYP3A4	CCS(=O)(=O)Nc1cc(-c2cn(C)c3c(=O)[nH]ccc23)cc2c1ccn2C(C)(c1ccccn1)c1ccccn1	J Med Chem	2020.0	CHEMBL4648912	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
9630	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	J Med Chem	2020.0	CHEMBL4647810	=	=	IC50	nM	7000.0	IC50	uM	7.0
9631	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	J Med Chem	2020.0	CHEMBL4647810	>	>	IC50	nM	20000.0	IC50	uM	20.0
9632	Inhibition of CYP3A4 (unknown origin)	Cc1cc(C[C@@H](NC(=O)N2CCC3(CC2)OC(=O)Nc2ncccc23)C(=O)N[C@@H](CC2CCNCC2)C(=O)N2CCN(c3ccncc3)CC2)cc2cn[nH]c12	J Med Chem	2020.0	CHEMBL4635331	<	>	IC50	nM	50118.72	pIC50		4.3
9633	Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H](NC(=O)c1cc(C(F)(F)F)ccc1F)C(=O)N1CCC2(CC1)C(=O)N(C)C(=O)N2c1ccc2[nH]ncc2c1	J Med Chem	2020.0	CHEMBL4636208	>	>	IC50	nM	50000.0	IC50	uM	50.0
9634	Inhibition of human CYP3A4 using testosterone as substrate	C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1	J Med Chem	2020.0	CHEMBL4644729	>	>	IC50	nM	25000.0	IC50	uM	25.0
9635	Inhibition of human CYP3A4 using midazolam as substrate	C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1	J Med Chem	2020.0	CHEMBL4644729	>	>	IC50	nM	25000.0	IC50	uM	25.0
9636	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2cc(C(F)(F)F)ccn2)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4637717	>	>	IC50	nM	30000.0	IC50	uM	30.0
9637	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	COc1ccnc(-c2nc(O)c(O)c(C(=O)N[C@H](C)C3CCCCC3)n2)c1	ACS Med Chem Lett	2020.0	CHEMBL4637524	>	>	IC50	nM	30000.0	IC50	uM	30.0
9638	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2cc(Cl)ccn2)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4633550	>	>	IC50	nM	30000.0	IC50	uM	30.0
9639	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2nccc3ccccc23)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4635907	>	>	IC50	nM	30000.0	IC50	uM	30.0
9640	Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	=	=	IC50	nM	45800.0	IC50	uM	45.8
9641	Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
9642	Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
9643	Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
9644	Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
9645	Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
9646	Inhibition of CYP3A4 (unknown origin)	CC1(C)CN2CCNCc3cccc1c32	Bioorg Med Chem Lett	2020.0	CHEMBL4645774	>	>	IC50	nM	50000.0	IC50	uM	50.0
9647	Inhibition of CYP3A4 (unknown origin)	c1cc2c3c(c1)C1(CCC1)CN3CCNC2	Bioorg Med Chem Lett	2020.0	CHEMBL4636196	>	>	IC50	nM	50000.0	IC50	uM	50.0
9648	Inactivation of CYP3A4 (unknown origin)	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2020.0	CHEMBL1276308	=	=	Ki	nM	4700.0	Ki	uM	4.7
9649	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4638454	=	=	IC50	nM	320.0	IC50	uM	0.32
9650	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4644850	=	=	IC50	nM	85.0	IC50	uM	0.085
9651	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4632678	=	=	IC50	nM	55.0	IC50	uM	0.055
9652	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4648061	=	=	IC50	nM	173.0	IC50	uM	0.173
9653	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4642007	=	=	IC50	nM	102.0	IC50	uM	0.102
9654	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4644724	=	=	IC50	nM	356.0	IC50	uM	0.356
9655	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4640859	=	=	IC50	nM	75.0	IC50	uM	0.075
9656	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4639605	=	=	IC50	nM	244.0	IC50	uM	0.244
9657	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4642617	=	=	IC50	nM	218.0	IC50	uM	0.218
9658	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg Med Chem	2020.0	CHEMBL163	=	=	IC50	nM	130.0	IC50	uM	0.13
9659	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4638454	=	=	IC50	nM	430.0	IC50	uM	0.43
9660	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4639033	=	=	IC50	nM	310.0	IC50	uM	0.31
9661	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4635548	=	=	IC50	nM	310.0	IC50	uM	0.31
9662	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4644634	=	=	IC50	nM	310.0	IC50	uM	0.31
9663	Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4645102	=	=	IC50	nM	310.0	IC50	uM	0.31
9664	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(CCCCCc1ccccc1)N[C@H]1CC[C@H](O)CC1	J Med Chem	2020.0	CHEMBL4648137	>	>	IC50	nM	30000.0	IC50	uM	30.0
9665	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCOc1ccc(-c2nnc([C@H]3C[C@H](NC(=O)c4ccccn4)C3)n2-c2ccccc2F)nc1	J Med Chem	2020.0	CHEMBL4633637	>	>	IC50	nM	25000.0	IC50	uM	25.0
9666	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1	J Med Chem	2020.0	CHEMBL4095003	=	=	IC50	nM	1260.0	IC50	uM	1.26
9667	Inhibition of CYP3A4 (unknown origin)	CC1Cc2cc(Cl)ccc2C(=O)N1c1cccnc1	J Med Chem	2020.0	CHEMBL4641568	>	>	IC50	nM	50000.0	IC50	uM	50.0
9668	Inhibition of CYP3A4 (unknown origin)	CC1CN(c2cccnc2)C(=O)c2ccc(Cl)cc21	J Med Chem	2020.0	CHEMBL4644373	>	>	IC50	nM	50000.0	IC50	uM	50.0
9669	Inhibition of CYP3A4 (unknown origin)	CC1(C)CN(c2cccnc2)C(=O)c2ccc(Cl)cc21	J Med Chem	2020.0	CHEMBL4638042	>	>	IC50	nM	50000.0	IC50	uM	50.0
9670	Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4634077	=	=	IC50	nM	3400.0	IC50	uM	3.4
9671	Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6ccnc6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4644787	=	=	IC50	nM	2600.0	IC50	uM	2.6
9672	Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4647183	>	>	IC50	nM	90000.0	IC50	uM	90.0
9673	Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)c(F)c2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4640665	>	>	IC50	nM	90000.0	IC50	uM	90.0
9674	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2020.0	CHEMBL4634542	>	>	IC50	nM	20000.0	IC50	uM	20.0
9675	Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccncc3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4634167	=	=	IC50	nM	1000.0	IC50	uM	1.0
9676	Inhibition of human CYP3A4	Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccn1	ACS Med Chem Lett	2020.0	CHEMBL4637136	=	=	IC50	nM	19000.0	IC50	uM	19.0
9677	Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C#N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4647791	=	=	IC50	nM	24000.0	IC50	uM	24.0
9678	Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4639252	>	>	IC50	nM	25000.0	IC50	uM	25.0
9679	Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4470860	>	>	IC50	nM	25000.0	IC50	uM	25.0
9680	Inhibition of CYP3A4 (unknown origin)	C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1	ACS Med Chem Lett	2020.0	CHEMBL4641354	>	>	IC50	nM	50000.0	IC50	uM	50.0
9681	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2ccoc2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL3786336	=	=	IC50	nM	2680.0	IC50	uM	2.68
9682	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2ccco2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL3787197	=	=	IC50	nM	2900.0	IC50	uM	2.9
9683	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cnoc1	J Med Chem	2020.0	CHEMBL4637204	=	=	IC50	nM	4920.0	IC50	uM	4.92
9684	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1ncc[nH]1	J Med Chem	2020.0	CHEMBL4632427	=	=	IC50	nM	4540.0	IC50	uM	4.54
9685	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cocn1	J Med Chem	2020.0	CHEMBL4637285	=	=	IC50	nM	6410.0	IC50	uM	6.41
9686	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2cocn2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL4646279	=	=	IC50	nM	5920.0	IC50	uM	5.92
9687	Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	27.0	IC50	uM	0.027
9688	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C	J Med Chem	2020.0	CHEMBL3040443	=	=	IC50	nM	16000.0	IC50	uM	16.0
9689	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C	J Med Chem	2020.0	CHEMBL3040443	=	=	Ki	nM	17000.0	Ki	uM	17.0
9690	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cc(-c2ccc(F)cc2)c2ccc(CN3C(=O)CCC3=O)cc2n1	Bioorg Med Chem Lett	2020.0	CHEMBL3892073	>	>	IC50	nM	50000000.0	IC50	mM	50.0
9691	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CCCCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4634571	>	>	IC50	nM	10000.0	IC50	uM	10.0
9692	Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4646118	>	>	IC50	nM	10000.0	IC50	uM	10.0
9693	Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4643996	>	>	IC50	nM	10000.0	IC50	uM	10.0
9694	Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](F)CCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4634281	>	>	IC50	nM	10000.0	IC50	uM	10.0
9695	Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)C2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4647147	>	>	IC50	nM	10000.0	IC50	uM	10.0
9696	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CC(F)(F)CN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4644553	>	>	IC50	nM	10000.0	IC50	uM	10.0
9697	Inhibition of CYP3A4 (unknown origin)	CCN(CC)C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4643735	>	>	IC50	nM	10000.0	IC50	uM	10.0
9698	Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4645439	>	>	IC50	nM	10000.0	IC50	uM	10.0
9699	Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(NC(=O)CC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4648138	>	>	IC50	nM	10000.0	IC50	uM	10.0
9700	Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N(CC)CC)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4639653	>	>	IC50	nM	10000.0	IC50	uM	10.0
9701	Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCCC[C@@H]2C)c(C(F)F)c1F)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4646215	>	>	IC50	nM	10000.0	IC50	uM	10.0
9702	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CNC(=O)c1nc(CC2CCCCC2)c(-c2ccc(S(=O)(=O)NC(C)(C)C)c3ccccc23)s1	Bioorg Med Chem Lett	2020.0	CHEMBL4129202	>	>	IC50	nM	5000.0	IC50	uM	5.0
9703	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	O=C(Nc1ccc(SC(F)(F)F)c(Cl)c1)c1ccc(CN2CCCCC2)cc1	J Med Chem	2020.0	CHEMBL4634276	=	=	IC50	nM	15100.0	IC50	uM	15.1
9704	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	CC(C)(C)c1ccc(NC(=O)c2ccc(CN3CCCCC3)cc2)c(C(C)(C)C)c1	J Med Chem	2020.0	CHEMBL4640955	>	>	IC50	nM	100000.0	IC50	uM	100.0
9705	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCCCC2)cc1	J Med Chem	2020.0	CHEMBL4644544	>	>	IC50	nM	100000.0	IC50	uM	100.0
9706	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	CC(c1ccc(C(=O)N2CCc3cc(C(C)(C)C)ccc32)cc1)N1CCCCC1	J Med Chem	2020.0	CHEMBL4640931	=	=	IC50	nM	24000.0	IC50	uM	24.0
9707	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay	CC1CCN(c2ccc(NC(=O)c3ccc(CN4CCOCC4)cc3)cc2C(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4638872	>	>	IC50	nM	100000.0	IC50	uM	100.0
9708	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay	O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCOCC2)cc1	J Med Chem	2020.0	CHEMBL4647732	>	>	IC50	nM	100000.0	IC50	uM	100.0
9709	Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(COc2ccccc2CC(=O)O)cc(-c2ccc3c(c2)[C@H](N)CO3)c1	J Med Chem	2020.0	CHEMBL4643449	>	>	IC50	nM	20000.0	IC50	uM	20.0
9710	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC-MS/MS analysis	CNC(=O)[C@H](C)Cn1cnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4Cl)c3)cc2c1=O	ACS Med Chem Lett	2020.0	CHEMBL4632970	=	=	IC50	nM	23300.0	IC50	uM	23.3
9711	Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2ccc(=O)n(C)c2C)cc2cn(C3CCNCC3)nc12	J Med Chem	2020.0	CHEMBL4641604	>	>	IC50	nM	20000.0	IC50	uM	20.0
9712	Inhibition of CYP3A4 (unknown origin)	O=c1ccc(-c2cc(C(F)(F)F)c3nn([C@H]4CCNC[C@@H]4F)cc3c2)c2n1CCC2	J Med Chem	2020.0	CHEMBL4641633	>	>	IC50	nM	25000.0	IC50	uM	25.0
9713	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1	J Med Chem	2020.0	CHEMBL4645216	=	=	IC50	nM	30000.0	IC50	uM	30.0
9714	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)cc(-n2cc(-c3ccc(C(F)(F)F)cc3)nn2)c1	J Med Chem	2020.0	CHEMBL4646514	>	>	IC50	nM	3290.0	IC50	uM	3.29
9715	Inhibition of CYP3A4 (unknown origin)	Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl	J Med Chem	2020.0	CHEMBL4633566	=	=	IC50	nM	8700.0	IC50	uM	8.7
9716	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4636716	>	>	IC50	nM	50000.0	IC50	uM	50.0
9717	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3Cl)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4643810	>	>	IC50	nM	20000.0	IC50	uM	20.0
9718	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(CN)cc3)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4632936	>	>	IC50	nM	20000.0	IC50	uM	20.0
9719	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc4c(c3)CNC4=N)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4648414	>	>	IC50	nM	20000.0	IC50	uM	20.0
9720	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc4c(c3Cl)CNC4=N)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4637996	>	>	IC50	nM	20000.0	IC50	uM	20.0
9721	Inhibition of CYP3A4 (unknown origin)	CC(C)Nc1cc(Nc2ccc3ncsc3c2)ncc1C(=O)NCCc1ccc(S(N)(=O)=O)cc1	ACS Med Chem Lett	2020.0	CHEMBL4636136	=	=	IC50	nM	0.9	IC50	nM	0.9
9722	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2ccccc2)c1=O	J Med Chem	2020.0	CHEMBL4635134	<	>	IC50	nM	39810.72	pIC50		4.4
9723	Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2cccc3[nH]ccc23)c1=O	J Med Chem	2020.0	CHEMBL4648431	<	>	IC50	nM	39810.72	pIC50		4.4
9724	Inhibition of CYP3A4 (unknown origin) by Cyprotex-protocol assay	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2ccccc2)c1=O	J Med Chem	2020.0	CHEMBL4635134	<	>	IC50	nM	199526.23	pIC50		3.7
9725	Inhibition of CYP3A4 (unknown origin)	Cc1ccc2[nH]c(C(=O)N[C@H]3CN(S(=O)(=O)c4ccccc4)C[C@@H]3C(=O)N[C@H]3CCCNC3)cc2c1	J Med Chem	2020.0	CHEMBL4647963	>	>	IC50	nM	30000.0	IC50	uM	30.0
9726	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC	J Med Chem	2020.0	CHEMBL4517408	>	>	IC50	nM	30000.0	IC50	uM	30.0
9727	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F	J Med Chem	2020.0	CHEMBL4636120	>	>	IC50	nM	20000.0	IC50	uM	20.0
9728	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC	J Med Chem	2020.0	CHEMBL4517408	>	>	IC50	nM	9000.0	IC50	uM	9.0
9729	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F	J Med Chem	2020.0	CHEMBL4636120	=	=	IC50	nM	14300.0	IC50	uM	14.3
9730	Inhibition of CYP3A4 (unknown origin)	Cl.NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1	ACS Med Chem Lett	2020.0	CHEMBL3544912	>	>	IC50	nM	100000.0	IC50	uM	100.0
9731	Inhibition of CYP3A4 in human liver microsomes	O=C1c2cc(C(F)(F)F)ccc2NC12CCN(CC1CCOCC1)CC2	Bioorg Med Chem	2020.0	CHEMBL4634061	>	>	IC50	nM	18000.0	IC50	uM	18.0
9732	Inhibition of CYP3A4 (unknown origin)	NC1=N[C@](CF)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)CCC1(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4643511	>	>	IC50	nM	10000.0	IC50	uM	10.0
9733	Inhibition of CYP3A4 (unknown origin)	CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C#N)c1	J Med Chem	2020.0	CHEMBL4640712	>	>	IC50	nM	20000.0	IC50	uM	20.0
9734	Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1	J Med Chem	2020.0	CHEMBL4635883	>	>	IC50	nM	20000.0	IC50	uM	20.0
9735	Inhibition of CYP3A4 in human liver microsomes using midazolam hydrochloride as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1nn([C@H](C)c2ccc(Cl)cc2Cl)c2nc(N3CC([C@H]4CCCN(CCO)C4)C3)cnc12	J Med Chem	2020.0	CHEMBL4634054	>	>	IC50	nM	40000.0	IC50	uM	40.0
9736	Inhibition of CYP3A4 in human liver microsomes using midazolam hydrochloride as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](c1ccc(Cl)cc1Cl)n1nc(C#N)c2ncc(N3CC([C@H]4CCCN(CCO)C4)C3)nc21	J Med Chem	2020.0	CHEMBL4637143	>	>	IC50	nM	40000.0	IC50	uM	40.0
9737	Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)cc(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4643105	=	=	IC50	nM	16000.0	IC50	uM	16.0
9738	Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)c(F)c(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4634921	=	=	IC50	nM	29000.0	IC50	uM	29.0
9739	Inhibition of CYP3A4 (unknown origin)	COc1cc(C2=CC3=NO[C@H](c4cc(F)c(F)c(F)c4)CN3CCC2)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4634696	=	=	IC50	nM	34000.0	IC50	uM	34.0
9740	Inhibition of CYP3A4 (unknown origin)	COc1cc(C2=CC3=NOC[C@H](c4cc(F)c(F)c(F)c4)N3CCC2)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4642697	=	=	IC50	nM	30000.0	IC50	uM	30.0
9741	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]ccc2cc(Nc3n[nH]c4cccnc34)ccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4784617	>	>	IC50	nM	30000.0	IC50	uM	30.0
9742	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(Nc3ccc4cnccc4c3)n[nH]c2c1	Bioorg Med Chem Lett	2019.0	CHEMBL4783372	=	=	IC50	nM	440.0	IC50	uM	0.44
9743	Inhibition of CYP3A4 (unknown origin)	c1cnc2c(Nc3ccc4c(-n5cccn5)nccc4c3)n[nH]c2c1	Bioorg Med Chem Lett	2019.0	CHEMBL4787268	=	=	IC50	nM	13000.0	IC50	uM	13.0
9744	Inhibition of CYP3A4 (unknown origin)	FC(F)c1nccc2cc(Nc3n[nH]c4cccnc34)ccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4779331	>	>	IC50	nM	30000.0	IC50	uM	30.0
9745	Inhibition of CYP3A4 (unknown origin)	COc1nnc2sc(C(=O)NC3CN(c4ncc(C(F)(F)F)cn4)C3)c(N)c2c1C	Bioorg Med Chem Lett	2019.0	CHEMBL4795177	>	>	IC50	nM	30000.0	IC50	uM	30.0
9746	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4750688	=	=	IC50	nM	871.0	IC50	nM	871.0
9747	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(S(F)(F)(F)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4755729	=	=	IC50	nM	159.0	IC50	nM	159.0
9748	Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(C)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4759278	=	=	IC50	nM	2500.0	IC50	nM	2500.0
9749	Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)F)n1	ACS Med Chem Lett	2019.0	CHEMBL4744705	>	>	IC50	nM	100000.0	IC50	uM	100.0
9750	Metabolism-dependent inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1c(F)cc(C(=O)N[C@H]2CC[C@H](O)CC2)cc1O[C@@H](C)c1ccccc1	J Med Chem	2020.0	CHEMBL4636881	<	>	IC50	nM	39810.72	pIC50		4.4
9751	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc(N2C=Nc3cc(C)c(-c4cc(F)cc(C(N)=O)c4)cc3C2C(=O)N(C)C[C@@H]2CCCN2)c1	Bioorg Med Chem Lett	2020.0	CHEMBL4761949	=	=	IC50	nM	1000.0	IC50	uM	1.0
9752	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate preincubated for 5 mins followed by addition of NADPH measured after 20 mins by LC-MS/MS analysis	O=C(O)CNC(=O)c1ncc(C#CCOc2ccc(Cl)cc2)cc1O	J Med Chem	2020.0	CHEMBL4162752	>	>	IC50	nM	30000.0	IC50	uM	30.0
9753	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate preincubated for 5 mins followed by addition of NADPH measured after 20 mins by LC-MS/MS analysis	O=C(O)CNC(=O)c1ncc(C#CCOc2ccc(Cl)cc2)cc1O	J Med Chem	2020.0	CHEMBL4162752	>	>	IC50	nM	30000.0	IC50	uM	30.0
9754	Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc(-c2cnc3ncn(-c4cc(O)cc(F)c4)c(=O)c3c2CN(C)C[C@@H]2CCCN2)c1	Bioorg Med Chem Lett	2020.0	CHEMBL4778342	<	>	IC50	nM	10000.0	pIC50		5.0
9755	inhibition of CYP3A4 in human liver microsomes	COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2c(cnn2C(C)C)C3)cc(-c2ccc(C(=O)O)cc2)n1	J Med Chem	2020.0	CHEMBL4567446	>	>	IC50	nM	50000.0	IC50	uM	50.0
9756	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2	J Med Chem	2020.0	CHEMBL4755842	=	=	IC50	nM	450.0	IC50	uM	0.45
9757	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1	J Med Chem	2020.0	CHEMBL4785086	=	=	IC50	nM	4600.0	IC50	uM	4.6
9758	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O	J Med Chem	2020.0	CHEMBL4782083	=	=	IC50	nM	600.0	IC50	uM	0.6
9759	Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(Sc1nc2ncccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O	J Med Chem	2020.0	CHEMBL4759016	>	>	IC50	nM	50000.0	IC50	uM	50.0
9760	Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(Sc1nc2cnccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O	J Med Chem	2020.0	CHEMBL4750462	=	=	IC50	nM	36500.0	IC50	uM	36.5
9761	Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	O=C(CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12)NS(=O)(=O)c1ccc(Br)cc1	J Med Chem	2020.0	CHEMBL4756866	>	>	IC50	nM	50000.0	IC50	uM	50.0
9762	Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	37.5	IC50	uM	0.0375
9763	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCCc1ccccn1	J Med Chem	2020.0	CHEMBL4778430	=	=	IC50	nM	6000.0	IC50	uM	6.0
9764	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC(C)Cc1ccccn1	J Med Chem	2020.0	CHEMBL4782206	=	=	IC50	nM	2000.0	IC50	uM	2.0
9765	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(C)CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12	J Med Chem	2020.0	CHEMBL4761725	=	=	IC50	nM	700.0	IC50	uM	0.7
9766	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(C)CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12	J Med Chem	2020.0	CHEMBL4761725	=	=	IC50	nM	700.0	IC50	uM	0.7
9767	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1	J Med Chem	2020.0	CHEMBL4764092	>	>	IC50	nM	20000.0	IC50	uM	20.0
9768	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4755942	>	>	IC50	nM	20000.0	IC50	uM	20.0
9769	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1CNc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4756085	=	=	IC50	nM	9000.0	IC50	uM	9.0
9770	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1COc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4790875	>	>	IC50	nM	20000.0	IC50	uM	20.0
9771	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Cl)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4751462	>	>	IC50	nM	20000.0	IC50	uM	20.0
9772	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(C(F)(F)F)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4782468	>	>	IC50	nM	20000.0	IC50	uM	20.0
9773	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(I)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4750703	>	>	IC50	nM	20000.0	IC50	uM	20.0
9774	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(C(C)(C)C)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4756068	>	>	IC50	nM	20000.0	IC50	uM	20.0
9775	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc(C(=O)O)cc2F)c2cc(Br)ccc2[n+]([O-])c1-c1ccccc1	J Med Chem	2020.0	CHEMBL4739939	>	>	IC50	nM	20000.0	IC50	uM	20.0
9776	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc(C(=O)O)cc2F)c2cc(Br)ccc2c(=O)n1-c1ccccc1	J Med Chem	2020.0	CHEMBL4759438	>	>	IC50	nM	20000.0	IC50	uM	20.0
9777	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)cc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4789967	=	=	IC50	nM	19000.0	IC50	uM	19.0
9778	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC12CCC(C(=O)O)(CC1)CC2	J Med Chem	2020.0	CHEMBL4789100	>	>	IC50	nM	10000.0	IC50	uM	10.0
9779	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743035	=	=	IC50	nM	15000.0	IC50	uM	15.0
9780	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743035	=	=	IC50	nM	12000.0	IC50	uM	12.0
9781	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4744552	>	>	IC50	nM	20000.0	IC50	uM	20.0
9782	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4744552	=	=	IC50	nM	13000.0	IC50	uM	13.0
9783	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12)CC(=O)O	J Med Chem	2020.0	CHEMBL4761670	>	>	IC50	nM	20000.0	IC50	uM	20.0
9784	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12)CC(=O)O	J Med Chem	2020.0	CHEMBL4761670	>	>	IC50	nM	20000.0	IC50	uM	20.0
9785	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1cccc(C(CNC(=O)c2c(C)c(-c3ccccc3)nc3ccc(Br)cc23)CC(=O)O)c1	J Med Chem	2020.0	CHEMBL4777724	>	>	IC50	nM	20000.0	IC50	uM	20.0
9786	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccc(C(CNC(=O)c2c(C)c(-c3ccccc3)nc3ccc(Br)cc23)CC(=O)O)cc1	J Med Chem	2020.0	CHEMBL4762787	>	>	IC50	nM	20000.0	IC50	uM	20.0
9787	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743411	>	>	IC50	nM	20000.0	IC50	uM	20.0
9788	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743411	>	>	IC50	nM	20000.0	IC50	uM	20.0
9789	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749767	>	>	IC50	nM	20000.0	IC50	uM	20.0
9790	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749767	=	=	IC50	nM	5000.0	IC50	uM	5.0
9791	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4754421	=	=	IC50	nM	20000.0	IC50	uM	20.0
9792	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4754421	=	=	IC50	nM	13000.0	IC50	uM	13.0
9793	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CC(F)(F)C2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4741813	>	>	IC50	nM	20000.0	IC50	uM	20.0
9794	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4643852	>	>	IC50	nM	20000.0	IC50	uM	20.0
9795	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@@H](CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4750758	>	>	IC50	nM	20000.0	IC50	uM	20.0
9796	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4779694	=	=	IC50	nM	15000.0	IC50	uM	15.0
9797	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4779694	=	=	IC50	nM	19000.0	IC50	uM	19.0
9798	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749822	=	=	IC50	nM	12000.0	IC50	uM	12.0
9799	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749822	=	=	IC50	nM	16000.0	IC50	uM	16.0
9800	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	5000.0	IC50	uM	5.0
9801	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	10000.0	IC50	uM	10.0
9802	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	2000.0	IC50	uM	2.0
9803	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	5000.0	IC50	uM	5.0
9804	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4784864	=	=	IC50	nM	9000.0	IC50	uM	9.0
9805	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4784864	=	=	IC50	nM	9000.0	IC50	uM	9.0
9806	Inhibition of CYP3A4 (unknown origin)	CC1(C)C(=O)Nc2nc(-n3nc(CCC(F)(F)F)c4cc(Cl)ccc43)nc(N)c21	Bioorg Med Chem Lett	2020.0	CHEMBL4758823	>	>	IC50	nM	30000.0	IC50	uM	30.0
9807	Inhibition of CYP3A4 in human liver microsomes by LC-MS analysis	C[C@@H]1CCN(c2cc(-c3ccccc3)ccn2)C[C@H]1c1cc(C(F)F)nc2ncnn12	J Med Chem	2020.0	CHEMBL4741218	>	>	IC50	nM	10000.0	IC50	uM	10.0
9808	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O	ACS Med Chem Lett	2020.0	CHEMBL3928976	=	=	IC50	nM	11000.0	IC50	uM	11.0
9809	Inhibition of CYP3A4 (unknown origin)	CCn1c(-c2cnc(C)nc2)nc2c(-c3cnc4c(c3)[C@](C)(NCC(C)(C)F)C(=O)N4)ncnc21	ACS Med Chem Lett	2020.0	CHEMBL4750385	>	>	IC50	nM	50000.0	IC50	nM	50000.0
9810	Inhibition of CYP3A4 (unknown origin)	Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5C)ncnc3n2C)cn1	ACS Med Chem Lett	2020.0	CHEMBL4776201	>	>	IC50	nM	50000.0	IC50	nM	50000.0
9811	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CN1C(=O)[C@H](F)C[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2020.0	CHEMBL4782326	>	>	IC50	nM	20000.0	IC50	nM	20000.0
9812	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	COc1cc(-c2ncc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)nc2CC(C)C)c(F)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4764485	>	>	IC50	nM	10000.0	IC50	uM	10.0
9813	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1cc(-c2ncc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)nc2CC(C)C)c(F)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4764485	=	=	IC50	nM	8000.0	IC50	uM	8.0
9814	Inhibition of human CYP3A4 expressed in Sacchrosomes using dibenzylfluorescein as substrate by fluorescence based assay	COc1c(-c2ccc3c(c2)OCO3)oc2c(ccc3occc32)c1=O	Bioorg Med Chem	2018.0	CHEMBL577397	>	>	IC50	nM	20000.0	IC50	uM	20.0
9815	Inhibition of human CYP3A4 expressed in Sacchrosomes using dibenzylfluorescein as substrate by fluorescence based assay	O=c1cc(-c2ccccc2)oc2c1ccc1occc12	Bioorg Med Chem	2018.0	CHEMBL224157	>	>	IC50	nM	20000.0	IC50	uM	20.0
9816	Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
9817	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
9818	Inhibition of human CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
9819	Inhibition of human CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3717363	>	>	IC50	nM	50000.0	IC50	uM	50.0
9820	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
9821	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3717363	>	>	IC50	nM	50000.0	IC50	uM	50.0
9822	Inhibition of CYP3A4 (unknown origin)	C[C@H]1CCN1c1nc(N2C[C@H]3[C@H](CC(=O)O)[C@H]3C2)cc(C(F)(F)F)n1	J Med Chem	2020.0	CHEMBL4549658	>	>	IC50	nM	100000.0	IC50	uM	100.0
9823	Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F	J Med Chem	2020.0	CHEMBL4650365	=	=	IC50	nM	2200.0	IC50	uM	2.2
9824	Inhibition of CYP3A4 in human liver microsomes	COc1cc(NC2CN(CCCF)C2)ccc1[C@@H]1c2ccc3[nH]ncc3c2C[C@@H](C)N1CC1(F)CC1	J Med Chem	2020.0	CHEMBL4742862	=	=	IC50	nM	11000.0	IC50	uM	11.0
9825	Irreversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1	J Med Chem	2020.0	CHEMBL4537788	>	>	IC50	nM	10000.0	IC50	uM	10.0
9826	Inhibition of CYP3A4 in human liver microsomes using dextromethorphan as substrate by LC-MS/MS analysis	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1	J Med Chem	2020.0	CHEMBL4537788	>	>	IC50	nM	10000.0	IC50	uM	10.0
9827	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CNC(=O)c1cn(C[C@H](F)CCc2ccc(NC(=O)Cc3cc(OC4CC(F)(F)C4)cc(C)n3)nn2)nn1	J Med Chem	2020.0	CHEMBL4741924	>	>	IC50	nM	10000.0	IC50	nM	10000.0
9828	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684611	=	=	IC50	nM	10000.0	IC50	uM	10.0
9829	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nccs2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4799974	=	=	IC50	nM	13000.0	IC50	uM	13.0
9830	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nnc(C)o2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4762641	=	=	IC50	nM	8000.0	IC50	uM	8.0
9831	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nc(C)no2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745262	=	=	IC50	nM	2000.0	IC50	uM	2.0
9832	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2noc(C)n2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745598	=	=	IC50	nM	13000.0	IC50	uM	13.0
9833	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ncco2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684614	=	=	IC50	nM	8000.0	IC50	uM	8.0
9834	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2cc(C)no2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4750518	=	=	IC50	nM	2000.0	IC50	uM	2.0
9835	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(C(=O)N(C)C)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4743161	>	>	IC50	nM	20000.0	IC50	uM	20.0
9836	Inhibition of CYP3A4 (unknown origin)	CCOC(=O)c1ccc(N2C(=O)c3n[nH]c(C(C)(C)C)c3C2c2ccccc2OC)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3679906	=	=	IC50	nM	5000.0	IC50	uM	5.0
9837	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745595	=	=	IC50	nM	18000.0	IC50	uM	18.0
9838	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4765176	>	>	IC50	nM	20000.0	IC50	uM	20.0
9839	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCCO)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL3679944	>	>	IC50	nM	20000.0	IC50	uM	20.0
9840	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1n[nH]c2c1C(c1ccccc1OCCS(C)(=O)=O)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL4758458	>	>	IC50	nM	20000.0	IC50	uM	20.0
9841	Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCC(=O)O)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL3679880	>	>	IC50	nM	20000.0	IC50	uM	20.0
9842	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(CCO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4741951	=	=	IC50	nM	16000.0	IC50	uM	16.0
9843	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)CO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4797432	>	>	IC50	nM	20000.0	IC50	uM	20.0
9844	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(CO)CO)C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684655	>	>	IC50	nM	20000.0	IC50	uM	20.0
9845	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(-c4ccc(F)cc4)c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)C(=O)O)n1	J Med Chem	2020.0	CHEMBL4788274	=	=	IC50	nM	1800.0	IC50	uM	1.8
9846	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates by LC/MS analysis	CC(=O)Nc1ncc(CN2CCC3(CCN(c4cc(C)nc5ccccc45)C3)C2)s1	J Med Chem	2020.0	CHEMBL4741417	>	>	IC50	nM	10000.0	IC50	uM	10.0
9847	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4791626	>	>	IC50	nM	30000.0	IC50	uM	30.0
9848	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4791626	>	>	IC50	nM	30000.0	IC50	uM	30.0
9849	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3nccc(F)c23)cs1	Bioorg Med Chem Lett	2021.0	CHEMBL4778806	=	=	IC50	nM	100000.0	IC50	uM	100.0
9850	Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2021.0	CHEMBL4245242	=	=	IC50	nM	21000.0	IC50	uM	21.0
9851	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncc(F)cc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4742150	=	=	IC50	nM	27000.0	IC50	uM	27.0
9852	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4245197	=	=	IC50	nM	18000.0	IC50	uM	18.0
9853	Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4248525	=	=	IC50	nM	19000.0	IC50	uM	19.0
9854	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Br)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4746642	=	=	IC50	nM	35000.0	IC50	uM	35.0
9855	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Cl)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4793675	=	=	IC50	nM	8000.0	IC50	uM	8.0
9856	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(Cl)c34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4778609	=	=	IC50	nM	8000.0	IC50	uM	8.0
9857	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(O)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4751643	=	=	IC50	nM	5000.0	IC50	uM	5.0
9858	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(F)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4752045	=	=	IC50	nM	6000.0	IC50	uM	6.0
9859	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(F)c34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4757625	=	=	IC50	nM	36000.0	IC50	uM	36.0
9860	Inhibition of CYP3A4 (unknown origin)	Cc1sc(NC(=O)Cc2cccc(NS(C)(=O)=O)c2)nc1-c1c[nH]c2ncccc12	Bioorg Med Chem Lett	2021.0	CHEMBL4763436	=	=	IC50	nM	5000.0	IC50	uM	5.0
9861	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)ncn2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4781437	=	=	IC50	nM	100000.0	IC50	uM	100.0
9862	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nccc(-c3c[nH]c4ncccc34)n2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4752171	=	=	IC50	nM	48000.0	IC50	uM	48.0
9863	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nnc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4800244	=	=	IC50	nM	100000.0	IC50	uM	100.0
9864	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4794318	=	=	IC50	nM	5000.0	IC50	uM	5.0
9865	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2ccc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4754058	=	=	IC50	nM	6000.0	IC50	uM	6.0
9866	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cnc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4754398	=	=	IC50	nM	12000.0	IC50	uM	12.0
9867	Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4249925	=	=	IC50	nM	8300.0	IC50	uM	8.3
9868	Inhibition of CYP3A4 (unknown origin)	C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34	J Med Chem	2020.0	CHEMBL4112930	>	>	IC50	nM	10000.0	IC50	uM	10.0
9869	Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	11.0	IC50	uM	0.011000000000000001
9870	Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2020.0	CHEMBL6966	=	=	IC50	nM	21330.0	IC50	uM	21.33
9871	Inhibition of CYP3A4 (unknown origin)	Cc1cccc(Cc2nc3cc(O[C@H]4CC[C@@H](C(=O)O)CC4)ccc3n2C)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4778736	>	>	IC50	nM	20000.0	IC50	uM	20.0
9872	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 120 mins by LC-MS/MS	Cc1nc(-c2cccc(C#N)c2)n(OCc2ccc(C#N)cc2)c1C(=O)O	J Med Chem	2020.0	CHEMBL4786038	>	>	IC50	nM	10000.0	IC50	uM	10.0
9873	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis	CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(Cn2ccnc2)c1	Bioorg Med Chem	2021.0	CHEMBL2086892	=	=	IC50	nM	120000.0	IC50	uM	120.0
9874	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis	COC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(C(=O)Cn2ccnc2C(C)(C)C)c1	Bioorg Med Chem	2021.0	CHEMBL4788892	=	=	IC50	nM	50000.0	IC50	uM	50.0
9875	Inhibition of CYP3A4 (unknown origin)	C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@]2(CC1)COc1cc(C(F)(F)F)ccc12	Bioorg Med Chem Lett	2021.0	CHEMBL4763375	=	=	IC50	nM	3100.0	IC50	uM	3.1
9876	Inhibition of CYP3A4 (unknown origin)	C[C@@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4161733	=	=	IC50	nM	5100.0	IC50	uM	5.1
9877	Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccc(Cl)cc1)C(=O)N1CC[C@H](c2ccnc3ccc(F)cc23)[C@@H](O)C1	Bioorg Med Chem Lett	2021.0	CHEMBL4753967	>	>	IC50	nM	10000.0	IC50	uM	10.0
9878	Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)c1ccc(CNC(=O)N2CC(C)(C)c3nc(-c4c(OC)ncnc4C4CC4)ccc32)cc1	ACS Med Chem Lett	2021.0	CHEMBL4799596	>	>	IC50	nM	30000.0	IC50	uM	30.0
9879	Inhibition of CYP3A4 (unknown origin)	CNS(=O)(=O)c1ccc(CNC(=O)N2CC3(CCCC3)c3nc(-c4ccc(O)cc4C)ccc32)cc1	ACS Med Chem Lett	2021.0	CHEMBL4790808	=	=	IC50	nM	900.0	IC50	uM	0.9
9880	Inhibition of human CYP3A4 in pooled human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS/MS	N#Cc1ccc(N2C3CCC2CN(C(=O)CCS(=O)(=O)c2cccc4ncsc24)C3)nc1	ACS Med Chem Lett	2021.0	CHEMBL4790083	>	>	IC50	nM	10000.0	IC50	uM	10.0
9881	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy resorufin as substrate	O=C(O)C1CN(Cc2ccc3c(c2)CCc2c-3noc2-c2onc(-c3ccccc3)c2C(F)(F)F)C1	J Med Chem	2016.0	CHEMBL3959509	=	=	IC50	nM	14000.0	IC50	uM	14.0
9882	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4747534	=	=	IC50	nM	970.0	IC50	uM	0.97
9883	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	CNC(=O)c1ccc(N2CCN(c3cccc(C(=O)NC4C5CC6CC4CC(O)(C6)C5)n3)[C@H](C)C2)cn1	J Med Chem	2016.0	CHEMBL4779054	>	>	IC50	nM	10000.0	IC50	uM	10.0
9884	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(C(C)(C)O)nc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4746745	=	=	IC50	nM	5400.0	IC50	uM	5.4
9885	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4788862	>	>	IC50	nM	10000.0	IC50	uM	10.0
9886	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2F)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4748750	>	>	IC50	nM	10000.0	IC50	uM	10.0
9887	Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1	J Med Chem	2018.0	CHEMBL3754515	>	>	IC50	nM	3000.0	IC50	uM	3.0
9888	Inhibition of CYP3A4 (unknown origin)	CC(C)(Oc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cc1)C(=O)O	J Med Chem	2018.0	CHEMBL4746566	>	>	IC50	nM	3000.0	IC50	uM	3.0
9889	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc5nonc5c4)c(=O)c(O)c3C(=O)N12	Eur J Med Chem	2020.0	CHEMBL4784137	>	>	IC50	nM	10000.0	IC50	uM	10.0
9890	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)nc4F)c(=O)c(O)c3C(=O)N12	Eur J Med Chem	2020.0	CHEMBL4744587	>	>	IC50	nM	10000.0	IC50	uM	10.0
9891	Competitive inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 15 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O	J Med Chem	2020.0	CHEMBL190461	=	=	Ki	nM	1000.0	Ki	uM	1.0
9892	Inhibition of recombinant CYP3A4 (unknown origin) in presence of BFC as substrate	Cc1nc2cc(F)c(-c3cnc(C(C)(C)O)nc3)nc2c(N[C@H](C)c2cc(C#N)ccc2F)c1Cl	J Med Chem	2020.0	CHEMBL4777447	>	>	IC50	nM	20000.0	IC50	uM	20.0
9893	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins by LC-MS/MS analysis	C[C@H]1CCCN1C[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1	ACS Med Chem Lett	2021.0	CHEMBL4798111	>	>	IC50	nM	50000.0	IC50	uM	50.0
9894	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CCCN1C[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1	ACS Med Chem Lett	2021.0	CHEMBL4798111	>	>	IC50	nM	50000.0	IC50	uM	50.0
9895	Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1	ACS Med Chem Lett	2021.0	CHEMBL4744727	=	=	IC50	nM	20000.0	IC50	uM	20.0
9896	Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CC1	ACS Med Chem Lett	2021.0	CHEMBL4749009	=	=	IC50	nM	60000.0	IC50	uM	60.0
9897	Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccnc(C(F)(F)F)n1	ACS Med Chem Lett	2021.0	CHEMBL4783395	=	=	IC50	nM	43000.0	IC50	uM	43.0
9898	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cc(F)c(N)cc2F)ccc2c3ocnc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4747990	>	>	IC50	nM	30000.0	IC50	uM	30.0
9899	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cc(F)c(N)cc2F)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4764598	=	=	IC50	nM	12900.0	IC50	uM	12.9
9900	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cnc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4787847	=	=	IC50	nM	22600.0	IC50	uM	22.6
9901	Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2ccc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4743440	=	=	IC50	nM	1300.0	IC50	uM	1.3
9902	Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(=O)n(C3CC3)c3c(Cl)c(N4CC[C@@H]([C@H](C)N)C4)c(F)cc3c2o1	RSC Med Chem	2020.0	CHEMBL4786331	=	=	IC50	nM	17500.0	IC50	uM	17.5
9903	Inhibition of CYP3A4 in human liver microsomes measured after 30 mins	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	ACS Med Chem Lett	2019.0	CHEMBL4209316	=	=	IC50	nM	200.0	IC50	uM	0.2
9904	Time dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	ACS Med Chem Lett	2019.0	CHEMBL4209316	=	=	Ki	nM	83000.0	Ki	uM	83.0
9905	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	>	>	IC50	nM	25000.0	IC50	uM	25.0
9906	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	>	>	IC50	nM	25000.0	IC50	uM	25.0
9907	Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	=	=	Ki	nM	50000.0	Ki	uM	50.0
9908	Inhibition of recombinant CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3cc(F)c(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	Bioorg Med Chem Lett	2020.0	CHEMBL4763134	>	>	IC50	nM	20000.0	IC50	uM	20.0
9909	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant by Kitz-Wilson plot analysis	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4209316	=	=	Ki	nM	82500.0	Ki	uM	82.5
9910	Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant by Kitz-Wilson plot analysis	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@@H]2c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4793756	=	=	Ki	nM	82500.0	Ki	uM	82.5
9911	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3ccc(N)nc3)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4793302	>	>	IC50	nM	10000.0	IC50	uM	10.0
9912	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3ccnc4[nH]ccc34)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4764922	>	>	IC50	nM	10000.0	IC50	uM	10.0
9913	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)s3)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4782133	>	>	IC50	nM	10000.0	IC50	uM	10.0
9914	Inhibition of CYP3A4 (unknown origin)	Nc1nc(OCc2ccccc2)c2[nH]nnc2n1	Bioorg Med Chem	2020.0	CHEMBL333928	>	>	IC50	nM	10000.0	IC50	uM	10.0
9915	Inhibition of CYP3A4 (unknown origin)	Nc1cc(Cc2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4753981	=	=	IC50	nM	6600.0	IC50	uM	6.6
9916	Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](Cc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4761170	=	=	IC50	nM	3400.0	IC50	uM	3.4
9917	Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4763067	=	=	IC50	nM	1800.0	IC50	uM	1.8
9918	Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCOCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4792720	=	=	IC50	nM	2600.0	IC50	uM	2.6
9919	Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCNCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4800005	=	=	IC50	nM	12000.0	IC50	uM	12.0
9920	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCC2	Bioorg Med Chem	2020.0	CHEMBL4445443	=	=	IC50	nM	3700.0	IC50	uM	3.7
9921	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C(C)(C)C)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4754724	=	=	IC50	nM	5300.0	IC50	uM	5.3
9922	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C3CCC3)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4795963	=	=	IC50	nM	590.0	IC50	uM	0.59
9923	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCF)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4750723	=	=	IC50	nM	1000.0	IC50	uM	1.0
9924	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCO)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4741060	=	=	IC50	nM	30000.0	IC50	uM	30.0
9925	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCCO)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4777113	=	=	IC50	nM	2200.0	IC50	uM	2.2
9926	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CC(C)(C)O)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4760389	=	=	IC50	nM	1100.0	IC50	uM	1.1
9927	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3C(C)C)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4794750	=	=	IC50	nM	2300.0	IC50	uM	2.3
9928	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CCF)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4786740	=	=	IC50	nM	40.0	IC50	uM	0.04
9929	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CC(F)(F)F)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4751736	=	=	IC50	nM	1000.0	IC50	uM	1.0
9930	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C2(C)CC2)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1	Bioorg Med Chem	2020.0	CHEMBL4749020	=	=	IC50	nM	4100.0	IC50	uM	4.1
9931	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C(F)(F)F)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1	Bioorg Med Chem	2020.0	CHEMBL4763513	=	=	IC50	nM	5300.0	IC50	uM	5.3
9932	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4741605	=	=	IC50	nM	4500.0	IC50	uM	4.5
9933	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2	Bioorg Med Chem	2020.0	CHEMBL4758131	=	=	IC50	nM	20000.0	IC50	uM	20.0
9934	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCF)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4759910	=	=	IC50	nM	10500.0	IC50	uM	10.5
9935	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CC(F)(F)F)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4777391	=	=	IC50	nM	1400.0	IC50	uM	1.4
9936	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCO)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4761020	<	<	IC50	nM	50.0	IC50	uM	0.05
9937	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2(C)C	Bioorg Med Chem	2020.0	CHEMBL4747572	=	=	IC50	nM	750.0	IC50	uM	0.75
9938	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)C(C)CC2(C)C	Bioorg Med Chem	2020.0	CHEMBL4798079	=	=	IC50	nM	1500.0	IC50	uM	1.5
9939	Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCCC2	Bioorg Med Chem	2020.0	CHEMBL4745955	=	=	IC50	nM	11000.0	IC50	uM	11.0
9940	Inhibition of CYP3A4 (unknown origin)	O=c1[nH]nc(-c2ccc(Cl)c(C(F)(F)F)c2)o1	J Med Chem	2020.0	CHEMBL4788846	>	>	IC50	nM	25000.0	IC50	uM	25.0
9941	Inhibition of CYP3A4 (unknown origin) incubated for 20 to 30 mins by P450-Glo assay	CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21	J Med Chem	2020.0	CHEMBL4781849	>	>	IC50	nM	10000.0	IC50	uM	10.0
9942	Inhibition of CYP3A4 (unknown origin)	CO[C@@H](C)c1c(NC(=O)Nc2cnc(-n3nccn3)c(Cl)c2)cnc2cc(Cl)nn12	J Med Chem	2020.0	CHEMBL4748253	>	>	IC50	nM	20000.0	IC50	uM	20.0
9943	Inhibition of CYP3A4 (unknown origin)	CO[C@@H](C)c1c(NC(=O)Nc2ccnc(C(F)(F)F)c2)cnc2cc(Cl)nn12	J Med Chem	2020.0	CHEMBL4746044	>	>	IC50	nM	20000.0	IC50	uM	20.0
9944	Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1CCN(CCOCc2ccn(-c3ccc(F)c(F)c3)n2)CC1.Cl	J Med Chem	2020.0	CHEMBL4743610	=	=	IC50	nM	100000.0	IC50	uM	100.0
9945	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	C[C@@H](c1cc(OCC(F)F)ccn1)n1cnc2c(N)nc(Cl)nc21	J Med Chem	2020.0	CHEMBL4762103	>	>	IC50	nM	25000.0	IC50	uM	25.0
9946	Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	O=C1N2C[C@@H](CC[C@H]2F)N1OS(=O)(=O)[O-].[Na+]	J Med Chem	2020.0	CHEMBL4753698	>	>	IC50	nM	50000.0	IC50	uM	50.0
9947	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS analysis	O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1	J Med Chem	2020.0	CHEMBL4782111	>	>	IC50	nM	50000.0	IC50	uM	50.0
9948	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by LC-MS/MS analysis	O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1	J Med Chem	2020.0	CHEMBL4782111	>	>	IC50	nM	50000.0	IC50	uM	50.0
9949	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3cc(Cl)ccc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4761666	>	>	IC50	nM	20000.0	IC50	uM	20.0
9950	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(N[C@H]2CCc3ccc(Cl)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4751920	>	>	IC50	nM	20000.0	IC50	uM	20.0
9951	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3cc(Br)ccc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4747214	>	>	IC50	nM	20000.0	IC50	uM	20.0
9952	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3ccc(Br)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4753862	>	>	IC50	nM	20000.0	IC50	uM	20.0
9953	Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2Cc3cc(F)c(F)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4794107	>	>	IC50	nM	20000.0	IC50	uM	20.0
9954	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1	J Med Chem	2016.0	CHEMBL4793954	>	>	IC50	nM	10000.0	IC50	uM	10.0
9955	Inhibition of CYP3A4 (unknown origin)	C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1	J Med Chem	2016.0	CHEMBL4740741	>	>	IC50	nM	10000.0	IC50	uM	10.0
9956	Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C3CC3)cn2)cn1	J Med Chem	2016.0	CHEMBL4792322	>	>	IC50	nM	10000.0	IC50	uM	10.0
9957	Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(Cl)cn2)cn1	J Med Chem	2016.0	CHEMBL4754960	>	>	IC50	nM	10000.0	IC50	uM	10.0
9958	Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(C(F)(F)F)cn2)cn1	J Med Chem	2016.0	CHEMBL4169078	>	>	IC50	nM	10000.0	IC50	uM	10.0
9959	Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	Nc1ccc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1	J Med Chem	2018.0	CHEMBL4785064	>	>	IC50	nM	10000.0	IC50	uM	10.0
9960	Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO	J Med Chem	2018.0	CHEMBL4749655	>	>	IC50	nM	10000.0	IC50	uM	10.0
9961	Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	Nc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1	J Med Chem	2018.0	CHEMBL4787267	>	>	IC50	nM	10000.0	IC50	uM	10.0
9962	Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1	J Med Chem	2018.0	CHEMBL1336	>	>	IC50	nM	10000.0	IC50	uM	10.0
9963	Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	240.0	IC50	uM	0.24
9964	Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	CC(=O)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL112	>	>	IC50	nM	10000.0	IC50	nM	10000.0
9965	Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	CNC(=O)c1ccccc1S(=O)(=O)NCC(=O)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL4800549	>	>	IC50	nM	10000.0	IC50	nM	10000.0
9966	Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	O=C(CNS(=O)(=O)c1ccccc1C(=O)NCCc1ccc(O)c(O)c1)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL4800229	=	=	IC50	nM	4820.0	IC50	nM	4820.0
9967	Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition by LC-MS/MS analysis	COc1ccc(C(Oc2ccc(N(CC(=O)O)S(=O)(=O)c3c(C)cc(C)cc3C)c3ccccc23)C(=O)O)cc1	Eur J Med Chem	2020.0	CHEMBL4740287	>	>	IC50	nM	10000.0	IC50	uM	10.0
9968	Inhibition of CYP3A4 in human liver microsome using testosterone as substrate	O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(-c3ccc(C(F)(F)F)cc3Cl)cc1)C2	Eur J Med Chem	2020.0	CHEMBL583256	>	>	IC50	nM	20000.0	IC50	uM	20.0
9969	Inhibition of CYP3A4 in human liver microsome using testosterone as substrate	CC1(COc2ccc(OC(F)(F)F)cc2)CCn2cc([N+](=O)[O-])nc2O1	Eur J Med Chem	2020.0	CHEMBL4066553	>	>	IC50	nM	20000.0	IC50	uM	20.0
9970	Inhibition of CYP3A4 in human liver microsomes	Cn1cc(-c2nc3c(-c4ccnc(OC5CC5)c4)cnn3cc2OCCC(C)(C)O)cn1	ACS Med Chem Lett	2021.0	CHEMBL4751832	>	>	IC50	nM	10000.0	IC50	uM	10.0
9971	Inhibition of CYP3A4 (unknown origin)	O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4750603	>	>	IC50	nM	20000.0	IC50	uM	20.0
9972	Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4754719	=	=	IC50	nM	19000.0	IC50	uM	19.0
9973	Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3cnc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4748187	=	=	IC50	nM	12000.0	IC50	uM	12.0
9974	Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ncc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4793083	>	>	IC50	nM	20000.0	IC50	uM	20.0
9975	Inhibition of CYP3A4 (unknown origin)	O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4435992	=	=	IC50	nM	13000.0	IC50	uM	13.0
9976	Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4763978	=	=	IC50	nM	10000.0	IC50	uM	10.0
9977	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4750756	>	>	IC50	nM	20000.0	IC50	uM	20.0
9978	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4800380	=	=	IC50	nM	9100.0	IC50	uM	9.1
9979	Inhibition of CYP3A4 (unknown origin)	O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12)C1CCS(=O)(=O)CC1	ACS Med Chem Lett	2021.0	CHEMBL4744956	>	>	IC50	nM	20000.0	IC50	uM	20.0
9980	Inhibition of CYP3A4 (unknown origin)	C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4760466	>	>	IC50	nM	20000.0	IC50	uM	20.0
9981	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4784900	=	=	IC50	nM	11000.0	IC50	uM	11.0
9982	Inhibition of CYP3A4 (unknown origin)	O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1CCS(=O)(=O)CC1	ACS Med Chem Lett	2021.0	CHEMBL4796103	=	=	IC50	nM	5800.0	IC50	uM	5.8
9983	Inhibition of CYP3A4 (unknown origin)	C[C@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4741364	>	>	IC50	nM	20000.0	IC50	uM	20.0
9984	Inhibition of CYP3A4 (unknown origin)	C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4779994	>	>	IC50	nM	20000.0	IC50	uM	20.0
9985	Inhibition of CYP3A4 (unknown origin)	CN[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NC(C)=O)C1	ACS Med Chem Lett	2021.0	CHEMBL4760098	>	>	IC50	nM	40000.0	IC50	uM	40.0
9986	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O	ACS Med Chem Lett	2021.0	CHEMBL4781426	>	>	IC50	nM	40000.0	IC50	uM	40.0
9987	Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(OC(F)(F)F)cc23)C1=O	ACS Med Chem Lett	2021.0	CHEMBL4746510	>	>	IC50	nM	40000.0	IC50	uM	40.0
9988	Inhibition of CYP3A4 (unknown origin)	Cc1cccc2c1c(=O)n(C[C@H]1CC[C@H](C(=O)O)CC1)c(=O)n2Cc1cccc(C(F)(F)F)c1C#N	ACS Med Chem Lett	2021.0	CHEMBL4761298	>	>	IC50	nM	100000.0	IC50	uM	100.0
9989	Inhibition of CYP3A4 (unknown origin)	CN[C@H](CNc1cc(F)c(S(=O)(=O)Nc2ncc(F)s2)cc1Cl)CC(C)(C)C.Cl	ACS Med Chem Lett	2021.0	CHEMBL4747709	>	>	IC50	nM	50000.0	IC50	uM	50.0
9990	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3651854	>	>	IC50	nM	25000.0	IC50	uM	25.0
9991	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL4798141	=	=	IC50	nM	3300.0	IC50	uM	3.3
9992	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL4762256	=	=	IC50	nM	4500.0	IC50	uM	4.5
9993	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL4779222	=	=	IC50	nM	4600.0	IC50	uM	4.6
9994	Inhibition of CYP3A4 (unknown origin)	CC[C@](CO)(c1ccc(Cl)cc1)n1ccc2c(NS(C)(=O)=O)cccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4439903	>	>	IC50	nM	13000.0	IC50	uM	13.0
9995	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4F)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4746135	=	=	IC50	nM	8390.0	IC50	uM	8.39
9996	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4Cl)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4759692	>	>	IC50	nM	50000.0	IC50	uM	50.0
9997	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4OC(F)(F)F)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4743615	>	>	IC50	nM	50000.0	IC50	uM	50.0
9998	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4751613	>	>	IC50	nM	50000.0	IC50	uM	50.0
9999	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4761139	>	>	IC50	nM	50000.0	IC50	uM	50.0
0	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Cc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4744842	=	=	IC50	nM	1060.0	IC50	uM	1.06
1	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4798957	>	>	IC50	nM	50000.0	IC50	uM	50.0
2	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	FC(F)(F)Oc1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4755454	=	=	IC50	nM	1610.0	IC50	uM	1.61
3	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	CCc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4752684	>	>	IC50	nM	50000.0	IC50	uM	50.0
4	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4788072	=	=	IC50	nM	48300.0	IC50	uM	48.3
5	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	FC(F)(F)c1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4790150	=	=	IC50	nM	516.0	IC50	uM	0.516
6	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4750179	=	=	IC50	nM	11800.0	IC50	uM	11.8
7	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	O=C(Nc1ccc(Cl)c(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4755668	=	=	IC50	nM	192000.0	IC50	mM	0.192
8	Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	O=C(Nc1cccc(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4787638	=	=	IC50	nM	325000.0	IC50	mM	0.325
9	Inhibition of CYP3A4 (unknown origin)	CCCCCCCCC1CCc2cc(CCC(N)(CO)CO)ccc2C1	J Med Chem	2016.0	CHEMBL4750944	=	=	IC50	nM	10400.0	IC50	uM	10.4
10	Inhibition of CYP3A4 (unknown origin)	CCCCCC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1	J Med Chem	2016.0	CHEMBL3806158	=	=	IC50	nM	19000.0	IC50	uM	19.0
11	Inhibition of human liver microsome CYP3A4 using dextromethorphan as substrate incubated for 5 mins followed by NADPH addition and further incubated for 10 mins in shaking water bath by LC-MS/MS analysis	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1	Eur J Med Chem	2018.0	CHEMBL4755698	=	=	IC50	nM	3190.0	IC50	uM	3.19
12	Inhibition of human CYP3A4 using midazolam as substrate	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F	Bioorg Med Chem	2018.0	CHEMBL4750196	>	>	IC50	nM	50000.0	IC50	uM	50.0
13	Inhibition of human CYP3A4	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12	Bioorg Med Chem Lett	2018.0	CHEMBL4794578	=	=	IC50	nM	158489.32	pIC50		3.8
14	Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	Eur J Med Chem	2018.0	CHEMBL3301620	=	=	IC50	nM	25000.0	IC50	uM	25.0
15	Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4533529	>	>	IC50	nM	25000.0	IC50	uM	25.0
16	Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4761836	>	>	IC50	nM	25000.0	IC50	uM	25.0
17	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	Eur J Med Chem	2018.0	CHEMBL3301620	=	=	IC50	nM	25000.0	IC50	uM	25.0
18	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4533529	>	>	IC50	nM	25000.0	IC50	uM	25.0
19	Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4761836	>	>	IC50	nM	25000.0	IC50	uM	25.0
20	Inhibition of CYP3A4 (unknown origin)	O=C1c2nc3ccccc3n2CCN1CCCCOc1ccc(OC(F)(F)F)cc1	Eur J Med Chem	2020.0	CHEMBL4780781	>	>	IC50	nM	10000.0	IC50	uM	10.0
21	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4789776	=	=	IC50	nM	240.0	IC50	uM	0.24
22	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4739976	=	=	IC50	nM	860.0	IC50	uM	0.86
23	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCOCCOCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4795924	=	=	IC50	nM	5650.0	IC50	uM	5.65
24	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCCCCCCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4760660	=	=	IC50	nM	430.0	IC50	uM	0.43
25	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4750995	=	=	IC50	nM	5530.0	IC50	uM	5.53
26	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4753756	=	=	IC50	nM	3560.0	IC50	uM	3.56
27	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C6CCCCC6)cc45)CC3)ncnc2cc1OC)C1CCCCC1	Bioorg Med Chem Lett	2021.0	CHEMBL4758649	=	=	IC50	nM	660.0	IC50	uM	0.66
28	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4781806	<	<	IC50	nM	620.0	IC50	uM	0.62
29	Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4788002	=	=	IC50	nM	460.0	IC50	uM	0.46
30	Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@@]1(O)CF	J Med Chem	2020.0	CHEMBL4781892	>	>	IC50	nM	30000.0	IC50	uM	30.0
31	Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@]1(C)O	J Med Chem	2020.0	CHEMBL4758068	=	=	IC50	nM	26000.0	IC50	uM	26.0
32	Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(C(F)F)c1	ACS Med Chem Lett	2021.0	CHEMBL4754334	=	=	IC50	nM	20800.0	IC50	uM	20.8
33	Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(F)c1	ACS Med Chem Lett	2021.0	CHEMBL4761323	=	=	IC50	nM	41000.0	IC50	uM	41.0
34	Inhibition of CYP3A4 (unknown origin)	Cc1cc(O[C@H]2CC[C@H](C(C)(C)C)CC2)c(CN2CCC(C(=O)O)CC2)c2ccccc12	ACS Med Chem Lett	2021.0	CHEMBL4748198	>	>	IC50	nM	10000.0	IC50	uM	10.0
35	Inhibition of recombinant human CYP3A4	CCC(c1nc2ncc(Cl)cc2[nH]1)[C@H]1CC[C@@H](c2ccnc3ccc(C(F)(F)F)cc32)CC1	ACS Med Chem Lett	2021.0	CHEMBL4756822	=	=	IC50	nM	1930.0	IC50	uM	1.93
36	Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(F)cc2)c(F)c1	J Med Chem	2020.0	CHEMBL4781596	>	>	IC50	nM	20000.0	IC50	uM	20.0
37	Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccccc2)c(F)c1	J Med Chem	2020.0	CHEMBL4784510	>	>	IC50	nM	20000.0	IC50	uM	20.0
38	Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(F)c(F)c2)c(F)c1	J Med Chem	2020.0	CHEMBL4762030	>	>	IC50	nM	20000.0	IC50	uM	20.0
39	Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(C)c(O)c2)c(F)c1	J Med Chem	2020.0	CHEMBL4790836	>	>	IC50	nM	20000.0	IC50	uM	20.0
40	Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(Cl)s2)c(F)c1	J Med Chem	2020.0	CHEMBL4760897	=	=	IC50	nM	5600.0	IC50	uM	5.6
41	Inhibition of CYP3A4 (unknown origin)	C[C@]1(c2cc(/C=C(\F)c3ccc(C#N)cn3)ccc2F)N=C(N)S[C@@]2(C(=O)N3CCOCC3)C[C@H]21	Bioorg Med Chem Lett	2020.0	CHEMBL4760458	=	=	IC50	nM	5300.0	IC50	uM	5.3
42	Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12	J Med Chem	2020.0	CHEMBL4791225	>	>	IC50	nM	50000.0	IC50	uM	50.0
43	Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	69.0	IC50	uM	0.069
44	Inhibition of CYP3A4 (unknown origin)	CNCCOc1ccccc1C(C)(C)Nc1nccn(-c2cc(C(=O)NC3CC3)ccc2C)c1=O	Bioorg Med Chem Lett	2020.0	CHEMBL4792347	=	=	IC50	nM	5011.87	pIC50		5.3
45	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
46	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
47	Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
48	Inhibition of CYP3A4 (unknown origin)	COc1ccc2c3c([nH]c2c1)[C@@H]1N(CC3)C(=O)c2c(OC)cccc2N1C	J Med Chem	2020.0	CHEMBL4745832	=	=	IC50	nM	10000.0	IC50	uM	10.0
49	Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@H](O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4764602	>	>	IC50	nM	50000.0	IC50	uM	50.0
50	Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@@H](O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4800257	=	=	IC50	nM	24800.0	IC50	uM	24.8
51	Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(N)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4746307	=	=	IC50	nM	13600.0	IC50	uM	13.6
52	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Bioorg Med Chem Lett	2020.0	CHEMBL8	>	>	IC50	nM	50000.0	IC50	uM	50.0
53	Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL2105637	>	>	IC50	nM	50000.0	IC50	uM	50.0
54	Inhibition of CYP3A4 (unknown origin)	COC[C@](CO)(OC[C@H]1O[C@@H](n2ncc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O)P(=O)(O)O	J Med Chem	2020.0	CHEMBL4764985	>	>	IC50	nM	20000.0	IC50	uM	20.0
55	Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1	ACS Med Chem Lett	2020.0	CHEMBL4754834	=	=	IC50	nM	37300.0	IC50	uM	37.3
56	Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	ACS Med Chem Lett	2020.0	CHEMBL1873475	=	=	IC50	nM	40800.0	IC50	uM	40.8
57	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate measured up to 20 mins by UHPLC-MS/MS analysis	CNC(=O)NC1CCN(C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC[C@H](C)c2ccccc2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4743180	>	>	IC50	nM	30000.0	IC50	uM	30.0
58	Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate measured up to 20 mins by UHPLC-MS/MS analysis	CNC(=O)NC1CCN(C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC[C@H](C)c2ccccc2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4743180	>	>	IC50	nM	30000.0	IC50	uM	30.0
59	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate measured after 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2	ACS Med Chem Lett	2020.0	CHEMBL4779873	=	=	IC50	nM	300.0	IC50	uM	0.3
60	Inhibition of recombinant CYP3A4 (unknown origin) using BFC as substrate measured after 30 mins by fluorescence assay	Nc1n[nH]c2cc(-c3ccc(=O)n(Cc4ccccc4F)c3)ccc12	Eur J Med Chem	2021.0	CHEMBL4752141	>	>	IC50	nM	10000.0	IC50	uM	10.0
61	Inhibition of recombinant CYP3A4 (unknown origin) using BFC as substrate measured after 30 mins by fluorescence assay	Nc1n[nH]c2cc(-c3ccc(=O)n(Cc4cccc(Cl)c4)c3)ccc12	Eur J Med Chem	2021.0	CHEMBL4764756	>	>	IC50	nM	10000.0	IC50	uM	10.0
62	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis	CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	J Med Chem	2021.0	CHEMBL4784911	=	=	IC50	nM	27100.0	IC50	uM	27.1
63	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis	CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	J Med Chem	2021.0	CHEMBL4784911	=	=	IC50	nM	17300.0	IC50	uM	17.3
64	Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1ccc(Nc2nc(=O)n(CC(C)(C)C(=O)O)c(=O)n2Cc2ccc(Cl)cc2)cc1F	Bioorg Med Chem Lett	2021.0	CHEMBL3985699	>	>	IC50	nM	20000.0	IC50	uM	20.0
65	Inhibition of CYP3A4 (unknown origin)	Cc1ccc(Cn2c(Nc3ccc(OC(C)C)c(Cl)c3)nc(=O)n(CCC(=O)O)c2=O)cc1	Bioorg Med Chem Lett	2021.0	CHEMBL4748113	>	>	IC50	nM	20000.0	IC50	uM	20.0
66	Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis	O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2	Eur J Med Chem	2021.0	CHEMBL4777349	=	=	IC50	nM	4590.0	IC50	uM	4.59
67	Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis	O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2	Eur J Med Chem	2021.0	CHEMBL4791586	=	=	IC50	nM	2110.0	IC50	uM	2.11
68	Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1	J Med Chem	2016.0	CHEMBL3707392	>	>	IC50	nM	10000.0	IC50	uM	10.0
69	Inhibition of CYP3A4 (unknown origin)	COc1ccc(C(NC(=O)c2cnc(-c3cccnn3)nc2O)c2ccc(OC)cc2)cc1	J Med Chem	2016.0	CHEMBL4783524	>	>	IC50	nM	60000.0	IC50	uM	60.0
70	Inhibition of CYP3A4 (unknown origin)	COc1ccccc1CC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1	J Med Chem	2019.0	CHEMBL4649457	=	=	IC50	nM	5500.0	IC50	uM	5.5
71	Inhibition of human liver microsome CYP3A4 in presence of NADPH incubated for 10 to 30 mins by LC-MS-MS analysis	COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5cc6c(cn5)OCCO6)CO[C@@H]43)c2n1	Eur J Med Chem	2020.0	CHEMBL4788651	>	>	IC50	nM	10000.0	IC50	uM	10.0
72	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc2cc(C(=O)NCCN(C)C)oc2c1.CS(=O)(=O)O	Eur J Med Chem	2020.0	CHEMBL4797998	>	>	IC50	nM	10000.0	IC50	uM	10.0
73	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	21.7	IC50	uM	0.0217
74	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccc2NC(=O)Cn2cc(CN(C)C)nn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Eur J Med Chem	2020.0	CHEMBL4784058	=	=	IC50	nM	6148.0	IC50	uM	6.148
75	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	>	>	IC50	nM	40000.0	IC50	uM	40.0
76	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	40000.0	IC50	uM	40.0
77	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	>	>	IC50	nM	40000.0	IC50	uM	40.0
78	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	40000.0	IC50	uM	40.0
79	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	=	=	IC50	nM	3020.0	IC50	uM	3.02
80	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	33000.0	IC50	uM	33.0
81	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	=	=	IC50	nM	2850.0	IC50	uM	2.85
82	Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	=	=	IC50	nM	16400.0	IC50	uM	16.4
83	Inhibition of CYP3A4 (unknown origin)	C[C@H](Oc1cc2cc(F)cc(F)c2nc1N)c1cc(C(=O)O)ccc1-n1cccn1	J Med Chem	2021.0	CHEMBL4785484	>	>	IC50	nM	30000.0	IC50	uM	30.0
84	Inhibition of CYP3A4 (unknown origin)	C[C@H](Oc1cc2cc(F)ccc2nc1N)c1[nH]c(=O)ccc1-n1cccn1	J Med Chem	2021.0	CHEMBL4650304	>	>	IC50	nM	30000.0	IC50	uM	30.0
85	Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(F)cn2)c1OC	J Med Chem	2021.0	CHEMBL4789639	>	>	IC50	nM	40000.0	IC50	uM	40.0
86	Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1ncc(S(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1N	J Med Chem	2021.0	CHEMBL4785210	>	>	EC50	nM	100000.0	EC50	uM	100.0
87	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylase activity by . high-pressure liquid chromatography-tandem mass spectrometry	CCCOc1nncc(-c2cnnc(OCCN(C)C)n2)n1	J Med Chem	2021.0	CHEMBL4853103	>	>	IC50	nM	20000.0	IC50	uM	20.0
88	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation activity by high-pressure liquid chromatography-tandem mass spectrometry	CCCOc1nncc(-c2cnnc(OCCN(C)C)n2)n1	J Med Chem	2021.0	CHEMBL4853103	>	>	IC50	nM	20000.0	IC50	uM	20.0
89	Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(-c3cc(CO)on3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1	J Med Chem	2021.0	CHEMBL4864408	>	>	IC50	nM	30000.0	IC50	uM	30.0
90	Direct inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
91	Direct inhibition of CYP3A5 in human liver microsomes using midazolam as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
92	Direct inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
93	Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
94	Time-dependent inhibition of CYP3A5 in human liver microsomes using midazolam as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
95	Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
96	Time-dependent inhibition of CYP3A5 in human liver microsomes using testosterone as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
97	Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N(C)CCN(C)C)n1	Bioorg Med Chem	2021.0	CHEMBL4852295	=	=	IC50	nM	22000.0	IC50	uM	22.0
98	Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4850549	=	=	IC50	nM	22000.0	IC50	uM	22.0
99	Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(Nc2ccc(C(=O)NCc3ccccc3C(F)(F)F)cc2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4873163	=	=	IC50	nM	19000.0	IC50	uM	19.0
100	Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL2392711	>	>	IC50	nM	33000.0	IC50	uM	33.0
101	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N(C)CCN(C)C)n1	Bioorg Med Chem	2021.0	CHEMBL4852295	>	>	IC50	nM	33000.0	IC50	uM	33.0
102	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4850549	>	>	IC50	nM	33000.0	IC50	uM	33.0
103	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(Nc2ccc(C(=O)NCc3ccccc3C(F)(F)F)cc2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4873163	>	>	IC50	nM	33000.0	IC50	uM	33.0
104	Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL2392711	>	>	IC50	nM	33000.0	IC50	uM	33.0
105	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	COc1cc2c(cc1OCCCCCCC(=O)O)C[C@@H](C(C)C)n1cc(C(=O)O)c(=O)cc1-2	ACS Med Chem Lett	2021.0	CHEMBL4850531	>	>	IC50	nM	10000.0	IC50	uM	10.0
106	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	COc1cc2c(cc1OCCCCCCC(=O)O)C[C@@H](C(C)C)n1cc(C(=O)O)c(=O)cc1-2	ACS Med Chem Lett	2021.0	CHEMBL4850531	>	>	IC50	nM	10000.0	IC50	uM	10.0
107	Inhibition of CYP3A4 in human liver microsomes using midazolam or testosterone as substrate substrate in presence of NADPH by LC-MS/MS analysis	CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3c(c21)CC(=O)N3	J Med Chem	2021.0	CHEMBL4853979	>	>	IC50	nM	25000.0	IC50	uM	25.0
108	Inhibition of CYP3A4 in human liver microsomes using midazolam or testosterone as substrate substrate in presence of NADPH by LC-MS/MS analysis	CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21	J Med Chem	2021.0	CHEMBL4297522	>	>	IC50	nM	25000.0	IC50	uM	25.0
109	Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1	J Med Chem	2021.0	CHEMBL3916243	=	=	IC50	nM	33000.0	IC50	uM	33.0
110	Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins in presence of NADPH followed by substrate addition and measured after 2 mins by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1	J Med Chem	2021.0	CHEMBL3916243	<	<	IC50	nM	10000.0	IC50	uM	10.0
111	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccc(F)cc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4869433	=	=	IC50	nM	110.0	IC50	nM	110.0
112	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccccc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4859908	=	=	IC50	nM	210.0	IC50	nM	210.0
113	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccccn3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855030	=	=	IC50	nM	210.0	IC50	nM	210.0
114	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855931	=	=	IC50	nM	7.1	IC50	nM	7.1
115	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccccc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4846080	=	=	IC50	nM	310.0	IC50	nM	310.0
116	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4ccccc4c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4853722	=	=	IC50	nM	40.0	IC50	nM	40.0
117	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4863015	=	=	IC50	nM	17.0	IC50	nM	17.0
118	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4cnccc4c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4871587	=	=	IC50	nM	210.0	IC50	nM	210.0
119	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4c(c3)CCNC4)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855956	=	=	IC50	nM	7000.0	IC50	nM	7000.0
120	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Cc4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4878518	=	=	IC50	nM	37.0	IC50	nM	37.0
121	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Oc4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4862053	=	=	IC50	nM	11.0	IC50	nM	11.0
122	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Oc4cccc5c4CNC5)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4860429	=	=	IC50	nM	140.0	IC50	nM	140.0
123	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(O[C@H]4CCNC4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4877407	=	=	IC50	nM	13000.0	IC50	nM	13000.0
124	Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(C4CCNCC4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4859470	=	=	IC50	nM	3300.0	IC50	nM	3300.0
125	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Nc1ncc(-c2cc3ccccc3o2)c(N2CCC3(CCNC3=O)CC2)c1Cl	Eur J Med Chem	2021.0	CHEMBL4878007	>	>	IC50	nM	25000.0	IC50	uM	25.0
126	Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC(C)c1cn[nH]c1	J Med Chem	2021.0	CHEMBL4850116	>	>	IC50	nM	20000.0	IC50	uM	20.0
127	Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC(C)c1cnn(C)c1	J Med Chem	2021.0	CHEMBL4850393	=	=	IC50	nM	8500.0	IC50	uM	8.5
128	Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)nc3)CC2)c[nH]c1C(=O)NC(C)c1nc[nH]n1	J Med Chem	2021.0	CHEMBL4848632	>	>	IC50	nM	20000.0	IC50	uM	20.0
129	Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)nc3)CC2)c[nH]c1C(=O)NC(C)c1c[nH]cn1	J Med Chem	2021.0	CHEMBL4851471	=	=	IC50	nM	1700.0	IC50	uM	1.7
130	Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)c(C#N)c3)CC2)c[nH]c1C(=O)NC(C)c1nc[nH]n1	J Med Chem	2021.0	CHEMBL4876457	>	>	IC50	nM	20000.0	IC50	uM	20.0
131	Inhibition of human CYP3A4 expressed in insect supersomes assessed as reduction in 10-hydroxymidazolam formation using midazolam as substrate measured after 30 mins in presence of NADPH by LC-MS/MS analysis	N=C(NO)c1ccc2nc(-c3cccc(-c4cn5ccccc5n4)c3)[nH]c2c1	Bioorg Med Chem	2021.0	CHEMBL4846752	=	=	IC50	nM	233.0	IC50	nM	233.0
132	Inhibition of CYP3A4 in human hepatocytes	COc1cc2c(cc1OC)C(=O)C(CC1(F)CCN(Cc3ccccc3F)CC1)C2	J Med Chem	2021.0	CHEMBL4859647	>	>	IC50	nM	30000.0	IC50	uM	30.0
133	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2nc(N)n(C(=O)c3ccc(C)cc3)n2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL4856492	=	=	IC50	nM	3950.0	IC50	uM	3.95
134	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSCCN(CC)CC)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL1234521	=	=	IC50	nM	1600.0	IC50	uM	1.6
135	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins by LC/MS/MS analysis	CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL2103760	=	=	IC50	nM	240.0	IC50	uM	0.24
136	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1	Eur J Med Chem	2021.0	CHEMBL4871799	=	=	IC50	nM	3230.0	IC50	uM	3.23
137	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1	Eur J Med Chem	2021.0	CHEMBL4871799	=	=	IC50	nM	1150.0	IC50	uM	1.15
138	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cc(c(F)cc1F)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4868571	>	>	IC50	nM	30000.0	IC50	uM	30.0
139	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4850101	=	=	IC50	nM	19600.0	IC50	uM	19.6
140	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCC1CCN(CC1)c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4866790	>	>	IC50	nM	30000.0	IC50	uM	30.0
141	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cccc(c1)-c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4854600	>	>	IC50	nM	30000.0	IC50	uM	30.0
142	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4872630	>	>	IC50	nM	30000.0	IC50	uM	30.0
143	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCCn1cc(cn1)-c1cnc3ccc-2nn13	Eur J Med Chem	2021.0	CHEMBL4873529	>	>	IC50	nM	30000.0	IC50	uM	30.0
144	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1cnc3ccc-2cn13	Eur J Med Chem	2021.0	CHEMBL4864407	>	>	IC50	nM	30000.0	IC50	uM	30.0
145	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCC1CCN(CC1)c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4850446	>	>	IC50	nM	30000.0	IC50	uM	30.0
146	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cc(c(F)cc1F)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2nc13	Eur J Med Chem	2021.0	CHEMBL4875906	=	=	IC50	nM	6500.0	IC50	uM	6.5
147	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cccc(c1)Cc1cnc3sc-2nn13	Eur J Med Chem	2021.0	CHEMBL4853785	>	>	IC50	nM	30000.0	IC50	uM	30.0
148	Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3sc-2cc13	Eur J Med Chem	2021.0	CHEMBL4852833	>	>	IC50	nM	30000.0	IC50	uM	30.0
149	Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	J Med Chem	2021.0	CHEMBL4761772	=	=	IC50	nM	11000.0	IC50	uM	11.0
150	Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1NN1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	J Med Chem	2021.0	CHEMBL4871326	=	=	IC50	nM	20000.0	IC50	uM	20.0
151	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1ccc2c(c1)CCCN2Cc1ccc(C(=O)NO)cc1	J Med Chem	2021.0	CHEMBL4846435	>	>	IC50	nM	100.0	IC50	nM	100.0
152	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CCC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4850551	>	>	IC50	nM	30000.0	IC50	uM	30.0
153	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4854083	>	>	IC50	nM	30000.0	IC50	uM	30.0
154	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CCC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4850551	>	>	IC50	nM	30000.0	IC50	uM	30.0
155	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4854083	>	>	IC50	nM	30000.0	IC50	uM	30.0
156	Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL3925871	>	>	IC50	nM	20000.0	IC50	uM	20.0
157	Inhibition of CYP3A4 (unknown origin)	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL3949501	>	>	IC50	nM	20000.0	IC50	uM	20.0
158	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4846941	=	=	IC50	nM	900.0	IC50	uM	0.9
159	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6C(F)(F)F)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4874257	=	=	IC50	nM	10800.0	IC50	uM	10.8
160	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6OC(F)(F)F)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4851875	=	=	IC50	nM	1000.0	IC50	uM	1.0
161	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4870156	=	=	IC50	nM	1800.0	IC50	uM	1.8
162	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)nc1	ACS Med Chem Lett	2021.0	CHEMBL4875500	=	=	IC50	nM	1100.0	IC50	uM	1.1
163	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)cn1	ACS Med Chem Lett	2021.0	CHEMBL4868516	=	=	IC50	nM	6200.0	IC50	uM	6.2
164	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4872481	=	=	IC50	nM	1900.0	IC50	uM	1.9
165	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cc(F)cc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4868096	=	=	IC50	nM	3100.0	IC50	uM	3.1
166	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4858615	=	=	IC50	nM	4700.0	IC50	uM	4.7
167	Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(C(F)(F)F)c2cc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4862974	>	>	IC50	nM	40000.0	IC50	uM	40.0
168	Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4650316	=	=	IC50	nM	6500.0	IC50	uM	6.5
169	Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4866043	=	=	IC50	nM	2700.0	IC50	uM	2.7
170	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4650316	=	=	IC50	nM	26000.0	IC50	uM	26.0
171	Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4866043	=	=	IC50	nM	1600.0	IC50	uM	1.6
172	Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc2ccc(O[C@H]3CC[C@@H](C(F)(F)F)CC3)c(C(F)(F)F)c2c1)N1C2CCC1CC(C(=O)O)C2	ACS Med Chem Lett	2021.0	CHEMBL4871014	>	>	IC50	nM	10000.0	IC50	uM	10.0
173	Inhibition of CYP3A4 (unknown origin)	CC(C)N1Cc2cc(C(F)(F)F)ncc2C2=CN=C(NCc3c(F)ccc4c3CCO4)N3C=NC(C1=O)C23	J Med Chem	2021.0	CHEMBL4870920	>	>	IC50	nM	30000.0	IC50	uM	30.0
174	Inhibition of CYP3A4 (unknown origin)	O=C1C2N=CN3C(NCc4c(F)ccc5c4CCO5)=NC=C(c4cnc(C(F)(F)F)cc4CN1CC(F)F)C23	J Med Chem	2021.0	CHEMBL4854800	>	>	IC50	nM	30000.0	IC50	uM	30.0
175	Inhibition of CYP3A4 (unknown origin)	CC(F)(F)CN1Cc2cc(C(F)(F)F)ncc2C2=CN=C(NCc3c(F)ccc4c3CCO4)N3C=NC(C1=O)C23	J Med Chem	2021.0	CHEMBL4861394	>	>	IC50	nM	30000.0	IC50	uM	30.0
176	Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1OC)[C@H]1C[C@@H](O)[C@H](CC(C)C)CN1CC2	Eur J Med Chem	2021.0	CHEMBL576222	>	>	IC50	nM	100000.0	IC50	uM	100.0
177	Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1OCC(F)(F)F)CCN1CC(CC(C)C)C(O)CC21	Eur J Med Chem	2021.0	CHEMBL4854730	>	>	IC50	nM	100000.0	IC50	uM	100.0
178	Inhibition of recombinant human CYP3A4	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc(C(F)(F)F)c4)n3)nc2)CC1	J Med Chem	2021.0	CHEMBL4859234	=	=	IC50	nM	7130.0	IC50	uM	7.13
179	Inhibition of CYP3A4 (unknown origin)	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1	J Med Chem	2021.0	CHEMBL4556790	>	>	IC50	nM	100000.0	IC50	uM	100.0
180	Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis	O=C(NC(Cn1ccnc1)C(=O)c1cccc(F)c1)c1ccc(-c2ccc(Cl)cc2)s1	Eur J Med Chem	2021.0	CHEMBL4863635	=	=	IC50	nM	1170.0	IC50	uM	1.17
181	Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis	Cc1ccc(C(=O)C(Cn2ccnc2)NC(=O)c2ccc(-c3ccc(Cl)cc3)s2)cc1	Eur J Med Chem	2021.0	CHEMBL4878311	=	=	IC50	nM	1240.0	IC50	uM	1.24
182	Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	CS(=O)(=O)c1nccc(-c2c(-c3cccc(OCc4ccccc4)c3)nc3sccn23)n1	Eur J Med Chem	2021.0	CHEMBL4860202	=	=	IC50	nM	17800.0	IC50	nM	17800.0
183	Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1	Eur J Med Chem	2021.0	CHEMBL4866102	=	=	IC50	nM	20910.0	IC50	nM	20910.0
184	Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	2.38	IC50	nM	2.38
185	Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1	J Med Chem	2021.0	CHEMBL175691	=	=	IC50	nM	2170.0	IC50	uM	2.17
186	Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc2c1CSCC2	J Med Chem	2021.0	CHEMBL4848008	=	=	IC50	nM	53900.0	IC50	uM	53.9
187	Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL295698	=	=	IC50	nM	26.9	IC50	uM	0.0269
188	Inhibition of CYP3A4 in human liver microsomes	CCS(=O)(=O)c1ccc([C@@H](NC(C)=O)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1	J Med Chem	2021.0	CHEMBL4562895	>	>	IC50	nM	30000.0	IC50	uM	30.0
189	Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1Cc2cc(S(C)(=O)=O)ccc2[C@@H]1C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1	J Med Chem	2021.0	CHEMBL4864604	>	>	IC50	nM	30000.0	IC50	uM	30.0
190	Inhibition of human hepatic CYP3A4	COc1c(OCc2ccc(F)cc2)cc2oc3cc4c(c(OC/C=C/C(=O)O)c3c(=O)c2c1CC=C(C)C)C=CC(C)(C)O4	J Med Chem	2021.0	CHEMBL4877549	>	>	IC50	nM	25000.0	IC50	uM	25.0
191	Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hyrozylation reaction incubated for 30 mins in presence of NADP by LC-MS/MS analysis	CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1	J Med Chem	2021.0	CHEMBL4847050	>	>	IC50	nM	100000.0	IC50	uM	100.0
192	Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6-beta-hydroxylation reaction incubated for 30 mins in presence of NADP by LC-MS/MS analysis	CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1	J Med Chem	2021.0	CHEMBL4847050	>	>	IC50	nM	100000.0	IC50	uM	100.0
193	Induction of CYP3A4 in human hepatocytes assessed as mRNA expression incubated for 3 days by RT-RTPCR analysis	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	J Med Chem	2021.0	CHEMBL4297517	=	=	EC50	nM	2200.0	EC50	uM	2.2
194	Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CCN(C(=O)C1CC1)c1cc(-c2ccc(N3CCN(CC4CC4)CC3)nc2C)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C	J Med Chem	2021.0	CHEMBL4862681	=	=	IC50	nM	7580.0	IC50	uM	7.58
195	Inhibition of CYP3A4 in pooled human liver microsomes using midazolam or testosterone as substrate preincubated for 30 mins in presence of NADPH followed by substrate addition by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc3c(c2)B(O)OC3)nnn1-c1ccccn1	J Med Chem	2021.0	CHEMBL4874673	>	>	IC50	nM	50000.0	IC50	uM	50.0
196	Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	Cc1cn(-c2ccnc(N[C@@H]3CCN(C(=O)c4nccs4)C3)n2)c(-c2ccccc2)n1	ACS Med Chem Lett	2021.0	CHEMBL4857273	=	=	IC50	nM	940.0	IC50	uM	0.94
197	Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3ccccc3)n2)C1	ACS Med Chem Lett	2021.0	CHEMBL4876338	=	=	IC50	nM	290.0	IC50	uM	0.29
198	Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3cccc(Cl)c3)n2)C1	ACS Med Chem Lett	2021.0	CHEMBL4875016	=	=	IC50	nM	190.0	IC50	uM	0.19
199	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1	J Med Chem	2021.0	CHEMBL4874034	=	=	IC50	nM	7800.0	IC50	uM	7.8
200	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C)NC(=O)NC2=O)CCN1c1ccc(Cl)c(Cl)c1	J Med Chem	2021.0	CHEMBL4859812	>	>	IC50	nM	100000.0	IC50	uM	100.0
201	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1	J Med Chem	2021.0	CHEMBL4650334	>	>	IC50	nM	100000.0	IC50	uM	100.0
202	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1	J Med Chem	2021.0	CHEMBL4874034	=	=	IC50	nM	1500.0	IC50	uM	1.5
203	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C)NC(=O)NC2=O)CCN1c1ccc(Cl)c(Cl)c1	J Med Chem	2021.0	CHEMBL4859812	>	>	IC50	nM	100000.0	IC50	uM	100.0
204	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1	J Med Chem	2021.0	CHEMBL4650334	>	>	IC50	nM	100000.0	IC50	uM	100.0
205	Inhibition of CYP3A4 (unknown origin)	CCn1c(-c2cnc(C)nc2)nc2c(N[C@H]3CCN(C(=O)C4CC4)C3)ncnc21	J Med Chem	2021.0	CHEMBL4853960	>	>	IC50	nM	50000.0	IC50	uM	50.0
206	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2c(Nc3ccccn3)[nH]c3c(C4=CCCCC4)c(-c4ccccc4)nn3c2=O)cc1	J Med Chem	2021.0	CHEMBL4573938	>	>	IC50	nM	10000.0	IC50	uM	10.0
207	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(CO[C@H]3C[C@@H](N=C=S)C3)nc2)cc1F	J Med Chem	2021.0	CHEMBL4874855	=	=	IC50	nM	2600.0	IC50	uM	2.6
208	Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	Cn1c(=O)[nH]c2c(Cl)cc3c(c21)CN(CC(F)(F)F)C(=O)[C@H](CC(=O)N1CCC(N2CCc4ccccc4NC2=O)CC1)C3	Bioorg Med Chem Lett	2021.0	CHEMBL4848032	=	=	IC50	nM	8100.0	IC50	uM	8.1
209	Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3[nH]c(=O)n(CC(F)(F)F)c3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4857649	=	=	IC50	nM	8400.0	IC50	uM	8.4
210	Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3c(c2CN(CC(F)(F)F)C1=O)C(F)(F)C(=O)N3)N1CCC(n2c(=O)[nH]c3ncccc32)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4849710	>	>	IC50	nM	40000.0	IC50	uM	40.0
211	Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3[nH]ncc3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4746351	=	=	IC50	nM	100.0	IC50	uM	0.1
212	Inhibition of CYP3A4 (unknown origin) assessed as MDI shift	CNC(=O)c1cc(C(=O)N[C@H]2CC[C@H](O)CC2)n([C@@H](C)c2ccccc2)n1	J Med Chem	2021.0	CHEMBL4854042	<	>	IC50	nM	39810.72	pIC50		4.4
213	Inhibition of CYP3A4 (unknown origin) assessed as MDI shift	CNC(=O)c1cc(C(=O)N[C@H]2CC[C@H](O)CC2)c([C@@H](C)c2ccccc2)o1	J Med Chem	2021.0	CHEMBL4865767	<	>	IC50	nM	39810.72	pIC50		4.4
214	Direct inhibition of CYP3A4 in human hepatocytes	CCOC(=O)[C@@H](Cc1cn(C)c2ccccc12)NC(=O)[C@@H](N)CC(C)C.Cl	Eur J Med Chem	2020.0	CHEMBL4876008	=	=	IC50	nM	5000.0	IC50	uM	5.0
215	Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@@]6(C)[C@@H](CC[C@H]6O)[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@H]2O	Eur J Med Chem	2021.0	CHEMBL4864434	=	=	Kd	nM	1600.0	Kd	uM	1.6
216	Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Eur J Med Chem	2021.0	CHEMBL4862783	=	=	Kd	nM	5500.0	Kd	uM	5.5
217	Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)C(=O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O	Eur J Med Chem	2021.0	CHEMBL4871524	=	=	Kd	nM	1400.0	Kd	uM	1.4
218	Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C\C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863362	=	=	Kd	nM	370.0	Kd	uM	0.37
219	Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C/C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863066	=	=	Kd	nM	7100.0	Kd	uM	7.1
220	Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@@]6(C)[C@@H](CC[C@H]6O)[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@H]2O	Eur J Med Chem	2021.0	CHEMBL4864434	=	=	IC50	nM	22000.0	IC50	uM	22.0
221	Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Eur J Med Chem	2021.0	CHEMBL4862783	=	=	IC50	nM	1200.0	IC50	uM	1.2
222	Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)C(=O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O	Eur J Med Chem	2021.0	CHEMBL4871524	=	=	IC50	nM	3600.0	IC50	uM	3.6
223	Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C\C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863362	=	=	IC50	nM	800.0	IC50	uM	0.8
224	Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C/C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863066	=	=	IC50	nM	6500.0	IC50	uM	6.5
225	Induction of CYP3A4 in human hepatocytes	Fc1cc(F)c(F)c(-c2ccc(N[C@H]3C[C@@H]4CN(CC5CCOCC5)C[C@@H]4C3)nn2)c1	ACS Med Chem Lett	2021.0	CHEMBL4850236	=	=	EC50	nM	1900.0	EC50	uM	1.9
226	Competitive inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	FC(F)c1cncc(-c2ccc3ncc4nnc(C5=CCCOCC5)n4c3c2)c1	J Med Chem	2021.0	CHEMBL4851439	=	=	IC50	nM	15000.0	IC50	uM	15.0
227	Inhibition of CYP3A4 (unknown origin)	COc1nc(C2=NOC(C3CC3)C(c3ccc(Cl)cc3)N2)ccc1-n1cnc(C)c1	J Med Chem	2021.0	CHEMBL4848062	>=	>=	IC50	nM	14000.0	IC50	uM	14.0
228	Inhibition of CYP3A4 (unknown origin) by titration method	Cc1nc2c(cnn2-c2csc(C(=O)NC3COC3)c2)cc1Nc1c(F)cccc1Cl	ACS Med Chem Lett	2021.0	CHEMBL4845770	=	=	IC50	nM	1700.0	IC50	uM	1.7
229	Inhibition of CYP3A4T in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N	J Med Chem	2021.0	CHEMBL4864983	>	>	IC50	nM	10000.0	IC50	uM	10.0
230	Inhibition of CYP3A4T in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	22.0	IC50	uM	0.022000000000000002
231	Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N	J Med Chem	2021.0	CHEMBL4864983	>	>	IC50	nM	10000.0	IC50	uM	10.0
232	Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	7.0	IC50	uM	0.006999999999999999
233	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1	J Med Chem	2021.0	CHEMBL3545369	=	=	IC50	nM	28000.0	IC50	uM	28.0
234	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4852532	=	=	IC50	nM	1100.0	IC50	uM	1.1
235	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@H](Oc3ccnc4ccccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4872522	=	=	IC50	nM	3300.0	IC50	uM	3.3
236	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@H](Oc3ccnc4ccc(F)cc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4846874	=	=	IC50	nM	1400.0	IC50	uM	1.4
237	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4875089	>	>	IC50	nM	5000.0	IC50	uM	5.0
238	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4852881	=	=	IC50	nM	2100.0	IC50	uM	2.1
239	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@H]21)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4872803	=	=	IC50	nM	1900.0	IC50	uM	1.9
240	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4873928	=	=	IC50	nM	6700.0	IC50	uM	6.7
241	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4cc(F)ccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4868112	=	=	IC50	nM	5400.0	IC50	uM	5.4
242	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4cccnc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4873892	=	=	IC50	nM	13000.0	IC50	uM	13.0
243	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccncc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4870664	=	=	IC50	nM	18000.0	IC50	uM	18.0
244	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CC(NC(=O)c1ccc(C#N)cc1)[C@@H]1[C@H]2C[C@H](Oc3ncnc4cc(F)ccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4853036	>	>	IC50	nM	17000.0	IC50	uM	17.0
245	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](NC(=O)c3cncc(F)c3)C[C@H]21	J Med Chem	2021.0	CHEMBL4854742	>	>	IC50	nM	50000.0	IC50	uM	50.0
246	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc4cccc(F)c4c3=O)C[C@H]21	J Med Chem	2021.0	CHEMBL4848111	>	>	IC50	nM	17000.0	IC50	uM	17.0
247	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cc(C4CC4)nn3)C[C@H]21	J Med Chem	2021.0	CHEMBL4865079	>	>	IC50	nM	50000.0	IC50	uM	50.0
248	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc(C4CC4)n3)C[C@H]21	J Med Chem	2021.0	CHEMBL4848055	=	=	IC50	nM	31000.0	IC50	uM	31.0
249	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc4cc(F)ccc43)C[C@H]21	J Med Chem	2021.0	CHEMBL4866113	=	=	IC50	nM	1300.0	IC50	uM	1.3
250	Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4ccccc4F)cc3)=N2)cc1	Eur J Med Chem	2021.0	CHEMBL4845963	=	=	IC50	nM	14800.0	IC50	uM	14.8
251	Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4cccc(F)c4)cc3)=N2)cc1	Eur J Med Chem	2021.0	CHEMBL4877100	=	=	IC50	nM	15200.0	IC50	uM	15.2
252	Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2021.0	CHEMBL64391	=	=	IC50	nM	32.6	IC50	nM	32.6
253	Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	11.7	IC50	nM	11.7
254	Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Eur J Med Chem	2021.0	CHEMBL91	=	=	IC50	nM	74.2	IC50	nM	74.2
255	Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1ncc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12	J Med Chem	2021.0	CHEMBL4865918	=	=	IC50	nM	9000.0	IC50	uM	9.0
256	Inhibition of CYP3A4 (unknown origin)	COc1ccc([C@H]2C[C@H](C(=O)O)C2)cc1-c1ccc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12	J Med Chem	2021.0	CHEMBL3933320	=	=	IC50	nM	6000.0	IC50	uM	6.0
257	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	J Med Chem	2021.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
258	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1Cc1ccccn1	J Med Chem	2021.0	CHEMBL4874790	=	=	IC50	nM	15800.0	IC50	uM	15.8
259	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COC[C@@H](C)n1c(C2CCOCC2)nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	J Med Chem	2021.0	CHEMBL4878439	=	=	IC50	nM	25100.0	IC50	uM	25.1
260	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(N(C)C)n(CC3CCOCC3)c12	J Med Chem	2021.0	CHEMBL4874356	=	=	IC50	nM	10000.0	IC50	uM	10.0
261	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1[C@H](C)c1ccccn1	J Med Chem	2021.0	CHEMBL4874801	=	=	IC50	nM	7900.0	IC50	uM	7.9
262	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21	J Med Chem	2021.0	CHEMBL1232461	>	>	IC50	nM	50000.0	IC50	uM	50.0
263	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	J Med Chem	2021.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
264	Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VR as probe substrate incubated for 15 to 60 mins by fluorometric assay	COC[C@@H](C)n1c(C2CCOCC2)nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	J Med Chem	2021.0	CHEMBL4878439	>	>	IC50	nM	50000.0	IC50	uM	50.0
265	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS analysis	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1	Eur J Med Chem	2021.0	CHEMBL4863078	>	>	IC50	nM	10.0	IC50	nM	10.0
266	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS analysis	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1	Eur J Med Chem	2021.0	CHEMBL4878090	>	>	IC50	nM	10.0	IC50	nM	10.0
267	Inhibition of CYP3A4 (unknown origin)	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1	J Med Chem	2021.0	CHEMBL1976040	=	=	IC50	nM	19000.0	IC50	uM	19.0
268	Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2c(Cl)cccc2Cl)c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc12	J Med Chem	2021.0	CHEMBL4867107	=	=	IC50	nM	4500.0	IC50	uM	4.5
269	Inhibition of CYP3A4 (unknown origin)	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)C(O)(CC)CC2	J Med Chem	2021.0	CHEMBL4871593	=	=	IC50	nM	7000.0	IC50	uM	7.0
270	Inhibition of CYP3A4 (unknown origin)	O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21	J Med Chem	2021.0	CHEMBL4867565	=	=	IC50	nM	57000.0	IC50	uM	57.0
271	Inhibition of human recombinant CYP3A4 by fluorescence assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2021.0	CHEMBL6966	=	=	IC50	nM	5700.0	IC50	uM	5.7
272	Inhibition of human recombinant CYP3A4 by fluorescence assay	COc1cc2ncnc(-c3c(-c4ccccc4)n(Cc4ccccc4Br)c4ccccc34)c2cc1OCCCN1CCOCC1	J Med Chem	2021.0	CHEMBL4876875	=	=	IC50	nM	4100.0	IC50	uM	4.1
273	Inhibition of human recombinant CYP3A4 by fluorescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	80.0	IC50	uM	0.08
274	Inhibition of CYP3A4 in human liver microsomes using probe substrate in presence of NADPH regenerating system incubated for 60 mins by UFLC-MS/MS analysis	COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1OC(C(=O)NO)C(C)C	J Med Chem	2021.0	CHEMBL4878408	=	=	IC50	nM	92790.0	IC50	uM	92.79
275	Inhibition of CYP3A4 (unknown origin)	CN(C[C@@H]1Cc2c(cccc2NC2CCNCC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4849088	>	>	IC50	nM	20000.0	IC50	uM	20.0
276	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N[C@H]2CC[C@H](N)CC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4864332	>	>	IC50	nM	20000.0	IC50	uM	20.0
277	Inhibition of CYP3A4 (unknown origin)	CN1CCC(N(C)c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4857452	>	>	IC50	nM	20000.0	IC50	uM	20.0
278	Inhibition of CYP3A4 (unknown origin)	CN(C)C1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4876951	>	>	IC50	nM	20000.0	IC50	uM	20.0
279	Inhibition of CYP3A4 (unknown origin)	CN1CCN(Nc2cccc3c2C[C@@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4858136	>	>	IC50	nM	20000.0	IC50	uM	20.0
280	Inhibition of CYP3A4 (unknown origin)	CN1C[C@H]2CN(c3cccc4c3C[C@H](CN(C)[C@H]3CCCc5cccnc53)NC4)C[C@H]2C1	ACS Med Chem Lett	2021.0	CHEMBL4862509	>	>	IC50	nM	20000.0	IC50	uM	20.0
281	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2NC2CCNCC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4874526	>	>	IC50	nM	20000.0	IC50	uM	20.0
282	Inhibition of CYP3A4 (unknown origin)	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL518924	>	>	IC50	nM	20000.0	IC50	uM	20.0
283	Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
284	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2CCC(N)CC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4846946	>	>	IC50	nM	20000.0	IC50	uM	20.0
285	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3CNC[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4853570	>	>	IC50	nM	20000.0	IC50	uM	20.0
286	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@H]3CCN(C)[C@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4862362	>	>	IC50	nM	20000.0	IC50	uM	20.0
287	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3CCN(C)[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4875030	>	>	IC50	nM	20000.0	IC50	uM	20.0
288	Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2CC[C@@H](N(C)C)C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4877757	>	>	IC50	nM	20000.0	IC50	uM	20.0
289	Inhibition of CYP3A4 (unknown origin)	CN(C)[C@H]1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C1	ACS Med Chem Lett	2021.0	CHEMBL4863276	>	>	IC50	nM	20000.0	IC50	uM	20.0
